purpos
pirfenidon
shown
antifibrot
antiinflammatori
effect
lung
purpos
studi
evalu
inhibitori
effect
pirfenidon
transform
growth
factor
tgf
myofibroblast
differenti
extracellular
matrix
accumul
also
determin
molecular
mechan
pirfenidon
nasal
polypderiv
fibroblast
npdf
method
npdf
isol
nasal
polyp
eight
patient
chronic
rhinosinus
nasal
polyp
pirfenidon
use
treat
npdf
cytotox
evalu
use
bromid
assay
fibroblast
migrat
evalu
scratch
assay
express
level
muscl
actin
sma
fibronectin
phosphoryl
determin
western
blot
andor
revers
transcriptionpolymeras
chain
reaction
immunofluoresc
stain
total
collagen
product
analyz
sircol
collagen
assay
contractil
activ
measur
collagen
gel
contract
assay
result
pirfenidon
mgml
signific
cytotox
effect
npdf
migrat
npdf
significantli
inhibit
pirfenidon
treatment
express
level
fibronectin
significantli
reduc
pirfenidonetr
npdf
collagen
contract
product
also
significantli
decreas
pirfenidon
treatment
final
pirfenidon
significantli
inhibit
phosphoryl
pathway
npdf
conclus
pirfenidon
inhibitori
effect
migrat
myofibroblast
differenti
extracellular
matrix
accumul
collagen
contract
block
phosphoryl
pathway
npdf
thu
pirfenidon
may
inhibit
extracellular
matrix
regul
even
though
antihistamin
mainstay
treatment
chronic
spontan
urticaria
csu
csu
patient
respond
antihistamin
mani
clinician
accept
efficaci
steroid
treatment
csu
howev
littl
evid
support
steroid
use
antihistamineresist
csu
purpos
studi
demonstr
efficaci
suggest
regimen
oral
steroid
treatment
csu
patient
refractori
high
dosag
antihistamin
conduct
retrospect
chart
review
patient
diagnos
urticaria
feburari
decemb
total
patient
csu
includ
patient
antihistamineresist
prescrib
cours
steroid
thirteen
patient
success
control
antihistamin
stop
first
cours
second
cours
steroid
induc
remiss
addit
two
patient
advers
event
complic
associ
oral
steroid
observ
studi
period
studi
demonstr
excel
cours
oral
corticosteroid
antihistamineresist
csu
propos
standard
corticosteroid
treatment
regimen
recent
studi
emphas
import
role
follicular
helper
tfh
cell
contribut
bcell
differenti
well
antibodi
product
aim
studi
investig
possibl
role
tfh
cell
pathogenesi
primari
syndrom
pss
first
part
studi
focus
peripheri
analyz
immunecompet
cell
serolog
marker
enrol
pss
patient
healthi
control
studi
patient
elev
ratio
peripher
tfh
cell
howev
divid
patient
two
group
defin
presenc
extraglandular
manifest
egm
patient
egm
differ
control
significantli
moreov
tfh
cell
percentag
correl
posit
activ
cell
cell
valu
tfh
cell
percentag
show
neg
correl
igm
igg
memori
b
cell
proport
elev
tfh
percentag
observ
antissassb
posit
patient
second
part
concentr
site
inflamm
determin
composit
lymphocyt
infiltr
labial
salivari
gland
lsg
biopsi
special
emphasi
tfh
cell
select
tissu
block
obtain
patient
time
diseas
onset
lsg
grade
base
organiz
level
periduct
lymphocyt
infiltr
tfh
cell
marker
occur
predominantli
organ
structur
higher
focu
score
coexpress
marker
identifi
tfh
cell
close
cell
typic
format
germin
center
system
featur
develop
later
diseas
cours
patient
structur
infiltr
result
indic
presenc
tfh
cell
lsg
diseas
onset
may
predict
pronounc
clinic
cours
pss
expect
understand
regul
tfh
cell
provid
new
potenti
therapeut
target
treatment
pss
patient
egm
object
well
known
langerhan
cell
lc
work
primari
orchestr
polar
immun
respons
toward
helper
type
helper
type
immun
respons
studi
investig
effect
tacrolimu
betamethason
cell
develop
lc
method
lclike
dendrit
cell
ldc
gener
mous
bone
marrow
cell
mice
prime
ovalbumin
ova
peptidepuls
ldc
treat
tacrolimu
betamethason
via
hind
footpad
day
cytokin
respons
drain
poplit
lymph
node
investig
enzymelink
immunosorb
assay
express
ldc
surfac
molecul
investig
use
revers
transcriptas
polymeras
chain
reaction
result
administr
ova
peptidepuls
ldc
treat
betamethason
hind
footpad
mice
inhibit
develop
repres
downregul
interleukin
il
product
well
develop
repres
downregul
interferon
ifn
product
howev
unlik
ldc
treat
betamethason
treat
tacrolimu
inhibit
cell
develop
inhibit
cell
cell
develop
betamethason
associ
suppress
express
respect
ldc
conclus
result
suggest
topic
applic
betamethason
lesion
skin
would
benefici
control
atop
dermat
act
epiderm
lc
inhibit
develop
cell
work
kasliwa
et
al
shivpuri
et
al
prove
beyond
doubt
definit
correl
pollen
peak
symptomatolog
patient
respiratoti
allergi
factor
mind
present
studi
conduct
aim
clinic
evalu
case
bronchial
asthma
know
spectrum
allergen
skin
test
case
intraderm
skin
test
find
season
climat
variat
case
patient
prepar
intraderm
skin
test
per
shivpuri
et
al
intraderm
skin
test
perform
mean
tuberculin
syring
gaug
length
short
bevel
needl
neg
control
test
done
similar
manner
buffer
salin
diluent
antigen
mark
c
posit
control
test
done
histamin
phosphat
solut
microgramml
mark
h
interpret
done
per
shivpuri
criteria
reaction
taken
markedli
posit
studi
show
preval
allerg
manifest
higher
first
degre
rel
second
degre
rel
patient
studi
pollen
antigen
gave
signific
posit
reaction
clinic
correl
patient
histori
descend
order
signific
cassiasiamea
adhantoda
moru
parthenium
artemesia
argemonemaxicana
cannabisoccidentali
rumex
asphodel
gynandropsi
amaranthu
cenchrusalbum
ricinuscommuni
crataeva
nurvuala
melia
kigelia
prosopsi
pennisetum
dodonaea
azadirechta
putranjiva
roxburghii
extens
botan
aerobiolog
survey
clinic
evalu
largr
number
case
aller
bronchial
asthma
carri
futur
order
draw
exact
polen
calend
region
introduct
attent
deficithyperact
disord
one
common
problem
children
adolesc
common
reason
visit
pediatr
psychologist
consult
disord
profound
effect
live
thousand
children
famili
manifest
earli
childhood
symptom
hyper
activ
inattent
impuls
studi
conduct
western
countri
point
associ
adhd
symptom
asthma
asthmat
children
also
respons
asthma
treatment
children
adhd
poor
studi
perform
aim
evalu
preval
adhd
children
refer
clinic
kashan
beheshti
hospit
materi
method
case
control
studi
children
refer
pediatr
clinic
kashan
beheshti
hospit
second
half
evalu
spirometeri
peak
flow
meteri
use
diagnosi
adhd
use
spss
softwar
version
chi
squar
test
fisher
exact
test
result
found
preval
adhd
children
asthma
signific
higher
control
group
increas
risk
five
fold
also
found
adhd
signific
correl
sever
asthma
conclus
found
asthma
one
risk
factor
develop
adhd
adhd
relat
sever
asthma
morbid
keyword
attent
deficithyperact
disord
asthma
background
stevenjohnson
syndrom
sj
children
caus
infect
thypoid
one
bacteri
etiolog
case
report
yearsold
boy
main
complaint
blister
bodi
fever
weak
condit
lip
ulcer
erythemat
swollen
cover
pseudomembran
hemorrhag
crust
prurit
hyperpig
plaqu
papilovesicular
erupt
center
bullou
target
lesion
cover
almost
whole
bodi
also
macula
erythemat
vesicl
ulcer
extern
genit
scrotum
suffer
blister
sinc
day
admiss
lesion
appear
first
face
mouth
spread
whole
bodi
mucosa
mouth
lip
ulcer
difficulti
swallow
medic
treatment
doctor
day
ill
red
blotch
vesicl
appear
bodi
sore
throat
oral
thrush
admit
hospit
day
condit
get
wors
came
hospit
widal
test
result
assess
sj
suspect
typhoid
fever
treatment
support
ceftriaxon
corticosteroid
patient
discharg
good
condit
summari
thypoid
one
sj
bacteri
etiolog
children
diagnosi
establish
clinic
examin
serolog
epidemiologicallypreval
probabl
infect
countri
area
antibiot
requir
sj
caus
infect
background
nonimmedi
reaction
induc
radio
contrast
media
rcm
import
health
problem
nearli
patient
suspect
nonimmedi
reaction
rcm
confirm
allerg
gomez
e
et
al
curr
opin
clin
immunol
case
record
femal
brought
emerg
depart
chief
complaint
hemoptysi
one
day
transient
dri
cough
past
medic
histori
includ
current
smoke
packperyear
acut
hypersensit
reaction
nicotin
receptor
partial
agonist
valeniclin
epilepsi
phenytoin
phenobarbitur
pollinosi
bodi
temperatur
f
blood
oxygen
satur
room
air
crackl
stridor
wheez
audibl
contrast
chest
comput
tomographi
show
atelectasi
left
lower
lobe
carven
lesion
pulmonari
arterioven
fistula
racemos
hemangioma
bronchoscopi
detect
thrombu
left
lower
lobe
mycobacterium
avium
intracellular
tuberculosi
neg
bronchoalveolar
lavag
fluid
specif
immunofluoresc
tuberculosi
also
neg
serum
test
thoroughli
neg
scc
cyfra
progrp
nse
mpoanca
aspergillu
ana
dsdnaigg
antirnp
antism
antigbm
antibodi
clinic
diagnosi
chronic
bronchiti
made
find
describ
pruritu
exanthema
trunk
oneandahalf
day
contrast
media
iomeprol
infus
dona
et
al
j
investig
allergi
clin
imunol
disappear
sever
day
bepotastin
besil
administr
discuss
global
initi
asthma
gina
step
hypothes
patient
treat
gina
step
report
risk
develop
acut
hypersensit
reaction
compar
patient
asthma
kobayashi
et
al
chest
conclus
pharmacogenet
andor
transcriptom
help
clarifi
tcell
mediat
mechan
develop
rcm
hypersensit
reaction
fernandez
td
et
al
allergi
purpos
asthma
one
common
allerg
diseas
depress
import
comorbid
asthma
howev
littl
known
differ
preval
depress
korean
adult
asthmat
normal
adult
studi
perform
find
associ
asthma
depress
investig
characterist
korean
adult
asthmat
depress
method
data
acquir
men
women
age
older
year
particip
fifth
korea
nation
health
nutrit
examin
survey
knhane
conduct
presenc
asthma
base
selfreport
physician
diagnosi
asthma
health
interview
survey
result
preval
asthma
depress
univari
analysi
adult
asthma
older
singl
unemploy
low
educ
lower
monthli
famili
incom
lower
household
member
obes
p
sex
resid
area
smoke
statu
associ
presenc
asthma
preval
hypertens
depress
higher
asthmat
p
diabet
mellitu
associ
asthma
adjust
age
marit
statu
number
household
member
monthli
famili
incom
bodi
mass
index
hypertens
found
unemploy
lower
educ
statu
depress
associ
higher
preval
asthma
p
depress
associ
femal
unemploy
associ
lung
function
asthmat
conclus
present
studi
show
depress
import
risk
factor
preval
asthma
korean
adult
result
warrant
futur
studi
explor
mechan
respons
associ
depress
asthma
introduct
allerg
diseas
exacerb
affect
matern
fetal
condit
pregnanc
allerg
diseas
exacerb
may
trigger
pregnanc
complic
lifethreaten
event
mother
fetu
eventu
predispos
risk
sever
damag
report
case
matern
allerg
diseas
exacerb
food
allergi
fa
anaphylaxi
bronchial
asthma
ba
atop
dermat
ad
allerg
rhiniti
ar
atop
erupt
pregnanc
aep
manag
discuss
case
report
femal
week
gestat
medic
histori
ba
childhood
ad
ar
fa
refer
otolaryngologist
persist
moderatetosever
asthma
symptom
sever
ar
introduc
longact
plu
inhal
corticosteroid
short
term
oral
methylprednisolon
nasal
corticosteroid
femal
week
gestat
medic
histori
ad
without
histori
fa
anaphylaxi
brought
emerg
depart
dyspnea
gener
itchi
rash
abdomin
pain
sever
uterin
contract
eaten
dinner
diagnos
anaphylaxi
threat
abort
immedi
treat
epinephrin
im
inject
time
obsterician
disclos
buckwheat
allergi
caus
anaphylaxi
femal
week
gestat
medic
histori
ad
refer
obsterician
sever
ad
ar
stop
medic
pregnanc
develop
sever
ad
ar
introduc
local
corticosteroid
nasal
corticosteroid
femal
week
gestat
medic
histori
ar
ad
childhood
came
hospit
sever
itchi
hive
arm
bodi
diagnos
aep
introduc
use
local
corticosteroid
mother
condit
improv
immedi
baibi
case
normal
deliv
without
neurolog
defici
congenit
malform
discuss
allerg
diseas
exacerb
may
common
event
pregnanc
reduc
matern
qol
even
develop
potenti
risk
pregnanc
complic
lifethreaten
event
mother
fetu
sever
fetal
brain
damag
prevent
situat
promot
appropri
therapi
educ
allerg
diseas
encourag
mother
keep
allerg
medic
pregnanc
prepregn
period
investig
toward
pharmacolog
manag
allerg
diseas
necessari
keep
pregnant
women
newborn
healthi
subcutan
immunotherapi
scit
clinic
effect
treatment
atop
dermat
howev
mous
model
understand
mechan
hous
dust
mite
immunotherapi
atop
dermat
aim
studi
establish
mous
model
scit
mous
model
hous
dust
mite
induc
atop
dermat
femal
ncnga
mice
treat
dermatophagoid
farina
dfarina
bodi
extract
ointment
week
induc
atop
dermat
like
skin
lesion
separ
mice
group
control
group
immunotherapi
group
group
continu
treat
dfarina
bodi
extract
ointment
week
howev
immunotherapi
group
treat
inject
dfarina
ug
subcutaneous
twice
week
along
dfarina
bodi
extract
ointment
treatment
subsequ
clinic
sever
skin
lesion
histolog
featur
total
ige
measur
observ
adlik
skin
lesion
group
milder
control
group
histolog
examin
epidermi
thinner
group
control
group
level
total
ige
decreas
group
control
group
week
begin
immunotherapi
level
remark
increas
group
control
group
begin
immunotherapi
increas
level
group
observ
week
begin
immunotherapi
control
group
howev
signific
differ
group
control
group
present
studi
establish
hous
dust
mite
scit
mous
model
demonstr
hous
dust
mite
scit
might
improv
atop
dermatitislik
skin
lesion
decreas
total
ige
increas
use
model
possibl
find
novel
way
potenti
effect
allergen
immunotherapi
background
concern
among
physician
posit
histori
advers
reaction
drug
andor
atop
diseas
remain
risk
factor
develop
hypersensit
reaction
local
anesthet
la
object
present
studi
aim
allergi
test
la
justifi
patient
posit
histori
hypersensit
reaction
drug
addit
atopi
atop
diseas
method
studi
conduct
among
patient
admit
allergi
clinic
gave
reliabl
histori
urticariaangioedema
nasoocular
symptom
bronchospasm
ingest
drug
standard
questionnair
regard
demograph
data
histori
atop
diseas
asthma
allerg
rhiniti
atop
dermat
urticaria
fill
total
ige
eosinophil
count
asses
patient
skin
prick
test
spt
intraderm
test
idt
subcutaneu
increment
challeng
test
ict
perfom
step
step
adrenalin
free
lidokain
prilokain
result
patient
women
histori
drug
allergi
admit
asthma
preval
atopi
rate
mean
total
ige
level
found
higher
studi
look
result
skin
test
provoc
la
posit
result
spt
werent
found
idt
ict
posit
patient
react
la
rhinosinus
posit
spt
reaction
aeroallergen
patient
also
food
allergi
patient
asthma
although
eosinofil
count
normal
patient
high
level
total
ig
e
conclus
increas
risk
requir
perform
skin
provoc
test
la
patient
histori
hypersensit
reaction
drug
alon
addit
presenc
atopi
atop
diseas
multidrug
allergi
histori
increas
risk
la
allergi
amount
evid
scarc
background
well
known
atop
dermat
ad
relat
food
hypersensit
although
preval
vari
among
sever
studi
object
examin
preval
statu
food
hypersensit
among
ad
patient
korea
method
histori
food
hypersensit
collect
interview
took
blood
sampl
examin
foodspecif
immunoglobulin
e
ige
level
base
patient
histori
serum
ige
level
open
oral
food
challeng
ofc
test
perform
result
childhood
ad
patient
adult
ad
patient
histori
food
hypersensit
common
suspici
food
childhood
ad
egg
pork
cow
milk
adult
ad
patient
common
suspici
food
instant
food
wheat
ramen
beef
pork
chocol
accord
open
ofc
test
nine
childhood
patient
show
posit
respons
common
offend
food
egg
milk
follow
pork
beef
peanut
adult
ad
patient
one
patient
show
posit
respons
pork
conclus
overal
preval
food
hypersensit
childhood
ad
patient
adult
ad
patient
assess
open
ofc
test
number
patient
actual
food
hypersensit
lower
number
patient
report
histori
food
hypersensit
therefor
dietari
restrict
must
conduct
confirm
food
hypersensit
medic
profession
background
index
patient
ant
allergi
rare
compar
bee
allergi
anaphylaxi
caus
brachyponera
chinensi
sporad
report
far
east
nation
experienc
case
otherwis
healthi
woman
develop
anaphylact
reaction
public
openair
bath
five
minut
ant
stung
hip
fell
experienc
diarrhea
dyspnea
urticaria
transfer
hospit
recov
catecholamin
antihistamin
later
ant
name
brachyponera
chinensi
emeri
often
refer
pachycondyla
chinensi
caught
place
specif
ige
venom
protein
detect
serum
first
case
specif
ige
ant
venom
prove
vitro
japan
b
method
explor
medlin
japanes
databas
seek
literatur
written
english
japanes
anaphylact
case
ant
japan
investig
natur
c
result
includ
present
case
case
age
male
femal
anaphylaxi
ant
site
report
japan
sinc
number
ant
sting
onset
anaphylaxi
interv
ant
sting
onset
anaphylaxi
case
less
minut
except
case
without
descript
case
onset
two
hour
ant
sting
symptom
includ
wheal
urticaria
diarrhea
dyspnea
hypotens
diagnosi
causal
relationship
ant
sting
anaphylaxi
establish
mainli
base
tempor
order
patient
doctor
charg
caught
ant
day
later
enabl
determin
ant
speci
case
ant
identifi
b
chinensi
proof
ige
antibodi
ant
protein
done
skin
prick
test
case
present
case
first
japanes
case
ige
antibodi
b
chinensi
protein
directli
prove
epinephrin
use
case
antihistamin
glucocorticoid
use
case
good
prognosi
patient
prior
histori
ant
sting
one
ant
sting
longest
interv
last
prior
sting
trigger
sting
month
notabl
patient
includ
case
prior
sting
year
month
suggest
second
sting
might
booster
effect
crossreact
bee
venom
seen
case
case
mention
one
case
ige
antibodi
paper
wasp
posit
without
obviou
former
sting
case
histori
anaphylaxi
wasp
sting
conclus
ant
allergi
rare
natur
similar
bee
allergi
lee
ek
jeong
ky
lyu
dp
lee
yw
sohn
jh
lim
kj
hong
cs
park
jw
character
major
allergen
pachycondyla
chinensi
ant
sting
anaphylaxi
patient
clin
exp
allergi
object
involv
sever
step
allerg
cascad
aim
find
novel
gene
significantli
induc
allerg
individu
significantli
downregul
treatment
method
thirtysix
mice
alloc
group
intraperiton
sensit
intranas
challeng
salin
group
b
sensit
challeng
ovalbumin
group
c
null
treatment
intraperiton
salin
group
intraperiton
inject
check
number
nosescratch
behavior
minut
serum
ovalbuminspecif
ige
titer
cytokin
bronchoalveolar
lavag
fluid
use
one
whole
lung
tissu
mous
perform
microarray
analysi
realtim
pcr
result
group
show
significantli
reduc
number
nosescratch
lower
serum
ovalbuminspecif
ige
cytokin
bronchoalveolar
lavag
fluid
significantli
decreas
treatment
microarray
analysi
group
b
immunoglobulin
free
light
chain
igflc
time
nitric
oxid
synthas
time
group
c
igflc
time
time
significantli
increas
express
igflc
gene
compar
group
treatment
group
show
significantli
decreas
express
igflc
time
time
realtim
pcr
group
b
igflc
time
time
group
c
igflc
time
time
significantli
increas
express
gene
treatment
group
show
significantli
decreas
express
igflc
time
time
conclus
antiallerg
effect
could
explain
suppress
igflc
murin
model
allerg
rhiniti
asthma
keyword
asthma
anim
model
immunoglobulin
background
etiolog
chronic
urticaria
cu
remain
unknown
patient
possibl
caus
case
includ
food
role
hypersensit
food
antigen
patient
cu
remain
controversi
object
aim
studi
evalu
associ
food
hypersensit
cu
korean
particip
method
patient
cu
assess
previou
histori
food
hypersensit
caus
symptom
cu
blood
sampl
taken
patient
measur
food
allergenspecif
ige
base
histori
laboratori
result
open
oral
food
challeng
ofc
test
perform
result
particip
claim
experienc
previou
food
hypersensit
pork
main
food
mention
follow
beef
shrimp
mackerel
found
particip
elev
level
foodspecif
ige
pork
wheat
beef
common
howev
open
ofc
test
conduct
particip
selfreport
food
hypersensit
rais
level
foodspecif
ige
four
particip
show
posit
reaction
pork
conclus
although
particip
claim
histori
cu
relat
food
intak
open
ofc
test
conduct
posit
result
therefor
conclud
food
allergi
uncommon
caus
chronic
cu
background
clinic
efficaci
depig
polymer
phleum
pollen
extract
shown
one
larg
phase
iii
studi
dppml
date
doserespons
studi
requir
show
optim
efficaci
allergen
dose
conjunctiv
provoc
test
cpt
outcom
paramet
accept
regulatori
author
ema
method
itt
patient
confirm
rhiniti
andor
rhinoconjunct
treat
doubleblind
studi
dose
dppml
dppml
dppml
dppml
allergen
extract
week
germani
poland
spain
czech
republ
buildup
phase
appli
ml
time
ml
extract
follow
mainten
period
appli
ml
week
interv
treatment
cpt
perform
increas
dose
hepml
nativ
phleum
extract
treatment
cpt
repeat
dose
hepml
primari
endpoint
paramet
percentag
patient
increas
allergen
extract
provok
posit
cpt
allergen
immunotherapi
ait
secondari
paramet
specif
ige
vitamin
baselin
level
well
safeti
primari
endpoint
paramet
investig
use
hierarch
test
procedur
compar
highest
dose
lowest
statist
signific
test
next
lower
dose
lowest
differ
longer
signific
result
respond
rate
dppml
dppml
group
respect
itt
dppml
dppml
group
respect
differ
dppml
group
dppml
group
dppml
group
dppml
group
itt
statist
signific
differ
found
pp
set
similar
result
observ
vitamin
baselin
result
low
group
influenc
result
specif
ige
remain
stabl
group
wherea
specif
show
dosedepend
increas
system
reaction
occur
dppml
dppml
dppml
dppml
patient
sr
grade
grade
grade
reaction
occur
dppml
group
conclus
determin
increas
allergen
amount
obtain
posit
cpt
ait
dppml
depig
polymer
phleum
pollen
extract
sinc
cpt
result
discrimin
differ
dose
dosefind
studi
repeat
differ
assess
method
background
food
allergen
play
pivot
role
manifest
atop
disord
like
asthma
rhiniti
eczema
children
cell
play
key
role
regul
inflammatori
diseas
studi
base
role
food
allerg
children
method
fifti
children
respiratori
allergi
histori
worsen
symptom
food
allergi
patient
group
nonatop
healthi
children
control
group
enrol
studi
food
allergi
assess
skin
prick
test
spt
variou
food
allergen
total
ige
level
determin
sandwich
elisa
depend
cytokin
determin
flow
cytometr
bead
array
result
studi
group
children
found
posit
cutan
hypersensit
variou
food
allergen
milk
banana
fish
averag
level
total
ige
studi
group
iuml
signific
posit
correl
total
ige
p
r
level
neg
correl
r
p
r
p
level
neg
correl
note
durat
breast
feed
total
ige
level
conclus
studi
demonstr
posit
correl
total
ige
cytokin
cytokin
also
demonstr
durat
breast
feed
significantli
correl
total
ige
polyketid
antibiot
includ
macrolid
known
affect
signal
pathway
transcript
factor
regul
number
gene
involv
potenti
antiinflammatori
effect
properti
use
clinic
set
due
risk
bacteri
resist
aim
studi
assess
effect
colabomycin
e
new
streptomycetederiv
secondari
metabolit
mrna
express
releas
proinflammatori
cytokin
chemokin
monocytemacrophag
cell
line
peripher
blood
monocyt
colabomycin
e
isol
purifi
natur
produc
streptomyc
aureu
extract
postferment
media
mycelia
organ
solvent
multipl
subsequ
liquid
chromatographi
purif
step
crystal
monocytesmacrophag
cultur
fetal
calf
serum
stimul
serum
free
condit
presenc
absenc
colabomycin
e
total
mrna
extract
cultur
monocytesmacrophag
rnaeasi
plu
mini
kit
qiagen
quantit
rtpcr
sabiosci
use
evalu
differ
gene
express
tnf
alpha
colabomycin
e
stimul
cultur
compar
unstimul
cell
concentr
cytokin
chemokin
cultur
supernat
monocyt
cell
measur
elisa
luminex
cell
colabomycin
e
inhibit
tnf
alpha
induc
mrna
express
sever
proinflammatori
gene
includ
effect
evid
cultur
gene
persist
furthermor
colabomycin
e
downregul
tnf
alpha
induc
chemokin
releas
dose
depend
manner
concentr
secret
cell
slightli
upregul
tnf
alpha
affect
colabomycin
e
data
suggest
colabomycin
e
potent
transcript
inhibitor
proinflammatori
cytokin
human
mononuclear
phagocyt
support
iga
mzcr
grant
mh
cz
dro
institut
clinic
experiment
medicin
ikem
refer
petrickova
k
et
al
chembiochem
atop
dermat
ad
one
common
dermatolog
diseas
affect
approxim
children
live
industri
countri
moreov
approxim
case
ad
affect
children
less
year
age
case
ad
effect
treat
topic
steroid
topic
calcineurin
inhibitor
intermitt
use
immunosuppress
agent
includ
oral
corticosteroid
cyclosporin
howev
recalcitr
ad
continu
use
system
immunosuppress
agent
limit
sever
advers
effect
especi
children
subgroup
patient
studi
test
system
immunomodulatori
drug
report
highdos
intraven
immunoglobulin
ivig
therapi
also
intermitt
report
effect
without
strong
evid
herein
report
case
intract
atop
dermat
girl
signific
clinic
improv
receiv
cycl
ivig
treatment
gkg
without
notabl
side
effect
sinc
first
infus
ivig
patient
skin
lesion
improv
steadili
improv
persist
followup
easi
score
decreas
remark
immunolog
paramet
correl
clinic
improv
ivig
monotherapi
consid
especi
use
children
sever
ad
sinc
immunoregulatori
function
profound
rel
immatur
immun
system
children
mechan
action
immunoglobulin
may
includ
cytolysi
target
cell
complement
antibodydepend
cellmedi
cytotox
induct
apoptosi
target
cell
blockad
costimulatori
molecul
neutral
pathogen
antibodi
solubl
factor
cytokin
receptor
ultim
lead
amelior
inflammatori
process
case
suggest
ivig
therapi
quit
effect
safe
children
resist
atop
dermat
background
wheat
allergi
common
children
adultsskin
prick
test
wheat
specif
ige
test
low
specif
valu
wheat
allergen
challeng
test
done
confirm
wheat
allergyit
notic
patient
wheat
allergi
reaction
may
occur
late
normal
food
allergen
challeng
maximum
number
reaction
found
within
one
hour
food
challeng
other
second
hour
wheat
allergen
challeng
less
number
reaction
occur
first
hour
follow
second
hour
rest
occur
hour
test
object
see
wheather
wheat
challeng
test
delay
respons
patient
wheat
allergi
method
databas
patient
wheat
allergi
attend
ent
allergi
centr
india
panchkula
retrospect
studi
wheat
allergi
patient
last
year
observ
patient
suspect
wheat
allergi
put
wheat
challeng
tesrt
posit
still
conclus
neg
wheat
allergi
challeng
test
patient
show
reaction
hour
patient
react
hour
reaction
occur
hour
conclus
wheat
allergi
patient
need
know
reaction
occur
even
hour
challeng
comparison
reallergen
reaction
occur
st
hour
challeng
background
antiinflammatori
effect
spirulina
demonstr
inhibit
histamin
releas
mast
cellmedi
allerg
reaction
studi
document
antiinflammatori
immunomodulatori
properti
supplement
adjunct
therapi
asthma
b
method
random
doubleblind
placebocontrol
studi
wherein
children
year
old
diagnos
mild
moder
persist
asthma
randomli
assign
receiv
either
spirulina
mg
mg
daili
placebo
three
month
asthma
control
test
act
composit
asthma
sever
index
casi
use
patient
reportbas
measur
forc
expiratori
volum
second
forc
vital
capac
fvc
peak
expiratori
flow
rate
pefr
determin
spirometri
postsupplement
assess
three
month
done
c
result
total
patient
spirulina
placebo
enrol
trial
supplement
phase
spirulina
placebo
group
show
signific
improv
act
score
spirulina
p
placebo
p
compar
baselin
signific
chang
casi
score
group
howev
postsupplement
phase
spirulina
group
show
significantli
sustain
improv
act
p
casi
score
p
compar
placebo
p
fvc
p
pefr
p
spirulina
group
significantli
improv
end
supplement
overal
signific
intergroup
differ
reveal
p
pefr
p
conclus
daili
supplement
spirulina
significantli
improv
asthma
control
pefr
compar
placebo
background
case
dermat
inject
certain
drug
report
advers
reaction
drug
present
variou
featur
like
eczematoid
patch
urticari
lesion
object
aim
studi
assess
caus
clinicopatholog
find
injectioninduc
dermat
reveal
whether
reaction
relat
age
site
concentr
drug
time
interv
inject
drug
occurr
skin
lesion
method
studi
enrol
patient
erythemat
skin
lesion
inject
caus
drug
lesion
compar
base
site
time
interv
inject
drug
occurr
skin
lesion
clinic
characterist
perforem
intraderm
test
patch
test
patient
differ
concentr
caus
drug
result
common
caus
drug
diclofenac
vitamin
eczemat
type
frequent
clinic
featur
intraderm
test
show
posit
result
patch
test
patch
test
diclofenac
vitamin
neg
patient
intraderm
test
diclofenac
vitamin
perform
patient
six
patient
posit
reaction
consist
erythema
indur
vesicul
day
conclus
result
common
caus
agent
found
diclofenac
vitamin
seem
intraderm
test
use
diagnosi
injectioninduc
dermat
background
sting
asian
needl
ant
import
caus
anaphylaxi
east
asia
protein
homolog
antigen
major
allergen
produc
ant
studi
aim
produc
recombin
allergen
method
recombin
allergen
asian
needl
ant
express
pichia
pastori
purifi
ammonium
sulfat
precipit
niaffin
chromatographi
ige
reactiv
demonstr
elisa
immunoblot
result
recombin
protein
recogn
serum
sampl
patient
demonstr
anaphylaxi
ant
ige
reactiv
allergen
venom
sac
extract
specif
inhibit
recombin
protein
conclus
recombin
allergen
asian
needl
ant
success
produc
methylotroph
yeast
p
pastori
protein
could
use
develop
componentresolv
diagnost
background
anaphylact
reaction
urticaria
edema
respiratori
symptom
anaphylact
shock
often
complic
cours
cystic
echinococcosi
ce
method
investig
role
ige
immunoreact
antigen
ag
seroposit
patient
ce
determin
ntermin
kda
subunit
respons
ige
ctermin
activ
antigen
relat
induct
igg
specif
result
immunoblot
analysi
show
specif
ige
kda
subunit
relat
interchain
disulphid
band
two
kda
kda
compon
conform
epitop
subunit
addit
sinc
compon
aris
remov
ctermain
portion
subunit
ag
thu
ige
specif
recogn
ntermin
kda
subunit
remain
bound
compon
wherea
igg
react
ctermin
kda
compon
conclus
recognit
specif
bind
site
subunit
lead
understand
regul
mechan
igeigg
product
immun
circumst
ige
tend
domin
wherea
igg
predomin
background
asthma
one
common
chronic
diseas
worldwid
grow
public
health
concern
character
chronic
bronchial
inflamm
multifactori
etiolog
includ
genet
immunolog
environment
factor
goal
develop
patientcustomiz
asthma
forecast
system
take
account
meteorolog
factor
air
pollut
pollen
viral
respiratori
infect
common
environment
factor
known
exacerb
asthma
method
analyz
health
insur
record
patient
visit
emerg
depart
seoul
due
asthma
attack
treat
salbutamol
potenti
predictor
asthma
symptom
includ
meteorolog
factor
temperatur
humid
air
pressur
amount
sunshin
air
pollut
factor
ozon
asian
yellow
dust
environment
factor
pollen
healthrel
factor
season
influenza
viral
infect
patient
assign
five
age
group
separ
accord
gender
season
group
result
total
group
three
model
multipl
regress
model
logist
regress
model
decis
tree
test
abil
predict
exacerb
asthma
symptom
refer
attent
symptom
suitabl
final
model
assess
use
predict
skill
score
result
logist
regress
decis
tree
provid
best
forecast
use
estim
binari
valu
continu
manag
versu
attent
symptom
optim
threshold
select
conclus
binari
forecast
model
may
improv
predict
asthma
exacerb
clinic
set
background
nasal
polyp
result
chronic
inflamm
upper
airway
develop
ethmoid
middl
turbin
area
character
presenc
number
inflammatori
cell
result
infiltr
eosinophil
cell
mast
cell
macrophag
nasal
mucos
immunereact
may
occur
vari
degre
accompani
polyp
allerg
nonallerg
rhiniti
rant
local
produc
within
nasal
microenviron
polyp
may
respons
eosinophil
recruit
tumor
necrosi
along
cytokin
may
stimul
nasal
polyp
fibroblast
produc
inflammatori
mediat
evalu
differ
level
rant
nasal
polyp
adolesc
allerg
nonallerg
rhiniti
goal
figur
pathogenesi
allerg
local
allerg
nonallerg
rhiniti
evalu
differ
level
rant
nasal
polyp
serum
method
recruit
total
adolesc
allerg
rhiniti
ar
mean
age
yr
old
local
allerg
rhiniti
lar
mean
age
yr
old
nonallerg
rhiniti
nar
mean
age
yr
old
undergo
polypectomi
atop
statu
defin
present
suffici
high
total
ige
serum
concentr
ige
iuml
posit
skin
prick
test
serum
allergen
test
mast
green
cross
ms
seoul
korea
immunocap
system
pharmacia
uppsala
sweden
immunoassay
perform
use
polyp
tissu
homogen
sera
quantifi
level
rant
sera
assess
total
ige
eosinophil
cation
protein
ecp
produc
result
rant
level
higher
lar
nar
signific
differ
ar
nar
level
higher
ar
lar
nar
level
differ
significantli
correl
concentr
rant
polyp
tissu
homogen
serum
p
also
demonstr
posit
correl
concentr
polyp
tissu
homogen
serum
howev
signific
conclus
rant
level
higher
polyp
tissu
homogen
lar
nar
therefor
rant
probabl
involv
pathogenesi
lar
level
higher
polyp
tissu
homogen
sera
ar
lar
nar
probabl
play
import
role
pathogenesi
ar
lar
background
vitamin
receptor
vdr
intracellulari
locat
cell
immun
system
involv
immun
respons
develop
allerg
inflamm
control
differ
gene
includ
gene
vdr
aim
investig
level
children
food
allergi
differ
variant
vdr
gene
polymorph
materi
method
examin
infant
allerg
diseas
age
month
artifici
feed
measur
level
perform
immunoenzym
method
rtpcr
melt
curv
analysi
use
taqi
bsmi
foki
vdr
singl
nucleotid
polymorph
snp
detect
statist
analysi
kruskalw
posthoc
test
use
result
frequenc
allel
homozyg
aa
heterozyg
ga
genotyp
vdr
gene
site
bsmi
significantli
increas
children
allerg
diseas
compar
popul
p
p
p
respect
significantli
decreas
serum
level
carrier
variant
ag
gg
compar
variant
aa
carrier
foki
site
aa
vs
ag
vs
gg
pgml
reveal
statist
signific
differ
serum
level
taqi
bsmi
site
vdr
gene
detect
conclus
foki
site
vdr
gene
polymorph
may
indirectli
influenc
synthesi
allergi
diseas
develop
background
immunolog
evalu
differ
diet
therapi
type
children
food
allergi
current
requir
goat
milk
formula
often
use
diet
therapi
children
food
allergi
aim
investig
dynam
immunolog
biomark
children
food
allergi
wich
use
goat
milk
formula
supplement
materi
method
examin
infant
food
allergi
age
month
artifici
feed
use
goat
milk
formula
dynam
immunoregulatori
substanc
allergenspecif
ige
igg
antibodi
cow
milk
protein
casein
soy
goat
milk
measur
immunoenzim
method
observ
durat
day
result
dynam
immunolog
biomark
character
decreas
level
allergenspecif
igg
antibodi
cow
milk
protein
fraction
reduc
level
allergenspecif
ige
antibodi
cow
milk
protein
reduct
level
chang
correl
clinic
food
allergi
symptom
reduct
conclus
assess
allergenspecif
igg
antibodi
cow
milk
protein
fraction
allergenspecif
ige
antibodi
cow
milk
protein
use
immunolog
evalu
effect
goat
milk
formula
supplement
background
whether
obes
risk
factor
atop
dermat
ad
remain
unclear
aim
studi
investig
associ
obes
ad
korean
young
adult
method
includ
nation
repres
data
korean
adult
age
year
obtain
crosssect
korea
nation
health
nutrit
examin
survey
result
ad
preval
exhibit
ushap
trend
relat
bodi
mass
index
bmi
waist
circumfer
wc
total
bodi
fat
bf
percentag
especi
young
adult
women
women
bmi
wc
cm
highest
quartil
total
bf
percentag
highest
preval
ad
odd
ratio
particip
bmi
wc
cm
confid
interv
ci
therefor
gener
abdomin
obes
consid
promin
risk
factor
ad
young
women
adjust
confound
factor
includ
age
smoke
alcohol
drink
exercis
vitamin
level
high
bmi
ci
high
wc
cm
ci
high
bf
percentag
ci
shown
significantli
associ
ad
young
adult
women
conclus
largescal
nationwid
studi
korean
adult
obes
posit
relat
presenc
ad
women
find
suggest
weight
manag
might
help
prevent
ad
background
asthma
influenc
natur
environment
factor
associ
still
inconsist
object
aim
explor
associ
natur
histori
environment
factor
asthma
urban
rural
children
china
method
questionnair
survey
perform
children
urban
guangzhou
rural
conghua
subsampl
children
guangzhou
conghua
recruit
casecontrol
studi
includ
detail
questionnair
natur
famili
histori
environment
exposur
eat
behavior
histamin
airway
provoc
allergen
skin
prick
test
serum
antibodi
analysi
hous
dust
sampl
guangzhou
conghua
famili
obtain
analyz
level
endotoxin
hous
dust
mite
cockroach
allergen
result
preval
doctordiagnosedasthma
lower
children
conghua
guangzhou
p
screen
survey
lower
percentag
confirm
asthma
vs
sensit
vs
found
rural
urban
subject
p
nest
casecontrol
studi
parent
allergi
antibiot
usag
high
frequenc
milk
consumpt
increas
level
hous
dust
der
f
posit
associ
confirm
asthma
p
breastfeed
rais
dog
level
hous
dust
endotoxin
neg
associ
confirm
asthma
p
conclus
parent
allergi
earli
antibiot
administr
high
frequenc
milk
intak
level
der
f
exposur
might
risk
factor
asthma
breastfeed
dog
ownership
endotoxin
exposur
protect
background
preval
allerg
diseas
increas
result
exposur
environment
pollut
aeroallergen
exposur
associ
allerg
rhiniti
asthma
pollen
long
known
signific
caus
allerg
diseas
pollen
heavili
pollut
zone
express
larger
amount
protein
describ
allergen
presenc
high
concentr
temperatur
plant
increas
pollen
output
method
ragwe
establish
chamber
studi
ten
plant
ragwe
establish
opentop
chamber
differ
concentr
field
studi
begin
march
rural
pocheon
kyunggido
annual
mean
urban
kangnam
seoul
annual
mean
locat
establish
seed
common
ragwe
ambrosia
artemisiifolia
giant
ragwe
trifida
obtain
daejin
univers
common
seed
lot
ragwe
final
harvest
entir
plant
collect
determin
qualit
chang
pollen
harvest
pollen
grain
suspend
ethanol
crude
solubl
pollen
protein
prepar
store
protein
content
extract
quantifi
concentr
allergen
common
ragwe
amb
giant
ragwe
amb
quantifi
use
doubl
sandwich
elisa
result
chamber
studi
chamber
studi
concentr
amb
increas
increas
conc
ngml
concentr
amb
increas
increas
conc
ngml
field
studi
significantli
differ
pocheon
seoul
conc
amb
also
pocheon
seoul
conc
amb
though
conc
amb
amb
increas
seoul
pocheon
conclus
increas
significantli
influenc
allergen
pollen
concentr
common
ragwe
chamber
field
studi
elementari
exampl
given
demonstr
strong
probabl
link
rise
level
increas
allerg
diseas
suggest
urban
might
provid
altern
current
experiment
method
evalu
plant
respons
climat
chang
keyword
allergen
plant
aeroallergen
allergen
environment
control
object
observ
dynam
chang
specif
ige
sige
specif
hous
dust
mite
includ
dermatophagoid
pteronyssinu
der
p
main
compon
der
der
specif
immunotherapi
sit
evalu
effect
applic
clinic
monitor
desensit
method
studi
observ
immun
index
children
patient
includ
serum
sige
five
period
pre
sit
pre
sit
half
year
year
year
patient
convent
drug
treatment
collect
control
group
result
half
year
sit
level
serum
sige
der
p
der
der
increas
continu
howev
began
declin
three
year
treatment
level
sige
der
der
reduc
step
step
particularli
sige
der
significantli
lower
pre
treatment
level
der
p
der
der
increas
significantli
along
process
sit
increas
rang
der
p
reach
maximum
follow
der
der
ratio
three
allergen
decreas
sit
biggest
drop
degre
ratio
der
low
age
group
children
respons
immun
higher
faster
high
age
group
children
sit
level
compon
der
der
elev
faster
der
p
conclus
earli
stage
treatment
level
der
p
der
der
sige
serum
bodi
state
immun
stimul
significantli
increas
sit
level
sige
gradual
decreas
level
increas
name
ratio
reduc
gradual
biggest
declin
sige
ratio
der
fastest
degre
sit
reaction
low
age
children
allergi
object
purpos
studi
evalu
effect
asian
dust
event
asthma
socioeconom
statu
use
claim
data
method
case
crossov
design
use
studi
base
nation
health
insur
claim
icd
air
pollut
co
ppb
ppb
ppb
ppb
climat
temperatur
humid
visibl
km
wind
speed
ms
air
pressur
hpa
data
seoul
incheon
korea
socioeconom
statu
classifi
health
insur
group
medic
aid
group
daili
maximum
valu
air
pollut
daili
averag
climat
calcul
daili
number
asthma
case
event
day
compar
control
day
select
event
day
criteria
appli
exclud
weekend
exclud
reoccur
asian
dust
event
day
asian
dust
event
observ
day
event
day
control
day
defin
day
event
day
log
poisson
regress
use
estim
ratio
averag
asthma
case
use
age
gender
region
climat
event
control
day
result
event
day
select
event
day
averag
number
asthma
case
much
control
day
gender
age
region
socioeconom
statu
howev
signific
differ
statist
humid
event
day
lower
wind
speed
higher
control
day
estim
ratio
averag
asthma
case
event
day
ci
accord
socioeconom
statu
ratio
asthma
patient
day
day
day
follow
day
day
day
day
day
day
day
health
insur
group
also
medic
aid
group
estim
ratio
day
conclus
asian
dust
event
worsen
asthma
effect
asthma
appear
differ
socioeconom
statu
time
lag
analysi
need
studi
asthma
effect
asian
dust
event
use
claim
data
tslp
downregul
human
pathway
keratinocyt
depart
dermatolog
korea
univers
colleg
medicin
atop
dermat
ad
chronic
prurit
inflammatori
skin
diseas
associ
defect
skin
barrier
dysregul
immun
respons
patient
ad
show
reduc
express
antimicrobi
peptid
amp
may
play
import
role
host
defens
bacteria
fungi
virus
infect
thymic
stromal
lymphopoietin
tslp
pathogenet
role
initi
mainten
allerg
inflammatori
diseas
includ
ad
function
tslp
reveal
previou
studi
howev
remain
unknown
regulatori
mechan
express
tslp
primari
human
keratinocyt
present
studi
demonstr
dosedepend
decreas
human
mrna
protein
level
keratinocyt
follow
stimul
tslp
addit
studi
demonstr
effect
tslp
express
human
skin
equival
model
investig
regulatori
mechan
tslpreduc
express
primari
human
keratinocyt
tslp
induc
protein
express
primari
human
keratinocyt
data
immunohistochem
stain
skin
lesion
atop
patient
demonstr
increas
express
normal
skin
regul
pathway
keratinocyt
result
chromatin
immunoprecipit
chip
assay
electrophoret
mobil
shift
assay
emsa
show
direct
regul
tslp
promot
taken
togeth
studi
reveal
tslp
stimul
may
reduc
express
depend
mechan
human
keratinocyt
present
studi
suggest
novel
key
role
tslpmediat
immun
respons
keratinocyt
moreov
would
help
understand
patholog
signal
transduct
ad
aim
netherton
syndrom
ns
associ
mutat
gene
code
lekti
lymphoepitheli
kazaltyp
relat
inhibitor
serin
proteas
inhibitor
lekti
express
epithelium
mucosa
thymu
local
stratum
granulosum
normal
skin
ns
rare
genodermatosi
character
autosom
recess
inherit
pattern
unknown
etiolog
ichthyosiform
cutan
chang
atop
diathesi
alter
hair
shaft
result
age
coupl
immun
defici
clinic
symptom
may
vari
materi
method
white
caucasian
male
present
allergyimmunolog
unit
pruritu
face
feet
skin
desquam
spars
thin
hair
dermatolog
examin
demonstr
brittl
scale
hair
eyebrow
eyelash
erythema
desquam
cheek
pinkishr
macul
scale
hypopig
macular
lesion
ichthyosiform
skin
involv
area
begin
patella
extend
distal
part
leg
lichenifi
erythemat
plaqu
patchi
fissur
antecubit
poplit
region
microscop
examin
materi
collect
nail
show
fungal
compon
subungu
hyperkeratosi
discolor
destruct
note
toe
nail
patient
present
clinic
spars
brittl
hair
along
prurit
erythemat
scale
cutan
lesion
patient
underw
clinic
examin
laboratori
analys
base
clinic
laboratori
find
patient
diagnos
netherton
syndrom
result
laboratori
analys
yield
normal
result
except
leukocyt
count
crp
mgml
normal
mgml
total
ige
iuml
normal
iuml
igg
normal
iga
normal
igm
normal
cow
milk
mite
grass
egg
hazelnut
orang
wheat
strawberri
allergi
detect
specif
ige
studi
anti
nuclear
antibodi
hepat
marker
hiv
rheumatoid
factor
neg
patient
renal
function
test
level
within
normal
rang
omalizumab
treatment
shortterm
month
treatment
omalizumab
decreas
crp
increas
level
conclus
ns
peel
skin
syndrom
type
b
skin
dermat
multipl
sever
allergi
metabol
wast
syndrom
autosom
recess
disord
result
aberr
regul
epiderm
desquam
knowledg
first
time
associ
omalizumab
use
ns
document
conclus
allerg
skin
symptom
pruritu
erythema
desquam
mucos
symptom
decreas
patient
purpos
express
nitric
oxid
level
exhal
nitric
oxid
increas
allerg
airway
diseas
howev
whether
upregul
no
deleteri
effect
airway
inflamm
hyperrespons
remain
controversi
aim
clarifi
pathophysiolog
role
competit
arginas
use
knockout
mice
model
allerg
asthma
method
compar
airway
inflamm
hyperrespons
well
arginas
express
use
no
arginas
inhibitor
femal
knockout
mice
result
airway
hyperrespons
unaffect
depelet
no
inhibit
howev
airway
inflamm
aggrav
knockout
mice
wildtyp
mice
augment
arginas
express
inhibit
arginas
attenu
airway
inflamm
wildtyp
knockout
mice
conclus
knockout
mice
show
increas
ovalbumininduc
airway
inflamm
augment
arginas
express
result
suggest
imbal
arginas
augment
arginas
express
result
aggrav
airway
inflamm
inhibitor
arginas
may
effect
suppress
allerg
inflamm
background
food
allergi
fa
one
import
health
issu
school
children
although
one
commonest
place
pediatr
anaphylaxi
occur
home
peer
percept
experi
caregiv
child
fa
unclear
method
anonym
paperbas
questionnair
distribut
caregiv
fa
children
fa
caregiv
nation
center
child
health
develop
caregiv
nonfa
children
nonfa
caregiv
public
school
tokyo
examin
percept
experi
fa
among
three
group
nonfa
caregiv
wit
advers
reaction
nearmiss
event
relat
fa
group
nonfa
caregiv
wit
advers
reaction
nearmiss
event
relat
fa
caregiv
child
fa
result
epinephrin
autoinjector
recogn
nonfa
caregiv
nonfa
caregiv
experienc
child
bulli
harass
refus
school
fa
caregiv
group
thought
could
take
appropri
action
wit
child
advers
respons
causal
food
compar
group
p
group
felt
anxiou
advers
event
relat
fa
conclus
experi
percept
fa
lack
low
among
nonfa
caregiv
therefor
also
import
provid
fa
educ
nonfa
caregiv
order
improv
qualiti
life
fa
children
background
aim
studi
evalu
common
caus
drug
type
b
advers
drug
reaction
adr
analyz
relationship
host
factor
result
drug
provoc
test
dpt
korean
children
method
retrospect
review
medic
record
children
younger
year
age
underw
dpt
novemb
novemb
open
provoc
test
perform
nonsteroid
antiinflammatori
drug
nsaid
acetaminophen
aminopenicillin
cephalosporin
antibiot
antiepilept
drug
drug
result
overal
dpt
perform
patient
whose
median
age
year
rang
month
year
dpt
posit
case
translat
posit
find
patient
drug
provid
posit
result
includ
nsaid
case
aminopenicillin
case
acetaminophen
case
cephalosporin
case
case
anaphylaxi
note
case
seriou
complic
dpt
subject
median
age
year
children
posit
result
follow
dpt
year
neg
result
pvalu
conclus
overal
posit
dpt
rate
lower
rate
note
younger
children
dpt
perform
safe
children
suspect
adr
order
achiev
correct
diagnosi
purpos
first
join
aaohnsf
annual
meet
washington
dc
resid
becam
interest
high
resolut
nasal
endoscopi
plan
studi
design
allerg
rhiniti
patient
research
diagram
danyoung
classif
consist
studi
design
three
period
year
strateg
plan
use
digit
hd
endoscopi
digit
hd
flexibl
videoendoscopi
endoscopi
danyoung
classif
updat
achiev
better
object
visual
data
file
method
jun
apr
nasoendoscop
video
data
file
collect
allerg
rhiniti
patient
nasoendoscop
video
system
consist
stryker
digit
hd
video
camera
system
model
kay
pentax
digit
hd
flexibl
videoendoscopi
model
stryker
video
camera
system
model
video
data
storag
system
consist
stryker
sdcpro
sdchd
record
system
naslg
system
result
danyoung
classif
hypothesi
base
surfac
chang
allerg
rhiniti
patient
inferior
turbin
mucosathi
classif
consist
stage
stage
hypertrophi
state
stage
dimpl
state
stage
wrinkl
state
clear
definit
stage
character
digit
hd
endoscop
evalu
especi
irrevers
chang
nasal
mucosa
dimpl
wrinkl
shape
confirm
conclus
danyoung
classif
simpl
object
advantag
use
earli
diagnosi
allerg
rhiniti
omuct
use
togeth
allerg
rhiniti
patient
stage
clear
danyoung
classif
updat
relat
aria
updat
one
futur
keyword
allerg
rhiniti
stryker
digit
hd
endoscopi
kay
pentax
digit
hd
flexibl
videoendoscopi
danyoung
classif
updat
background
although
mani
patient
allerg
rhiniti
symptom
due
sensit
one
kind
allergen
mix
allergen
extract
wide
use
immunotherapi
publish
trial
method
perform
singlecentr
cohort
studi
subcutan
immunotherapi
use
hous
dust
mite
extract
weed
pollen
extract
mix
hous
dust
mitewe
pollen
extract
allerg
rhiniti
patient
allergen
respons
symptom
patient
includ
immunotherapi
qualiti
life
evalu
rhinoconjunct
qualiti
life
questionnair
rqlq
immunotherapi
result
subcutan
immunotherapi
rqlq
score
hous
dust
mite
group
significantli
better
baselin
rqlq
score
rqlq
score
weed
pollen
season
weed
pollen
group
significantli
better
baselin
level
rqlq
score
weed
pollen
season
mix
hous
dust
mitewe
pollen
group
significantli
better
baselin
level
rqlq
ordinari
time
mix
hous
dust
mitewe
pollen
group
significantli
better
baselin
score
reduct
rqlq
score
hous
dust
mite
group
weed
pollen
group
treatment
mix
hous
dust
mitewe
pollen
group
rqlq
ordinari
time
deceas
differ
compar
hous
dust
mite
group
rqlq
weed
pollen
season
decreas
differ
compar
weed
pollen
group
conclus
signific
differ
effect
qualiti
life
mix
hous
dust
mitewe
pollen
extract
immunotherapi
effect
hous
dust
mite
extract
weed
pollen
extract
immunotherapi
efficaci
multiallergen
immunotherapi
weaker
singleallergen
immunotherapi
background
accumul
evid
suggest
desertif
climat
variabl
contribut
increas
desert
dust
format
air
desert
dust
shown
exert
adjuv
effect
anim
object
examin
desert
dust
enhanc
allerg
symptom
reallif
set
investig
effect
modifi
method
conduct
cohort
studi
pregnant
women
spring
fall
period
span
octob
may
three
region
japan
adjunct
studi
japan
environ
children
studi
time
acquir
particip
daili
symptom
score
send
webbas
questionnair
high
desertdust
day
randomli
select
day
control
day
particip
result
pregnant
women
show
increas
risk
allerg
symptom
protocoldefin
high
desertdust
day
ci
risk
elev
observ
low
level
desert
dust
dosedepend
manner
even
control
day
riskincreas
accord
desert
dust
level
observ
air
simultan
contain
pollen
japanes
cedar
cypress
among
subject
posit
serum
ige
antibodi
japanes
cedar
pollen
clear
riskincreas
observ
absenc
pollen
air
conclus
ambient
desert
dust
level
associ
increas
risk
allerg
symptom
exacerb
pollensensit
pregnant
women
pollen
present
air
increas
dosedepend
observ
low
level
result
support
hypothesi
desert
dust
exert
adjuv
effect
human
background
natur
marbl
beef
popular
japan
expens
inject
beef
process
improv
textur
dairi
cow
meat
give
palat
feel
marbl
beef
inject
fat
sometim
serv
rel
low
price
restaur
meat
might
contain
milk
protein
casein
one
food
addit
method
boy
histori
advers
reaction
hen
egg
cow
milk
wheat
age
month
anaphylact
reaction
eat
beef
steak
hotel
restaur
reaction
occur
even
though
parent
ask
restaur
ensur
dish
free
hen
egg
cow
milk
wheat
tri
discov
caus
anaphylact
reaction
ask
hotel
restaur
telephon
ingredi
dish
serv
send
piec
beef
undertook
skin
prick
test
meat
sent
determin
quantiti
cow
milk
protein
piec
inject
beef
use
enzymelink
immunosorb
assay
nipponham
tokyo
japan
result
hotel
restaur
use
hen
egg
cow
milk
wheat
use
inject
beef
label
contain
casein
awar
fact
skin
prick
test
strongli
posit
raw
inject
beef
heat
beef
piec
inject
beef
contain
mgml
cow
milk
protein
suffici
induc
allerg
reaction
conclus
even
inject
beef
label
appropri
allerg
reaction
occur
chef
know
casein
milk
protein
chef
need
inform
detail
food
allergi
background
first
studi
kind
investig
relationship
chronic
rhinosinus
cr
without
nasal
polyp
np
healthrel
qualiti
life
hrqol
within
korean
popul
object
sought
evalu
associ
cr
hrqol
adjust
confound
factor
gener
adult
korean
popul
also
evalu
hrqol
accord
presenc
np
cr
patient
method
crosssect
studi
use
nation
repres
sampl
korea
nation
health
nutrit
examin
survey
total
particip
includ
studi
diagnos
cr
univari
analysi
conduct
healthi
versu
cr
group
segreg
gender
weight
preval
demograph
characterist
socioeconom
statu
comorbid
diseas
subanalysi
carri
evalu
relationship
cr
without
np
hrqol
use
euroqol
odd
ratio
estim
multipl
logist
regress
analys
confound
adjust
result
weight
preval
cr
adult
male
particip
found
cr
nasal
polyp
crswnp
femal
cr
crswnp
signific
differ
group
p
score
femal
index
p
trend
eqva
p
trend
show
decreas
trend
healthi
particip
cr
without
nasal
polyp
crssnp
crssnp
crswnp
adjust
demograph
characterist
socioeconom
statu
comorbid
diseas
score
index
p
eqva
p
exhibit
poorer
hrqol
compar
healthi
particip
exclus
within
femal
group
conclus
data
suggest
femal
patient
cr
higher
risk
poor
hrqol
addit
hrqol
femal
crswnp
lower
compar
crssnp
healthi
particip
background
exposur
sensit
hous
dust
mite
hdm
allergen
trigger
asthma
exacerb
indoor
concentr
hdm
allergen
preval
asthma
exacerb
higher
fall
season
south
korea
method
studi
particip
children
visit
emerg
room
acut
asthma
exacerb
measur
serum
level
total
immunoglobulin
e
ige
hdmspecif
ige
sige
cytokin
chemokin
result
total
ige
hdmsige
level
higher
sera
children
present
asthma
exacerb
fall
found
differ
level
cytokin
chemokin
fall
season
conclus
base
fact
acut
asthma
exacerb
preval
fall
indoor
concentr
hdm
allergen
highest
fall
higher
level
serum
hdmsige
children
asthma
exacerb
present
fall
may
suggest
hdm
sensit
could
risk
factor
asthma
exacerb
fall
background
mani
parent
seek
healthcar
advic
household
pet
keep
may
detriment
atop
eczema
ae
aim
investig
skin
sensit
catdog
dander
associ
diseas
sever
qualiti
life
children
eczema
method
demograph
skin
prick
test
spt
result
diseas
sever
nottingham
eczema
sever
score
ness
children
dermatolog
life
qualiti
index
cdlqi
skin
hydrat
sh
transepiderm
water
loss
tewl
cohort
ae
patient
review
result
ae
patient
follow
pediatr
dermatolog
clinic
evalu
person
histori
asthma
lowest
dogdanderpositivegroup
highest
bothcatanddogdanderposit
group
binomi
logist
regress
ascertain
catdand
sensit
associ
increas
age
adjust
odd
ratio
aor
confid
interv
ci
dustmit
sensit
aor
ci
foodallergen
sensit
aor
ci
keepingcatev
aor
ci
wherea
dogdand
sensit
associ
dustmit
sensit
aor
ci
foodallergen
sensit
aor
ci
keepingdogev
aor
ci
howev
neither
cat
dog
sensit
associ
asthma
allerg
rhiniti
parent
sibl
atop
statu
diseas
sever
qualiti
life
conclus
studi
summar
evid
parentalpati
guidanc
direct
correl
ae
sever
qualiti
life
skin
sensit
cat
dog
howev
furri
pet
good
sourc
housedust
mite
shown
studi
ae
patient
like
sensit
sensit
patient
especi
concomit
asthma
sever
symptom
may
consid
nonfurri
altern
plan
pet
highli
sensit
individu
especi
asthma
comorbid
may
remov
pet
trial
period
determin
symptom
improv
background
nationwid
populationbas
investig
relationship
allerg
rhiniti
ar
mental
health
korea
object
evalu
associ
ar
mental
health
statu
gener
adult
korean
popul
also
investig
rel
burden
ar
mental
health
use
allerg
rhiniti
impact
asthma
aria
classif
method
crosssect
studi
perform
use
data
individu
year
old
older
collect
korean
nation
health
nutrit
examin
survey
univari
analysi
conduct
healthi
ar
group
weight
preval
demograph
characterist
socioeconom
statu
comobid
diseas
subanalysi
classifi
ar
sever
accord
aria
classif
carri
evalu
relationship
ar
sever
mental
health
odd
ratio
or
compon
repres
mental
health
statu
estim
multipl
logist
regress
analys
confound
adjust
result
univari
analysi
chisquar
test
adjust
age
sex
bmi
smoke
statu
alcohol
use
statu
exercis
statu
compon
repres
mental
health
statu
show
linear
trend
sever
ar
accord
aria
classif
stress
depress
mood
suicid
thought
psycholog
consult
factor
correl
ar
adjust
demograph
characterist
socioeconom
statu
even
adjust
comorbid
allerg
diseas
correl
remain
signific
stress
depress
mood
psycholog
consult
factor
ci
conclus
patient
ar
appear
higher
risk
mental
health
disord
gener
adult
korean
popul
moreov
persist
sever
ar
correl
poor
mental
health
therefor
better
control
ar
may
conduc
better
mental
health
attent
paid
psycholog
statu
ar
patient
background
assess
respiratori
function
vital
diagnosi
monitor
children
asthma
measur
respons
bronchodil
salbutamol
ideal
children
year
old
effort
depend
less
invas
requir
less
cooper
patient
object
compar
chang
oscillometr
paramet
inhal
beta
agonist
among
healthi
asthmat
children
age
year
old
use
impulseoscillometri
method
respiratori
imped
baselin
minut
one
dose
salbutamol
nebul
measur
impuls
oscillometri
io
use
viasi
healthcar
leibnizstr
hoechberg
germani
resist
hz
reactanc
children
age
old
calcul
threshold
cutoff
valu
receiv
oper
characterist
roc
curv
drawn
determin
youden
index
j
max
sensit
specif
partial
correl
studi
done
among
multipl
paramet
determin
best
posit
correl
diagnosi
asthma
result
fiftysix
asthmat
subject
healthi
subject
abl
complet
studi
mean
percent
standard
error
mean
baselin
pre
bronchodil
indic
asthma
kpal
kpal
kpal
kpal
normal
healthi
subject
baselin
mean
valu
kpal
kpal
kpal
hz
kpal
mean
percent
chang
initi
valu
asthmat
hz
cut
valu
bronchodil
respons
diagnos
asthma
use
percent
chang
initi
follow
sensit
specif
sensit
specif
hz
sensit
specif
sensit
specif
percent
initi
chang
r
p
significantli
correl
conclus
valu
baselin
postbronchodil
differ
io
paramet
significantli
higher
asthmat
group
postbronchodil
chang
initi
strong
posit
correl
diagnosi
asthma
comput
percent
chang
postbronchodil
best
paramet
show
better
accuraci
term
specif
sensit
diagnosi
asthma
use
impuls
oscillometri
popul
introduct
eosinophil
esophag
eoe
character
symptom
esophag
dysfunct
eosinophilia
esophagu
may
associ
atop
disord
pathogenesi
eoe
like
mix
ige
nonig
foodmedi
reaction
cytokin
drive
esophag
eosinophilia
henc
therapi
aim
inflamm
control
corticosteroid
oral
topic
andor
food
antigen
avoid
howev
treatment
specif
impair
qualiti
life
signific
side
effect
therefor
ongo
effort
design
altern
therapi
background
determin
eoe
patient
concomit
season
perenni
allerg
rhiniti
improv
aeroallergen
immunotherapi
method
present
case
seri
caucasian
patient
histori
atopi
eoe
base
characterist
clinic
symptom
egd
find
esophag
biopsi
one
oral
allergi
syndrom
none
patient
peripher
eosinophilia
two
season
exacerb
eoe
symptom
patient
start
aeroallergen
immunotherapi
atop
diseas
eoe
result
small
group
aeroallergen
food
sensit
adult
patient
demonstr
lack
improv
clinic
symptom
eoe
aeroallergen
immunotherapi
make
modif
diet
oral
medic
difficult
ascertain
improv
due
lack
valid
adult
symptom
score
inher
restraint
repeat
esophag
endoscopi
due
cost
procedur
risk
also
unclear
biopsi
alway
accur
reflect
diseas
activ
sever
limit
small
sampl
includ
absenc
control
group
statist
valid
possibl
select
bia
conclus
would
like
continu
evalu
preval
aeroallergen
sensit
adult
eoe
consid
similar
evalu
pediatr
patient
review
data
attempt
isol
popul
improv
aeroallergen
immunotherapi
may
success
improv
control
eoe
without
aggress
dietari
modif
medic
manag
background
eczema
herpeticum
eh
widespread
herp
simplex
viru
infect
often
present
complic
atop
dermat
ad
along
increas
incid
ad
number
patient
eh
seem
increas
year
howev
populationbas
epidemiolog
data
eh
insuffici
rariti
aim
evalu
epidemiolog
trend
eh
korean
last
year
compar
preval
ad
method
retrospect
analysi
carri
patient
diagnos
eh
januari
decemb
singl
tertiari
hospit
korea
variabl
interest
includ
age
sex
season
onset
treatment
outcom
recurr
whether
underli
ad
preval
ad
period
investig
year
result
total
episod
eh
patient
diagnos
ten
year
number
eh
episod
per
patient
rang
one
episod
patient
mean
age
onset
year
sex
ratio
f
patient
recurr
episod
tend
older
year
eh
episod
year
signific
differ
sex
ratio
two
group
season
variat
onset
found
durat
treatment
day
treatment
includ
system
antivir
agent
eleven
patient
hospit
improv
intraven
antivir
agent
six
show
recurr
discharg
major
patient
eh
underli
ad
except
four
patient
period
total
patient
diagnos
ad
clinic
continu
increas
preval
annual
ratio
ehad
averag
steadili
decreas
year
eh
commonli
complic
old
age
show
significantli
increas
ehad
ratio
year
old
conclus
eh
rare
complic
ad
affect
ad
patient
preval
ad
increas
year
total
number
eh
patient
littl
chang
lead
slight
continu
declin
ehad
ratio
patient
get
older
eh
could
commonli
complic
ad
show
recurr
cours
younger
patient
background
sublingu
immunotherapi
slit
hous
dust
mite
hdm
prepar
recent
proven
benefici
treat
allerg
rhiniti
asthma
howev
report
regard
efficaci
safeti
slit
korean
patient
atop
dermat
ad
object
investig
efficaci
safeti
slit
korean
patient
ad
method
total
patient
ad
igeproven
hdm
sensit
class
recruit
pusan
nation
univers
hospit
juli
septemb
patient
treat
slit
least
month
eczema
area
sever
index
easi
score
total
serum
ige
level
result
specif
ige
assay
dermatophagoid
pteronyssinu
farina
advers
effect
record
schedul
visit
respond
defin
patient
improv
easi
score
slit
result
twentythre
patient
continu
slit
month
patient
drop
exacerb
dermat
lost
followup
averag
durat
slit
treatment
month
rang
month
easi
score
reduc
significantli
month
treatment
p
compar
baselin
total
patient
determin
respond
slit
month
total
specif
ige
serum
level
significantli
reduc
slit
patient
experienc
seriou
advers
event
except
two
patient
develop
transient
lip
tongu
swell
conclus
studi
demonstr
slit
hdm
extract
effect
toler
korean
patient
ad
control
longterm
trial
requir
reinforc
current
result
background
bitter
tast
receptor
human
airway
smooth
muscl
recent
shown
import
role
bronchodil
togeth
receptor
object
evalu
associ
genet
variat
clinic
featur
includ
bronchodil
respons
asthma
control
method
analys
associ
singl
nucleotid
polymorph
snp
variabl
includ
demograph
data
atopi
durat
diseas
asthma
control
statu
includ
variabl
asthma
control
test
act
score
percent
predict
valu
forc
vital
capac
fvc
ratio
bronchodil
respons
bdr
asthma
patient
korea
result
three
novel
snp
three
known
snp
analys
increas
bdr
significantli
associ
snp
c
confid
interv
ci
g
ci
ci
gene
signific
associ
c
low
mean
act
score
ci
haplotyp
analysi
tgt
cat
tgt
tg
ca
haplotyp
significantli
associ
increas
bdr
cat
ca
haplotyp
significantli
associ
low
act
score
conclus
genet
variat
may
valuabl
genet
marker
predict
therapeut
respons
outcom
asthma
although
suffici
clarifi
relationship
genet
polymorph
gene
respons
agonist
research
independ
cohort
need
abstract
background
idiopath
pulmonari
fibrosi
ipf
chronic
progress
multifactori
diseas
limit
treatment
option
aim
evalu
efficaci
glycosid
base
standard
fenugreek
seed
extract
sfseg
behavior
biochem
molecular
ultrastructur
chang
bleomycin
blm
induc
pulmonari
fibrosi
laboratori
rat
materi
method
ipf
induc
male
spraguedawley
rat
singl
intratrach
blm
iukg
inject
follow
sfseg
mgkg
po
methylprednisolon
mgkg
po
treatment
day
sham
control
rat
receiv
salin
instead
blm
lung
function
test
biochem
molecular
histopatholog
ultrastructur
chang
analyz
lung
bronchoalveolar
lavag
fluid
balf
day
drug
treatment
result
treatment
sfseg
significantli
restor
blm
induc
alter
bodi
weight
lung
index
lung
function
test
hematolog
sfseg
treatment
significantli
restor
alter
total
differenti
cell
count
balf
blood
blm
induc
peripher
blood
oxygen
content
reduct
significantli
revers
sfseg
treatment
sfseg
significantli
enhanc
balf
lung
antioxid
statu
modul
sod
gsh
taoc
mda
level
mrna
express
signific
reduct
lung
level
sfseg
treatment
alter
mrna
express
lung
inflammatori
marker
fibrot
marker
nfkb
vegf
apoptot
marker
bax
significantli
restor
sfseg
treatment
blm
induc
histolog
inflammatori
fibrot
ultrastructur
chang
lung
revers
sfseg
treatment
conclus
sfseg
potenti
efficaci
fibrot
pathogenesi
blm
induc
pulmonari
fibrosi
probabl
antiinflammatori
antiapoptot
pathway
refer
bei
huahuy
duongquy
nguyen
vh
chen
w
nicco
c
et
al
longterm
treatment
fasudil
improv
bleomycininduc
pulmonari
fibrosi
pulmonari
hypertens
via
inhibit
pulmonari
pharmacol
therap
chitra
p
saiprasad
g
manikandan
r
sudhandiran
g
berberin
attenu
bleomycininduc
pulmonari
toxic
fibrosi
via
suppress
depend
activ
biphas
experiment
studi
toxicol
lett
ogikenchuto
one
tradit
japanes
medic
system
call
kampo
medicin
formula
report
ogikenchuto
show
domin
effect
parasympathet
nerv
system
clinic
use
antifatigu
effect
immuneactiv
relax
peripher
capillari
report
three
infant
case
sever
atop
dermat
impoverish
skin
show
therapeut
promis
efficaci
treatment
ogikenchuto
three
infant
visit
clinic
treatment
atop
dermat
three
infant
show
full
bodi
atop
skin
high
level
ige
tarc
serum
two
three
case
erythroderma
one
persist
airway
inflamm
suffici
volum
steroid
ointment
treatment
necessari
three
patient
prevent
atop
march
howev
impoverish
skin
found
case
initi
administr
longterm
insuffici
manag
sinc
impoverish
skin
caus
chronic
inflamm
continu
activ
eosinophil
control
domin
effect
sympathet
nerv
system
ogikenchuto
administr
tree
patient
combin
suffici
steroid
ointment
treatment
month
later
impoverish
skin
atop
dermat
improv
serum
level
ige
tarc
decreas
result
decreas
steroid
ointment
dose
difficult
continu
steroid
ointment
treatment
atop
infant
impoverish
skin
case
indic
ogikenchuto
might
play
import
role
treatment
impoverish
skin
patient
intract
atop
dermat
although
efficaci
kampo
medicin
clarifi
enough
sever
immunepharmacolog
studi
report
compon
relat
kampo
formula
includ
ogikenchuto
might
effect
antiallerg
action
conclus
therapi
combin
kampo
formula
might
achiev
better
respons
atop
dermat
impoverish
skin
therebi
extend
common
use
complementari
medicin
background
asthma
chronic
inflammatori
disord
airway
character
recurr
episod
wheez
breathless
chest
tight
cough
particularli
night
earli
morn
episod
usual
associ
variabl
airflow
obstruct
within
lung
often
revers
either
spontan
treatment
method
two
hundr
patient
initi
screen
outpati
clinic
depart
pediatr
post
graduat
institut
medic
educ
research
chandigarh
patient
select
inform
consent
one
parent
obtain
prior
enrol
studi
includ
patient
also
daili
budesonid
therapi
asthma
control
live
around
chandigarh
patient
assess
everi
two
week
symptomat
control
asthma
particip
parent
explain
demonstr
function
nebul
pefr
height
weight
measur
taken
everi
visit
nebul
use
patient
assess
improv
deterior
symptom
studi
approv
institut
ethic
commite
result
seventi
percent
patientsparentsguardian
prefer
use
nebul
one
follow
reason
better
symptom
control
decreas
frequenc
exacerb
manag
exacerb
done
home
increas
durat
drug
deliveri
nebul
thirti
percent
patientsparentsguardian
prefer
use
spacer
felt
children
could
use
spacer
easili
compar
nebul
conclus
thirti
patient
complet
eight
week
inhal
therapi
nebul
signific
deterior
symptom
therapi
nebul
prefer
use
spacer
drug
deliveri
system
control
symptom
asthma
background
housedust
mite
hdm
import
sourc
indoor
allergen
aim
defin
sensit
rate
specif
immunoglobulin
e
ige
der
p
compon
investig
clinic
featur
children
allerg
diseas
method
perform
prospect
evalu
hdm
sensit
patient
histori
allerg
rhiniti
ar
atop
dermat
ad
asthma
urticaria
uc
patient
underw
allergen
identif
test
use
immunocap
total
ige
der
p
der
f
der
p
der
p
der
p
result
seventynin
patient
detect
serum
level
der
p
specif
ige
patient
sensit
der
f
der
p
der
p
der
p
respect
level
der
p
ige
significantli
lower
uc
group
ad
ar
group
total
ige
level
significantli
higher
der
p
group
der
p
serum
ige
level
highli
correl
crab
shrimp
specif
ige
signific
posit
correl
observ
total
ige
specif
ige
der
p
compon
der
f
conclus
sensit
hdm
compon
studi
similar
report
previou
studi
temper
climat
signific
differ
der
p
patient
uc
ad
ar
background
lasparaginas
crucial
chemotherapeut
agent
treatment
acut
lymphoblast
leukemia
howev
hypersensit
lasparaginas
common
limit
usag
aim
evalu
use
premed
desensit
lasparaginas
hypersensit
method
perform
case
premed
case
desensit
patient
hypersensit
lasparaginas
result
premed
case
complet
lasparaginas
inject
hypersensit
reaction
case
show
mild
hypersensit
reaction
urticaria
desensit
perform
case
case
success
case
medic
switch
erwinia
asparaginas
conclus
premed
desensit
appear
use
help
patient
receiv
desir
dose
lasparaginas
pediatr
patient
acut
lymphoblast
leukemia
background
angioedema
eosinophilia
ae
uncommon
form
angioedema
although
pathogenesi
remain
unclear
classifi
episod
angioedema
eosinophilia
eae
nonepisod
angioedema
eosinophilia
neae
eae
gener
observ
western
popul
almost
patient
neae
asian
exclus
japanes
korean
previous
ae
never
report
thai
patient
method
case
seri
patient
ae
thailand
describ
result
three
thai
patient
ae
identifi
april
patient
femal
mean
age
onset
symptom
year
patient
present
symmetr
swell
distal
extrem
without
system
symptom
fever
weight
gain
observ
arthralgia
urticaria
present
patient
respect
potenti
trigger
identifi
except
patient
preced
upper
respiratori
tract
infect
week
prior
swell
previou
histori
signific
medic
allerg
diseas
unremark
except
patient
hepat
b
carrier
recurr
eczema
patient
eosinophilia
mean
eosinophil
count
blood
chemistri
liver
kidney
function
test
inflammatori
marker
esr
crp
immunoglobulin
level
within
normal
rang
patient
secondari
disord
might
respons
eosinophilia
exclud
recurr
episod
angioedema
observ
patient
antihistamin
briefli
prescrib
patient
coexist
urticaria
patient
complet
spontan
resolut
symptom
parallel
normal
eosinophil
count
within
month
present
conclus
ae
consid
young
asian
women
whose
present
featur
includ
peripher
swell
eosinophilia
without
constitut
symptom
intern
organ
involv
elev
immunoglobulin
level
similar
previou
report
japan
korea
neae
preval
thai
patient
eae
corticosteroid
therapi
gener
requir
sinc
patient
selflimit
diseas
keyword
hypereosinophil
syndrom
angioedema
background
korean
red
ginseng
krg
ginsenoid
show
sever
biolog
effect
variou
field
includ
antiinflammatori
antiallerg
effect
aim
investig
antiinflammatori
antiprurit
effect
krg
atop
dermat
murin
model
materi
method
atop
dermatitislik
skin
lesion
induc
percutan
challeng
tncb
ear
back
ncnga
mice
krg
extract
even
primros
oil
cyclosporin
phosphatebuf
salin
administ
oral
gastric
tube
effect
krg
drug
assess
measur
clinic
sever
score
ear
thick
transepiderm
water
loss
tewl
number
scratch
count
total
system
ige
elisa
histolog
chang
skin
mrna
express
tslp
studi
group
divid
scratchabl
nonscratch
subgroup
evalu
impact
scratch
behavior
atop
dermat
result
oral
administr
krg
significantli
reduc
clinic
sever
ear
thick
tewl
elev
number
scratch
count
also
effect
lower
krg
administ
group
compar
treatment
group
clinic
result
also
reveal
serolog
histolog
chang
krg
group
system
ige
level
significantli
lower
last
day
experi
histolog
epiderm
hyperkeratosi
parakeratosi
hyperplasia
dermal
leukocyt
mast
cell
infiltr
suppress
krg
immunochemistri
tslp
express
quantit
rtpcr
show
krg
effect
suppress
proinflammatori
cytokin
respons
addit
proactiv
restrict
scratch
behavior
physic
barrier
reduc
scratch
count
improv
clinic
symptom
also
nonscratch
group
lower
inflammatori
cell
infiltr
lower
tnf
tslp
express
back
tissu
well
lower
system
level
conclus
therefor
expect
oral
administr
krg
may
control
pruritu
skin
inflamm
inhibit
respons
addit
restrict
scratch
behavior
earli
stage
could
help
suppress
itchscratch
viciou
cycl
improv
clinic
system
inflamm
chronic
spontan
urticaria
csu
vex
problem
also
subject
huge
antihistamin
pill
burden
symptom
autoreact
urticaria
au
autoantibodi
blood
flaresup
condit
search
newer
effect
modal
reduc
pill
burden
felt
need
urticria
one
challeng
therapeut
problem
face
dermatologist
auto
serum
therapi
therapi
repeat
inject
autolog
serum
administ
subcutan
complet
absorpt
possibl
subcutan
autoseru
therapythi
studi
evalu
effect
subcutan
autolog
serum
therapi
ast
csu
also
determin
use
autoreact
urticaria
singl
blind
placebo
control
group
random
control
studi
patient
f
given
subcutan
ast
patient
given
subcutan
inject
normal
salin
placebo
along
levocetirizin
ondemand
basi
group
age
group
year
mean
age
durat
urticaria
month
month
associ
condit
patient
patient
hypochrom
anemia
patient
serum
skin
test
serum
group
salin
group
urticaria
activ
score
ua
came
form
averag
end
weekssalin
group
show
reduct
ua
daili
requir
antihistamin
also
came
serum
group
ast
use
adjunct
antihistamin
cu
effect
persist
even
four
month
cessat
therapi
thu
improv
qualiti
life
therapi
could
use
india
cost
effect
benefici
poor
man
biolog
chronic
urticaria
patient
background
allerg
bronchopulmonari
aspergillosi
abpa
lung
diseas
caus
hypersensit
reaction
fungu
aspergillu
fumigatu
colon
often
found
chronic
respiratori
diseas
either
bronchial
asthma
lung
tuberculosi
histori
asthma
abpa
often
obtain
year
earlier
lung
tuberculosi
often
difficult
distinguish
abpa
due
similar
radiolog
featur
often
found
misdiagnosi
previou
studi
method
observ
descript
analyt
cross
section
approach
conduct
prof
drrd
kandou
hospit
manado
julydecemb
total
sampl
group
sampl
moderatesever
persist
asthma
acidfast
bacilli
afb
posit
lung
tb
afb
neg
lung
tb
chest
xray
examin
skin
prick
test
spt
use
fumigatu
antigen
rapid
reactiontyp
earli
hour
type
iii
total
ige
igg
anti
fumigatu
obtain
greenberg
assess
criteria
use
abpa
result
abpa
found
moderatepersist
asthma
fab
posit
lung
tb
afb
neg
lung
tb
correl
type
spt
total
ige
show
signific
result
p
moderatesever
persist
asthma
afb
neg
lung
tb
signific
afb
posit
lung
tb
correl
igg
fumigatu
type
iii
spt
signific
p
result
group
conclus
abpa
found
either
asthma
lung
tuberculosi
patient
signific
correl
igg
afumigatu
type
iii
spt
may
indic
spt
replac
igg
fumigatu
examin
current
research
kit
spt
examin
may
consid
screen
suspect
abpa
background
gut
microbiota
increasingli
recognis
play
crucial
role
pathogenesi
asthma
obes
autoimmun
diseas
faecal
microbiom
like
ethnic
dietspecif
data
lack
asian
studi
characteris
faecal
microbi
composit
hong
kong
chines
infant
method
random
stool
sampl
obtain
infant
eczema
without
allergi
month
genom
dna
extract
powersoil
dna
isol
kit
mo
bio
laboratori
sequenc
use
ion
pgm
seqeunc
kit
ion
tm
chip
ion
pgm
system
ion
torrent
read
patient
filter
low
qualiti
phred
microbi
divers
evalu
use
shannonweav
divers
index
swedish
j
allergi
clin
immunol
taxonom
classif
read
assign
blastn
result
control
insuffici
dna
sequenc
signific
associ
detect
eczema
bacteria
rel
abund
includ
bacteroid
escherichia
klebsiella
bifidobacterium
streptococcu
lactobacillu
among
less
abund
genera
rel
abund
campylobact
abund
case
median
iqr
control
median
iqr
roseburia
less
abund
eczema
median
iqr
control
median
iqr
nonetheless
shannonweav
divers
index
stool
microbiota
week
similar
infant
eczema
nonallerg
control
month
median
iqr
versu
p
compar
microbi
composit
newborn
swedish
escherichia
coli
found
among
top
genera
case
control
wherea
enterobact
swedish
newborn
clostridium
parabacteroid
lactobacillu
found
chines
eczema
healthi
swedish
newborn
conclus
campylobact
roseburia
appear
less
frequent
detect
stool
chines
infant
subsequ
develop
eczema
microbi
divers
associ
eczema
suscept
studi
confirm
ethnicspecif
earlylif
faecal
microbi
composit
fund
research
committe
group
research
scheme
direct
grant
research
cuhk
background
object
bakeri
worker
expos
wheat
allergen
bacteri
endotoxin
fungu
interact
induc
allerg
respons
workrel
respiratori
symptom
wrss
previou
studi
demonstr
wrss
bakeri
worker
associ
polymorph
well
immun
respons
indic
possibl
involv
innat
immun
respons
pathogen
mechan
baker
asthma
hypothes
chitinas
wheat
flour
may
involv
develop
wr
bakeri
worker
measur
serum
chitinas
level
bakeri
worker
analyz
associ
polymorph
singl
cohort
bakeri
worker
method
three
hundr
eighti
three
bakeri
worker
control
unexpos
healthi
subject
enrol
wrss
evalu
use
questionnair
survey
serum
level
chitinas
mpo
specif
igeigg
antibodi
wheat
flour
extract
measur
elisa
promot
polymorph
genotyp
result
serum
chitinas
level
significantli
higher
bakeri
worker
unexpos
control
howev
signific
differ
note
accord
presenc
wrss
preval
serum
specif
ige
igg
antibodi
wheat
flour
p
respect
worker
carri
significantli
higher
chitinas
level
aagg
haplotyp
analysi
indic
worker
significantli
higher
chitinas
level
without
signific
correl
found
serum
chitinas
level
signific
correl
found
serum
mpo
level
conclus
find
suggest
chitinas
may
contribut
develop
wrss
bakeri
worker
modul
function
purpos
nasal
polyp
np
impli
refractori
clinic
cours
case
chronic
rhinosinus
cr
although
numer
etiolog
factor
includ
allergi
infect
hypoxia
associ
nasal
polyp
np
mechan
underli
np
fulli
understood
previous
report
hypoxiainduc
epithelialtomesenchym
transit
emt
frequent
observ
asian
np
could
therapeut
target
nasal
polyposi
ref
howev
nasal
epitheli
cell
np
patient
expos
hypoxia
also
divers
type
combin
inflammatori
milieu
hypothes
specif
immunolog
endotyp
could
induc
acceler
emt
nasal
epitheli
cell
lead
nasal
polyp
format
method
human
nasal
epitheli
cell
hnec
cell
line
use
immunoblot
immunofluoresc
immunohistochemistri
done
evalu
emt
marker
signal
molecul
vitro
sinonas
tissu
cr
patient
without
np
boyden
transwel
system
util
measur
capac
migrat
result
four
differ
cytokin
treat
hnec
cell
respect
emt
marker
trace
among
could
induc
emt
confirm
spindleshap
cell
morpholog
modest
cytoskeleton
rearrang
increas
migrat
potenti
emt
marker
chang
mechanist
emt
via
erk
pathway
known
nonsmad
pathway
emt
next
investig
whether
erk
inhibitor
could
prevent
emt
phenomenon
actual
inhibitor
erk
inhibitor
suppress
emt
final
check
emt
marker
level
human
nasal
mucosa
tissu
express
upregul
np
mucosa
compar
tissu
control
cr
patient
addit
express
found
correl
ecadherin
epitheli
marker
loss
muscl
actin
mesenchym
marker
express
conclus
induc
emt
hnec
process
critic
mediat
erk
pathway
studi
show
emt
like
contribut
nasal
polyposi
cr
suggest
erk
inhibitor
view
therapeut
target
nasal
polyposi
refer
ref
shin
hw
et
al
hypoxiainduc
factor
mediat
nasal
polypogenesi
induc
epithelialtomesenchym
transit
amer
j
resp
crit
care
med
background
evalu
relev
manag
educ
anaphylaxi
patient
emphas
import
educ
understand
diseas
method
one
hundr
nineti
five
patient
visit
er
enrol
three
hospit
analyz
clinic
featur
prior
histori
anaphylaxi
manag
educ
analyz
associ
factor
inject
epinephrin
pearson
chisquar
test
use
spss
version
result
nineti
nine
patient
visit
er
oneself
time
latenc
symptom
onset
er
visit
min
drug
frequenc
suspici
caus
anaphylaxi
cutan
respiratori
symptom
frequent
hypotens
present
patient
patient
histori
anaphylaxi
patient
suspici
caus
current
anaphylaxi
mean
observ
time
er
hr
epinephrin
inject
patient
patient
epinephrin
inject
via
muscl
mean
dose
associ
factor
inject
epinephrin
patient
anaphylaxi
hypotens
p
twenti
four
patient
need
hospit
icu
ward
autoinject
epinephrin
prescrib
patent
patient
consult
allergist
er
patient
consult
outpati
depart
allergi
conclus
suggest
manag
educ
anaphylaxi
fulli
carri
er
avoid
reexperi
anaphylaxi
educ
action
plan
emerg
state
necessari
consult
allergist
background
shellfish
second
common
food
allergen
caus
sensit
children
year
old
despit
preval
clinic
manag
shellfish
allergi
limit
convent
approach
avoid
although
tropomyosin
identifi
major
shellfish
allergen
allergen
specif
immunotherapi
sit
current
exist
treat
prevent
shellfish
allergi
investig
possibl
dna
vaccin
construct
two
hypoallergen
shrimp
tropomyosin
met
e
wai
et
al
plo
one
express
plasmid
pcineo
use
establish
mous
model
shrimp
hypersensit
examin
immunoprophylact
potenti
two
hypoallergenbas
dna
vaccin
method
week
old
balbc
mice
randomli
divid
five
group
n
per
group
two
group
intraderm
inject
pcineo
clone
thrice
weekli
interv
remain
group
inject
nake
pcineo
pb
serv
vector
pb
neg
control
one
week
last
inject
group
except
neg
control
mice
inject
pb
throughout
experi
sensit
subcutan
met
e
adsorb
freund
complet
incomplet
adjuv
oral
challeng
use
high
dose
met
e
blood
spleen
small
intestin
collect
antibodi
cytokin
gene
express
histolog
analysi
result
pb
vector
control
group
display
typic
respons
upon
met
e
challeng
mice
exhibit
high
level
specif
ige
cytokin
well
inflammatori
respons
mast
cell
eosinophil
infiltr
goblet
cell
hyperplasia
gut
contrast
vaccin
group
show
system
allerg
symptom
inflammatori
respons
gut
upon
challeng
met
e
ige
cytokin
mice
remain
basal
level
dna
vaccin
provid
robust
protect
respons
protect
offer
vaccin
includ
higher
level
specif
antibodi
possess
vitro
vivo
block
abil
well
higher
splenic
level
cytokin
vaccin
increas
express
small
intestin
vaccin
increas
express
conclus
hypoallergenbas
dna
vaccin
could
effect
protect
tropomyosin
sensit
mice
via
establish
respons
recruit
regulatori
cell
induct
block
igg
antibodi
work
fulli
support
health
medic
research
fund
hksar
govern
background
pentraxin
solubl
pattern
recognit
receptor
acut
phase
protein
emerg
new
serolog
marker
reflect
tissu
inflamm
damag
divers
diseas
determin
whether
sputum
level
elev
patient
childhood
asthma
also
investig
relationship
sputum
level
airway
inflamm
pulmonari
function
bronchial
hyperrespons
children
method
total
children
patient
asthma
control
subject
enrol
studi
level
measur
sputum
supernat
elisa
perform
spirometri
methacholin
challeng
test
measur
total
eosinophil
count
serum
level
total
ige
ecp
children
result
sputum
concentr
significantli
higher
children
asthma
mean
se
pgml
control
subject
mean
se
pgml
p
posit
signific
correl
found
sputum
bronchodil
respons
r
p
sputum
level
neg
correl
r
p
r
p
r
p
sputum
level
also
show
signific
neg
correl
post
bronchodil
bd
r
p
postbd
r
p
conclus
result
could
support
involv
pathogenesi
asthmat
airway
sputum
would
support
biomark
reflect
asthmat
airway
inflamm
remodel
childhood
asthma
background
purpos
ar
common
increas
allerg
diseas
dfarina
common
caus
allergen
aim
studi
compar
local
produc
antibodi
dfarina
nasal
mucosa
posit
neg
respond
nasal
provoc
test
npt
dfarina
evalu
relationship
level
inflammatori
mediat
subject
method
sixti
ar
patient
went
npt
dfarina
sinu
pack
place
patient
nasal
caviti
minut
earn
nasal
secret
npt
total
ige
specif
ige
farina
ecp
vegf
tryptas
level
measur
use
immunocap
thermofish
uppsala
sweden
dfarinaespecif
ige
iga
igg
secretori
iga
antibodi
measur
elisa
vegf
level
measur
elisa
kit
endogen
woburn
r
system
inc
minneapoli
mn
respect
result
high
level
total
ige
specif
ige
specif
igg
specif
iga
secretori
iga
well
ecp
vegf
tryptas
detect
nasal
secret
show
signific
differ
posit
neg
respond
inflammatori
mediat
includ
ecp
vegf
detect
well
correl
specif
antibodi
dfarina
p
respect
compar
elisa
method
immunocap
system
sensit
detect
specif
ige
dfarina
differ
right
left
nasal
secret
statist
signific
conclus
find
confirm
presenc
specif
antibodi
dfarinaesensit
ar
patient
local
antibodi
abund
nasal
mucosa
may
role
nasal
inflamm
ar
patient
sensit
dfarina
anaphylaxi
induc
ofloxacin
rare
report
pathogenet
mechan
yet
fulli
understood
report
nonig
mediat
ofloxacininduc
anaphylaxi
femal
patient
suffer
allerg
rhiniti
previou
histori
acut
urticaria
induc
nonsteroid
antiinflammatori
drug
develop
gener
urticaria
anaphylaxi
follow
oral
ingest
ofloxacin
measur
specif
serum
antibodi
ofloxacinhuman
serum
albumin
hsa
conjug
use
elisa
high
level
specif
serum
detect
serum
specif
ige
detect
moreov
basophil
activ
test
show
signific
upregul
addit
ofloxacin
antibodi
patient
signific
chang
non
atop
healthi
control
find
suggest
ofloxacin
induc
anaphylaxi
via
pathogenet
mechan
involv
non
igemedi
specif
respons
background
provoc
test
aspirin
reliabl
method
confirm
diagnosi
aspirin
exacerb
respiratori
diseas
aerd
date
appropri
vitro
test
diagnos
aerd
object
understand
pathogen
mechan
aerd
investig
potenti
biomark
aerd
use
metabolom
subject
method
forti
five
aerd
aspirin
toler
asthma
ata
normal
control
enrol
urin
serum
sampl
collect
asthma
subject
lysineaspirin
bronchoprovoc
test
lysasa
bpt
metabolit
analyz
use
liquid
chromatographi
mass
spectrometri
result
baselin
serum
urin
level
significantli
higher
aerd
ata
pgml
vs
pgml
p
pmolmg
creatinin
vs
pmolmg
creatinin
respect
roc
curv
analysi
discrimin
aerd
ata
indic
cutoff
valu
serum
pgml
sensit
specif
auc
p
improv
combin
serum
periostin
level
sensit
specif
auc
p
howev
roc
curv
form
use
urin
level
signific
correl
serum
urin
level
two
metabolit
urin
level
significantli
correl
lysasa
bpt
r
p
r
p
baselin
urin
significantli
correl
fall
lysasa
bpt
r
p
r
p
respect
conclus
serum
level
use
serum
biomark
repres
phenotyp
aerd
consid
serum
collect
simpler
sampl
collect
overproduct
mast
cell
activ
contribut
induc
bronchoconstrict
inhal
aspirin
pathogen
mechan
aerd
background
allergenspecif
immunotherapi
current
cur
modal
treat
allergi
previou
studi
demonstr
local
cutan
reaction
inject
common
report
lifethreaten
anaphylact
reaction
limit
clinic
use
method
determin
preval
dust
mite
dermatophagoid
farina
dermatophagoid
pteronyssinu
subcutan
immunotherapi
reaction
among
children
pediatr
patient
allerg
rhiniti
andor
bronchial
asthma
undergo
subcutan
immunotherapi
dust
mite
includ
local
small
larg
consecut
recurr
system
reaction
record
result
januari
august
pediatr
patient
receiv
total
inject
local
reaction
rate
ci
small
local
reaction
rate
ci
larg
local
reaction
rate
system
reaction
rate
consecut
local
reaction
increas
probabl
develop
either
small
larg
local
reaction
p
signific
correl
consecut
local
reaction
system
reaction
found
local
reaction
rate
patient
diagnosi
concomit
asthma
allerg
rhiniti
significantli
higher
patient
allerg
rhiniti
alon
potenti
risk
factor
system
reaction
bronchial
asthma
buildup
phase
immunotherapi
high
allergen
extract
concentr
conclus
major
reaction
dust
mite
farina
pteronyssinu
subcutan
immunotherapi
among
children
respiratori
allergi
local
rel
low
local
reaction
rate
mild
system
reaction
occur
inject
consecut
recurr
local
reaction
presumpt
system
reaction
background
betaglucan
known
immunomodul
anticarcinogen
properti
may
caus
skew
helper
th
immun
respons
respons
thu
potenti
role
decreas
allerg
symptom
among
patient
rhiniti
asthma
method
evalu
effect
cmglucan
allerg
rhiniti
symptom
asthma
control
among
children
polysensit
children
age
year
allerg
rhiniti
asthma
enrol
patient
random
receiv
cmglucan
mg
per
orem
bid
placebo
period
day
total
nasal
symptom
score
tnss
asthma
control
test
act
questionnair
use
assess
symptom
improv
baselin
week
posttreat
lung
function
paramet
nasal
eosinophil
count
measur
result
patient
cmglucan
placebo
includ
studi
patient
cmglucan
placebo
complet
studi
treatment
cmglucan
significantli
improv
runni
nose
rhinorrhea
nasal
congest
itchi
nose
postnas
drip
sneez
improv
treatment
group
differ
significantli
p
mean
nasal
eosinophil
count
significantli
decreas
baselin
posttreat
howev
signific
differ
group
seen
similarli
cmglucan
significantli
improv
nocturn
asthma
symptom
wheez
cough
short
breath
mean
fvc
p
p
p
pefr
p
significantli
increas
group
although
differ
p
found
compar
posttreat
improv
group
conclus
cmglucan
significantli
reduc
rhinorrhea
nocturn
asthma
symptom
among
children
allerg
rhiniti
asthma
background
recent
studi
impli
possibl
involv
autophagi
sever
asthma
sa
object
investig
role
autophagi
sa
pathogenesi
method
enrol
sa
patient
nonsever
asthma
nsa
patient
normal
healthi
control
nc
autophagi
evalu
sputum
granulocyt
peripher
blood
cell
pbc
use
western
blot
confoc
microscopi
transmiss
electron
microscopi
flow
cytometri
induc
autophagi
vitro
cell
primari
eosinophil
cell
treat
interleukin
il
cell
primari
airway
epitheli
cell
treat
result
increas
express
microtubuleassoci
protein
light
chain
ii
note
sputum
granulocyt
pbc
sa
group
compar
nsa
nc
group
confoc
microscopi
autophagosom
observ
eosinophil
sputum
granulocyt
pbc
sa
patient
induc
autophagi
cell
increas
eosinophil
cation
protein
express
treat
primari
eosinophil
sa
patient
autophagi
express
increas
affect
dexamethason
treatment
cell
primari
airway
epitheli
cell
autophagi
express
product
increas
attenu
autophagi
inhibitor
includ
dexamethason
cell
significantli
decreas
product
well
autophagi
express
peripher
eosinophil
sa
patient
significantli
higher
nc
conclus
suggest
autophagi
play
pivot
role
sa
pathogenesi
autophagi
modul
may
novel
therapeut
target
convent
therapyresist
sa
patient
background
investig
chang
upper
lower
airway
inflamm
respons
follow
dermatophagoid
pteronyssinu
derp
nasal
provoc
test
npt
derp
sensit
rhiniti
patient
without
asthmat
symptom
method
studi
subject
includ
nonasthmat
derp
sensit
rhiniti
ar
patient
airway
hyperrespons
ahr
arahr
ar
patient
without
ahr
arahr
healthi
control
hc
derp
sensit
hcdp
hc
without
derp
sensit
hcdp
underw
derp
npt
nasal
lavag
resist
sputum
induct
forc
expiratori
volum
second
airway
respons
histamin
bronchoprovoc
exhal
nitric
oxid
feno
perform
hour
npt
number
eosinophil
nasal
lavag
fluid
induc
sputum
eosinophil
determin
result
nasal
airway
resist
increas
npt
subject
four
group
p
predict
decreas
arahr
patient
npt
p
eosinophil
nasal
lavag
fluid
sputum
increas
significantli
npt
arahr
arahr
patient
p
decreas
feno
increas
significantli
npt
arahr
patient
p
whereas
signific
chang
observ
hcdp
hcdp
subject
npt
number
eosinophil
nasal
lavag
strongli
correl
sputum
eosinophil
level
feno
neg
correl
conclus
hous
dust
mite
nasal
provoc
test
may
induc
upper
lower
airway
inflamm
hyperrespons
patient
persist
allerg
rhiniti
without
asthmat
symptom
background
vitamin
sever
immunolog
function
data
relat
vitamin
statu
allergi
controversi
method
studi
investig
associ
serum
concentr
allergi
childhood
studi
popul
part
random
doubleblind
placebocontrol
trial
mother
offspr
high
risk
allergi
receiv
last
week
pregnanc
mixtur
probiot
placebo
birth
child
receiv
month
studi
subject
follow
emerg
sensit
allerg
symptom
year
medic
examin
age
month
year
case
allerg
symptom
level
measur
umbil
cord
blood
sampl
serum
sampl
drawn
age
year
data
categor
tertil
quartil
relat
level
sensit
allergi
analyz
multivari
logist
regress
analysi
result
level
second
tertil
umbil
cord
blood
associ
higher
risk
sensit
age
year
allerg
disord
age
year
serum
sampl
age
year
third
quartil
level
associ
higher
risk
sensit
igemedi
allergi
age
year
conclus
level
earli
childhood
associ
emerg
allergi
associ
appear
nonlinear
instrument
known
fric
test
friction
test
dermatographomet
biomedizinischewekstatt
der
charit
berlin
germani
flat
rectangular
plastic
templat
four
smooth
plastic
tip
vari
length
mm
mm
mm
mm
set
cm
apart
tip
mm
diamet
slightli
round
end
thirti
diagnos
adult
case
femal
male
symptomat
dermatograph
basi
histori
clinic
find
enrol
studi
obtain
written
inform
constentlikewis
thirti
patient
activ
prurit
skin
diseas
alloc
control
grouppati
antihistamin
steroid
otherimmunosuppres
exclud
studi
children
pregnant
femal
unwil
enrol
result
util
fric
test
tradit
ball
point
pen
test
quit
remark
subject
voluntarili
enrol
studi
astound
display
posit
fric
test
defin
one
produc
wheal
centimet
diamet
least
one
tip
unsurprisingli
individu
gener
posit
fric
test
posit
mm
tip
length
control
group
compar
result
differ
tip
length
patient
posit
fric
test
also
record
tabul
expect
length
tip
instrument
posit
correl
probabl
posit
test
subject
posit
mm
length
show
posit
mm
length
procedur
carri
use
ball
point
pen
left
forearm
subject
develop
posit
ball
point
pen
test
develop
wheal
centimet
diamet
within
minut
provoc
whilst
mere
individu
develop
wheal
control
group
advent
fric
test
mani
drawback
ball
point
pen
possibl
elimin
thu
practic
clinician
could
assess
sever
diseas
respons
treatment
without
take
recours
expens
investig
fric
test
use
instrument
assess
sever
symptomat
dermograph
background
previou
studi
suggest
involv
activ
neutrophil
pathogenesi
sever
asthma
howev
mechan
neutrophil
activ
fulli
understood
hypothes
neutrophil
autophagi
extracellular
trap
net
product
may
contribut
activ
neutrophil
sever
asthma
method
neutrophil
isol
peripher
blood
patient
sever
asthma
sa
non
sever
asthma
nsa
left
untreat
treat
ngml
hr
autophagi
level
evalu
microtubuleassoci
light
chain
express
use
western
blot
immunoflruoresc
microscopi
net
product
measur
picogreen
assay
immunoflruoresc
microscopi
effect
autophagi
inhibitor
hydrochloroquinehcq
neutrophil
migrat
assess
neutrophil
chemotaxi
assay
use
system
result
treat
neutrophil
sa
group
produc
significantli
higher
express
nsa
group
p
p
respect
treat
neutrophil
gener
significantli
higher
autophagi
level
compar
neutrophil
sa
group
p
observ
nsa
group
net
product
level
neutrophil
differ
sa
nsa
group
howev
net
level
produc
treat
neutrophil
sa
group
significantli
higher
nsa
group
p
significantli
posit
correl
autophagi
net
product
observ
treat
neutrophil
p
nm
inhibit
express
hcq
induc
accumul
block
autophagosom
degrad
could
significantli
inhibit
migrat
neutrophil
p
p
respect
conclus
autophagi
net
could
contribut
sever
asthma
modul
autophagi
may
help
improv
asthma
sever
reduc
neutrophil
migrat
asthmat
airway
toluen
diisocyan
tdi
lowmolecularweight
high
reactiv
chemic
wide
use
industri
product
polyurethan
foam
vanish
paint
isol
materi
worker
expos
tdi
may
caus
occup
asthma
show
mimic
symptom
asthma
sever
mechan
tdiinduc
occup
asthma
suggest
indic
pathogenesi
may
complex
type
asthma
one
candid
mechan
oxid
stress
previou
investig
found
mice
lack
leukocyt
nadph
oxidas
produc
ro
activ
may
less
lung
inflamm
airway
hyperrespons
wildtyp
wt
mice
tdi
exposur
result
implic
tdi
exposur
may
induc
oxid
stress
mice
lung
caus
lung
inflamm
liu
et
al
therefor
studi
test
use
clinic
antioxid
drug
nacetylcystein
nac
treat
mice
suffer
tdi
experiment
design
treat
mice
nac
three
differ
method
pretreat
mice
pretreat
nac
sensit
tdi
continu
treatment
mice
treat
nac
continu
sensit
tdi
posttreat
mice
treat
nac
sensit
tdi
use
mda
detect
assay
kit
determin
oxid
stress
histolog
analysi
cytokin
profil
screen
perform
determin
inflamm
level
last
measur
mice
lung
resist
complianc
finepoint
resist
complianc
system
lung
mda
product
repres
oxid
level
success
reduc
method
nac
treatment
indic
nac
treatment
success
reduc
oxid
stress
produc
tdi
exposur
histopatholog
analysi
show
reduc
level
inflamm
lung
fibrosi
mucu
product
nac
treatment
tdiinduc
mice
moreov
tditreat
mice
nac
treatment
better
lung
function
paramet
group
without
nac
treatment
treatment
nac
three
differ
method
could
success
cure
mice
suffer
tdi
exposur
mechan
antioxid
drug
reveal
therapi
tdi
induc
occup
asthma
refer
liu
sy
wang
wz
yen
cl
tsai
yang
pw
wang
jy
ho
cy
shieh
cc
leukocyt
nicotinamid
adenin
dinucleotid
phosphatereduc
oxidas
requir
isocyanateinduc
lung
inflamm
journal
allergi
clinic
immunolog
korean
ginseng
panax
ginseng
sanyak
dioscorea
batata
wide
use
food
herbal
medicin
case
ginsenginduc
occup
asthma
oa
rhiniti
inhal
powder
herbal
materi
ginseng
report
case
anaphylaxi
due
ginseng
sanyak
sensit
via
inhal
woman
present
symptom
indigest
abdomin
pain
dyspnea
chest
discomfort
ingest
fresh
ginseng
hemp
juic
diagnos
nonallerg
asthma
rhiniti
howev
oa
due
variou
herbal
materi
ginseng
sanyak
powder
sensit
work
pharmacist
serum
total
ige
level
increas
serum
specif
ige
ginseng
undetect
posit
sanyak
extract
enzymelink
immunosorb
assay
elisa
high
serum
specif
ginseng
extract
note
howev
serum
specif
sanyak
detect
ige
elisa
inhibit
test
show
signific
inhibit
hemp
ginseng
elisa
inhibit
test
show
signific
inhibit
ginseng
sanyak
indic
extract
crossreact
compar
taxonom
classif
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
analysi
reveal
two
bind
compon
find
suggest
although
ige
sensit
occur
via
inhal
rout
repeat
exposur
via
oral
rout
induc
sever
food
allergi
gener
symptom
anaphylaxi
addit
studi
includ
basophil
activ
test
two
extract
need
background
even
though
eczema
herpeticum
hypoalbuminemia
seriou
increasingli
preval
complic
ad
littl
studi
investig
ad
children
investig
relationship
clinic
factor
allerg
laboratori
featur
group
ad
children
depend
presenc
eczema
herpeticum
hypoalbuminemia
method
crosssect
studi
carri
patient
age
month
year
june
april
retrospect
data
collect
individu
medic
record
depend
presenc
eh
hypoalbuminemia
ad
children
divid
three
group
eh
group
hypoalbuminemia
group
sever
ad
group
result
male
gender
relat
presenc
eh
ci
age
relat
age
relat
presenc
hypoalbuminemia
ci
gender
relat
serum
total
ige
ecp
level
higher
eh
group
serum
total
eosinophil
count
level
higher
sever
ad
statist
differ
three
group
skin
cultur
p
even
adjust
age
gender
correl
posit
result
skin
cultur
presensc
eh
signific
p
mrsa
relat
ehgroup
ci
conclus
identifi
male
gender
posit
result
skin
cultur
mrsa
factor
influenc
factor
eh
age
influenc
factor
hypoalbuminemia
ad
children
innat
type
respons
aspergillusfumigatu
murin
model
atop
dermatitislik
skin
inflamm
purpos
atop
dermat
ad
chronic
relaps
inflammatori
skin
diseas
mediat
cell
acut
phase
type
innat
lymphoid
cell
role
initi
respons
investig
whether
involv
skin
inflamm
murin
model
adlik
skin
induc
aspergillusfumigatu
af
method
appli
afcrud
extract
dorsal
skin
balbc
mice
time
week
repeatedli
interv
clinic
score
transepiderm
water
loss
tewl
assess
histolog
examin
level
interferon
ifn
skin
drain
lymph
node
ln
immunoglobulin
e
ige
serum
measur
use
elisa
mrna
express
thymic
stromal
lymphopoietin
tslp
skin
measur
use
realtim
pcr
lin
skin
ln
analyz
use
flow
cytometri
result
clinic
score
tewl
increas
mice
appli
af
afgroup
compar
control
group
histolog
find
show
epiderm
dermal
thick
eosinophil
mast
cell
infiltr
skin
afgroup
level
total
ige
increas
serum
af
group
moreov
afgroup
show
increas
level
supernat
cultur
skin
drain
ln
stimul
af
popul
lin
increas
skin
af
group
mrna
express
increas
skin
afgroup
conclus
studi
suggest
innat
type
respons
af
may
role
skin
inflamm
murin
model
adlik
skin
lesion
induc
af
background
sensit
skin
hyperact
skin
condit
character
sensori
symptom
show
exagger
reaction
respons
intern
stimul
extern
irrit
recent
use
microarraydriven
approach
found
sever
signal
pathway
regul
gene
includ
activin
receptor
downregul
sensit
skin
type
serinethreonin
kinas
receptor
transform
growth
factor
tgf
famili
activ
variou
ligand
nodal
activin
b
method
studi
investig
role
pathogenesi
skin
hypersensit
use
vitro
model
well
human
skin
result
mrna
protein
express
significantli
decreas
sensit
skin
compar
nonsensit
skin
decreas
level
ph
sensit
skin
induc
increas
calcium
influx
transient
receptor
potenti
cation
channel
subfamili
v
member
inde
sensit
skin
show
excess
calcium
accumul
compar
nonsensit
skin
rd
cell
transfect
sirna
exhibit
markedli
enhanc
respons
intracellular
concentr
follow
calcium
ionophor
treatment
furthermor
knockdown
induc
express
calcitonin
generel
peptid
cgrp
indic
caus
role
pathogenesi
pain
sensit
skin
final
investig
whether
stimul
pathway
therapeut
potenti
allevi
sensit
skin
intriguingli
treatment
rd
cell
nodal
induc
substanti
reduct
influx
express
cgrp
increas
knockdown
support
possibl
therapeut
role
stimul
sensit
skin
conclus
taken
togeth
result
demonstr
play
crucial
role
pathogenesi
sensit
skin
activ
signal
pathway
vitro
success
revers
pain
sensat
rd
cell
therebi
rais
possibl
novel
therapeut
approach
skin
hypersensit
background
genomewid
associ
studi
gwass
allerg
sensit
selfreport
allerg
rhiniti
ramasami
jaci
hind
nat
genet
bonnelykk
nat
genet
consist
identifi
nine
genom
region
lpp
atop
nonatop
asthma
repres
two
distinct
subphenotyp
howev
gene
involv
atopicnonatop
asthma
studi
method
genet
associ
analysi
one
singl
nucleotid
polymorph
snp
candid
region
perform
nonhispan
white
asthmat
subject
sarp
csga
acrn
tenor
cohort
n
atop
nonatop
asthma
respect
use
logist
regress
model
express
quantit
trait
loci
eqtl
analysi
use
linear
regress
model
candid
snp
perform
cell
human
bronchial
epitheli
biopsi
bec
n
bronchial
alveolar
lavag
bal
n
sarp
cohort
geo
seri
access
number
result
snp
seven
gene
lpp
associ
gener
physiciandiagnos
asthma
gabriel
studi
p
moffatt
nejm
studi
snp
five
gene
lpp
associ
atop
statu
asthma
subject
p
snp
lpp
show
opposit
risk
allel
asthma
autoimmun
diseas
gene
express
pattern
bec
bal
distinct
bal
ciscorrel
mrna
express
level
lpp
tslp
respect
p
conclus
gene
associ
allerg
sensit
selfreport
allerg
rhiniti
also
associ
gener
asthma
indic
share
genet
factor
among
allerg
diseas
lpp
associ
atop
asthma
gener
asthma
howev
associ
effect
odd
ratio
stronger
atop
asthma
associ
atop
statu
asthma
associ
gener
asthma
indic
import
perform
genet
analysi
homogen
asthma
subphenotyp
asthma
autoimmun
diseas
share
immunopathogenesi
pathway
opposit
direct
tissuespecif
gene
express
regul
snp
lpp
associ
atop
asthma
ciscorrel
gene
express
bal
indic
like
function
snp
abstract
fund
nih
go
grant
object
investig
gastroscop
featur
explor
relationship
clinic
characterist
gastroscop
featur
henochschonlein
puepura
hsp
children
method
take
gastroscop
case
children
hsp
hospit
summar
gastroscop
perform
case
divid
two
group
gastroduoden
mucos
bleed
compar
among
total
time
abdomin
pain
pain
relief
hospit
fast
kidney
injuri
case
group
result
gastroscop
vari
degre
injuri
case
account
case
gastroscop
mainli
reveal
gastroduoden
mucos
congest
edema
rough
eros
bleed
ulcer
involv
case
gastric
case
duoden
involv
mucos
eros
bleed
occur
mainli
duodenum
mostli
descend
duodenum
duoden
bleed
account
case
bulb
case
descend
five
case
ulcer
occur
duodenum
four
case
bulbar
ulcer
one
case
descend
ulcer
esophag
gastric
cardia
mucos
occur
one
case
signific
differ
p
among
time
abdomin
pain
pain
relief
hospit
fast
group
signific
differ
p
incid
kidney
injuri
two
group
children
hospit
conclus
gastroscop
featur
hsp
children
character
bleed
eros
duoden
mucosa
occasion
duoden
ulcer
format
mostli
involv
antral
mucosa
rare
involv
esophagu
cardia
signific
differ
p
among
sever
gastroscop
perform
time
abdomin
pain
fast
hospit
kidney
injuri
case
hospit
background
transient
receptor
potenti
vanilloid
identifi
molecular
target
activ
sensori
neuron
variou
pain
stimuli
report
play
role
signal
activ
cell
howev
role
remain
poorli
understood
allerg
rhiniti
object
exploit
role
use
antagonist
n
tetrahydropyrazin
carboxamid
bctc
knockout
mice
allerg
rhiniti
mice
model
use
sampl
patient
allerg
rhiniti
evalu
molecular
mechan
cell
mediat
signal
pathway
allerg
rhiniti
method
express
measur
cell
cytokin
analysi
cell
receptor
signal
pathway
evalu
bctc
pretreat
cell
line
cell
allerg
paramet
evalu
use
antagonist
knockout
mice
ovachalleng
mice
model
addit
express
assess
patient
allerg
rhiniti
result
express
local
cell
bctc
pretreat
knockout
suppress
cell
cytokin
product
suppress
cell
receptor
signal
pathway
includ
nfkb
map
kinas
nfat
signal
jurkat
cell
line
cell
vitro
antagonist
bctc
theobromin
significantli
reduc
allerg
paramet
symptom
total
ovaspecif
ige
level
mice
model
allerg
rhiniti
knockout
bctc
treat
mice
nasal
eosinophil
infiltr
nasal
mucos
cytokin
transcript
activ
decreas
compar
ovachalleng
wildtyp
mice
human
nasal
mucosa
inflammatori
cell
frequent
observ
doubl
posit
inflammaotri
cell
increas
nasal
mucosa
patient
allerg
rhiniti
compar
nonallerg
rhiniti
normal
control
conclus
activ
cell
involv
tcr
signal
could
novel
therapeut
strategi
allerg
rhiniti
background
allerg
rhiniti
ar
wide
rang
clinic
aspect
comorbid
allerg
diseas
may
accompani
aim
identifi
rhiniti
phenotyp
school
children
predict
prognosi
develop
bronchial
hyperrespons
bhr
method
part
children
health
environment
research
cheer
studi
prospect
followup
studi
year
everi
year
interv
children
age
yearsold
enrol
first
survey
among
children
current
rhiniti
defin
parentalreport
doctordiagnos
rhiniti
rhiniti
symptom
last
month
variabl
includ
age
sex
bodi
mass
index
parent
allerg
histori
incom
matern
educ
level
ar
treatment
last
month
environment
tobacco
smoke
exposur
total
serum
ige
level
eosinophil
percentag
diagnosi
atop
dermat
asthma
lung
function
test
bhr
methacholin
skin
prick
test
use
latent
class
analysi
result
identifi
phenotyp
rhiniti
best
fit
studi
cluster
type
character
nonatopi
low
socioeconom
statu
sampl
cluster
atopi
normal
lung
function
cluster
atopi
impair
lung
function
cluster
nonatopi
high
socioeconom
statu
cluster
total
serum
ige
level
serum
eosinophil
percentag
highest
cluster
children
cluster
show
highest
preval
new
develop
bhr
followup
conclus
rhiniti
phenotyp
rhiniti
cluster
high
atopi
impair
lung
function
children
associ
new
develop
bhr
find
suggest
identif
distinct
rhiniti
phenotyp
help
prevent
progress
new
develop
bhr
aspect
allerg
march
background
anaphylaxi
food
drug
diagnost
reagent
increasingli
report
adult
patient
howev
pathogen
mechan
effici
diagnost
test
settl
basophil
activ
test
bat
use
two
activ
marker
readili
use
assess
basophil
activ
statu
consid
mast
cellbasophil
play
import
role
anaphylaxi
evalu
basophil
activ
statu
use
express
anaphylaxi
patient
compar
allerg
patient
without
anaphylaxi
method
patient
variou
allerg
diseas
includ
asthmarhin
chronic
urticaria
well
anaphylaxi
normal
healthi
control
nc
enrol
studi
allerg
patient
divid
two
group
anaphylaxi
nonanaphylaxi
group
base
presenc
anaphylaxi
differ
drug
food
diagnost
reagent
bat
use
express
perform
baselin
stimul
antiig
calcium
ionophor
bat
base
doubl
stain
antihladr
subsequ
determin
percentag
activ
basophil
flow
cytometri
result
baselin
express
vs
vs
basophil
significantli
higher
anaphylaxi
group
compar
nc
differ
note
nonanaphylaxi
group
posit
cutoff
valu
posit
bat
result
defin
express
posit
bat
rate
tend
higher
anaphylaxi
group
nonanaphylaxi
group
differ
note
express
level
signific
differ
baselin
express
induc
ionophor
accord
age
sex
atop
statu
total
ige
ecp
level
conclus
find
suggest
increas
basal
activ
statu
basophil
may
contribut
develop
anaphylaxi
adult
patient
regardless
atopi
statu
serum
total
ige
ecp
level
bat
appli
allergen
use
confirm
caus
agent
background
antibiot
hypersensit
hospit
patient
challeng
dilemma
sometim
thorough
histori
might
suffici
identifi
culprit
agent
vulner
condit
often
hamper
investig
vivo
test
meanwhil
decis
drug
continu
substitut
urgent
need
enzymelink
immunospot
elispot
assay
previous
shown
effect
detect
drugspecif
cell
respons
thu
conduct
studi
assess
role
elispot
manag
antibiot
hypersensit
clinic
set
method
medic
record
inpati
diagnos
develop
nonimmedi
allerg
reaction
antibiot
underw
interferongamma
elispot
assay
king
chulalongkorn
memori
hospit
bangkok
retrospect
determin
result
total
patient
evalu
mean
age
year
rang
year
femal
twentyeight
patient
underli
diseas
includ
hematolog
malign
solid
tumor
cancer
hiv
infect
autoimmun
diseas
fifteen
individu
concurr
system
corticosteroid
major
subject
experienc
maculopapular
exanthem
mpe
sever
cutan
advers
reaction
mean
durat
drug
intak
onset
symptom
day
mean
interv
symptom
onset
collect
peripher
blood
mononuclear
cell
pbmc
day
case
number
drugspecif
ifngamma
secret
cell
later
analyz
elispot
incub
pbmc
culprit
drug
potenti
altern
drug
beta
lactam
occupi
analysi
penicillin
cephalosporin
carbapenem
frequent
suspect
compound
number
drugspecif
ifngamma
secret
cell
spotform
pbmc
consid
posit
test
among
examin
respons
drug
test
yield
posit
proport
posit
outcom
acut
gener
exanthemat
pustulosi
mpe
drug
rash
eosinophilia
system
symptom
lowest
steven
johnson
syndrom
subsequ
twentyfour
person
underw
drug
challeng
test
abl
toler
altern
medic
elispot
display
neg
result
conclus
provid
excel
neg
predict
valu
favor
sensit
particular
cellmedi
reaction
ifngamma
elispot
might
applic
confirm
antibiot
hypersensit
patient
histori
nonimmedi
reaction
reduc
allerg
risk
prior
receiv
potenti
allergen
drug
background
recent
studi
shown
serum
oh
level
invers
associ
food
allergi
develop
time
studi
relationship
vdr
polymorph
serum
oh
level
allergi
limit
aim
current
studi
investig
vitamin
level
children
food
allergi
differ
variant
taqi
bsmi
foki
vdr
polymorph
understand
function
mechan
vdr
gene
polymorph
may
provid
strategi
prevent
treatment
food
allergi
materi
method
examin
infant
food
allergi
age
month
artifici
feed
measur
oh
level
perform
immunoenzym
method
rtpcr
melt
curv
analysi
use
taqi
bsmi
foki
vdr
singl
nucleotid
polymorph
snp
detect
statist
analysi
kruskalw
posthoc
unpair
aspinwelch
test
use
result
frequenc
allel
variant
aa
ag
gg
foki
site
respect
aa
ag
gg
bsmi
site
cc
tc
tt
taki
site
significantli
decreas
serum
oh
level
carrier
variant
ag
gg
compar
variant
aa
carrier
foki
site
vs
ngml
reveal
statist
signific
differ
serum
oh
level
taqi
bsmi
site
detect
concluson
foki
vdr
polymorph
determin
vitamin
statu
children
food
allergi
background
tree
nut
known
capabl
caus
sever
allerg
reaction
howev
littl
report
detail
oral
challeng
test
individu
tree
nut
purpos
studi
analyz
risk
factor
posit
almond
challeng
test
perform
sagamihara
nation
hospit
b
method
subject
patient
receiv
open
almond
challeng
test
greater
march
april
sagamihara
nation
hospit
oral
food
challeng
ofc
administ
either
divid
dose
hour
interv
divid
dose
minut
interv
challeng
patient
observ
least
hour
sign
subject
object
symptom
deem
clinic
signific
challeng
termin
necessari
treatment
provid
measur
patient
almond
specif
ige
within
one
year
challeng
patient
characterist
posit
rate
ofc
symptom
induc
ofc
retrospect
analyz
c
result
age
rang
subject
year
median
year
male
femal
patient
median
almond
specif
ige
rang
less
kual
median
kual
almond
elimin
children
diet
due
immedi
reaction
almond
patient
due
posit
almond
specif
ige
patient
reason
anxieti
parent
patient
none
patient
histori
immedi
reaction
almond
experienc
case
anaphylaxi
associ
atop
disord
atop
dermat
patient
asthma
patient
allerg
rhiniti
patient
allerg
conjunct
patient
ofc
posit
patient
symptom
posit
ofc
oral
mucos
symptom
patient
cutan
symptom
patient
gastrointestin
symptom
patient
case
anaphylaxi
patient
requir
treatment
dose
oral
antihistamin
need
comparison
ofc
posit
neg
patient
signific
differ
seen
histori
immedi
reaction
almond
vs
signific
differ
seen
factor
includ
almond
specif
ige
kual
vs
kual
conclus
risk
factor
posit
almond
challeng
histori
immedi
reaction
almond
ofc
perform
patient
sensit
almond
confirm
diagnosi
especi
patient
without
histori
immedi
reaction
almond
object
studi
test
specif
formul
diet
supplement
creatin
decreas
express
main
fish
allergen
muscl
sparu
aurata
aurata
effect
creatin
muscl
proteom
also
analyz
method
aquacultur
allow
fish
farm
strict
control
condit
howev
knowledg
farm
practic
use
modul
fish
allergen
inexist
creatin
nitrogen
organ
acid
occur
natur
vertebr
help
suppli
energi
cell
primarili
muscl
creatin
verifi
reduc
express
parvalbumin
rat
skelet
muscl
trial
perform
aurata
use
differ
concentr
creatin
ad
control
diet
creatin
supplement
test
tank
individu
triplic
end
trial
plasma
muscl
individu
collect
analysi
creatin
level
muscl
sampl
analys
cortisol
measur
plasma
address
fish
welfarestress
level
parvalbumin
detect
muscl
sampl
studi
use
proteom
western
blot
techniqu
elisa
commerci
kit
biocheck
uk
compar
proteom
perform
muscl
sampl
studi
differ
protein
express
variou
treatment
understand
effect
creatin
fish
metabol
address
use
differ
gel
electrophoresi
dige
differ
express
analys
use
samespot
softwar
totallab
protein
signific
differ
p
excis
manual
identifi
malditoftof
result
cortisol
level
similar
basal
level
report
aurata
although
treatment
creatin
show
signific
reduct
compar
control
diet
parvalbumin
concentr
show
signific
differ
treatment
creatin
concentr
muscl
show
slight
decreas
fish
fed
supplement
diet
compar
proteom
muscl
show
differ
protein
express
submit
diet
supplement
creatin
four
protein
spot
identifi
parvalbumin
show
signific
differ
express
protein
differenti
express
current
identifi
malditoftof
conclus
current
work
accumul
creatin
found
muscl
fish
fed
diet
supplement
creatin
test
creatin
percentag
fish
diet
significantli
affect
aurata
allergen
potenti
current
work
involv
new
formul
diet
andor
differ
fish
speci
underway
expect
near
futur
develop
specif
fish
diet
target
express
fish
parvalbumin
order
reduc
allergen
potenti
refer
gallo
et
al
j
physiol
background
invari
natur
killer
inkt
cell
play
critic
role
pathogenesi
asthma
previous
report
associ
blood
inkt
cell
lung
function
asthma
patient
suppress
effect
tolllik
receptor
ligand
flagellin
b
flab
asthma
mous
model
object
investig
whether
flab
modul
function
blood
inkt
cell
asthma
patient
method
peripher
blood
mononuclear
cell
pbmc
treat
flab
inkt
cellsderiv
intracellular
cytokin
determin
elisa
flow
cytometri
respect
follow
stimul
agalactosylceramid
agalc
inkt
cell
measur
determin
effect
flabtreat
dendrit
cell
dc
inkt
cell
dc
cell
patient
hous
dust
mitesensit
asthma
cocultur
intracellular
cytokin
inkt
cell
determin
experi
mab
use
result
flab
treatment
reduc
product
inkt
cell
pbmc
cultur
effect
amelior
follow
addit
mab
flabtreat
dc
decreas
frequenc
inkt
cell
effect
elimin
addit
mab
contrast
cell
induc
flab
treatment
effect
disappear
addit
mab
conclus
flab
may
inhibit
inkt
cell
enhanc
inkt
cell
via
dc
fashion
asthma
patient
patient
asthma
phenotyp
associ
inkt
cell
flab
effect
immunomodul
inkt
cellbas
immunotherapi
background
allopurinol
xanthin
oxidas
inhibitor
use
sinc
gout
hyperuricaemia
associ
treatment
malign
renal
calculi
due
hyperuricosuria
known
lead
caus
sever
cutan
advers
drug
reaction
scar
compris
stevensjohnson
syndrom
sj
toxic
epiderm
necrolysi
ten
hypersensit
syndrom
hss
drugrash
eosinophilia
system
symptom
dress
halevi
et
al
vietnam
observ
high
preval
allopurinol
induc
scar
like
due
common
use
high
preval
hlab
hoa
et
al
role
viral
activ
scar
well
establish
review
patient
allopurinol
induc
scar
reveal
possibl
nongenet
risk
factor
methodolog
clinic
histori
examin
find
result
laboratori
investig
eighti
eight
confirm
case
scar
caus
allopurinol
seen
survey
result
total
patient
compris
sj
ten
hssdress
mean
age
year
median
sjsten
vs
hssdress
p
male
preponder
note
male
femal
indic
allopurinol
chronic
gout
acut
gout
asymptomat
hyperuricaemia
unknown
patient
commenc
allopurinol
dose
comed
diuret
anti
hypertens
agent
colchicin
digoxin
probenecid
comorbid
consist
hypertens
renal
insuffici
diabet
dyslipidemia
cardiac
diseas
liver
diseas
indexday
day
median
rang
day
sjsten
vs
hssdress
p
viru
serolog
human
simplex
viru
hsv
posit
igg
igm
epstein
barr
viru
ebv
posit
igg
igm
cytomegaloviru
cmv
posit
igg
igm
abnorm
creatinin
seen
elev
ast
alt
patient
respect
mortal
rate
observ
ten
sjsten
averag
number
natur
caviti
affect
ocular
lesion
occur
patient
mean
scorten
hssdress
fever
eosinophilia
median
gl
patient
facial
oedema
observ
conclus
presenc
viru
infect
common
allopurinol
induc
scar
patient
vietnam
signific
number
scar
could
prevent
avoid
treatment
asymptomat
hyperuricaemia
reduc
start
dose
allopurinol
background
specif
allergen
immunotherapi
sit
effect
treatment
igemedi
allerg
diseas
involv
specif
level
increas
elev
accompani
increas
iggdepend
serum
inhibitori
activ
igefacilit
allergen
bind
igefab
assay
object
function
assay
inhibitori
antibodi
may
correl
close
clinic
outcom
investig
time
cours
serum
inhibitori
activ
igefab
differ
period
dermatophagoid
pteronyssinu
subcutan
immunotherapi
der
psit
rhiniti
andor
asthma
patient
method
studi
involv
adult
patient
allerg
rhiniti
andor
asthma
receiv
cours
der
psit
adult
patient
allerg
rhiniti
andor
asthma
receiv
drug
therapi
control
symptom
medic
score
forc
expiratori
volum
one
second
der
level
serum
inhibitori
activ
week
analyz
result
rhiniti
andor
asthma
symptom
medic
score
well
predict
show
improv
week
week
signific
differ
sit
patient
p
symptom
score
signific
differ
week
week
p
level
der
show
signific
increas
week
der
psit
p
continu
increas
sit
period
serum
obtain
der
psit
significantli
inhibit
der
pige
bind
bcell
igefab
week
sit
rel
der
pige
complex
bind
b
cell
w
w
w
week
w
w
w
p
igefab
signific
differ
week
week
p
conclus
serum
level
inhibitori
activ
igefab
increas
significantli
sit
inhibitori
activ
igefab
may
relev
clinic
efficaci
der
psit
background
periostin
extracellular
matrix
protein
known
play
import
role
process
tissu
remodel
recent
periostin
discov
novel
mediat
allerg
diseas
bronchial
asthma
atop
dermat
howev
role
periostin
patient
chronic
rhinosinus
cr
remain
unclear
therefor
object
studi
investigt
role
periostin
pathophysiolog
cr
patient
method
investig
periostin
express
cellular
origin
uncin
process
mucosa
nasal
polyp
np
tissu
immunohistochemistri
ihc
quantit
revers
transcript
pcr
qrtpcr
enzymelink
immunosorb
assay
elisa
correl
periostin
express
inflammatori
marker
includ
interleukin
il
interferon
ifn
also
explor
result
periostin
express
upregul
np
mucosa
patient
crswnp
compar
uncin
process
tissu
control
crssnp
crswnp
patient
overexpress
periostin
eosinophil
np
compar
noneosinophil
np
confirm
qrtpcr
elisa
posit
correl
periostin
protein
concentr
lundmackay
ct
score
eosinophil
np
doubl
ihc
stain
show
tryptas
cell
one
main
sourc
periostin
among
immun
cell
addit
periostin
mrna
express
posit
correl
express
tryptas
cell
total
ige
homogen
eosinophil
np
overexpress
epitheli
integrin
detect
np
mucosa
crswnp
patient
compar
control
crssnp
moreov
eosinophil
np
express
epitheli
integrin
higher
noneosinophil
np
posit
correl
concentr
periostin
furthermor
periostin
mrna
express
eosinophil
np
patient
posit
correl
neg
relat
howev
associ
conclus
data
suggest
role
periostin
pathogenesi
nasal
polypogenesi
especi
eosinophil
np
therefor
periostin
protein
might
new
treatment
target
patient
crswnp
background
investig
dna
copi
number
mycoplasma
pneumonia
express
helper
th
cell
produc
cytokin
bronchoalveolar
lavag
fluid
balf
children
refractori
mp
pneumonia
mpp
method
enrol
children
mpp
case
assign
refractori
mpp
fail
respond
least
treatment
macrolid
antibiot
case
common
mpp
total
children
congenit
bronchial
atresia
stenosi
includ
control
elisa
use
assess
balf
level
rtpcr
use
determin
mpdna
copi
number
balf
result
compar
common
mpp
group
refractori
mpp
group
significantli
higher
mpdna
copi
number
vs
ml
p
children
refractori
mpp
achiev
significantli
increas
balf
level
common
mpp
control
vs
vs
vs
vs
vs
vs
pgml
p
signific
differ
balf
level
found
among
three
group
vs
vs
pgml
p
conclus
refractori
mpp
may
associ
high
mp
load
mediat
respons
may
domin
develop
refractori
mpp
background
surg
incid
bronchial
asthma
around
world
especi
develop
countri
like
india
mani
factor
chang
ambient
air
qualiti
increas
air
pollut
metamorph
chang
live
habit
lifestyl
climat
allergen
like
pollen
fungi
etc
present
air
play
pivot
role
pathogenesi
sever
allerg
complaint
allerg
rhiniti
bronchial
asthma
etc
studi
reveal
complex
interact
genet
environment
factor
involv
asthma
india
home
around
million
asthmat
asthma
preval
increas
india
especi
kolkata
provid
patient
best
possibl
diagnosi
treatment
identif
offend
allergen
major
import
howev
earli
detect
individu
genet
risk
develop
pollen
mold
allergi
also
essenti
element
adopt
effect
avoid
strategi
design
appropri
therapi
accustom
inform
respect
mostli
avail
develop
western
countri
preliminari
inform
develop
countri
like
india
particularli
kolkata
metropolitan
area
still
fragmentari
insuffici
therefor
present
studi
involv
identif
offend
outdoor
aeroallergen
also
associ
genet
pathway
nasobronchi
asthma
among
kolkata
popul
method
skinprick
test
done
among
asthmat
patient
common
aeroallergen
total
serum
ige
concentr
measur
pcrrflp
done
patient
nonasthmat
control
character
function
polymorph
c
posit
candid
gene
allergi
associ
genet
polymorph
made
clinicopatholog
condit
result
present
studi
identifi
coco
predomin
outdoor
aeroallergen
kolkata
follow
caesalpinia
peltophorium
belong
pollen
categori
patient
childhoodonset
asthma
significantli
sensit
toward
aeroallergen
significantli
higher
serum
ige
level
adultonset
signific
differ
found
distribut
snp
genotyp
among
case
control
howev
among
patient
frequenc
c
allel
significantli
higher
childhoodonset
group
adultonset
concordantli
former
cc
genotyp
associ
signific
higher
level
total
serum
ige
ct
tt
conclus
kolkata
pollen
common
outdoor
aeroallergen
coco
predomin
among
pollen
childhoodonset
adultonset
asthma
show
signific
differ
allergen
sensit
differenti
associ
polymorph
might
involv
process
background
although
preval
allerg
diseas
common
western
develop
countri
incid
increas
rapid
pace
develop
countri
like
india
becom
doubl
tripl
even
quadrupl
last
decad
howev
data
regard
still
fragmentari
except
scatter
inform
indian
context
rough
estim
india
million
peopl
suffer
one
allerg
manifest
method
last
year
studi
differ
aspect
hous
dust
mite
allergi
carri
kolkata
popul
includ
entomolog
clinic
immunolog
paramet
identif
allergen
mite
allergi
skin
test
estim
total
ige
level
identif
allergen
specif
ige
antibodi
result
inventori
hous
dust
mite
fauna
kolkata
india
prepar
total
speci
belong
genera
famili
order
identifi
speci
record
first
time
india
speci
identifi
new
scienc
genu
dermatophagoid
alon
constitut
total
acarin
fauna
predomin
dpteronyssinu
follow
blomia
tropicali
farina
austroglyciphag
geniculatu
pterinyssinu
dp
farina
df
coexist
habitat
maximum
number
mite
isol
individu
dust
sampl
dust
season
trend
indic
mite
count
higher
premonsoon
minimum
winter
preliminari
screen
skin
prick
test
show
patient
react
posit
toward
allergen
mite
either
dp
df
patient
elev
level
serum
ige
mean
valu
higher
control
sera
p
patient
studi
group
show
allergen
specif
ige
antibodi
hous
dust
dermatophagoid
mite
conclus
studi
confirm
df
main
sourc
allergen
hous
dust
kolkata
metropoli
follow
dp
increas
use
heavi
curtain
blanket
pad
furnitur
sofa
set
soft
toy
use
foam
mattress
instead
convent
cotton
mattress
favour
growth
multipl
hous
dust
mite
ultim
increas
chanc
durat
exposur
indoor
allergen
metamorph
chang
life
style
includ
diet
dietari
habit
acquisit
western
lifestyl
low
standard
indoor
environ
increas
air
pollut
intoler
psycholog
stress
blame
increas
occurr
frequent
recurr
india
background
object
cysteinyl
leukotrien
mediat
allerg
inflamm
interact
type
cysteinyl
leukotrien
receptor
g
proteincoupl
receptor
gpr
indirectli
purinerg
receptor
express
platelet
eosinophil
granul
requir
platelet
activ
thu
result
recruit
eosinophil
lung
understand
role
leukotrien
relat
receptor
allerg
asthma
compar
express
ovalbumininduc
allerg
asthma
mous
model
method
balbc
mice
inject
intraperiton
ovalbumin
ova
follow
nebul
ova
challeng
bronchoalveolar
lavag
fluid
balf
cell
lung
tissu
collect
vehicl
treat
control
group
platelet
remov
mice
inject
antibodi
western
blot
immunocytochemistri
immunohistochemistri
appli
evalu
express
receptor
result
signal
distribut
epitheli
line
lung
parenchyma
plateletdeplet
nonplateletdeplet
mice
respect
express
significantli
higher
lung
tissu
ovasensit
mice
vehicletr
mice
p
p
p
respect
express
ratio
vehicletr
mice
ovasensit
mice
local
eosinophil
balf
elev
markedli
ova
challeng
ovasensit
mice
found
lowest
level
balf
cell
lung
tissu
conclus
increas
express
note
lung
tissu
mous
model
allerg
asthma
addit
effect
antagonist
antagonist
investig
futur
therapeut
target
refer
sc
pitchford
blood
pp
cum
j
immunol
background
aim
studi
verifi
associ
autolog
serum
skin
test
asst
laboratori
marker
autoimmun
patient
chronic
idiopath
urticaria
ciu
evalu
whether
paramet
like
asst
thyroid
autoantibodi
ta
antinuclear
antibodi
ana
serum
total
immunoglobulin
e
ige
could
predict
ciu
sever
includ
urticari
activ
refractori
method
total
ciu
patient
perform
asst
identifi
autoreact
serum
antibodi
thyroglobulin
atg
thyroid
peroxidas
atpo
ana
total
ige
measur
clinic
sever
ciu
estim
urticaria
sever
score
ua
maximum
level
medic
abrog
wheal
pruritu
analyz
associ
among
asst
laboratori
marker
clinic
sever
differ
subgroup
base
asst
laboratori
marker
result
total
patient
test
posit
asst
patient
test
posit
atpo
atg
posit
percent
ana
femal
preponder
serum
total
ige
level
measur
patient
found
elev
asst
analyz
relat
laboratori
marker
invers
correl
asst
serum
ige
level
observ
significantli
higher
percentag
posit
ana
found
patient
posit
asst
compar
patient
neg
asst
correl
atpo
atg
asst
signific
statist
differ
patient
posit
asst
significantli
higher
score
ua
compar
patient
neg
asst
howev
signific
statist
differ
maximum
level
medic
asst
maximum
level
medic
patient
elev
ige
significantli
higher
normal
ige
conclus
signific
associ
asst
thyroid
autoimmun
identifi
studi
patient
posit
asst
diseas
activ
patient
elev
total
ige
found
refractori
lower
level
medic
like
antihistamin
introduct
asthma
chronic
natur
may
advers
affect
life
qualiti
patient
lead
mental
disturb
anxieti
depress
accur
patient
compar
healthi
popul
life
qualiti
survey
use
evalu
effect
asthma
term
physic
psycholog
social
function
patient
life
particular
import
emot
factor
come
forefront
case
symptom
control
anxieti
common
psycholog
disord
among
patient
respiratori
system
diseas
materi
method
aim
compar
anxieti
depress
level
patient
sever
asthma
omalizumab
treatment
patient
anxieti
level
measur
state
trait
anxieti
inventori
stai
depress
level
measur
beck
depress
scale
find
five
male
fifteen
femal
patient
enrol
studi
averag
age
patient
averag
score
beck
depress
scale
patient
treatment
rel
score
higher
treatment
static
meaning
compar
treatment
score
p
stai
averag
score
treatment
statist
meaning
differ
anxieti
score
averag
treatment
p
anxieti
score
higher
treatment
failur
symptom
control
asthma
lead
depress
think
patient
examin
psycholog
disord
may
improv
qualiti
life
keyword
antiig
asthma
adult
qualiti
life
introduct
object
chronic
spontan
urticaria
csu
common
debilit
problem
worldwid
despit
preval
middl
east
littl
data
avail
econom
impact
csu
public
health
system
studi
evalu
direct
medic
cost
treat
refractori
csu
patient
kuwait
also
evalu
budget
impact
omalizumab
monoclon
antiig
antibodi
use
patient
method
preval
csu
estim
delphi
method
data
regard
drug
util
health
care
system
util
collect
retrospect
chart
refractori
csu
patient
follow
alrash
allergi
center
kuwait
cost
calcul
health
system
perspect
oneway
sensit
analys
conduct
price
util
cost
compon
result
omalizumab
use
total
direct
cost
treat
refractori
csu
patient
estim
kd
us
per
year
correspond
around
kd
per
patient
per
annum
us
total
cost
princip
gener
outpati
visit
kd
correspond
total
cost
omalizumab
use
cost
estim
kd
us
per
year
correspond
around
kd
per
patient
per
annum
us
total
cost
princip
gener
omalizumab
cost
kd
correspond
total
cost
direct
cost
treat
csu
patient
decreas
use
omalizumab
convent
medic
cost
hospit
cost
reduc
er
cost
reduc
cost
estim
sensit
variat
price
util
outpati
visit
price
omalizumab
conclus
econom
burden
refractori
csu
kuwait
high
introduct
omalizumab
health
care
system
costli
high
price
howev
omalizumab
proven
effect
drive
direct
cost
background
maiz
major
crop
grown
india
consum
variou
form
although
mani
patient
report
allerg
symptom
maiz
systemat
studi
allergen
roperti
lack
investig
aim
find
maiz
sensit
indian
patient
respiratori
allergi
character
allergen
clinic
signific
clinico
immunolog
evalu
method
patient
attend
allergi
clinic
respiratori
allergi
screen
maiz
sensit
spt
allergen
specif
ige
elisa
ige
bind
epitop
identifi
immunoblot
transfer
sd
page
separ
protein
nc
membran
major
allergen
identifi
indian
patient
subject
situ
trypsin
digest
malditof
determin
molecular
mass
peptid
sequenc
similar
cross
reactiv
maiz
seed
extract
evalu
extract
pea
nut
rice
unrel
putranjiva
roxburghiipollen
extract
immunoblot
inhibit
studi
result
antigen
extract
maiz
seed
contain
mgml
protein
extract
subject
sd
protein
profil
protein
band
molecular
weight
rang
kd
five
protein
fraction
kd
record
stabl
min
simul
gastric
fluid
sgf
digest
assay
use
clinic
maiz
posit
patient
sera
significantli
rais
maiz
specif
ige
titer
ige
bind
activ
kd
protein
smear
record
cross
inhibit
studi
suggest
cross
reactiv
reactiv
maiz
rice
account
complet
disappear
observ
kd
immunoreact
protein
smear
howev
biochem
character
smear
correspond
two
protein
band
kd
gel
ms
spectra
observ
hypothet
molecular
weight
kd
kd
share
sequenc
homolog
greater
un
annot
rice
seed
protein
databas
conclus
two
import
immuno
reactiv
protein
fraction
maiz
identifi
specul
belong
major
famili
endosperm
protein
zein
background
hous
dust
mite
hdm
allergen
major
caus
asthma
worldwid
hdm
extract
purifi
allergen
current
treatment
choic
known
specif
immunotherapi
aim
strategi
drive
immun
reaction
away
allerg
respons
induc
andor
treg
cellular
respons
regard
toll
like
receptoractiv
adjuv
use
induc
respons
adjuv
capabl
induc
somehow
safer
treg
respons
poorli
investig
method
describ
antiallerg
properti
therapeut
murin
model
asthma
hdm
allergen
der
der
coencapsul
dexamethason
dehydrationrehydr
vesicl
drv
dexamethason
cortisol
analogu
immunesuppressor
activ
known
induc
specif
treg
respons
still
advers
effect
associ
system
prolong
use
optim
lipid
composit
term
physicalchem
antiallerg
properti
assess
use
drv
liposom
cholesterol
differ
phosphatidylcholin
pc
encapsul
der
allergen
dipalmitoilpc
cholesterol
liposom
encapsul
differ
dose
dexamethason
use
assess
antiallerg
effect
result
liposom
composit
produc
similar
vesicl
size
protein
encapsul
overal
safe
profil
treat
mice
preliminari
result
indic
encapsul
hdm
allergen
der
dexamethason
liposom
diminish
allerg
respons
trait
interleukin
ige
antibodi
level
conclus
result
highlight
possibl
use
deliveri
system
liposom
modul
immun
respons
prevent
advers
reaction
free
solubl
pharmacolog
compound
like
dexamethason
background
chronic
rhinosinus
nasal
polyp
crswnp
one
preval
chronic
inflammatori
diseas
signific
impact
morbid
qualiti
life
yet
littl
known
pathogenesi
object
sought
evalu
immunomodulatori
effect
tonsil
deriv
mesenchym
stem
cell
tmsc
mous
model
eosinophil
rhinosinus
nasal
polyp
erswnp
method
effect
tmsc
evalu
balbc
mice
randomli
divid
group
neg
control
group
nasal
polyp
group
tmsc
group
tmsc
ad
group
tmsc
incub
adipogen
differenti
medium
induct
ova
induc
erswnp
model
tmsc
administ
intraven
tmsc
tmsc
ad
group
one
time
per
week
subsequ
ovaseb
three
time
per
week
ova
one
time
per
week
seb
challeng
conduct
week
studi
mrna
protein
express
profil
cytokin
chemokin
adhes
molecul
nasal
mucosa
spleen
lymphnod
use
molecular
biochem
histopathologicaland
immunohistolog
method
result
intraven
inject
tmsc
significantli
reduc
allerg
symptom
eosinophil
neutrophil
nasal
polyp
count
serum
ova
level
moreov
nasal
lymphnod
system
cytokin
profil
nasal
innat
cytokin
chemokin
express
reduc
tmsc
inject
group
compar
nasal
polyp
group
usual
tmsc
ad
group
show
better
inhibitori
effect
inflamm
tmsc
group
addit
result
show
tmsc
inject
groupssignificantli
increas
treg
posit
cell
cell
cervic
lymphnod
compar
nasal
polyp
group
conclus
demonstr
administrationof
tmsc
effect
reduc
polyp
format
inflammatori
cell
influx
cytokin
profil
chemokin
molecul
express
tcell
subset
distribut
suggest
mechan
reduc
cr
inflamm
less
polyp
format
mous
model
erswnp
therefor
tmsc
treatment
potenti
altern
therapeut
modal
crswnp
background
dermograph
urticaria
du
subtyp
urticaria
character
strong
itch
wheal
induc
mechan
scratch
oral
histamin
antagonist
antihistamin
recommend
first
line
treatment
may
reduc
symptom
certain
popul
patient
howev
du
mani
patient
refractori
antihistamin
serious
impair
qol
sever
medic
high
dose
antihistamin
montelukast
cyclosporin
suggest
second
line
therapi
japanes
european
american
guidelin
howev
clinic
evid
treatment
mostli
obtain
chronic
spontan
urticaria
effect
specif
studi
du
report
case
antihistamineresist
du
treat
second
line
medic
suggest
guidelin
b
method
thirtyf
patient
visit
hiroshima
univers
dermatolog
clinic
januari
april
treatment
du
studi
retrospect
c
result
du
patient
refractori
standard
dose
antihistamin
howev
symptom
disappear
patient
increas
dose
antihistamin
twice
ten
patient
treat
antihistamin
montelukast
clear
symptom
patient
whose
symptom
subsid
high
dose
antihistamin
montelukast
addit
took
cyclosporin
six
symptom
diminish
two
show
chang
two
patient
drop
side
effect
conclus
approxim
patient
du
refractori
standard
dose
antihistamin
howev
satisfactorili
treat
higher
dose
antihistamin
andor
combin
medic
second
line
treatment
suggest
guidelin
urticaria
worth
tri
du
refractori
antihistamin
background
report
peanut
allergi
peanut
componentresolv
diagnost
crd
korean
children
present
studi
tri
establish
diagnost
decis
point
ddp
peanut
sige
antibodi
predict
outcom
oral
food
challeng
ofc
addit
evalu
use
ige
antibodi
recombin
peanut
compon
ara
h
diagnos
peanut
allergi
method
korean
children
age
month
suspect
igemedi
peanut
allergi
enrol
diagnosi
peanut
allergi
confirm
open
ofc
presenc
anaphylaxi
histori
cutoff
level
sige
peanut
peanut
compon
determin
analyz
receiv
oper
characterist
curv
result
fortyeight
children
boy
girl
suspect
peanut
allergi
analyz
previous
establish
ddp
peanutsig
antibodi
kul
show
sensit
specif
ppv
npv
studi
popul
median
level
peanutsig
kul
vs
kul
p
ara
h
kul
vs
kul
p
statist
signific
higher
peanutallerg
group
peanuttoler
group
peanutsig
concentr
indic
posit
predict
valu
ppv
kul
ara
h
level
kul
show
ppv
conclus
result
show
previous
establish
ddp
peanutsig
level
may
use
predictor
outcom
ofc
korean
children
suspect
peanut
allergi
ara
h
import
allergen
korean
children
peanut
allergi
cutoff
level
peanut
kul
ara
h
kul
might
help
diagnosi
peanut
allergi
korean
children
background
limit
efficaci
topic
tacrolimu
may
result
insuffici
frequenc
applic
amount
appli
eczema
patient
object
investig
frequenc
applic
amount
use
topic
tacrolimu
patient
variou
type
eczema
method
frequenc
applic
appli
amount
topic
tacrolimu
assess
week
result
total
eczema
patient
complet
studi
averag
number
applic
per
day
despit
instruct
appli
topic
tacrolimu
twice
daili
respect
frequenc
applic
patient
follow
prescript
first
second
week
respect
averag
amount
appli
per
total
bodi
surfac
area
g
patient
appli
expect
amount
topic
tacrolimu
limit
frequenc
applic
selfreport
possibl
result
limit
accuraci
conclus
korean
patient
eczema
tend
appli
topic
tacrolimu
less
frequent
inappropri
amount
clear
instruct
regard
frequenc
amount
applic
need
improv
therapeut
outcom
treatment
topic
tacrolimu
background
clinic
practic
basophil
activ
test
bat
thought
safe
sensit
test
diagnos
igemedi
allerg
diseas
test
whether
bat
use
mice
cours
develop
murin
bat
use
igemedi
activ
marker
found
express
murin
basophil
identif
marker
antigensensit
basophil
decreas
follow
specif
antigen
challeng
interestingli
decreas
alway
harmon
increas
express
sinc
igg
well
ige
contribut
mous
anaphylaxi
hypothes
decreas
basophil
induc
iggmedi
cell
activ
object
aim
establish
whether
marker
iggmedi
basophil
activ
whether
express
correl
iggmedi
anaphylaxi
mous
model
furthermor
attempt
evalu
whether
bat
use
basophil
activ
marker
indic
antigen
cow
milkbas
infant
formula
compar
system
anaphylaxi
test
mice
method
mous
basophil
stimul
via
level
analyz
flow
cytometri
basophil
deriv
mice
passiv
sensit
antiserum
iggigg
subclassdeplet
antiserum
challeng
system
anaphylaxi
induc
iv
inject
monoclon
antibodi
express
peripher
basophil
analyz
evalu
antigen
infant
formula
basophil
mice
activ
sensit
casein
stimul
serial
dilut
convent
partial
hydrolyz
extens
hydrolyz
infant
formula
addit
system
anaphylaxi
assess
follow
iv
inject
formula
immun
mice
result
stimul
via
induc
signific
increas
express
small
effect
howev
stimul
strongli
reduc
express
passiv
sensit
experi
decreas
express
induc
antigen
challeng
cancel
deplet
igg
intraven
inject
led
downregul
basophil
accompani
drop
rectal
temperatur
basophil
activ
induc
convent
extensivelyhydrolyz
formula
partial
hydrolyz
formula
induc
basophil
activ
somewhat
weakli
induct
system
anaphylaxi
formula
correl
bat
result
conclus
use
activ
marker
enabl
evalu
ige
iggmedi
murin
basophil
activ
respect
bat
system
would
use
evalu
food
antigen
background
nitric
oxid
might
variou
role
develop
defens
upper
airway
inflamm
fraction
exhal
nitric
oxid
feno
nasal
nitric
oxid
nno
use
screen
tool
evalu
airway
inflamm
chronic
rhinosinus
cr
allerg
rhiniti
whether
level
feno
nno
increas
decreas
diseas
evid
studi
perform
assess
whether
feno
use
screen
tool
evalu
cr
patient
whether
use
evalu
postop
state
cr
method
thirti
patient
cr
twenti
normal
control
group
recruit
feno
measur
perform
use
handheld
electrochem
analyz
nasal
oral
rout
mean
valu
consecut
measur
record
nasal
feno
oral
feno
check
preoper
month
month
result
preoper
nasal
oral
feno
nasal
ppb
oral
ppb
patient
cr
significantli
higher
normal
control
group
nasal
ppb
oral
ppb
nasal
oral
feno
decreas
oper
time
manner
three
month
oper
nasal
feno
oral
feno
significantli
decreas
compar
preoper
level
nasal
ppb
vs
ppb
oral
ppb
vs
ppb
p
conclus
feno
could
use
screen
tool
assess
evalu
cr
patient
also
use
evalu
postop
state
cr
chang
feno
level
background
chronic
rhinosinus
nasal
polyp
hard
treat
therapeut
effect
doxycyclin
oral
glucocorticoid
mepolizumab
omalizumab
signific
reduct
nasal
polyp
score
previous
investig
random
control
trial
aim
studi
compar
effect
treatment
polyp
score
symptom
score
inflammatori
paramet
method
total
patient
randomli
assign
receiv
doxycyclin
day
methylprednisolon
decreas
dose
day
mepolizumab
singl
intraven
inject
omalizumab
subcutan
dose
placebo
three
separ
clinic
doubleblind
placebocontrol
trial
particip
follow
week
endoscop
evalu
nasal
polyp
score
assess
symptom
score
measur
marker
inflamm
nasal
secret
serum
occur
baselin
week
week
treatment
complet
week
except
patient
receiv
fourth
subcutan
dose
omalizumab
week
result
treatment
option
significantli
reduc
nasal
polyp
score
compar
baselin
placebo
methylprednisolon
initi
dramat
effect
symptom
score
cessat
treatment
symptom
score
worsen
progress
return
baselin
week
mepolizumab
doxycyclin
methylprednisolon
specif
effect
local
system
inflammatori
marker
omalizumab
alter
eosinophilia
marker
inflamm
conclus
omalizumab
mepolizumab
oral
doxycyclin
caus
longterm
reduct
nasal
polyp
size
wherea
methylprednisolon
initi
caus
strongest
reduct
polyp
size
recurr
occur
earlier
total
symptom
score
parallel
trend
doxycylin
work
eosinophil
neutrophil
inflamm
nasal
polyp
wherea
effect
mepolizumab
methylprednisolon
appar
eosinophil
marker
omalizumab
reduc
marker
eosinophil
inflamm
neutrophil
inflamm
nasal
secret
benefici
effect
omalizumab
seem
mediat
direct
effect
ige
receptor
rather
effect
marker
eosinophil
cascad
rational
investig
role
helper
th
cell
steroid
resist
sr
asthma
steroid
sensit
ss
resist
sr
th
clone
select
vitro
adopt
transfer
unprim
mice
effect
analyz
vitro
vivo
method
vitro
evalu
ovalbumin
ova
reactiv
th
clone
cultur
antigen
present
cell
ova
presenc
variou
concentr
dexamethason
dex
prolif
respons
th
clone
measur
incorpor
vivo
assess
unprim
balbc
mice
transfer
th
clone
challeng
ova
administ
dex
subcutan
bronchoalveolar
lavag
fluid
balf
obtain
hr
challeng
number
infiltr
cell
differenti
count
administ
nasal
inhal
venou
inject
result
ss
sr
clone
select
base
effect
dex
prolif
respons
antigenstimul
th
clone
airway
infiltr
eosinophil
lymphocyt
mice
transfer
ss
clone
effect
inhibit
administr
dex
contrast
mice
transfer
sr
clone
significantli
inhibit
dex
administr
significantli
suppress
prolifer
dextreat
sr
clone
vitro
eosinophil
infiltr
sr
asthma
model
transfer
sr
clone
vivo
conclus
steroid
sensit
th
clone
assess
vitro
consist
adopt
transfer
asthma
model
assess
vivo
costimulatori
signal
mediat
crucial
induct
steroid
resist
vitro
vivo
background
periostin
matricelluar
protein
synthes
airway
epitheli
cell
induc
interleukin
recent
serum
periostin
level
suggest
biomark
th
airway
inflamm
prognost
indic
asthma
treatment
howev
serum
periostin
level
allerg
rhiniti
elucid
well
aim
investig
relationship
serum
periostin
allerg
rhiniti
korea
children
method
total
children
boy
girl
age
year
enrol
studi
serum
periostin
level
measur
skin
prick
test
perform
aeroallergen
commonli
found
korea
inform
collect
includ
sex
age
bmi
parent
allergi
histori
parent
smoke
statu
multivari
analysi
use
confirm
associ
serum
periostin
level
allerg
rhiniti
result
children
children
show
allerg
rhiniti
symptom
past
month
children
show
posit
skin
prick
test
least
one
allergen
serum
periostin
level
differ
allerg
sensit
group
control
group
vs
divid
subject
group
control
sensit
without
allerg
rhiniti
symptom
b
allerg
symptom
without
sensit
c
allerg
rhiniti
symptom
sensit
statist
differ
mean
valu
group
ad
also
could
find
signific
associ
serum
periostin
allerg
rhiniti
multivari
analysi
conclus
allerg
rhiniti
allerg
sensit
korean
children
influenc
serum
periostin
level
studi
need
elucid
mean
serum
periostin
level
allerg
rhiniti
background
disintegrin
metalloproteas
adam
multifunct
gene
famili
contribut
homeostasi
extracellular
matrix
transduct
specif
intracellular
signal
organogenesi
inflamm
tissu
remodel
adhes
cell
migrat
best
character
sheddas
put
substrat
widespread
includ
variou
inflammatori
modul
similar
term
protein
sequenc
structur
properti
catalyt
domain
object
assess
role
adam
adam
allerg
rhiniti
assay
express
materi
method
express
adam
investig
allerg
nasal
mucosa
compar
nonallerg
nasal
mucosa
tissu
sampl
analyz
real
time
polymeras
chain
reaction
pcr
western
blot
result
mrna
protein
level
significantli
lower
allerg
nasal
mucosa
nonallerg
nasal
mucosa
p
mrna
differ
significantli
allerg
nasal
mucosa
nonallerg
nasal
mucosa
protein
level
significantli
higher
nonallerg
nasal
mucosa
allerg
nasal
mucosa
p
background
atop
dermat
ad
presenc
activ
correl
loss
filaggrin
dysregul
dolichylphosph
udpnacetylglucosamin
nacetylglucosaminephosphotransferas
transferas
caus
disturb
filaggrin
express
find
indic
overexpress
keratinocyt
treat
overcom
pp
provid
dolichyl
phosphat
substitut
normal
express
nglycosyl
filaggrin
loss
prevent
aim
present
studi
investig
clinic
efficaci
polyprenol
pp
children
ad
method
scorad
index
use
measur
sever
diseas
evalu
effect
treatment
children
month
old
leukotrien
dolichol
dol
assay
urin
excret
immunocap
total
ige
level
measur
serum
dolichol
phosphat
phosphat
transferas
gpt
activ
defin
dermal
fibroblast
metabol
label
ml
method
h
mannos
pp
mgkgday
per
os
topic
ointment
pp
given
random
doubleblind
placebocontrol
studi
effect
treatment
evalu
weekli
six
month
result
initi
patient
ad
found
statist
signific
increas
leukotrien
dol
excret
total
ig
e
level
gpt
activ
fibroblast
comparison
control
overexpress
higher
ad
skin
biopsi
normal
skin
biopsi
ad
cell
differ
normal
one
filaggrin
content
lost
time
caus
overexpress
abber
nglycosyl
filaggrin
dpc
studi
show
overexpress
dpc
intermedi
decreas
keratinocyt
presenc
presenc
cell
normal
dol
excret
achiev
week
treatment
ige
week
gpt
one
month
patient
remiss
month
signific
differ
ad
score
pp
placebo
p
recogn
conclus
present
studi
demonstr
allevi
ad
children
use
oral
topic
polyprenol
mechan
activ
involv
main
link
ad
pathogenesi
rational
perform
newli
develop
mobil
allergen
exposur
chamber
allow
multicent
trial
exactli
standard
procedur
valid
technic
clinic
point
view
technic
paramet
includ
particl
eg
pollen
dispers
stabil
spatial
particl
distribut
subject
posit
test
period
temperatur
rel
humid
stabil
sinc
chamber
use
individu
pollen
exposur
seat
posit
particl
sourc
particl
relat
paramet
measur
seat
posit
accept
appropri
altern
natur
allergen
exposur
clinic
trial
clinic
valid
must
document
high
reliabl
provok
symptom
repeat
provoc
method
temperatur
rel
humid
level
within
chamber
monitor
without
subject
present
chamber
test
execut
sever
day
outsid
temperatur
rang
pollen
distribut
valid
use
sediment
measur
posit
variou
particl
concentr
particl
test
grass
pollen
use
chamber
use
exposur
grass
birch
pollen
adult
subject
without
allerg
symptom
due
birch
andor
grass
pollen
last
two
season
exposur
min
done
outsid
season
nasal
conjunctiv
bronchial
symptom
record
subject
paramet
everi
min
object
paramet
spirometri
peakflow
exhal
nitrogen
oxid
feno
peak
nasal
inspiratori
flow
nasal
secret
obtain
baselin
exposur
result
measur
show
temperatur
varianc
humid
varianc
without
subject
present
circular
area
diamet
cm
particl
concentr
defin
concentr
accuraci
remain
cours
hour
particl
found
breathabl
air
nonact
seat
posit
refloat
measur
show
particl
concentr
increas
repeat
exposur
four
time
birch
grass
pollen
differ
concentr
elicit
reproduc
clinic
symptom
three
organ
signific
differ
placebo
verum
pollen
exposur
gener
symptom
start
occur
min
reach
plateau
follow
min
continu
exposur
pollen
strongest
symptom
nasal
origin
conclus
novel
mobil
allergen
exposur
chamber
fulfil
need
reproduc
well
control
pollen
exposur
regard
appropri
allergen
immunotherapi
studi
phase
one
two
pharmaceut
drugsantiallerg
drug
background
lead
exposur
could
caus
variou
immunolog
effect
human
sever
studi
shown
blood
lead
concentr
posit
associ
total
immunoglobulin
e
ige
howev
studi
investig
whether
allerg
sensit
could
respons
associ
lead
exposur
total
ige
investig
whether
differ
associ
lead
exposur
total
ige
depend
presenc
absenc
dermatophagoid
farina
df
sensit
base
data
larg
populationbas
survey
method
use
data
korea
nation
health
nutrit
examin
survey
knhane
conduct
serum
level
heavi
metal
mercuri
cadmium
lead
measur
total
df
specif
ige
measur
urinari
cotinin
level
investig
inform
particip
sex
age
bodi
mass
index
bmi
household
incom
also
obtain
data
particip
analyz
multivari
linear
regress
analys
use
determin
independ
effect
variabl
result
found
serum
lead
concentr
posit
correl
total
ige
use
spearman
correl
test
spearman
rho
p
bmi
serum
mercuri
level
urin
cotinin
level
also
posit
correl
total
ige
adjust
linear
regress
analysi
serum
concentr
lead
among
three
heavi
metal
posit
associ
logarithm
transform
total
ige
logtig
coeffici
b
confid
interv
ci
perform
analysi
group
divid
allerg
df
sensit
statu
found
signific
posit
associ
serum
lead
logtig
subject
df
sensit
b
ci
subject
without
df
sensit
b
ci
conclus
serum
lead
level
posit
associ
total
ige
level
howev
correl
statist
signific
subject
df
sensit
result
suggest
immunolog
effect
lead
exposur
may
greater
peopl
allerg
sensit
background
allerg
rhiniti
ar
defin
clinic
symptom
includ
nasal
obstruct
rhinorrhea
nasal
itch
sneez
posit
allergen
sensit
test
howev
posit
skin
prick
test
spt
alway
impli
occurr
clinic
symptom
asymptomat
allergen
sensit
patient
accompani
septal
deviat
dsn
could
caus
nasal
obstruct
easili
confus
typic
symptomat
allerg
rhiniti
patient
object
aim
studi
investig
clinic
laboratori
characterist
nasal
obstruct
domin
allerg
sensit
nod
base
allerg
rhiniti
cohort
studi
method
patient
nationwid
allerg
rhiniti
cohort
studi
arco
conduct
univers
hospit
investig
allerg
rhiniti
diagnos
least
one
rhiniti
symptom
posit
spt
result
nod
group
includ
patient
sever
nasal
obstruct
less
symptom
posit
skin
prick
test
septal
deviat
clinic
laboratori
characterist
compar
nod
group
typic
allerg
sensit
group
result
total
patient
includ
averag
age
patient
septal
deviat
laboratori
test
result
reveal
eosinophil
level
lower
nod
group
total
ige
level
show
differ
spt
analysi
show
hous
dust
mite
less
sensit
nod
patient
signific
sex
differ
male
femal
ratio
higher
nod
group
howev
statist
signific
differ
found
age
famili
histori
bmi
conclus
asymptomat
allergen
sensit
peopl
septal
deviat
mimic
allerg
rhiniti
met
allergen
sensit
peopl
nasal
obstruct
predominantli
septal
deviat
consid
diagnosi
allerg
rhiniti
background
standard
studi
protocol
diagnost
criteria
base
nasal
provoc
test
npt
acoust
rhinometri
ar
result
avail
allerg
rhiniti
object
aim
evalu
use
npt
plu
ar
differenti
diagnosi
local
allerg
rhiniti
lar
allerg
nonallerg
rhiniti
method
medic
record
skin
prick
test
spt
npt
result
patient
symptom
chronic
rhiniti
review
patient
alloc
one
three
group
group
neg
spt
result
dermatophagoid
pteronyssinu
dp
group
b
weakli
posit
result
group
c
strongli
posit
result
result
twelv
patient
neg
spt
result
provok
respons
npt
decreas
minim
crosssect
area
mca
dp
challeng
diagnos
lar
dp
challeng
group
c
show
signific
aggrav
nasal
symptom
greater
decreas
acoust
paramet
group
b
p
patient
visual
analogu
scale
va
increas
nasal
obstruct
dp
challeng
criterion
chang
total
nasal
symptom
score
tnss
sensit
specif
diagnosi
allerg
rhiniti
wherea
diagnost
criterion
tnv
chang
minut
dp
challeng
sensit
specif
conclus
npt
ar
could
use
tool
differenti
diagnosi
allerg
nonallerg
local
allerg
rhiniti
background
aspirinfacilit
absorpt
ingest
allergen
consid
exacerb
factor
develop
food
allergi
studi
examin
effect
aspirin
oral
sensit
eggwhit
allergen
ovalbumin
ova
well
ova
absorpt
rat
method
clarifi
intestin
absorpt
mechan
ova
effect
aspirin
situ
intestin
recircul
perfus
studi
perform
use
ova
fluorescein
isothiocyanatelabel
dextran
marker
nonspecificabsorpt
pathway
presenc
absenc
variou
endocytosi
inhibitor
aspirin
addit
plasma
concentr
ova
measur
oral
administr
gavag
rat
investig
effect
aspirin
oral
sensit
ova
rat
oral
administ
ova
gavag
time
week
everi
day
week
aspirin
absorpt
enhanc
spermin
administ
min
simultan
ova
respect
evalu
sensit
ova
plasma
level
ovaspecif
ige
determin
elisa
week
initi
ova
sensit
result
absorpt
rate
ova
distal
intestin
higher
compar
marker
colchicin
gener
endocytosi
inhibitor
bafiromycin
inhibitor
receptormedi
endocytosi
phenylarsin
oxid
inhibitor
clathrinmedi
endocytosi
suppress
ova
absorpt
wherea
inhibitor
caveolinmedi
endocytosi
exert
signific
effect
distal
region
indic
ova
preferenti
absorb
distal
intestin
via
paracellular
receptor
clathrinmedi
endocyt
pathway
aspirin
increas
intestin
absorpt
ova
via
paracellular
pathway
exhibit
higher
plasma
level
ovaspecif
ige
control
week
spermin
also
increas
oral
absorpt
ova
almost
extent
aspirin
wherea
plasma
ige
exhibit
signific
differ
untreat
control
conclus
facilit
ova
absorpt
via
paracellular
pathway
due
impair
intestin
barrier
function
aspirin
consid
one
reason
enhanc
oral
sensit
ova
aspirin
howev
result
also
shown
facilit
oral
sensit
ova
ascrib
increas
absorpt
ova
intestin
tract
background
atop
dermat
ad
affect
approxim
children
rise
tendenc
exact
caus
ad
known
pregnant
women
still
expos
secondhand
smoke
latvia
smoke
exposur
pregnanc
might
increas
risk
ad
children
aim
present
studi
investig
mechan
ad
develop
children
born
pregnanc
affect
secondhand
smoke
object
favour
idea
nglycosyl
keratinocyt
cell
limit
dolichyl
phosphat
cycl
dpc
intermedi
regul
dolichylphosph
udpnacetylglucosamin
nacetylglucosaminephosphotransferas
transferas
dysregul
caus
disturb
filaggrin
express
epitheli
cell
loss
filaggrin
correl
atop
dermat
ad
presenc
activ
method
two
group
mother
children
compar
sampl
obtain
women
selfreport
secondhand
smoke
pregnanc
children
group
women
contact
tobacco
smoke
pregnanc
group
cotinin
cot
dolichol
dol
measur
blood
urin
pregnanc
filaggrin
express
measur
skin
biopsi
newborn
follow
year
immunohistochem
western
blot
method
use
detect
chang
express
level
filaggrin
intermedi
dpc
fraction
analys
hplc
method
result
group
period
observ
children
diagnos
ad
mother
children
cot
blood
elev
urin
dol
excret
pregnanc
group
period
observ
children
diagnos
ad
mother
elev
urin
dol
excret
overexpress
higher
ad
skin
biopsi
normal
skin
biopsi
differ
normal
one
filaggrin
content
lost
time
suspect
urinari
dol
level
pregnanc
posit
cot
ad
risk
newborn
calcul
mkgmmol
conclus
secondhand
smoke
pregnanc
could
caus
dpagt
overexpress
dysregul
nglycosyl
keratinocyt
lead
ad
fenotyp
affect
stabil
tight
assembl
adher
junction
skin
newborn
reason
suggest
elev
dol
correl
detect
cot
urin
pregnanc
may
evid
secondhand
smoke
relat
disord
nglycosyl
dol
appear
urinari
excret
pregnanc
affect
secondhand
smoke
one
first
manifest
ad
risk
newborn
dol
detect
urin
gestat
secondhand
smoke
exposur
open
possibl
environment
control
addit
motiv
prevent
ad
children
background
kashmir
valley
wit
increas
allergi
relat
disord
aeroallergen
preval
caus
agent
allergenspecif
immunotherapi
allergensit
potenti
cur
treatment
modal
allerg
diseas
act
induc
peripher
cell
toler
promot
format
regulatori
tcell
studi
design
analys
treatment
respons
patient
allerg
rhiniti
allerg
asthma
kashmir
valley
use
allergensit
approach
method
total
patient
suffer
allerg
rhiniti
allerg
asthma
recruit
studi
skin
prick
test
spt
perform
panel
aeroallergen
allergensit
given
therapeut
modal
spt
posit
patient
symptom
score
medic
requir
analys
time
cours
allergensit
result
allergensit
effect
reduc
sever
symptom
patient
sptposit
allerg
rhiniti
sptposit
allerg
asthma
patient
moreov
allergensit
show
reduct
medic
sptposit
allerg
rhiniti
sptposit
allerg
asthma
patient
mainten
therapi
usual
period
one
year
conclus
studi
prove
efficaci
benefici
effect
allergensit
patient
allerg
rhiniti
allerg
asthma
kashmir
valley
studi
show
allergensit
effect
therapi
reduc
allerg
symptom
also
act
specif
restor
normal
immun
allergen
longterm
cours
diseas
background
asthma
andor
allerg
rhiniti
associ
sleep
disord
aim
studi
evalu
sleep
disord
latinamerican
children
year
countri
persist
asthma
andor
allerg
rhiniti
ar
normal
control
c
method
parent
c
andor
ar
children
follow
refer
clinic
answer
children
sleep
habit
questionnair
cshq
oneweek
retrospect
questionnair
compos
question
divid
subscal
bedtim
resist
sleep
durat
sleep
anxieti
night
awak
parasomnia
sleepdisord
breath
daytim
sleepi
total
cshq
scale
subscal
compar
c
aar
vs
ar
control
ca
vs
partial
controlleduncontrol
ua
result
comparison
c
aar
show
signific
differ
age
vs
year
respect
total
cshq
vs
respect
subscal
significantli
higher
among
aar
group
comparison
ar
group
except
sleep
anxieti
show
significantli
higher
valu
total
cshq
vs
respect
subscal
ua
show
significantli
higher
valu
total
cshq
subscal
comparison
ca
vs
respect
conclus
latinamerican
asthmat
andor
allerg
rhiniti
children
show
sleep
disord
defin
cshq
compar
normal
control
despit
treat
asthma
caus
sleep
compromis
mainli
uncontrol
background
epidemiolog
studi
mainli
usa
europ
asia
indic
high
preval
asthma
howev
littl
known
asthma
among
popul
afghanistan
patient
asthma
high
level
exhal
nitric
oxid
fraction
feno
aim
compar
respiratori
symptom
feno
lung
function
test
afghanistan
method
respiratori
symptom
assess
pulmonolog
physician
feno
measur
niox
mino
devic
aerocrin
ab
solna
sweden
lung
function
examin
portabl
spiromet
airway
hyperrespos
asthma
control
questionnair
acq
blood
eosinophil
assess
time
result
respiratori
symptom
cough
dyspnea
wheez
physic
exam
lower
p
higher
feno
valu
observ
afghanistan
blood
eosinophil
count
feno
show
associ
conclus
first
studi
perform
afghanistan
peopl
respiratori
symptom
feno
associ
afghanistan
futur
subject
enrol
environment
factor
need
background
eosinophil
recogn
variou
stimuli
result
accumul
mucos
tissu
progress
inflamm
uric
acid
ua
import
endogen
danger
signal
releas
injur
cell
inflamm
infect
eosinophil
also
involv
innat
immun
respons
mediat
endogen
danger
signal
includ
uric
acid
ua
atp
nonsensit
mice
expos
environment
allergen
howev
mechan
involv
eosinophil
respons
danger
signal
remain
insuffici
understood
method
eosinophil
isol
peripher
blood
normal
individu
incub
presenc
absenc
monosodium
urat
msu
crystal
nonhydrolys
atp
analogu
determin
involv
receptor
eosinophil
respons
ua
atp
eosinophil
preincub
receptor
inhibitor
oxid
atp
oatp
incub
msu
crystal
result
msu
crystal
induc
adhes
eosinophil
recombin
human
rh
induc
product
superoxid
anion
oatp
abolish
eosinophil
respons
msu
crystal
suggest
involv
endogen
atp
receptor
furthermor
exogen
atp
activ
eosinophil
induc
migrat
across
model
basement
membran
adhes
gener
superoxid
anion
degranul
eosinophilderiv
neurotoxin
edn
oatp
reduc
eosinophil
respons
conclus
ua
stimul
eosinophil
releas
atp
atp
serv
essenti
mediat
function
respons
human
eosinophil
thu
human
eosinophil
may
respond
particul
damageassoci
endogen
danger
signal
respons
eosinophil
tissu
damag
may
explain
selfperpetu
natur
airway
inflamm
patient
asthma
background
atop
dermat
ad
associ
impair
sleep
aim
studi
evalu
sleep
disord
ad
latinamerican
children
year
countri
normal
control
c
method
parent
c
ad
children
follow
refer
clinic
answer
children
sleep
habit
questionnair
cshq
oneweek
retrospect
questionnair
compos
question
divid
subscal
bedtim
resist
sleep
durat
sleep
anxieti
night
awak
parasomnia
sleepdisord
breath
daytim
sleep
total
cshq
scale
subscal
compar
c
da
group
spearman
correl
coeffici
scorad
score
atop
dermat
subscal
total
cshq
also
obtain
result
c
da
group
similar
regard
age
howev
significantli
higher
valu
total
cshq
respect
subscal
observ
among
da
children
comparison
c
higher
among
moder
sever
ad
except
sleep
durat
signific
spearman
correl
index
bedtim
resist
p
sleep
anxieti
p
night
awak
p
parasomnia
p
sleepdisord
breath
p
daytim
sleepi
p
total
cshq
p
conclus
although
properli
treat
latinamerican
children
ad
show
sleep
disord
evalu
cshq
children
moder
sever
form
ad
biggest
chang
cshq
background
recent
identifi
hous
dust
mite
hdm
allergen
der
p
consid
major
allergen
accord
high
ige
reactiv
quit
similar
measur
major
hdm
allergen
der
p
der
p
wherea
high
ige
bind
frequenc
der
p
der
p
could
partial
explain
rel
abund
protein
mite
fecal
pellet
discrep
ige
reactiv
der
p
poor
amount
intact
der
p
mite
fece
aqueou
extract
goal
studi
evalu
releas
der
p
fecal
pellet
well
allergen
sensit
proteas
method
hdm
enrich
fecal
pellet
extract
pb
urea
sd
mm
dtt
releas
nder
p
extract
well
commerci
mite
bodi
extract
greer
measur
western
blot
recombin
der
p
rder
p
gstder
p
produc
p
pastori
e
coli
respect
two
recombin
form
incub
activ
natur
der
p
trypsin
hdm
extract
der
p
proteolysi
monitor
sdspage
western
blot
result
tini
amount
nder
p
releas
fecal
pellet
upon
incub
pb
unexpect
high
molecular
weight
immunoreact
band
present
also
low
amount
detect
extract
perform
denatur
reduc
condit
intact
nder
p
present
mite
bodi
extract
recombin
der
p
degrad
der
p
trypsin
der
p
oglycosyl
partial
reduc
proteolysi
der
p
sensit
cystein
proteas
hdm
fecal
pellet
extract
also
demonstr
conclus
result
suggest
natur
der
p
probabl
tight
interact
peritroph
matrix
poorli
releas
fecal
pellet
accord
nder
p
low
abund
mite
extract
high
sensit
proteolyt
degrad
recombin
der
p
may
valuabl
materi
diagnosi
well
treatment
der
p
sensit
background
hypersensit
reaction
corticosteroid
known
occur
unexpect
phenomenon
howev
immedi
hypersensit
sever
anaphylact
reaction
scarc
literatur
method
diagnosi
confirm
use
patch
test
suspect
delay
type
hypersensit
skin
prick
andor
intraderm
test
immedi
type
hypersensit
identifi
respons
agent
potenti
crossreact
pattern
result
patient
present
season
allergi
asthma
adequ
control
inhal
albuterol
inhal
budesonideformoterol
daili
prescrib
treatment
first
dose
well
toler
minut
second
dose
next
day
patient
develop
short
breath
feel
throat
tight
swell
lip
tongu
blister
along
oral
mucosa
patient
treat
oral
antihistamin
symptom
abat
within
one
hour
patient
unawar
previou
allergi
corticosteroid
report
use
variou
topic
prepar
treat
dermat
one
year
without
resolut
open
test
applic
budesonideformoterol
spray
onto
patient
arm
result
erythemat
plaqu
hour
patch
test
reveal
delay
reaction
hour
budesonid
hydrocortison
skin
test
ii
perform
evalu
document
corticosteroid
hypersensit
use
ciclosenid
methylprednisolon
mometason
budesonid
budesonideformoterol
formoterol
fluticasonesalmeterol
along
normal
salin
histamin
control
within
hour
posit
result
two
differ
inhal
budesonid
formul
one
budesonideformoterol
observ
conclus
inhal
corticosteroid
first
line
agent
treatment
persist
asthma
patient
sensit
drug
class
clinician
awar
crossreact
pattern
identifi
appropri
corticosteroid
therapi
test
identifi
class
product
would
deem
safe
furthermor
practition
awar
prior
atopi
risk
factor
sensit
topic
appli
therapeut
lastli
antiinflammatori
effect
corticosteroid
may
mask
allergi
although
patch
skin
test
support
delay
hypersensit
reaction
patient
present
immedi
hypersensit
reaction
suspect
occur
previou
sensit
topic
corticosteroid
use
refer
coopman
degreef
h
doomsgoossen
identif
crossreact
pattern
allerg
contact
dermat
topic
corticosteroid
br
j
dermatol
ii
asakawa
h
araki
imai
tsutsumi
kawakami
f
skin
test
steroid
allergi
allergi
background
hous
dust
harbor
ambient
immunomodulatori
particul
reflect
live
environ
lipid
compound
may
manifold
impact
host
immun
yet
extens
describ
object
investig
compar
lipid
mattress
dust
urban
rural
school
children
china
method
dust
bed
twenti
schoolchildren
urban
guangzhou
rural
conghua
collect
extract
follow
bligh
dyer
method
lipidom
profil
carri
ultraperform
liquid
chromatographyquadrupoletimeofflight
qtof
msbase
approach
use
water
xevo
qtof
mass
spectromet
electrospray
ion
sourc
esi
mass
spectra
acquir
rang
mz
posit
neg
ioniz
mode
raw
data
process
use
xcm
simcap
multivari
statist
analysi
compar
databas
identifi
lipid
compon
result
establish
model
lipid
profil
statist
valid
well
fit
urban
rural
dust
show
differenti
composit
lipid
molecul
total
metabolit
detect
posit
neg
ioniz
mode
respect
fourteen
lipid
molecul
final
identifi
oleamid
cer
mg
two
lysopa
hexadecano
acid
phytomon
acid
abund
rural
dust
wherea
cer
dg
two
lysopc
pa
pc
pg
abund
urban
dust
conclus
first
report
suggest
children
urban
rural
area
expos
discrep
environment
lipid
potenti
respons
identifi
lipid
investig
background
chronic
nasal
obstruct
children
common
symptom
allerg
rhiniti
chronic
inflammatori
diseas
nasal
mucosa
one
common
caus
nasal
obstruct
besid
adenotonsillar
hypertrophi
also
first
blame
two
diseas
quit
common
children
allerg
rhiniti
adenotonsillar
hypertrophi
often
coexist
evalu
surgic
outcom
adenotonsillectomi
children
allerg
rhiniti
goal
studi
better
understand
role
adenotonsillar
hypertrophi
impact
qualiti
life
allerg
rhiniti
children
method
conduct
studi
pediatr
patient
allerg
rhiniti
adenotonsil
hypertrophi
patient
adenotonsillar
hypertrophi
demograph
data
clinic
examin
includ
oral
nasal
endoscopi
skull
later
view
obtain
mean
age
brodski
tonsil
size
adenoid
size
bmi
similar
two
group
followup
evalu
includ
questionnair
clinic
score
physic
examin
skull
later
view
perform
month
adenotonsillectomi
result
preoper
postop
result
compar
postop
score
sleep
relat
symptom
significantli
improv
preoper
score
group
histori
frequent
uri
antibiot
therapi
surgeri
signific
differ
two
group
improv
nasal
symptom
includ
nasal
obstruct
significantli
higher
nonallerg
group
p
adenoid
regrowth
rate
slightli
higher
nonallerg
group
p
conclus
find
confirm
adenotonsillectomi
satisfactori
treatment
sleep
relat
adenotonsillar
hypertroph
children
without
allerg
rhiniti
though
nasal
symptom
depend
post
oper
allerg
treatment
dramat
improv
qualiti
life
adenotonsillectomi
allerg
rhiniti
children
background
recognit
clear
season
monthli
pattern
asthma
exacerb
ae
particular
area
may
allow
prevent
strategi
develop
athen
capit
citi
greec
mediterranean
countri
prevail
pollen
differ
compar
central
northern
europ
countri
aim
studi
determin
season
monthli
variat
ae
allergi
pollen
greec
method
data
obtain
depart
athen
octob
septemb
month
evalu
ae
occur
period
patient
allerg
pollen
accord
result
skin
prick
test
posit
spt
defin
wheal
size
least
mm
greater
neg
control
ae
defin
deterior
asthma
result
unschedul
visit
ie
patientiniti
lead
chang
asthma
treatment
need
oral
steroid
day
andor
emerg
room
visithospit
data
present
monthli
averag
year
combin
data
percent
averag
monthli
valu
month
studi
result
ae
male
femal
asthmat
patient
male
femal
ae
identifi
patient
year
patient
year
patient
year
patient
year
result
month
ae
number
percent
averag
monthli
valu
respect
follow
conclus
find
suggest
ae
athen
region
clear
cut
season
monthli
variat
patient
allerg
pollen
increas
ae
occur
three
month
april
may
june
decreas
rest
month
great
interest
note
especi
may
occur
huge
increas
peak
ae
patient
allerg
pollen
may
epidem
studi
suggest
aeroallergen
pollen
exacerb
asthma
especi
may
greec
result
may
offer
signific
opportun
improv
diseas
manag
nuclear
famili
includ
patient
suffer
hous
dust
mite
allerg
rhiniti
ar
enrol
present
studi
whole
genom
sequenc
employ
screen
possibl
candid
variat
suscept
ar
common
variat
share
studi
subject
report
relat
allerg
diseas
previous
detect
moreov
lowfrequ
rare
variat
identifi
involv
antigen
process
present
endocytosi
phagosom
pathway
replic
variat
found
wholegenom
sequenc
perform
independ
ar
patient
healthi
control
demonstr
gene
variat
region
prove
associ
allergi
includ
addit
still
discov
novel
ar
gene
variat
region
involv
ydjc
egfr
well
background
pathogenesi
nasal
polyp
associ
interact
mucos
epitheli
cell
extracellular
matrix
inflammatori
cell
chemic
mediat
fibroblast
major
structur
compon
nasal
mucosa
play
import
role
sourc
chemic
mediat
tissu
remodel
aim
studi
evalu
effect
airborn
fungi
product
extracellular
matrix
nasal
fibroblast
interact
activ
eosinophil
method
nasal
fibroblast
isol
nasal
polyp
normal
inferior
turbin
nasal
fibroblast
stimul
alternaria
altern
ugml
aspergillu
fumigatu
ugml
eosinophil
peripher
blood
extract
stimul
fungi
nasal
fibroblast
cocultur
activ
eosinophil
without
physic
contact
hour
muscl
actin
collagen
type
fibronectin
mrna
express
determin
real
time
rtpcr
protein
product
determin
western
blot
method
result
alternaria
aspergillu
enhanc
extracellular
matrix
mrna
express
nasal
polyp
fibroblast
time
normal
control
howev
alternaria
induc
product
eosinophil
peroxid
superoxid
eosinophil
cocultur
activ
eosinophil
fungi
nasal
fibroblast
enhanc
extracellular
matrix
mrna
express
time
cocultur
nonactiv
eosinophil
group
conclus
airborn
fungi
enhanc
extracellular
matrix
mrna
express
protein
product
direct
stimul
fibroblast
also
interact
activ
eosinophil
fibroblast
pathogenesi
nasal
polyp
fungi
play
import
role
product
extracellular
matrix
fibroblast
induc
tissu
remodel
background
respiratori
syncyti
viru
rsv
main
etiolog
agent
bronchiol
worldwid
rsv
bronchiol
seem
sever
diseas
caus
virus
aim
studi
observ
clinic
pulmonari
function
bronchodil
respons
differ
respiratori
syncyti
viru
rsv
nonrsv
bronchiol
method
bronchiol
inpati
shengj
hospit
novemb
march
enrol
rsv
detect
perform
enrol
patient
divid
rsv
group
nonrsv
group
patient
inform
demographi
allergi
durat
onset
collect
infant
pulmonari
function
bronchial
dilat
test
serum
total
ige
test
modifiedt
score
length
hospit
also
record
admiss
result
rsv
bronchiol
n
younger
hospit
vs
month
diseas
sever
defin
length
hospit
modifiedt
score
significantli
wors
children
rsv
bronchiol
differ
sensit
two
group
respiratori
rate
rr
respiratori
system
resist
rr
significantli
increas
tidal
volum
per
kilogram
vtkg
ratio
time
peak
tidal
expiratori
flow
total
expiratori
time
tpteft
ratio
volum
peak
expiratori
flow
total
expiratori
volum
vptefv
respiratori
system
complianc
per
kilogram
crskg
significantli
decreas
compar
nonrsv
bronchiol
plethysmograph
function
residu
capac
frcp
show
statist
signific
differ
bronchodil
vtkg
tpteft
vptefv
significantli
improv
rsv
bronchiol
good
correl
diseas
sever
lung
function
conclus
conclus
studi
support
younger
age
risk
factor
rsv
bronchiol
airway
obstruct
rsv
bronchiol
seem
sever
higher
bronchodil
respons
infant
pulmonari
function
may
reflect
diseas
sever
need
consid
affect
factor
assess
diseas
sever
base
infant
pulmonari
function
purpos
role
develop
allerg
diseas
remain
controversi
among
epidemiolog
studi
partli
due
inabl
control
spatial
variat
largescal
risk
factor
studi
aim
investig
spatial
correspond
level
allerg
diseas
subdistrict
level
seoul
korea
order
evalu
whether
impact
observ
spatial
vari
across
subdistrict
method
measur
monitor
station
citi
interpol
subdistrict
annual
inpati
outpati
count
data
three
type
allerg
diseas
atop
dermat
asthma
allerg
rhiniti
collect
estim
multipl
ordinari
least
squar
regress
model
examin
associ
level
allerg
diseas
control
variou
subdistrict
level
covari
geograph
weight
regress
model
conduct
evalu
impact
vari
across
subdistrict
result
found
signific
predictor
atop
dermat
patient
count
p
greater
associ
spatial
interpol
subdistrict
level
signific
effect
observ
allerg
rhiniti
asthma
socioeconom
factor
control
geograph
weight
regress
model
reveal
spatial
variat
effect
atop
dermat
across
subdistrict
seoul
relationship
level
atop
dermat
patient
count
found
signific
gangbuk
region
p
along
covari
includ
averag
land
valu
poverti
rate
level
educ
apart
rate
p
conclus
find
impli
effect
allerg
diseas
might
consist
throughout
seoul
gisbas
spatial
model
techniqu
could
play
role
evalu
spatial
variat
air
pollut
impact
allerg
diseas
subdistrict
level
could
provid
valuabl
guidelin
environment
public
health
policymak
background
earli
studi
show
respiratori
syncyti
viru
rsv
main
trigger
wheez
infant
new
evid
indic
rhinoviru
rv
may
play
signific
role
develop
asthma
object
investig
role
rv
infect
episod
recurr
wheez
young
children
year
younger
casecontrol
studi
clinic
featur
durat
symptom
analyz
accord
result
followup
week
method
children
recurr
wheez
attack
children
without
wheez
includ
studi
specimen
nasopharyng
aspir
obtain
detect
viru
rv
human
metapneumoviru
hmp
bocaviru
hbov
test
revers
transcriptionpolymeras
chain
reaction
rsv
parainfluenza
virus
type
ii
iii
influenza
viru
b
adenovirus
adv
confirm
detect
viral
antigen
via
fluoroimmunoassay
count
white
blood
cell
sever
diseas
access
first
visit
durat
symptom
interv
episod
record
week
followup
result
nasopharyng
aspir
collect
recurr
wheez
children
nonwheez
children
compar
control
group
wheez
children
higher
posit
rate
total
detect
viru
p
rv
vs
rsv
vs
posit
rate
rv
higher
toddler
wheez
infant
wheez
group
vs
eo
count
l
rvposit
wheez
children
much
higher
virusposit
case
l
compar
virusposit
case
rvposit
wheez
children
higher
lymp
wbc
count
p
differ
virusneg
virusposit
case
symptom
wheez
cough
nasal
week
followup
p
conclus
high
respiratori
viru
found
children
wheez
exacerb
rv
import
pathogen
recurr
wheez
patient
rv
induc
wheez
associ
high
level
eo
lymp
wbc
count
impli
rv
may
associ
atopi
immunoreact
clinic
symptom
differ
rv
viru
infect
short
time
background
staphylococcu
aureu
known
frequent
caus
skin
infect
aggrav
factor
atop
dermat
patient
colon
rate
aureu
reach
atop
dermat
patient
much
higher
healthi
subject
bacteria
could
identifi
bacteri
cultur
techniqu
total
bacteria
identifi
perform
metagenom
analysi
determin
major
colon
bacteria
skin
atop
dermat
patient
vs
healthi
control
subject
method
seventeen
patient
atop
dermat
healthi
control
subject
enrol
skin
wash
fluid
obtain
moisten
gauz
load
skin
lesion
cubit
fossa
atop
dermat
patient
part
normal
control
genom
dna
extract
skin
wash
fluid
ribosom
dna
amplifi
use
univers
primer
sequenc
next
gener
sequenc
sequenc
data
analyz
use
bioinformat
result
staphylococcu
spp
domin
skin
atop
dermat
patient
undetect
control
subject
skin
mean
proport
staphylococcu
total
bacteri
dna
atop
dermat
patient
howev
normal
control
addit
analysi
speci
staphylococcu
spp
reveal
staphylococcu
spp
staphylcoccu
aureu
follow
frequent
bacteria
pseudomona
streptococcu
spp
proport
patient
vs
control
respect
hand
alcaligenacea
famili
sediminibacterium
spp
frequent
bacteria
skin
control
proport
control
vs
patient
respect
conclus
staphylcoccu
aureu
predomin
colon
atop
dermat
skin
metagenom
analysi
bacteri
dna
background
aim
studi
estim
efficaci
safeti
combin
micron
cellulos
powder
local
appli
glucocorticoid
symptom
allerg
rhiniti
method
singl
blind
control
studi
conduct
subject
year
age
mean
age
allerg
rhiniti
men
women
particip
posit
medic
histori
allerg
rhiniti
random
puff
mometason
furoat
follow
puff
commerci
avail
micron
cellulos
powder
morn
puff
micron
cellulos
powder
even
test
treatment
tt
puff
mometason
furoat
bid
refer
treatment
rt
particip
allow
take
oral
antihistamin
eye
drop
wish
symptom
score
record
treatment
mean
valu
sum
score
calcul
pre
vs
posttreat
differ
compar
use
ttest
also
decreas
symptom
score
group
compar
use
ttest
efficaci
analyz
use
test
result
treatment
could
reduc
symptom
score
significantli
p
improv
rate
similar
total
efficaci
rt
tt
respect
without
signific
differ
advers
reaction
found
group
conclus
combin
micron
cellulos
powder
local
appli
glucocorticoid
could
reduc
dose
glucocorticoid
treatment
safe
background
intracellular
signal
via
variou
calcium
channel
transient
receptor
potenti
trp
shown
directli
modul
inflamm
also
barrier
homeostasi
inflamm
influx
channel
eventu
gener
intracellular
signal
result
differ
outcom
depend
individu
type
exampl
keratinocyt
prolifer
migrat
epiderm
barrier
format
keratinocyt
differenti
keratinocyt
cornif
therefor
specif
agonistantagonist
calcium
channel
requir
maintain
skin
barrier
homeostasi
treatment
atop
dermat
object
identifi
applic
topic
botan
deriv
chemic
treatment
atop
dermat
method
novel
modul
identifi
identifi
screen
methanol
meoh
extract
plu
fraction
medicin
herb
constitu
potenc
activ
inhibitori
compound
channel
determin
autom
patch
clamp
system
biophys
properti
channel
modul
hit
product
reanalyz
use
convent
wholecel
patch
clamp
fluorometr
calcium
imag
result
prepar
meoh
extract
medicin
herb
perform
bioassayguid
fraction
activ
extract
isol
identifi
bioactiv
constitu
perform
combin
autom
convent
wholecel
patch
clamp
studi
found
eight
medicin
herb
fraction
four
two
one
show
inhibit
rate
also
found
three
fraction
agonist
activ
also
identifi
chemic
constitu
inhibit
compound
v
inhibit
compound
inhibit
compound
cyp
inhibit
chemic
constitu
show
agonistantagonist
effect
also
discuss
conclus
consid
region
plant
investig
chemic
pharmaceut
remain
untap
potenti
sourc
topic
agent
drug
applic
found
major
activ
compon
chemic
constitu
plant
extract
modul
variou
calcium
ion
channel
may
potenti
clinic
applic
atop
dermat
limit
extens
clinic
studi
lead
compound
need
develop
topic
agent
atop
dermat
relat
skin
barrier
function
background
microbi
infect
one
local
factor
contribut
pathogenesi
atop
dermat
howev
mani
studi
report
system
effect
microorgan
especi
lactic
acid
bacteria
studi
system
effect
local
microorgan
system
microbi
distribut
studi
reveal
relationship
system
bacteria
atop
dermat
perform
metagenom
analysi
determin
system
bacteria
distribut
atop
dermat
patient
vs
healthi
control
subject
method
twentyeight
patient
atop
dermat
healthi
control
subject
enrol
urin
obtain
subject
serum
obtain
eighteen
atop
dermat
patient
genom
dna
extract
urin
serum
ribosom
dna
amplifi
use
univers
primer
sequenc
next
gener
sequenc
sequenc
data
analyz
use
bioinformat
result
bacteri
composit
nearli
ident
serum
urin
howev
notabl
differ
bacteri
composit
urin
normal
control
atop
dermat
patient
control
group
proport
lactococcu
leuconostoc
lactobacillu
lactobacillal
significantli
higher
patient
group
alicyclobacillu
propionibacterium
streptophyta
increas
patient
group
control
group
pseudomona
commonli
found
group
treatment
alicyclobacillu
comamonadacea
frequent
found
howev
proport
decreas
acinetobact
oxalobacteracea
f
increas
treatment
urin
atop
dermat
patient
conclus
confirm
system
bacteri
composit
atop
dermat
normal
control
metagenom
analysi
bacteri
dna
urin
serum
background
reveal
occurr
physiolog
function
immun
complex
ic
food
protein
iga
human
breast
milk
univers
find
examin
time
anoth
exocrin
fluid
human
saliva
b
method
ic
sever
food
protein
human
exocrin
fluid
determin
sandwich
elisa
construct
antiindividu
protein
antihuman
iga
antibodi
ic
fraction
obtain
human
pool
saliva
ammonium
sulfat
precipit
gel
filtrat
administ
oral
success
day
week
old
balbc
mice
fed
caseinbas
commerci
avail
mous
diet
day
immun
egg
white
protein
freund
complet
adjuv
boost
day
egg
white
protein
freund
incomplet
adjuv
blood
drawn
orbit
vein
serum
ovalbumin
ovomucoid
specif
measur
day
control
free
ovalbumin
correspond
amount
ic
fraction
administ
c
result
food
protein
detect
respect
ic
healthi
human
saliva
product
ovalbumin
ovomucoid
significantli
suppress
p
ic
administ
mice
comparison
control
mice
conclus
ic
food
protein
iga
could
determin
human
saliva
well
breast
milk
evid
indic
physiolog
function
induc
oral
toler
prove
mice
ic
food
protein
iga
human
exocrin
fluid
thought
natur
drinkabl
vaccin
function
prevent
food
allergi
induct
oral
immun
toler
e
refer
biosci
biotech
biochem
food
nutr
sci
background
allerg
rhiniti
ar
complex
diseas
geneenviron
interact
contribut
pathogenesi
epigenet
modif
dna
methyl
play
import
role
regul
gene
function
pleiotrop
cytokin
may
import
confer
suscept
ar
aim
present
work
assess
relationship
cpg
island
methyl
statu
upstream
hous
dust
mite
hdm
sensit
ar
han
chines
subject
method
total
hdmsensit
ar
patient
control
subject
enrol
two
independ
cohort
beij
liaon
massarray
epityp
use
systemat
screen
statu
dna
methyl
peripher
blood
leukocyt
express
measur
realtim
quantit
pcr
result
mean
level
methyl
decreas
ar
patientgroup
compar
controlgroup
p
two
total
unit
analyz
cpg
unit
show
signific
differ
methyl
statu
ar
patientgroup
controlgroup
dna
hypomethyl
significantli
associ
higher
risk
hdmsensit
ar
independ
cohort
combin
cohort
beij
liaon
combin
methyl
level
correl
neg
express
serum
total
ige
level
conclus
dna
hypomethyl
gene
may
associ
increas
risk
ar
hdmsensit
background
object
recent
data
shown
preval
asthma
allerg
diseas
continu
increas
diet
prevent
asthma
allerg
diseas
epigenet
chang
includ
dna
methyl
aim
studi
investig
associ
dietari
methyl
donor
folat
vitamin
vitamin
develop
asthma
allerg
sensit
children
method
children
age
year
korean
elementari
school
survey
part
first
children
health
environment
research
cheer
survey
children
includ
studi
korean
version
intern
studi
asthma
allergi
childhood
isaac
questionnair
food
frequenc
questionnair
ffq
done
parent
skin
prick
test
perform
use
common
allergen
korea
genotyp
mthfr
polymorph
perform
taqman
assay
result
dietari
folat
intak
protect
factor
wheez
symptom
past
month
aor
ci
asthma
diagnosi
aor
ci
vitamin
also
relat
reduc
risk
allergen
sensit
aor
ci
high
intak
folat
vitamin
vitamin
protect
factor
allergen
sensit
aor
ci
aor
ci
aor
ci
respect
atop
wheez
symptom
past
month
aor
ci
aor
ci
aor
ci
respect
especi
ct
tt
genotyp
nucleotid
mthfr
compar
low
intak
cc
posit
conclus
result
indic
dietari
methyl
donor
decreas
risk
asthma
atopi
may
modifi
mthfr
polymorph
fund
studi
support
grant
environment
health
center
children
health
environment
research
fund
ministri
environ
republ
korea
object
thymic
stromal
lymphopoietin
tslp
epithelialcel
deriv
cytokin
may
import
initi
allerg
inflamm
studi
aim
investig
whether
tslp
reduc
airway
inflamm
murin
model
asthma
method
balbc
mice
sensit
challeng
ovalbumin
ova
effect
tslp
airway
inflamm
airway
hyperrespons
ahr
evalu
furthermor
measur
chang
variou
cytokin
bronchoalveolar
lavag
bal
fluid
treat
tslp
result
observ
tslp
exert
neg
regul
ova
mediat
allerg
airway
inflamm
tslp
treatment
reduc
total
cell
count
eosinophil
count
bal
fluid
ahr
methacholin
cytokin
bal
fluid
also
decreas
tslp
treatment
conclus
result
suggest
tslp
therapeut
potenti
allerg
asthma
inhibit
cytokin
product
background
object
faspirinexacerb
respiratori
diseas
aerd
clinic
tetrad
nasal
polyp
chronic
hypertroph
eosinophil
sinus
asthma
sensit
aspirin
aspirin
provoc
test
gold
standard
diagnos
aerd
aim
studi
evalu
clinic
featur
prognosi
surgic
treatment
chronic
rhinosinus
cr
patient
aspirin
hypersensit
subject
method
fwe
conduct
analysi
cr
patient
underw
endoscop
sinu
surgeri
depart
otorhinolaryngolog
hospit
octob
march
measur
nasal
volum
chang
symptom
chang
aspirin
nasal
provoc
test
anpt
examin
patient
asthma
histori
allergi
lundmackay
score
lm
total
immunoglobulin
e
peripher
eosinophil
percentag
object
measur
relaps
result
fchronic
rhinosinus
patient
nasal
polyp
crswnp
like
posit
anpt
test
result
compar
patient
without
nasal
polyp
crssnp
vs
anpt
group
higher
lm
requir
revis
endoscop
sinu
surgeri
anpt
group
result
similar
crswnp
compar
crssnp
conclus
f
lm
recurr
rate
higher
anpt
compar
anpt
especi
recurr
rate
higher
anpt
regardless
nasal
polyp
thu
care
endoscop
examin
requir
follow
cr
patient
show
posit
anpt
result
background
chronic
cough
without
wheez
young
children
often
present
diagnost
challeng
object
investig
use
nasal
endoscopi
differenti
bacteri
sinus
viral
upper
respiratori
infect
cough
variant
asthma
allerg
rhiniti
gerd
method
retrospect
analyz
data
young
children
age
present
clinic
chronic
cough
without
wheez
nine
children
evalu
nasal
endoscopi
result
children
evalu
nasal
endoscopi
thick
purul
discharg
nasopharynx
five
adenoid
enlarg
age
ten
children
given
antibiot
treatment
report
symptom
resolut
two
week
followup
appoint
conclus
use
nasal
endoscopi
found
major
children
chronic
cough
without
wheez
chronic
bacteri
sinus
strike
respons
appropri
antibiot
therapi
adenoid
hypertrophi
may
caus
like
result
chronic
upper
airway
infect
background
aim
studi
investig
express
muscarin
receptor
resultantli
effect
muscarin
antagonist
tiotropium
bromid
depend
age
process
murin
model
chronic
asthma
method
differ
age
femal
balbc
week
old
month
old
femal
balbc
mice
sensit
challeng
ovalbumin
ova
three
month
tiotroipum
bromid
mm
administ
via
intranas
rout
ova
challeng
measur
cell
count
cytokin
bronchoalveolar
lavag
fluid
airway
hyperrespons
paramet
airway
remodel
express
muscarin
receptor
subtyp
assess
result
airway
resist
decreas
age
month
old
ova
group
young
week
old
ova
group
inflammatori
cell
includ
eosinophil
decreas
tendenc
accord
age
among
ova
group
administr
tiotropium
show
improv
infiltr
inflammatori
cell
cytokin
goblet
cell
hyperplasia
smooth
muscl
hypertrophi
pivot
marker
airway
remodel
amelior
tiotropium
treat
group
ova
group
three
age
group
ova
group
increas
express
subtyp
decreas
express
subtyp
accord
age
conclus
studi
show
tiotropium
bromid
could
effect
airway
inflamm
also
remodel
regardless
age
effect
might
relat
pattern
express
muscarin
receptor
subtyp
background
chronic
rhinosinus
nasal
polyp
crswnp
classifi
eosinophil
noneosinophil
crswnp
depend
histopatholog
featur
howev
use
marker
differenti
diagnosi
crswnp
therefor
sought
investig
use
surrog
marker
crswnp
endotyp
asian
patient
method
total
patient
noneosinophil
nasal
polyp
eosinophil
nasal
polyp
enrol
clinic
inform
comput
tomographi
ct
endoscop
histolog
find
investig
tissu
sampl
analyz
total
ige
protein
concentr
level
mrna
express
level
interleukin
il
interferon
ifn
tumor
necrosi
factor
tnf
transform
growth
factor
tgf
periostin
immunostain
assess
prolifer
marker
perform
result
noneosinophil
crswnp
show
greater
local
maxillari
involv
lesser
olfactori
involv
ct
earli
stage
diseas
compar
eosinophil
crswnp
addit
ethmoidalmaxillari
ct
score
indic
ethmoid
domin
involv
posit
correl
level
inflammatori
marker
periostin
mrna
express
total
ige
level
nasal
polyp
np
tissu
wherea
score
invers
correl
level
cytokin
noneosinophil
np
express
upregul
especi
epithelia
addit
epitheli
ingrow
pattern
pseudocyst
frequent
observ
histolog
endoscop
evalu
noneosinophil
np
compar
eosinophil
np
criterion
combin
cutoff
level
ethmoidalmaxillari
ct
score
presenc
pseudocyst
endoscop
examin
yield
sensit
specif
diagnosi
noneosinophil
crswnp
conclus
demonstr
combin
ethmoidalmaxillari
ct
score
presenc
pseudocyst
endoscopi
may
use
surrog
marker
distinguish
noneosinophil
crswnp
eosinophil
crswnp
asian
patient
background
earlier
shown
matern
supplement
nondigest
carbohydr
pregnanc
led
signific
reduct
develop
sever
allerg
asthma
featur
adult
offspr
current
studi
investig
whether
matern
supplement
lactat
would
similar
effect
method
mice
mate
week
arriv
week
age
directli
birth
offspr
mice
lactat
group
transfer
control
diet
supplement
shortchain
galacto
longchain
fructooligosaccharid
scgoslcfo
ratio
mice
sham
control
group
kept
control
male
offspr
sensit
ova
age
week
except
sham
group
acut
allerg
skin
respons
measur
age
week
airway
hyperreact
metacholin
measur
consecut
airway
challeng
ova
aerosol
result
although
acut
allerg
skin
respons
airway
hyperreact
differ
control
group
lactat
group
allerg
inflamm
significantli
downregul
dietari
intervent
lactat
total
cell
number
percentag
eosinophil
lymphocyt
bronchoalveolar
lavag
fluid
marker
allerg
inflamm
significantli
decreas
offspr
dam
fed
scgoslcfo
lactat
analysi
total
ova
specif
immunoglobulin
level
show
specif
diet
lead
lower
level
ovaspecif
total
level
ovaspecif
ige
level
differ
lactat
control
group
although
level
total
ige
significantli
lower
lactat
group
conclus
matern
supplement
scgoslcfo
lactat
downregul
allerg
inflamm
lung
addit
immunoglobulin
level
relev
allerg
diseas
downregul
well
contrast
allerg
skin
reaction
lung
function
affect
data
compar
studi
perform
earlier
dietari
intervent
scgoslcfo
perform
pregnanc
although
anim
skin
reaction
lung
function
affect
well
altogeth
data
suggest
earli
life
dietari
intervent
nondigest
carbohydr
may
benefici
allerg
outcom
later
life
may
also
highli
relev
develop
atop
diseas
human
studi
part
multiphas
project
aim
valid
mous
model
assess
potenti
allergen
hydrolys
infant
formula
sensit
properti
partial
hydrolys
whey
protein
pwha
b
c
investig
mous
model
well
classic
use
guinea
pig
model
mice
guinea
pig
oral
sensit
whey
gavag
ad
libitum
via
drink
water
respect
mice
wheyig
acut
allerg
skin
respons
releas
bodi
temperatur
anaphylact
shock
symptom
determin
upon
oral
challeng
research
center
guinea
pig
anaphylact
shock
symptom
upon
intraven
challeng
measur
singl
paramet
center
elev
level
wheyspecif
detect
wheysensit
mice
center
although
groupaverag
reach
signific
ige
center
contrast
wheysensit
mice
acut
skin
respons
releas
upon
whey
challeng
observ
pwhatreat
mice
correspond
absenc
anaphylact
shock
symptom
mous
guinea
pig
model
pwhb
pwhc
show
posit
guineapig
asatest
result
mice
inconclus
none
center
abl
differenti
residu
sensit
capac
pwhb
c
base
singl
elicit
paramet
result
per
center
differ
determin
potenti
influenc
alter
microbiota
differ
locat
sensit
capac
analysi
microbi
composit
start
end
studi
conduct
result
show
wellbalanc
predict
potenti
allergen
hydrolys
infant
formula
multipl
paramet
model
need
therefor
conclud
murin
model
suitabl
give
safe
nuanc
predict
allergen
pwh
futur
challeng
develop
overal
score
system
proper
risk
assess
take
assess
paramet
account
introduct
eosinophil
cation
protein
ecp
small
polypeptid
origin
activ
eosinophil
granulocyt
studi
human
neutrophil
allerg
pateitn
abl
produc
ecp
igedepend
mechan
eosinophil
shown
contribut
tlymphocyt
activ
increas
inflammatori
respons
allerg
inflamm
object
purpos
studi
evalu
relationship
allerg
test
skin
test
multipl
allergosorb
test
system
mast
ecp
count
method
total
patient
underw
skin
test
mast
includ
studi
test
serum
ecp
total
ig
e
eosinophil
count
data
skin
test
data
mast
patient
variou
paramet
compar
ecp
use
mannwhitney
u
test
pearson
correl
coeffici
use
analyz
relationship
variabl
ecp
data
result
total
patient
men
women
includ
studi
regress
analysi
show
ecp
significantli
correl
asthma
r
p
score
mast
dermatophagoid
farina
r
p
score
mast
mite
dermatophagoid
pteronyssinu
r
p
score
skin
test
derf
r
p
differ
ecp
data
significantli
conclus
might
posit
relationship
ecp
mast
dermatophagoid
hydroclorothiazid
hctz
wide
use
treatment
essenti
hypertens
may
given
alon
togeth
antihypertens
agent
fix
combin
prepar
frequent
advers
reaction
hypotens
disturb
level
serum
electrolyt
nevertheless
sever
advers
reaction
shock
also
describ
describ
patient
suffer
episod
suddenonset
pulmonari
edema
immedi
ingest
hctz
five
femal
patient
age
yearsold
present
episod
dyspnea
malais
chill
dizzi
fever
two
patient
loss
conscious
chest
xray
show
bilater
interstiti
infiltr
suggest
pulmonari
edema
patient
admit
hospit
three
sever
respiratori
failur
two
intub
mechan
ventil
common
caus
shock
pulmonari
edema
rule
case
patient
receiv
dose
hctz
minut
onset
symptom
discharg
without
diagnos
cutan
prick
intraderm
test
patch
test
hctz
neg
patient
diagnos
allergi
unit
hctzinduc
noncardiogen
pulmonari
edema
close
tempor
relationship
ingest
hctz
onset
symptom
clinic
pattern
fast
recoveri
afterwithdraw
drug
relaps
reexposur
support
diagnosi
accord
naranjo
advers
drug
reaction
probabl
scale
patient
diagnosi
consid
definit
fifth
patient
score
indic
probabl
relationship
hypersensit
reaction
hctz
report
potenti
fatal
advers
drug
reaction
due
hctz
recogn
patient
hospit
stay
case
report
affect
women
accord
femal
predomin
previous
publish
literarur
doctor
consid
potenti
lifethreaten
advers
drug
reaction
earli
withdraw
drug
event
introduct
infant
born
csection
miss
exposur
matern
vagin
microbiota
absenc
microbi
inocul
associ
delay
colon
commens
bacteri
member
bifidobacterium
compromis
microbi
inocul
may
impact
health
newborn
epidemiolog
data
cohort
studi
indic
associ
csection
immun
metabol
disord
asthma
obes
object
studi
determin
effect
specif
mixtur
shortchain
galactooligosaccharid
longchain
fructooligosaccharid
scgoslcfo
ratio
bifidobacterium
breve
restor
delay
colon
bifidobacterium
observ
term
csection
deliv
infant
method
multicountri
doubleblind
randomis
control
studi
infant
born
elect
csection
randomis
receiv
infant
formula
supplement
scgoslcfo
b
breve
formula
supplement
scgoslcfo
control
formula
birth
age
month
refer
group
vagin
born
breast
fed
infant
studi
parallel
stool
sampl
collect
day
day
week
week
week
week
week
week
postintervent
proport
bifidobacteria
differ
bifidobacterium
speci
b
longum
probiot
strain
b
breve
determin
molecular
tool
ph
scfa
also
measur
stool
sampl
result
data
confirm
delay
colon
bifidobacterium
csection
deliv
infant
synbiot
supplement
result
signific
higher
proport
bifidobacteria
first
day
life
bifidogen
effect
remain
signific
month
age
compar
control
group
prebiot
group
show
signific
bifidogen
effect
age
month
compar
control
group
synbiot
arm
b
breve
still
detect
infant
week
indic
persist
probiot
strain
signific
lower
faecal
ph
higher
acet
level
observ
synbiot
group
first
day
life
remain
signific
month
age
compar
control
group
lower
number
subject
advers
event
eczemaatop
dermat
report
synbiot
group
compar
control
prebiot
group
correct
famili
allergi
histori
conclus
infant
formula
supplement
scgoslcfo
b
breve
abl
restor
delay
colon
bifidobacterium
csection
deliv
infant
first
day
life
bifidogen
effect
associ
posit
modul
gut
ecosystem
milieu
effect
may
potenti
long
term
health
benefit
background
diagnost
criteria
asthmacopd
overlap
syndrom
aco
lack
often
perceiv
share
characterist
asthma
copd
howev
atop
characterist
aco
well
describ
aim
assess
atopyrel
characterist
aco
comparison
copd
method
retrospect
studi
aco
defin
physiciandiagnos
case
aco
copd
met
spirometr
standard
compar
clinic
characterist
atopi
aco
copd
result
enrol
patient
physiciandiagnos
aco
n
copd
n
medic
record
univers
hospit
patient
aco
younger
age
lower
copd
patient
regard
skin
prick
test
spt
respons
overal
posit
rate
higher
aco
copd
vs
p
howev
posit
spt
respons
allergen
differ
aco
copd
addit
signific
differ
level
peripher
blood
eosinophil
percentag
total
ige
conclus
conclus
spt
posit
higher
aco
featur
atopi
differ
aco
copd
diagnosi
aco
copd
spt
posit
need
consid
import
clinic
featur
background
sever
asthma
asthmacopd
overlap
syndrom
aco
gain
attent
sinc
diseas
hard
control
often
associ
poor
clinic
outcom
howev
diagnosi
manag
vari
depend
clinician
agreement
definit
therapeut
approach
diseas
evalu
current
understand
clinic
practic
sever
asthma
copd
among
asthma
copd
specialist
korea
design
questionnair
survey
use
email
webbas
platform
method
subject
select
base
clinic
specialti
member
korean
academi
asthma
allergi
clinic
immunolog
studi
group
korean
academi
tuberculosi
respiratori
diseas
subject
receiv
email
subject
allergist
pulmonologist
respond
submit
answer
onlin
administr
result
regard
sever
asthma
featur
common
type
asthma
aggrav
step
treatment
follow
frequent
exacerb
uncontrol
asthma
despit
higher
treatment
step
sever
exacerb
subject
respond
proport
sever
asthma
asthma
patient
clinic
differ
allergist
pulmonologist
aco
estim
asthma
sever
asthma
copd
allergist
gave
proport
aco
among
copd
pulmonologist
vs
regard
diagnost
criteria
aco
among
asthma
patient
smoke
histori
persist
low
low
variat
frequent
chosen
major
criteria
contrarili
highli
select
major
criteria
aco
among
copd
patient
high
variat
posit
bronchodil
respons
person
histori
allergi
conclus
asthma
copd
specialist
divers
view
percept
clinic
practic
sever
asthma
aco
heterogen
need
consid
develop
guidelin
health
polici
sever
asthma
aco
introduct
eosinophil
enter
rare
diseas
eosinophil
infiltr
colon
mucosa
without
definit
caus
eosinophilia
patient
eosinophil
enter
intussuscept
extrem
rare
adult
case
second
report
korea
case
twentytwo
yearold
man
visit
offic
due
two
month
last
abdomin
discomfort
diarrhea
underli
medic
diseas
allerg
histori
famili
histori
except
allerg
pupa
physic
examin
ruq
tender
shown
laboratori
find
show
hemoglobin
level
mgdl
platelet
count
wbc
count
differenti
eosinophil
correct
blood
chemistri
blood
chemistri
exclud
presenc
organ
involv
kidney
liver
serolog
marker
parasit
stool
studi
might
caus
gastrointestin
symptom
peripher
eosinophilia
ancylostoma
anisaki
ascari
strongyloid
toxocara
trichinella
done
shown
posit
result
posit
respons
mite
cockroach
mast
evid
eosinophil
infiltr
lung
heart
chest
xray
pulmonari
function
test
echocardiogram
perform
comput
tomographi
show
proxim
small
bowel
intussuscept
ascend
colon
patholog
find
repres
eosinophil
infiltr
entir
bowel
layer
patient
symptom
reliev
surgeri
follow
blood
chemistri
show
improv
peripher
eosinophilia
conclus
eosinophil
gastroenter
diagnos
eosinophil
infiltr
gastrointestin
tract
without
caus
eosinophilia
common
caus
diseas
exposur
sensit
food
allergen
pathogenesi
wellknown
treatment
base
limit
evid
vari
base
upon
symptom
case
uncertain
caus
symptom
deriv
surgeri
diagnost
therapeut
method
suggest
clinic
experi
studi
would
necessari
make
diseas
background
valu
total
ige
vari
wide
limit
kul
depend
lot
factor
genet
allergi
parasit
infect
age
gender
immun
statu
geograph
region
aim
studi
find
factor
influenc
valu
total
ige
estonian
children
establish
refer
valu
method
studi
group
compris
children
two
prospect
allergi
studi
follow
birth
age
year
data
allergi
symptom
collect
interviewquestionnair
clinic
examin
carri
skin
prick
test
made
common
food
inhal
allergen
followup
investig
measur
total
ige
level
sera
made
birth
month
year
life
use
unicap
method
result
cord
blood
ige
level
predict
valu
allergi
develop
first
year
life
valu
total
ige
increas
age
ci
kul
month
age
ci
kul
age
five
year
teenag
refer
valu
year
lower
ci
kul
compar
preschool
children
age
year
ci
male
higher
ige
valu
comparison
femal
everi
age
statist
signific
differ
month
vs
kul
two
year
vs
kul
age
total
ige
higher
children
allerg
diseas
compar
nonallerg
age
year
vs
kul
might
indic
quit
high
preval
parasit
nonallerg
children
test
ige
antibodi
ascari
children
total
ige
level
ku
month
kul
year
life
antibodi
ascari
found
preschool
children
teenag
howev
posit
correl
total
ige
atopi
consid
posit
skin
prick
test
result
presenc
allergen
specif
ige
antibodi
sera
age
group
conclus
peak
valu
total
ige
age
five
teenag
usual
refer
laboratori
manual
posit
correl
total
ige
skin
prick
test
result
allergenspecif
ige
antibodi
ige
antibodi
ascari
blood
allerg
diseas
except
age
year
man
visit
local
clinic
complain
malais
weight
loss
fever
dyspnea
complet
blood
count
perform
reveal
eosinophilia
peripher
blood
receiv
antibiot
week
howev
symptom
allevi
multipl
purpur
papul
ankl
left
forearm
buttock
acut
renal
dysfunct
develop
refer
univers
hospit
pulmonari
function
test
carri
yield
decreas
lung
function
posit
bronchodil
respons
kidney
biopsi
skin
biopsi
perform
histolog
examin
show
acut
necrot
crescent
glomerulonephr
leukoclast
vascul
skin
led
diagnosi
churgstrauss
syndrom
eosinophil
granulomatosi
polyangi
egpa
combin
rapidli
progress
glomerulonephr
rpgn
patient
receiv
puls
steroid
therapi
parenter
methylprednisolon
follow
oral
prednisolon
clinic
laboratori
find
improv
dramat
remiss
attain
rapidli
patient
continu
remiss
month
egpa
consid
asthma
patient
present
sever
system
symptom
eosinophilia
progress
renal
insuffici
occur
acut
phase
egpa
accompani
renovascular
involv
prompt
aggress
treatment
system
corticosteroid
mandatori
control
diseas
activ
achiev
remiss
background
urticaria
frequent
skin
diseas
major
case
unknown
caus
idiopath
urticaria
strong
associ
infecti
trigger
factor
pathogenesi
acut
urticaria
au
infecti
trigger
factor
may
also
involv
chronic
urticaria
cu
method
determin
preval
bacteri
viral
parasit
infecti
diseas
patient
femal
male
northeastern
romania
age
year
admit
depart
last
month
acut
episod
urticaria
femal
male
chronic
idiopath
urticaria
femal
male
order
identifi
infecti
trigger
blood
sampl
use
evalu
level
antibodi
toxocara
canni
toxoplasma
gondii
herp
simplex
viru
viru
cytomegaloviru
measl
viru
additionali
microscop
stool
examin
fecal
antigen
essay
helicobact
pylori
giardia
lambliawer
perform
serum
antihcv
antibodi
hb
antigen
assess
result
frequent
infecti
agent
detect
case
au
cu
giardia
lamblia
case
au
case
cu
follow
toxocara
canni
case
au
case
cu
hepat
c
viru
case
au
case
cu
helicobact
pylori
case
au
case
cu
hepat
b
viru
case
au
case
cu
acut
infect
viru
patient
measl
viru
patient
diagnos
au
case
found
among
patient
cu
patient
au
cu
diagnos
acut
infect
herp
simplex
viru
patient
neg
result
cytomegaloviru
igm
antibodi
parasit
infect
blastocysti
homini
found
patient
case
au
case
cu
one
patient
cu
present
ascari
lumbricoid
conclus
infecti
trigger
factor
especi
parasit
infect
prelev
develop
countri
world
may
play
import
role
acut
episod
urticaria
also
chronic
urticaria
although
found
parasit
infect
present
type
urticaria
studi
need
elucid
associ
infecti
trigger
factor
urticaria
identifi
new
infecti
trigger
background
mani
social
cultur
factor
influenc
sleep
pattern
sleep
condit
child
may
differ
depend
approach
concern
parent
object
studi
assess
sleep
condit
korean
infant
method
total
korean
parentscaregiv
infant
boy
age
till
month
complet
internetbas
expand
version
brief
infant
sleep
questionnair
bisq
includ
specif
question
infant
daytim
nighttim
sleep
pattern
well
sleep
relat
behavior
result
among
subject
number
boy
infant
went
bed
hour
night
woke
around
hour
morn
night
sleep
time
durat
hour
total
sleep
time
day
hour
month
old
children
group
less
nighttim
sleep
durat
vs
vs
hour
p
daytim
sleep
durat
vs
vs
hour
p
older
children
signific
differ
number
nightwak
month
old
children
group
month
old
children
group
month
old
children
group
signific
less
frequent
nightwak
vs
vs
half
children
survey
sleep
parent
bed
common
bedtim
routin
milk
feed
sleep
second
one
cradl
conclus
korean
infant
short
sleep
time
bedtim
routin
bedshar
korean
infant
show
differ
pattern
compar
western
countri
result
suggest
aggress
educ
sleep
condit
need
korean
infant
parent
purpos
chronic
rhinosinus
cr
nasal
polyposi
chronic
inflammatori
diseas
upper
airway
often
associ
asthma
character
markedli
increas
number
eosinophil
type
lymphocyt
fibroblast
goblet
cell
mast
cell
inflamm
lead
prolif
respons
extracellular
matrix
ecm
periostin
ecm
protein
known
play
role
tissu
remodel
inflammatori
diseas
upper
lower
airway
furthermor
epithelialderiv
gene
filaggrin
highlight
asthma
atop
dermat
ad
via
role
barrier
function
investig
express
periostin
filaggrin
nasal
polyp
np
atop
nonatop
comparison
nasal
mucosa
patient
allerg
rhiniti
ar
potenti
role
nasal
polyposi
method
nasal
polyp
specimen
biopsi
nasal
mucosa
obtain
surgeri
part
treatment
remov
np
hypertrophi
turbin
immunoreact
periostin
tslp
filaggrin
np
atop
nonatop
patient
nasal
mucosa
patient
ar
analyz
immunohistochemistri
use
peroxidasebas
avidinbiotin
complex
abc
method
cell
count
analyz
use
object
micromet
densiti
immunoreact
quantifi
imag
j
analysi
system
real
time
pcr
done
analyz
mrna
express
result
filaggrin
immunoreact
detect
epitheli
cell
inflammatori
cell
number
filaggrin
cell
epithelium
patient
np
significantli
higher
nasal
mucosa
ar
patient
number
filaggrin
cell
lamina
propria
patient
np
significantli
higher
nasal
mucosa
ar
patient
differ
number
filaggrin
cell
nasal
polyp
atop
nonatop
patient
periostin
immunoreact
mainli
detect
basement
membran
densiti
immunoreact
periostin
np
significantli
higher
np
nasal
mucosa
ar
patient
tslp
detect
epitheli
cell
immun
cell
greater
np
ar
mucosa
differ
densiti
immunoreact
periostin
np
atop
nonatop
patient
cell
express
also
higher
np
good
correl
cell
periostin
conclus
base
previou
find
high
level
tgfbeta
np
present
find
increas
express
filaggrin
periostin
np
irrespect
atop
statu
filaggrin
may
potenti
play
role
barrier
function
periostin
may
play
role
introduct
although
urinari
tract
infect
uti
consid
among
common
infecti
disord
human
usual
follow
uncompl
cours
variou
infect
may
role
induc
hae
attack
danazol
treatment
associ
hematuria
studi
intend
evalu
abnorm
urinalysi
patient
method
urin
specimen
contribut
patient
annual
control
visit
studi
retrospect
rbc
wbc
count
microorgan
analyz
laboratori
paramet
relat
clinic
symptom
view
longterm
danazol
therapi
result
take
account
randomli
select
urin
specimen
found
cumul
number
edemat
attack
higher
patient
without
bacteriuria
consid
patient
attack
number
significantli
higher
vs
patient
without
bacteriuria
p
cumul
incid
microhematuria
found
upon
singl
repeat
examin
annual
checkup
per
patient
take
account
observ
period
year
alter
detect
urinari
sediment
unrel
treatment
dose
danazol
conclus
cumul
incid
microhematuria
substanti
higher
compar
histor
data
healthi
individu
regard
background
phenomenon
found
relationship
danazol
therapi
main
find
studi
increas
incid
edema
associ
bacteriuria
find
emphas
trigger
role
bacteriuria
occurr
edemat
episod
support
otka
grant
background
investig
role
helicobact
pylori
hp
eros
ulcer
eu
upper
gastrointestin
tract
esophagu
stomach
duodenum
independ
develop
spontan
urticaria
method
adult
patient
acut
chronic
spontan
urticaria
examin
upper
gastrointestin
endoscopi
ugi
hptest
gastric
biopsi
treatment
observ
abnorm
result
hp
found
patient
less
across
ablebodi
popul
moscow
differ
insignific
wherein
eu
found
patient
gastric
eros
time
asymptomat
volunt
two
patient
sever
urticaria
duoden
ulcer
despit
fact
patient
report
mild
gastrointestin
complaint
thorough
question
hpposit
patient
receiv
erad
therapi
hpneg
patient
eu
receiv
antacid
antisecretori
therapi
second
hpdetermin
pcr
therapi
carri
patient
chronic
spontan
urticaria
hpposit
hpneg
first
ugi
patient
eu
agre
new
examin
hpposit
patient
erad
success
fail
patient
success
erad
remiss
achiev
case
case
remiss
patient
fail
erad
remiss
achiev
also
case
case
remiss
fisher
exact
test
show
highli
insignific
result
erad
therapi
treatment
urticaria
follow
patient
second
ugi
patient
eu
appear
heal
eros
show
complet
remiss
symptom
wherea
patient
unheal
eu
improv
fisher
exact
test
show
signific
differ
patient
acut
spontan
urticaria
includ
statist
test
due
high
possibl
spontan
remiss
conclus
eros
upper
gastrointestin
mucosa
seem
import
role
develop
spontan
urticaria
independ
hp
refer
german
sv
zykova
ie
modestova
av
ermakov
nv
epidemiolog
characterist
helicobact
pylori
infect
moscow
gig
toljamo
k
gastric
eros
clinic
signific
patholog
longterm
followup
studi
acta
universitati
ouluensi
medica
univers
oulu
p
introduct
natur
killer
nk
cell
subset
lymphocyt
import
role
innat
immun
nk
cell
releas
cytokin
infect
cytokin
stimul
increas
activ
innat
adapt
immun
respons
one
stimul
nk
receptor
bind
mica
micb
ulbp
ligand
tumor
virusinfect
cell
lead
increas
nk
secret
lytic
protein
perforin
granzym
target
cell
play
import
role
activ
cellular
immun
function
well
destruct
elimin
cancer
cell
previou
studi
confirm
vaccin
import
role
control
asthma
via
affect
cell
control
allerg
respons
prevent
increas
eosinophil
basophil
inhibit
respons
thu
studi
evalu
effect
vaccin
gene
express
receptor
present
nk
cell
peripher
blood
materi
method
obtain
nk
cell
blood
mononuclear
cell
isol
viabl
cell
cultur
medium
rpmi
affect
vaccin
time
hour
vaccin
buffalo
spleen
extract
act
th
cell
stimul
first
time
regist
saleh
mohaghegh
hazrati
iran
extract
rna
cell
cdna
synthesi
perform
gene
express
evalu
realtim
pcr
also
receptor
present
cell
surfac
evalu
via
monoclon
antibodi
flow
cytometri
result
result
studi
shown
vaccin
lead
upregul
gene
express
receptor
present
nk
cell
lead
increas
nk
cell
cytotox
receptor
conclus
due
increas
receptor
nk
cell
increas
nk
cell
cytotox
activ
viral
infect
cancer
also
vaccin
regul
balanc
induc
stimul
therefor
futur
vaccin
use
cancer
immunotherapi
treatment
allerg
diseas
keyword
natur
killer
flow
cytometri
qrt
pcr
immunotheraphi
refer
boskabadi
mh
neamati
hazrati
sm
khakzad
mr
moosavi
sh
gholamnezhad
z
prevent
effect
natur
adjuv
tracheal
respons
serum
ifn
balanc
sensit
guinea
pig
clinic
background
preval
eczema
vari
markedli
across
globe
unclear
whether
geograph
variat
due
raceethn
differ
environment
exposur
genet
factor
investig
effect
ethnic
environment
exposur
eczema
hispan
white
hw
nonhispan
white
nhw
children
particip
southern
california
children
health
studi
ch
method
examin
sociodemograph
predictor
environment
exposur
among
hw
nhw
children
age
year
enrol
ch
result
eczema
preval
differ
ethnic
hw
show
lower
preval
compar
nhw
adjust
sociodemograph
factor
account
ethnic
differ
odd
ratio
confid
interv
ci
parent
histori
allerg
diseas
larger
effect
hw
nhw
p
high
matern
educ
level
parent
histori
allerg
diseas
matern
smoke
pregnanc
increas
risk
eczema
indoor
environment
factor
eg
mold
water
damag
humidifi
use
increas
risk
eczema
nhw
independ
parent
histori
allerg
diseas
hw
increas
risk
observ
primarili
children
without
parent
histori
allerg
diseas
conclus
hw
children
southern
california
lower
preval
eczema
nhw
ethnic
differ
account
sociodemograph
differ
effect
parent
histori
allerg
diseas
indoor
environment
exposur
eczema
vari
ethnic
suggest
etiolog
eczema
may
differ
hw
nhw
among
variou
dermatolog
entiti
toxic
epiderm
necrolysi
ten
rare
potenti
fatal
delay
hypersensit
reaction
numer
medic
methazolamid
one
rare
culprit
drug
report
patient
present
ten
take
methazolamid
yearold
male
visit
clinic
system
hypersensit
reaction
high
fever
pain
eye
diffus
prurit
erythemat
maculopapular
erupt
multipl
targetoid
plaqu
becam
vesicular
bullou
involv
oral
mucosa
conjunctiva
first
sign
appear
week
take
methazolamid
bid
due
glaucomat
eye
blood
test
admiss
show
hemoglobin
gdl
total
leukocyt
count
ul
neutrophil
lymphocyt
eosinophil
ast
iul
alt
iul
serum
bilirubin
mgdl
serum
creatinin
mgdl
blood
glucos
mgdl
urinalysi
show
red
blood
cell
white
blood
cell
although
methazolamid
discontinu
blister
skin
denuat
progress
affect
bodi
surfac
area
posit
nikolski
sign
note
high
fever
also
persist
manag
fluid
supplement
total
parenter
nutrit
daili
dress
involv
bodi
surfac
ivig
administ
day
addit
methylprednisolon
acetylcystein
moxifloxacin
skin
lesion
start
improv
week
manag
fever
subsid
cutan
lesion
improv
minim
perman
sequel
month
later
hlab
found
highresolut
genotyp
strong
genet
associ
hla
b
methazolamideinduc
sjsten
suggest
korean
screen
hlab
may
use
avoid
methazolamideinduc
sjsten
therefor
methazolamid
prescrib
hlab
posit
patient
background
human
adipos
tissuederiv
stem
cell
hadsc
variou
influenc
mani
type
cell
product
secret
sever
cytokin
studi
present
abil
suppress
modul
inflammatori
respons
way
show
variou
inflammatori
behavior
meet
certain
materi
environ
thu
investig
effect
lp
titanium
dioxid
nanoparticl
product
inflammatori
cytokin
hadsc
method
human
adipos
tissuederiv
stem
cell
hadsc
cultur
medium
contain
fb
ngml
egf
ngml
bfgf
cell
cultur
contain
fb
cell
treat
hr
lp
ngml
nanoparticl
ugml
ugml
ugml
medium
control
cell
viabil
determin
mtt
assay
express
level
tnfa
mrna
determin
realtim
pcr
result
viabil
hadsc
cell
affect
treatment
lp
lp
increas
express
tnfa
mrna
decreas
express
hadsc
increas
express
mrna
decreas
express
hadsc
cell
lp
decreas
express
mrna
affect
express
tnfa
mrna
conclus
studi
show
differ
inflammatori
respons
hadsc
cell
differ
stimul
materi
respons
hadsc
inflammatori
agent
dynam
cell
suggest
hadsc
may
facilit
manipul
certain
inflammatori
situat
chronic
airway
diseas
object
purpos
studi
analyz
risk
factor
posit
oral
food
challeng
ofc
cashew
nut
cn
perform
sagamihara
nation
hospit
b
method
subject
patient
receiv
ofc
cn
purpos
diagnosi
confirm
toler
acquisit
june
august
measur
patient
cn
specif
ige
within
year
ofc
retrospect
analyz
ofc
patient
background
clear
object
symptom
seen
ofc
judg
posit
symptom
unclear
ofc
conclud
final
diagnosi
confirm
reproduc
symptom
home
next
visit
outpati
c
result
patient
male
femal
median
age
year
rang
year
reason
elimin
cn
patient
includ
anaphylaxi
histori
immedi
reaction
cn
fifti
seven
patient
elimin
cn
due
posit
cn
specif
ige
atop
dermat
seen
asthma
allerg
rhiniti
allerg
conjunct
histori
immedi
reaction
nut
cn
seen
patient
histori
immedi
reaction
peanut
eighteen
patient
posit
ofc
neg
patient
posit
ofc
anaphylaxi
seen
patient
oral
mucos
symptom
seen
case
gastrointestin
symptom
case
cutan
symptom
case
respiratori
symptom
case
neurolog
symptom
case
cardiovascular
symptom
case
seven
patient
treat
antihistamin
patient
steroid
patient
inhal
stimul
patient
adrenalin
comparison
ofc
posit
neg
patient
signific
differ
p
seen
histori
immedi
reaction
cn
cn
specif
ige
signific
differ
factor
includ
sex
age
histori
immedi
reaction
nut
cn
immedi
reaction
peanut
anaphylaxi
due
cn
conclus
histori
immedi
reaction
cn
high
cn
specif
ige
risk
factor
posit
ofc
cn
ofc
patient
risk
factor
perform
caution
consid
possibl
anaphylaxi
fungal
sensit
associ
asthma
sever
data
singl
tertiari
hospit
korea
background
despit
implement
guidelinebas
asthma
treatment
asthma
popul
still
suffer
sever
asthma
recent
studi
fungal
allergi
recogn
import
risk
factor
sever
asthmaw
aim
analyz
preval
fungal
sensit
retrospect
cohort
asthma
patient
evalu
differ
clinic
characterist
presenc
fungal
sensit
materi
method
review
medic
record
asthma
patient
visit
tertiari
referr
hospit
may
jul
perform
skin
prick
test
pulmonari
function
test
crosssect
data
serum
total
ige
blood
eosinophil
bronchodil
respons
asthma
sever
longitudin
data
number
exacerb
mean
ic
dose
variabl
compar
presenc
fungal
sensit
defin
posit
ah
mean
wheal
diamet
greater
skin
prick
test
fungal
allergen
aspergillu
alternaria
cladosporium
epicoccum
fusarium
penicilliium
trichopyton
furthermor
compar
variabl
accord
degre
sensit
neg
ah
ratio
ah
ratio
act
variabl
calcul
averag
absolut
valu
subtract
act
valu
measur
everi
month
sever
asthma
defin
prebronchodil
lower
result
proport
sever
asthma
among
asthma
patient
fungal
sensiz
approxim
among
without
fungal
sensiz
differ
statist
signific
serum
total
ige
increas
higher
degre
fungal
sensit
howev
bronchodil
respons
blood
eosinophil
number
exacerb
variabl
mean
ic
dose
similar
across
three
group
conclus
fungal
sensit
correl
asthma
sever
degre
fungal
sensit
associ
clinic
variabl
total
ige
addit
studi
larger
number
patient
requir
better
understand
role
fungal
sensit
asthma
introduct
atop
dermat
ad
common
chronic
inflammatori
skin
diseas
preval
children
children
ad
parent
face
difficulti
relat
daili
care
manag
relaps
cours
may
aggrav
multipl
trigger
recent
therapeut
patient
educ
tpe
individu
consult
use
treatment
mani
chronic
diseas
optim
manag
therefor
preliminarili
evalu
necess
tpe
individu
consult
program
therapeut
manag
ad
subject
method
organ
individu
tailor
tpe
consult
program
provid
multispecialti
allergist
nurs
nutritionist
environment
coordin
program
patientcent
process
consist
inform
consult
address
patient
specif
problem
includ
psychosoci
support
enough
time
allow
parent
ask
question
program
conduct
questionnair
survey
diseas
knowledg
program
center
initi
visit
month
minmax
particip
contact
nurs
telephon
interview
ti
structur
questionnair
effici
tpe
program
symptom
qualiti
life
qol
sever
ad
assess
allergist
use
score
atop
dermat
scorad
result
parent
children
ad
took
tpe
program
complet
questionnair
survey
may
novemb
children
ad
commonli
age
group
year
follow
age
group
mean
scorad
index
patient
percentag
children
mild
moder
sever
ad
respect
signific
improv
diseas
awar
among
parent
respond
questionnair
ti
followup
ti
answer
tpe
program
use
manag
problem
relat
ad
experienc
improv
ad
symptom
furthermor
posit
chang
qol
parent
conclus
result
studi
demonstr
use
need
tpe
individu
consult
enabl
children
famili
care
daili
condit
prevent
avoid
complic
improv
qol
ultim
optim
therapi
ad
background
immulit
new
method
measur
serum
antigenspecif
ige
level
alphalactalbumin
one
milk
compon
util
milk
allergi
rare
report
object
purpos
studi
evalu
util
alphalactalbumin
ala
specif
ige
level
use
predict
clinic
toler
patient
milk
allergi
method
fortythre
patient
milk
allergi
boy
girl
age
month
year
median
year
old
examin
ala
specif
ige
level
use
immunocapspecif
ige
assay
immunocap
addit
specif
ige
cow
milk
casein
betalactoglobulin
blg
measur
immunocap
subject
categor
group
accord
much
heat
milk
patient
could
toler
group
less
group
b
group
c
two
patient
avoid
cow
milk
product
strictli
sever
anaphylact
histori
milk
intak
other
undertak
oral
immunotherapi
heat
milk
sinc
data
assum
gaussian
distribut
shown
median
rang
minimum
maximum
analyz
spearman
method
oneway
anova
dunn
multipl
comparison
result
level
cow
milk
specif
ige
use
significantli
correl
level
use
immunocap
p
likewis
casein
blg
ala
specif
ige
level
show
similar
correl
p
p
p
respect
month
age
serum
total
ige
level
significantli
differ
among
group
ala
specif
ige
level
group
uaml
group
b
uaml
significantli
higher
group
c
uaml
p
p
signific
differ
level
group
group
b
level
milk
casein
blg
show
similar
result
howev
ala
specif
ige
total
ige
ratio
group
significantli
higher
group
b
group
c
p
p
well
ratio
group
b
significantli
higher
group
c
p
hand
signific
differ
ala
data
use
immunocap
among
group
conclus
ala
specif
ige
level
use
use
evalu
clinic
toler
milk
allergi
especi
consid
influenc
total
ige
level
background
antituberculosi
drug
atd
combin
isoniazid
rifampicin
pyrazinamid
ethambutol
commonli
use
treatment
tuberculosi
occasion
associ
drug
hypersensit
immun
reaction
drug
rash
eosinophilia
system
symptom
dress
syndrom
hepat
culprit
drug
mechanist
basi
hypersensit
reaction
defin
object
aim
studi
find
whether
drugrespons
cell
respons
detect
patient
atdrel
dress
character
mechanist
featur
tcell
respons
method
lymphocyt
transform
test
ltt
assay
use
atd
perform
use
peripher
blood
mononuclear
cell
patient
subsequ
drugspecif
tcell
clone
gener
serial
dilut
result
high
prolif
respons
isoniazid
rifampicin
detect
patient
dress
ltt
isoniazidrifampicin
specif
tcell
clone
gener
blood
patient
pyrazinamid
ethambutol
cell
clone
prolifer
secret
stimul
isoniazid
rifampicin
crossreact
conclus
studi
identifi
isoniazidrifampicin
specif
tcell
peripher
blood
certain
patient
atdinduc
dress
studi
need
defin
mechan
drugrespons
cell
activ
background
common
clinic
syndrom
aspirin
hypersensit
aspirinexacerb
respiratori
diseas
aerd
aspirinexacerb
cutan
diseas
aecd
subject
genomewid
associ
studi
identifi
differenti
genet
biomark
aspirin
hypersensit
korean
popul
method
comparison
snp
genotyp
frequenc
affymetrix
genomewid
human
snp
array
aerd
patient
aecd
patient
healthi
normal
control
subject
nc
reveal
snp
chromosom
associ
aerd
aecd
valid
associ
enrol
second
cohort
compris
aerd
normal
healthi
control
diseasecontrol
aspirin
toler
asthma
ata
group
diagnost
valu
evalu
area
curv
auc
valu
receiv
oper
characterist
roc
curv
combin
result
three
snp
gene
chromosom
two
snp
gene
chromosom
show
signific
associ
aerd
phenotyp
minor
genotyp
frequenc
ag
aa
particular
snp
region
higher
aerd
group
compar
ata
nc
group
codomin
analysi
model
respect
comparison
allel
clinic
featur
asthmat
reveal
patient
harbor
allel
particular
snp
region
show
increas
bronchial
hyperrespons
inhal
aspirin
methacholin
higher
level
without
allel
three
intron
snp
gene
significantli
associ
aerd
phenotyp
serum
level
significantli
higher
aerd
compar
control
group
ata
nc
combin
snp
gene
serum
level
show
good
diagnost
valu
close
correl
ckit
ykl
conclus
impli
potenti
two
snp
genet
biomark
aerd
phenotyp
background
hypersensit
aspirin
nonsteroid
antiinflammatori
drug
nsaid
second
frequent
allerg
reaction
drug
includ
immunolog
nonimmunolog
airway
andor
skin
manifest
provoc
test
gold
standard
diagnos
nsaid
hypersensit
although
nsaid
report
safe
nsaidintoler
patient
suggest
confirm
safeti
singleblind
oral
drug
provoc
test
object
assess
role
oral
drug
provoc
test
diagnosi
nsaid
hypersensit
find
safe
altern
drug
method
provoc
test
four
type
nsaid
aspirin
ibuprofen
meloxicam
etoricoxib
e
administ
patient
suspect
intoler
nsaid
specialist
centr
allergi
clinic
immunolog
bach
mai
hospit
result
total
patient
histori
suspect
allerg
nsaid
fm
mean
age
year
enrol
may
april
oral
provoc
test
nsaid
perform
posit
patient
posit
test
posit
one
drug
patient
patient
patient
e
patient
two
drug
preval
e
hypersensit
respect
averag
dose
mg
posit
result
e
respect
averag
respons
time
minut
last
dose
e
respect
preval
crossreact
e
main
clinic
manifest
posit
test
combin
allerg
rhiniti
urticaria
angioedema
one
patient
bronchospasm
patient
anaphylaxi
conclus
research
show
oral
provoc
test
safe
test
also
gold
standard
nsaid
hypersensitivoti
diagnosi
choos
alten
nsaid
base
singleblind
provoc
test
background
treatment
guidelin
korean
atop
dermat
releas
korean
atop
dermat
associ
kada
work
group
due
recent
advanc
atop
dermat
ad
research
control
clinic
studi
establish
updat
evidencebas
treatment
guidelin
korean
atop
dermat
demand
b
method
task
forc
team
conven
kada
collect
databas
refer
relev
systemat
review
guidelin
atop
dermat
rais
relev
key
statement
manag
ad
evid
statement
grade
classifi
strength
recommend
statement
evid
statement
grade
use
classif
oxford
centr
evidencebas
medicin
level
strength
recommend
classifi
follow
level
b
level
c
level
level
fifti
four
council
member
kada
ask
vote
statement
draft
guidelin
particip
indic
level
agreement
draft
statement
use
vote
scale
disagr
agreement
consensu
defin
particip
score
within
rang
agreement
three
round
vote
expert
consensu
recommend
establish
c
result
updat
guidelin
provid
uptod
evid
base
systemat
combin
treatment
algorithm
includ
basic
proactiv
induct
mainten
treatment
addit
averag
agreement
score
expert
panel
present
consid
korean
healthcar
system
patient
adher
guidelin
compris
topic
manag
ad
via
bath
skin
care
avoid
exacerb
factor
educ
psychosoci
support
moistur
topic
antiinflammatori
drug
antibiot
antiprurit
drug
system
manag
ad
includ
antihistamin
antimicrobi
system
immunomodul
allergenspecif
immunotherapi
asit
phototherapi
complementari
altern
medicin
clinic
question
focus
therapeut
effect
action
plan
detail
side
effect
cost
effect
measur
enhanc
patient
complianc
treatment
conclus
achiev
high
treatment
efficaci
patient
satisfact
treatment
decis
made
jointli
physician
patient
expect
evid
experiencebas
treatment
recommend
ad
expert
refer
guid
physician
ad
patient
choos
appropri
treatment
improv
qualiti
life
decreas
unnecessari
social
medic
cost
background
subcutan
immunotherapi
scit
one
evidencebas
treatment
allerg
rhiniti
howev
advent
sublingu
immunotherapi
slit
slit
prefer
scit
proven
safeti
although
report
scit
show
system
reaction
fatal
patient
fatal
scit
still
need
elucid
object
object
studi
categor
side
reaction
scit
local
system
one
identifi
correl
anteced
local
reaction
system
reaction
dose
concentr
allergen
system
reaction
method
allerg
rhiniti
patient
scit
age
includ
retrospect
medic
chart
review
investig
incid
side
reaction
scit
relationship
dose
concentr
allergen
result
patient
met
criteria
inclus
patient
one
side
reaction
patient
local
reaction
patient
system
reaction
patient
local
system
reaction
among
patient
system
reaction
patient
show
anteced
local
reaction
among
system
reaction
urticaria
common
follow
aggrav
rhiniti
symptom
dyspnea
patient
show
system
reaction
minut
shot
concentr
dose
inject
system
reaction
occur
conclus
although
system
side
reaction
common
sever
symptom
like
dyspnea
rare
local
side
reaction
forewarn
system
reaction
advis
caution
need
administ
high
dose
concentr
rational
clinic
profil
asian
patient
suffer
chronic
spontan
urticaria
csu
rel
unknown
demograph
baselin
characterist
asian
versu
nonasian
patient
three
random
placebocontrol
omalizumab
trial
asteria
asteria
ii
glacial
describ
compar
method
pool
baselin
data
asian
nonasian
patient
suffer
csu
remain
symptomat
despit
anti
asteria
asteria
anti
andor
leukotrien
receptor
antagonist
glacial
treatment
assess
posthoc
descript
analysi
demograph
baselin
diseas
characterist
describ
compar
result
among
mitt
popul
patient
enrol
asian
patient
enrol
unit
state
europ
femal
asian
group
nonasian
mean
age
year
mean
bodi
weight
kg
mean
bmi
asian
subgroup
year
kg
respect
nonasian
subpopul
mean
durat
diseas
year
asian
year
nonasian
baselin
ige
level
iuml
asian
nonasian
respect
baselin
mean
urticaria
activ
score
day
weekli
itch
sever
score
weekli
number
hive
score
asian
respect
nonasian
angioedema
present
asian
patient
nonasian
dermatolog
life
qualiti
index
dlqi
asian
nonasian
respect
baselin
sleep
interfer
score
daili
activ
interfer
score
asian
nonasian
respect
previou
number
csu
medic
antihistamin
ltra
corticosteroid
asian
nonasian
conclus
except
bodi
weight
previou
histori
csu
treatment
clinic
profil
patient
refractori
csu
similar
asian
nonasian
background
recent
metagenom
approach
succeed
character
microbi
commun
airway
diseas
present
bronchoalveolar
lavag
supernat
induc
sputum
result
limit
small
sampl
size
lack
microbi
inform
inflammatori
cell
epitheli
cell
airway
investig
use
termin
restrict
fragment
length
polymorph
trflp
analysi
conjunct
multivari
statist
method
examin
differ
micro
biota
whole
induc
sputum
inflammatori
cell
epitheli
cell
addit
supernat
normal
control
asthma
method
induc
sputum
sampl
obtain
normal
nonsmok
subject
patient
steroid
asthma
trflp
analysi
oper
taxonom
unit
otu
repres
bacteri
speci
taxonom
relat
group
rel
amount
otu
evalu
result
global
r
valu
differ
normal
control
asthma
dissimilar
bacteri
commun
induc
sputum
normal
control
asthma
otu
contribut
normal
controlasthma
differ
identifi
otu
lachnospiracea
fold
comamonadacea
acetobacteracea
chloroplast
fold
prevotella
fold
actinobacteria
propionibacterium
acn
fold
lactobacillu
buchneri
lactobacillu
otakiensi
lactobacillu
sunkii
rhodobacteracea
fold
acinetobact
pseudomona
leptotrichiacea
fold
brevibacteriacea
lachnospiracea
fusobacterium
fold
lachnospiracea
acinetobact
actinomyc
fold
comamonadacea
streptomycetacea
fold
significantli
preval
sputum
asthma
patient
normal
control
conclus
patient
asthma
alter
microbi
composit
respiratori
tract
background
eosinophilia
specif
condit
allerg
diseas
helminth
infect
druginduc
reaction
well
recogn
present
studi
evalu
clinic
characterist
eosinophilia
chang
preval
year
recipi
health
screen
program
tertiari
hospit
south
korea
method
collect
data
health
screen
program
recipi
health
promot
center
chungang
univers
hospit
eosinophilia
defin
absolut
eosinophil
count
exce
peripher
blood
review
healthrel
questionnair
laboratori
find
health
screen
program
might
relat
eosinophilia
result
cumul
preval
eosinophilia
eosinophilia
case
mild
degre
eosinophil
subject
older
malepredomin
p
respect
subject
eosinophilia
show
lower
level
fvc
without
eosinophilia
p
respect
note
annual
preval
decreas
trend
ci
p
eosinophil
subject
show
higher
posit
rate
common
parasit
elisa
p
posit
rate
elisa
parasit
increas
advanc
age
subject
eosinophilia
conclus
eosinophilia
gener
healthi
popul
uncommon
usual
mild
degre
preval
eosinophilia
decreas
might
relat
decreas
parasit
infect
young
korean
popul
purpos
toxocariasi
common
caus
peripher
blood
eosinophilia
korea
produc
eosinophil
infiltr
variou
organ
includ
lung
howev
preval
toxocariasi
gener
popul
rare
report
method
investig
seropreval
toxocara
larval
antibodi
among
asymptomat
peopl
attend
samsung
medic
center
health
checkup
includ
lowdos
chest
comput
tomographi
ct
march
decemb
total
peopl
men
women
recruit
result
toxocaraseroposit
rate
use
current
cutoff
valu
base
toxocara
enzymelink
immunosorb
assay
elisa
men
women
multivariateadjust
model
age
odd
ratio
confid
interv
ci
male
sex
ci
rural
resid
ci
histori
raw
liver
intak
ci
significantli
associ
toxocara
seroposit
subject
divid
group
use
cutoff
valu
base
weak
posit
strong
posit
control
optic
densiti
od
or
peripher
blood
eosinophilia
serum
hyperigeaemia
ci
weakposit
group
ci
strong
posit
group
compar
seroneg
group
similarli
or
solid
nodul
surround
halo
ci
weak
posit
group
ci
strong
posit
group
compar
seroneg
group
conclus
studi
indic
toxocaraseroposit
rate
obtain
use
current
cutoff
valu
base
elisa
high
asymptomat
popul
korea
result
studi
suggest
activ
toxocariasi
may
frequent
seen
toxocarastrong
posit
group
toxocaraweak
posit
group
background
sinc
larg
proport
advers
drug
reaction
adr
affect
skin
investig
cutan
drug
hypersensit
reaction
dhr
import
evalu
impact
dermatolog
health
care
gener
well
burden
affect
patient
howev
littl
known
characterist
druginduc
cutan
reaction
korean
children
method
analyz
individu
case
safeti
report
icsr
cutan
advers
reaction
kept
korea
advers
event
report
system
kare
januari
decemb
case
cutan
dhr
select
analyz
regard
age
gender
caus
agent
fatal
case
base
whoumc
causal
assess
system
case
assess
unlik
unclassifi
unassess
exclud
result
total
case
identifi
case
male
mean
age
year
common
agent
vancomycin
follow
amoxicillin
ampicillin
common
advers
reaction
rash
follow
urticaria
itch
among
certain
case
whoumc
causal
assess
system
common
agent
acetylsalicyl
acid
follow
paracetamol
iopromid
case
seriou
adr
among
seriou
adr
acut
gener
exanthemat
pustulosi
agep
common
case
follow
stevenjohnson
syndrom
sj
case
toxic
epiderm
necrolysi
ten
case
drug
reaction
eosinophilia
system
symptom
dress
case
paracetamol
common
caus
seriou
adr
case
conclus
brief
analysi
icsrskar
adr
report
reveal
antibiot
commonli
use
antipyret
common
caus
agent
cutan
reaction
activ
report
cutan
dhr
encourag
indic
unlabel
adr
background
patient
allerg
rhiniti
ar
per
predomin
symptom
classifi
sneezer
runner
sr
blocker
ann
allergi
asthma
immunol
sinc
two
group
distinct
profil
assess
compar
term
qualiti
life
qol
sleep
disturb
method
studi
compris
consecut
patient
year
ar
diagnos
per
aria
guidelin
enrol
outpati
depart
vp
chest
institut
univers
delhi
patient
categoris
sr
blocker
help
visual
analog
scale
va
centimetr
symptom
symptom
extrem
bothersom
score
global
va
sneez
runni
nose
nasal
congest
post
nasal
drip
loss
smell
record
patient
classifi
sr
blocker
impact
qol
assess
sinonas
outcom
test
sleep
assess
nocturn
rhinoconjunct
qualiti
life
questionnair
nrqlq
epworth
sleepi
scale
ess
pittsburgh
sleep
qualiti
index
psqi
instrument
result
two
third
patient
categoris
sr
remain
third
categoris
blocker
signific
featur
age
onset
lower
year
birth
date
june
septemb
famili
histori
atopi
itch
skin
eye
ear
throat
palat
aggrav
dust
histori
breathless
mouth
breath
loss
smell
prior
nasal
surgeri
significantli
higher
patient
significantli
sensitis
season
allergen
like
pollen
kigelia
salvador
patient
sensitis
perenni
allergen
like
hous
dust
hous
dust
mite
fungu
includ
aspergillu
speci
mean
score
mean
nrqlq
score
significantli
differ
group
mean
ess
p
mean
global
psqi
score
significantli
higher
conclus
two
group
differ
significantli
term
respect
profil
whether
demograph
clinic
sensit
pattern
allergen
differ
significantli
group
blocker
experienc
significantli
sleep
disturb
compar
sneezer
runner
background
snitrosothiol
sno
potent
endogen
bronchodil
genet
ablat
snitrosoglutathion
reductas
gsnor
catalyz
metabol
sno
result
protect
airway
hyperrespons
ahr
mous
studi
perform
know
whether
activ
gsnor
mice
may
explain
strain
differ
ahr
method
three
differ
strain
mice
aj
balbc
untreat
control
sensit
challeng
ovalbumin
asthma
model
ahr
measur
use
methacholin
activ
gsnor
measur
whole
lung
lysat
result
persist
increas
ahr
observ
aj
compar
balbc
control
mice
gsnor
activ
significantli
higher
aj
balbc
control
mice
au
nmolminmg
p
asthma
model
ahr
also
increas
aj
mice
compar
strain
gsnor
activ
higher
balbc
asthma
model
mice
au
nmolminmg
conclus
gsnor
activ
may
contribut
differ
ahr
mous
strain
background
snitrosoglutathion
reductas
gsnor
import
regul
snitrosoglutathion
gsno
main
sourc
bioavail
protect
cell
nitros
stress
hypothes
aerosol
deliveri
gsno
could
reduc
bronchoconstrict
pulmonari
inflamm
mous
model
asthma
method
evalu
whether
gsno
could
amelior
ahr
inflamm
compar
ahr
inflamm
femal
balbc
mice
treat
cc
aerosol
mm
gsno
result
gsno
inhal
significantli
decreas
airway
hyperrespons
increas
gsno
dose
ngml
increas
dose
gsno
ngml
absenc
bronchoprotect
even
aggrav
bronchocontrict
conclus
result
suggest
gsno
may
import
factor
control
airway
hyperrespon
might
concentr
threshold
effect
action
gsno
object
exerciseinduc
asthma
eia
signific
burden
children
bronchial
asthma
eia
often
interfer
exercis
activ
children
properli
treat
children
uncontrol
eia
may
fall
inact
sedentari
life
hypothes
daili
activ
children
eia
improv
control
eia
test
hypothesi
evalu
physic
activ
children
eia
eiatarget
therapi
achiev
activ
life
control
eia
asthmat
kid
ace
kid
studi
method
enrol
year
old
boy
untreat
eia
patient
elig
current
histori
exerciseinduc
symptom
reduct
treadmil
exercis
challeng
entri
antiinflammatori
treatment
physic
activ
subject
monitor
use
acceleromet
lifecod
suzuken
week
runin
period
week
treatment
salmeterolfluticason
combin
sfc
primari
outcom
length
strenuou
activ
day
secondari
outcom
fall
exercis
challeng
peak
flow
exhal
result
eight
patient
mean
year
enrol
gave
full
dataset
length
strenuou
activ
day
increas
patient
fall
exercis
challeng
significantli
smaller
treatment
morn
even
peak
flow
significantli
increas
exhal
significantli
decreas
sfc
conclus
eiatarget
treatment
boy
eia
improv
physic
activ
measur
physic
activ
acceleromet
may
surrog
marker
asthma
control
children
background
clinic
report
cough
variant
asthma
cva
nonasthmat
eosinophil
bronchiti
naeb
rare
suggest
symptom
import
diagnost
clue
aim
studi
investig
whether
histori
wheez
use
detect
cva
naeb
among
patient
chronic
cough
method
patient
cough
persist
week
prospect
enrol
divid
two
group
accord
presenc
wheez
past
result
methacholin
bronchial
challeng
induc
sputum
examin
compar
two
group
result
four
hundr
sixti
patient
men
women
enrol
analyz
mean
age
year
median
durat
cough
month
patient
experienc
wheez
preval
cva
vs
p
naeb
vs
p
significantli
higher
wheez
group
compar
nonwheez
group
conclus
histori
wheez
past
significantli
increas
chanc
cva
naeb
patient
chronic
cough
care
histori
take
import
diagnos
caus
chronic
cough
background
previou
report
upregul
allerg
airway
inflamm
mediat
immun
respons
studi
design
investig
effect
antagon
mous
model
acut
bronchial
asthma
method
balbc
mice
sensit
challeng
ovalbumin
ova
antagomir
control
scrambl
rna
daili
inject
intranas
inhal
day
sensit
time
week
chang
cell
count
cytokin
bronchoalveolar
bal
fluid
airway
hyperrespons
ahr
evalu
histopatholog
chang
express
compar
lung
tissu
antagomir
treatment
group
control
group
result
treatment
antagomir
suppress
ahr
compar
ova
challeng
group
scrambl
rna
treatment
group
antagomir
treatment
reduc
total
cell
count
eosinophil
count
bal
fluid
cytokin
significantli
decreas
bal
fluid
antagomir
treatment
group
conclus
antagon
antagomir
inhal
suppress
effect
develop
allerg
airway
inflamm
acut
bronchial
asthma
model
result
suggest
antagomir
could
potenti
target
agent
treatment
bronchial
asthma
refer
lu
tx
munitz
rothenberg
upregul
allerg
airway
inflamm
regul
express
journal
immunolog
lu
tx
hartner
j
lim
ej
fabri
v
mingler
mk
cole
et
et
al
limit
vivo
immun
responsemedi
activ
pathway
polar
sever
delayedtyp
hypersensit
journal
immunolog
background
chlorhexidin
wide
use
antisept
disinfect
increas
number
immedi
igemedi
reaction
drug
report
present
two
case
sever
reaction
topic
use
method
two
patient
age
suffer
anaphylact
shock
contact
topic
chlorhexidin
studi
first
case
boy
underw
hypospadia
surgeri
among
drug
chlorhexidin
use
develop
sudden
hypotens
desatur
facial
swell
boy
respond
adrenalin
efedrin
inotrop
support
paediatr
intens
care
unit
requir
second
case
woman
wound
sutur
emerg
room
er
present
cough
dysphonia
palmar
itch
univers
erythema
hypotens
refractari
intramuscular
adrenalin
mepivacain
use
local
anaesthet
clorhexidin
disinfect
case
tryptas
specif
ige
clorhexidin
latex
measur
immunocap
feia
thermo
fisher
scientif
skin
test
clorhexidin
chlorhexidin
diglucon
salin
implic
drug
perform
also
challeng
test
done
need
result
case
tryptas
reaction
basal
tryptas
prick
test
clorhexidin
neg
prick
test
latex
neg
prick
intraderm
test
rocuronium
fentanyl
bupivacain
obtain
ige
clorhexidin
kul
subcutan
challeng
test
bupivacain
neg
case
tryptas
reaction
basal
tryptas
prick
test
mm
neg
prick
test
latex
neg
prick
intraderm
test
mepivacain
obtain
ige
kul
subcutan
challeng
test
mepivacain
neg
conclus
allerg
reaction
chlorhexidin
common
consid
widespread
use
healthcar
set
howev
reaction
lifethreaten
even
topic
use
awar
need
especi
er
periop
environ
ige
determin
skin
test
use
tool
get
accur
diagnosi
patient
chlorhexidin
use
excipi
sever
medic
cosmet
therefor
thorough
inform
must
given
chlorhexidin
allerg
patient
order
avoid
contact
agent
background
ambient
pollut
associ
advers
respiratori
health
effect
although
meteorolog
variabl
known
impact
respiratori
hospit
studi
investig
effect
ambient
pollut
consid
temperatur
humid
identifi
effect
ambient
particul
matter
daili
respiratori
admiss
consid
meteorolog
factor
method
use
daili
hospit
admiss
respiratori
diseas
busan
hospit
record
use
intern
classic
diseas
period
respiratori
allerg
diseas
use
studi
allerg
rhiniti
asthma
age
categor
group
group
ii
group
iii
yr
hourli
particul
matter
level
particul
matter
level
obtain
monitor
station
busan
collect
made
avail
korean
ministri
environ
meteorolog
observ
data
busan
provid
korean
meteorolog
administr
includ
temperatur
rel
humid
result
mean
valu
hospit
admiss
allergi
rhiniti
asthma
peopl
peopl
respect
dailyaverag
valu
concentr
level
respect
mean
temperatur
rel
humid
admiss
allerg
rhiniti
associ
increas
temperatur
anomali
decreas
rel
humid
p
rel
humid
constant
increas
level
significantli
associ
higher
admiss
allerg
rhiniti
asthma
hospit
correl
decreas
rel
humid
p
increas
even
consid
rel
humid
higher
level
still
associ
higher
hospit
rate
subgroup
analysi
accord
age
admiss
rate
group
group
iii
strongli
affect
level
group
ii
irr
respect
furthermor
show
associ
higher
level
admiss
asthma
regardless
effect
conclus
particul
matter
level
meteorolog
factor
effect
hospit
allerg
rhiniti
asthma
adjust
meteorolog
factor
level
increas
significantli
admiss
rate
respiratori
allerg
diseas
background
increas
evid
asthmat
patient
demonstr
neutrophil
airway
inflamm
howev
clinic
featur
neutrophil
asthma
remain
elucid
object
determin
clinic
featur
neutropil
asthma
investig
clinic
variabl
patient
asthma
attend
hospit
regularli
method
stabl
patient
bronchial
asthma
mainten
treatment
underw
sputum
induct
administr
hyperton
salin
nebul
patient
classifi
neutrophil
na
nonneutrophil
asthma
nna
accord
neutrophil
ratio
sputum
characterist
asthma
subphenotyp
analyz
diseas
sever
pulmonari
function
blood
eosinophil
count
total
ige
level
serum
specif
ige
antibodi
environment
allergen
result
one
hundr
nineteen
patient
divid
na
nna
signific
differ
distribut
sever
percent
predict
blood
eosinophil
count
total
ige
level
na
patient
specif
ige
antibodi
environment
allergen
wherea
patient
nna
conclus
proport
patient
na
sensit
environment
allergen
equal
nna
immun
respons
aeroallergen
might
contribut
develop
neutrophil
inflamm
asthma
background
urticaria
common
diseas
one
common
caus
emerg
unit
visit
children
howev
standard
manag
acut
urticaria
articl
report
urticaria
infant
children
aim
studi
defin
clinic
featur
caus
current
statu
treatment
infant
children
emerg
depart
method
retrospect
review
children
age
less
visit
emerg
depart
acut
urticaria
angioedema
seoul
nation
univers
hospit
seoul
korea
juli
decemb
diagnosi
urticaria
angioedema
made
clinic
ground
review
includ
histori
base
standard
questionnair
precipit
event
eg
food
intak
drug
insect
bite
factor
complet
physic
examin
evalu
tri
find
etiolog
skinprick
test
serumspecif
ige
multipl
allergen
stimul
test
treatment
perform
emerg
unit
result
consecut
infant
age
less
visit
emerg
depart
final
diagnosi
acut
urticaria
patient
angioedema
patient
caus
event
identifi
patient
rest
patient
unidentifi
associ
food
identifi
patient
drug
intak
patient
other
caus
patient
caus
vaccin
contact
dog
insect
bite
grass
exposur
patient
treat
oral
antihistamin
antihistamin
inject
given
patient
system
steroid
patient
bronchodil
patient
patient
one
discharg
oral
antihistamin
one
children
hospit
suspect
stevensjohnson
syndrom
allergi
test
perform
patient
outpati
clinic
patient
show
posit
result
conclus
caus
factor
urticaria
identifi
allergi
test
preform
patient
visit
emerg
depart
urticaria
angioedema
caus
domin
food
drug
caus
order
routin
treatment
includ
oral
antihistamin
therapi
antihistamin
inject
system
steroid
bronchodil
ad
accord
clinic
characterist
outcom
quiet
good
background
fraction
exhal
nitric
oxid
feno
induc
sputum
eosinophil
count
ise
noninvas
method
assess
airway
inflamm
patient
asthma
despit
signific
correl
feno
ise
frequent
disagre
studi
perform
investig
characterist
patient
show
discord
two
paramet
method
data
nonsmok
patient
asthmat
symptom
singl
tertiari
center
analyz
feno
level
classifi
group
high
intermedi
low
feno
cutoff
valu
differenti
high
low
ise
eosinophil
induc
sputum
combin
two
criteria
patient
classifi
group
concord
high
feno
high
ise
low
feno
low
ise
intermedi
intermedi
feno
either
level
ise
discord
high
feno
low
ise
low
feno
high
ise
result
among
total
patient
patient
classifi
discord
group
among
show
high
feno
low
ise
show
low
feno
high
ise
comparison
concord
discord
group
show
male
sex
absenc
airway
hyperrespons
increas
age
increas
neutrophil
count
sputum
frequent
seen
discord
group
current
previou
use
corticosteroid
presenc
atopi
salivari
contamin
induc
sputum
significantli
differ
two
group
conclus
discord
feno
ise
observ
quit
patient
discord
result
high
feno
low
ise
studi
necessari
find
proper
method
assess
airway
inflamm
subset
patient
background
pathomechan
antituberculosi
drug
atd
induc
hepat
poorli
understood
yet
grow
bodi
evid
support
role
adapt
immun
respons
atdinduc
hepat
costimulatori
molecul
modulatori
effect
activ
cell
b
cell
antigen
present
cell
examin
polymorph
costimulatori
molecul
associ
atdinduc
hepat
method
enrol
patient
atdinduc
hepat
atdtoler
subject
dna
isol
whole
blood
genotyp
singl
nucleotid
polymorph
snp
genotyp
frequenc
snp
haplopty
compar
patient
atdinduc
hepat
atdtoler
patient
result
select
snp
genotyp
frequenc
differ
case
control
subject
analysi
haplotyp
gene
signific
relationship
atdinduc
hepat
conclus
find
indic
genet
polymorph
costimulatori
molecul
associ
develop
atdinduc
hepat
korean
popul
suggest
costimulatori
molecul
play
import
role
pathogenesi
atdinduc
hepat
background
common
coexist
cough
gastroesophag
reflux
diseas
gerd
well
establish
sever
respiratori
guidelin
manag
chronic
unexplain
cough
adult
advoc
empir
treatment
gerd
contrast
guidelin
gastroenterolog
societi
conclud
cough
unlik
relat
gerd
absenc
heartburn
acid
regurgit
studi
perform
assess
preval
gerd
adult
chronic
unknown
cough
method
adult
patient
cough
persist
week
prospect
enrol
januari
decemb
patient
upper
airway
cough
syndrom
cough
variant
asthma
nonasthmat
eosinophil
bronchiti
exclud
enrol
patient
underw
impedanceph
monitor
esophagu
result
preval
gerd
chronic
unexplain
cough
evidenc
abnorm
imped
ph
profil
patient
among
patient
given
antireflux
medic
least
month
patient
achiev
total
neartot
elimin
cough
conclus
gerd
readili
detect
impedanceph
monitor
common
caus
chronic
unexplain
cough
success
manag
antireflux
therapi
background
natur
allerg
rhiniti
ar
preschool
children
yet
clearli
character
aim
studi
investig
preval
risk
factor
ar
relationship
feno
preschool
children
method
populationbas
crosssect
survey
preschool
children
age
year
korea
modifi
intern
studi
asthma
allergi
childhood
isaac
questionnair
use
addit
skin
prick
test
spt
serum
total
ige
specif
ige
assess
current
ar
defin
nasal
symptom
within
last
month
diagnos
ar
clinician
atopi
defin
one
posit
reaction
spt
result
preval
current
ar
preschool
age
atop
current
ar
parent
ar
aor
ci
past
histori
asthma
diagnosi
aor
ci
past
histori
atop
dermat
diagnosi
aor
ci
independ
risk
factor
current
ar
specif
mold
exposur
infanc
aor
ci
use
antibiot
infanc
aor
ci
also
associ
increas
risk
current
ar
wherea
older
sibl
aor
ci
reduc
risk
furthermor
atop
current
ar
without
asthma
diagnosi
significantli
higher
geometr
mean
feno
level
compar
nonatop
current
ar
ci
vs
ci
well
higher
compar
nonatop
healthi
children
ci
ige
level
ci
vs
ci
p
eosinophil
fraction
ci
vs
ci
p
atop
current
ar
higher
non
atop
current
ar
group
conclus
ar
common
diseas
korean
preschool
children
mold
exposur
antibiot
use
infanc
increas
risk
wherea
older
sibl
decreas
risk
ar
furthermor
feno
level
ige
eosinophil
higher
atop
current
ar
without
asthma
group
suggest
feno
use
diagnost
tool
ar
preschool
children
fund
studi
support
grant
korean
health
technolog
r
project
ministri
health
welfar
republ
korea
background
vitamin
defici
declar
public
health
problem
adult
children
worldwid
grow
data
suggest
vitamin
defici
play
import
role
develop
childhood
asthma
object
studi
investig
potenti
relationship
asthma
exacerb
sever
serum
children
method
studi
conduct
shengj
hospit
china
medic
univers
septemb
march
total
children
asthma
exacerb
age
year
enrol
children
underl
diseas
chronic
lung
diseas
congenit
heart
diseas
chronic
renal
diseas
etc
vitamin
supplement
recent
month
accord
gina
assess
asthma
exacerb
divid
mild
moder
sever
exacerb
group
serum
assess
children
result
patient
boy
girl
mean
age
year
old
accord
gina
assess
asthma
exacerb
children
enrol
mild
exacerb
group
children
enrol
moder
exacerb
group
children
enrol
sever
exacerb
group
signific
differ
age
height
weight
among
three
group
p
concentr
serum
vitamin
mild
moder
sever
exacerb
group
nmoll
nmoll
nmoll
separ
serum
mild
exacerb
group
significantli
higher
moder
sever
exacerb
group
signific
found
moder
sever
exacerb
group
conclus
children
moder
sever
asthma
exacerb
lower
serum
vitamin
mild
case
suggest
associ
asthma
exacerb
sever
children
research
focus
vitamin
supplement
prevent
childhood
asthma
backgroud
aim
studi
assess
clinic
use
ad
diagnost
valu
specif
ige
antibodi
wheat
gluten
gliadin
diagnos
wheat
allergi
distinguish
wheat
anaphylaxi
b
method
studi
includ
children
visit
ajou
univers
hospit
suspici
food
allergi
subject
divid
two
group
wheat
allergi
wa
group
nonwheat
allergi
nonwa
group
subject
wheat
allergi
divid
two
group
accord
symptom
wheat
anaphylaxi
waana
group
nonwheat
anaphylaxi
wanonana
group
serum
concentr
total
ige
specif
ige
antibodi
wheat
gluten
gliadin
measur
diagnost
valu
specif
antibodi
analyz
compar
use
mannwhitney
test
receiv
oper
characterist
curv
c
result
median
valu
specif
ige
antibodi
wheat
gluten
gliadin
significantli
higher
wa
compar
nonwa
optim
cutoff
point
kual
kual
kual
respect
posit
decis
point
specif
specif
ige
antibodi
wheat
gluten
gliadin
kual
kual
kual
respect
accuraci
level
correspondingli
combin
specif
ige
antibodi
wheat
gliadin
result
highest
accuraci
diagnos
wheat
allergi
differenti
waana
wanonana
specif
ige
antibodi
gliadin
show
signific
differ
optim
cutoff
point
kual
conclus
result
show
individu
level
specif
ige
antibodi
wheat
gluten
gliadin
consider
high
accuraci
diagnos
wheat
allergi
specif
ige
antibodi
gliadin
particularli
use
predict
wheat
anaphylaxi
background
disrupt
skin
barrier
atop
dermat
ad
permit
easier
penetr
sensit
extern
allergen
induc
develop
asthma
allerg
rhiniti
call
atop
march
mainten
normal
acid
stratum
corneum
sc
import
factor
normal
skin
barrier
function
elev
sc
ph
accompani
increas
serin
proteas
activ
tslp
express
provok
skin
inflamm
object
determin
whether
neutral
sc
environ
acceler
airway
inflamm
easili
flaki
tail
mice
repres
ad
murin
model
congenit
skin
barrier
abnorm
exposur
hous
dust
mite
hdm
method
dermatofagoid
pteronyssinu
dp
hdm
appli
dorsal
skin
flaki
tail
mice
twice
week
accompani
applic
neutral
cream
ph
acid
cream
ph
twice
day
week
intranas
inhal
dp
done
daili
last
day
gross
find
function
studi
skin
barrier
blood
sampl
bronchoalveolar
lavag
biopsi
skin
lung
done
h
last
treatment
result
repeat
topic
applic
follow
intranas
inhal
dp
flaki
tail
mice
made
respiratori
allerg
inflamm
well
adlik
skin
lesion
accompani
neutral
cream
treatment
acceler
aggrav
allerg
inflamm
respiratori
system
well
skin
conclus
atop
marchlik
progress
ad
asthmalik
lesion
observ
flaki
tail
mice
topic
intranas
applic
hdm
neutral
sc
acceler
aggrav
number
patient
food
allergi
increas
global
level
estim
preval
japan
among
infant
among
schoolchildren
use
oral
food
challeng
ofc
gold
standard
diagnosi
food
allergi
japan
current
countri
world
ofc
test
cover
health
insur
perform
questionnair
survey
specialist
train
facil
belong
japan
pediatr
societi
one
time
per
year
exclud
fiscal
year
prospect
total
facil
receiv
questionnair
sixyear
period
respons
return
total
ofc
test
rate
includ
outpati
inpati
ofc
fiscal
year
respect
percentag
nonspecialist
perform
inpati
ofc
test
fiscal
year
significantli
higher
comparison
year
fiscal
year
fiscal
year
p
fiscal
year
fiscal
year
total
estim
ofc
test
fillrat
japan
year
respect
result
indic
increas
percentag
nonallergist
perform
inpati
ofc
test
lead
increas
total
estim
ofc
test
fillrat
japan
background
alter
divers
composit
human
gut
microbiota
associ
myriad
diseas
includ
inflammatori
bowel
diseas
metabol
syndrom
studi
explor
associ
host
gut
microbiom
food
allergi
b
method
ng
isol
dna
fecal
sampl
children
peanut
allergi
peanut
specif
ige
kual
healthi
nonatop
control
amplifi
use
primer
specif
region
rrna
gene
uniqu
bacteria
sequenc
differ
within
variabl
region
use
bacteri
classif
amplifi
amplicon
dualindex
multiplex
sequenc
pool
librari
sequenc
illumina
miseq
use
cycl
pair
end
read
sequenc
data
process
miseq
report
metagenom
applic
greengen
ribosom
rna
gene
databas
data
regard
famili
histori
atop
diseas
histori
breastfeed
antibiot
treatment
per
year
medic
histori
atop
diseas
collect
via
questionnair
mannwhitney
utest
use
comparison
contin
variabl
two
group
fisher
exact
test
use
compar
proport
group
analys
carri
use
sa
c
result
median
age
subject
peanut
allergi
year
averag
peanut
specif
kual
median
age
healthi
control
year
patient
peanut
allergi
histori
atop
diseas
phylogent
differ
show
peanut
allerg
subject
increas
proport
firmicut
vs
p
decreas
proport
proteobacteria
vs
p
compar
healthi
control
class
level
clostridia
abund
peanut
allerg
subject
vs
p
clostridial
order
significantli
abund
peanut
allerg
subject
vs
p
alcaligenacea
famili
found
healthi
control
none
peanut
allerg
subject
vs
p
genera
identifi
healthi
control
genera
identifi
peanut
allerg
subject
genera
identifi
peanut
allerg
subject
account
total
sequenc
found
healthi
control
genera
found
healthi
control
account
total
sequenc
conclus
analysi
human
gut
microbiom
children
peanut
allergi
healthi
nonatop
control
reveal
differ
specif
composit
divers
microbiota
may
contribut
pathogenesi
food
allergi
studi
larger
sampl
size
need
investig
associ
background
suggest
initi
prime
tcell
system
environment
allergen
may
occur
birth
cytokin
express
cord
blood
increasingli
use
use
marker
assess
neonat
immunolog
develop
futur
lifetim
risk
variou
allerg
diseas
among
offspr
aim
studi
evalu
relationship
cytokin
express
neonat
cord
blood
exposur
hous
dust
mite
hdm
food
intak
pregnanc
b
method
pregnant
women
recruit
april
novemb
women
complet
studi
pregnant
women
genet
diseas
autoimmun
diseas
endocrinolog
diseas
exclud
parent
allerg
diseas
allergen
sensit
exposur
hdm
matern
diet
pregnanc
cytokin
express
neonat
cord
blood
subject
investig
inform
allerg
diseas
subject
andor
spous
gather
questionnair
allergi
specialist
confirm
diagnosi
examin
subject
declar
allerg
diseas
questionnair
allergen
sensit
perform
use
skin
prick
test
includ
der
p
der
p
tree
mixtur
grass
mixtur
weed
dog
cat
dietari
intak
nutrit
last
month
pregnanc
period
assess
use
semiquantit
food
questionnair
indoor
environ
household
includ
exposur
dust
mite
investig
semiquantit
rapid
test
express
neonat
cord
blood
examin
use
quantit
realtim
pcr
c
result
among
subject
pregnant
women
diagnos
allerg
diseas
common
allerg
diseas
allerg
rhiniti
women
expos
tobacco
smoke
women
live
pet
subject
show
signific
differ
express
p
ifn
ratio
signific
relationship
observ
neonat
cord
blood
subject
environ
includ
exposur
tobacco
smoke
pet
ownership
carpet
use
detect
hdm
bed
protect
hdm
use
hdm
detect
pregnant
women
household
signific
differ
hdm
detect
hdm
nondetect
show
cord
blood
neonat
allerg
mother
higher
express
nonallerg
mother
p
amount
nutrit
relat
neonat
cord
blood
ifn
conclus
studi
relationship
matern
food
intak
exposur
hdm
pregnanc
fetal
immun
studi
found
infant
polar
birth
express
relat
matern
allerg
diseas
background
rupatadin
second
gener
antihistamin
paf
antagonist
authoris
treatment
allerg
rhiniti
urticaria
dose
mg
aim
studi
assess
pharmacokinet
safeti
rupatadin
follow
singl
multipl
oral
administr
healthi
japanes
subject
method
phase
randomis
doubleblind
placebo
control
parallel
group
studi
oral
singl
multipl
dose
administ
male
femal
healthi
japanes
subject
year
age
twenti
seven
subject
nine
per
cohort
dose
randomis
ratio
rupatadin
mg
match
placebo
day
subject
receiv
singl
dose
placebo
follow
one
singl
daili
oral
dose
day
singl
daili
dose
day
plasma
sampl
collect
differ
timepoint
throughout
studi
analys
mean
valid
lcmsm
analyt
method
determin
rupatadin
metabolit
concentr
pharmacokinet
paramet
evalu
use
noncompartment
analysi
regress
model
use
assess
dose
linear
result
pk
exposur
rupatadin
administr
singl
multipl
dose
japanes
subject
found
increas
dose
depend
manner
dose
proportion
analysi
reveal
ci
slope
cmax
rupatadin
rupatadin
day
cmax
rupatadin
rupatadin
day
rupatadin
close
rang
clearli
includ
singl
multipl
oral
dose
rupatadin
well
toler
seriou
advers
event
studi
subject
withdrew
due
safeti
reason
reason
conclus
pk
data
incompat
dose
proportion
appear
even
conclus
repeat
dose
instead
singl
dose
addit
pk
valu
japanes
show
similar
histor
valu
obtain
caucasian
studi
rupatadin
safe
well
toler
japanes
subject
sae
studi
subject
withdraw
due
ae
reason
background
present
avail
manag
food
allergi
avoid
wheat
avoid
result
dietari
limit
affect
qualiti
life
oral
immunotherapi
oit
method
shown
increas
toler
wheat
allerg
patient
object
aim
studi
desensit
patient
five
year
wheat
allergi
evalu
safeti
efficaci
rush
oral
immunotherapi
roit
children
ige
mediat
wheat
allergi
method
accord
patient
histori
symptom
occur
doubleblind
placebocontrol
food
challeng
test
dbpcfc
eleven
children
year
old
igemedi
wheat
allergi
anaphylaxi
underw
roit
skin
prick
test
measur
serum
specif
ige
wheat
flour
oral
food
challeng
ofc
perform
oit
protocol
consist
initi
build
phase
follow
mainten
phase
maximum
dose
build
phase
g
wheat
protein
use
bread
contain
wheat
protein
roit
method
patient
hospit
build
phase
perform
sever
day
complet
buildup
phase
patient
ask
ingest
mainten
dose
g
bread
daili
month
home
receiv
confirm
ofc
challeng
neg
regard
desensit
state
eat
wheat
product
daili
without
interrupt
result
among
patient
male
averag
age
patient
begin
studi
year
old
rang
year
patient
complet
buildup
phase
success
one
patient
discontinu
mainten
phase
person
reason
ten
patient
complet
mainten
phase
success
becam
desensit
consum
wheat
product
freeli
without
complic
threshold
dose
wheat
dbpcfc
g
g
wheat
protein
build
phase
continu
day
eight
patient
show
symptom
period
total
number
dose
appli
dose
show
symptom
mostli
mild
reaction
number
epinephrin
took
advantag
total
appli
dose
mainten
phase
seven
patient
show
mild
reaction
first
month
mainten
phase
total
number
dose
mainten
phase
appli
dose
show
mild
symptom
conclus
wheat
oit
method
could
simpl
safe
effect
select
patient
wheat
allergi
although
need
investig
patient
posttranscript
control
rna
bind
protein
rbp
cell
develop
poorli
understood
previous
demonstr
rbp
hur
control
differenti
via
increas
stabil
hur
transgen
mice
overexpress
hur
signific
increas
cytokin
primari
growth
factor
activ
cell
engag
low
affin
receptor
result
phosphoryl
turn
via
encod
transcript
repressor
also
open
access
gene
transcript
lead
activ
essenti
differenti
hypothes
hur
regul
cell
differenti
requir
normal
homeostasi
gener
hur
condit
ko
model
studi
effect
hur
ablat
cell
activ
distal
lckcrerosa
hurflfl
rosa
gene
express
yfp
use
track
hur
ko
cell
sort
cell
yfp
yfp
group
activ
activ
yfp
hur
ko
cell
profound
defect
express
could
shut
activ
cell
unabl
turn
express
hur
ko
cell
defect
prolifer
jakstat
signal
reduc
unabl
upregul
found
significantli
increas
decreas
transcript
investig
whether
hur
directli
control
express
verifi
hur
interact
defin
aurich
element
are
utr
mrna
stabil
unchang
hur
ko
cell
translat
defect
recruit
mrna
transcript
heavi
polysom
determin
vivo
relev
use
ovalbumin
challeng
model
allerg
airway
inflamm
hur
ko
mice
signific
decreas
lung
neutrophil
lymphocyt
eosinophil
remark
immun
hur
ko
mice
compar
level
total
lung
inflamm
unimmun
control
confirm
increas
reduc
phenotyp
cell
immun
hur
ko
mice
summari
data
suggest
hur
play
major
role
differenti
normal
homeostasi
control
mrna
translat
furthermor
hur
ko
cell
complet
abrog
allergen
induc
lung
inflamm
therefor
interact
requir
normal
homeostasi
allerg
airway
inflamm
background
chang
time
preval
sever
recurr
wheez
wheez
episod
infant
virtual
unknown
determin
trend
rw
preval
sever
rw
infant
first
year
life
two
survey
separ
seven
year
method
part
intern
studi
wheez
infant
eisl
populationbas
studi
infant
age
month
compar
data
two
survey
perform
use
methodolog
three
larg
citi
particip
survey
curitiba
paulo
brazil
santiago
chile
result
averag
preval
wheez
first
year
life
decreas
ci
ci
p
signific
decreas
mean
preval
rw
ci
ci
infant
rw
mean
preval
sever
marker
remain
high
sever
episod
p
ed
visit
p
signific
increas
admiss
wheez
p
conclus
preval
rw
sever
marker
first
year
life
remain
high
survey
infant
suffer
rw
markedli
high
preval
sever
marker
visit
ed
admiss
wheez
indic
import
group
infant
troublesom
progress
certainli
affect
qualiti
life
put
infant
risk
sever
complic
background
cyclophosphamid
cyc
alkyl
agent
use
treat
malign
autoimmun
diseas
often
given
mercaptoethan
sulfon
mesna
prevent
bladder
toxic
hypersensit
cyc
well
describ
adult
patient
malign
reaction
typic
igemedi
cyc
metabolit
previou
exposur
patient
toler
subsequ
treatment
desensit
report
first
describ
case
anaphylaxi
initi
exposur
cyc
pediatr
patient
system
lupu
erythematosu
sle
success
toler
subsequ
cyc
desensit
method
case
descript
result
girl
sle
class
iiiv
nephriti
admit
hematuria
anasarca
uncontrol
hypertens
consist
sle
nephriti
flair
treatment
switch
mycophenol
mofetil
monthli
cyc
intraven
iv
mesna
infus
given
minut
prior
hour
cyc
infus
immedi
complet
first
cyc
infus
develop
increas
erythema
iv
site
angioedema
lip
tongu
facial
flush
short
breath
chest
tight
wheez
treat
anaphylaxi
intramuscular
epinephrin
iv
diphenhydramin
methylprednisolon
famotidin
hour
later
becam
hypotens
bp
bp
antihypertens
held
continu
receiv
iv
diphenhydramin
methylprednison
receiv
posttreat
mesna
infus
without
advers
event
histori
allergi
exposur
alkyl
agent
past
cyc
prefer
therapi
renal
function
improv
first
treatment
allergi
consult
evalu
whether
anaphylaxi
secondari
mesna
cyc
possibl
desensit
allergi
evalu
reveal
neg
percutan
test
mesna
skin
prick
intraderm
cyc
skin
test
defer
patient
guardian
admit
intens
care
unit
receiv
cyc
via
desensit
protocol
daili
prednison
mg
dose
increas
methylprednison
gm
minut
prior
desensit
also
premed
diphenhydramin
mg
famotidin
mg
minut
prior
desensit
toler
desensit
without
advers
reaction
sinc
receiv
cyc
desensit
everi
month
outpati
infus
set
without
advers
event
conclus
hypersensit
cyc
seen
pediatr
patient
autoimmun
diseas
occur
initi
exposur
sever
anaphylaxi
desensit
one
approach
continu
treatment
cyc
pediatr
patient
sle
success
background
compar
group
hous
dust
mite
hdm
allergen
der
p
remain
poorli
character
recent
produc
recombin
form
der
p
ppastori
demonstr
allergen
bind
lipidsfatti
acid
studi
investig
ige
sensit
rder
p
larg
thai
hdm
allerg
cohort
well
allergeninduc
airway
epitheli
cell
activ
method
ige
reactiv
rder
p
analys
elisa
use
sera
posit
skin
prick
test
spt
dpteronyssinu
collect
four
differ
hospit
bangkok
allergen
activ
rder
p
test
use
igeload
rat
basophil
leukaemia
cell
rbl
express
human
direct
airway
epitheli
cell
activ
rder
p
also
evalu
result
hdmallerg
patient
show
igereact
rder
p
wherea
ige
bind
frequenc
rder
p
reach
rbl
assay
rder
p
trigger
basophil
degranul
effector
activ
lower
measur
rder
p
treatment
respiratori
epitheli
cell
rder
p
trigger
product
concentrationdepend
manner
conclus
although
rder
p
display
allergen
activ
weak
ige
reactiv
clearli
confirm
der
p
minor
allergen
hypothes
poor
ige
bind
frequenc
der
p
line
appar
limit
amount
allergen
mite
fecal
pellet
aqueou
extract
nevertheless
der
p
fatti
acid
bind
capac
could
play
role
activ
innat
signal
pathway
initi
allerg
respons
background
nationwid
incid
stevensjohnson
syndrom
sj
toxic
epiderm
necrolysi
ten
hard
estim
report
nationwid
incid
sj
ten
use
administr
databas
method
use
databas
health
insur
review
assess
servic
hira
korea
employ
hira
databas
estim
annual
incid
inhospit
mortal
relat
complic
due
sj
ten
studi
use
intern
classif
revis
target
studi
popul
defin
patient
sj
ten
primari
diagnost
code
sj
ten
respect
result
fouryear
studi
period
estim
annual
incid
sj
ten
per
million
peopl
mortal
rate
sj
ten
mean
age
year
old
femal
predomin
appar
data
ocular
urethr
sequela
signific
sequela
clinic
patient
diseas
suffer
ocular
sequela
sj
ten
patient
affect
urethr
sequela
mortal
rate
increas
patient
age
got
older
conclus
incid
sj
ten
much
chang
sinc
howev
mortal
rate
decreas
would
due
evolut
support
manag
background
suggest
vitamin
defici
influenc
increas
preval
allerg
diseas
studi
report
epinephrin
prescript
vari
latitud
region
present
studi
aim
examin
region
differ
incid
foodinduc
anaphylaxi
fia
serum
vitamin
level
korea
method
nationwid
data
fia
obtain
health
insur
review
assess
servic
use
serum
vitamin
level
korea
nation
health
nutrit
examin
survey
period
correspond
fia
region
divid
categori
base
latitud
region
high
latitud
region
low
latitud
examin
differ
incid
fia
serum
vitamin
level
region
adjust
age
result
number
case
fia
serum
vitamin
level
obtain
person
fia
incid
significantli
higher
vs
per
personyear
serum
vitamin
level
lower
vs
ngml
p
region
compar
region
age
group
year
serum
vitamin
level
significantli
higher
region
region
region
differ
fia
incid
signific
person
age
year
vs
region
p
insignific
age
group
serum
vitamin
level
region
higher
region
male
femal
howev
differ
fia
incid
region
accord
gender
conclus
overal
higher
fia
incid
lower
vitamin
level
found
rel
higher
latitud
region
compar
lower
region
stratif
age
group
gender
fia
incid
serum
vitamin
level
inconsist
aspect
region
differ
investig
necessari
identifi
relationship
fia
vitamin
background
atop
dermat
exacerb
sever
trigger
factor
allergen
stress
infect
climat
investig
trigger
factor
better
control
atop
dermat
children
method
subject
diagnos
atop
dermat
pediatrician
allergi
clinic
busan
stmari
hospit
april
march
got
histori
take
allergi
test
spt
immunocap
skin
cultur
physic
examin
check
trigger
factor
also
classifi
sever
scorad
score
analyz
group
trigger
factor
result
subject
number
male
year
old
averag
trigger
factor
skin
infect
food
immedi
delay
itch
tradit
medicin
system
infect
skin
infect
bacteria
saureu
sa
methicillinresist
sa
mrsa
fungi
malassezia
averag
ige
viru
kaposi
varicelliform
erupt
mild
group
male
averag
age
trigger
samrsa
malassezia
ige
kve
food
immediatedelay
itch
sweat
irrit
system
infect
environ
order
frequenc
moder
group
samrsa
malassezia
ige
kve
food
immediatedelay
itch
tradit
medicin
system
infect
topic
ointment
toler
sweat
sever
group
male
averag
trigger
samrsa
malassezia
ige
kve
tradit
medicin
food
immediatedelay
itch
system
infect
irrit
dye
conclus
skin
infect
tradit
medicin
high
proport
trigger
factor
atop
dermat
sever
group
mildmoder
group
mainli
trigger
skin
infect
food
itch
background
recent
monoclon
antibodi
mab
wide
use
variou
clinic
field
although
safeti
demonstr
prior
approv
target
pharmacovigil
essenti
recognit
assess
advers
drug
reaction
adr
purpos
studi
identifi
frequenc
major
clinic
featur
adr
refer
mab
koreaa
method
adr
attribut
eighteen
mab
submit
spontan
korea
advers
event
report
system
kaer
extract
databas
januari
june
analyz
report
inform
relat
patient
characterist
type
adr
result
total
adr
obtain
patient
frequent
symptom
adr
abnorm
leukocyt
follow
infect
drug
erupt
drug
fever
hypersensit
reaction
report
almost
ten
percent
furthermor
mab
induc
total
seriou
adr
patient
includ
sever
infect
neutropenia
drug
fever
visual
dysfunct
patient
die
due
adr
mab
mab
highest
number
adr
report
rituximab
follow
adalimumab
cetuximab
bevacizumab
conclus
near
ten
percent
adr
allergiclik
previous
unrecogn
adr
observ
increas
awar
among
healthcar
profession
requir
signal
prevent
consequ
advers
reaction
caus
monoclon
antibodi
background
food
allergi
previous
associ
impair
growth
children
howev
investig
longitudin
studi
investig
growth
time
previou
studi
account
impact
coexist
eczema
aim
examin
associ
igemedi
food
allergi
month
age
anthropometr
measur
year
age
whether
associ
differ
eczema
statu
method
healthnut
populationbas
cohort
consist
children
recruit
age
year
infant
underw
skin
prick
test
egg
peanut
sesam
sensit
food
challeng
age
year
food
challeng
repeat
children
previous
identifi
food
allerg
determin
persist
resolut
weight
height
year
report
parent
child
health
record
weight
height
zscore
determin
world
health
organis
growth
chart
standardis
age
sex
multivari
linear
regress
model
fit
examin
effect
food
allergi
eczema
age
weight
height
zscore
age
adjust
birthweight
prematur
socioeconom
index
ethnic
durat
breast
feed
result
compar
children
food
allergi
eczema
children
eczema
food
allergi
age
lower
weight
p
height
age
lower
weight
age
control
potenti
confound
differ
children
food
allergi
eczema
age
height
differ
greater
egg
allergi
eczema
weight
p
height
peanut
allergi
eczema
weight
height
compar
eczema
food
allergi
differ
continu
age
children
egg
allergi
eczema
age
weight
height
particularli
persist
egg
allergi
eczema
age
weight
height
peanut
allergi
without
eczema
age
associ
differ
weight
height
age
conclus
children
igemedi
food
allergi
eczema
age
reduc
growth
paramet
age
age
eczema
food
allergi
alon
associ
reduc
growth
result
emphasis
need
adequ
nutrit
follow
food
allerg
children
infanc
particularli
eczema
background
preliminari
determin
impact
factor
clinic
efficaci
period
followup
visit
dust
mite
allerg
asthma
rhiniti
children
one
year
treatment
dust
mite
specif
immunotherapi
method
dust
mite
allerg
asthma
rhiniti
children
mild
moder
sever
enrol
male
femal
year
old
februari
novemb
patient
took
addon
therapi
sublingu
dust
mite
specif
immunotherapi
slit
patient
subcutan
immunotherapi
scit
patient
visit
baselin
period
follow
everi
three
month
assess
asthma
control
test
act
visual
analog
scale
va
asthma
rhiniti
symptom
spirometri
pulmonari
function
test
subject
requir
continu
record
daili
symptom
medic
score
sm
diari
card
monitor
morn
night
peak
expiratori
flow
valu
pefr
day
control
medic
adjust
step
accord
control
level
baselin
period
treatment
month
month
serum
sige
dermatophagoid
pteronyssinu
dermatophagoid
farina
total
ige
determin
enzymelink
immunoassay
immuncap
system
result
analysi
clinic
efficaci
dust
mite
specif
immunotherapi
allerg
asthma
rhiniti
children
patient
complet
treatment
month
averag
daili
sm
use
evalu
index
clinic
respons
sit
effect
case
month
sit
respect
actcact
assess
averag
daili
sm
va
score
pred
mmef
pred
pred
mmef
pred
improv
treatment
analysi
impact
factor
clinic
efficaci
dust
mite
specif
immunotherapi
sm
baselin
period
asthma
histori
pef
pred
baselin
period
could
affect
clinic
efficaci
dust
mite
specif
immunotherapi
conclus
patient
show
effect
respons
sit
one
year
patient
higher
baselin
sm
shorter
asthma
histori
lower
pef
pred
respons
effect
sit
background
otiti
media
effus
ome
wellknown
diseas
entiti
chronic
inflammatori
diseas
middl
ear
space
character
accumul
fluid
allerg
otiti
media
still
well
recogn
previou
investig
suggest
composit
inflammatori
substrat
effus
allerg
otiti
media
similar
latephas
allerg
respons
seen
elsewher
respiratori
tract
asthma
allerg
rhiniti
studi
aim
determin
whether
prior
treatment
der
f
effect
inflammatori
respons
induc
subsequ
lp
infect
signal
pathway
involv
method
primari
human
middl
ear
epitheli
cell
hmeec
expos
der
f
crude
bodi
extract
lp
differ
sequenc
magnitud
immunolog
respons
produc
hmeec
compar
mrna
express
level
mucin
gene
muc
gmcsf
tnfa
tlr
md
evalu
use
realtim
polymeras
chain
reaction
qrtpcr
muc
protein
level
knock
tlr
via
sirna
transfect
assess
western
blot
analysi
accordingli
involv
cell
signal
pathway
evalu
western
blot
analysi
confoc
microscop
imag
result
inflammatori
respons
cytokin
gmcsf
tnfa
express
muc
augment
pretreat
der
f
follow
lp
howev
sequenti
treatment
hmeec
lp
der
f
ad
togeth
time
induc
amount
respons
muc
express
decreas
prior
knockdown
sirna
muc
protein
level
increas
pretreat
der
f
follow
lp
decreas
treatment
inhibitor
bay
nfkb
inhibitor
nuclear
factor
kb
nfkb
transloc
demonstr
pretreat
der
f
follow
lp
condit
conclus
these
result
suggest
der
f
may
act
substitut
make
strong
augment
respons
subsequ
lp
infect
increas
nfkb
activ
within
human
middl
epitheli
cell
suggest
import
role
develop
ome
patient
conceal
allergi
airway
sensit
abstract
background
drug
allergi
neg
effect
anaphylaxi
constitut
import
health
problem
worldwid
object
determin
relationship
famili
person
anteced
allergi
activ
smoke
alcohol
consumpt
drug
allergi
pregnant
adolesc
method
conduct
research
pregnant
adolesc
mean
crosssect
studi
data
collect
perform
use
selfadminist
questionnair
evalu
differ
drugallergi
risk
pregnant
adolesc
famili
person
anteced
allergi
activ
smoke
alcohol
consumpt
calcul
odd
ratio
confid
interv
ci
uni
multivari
regress
analys
result
preval
drug
allergi
famili
person
anteced
allergi
respect
percentag
activ
smoke
alcohol
consumpt
result
multivari
logist
regress
analysi
show
famili
histori
atop
adjust
ci
p
person
anteced
allergi
adjust
ci
p
activ
smoke
adjust
ci
p
alcohol
consumpt
adjust
ci
p
significantli
associ
drug
allergi
conclus
famili
person
anteced
allergi
activ
smoke
alcohol
consumpt
appear
import
factor
develop
drug
allergi
pregnant
adolesc
age
year
background
realis
asia
twopart
studi
part
patient
survey
part
physician
survey
conduct
understand
patient
physician
percept
perspect
toward
asthma
manag
report
extent
discrep
understand
wellcontrol
asthma
patient
physician
asia
method
realis
asia
conduct
two
part
across
follow
countri
asia
china
hong
kong
sar
indonesia
malaysia
philippin
singapor
south
korea
taiwan
part
onlin
questionnair
base
survey
involv
patient
asthma
age
year
part
carri
facetofac
onlin
interview
amongst
physician
manag
asthma
patient
specialist
ie
respiratori
medicin
allergi
clinic
immunolog
rest
primari
care
practic
result
significantli
higher
proport
specialist
compar
primari
care
physician
pcp
report
use
global
initi
asthma
gina
assess
asthma
control
specialist
state
use
guidelin
compar
pcp
patient
consid
asthma
control
physician
perceiv
patient
wellcontrol
overestim
actual
proport
patient
achiev
control
base
ginadefin
criteria
seven
physician
mention
patient
definit
wellcontrol
asthma
align
definit
physician
perceiv
patient
relat
wellcontrol
asthma
minim
impact
daili
life
absenc
symptom
noreduc
attack
stark
contrast
patient
understand
concept
relat
control
medic
cope
symptom
quickli
control
asthma
attack
reflect
crisisori
mindset
toward
diseas
conclus
physician
patient
overestim
level
asthma
control
highlight
import
accur
assess
clinic
practic
role
physician
improv
understand
concept
wellcontrol
asthma
amongst
patient
standard
tool
may
aid
better
assess
control
use
share
languag
discuss
treatment
goal
may
help
ensur
physician
patient
concept
wellcontrol
asthma
align
background
previou
research
shown
neurohumor
factor
play
import
role
pathogenesi
asthma
children
relationship
plasma
level
norepinephrin
vasoact
intestin
peptid
cortisol
clinic
statu
pulmonari
function
patient
asthma
period
exacerb
investig
method
children
age
year
asthma
examin
accord
purpos
studi
control
group
consist
healthi
volunt
appropri
age
gender
compar
clinic
sever
spirometri
neuroendocrin
factor
asthmat
patient
healthi
volunt
use
multipl
analys
varianc
repeat
measur
interpret
data
addit
use
pearson
product
moment
test
investig
correl
among
differ
variabl
result
level
vasoact
intestin
peptid
norepinephrin
cortisol
significantli
higher
patient
asthma
healthi
volunt
p
found
concentr
vip
serum
patient
asthma
period
exacerb
nmoll
significantli
higher
control
group
valu
nmoll
p
patient
asthma
period
exacerb
level
vasoact
intestin
peptid
correl
posit
clinic
sever
rate
r
p
neg
r
p
patient
mild
attack
asthma
concentr
vip
blood
nmoll
moder
nmoll
sever
nmoll
addit
clinic
sever
rate
show
neg
correl
r
p
assum
mobil
bodi
defens
child
acut
period
diseas
form
addit
eject
neurotransmitt
lead
rapid
relief
obstruct
airway
conclus
found
vasoact
intestin
peptid
neuroendocrin
factor
close
associ
clinic
sever
pulmonari
function
suggest
factor
play
import
role
pathophysiolog
acut
asthma
purpos
atop
dermat
ad
one
common
allerg
diseas
korean
children
aim
studi
find
associ
serum
level
accord
sever
atop
dermat
korean
children
method
one
hundr
twentyf
ad
children
assess
accord
scorad
index
mild
moder
sever
serum
specif
ige
egg
white
cow
milk
soy
bean
wheat
peanut
hous
dust
mite
df
measur
immunocap
system
skin
prick
test
serum
measur
mean
flow
cytometri
result
bronchial
asthma
allerg
rhiniti
combin
frequent
mild
atop
dermat
howev
differ
allerg
diseas
famili
differ
total
ige
among
group
howev
serum
total
eosinophil
count
highest
sever
atop
dermat
p
sensitizatioin
rate
egg
white
cow
milk
soy
bean
peanut
wheat
increas
significantli
accord
scorad
index
p
sensit
rate
hous
dust
mite
signific
differ
accord
scorad
index
although
differ
serum
level
among
group
highest
sever
atop
dermat
p
conclus
suggest
sensit
rate
common
food
allergen
higher
sever
ad
serum
level
higher
sever
ad
object
compar
influenc
regulatori
cell
treg
differ
hous
dust
mite
specif
immunotherpi
rout
subcutan
immunotherapi
scit
versu
sublingu
immunotherapi
slit
method
dust
mite
allerg
asthma
children
mild
moder
sever
enrol
asthma
center
beij
children
hospit
februari
octob
among
patient
femal
took
sublingu
dust
mite
specif
immunotherapi
slit
group
patient
femal
took
subcutan
immunotherapi
scit
group
subject
femal
complet
treatment
process
scit
treatment
group
asthmat
children
without
immunotherapi
enrol
control
group
peripher
blood
mononuclear
cell
pbmc
isol
subject
vitro
stimul
hdm
extract
hour
rel
percentag
treg
measur
flow
cytometri
result
unstimul
condit
der
baselin
rel
percentag
treg
group
significantli
higher
stimul
condit
besid
baselin
treg
scit
group
significantli
higher
control
group
slit
group
howev
signific
differ
treg
scit
group
accomplish
scit
treatment
conclus
seem
like
effect
induc
regulatori
cell
asthmat
children
scit
compar
slit
effect
could
remain
period
time
even
whole
specif
treatment
procedur
background
asthma
remain
seriou
healthcar
burden
asia
despit
avail
efficaci
treatment
asthma
control
remain
suboptim
realis
asia
aim
identifi
treatment
gap
explor
patient
percept
attitud
diseas
treatment
well
insight
physician
manag
diseas
main
object
provid
broad
view
asthma
region
countryspecif
variat
report
method
realis
asia
conduct
twopart
follow
countri
china
hong
kong
sar
indonesia
malaysia
philippin
singapor
south
korea
taiwan
part
onlin
survey
involv
patient
asthma
age
year
access
social
media
part
done
facetofac
onlin
interview
among
physician
involv
asthma
patientcar
result
dispar
proport
wellcontrol
asthma
patientreport
physicianperceiv
rang
malaysia
hong
kong
significantli
higher
proport
physician
hong
kong
report
use
guidelin
assess
asthma
control
versu
countri
length
consult
rang
minut
initi
followup
korea
minut
philippin
respect
percentag
patient
agre
full
discuss
physician
best
medic
treat
asthma
rang
korea
china
indonesia
philippin
almost
physician
indic
explain
purpos
inhal
initi
consult
though
significantli
lower
china
averag
physician
believ
combin
corticosteroid
long
act
bronchodil
inhal
improv
patient
adher
significantli
lower
indonesia
proport
patient
report
use
control
inhal
daili
rang
korea
singapor
half
patient
inhal
said
inhal
techniqu
check
healthcar
profession
past
month
lowest
korea
hong
kong
conclus
variat
among
countri
percept
manag
asthma
exist
common
aspect
care
need
optimis
eg
adher
control
inhal
techniqu
patient
educ
understand
differ
context
healthcar
system
countri
provid
addit
insight
use
develop
relev
intervent
improv
asthma
control
background
asthma
known
diseas
mani
variat
one
subtyp
aspirin
exacerb
respiratori
diseas
aerd
aerd
patient
experi
sever
bronchoconstrict
aspirin
nsaid
aerd
patient
gener
rel
sever
asthma
high
proport
requir
longterm
oral
corticosteroid
oc
aim
classifi
aerd
phenotyp
cluster
method
aerd
patient
follow
least
year
ajou
univers
hospit
jan
jul
enrol
fractur
aerd
phenotyp
use
atopi
chronic
rhinosinus
cr
urticaria
perform
two
step
cluster
analysi
sever
exacerb
defin
patient
taken
intraven
steroid
treatment
least
burst
oc
year
mean
follow
durat
clinic
characterist
among
cluster
examin
fisher
exact
test
anova
gener
estim
equat
appli
possess
rate
antiasthmat
sever
exacerb
year
result
aerd
cluster
good
qualiti
silhouett
obtain
accord
urticari
cr
atopi
cluster
aerd
cr
atopi
without
urticaria
cluster
aerd
cr
cluster
aerd
atopi
cluster
aerd
urticaria
significantli
differ
sever
asthma
cluster
respect
total
ige
p
sputum
eosinophil
peripher
eosinophil
count
p
occurr
sever
exacerb
signific
higher
cluster
cluster
patient
cluster
show
significantli
higher
possess
rate
icslaba
cluster
p
oc
cluster
possess
rate
ltra
significantli
higher
cluster
vs
cluster
p
possess
rate
antihistamin
significantli
lower
cluster
vs
p
conclus
sever
exacerb
rate
possess
rate
major
antiasthmat
quit
differ
among
cluster
even
aerd
recogn
subtyp
asthma
result
suggest
sophist
therapeut
approach
need
patient
aerd
background
concern
rais
advers
impact
dusti
air
pollut
dap
iran
human
health
studi
show
effect
dap
immun
system
toward
allerg
diseas
method
effect
ambient
dap
exposur
base
cytokin
profil
lymphocyt
immunophenotyp
blood
among
individu
gener
popul
hazard
aqi
good
condit
weather
aqi
examin
measur
cytokin
product
use
elisa
well
blood
sampl
use
facsort
flow
cytomet
determin
phenotyp
tlymphocyt
blymphocyt
cell
result
mean
serum
level
vs
pgdl
vs
pgdl
subject
exposur
ambient
dap
increas
significantli
individu
good
condit
weather
p
addit
blymphocyt
vs
cell
vs
count
peripher
blood
increas
parallel
increas
dap
exposur
level
p
p
respect
conclus
studi
may
suggest
ambient
dap
may
affect
immun
system
shift
allerg
inflamm
gener
popul
key
word
dusti
air
pollut
immun
system
allerg
diseas
cytokin
lymphocyt
background
antituberculosi
drug
atd
major
caus
druginduc
liver
injuri
dili
although
genet
factor
known
play
role
develop
atdinduc
hepat
genet
suscept
condit
poorli
understood
yet
method
perform
genomewid
associ
studi
gwa
identifi
genet
variant
associ
risk
atdinduc
hepat
korean
popul
dna
obtain
patient
atdinduc
hepat
atdtoler
subject
genotyp
affymetrix
genomewid
human
snp
array
identif
genet
variant
signific
associ
gene
set
enrich
analysi
done
find
relev
pathway
associ
atdinduc
hepat
result
casecontrol
analysi
found
signific
genet
variant
x
ci
x
ci
x
ci
pathway
analysi
identifi
sever
pertin
pathway
includ
axon
guidanc
cgmp
effect
development
biolog
signal
rho
gtpase
interact
ankyri
conclus
gwa
identifi
genet
variant
pathway
underli
develop
atdinduc
hepat
result
provid
insight
genet
suscept
atdinduc
hepat
oxid
stress
play
role
pathogenesi
chronic
obstruct
airway
diseas
asthma
copd
thu
regul
reactiv
oxygen
speci
ro
antioxid
defens
also
critic
gener
major
sourc
ro
mitochondri
respir
cell
antioxid
exist
mitochondriaspecif
form
import
regul
signific
quantiti
ro
known
dual
function
protein
gsh
peroxidas
phospholipas
activ
report
predominantli
express
airway
epithelium
recent
knockdown
report
induc
mitochondri
dysfunct
although
well
known
mainli
locat
cytoplasm
secretori
organel
lysosom
aim
studi
investig
influenc
mitochondri
function
cellular
transloc
mitochondria
oxid
stress
mitochondri
transloc
subcellular
fraction
human
bronchial
epitheli
cell
line
mous
lung
tissu
oxid
stress
analyz
immunoblot
evalu
chang
mitochondri
function
measur
consumpt
atp
synthesi
ro
gener
express
increas
oxid
stress
induc
paraquat
lipid
peroxid
protein
carbonyl
significantli
higher
knockdown
cell
compar
overexpress
cell
intracellular
transloc
enhanc
oxid
stress
confirm
immunoblot
subcellular
fraction
confoc
microscop
analysi
immunofluoresc
probe
result
studi
demonstr
play
import
role
regul
mitochondria
oxid
stress
airway
dysregul
function
might
critic
develop
perpetu
chronic
obstruct
airway
diseas
clarif
precis
function
mechan
may
valuabl
understand
pathogenesi
diseas
background
silica
nanoparticl
snp
easili
expos
via
inhal
owe
low
particl
weight
eas
dispers
howev
toxic
adjuv
effect
snp
airway
system
accord
surfac
pattern
well
establish
evalu
effect
airway
system
murin
model
use
type
snp
method
femal
balbc
mice
intranas
administ
type
snp
sphericaltyp
ssnp
mesoporoustyp
msnp
polyethylen
glycol
conjug
type
psnp
without
ovalbumin
ova
thrice
weekli
week
mice
sacrif
h
last
dose
evalu
airway
hyperrespons
ahr
bronchoalveolar
lavag
fluid
balf
cytokin
level
histolog
lung
result
model
administ
snp
alon
msnp
induc
signific
ahr
compar
sham
group
wherea
snptreat
group
show
signific
increas
total
cell
macrophag
neutrophil
count
balf
ssnp
msnp
induc
increas
cytokin
interleukin
il
level
model
administ
snp
ova
ssnp
msnp
induc
signific
ahr
compar
sham
group
administ
ova
alon
overal
greater
inflammatori
cell
infiltr
balf
extens
patholog
chang
higher
cytokin
level
observ
group
administ
snp
ova
administ
snp
ova
alon
howev
psnp
induc
lesser
inflamm
type
snp
model
conclus
snp
alon
signific
toxic
effectc
airway
system
moreov
snp
administ
ova
caus
adjuv
effect
recommend
use
psnp
rel
safeti
compar
ssnp
msnp
object
studi
develop
procedur
assess
diagnost
treatment
children
ch
differ
immunopathogenet
phenotyp
ipp
atop
dermat
ad
materi
method
particip
studi
ch
age
moder
cours
ad
exacerb
phase
control
group
compris
healthi
ch
age
patient
underw
gener
physic
examin
clinic
assess
immunoallergolog
assess
iaa
aim
detect
clinic
laboratori
sign
allergeninduc
inflamm
gener
physic
examin
includ
clinic
blood
urin
analys
screen
parasit
viral
infect
iaa
consist
immunogram
determin
level
pro
antiinflammatori
cytokin
fluoresc
immunoassay
skin
test
challeng
elimin
test
indic
total
specif
ige
blood
test
hous
dust
mite
allergen
hdma
use
causesignific
allergen
clinic
assess
aim
collect
allerg
anamnesi
evalu
sever
clinic
symptom
accord
scorad
scale
result
integr
studi
conduct
enabl
us
divid
ch
two
group
base
princip
ipgp
ad
igemedi
nonigemedi
form
ad
ch
nonigemedi
type
ad
show
igesensit
hdma
lower
paramet
macrophagephagocyt
compon
immun
system
mpci
igemedi
ad
phenotyp
includ
form
ad
allerg
form
mix
form
combin
allerg
rhiniti
bronchial
asthma
combin
form
studi
allerg
mix
form
ad
prove
exist
sensit
nonelimin
hdma
promot
allerg
provok
develop
symptom
cours
ad
ch
combin
form
ad
decreas
paramet
mpci
phagocyt
number
phagocyt
index
nbt
reduct
test
also
found
basi
reveal
disord
sever
multimod
immunotherapi
mit
program
develop
igemedi
form
ad
propos
mit
includ
basic
therapi
bt
parenter
antigenspecif
immunotherapi
asit
acceler
treatment
regimen
immunomodul
im
select
basi
capac
affect
cell
monocyticmacrophag
natur
increas
macrophag
cytotox
toward
bacteri
antigen
virulifer
cell
well
correct
imbal
cytokin
profil
intensifi
product
ifni
would
eventu
contribut
lower
rate
infecti
complic
ad
nonallerg
form
ad
bt
im
use
conclus
procedur
assess
diagnost
ch
ad
develop
us
provid
opportun
correctli
select
adequ
mit
accord
ipp
diseas
take
account
reveal
immun
disord
background
preval
immedi
hypersensit
reaction
ihsr
platinumbas
chemotherapi
rise
increas
chemotherapi
usag
although
proven
ultim
solut
desensit
protocol
yet
appli
mani
institut
impract
cost
procedur
durat
lack
train
manpow
predict
success
desensit
protocol
help
reduc
unnecessari
workload
object
aim
determin
clinic
characterist
current
adopt
measur
oxaliplatin
ihsr
predict
success
newli
develop
practic
desensit
protocol
method
retrospect
review
case
oxaliplatin
ihsr
oxaliplatin
user
admit
sever
hospit
prospect
use
new
desensit
protocol
time
patient
hypersensit
platinumbas
chemotherapi
new
desensit
protocol
conduct
escal
infus
rate
regularli
regardless
concentr
bag
order
mlh
mlh
mlh
everi
minut
result
patient
administ
oxaliplatin
patient
experienc
oxaliplatin
ihsr
patient
experienc
ihsr
need
keep
oxaliplatin
patient
stop
due
ihsr
patient
kept
regimen
regardless
anticip
risk
signific
risk
factor
ihsr
found
new
desensit
protocol
success
complet
patient
howev
among
patient
protocol
ineffect
patient
fever
without
urticaria
neg
respons
skin
prick
test
conclus
mani
patient
experi
oxaliplatin
ihsr
requir
stop
effect
regimen
maintain
regimen
without
desensit
anticip
risk
ihsr
new
practic
desensit
protocol
might
appli
easili
conveni
real
clinic
practic
fever
without
urticaria
neg
respons
skin
prick
test
indic
desensit
protocol
might
ineffect
background
bacteri
flagellin
tolllik
agonist
use
adjuv
immunomodul
recent
intranas
administr
ova
flagellin
mixtur
report
effect
allerg
inflamm
studi
aim
evalu
effect
mechan
intralymphat
administr
ovaflagellin
mixtur
treatment
allerg
rhiniti
materi
method
balbc
mice
sensit
ova
treat
ovaflagellin
flab
mixtur
via
intranas
sublingu
intralymphat
routr
evalu
effect
intralymphat
administr
sever
paramet
allerg
inflamm
assess
includ
symptom
score
eosinophil
neutrophil
infiltr
nasal
mucosa
system
cytokin
level
total
ovaspecif
imuunoglobulin
e
evalu
mechan
intralymphat
inject
local
cytokin
chemokin
innat
cytokin
analysi
undertaken
use
real
time
pcr
western
blot
immunohistochemistri
result
intralymphat
inject
ovaflab
mixtur
reduc
symptom
score
eosinophil
infiltr
nasal
mucosa
total
ovaspecif
ige
level
significantli
intranas
sublingu
administr
system
cytokin
ifnr
local
cytokin
product
also
decreas
significantli
intralymphat
inject
ovaflab
doubl
administr
mixtur
effect
singl
administr
moerov
express
innat
cytokin
nasal
epitheli
cell
decreas
chemokin
express
decreas
nasal
mucosa
suggest
underli
mechan
intralymphitc
administr
ovaflab
mixtur
conclus
intralymphat
administr
ovaflab
mixtur
effect
allevi
allerg
inflamm
intranas
sublingu
administr
mous
model
allerg
rhiniti
effect
could
attribut
reduc
express
innat
cytokin
chemokin
modal
could
consid
new
therapeut
method
agent
background
nonsteroid
antiinflammatori
drug
nsaid
hypersensit
commonli
found
drug
allergi
two
major
phenotyp
respiratori
aspirinexacerb
respiratori
diseas
aerd
cutan
aspirinexacerb
cutan
diseas
aecd
aspirinintoler
acut
urticaria
aiau
type
note
countri
periostin
extracellular
matrix
protein
structur
homolog
fasciclin
insect
adhes
molecul
previou
studi
demonstr
serum
periostin
level
significantli
higher
aerd
aspirin
toler
asthma
evalu
serum
periostin
level
biomark
differenti
phenotyp
nsaid
hypersensit
compar
serum
periostin
level
respiratori
cutan
type
nsaid
hypersensit
method
serum
periostin
level
measur
human
periostin
elisa
sera
adult
patient
nsaid
hypersensit
healthi
normal
control
nc
phenotyp
nsaid
hypersensit
defin
accord
previou
histori
advers
drug
reaction
andor
aspirin
provoc
test
result
respiratori
type
nsaid
hypersensit
cutan
type
mean
serum
periostin
level
significantli
higher
respiratori
type
ngml
cutan
type
ngml
nc
group
ngml
howev
signific
differ
serum
periostin
level
aecd
aiau
group
p
aecd
nc
group
p
aiau
nc
group
p
roc
analysi
reveal
serum
periostin
level
could
differenti
aerd
cutan
type
nsaid
hypersensit
auc
p
cutoff
level
ngml
sensit
specif
conclus
find
suggest
serum
periostin
level
use
biomark
predict
phenotyp
aerd
among
nsaid
hypersensit
patient
background
earli
identif
sensit
pattern
suspect
allerg
children
may
suppli
clue
prevent
manag
allerg
diseas
object
analyz
sensit
statu
common
inhal
allergen
children
suspect
allergi
beij
children
hospit
year
method
enrol
children
screen
allergi
semiquantit
test
method
mediswiss
allergi
screen
allergen
test
system
germani
comparison
sensit
pattern
among
differ
subgroup
perform
result
conclus
total
children
screen
allergi
outpati
subject
posit
rate
sige
case
top
three
posit
allergen
mold
dog
hair
dust
mite
inpati
group
posit
rate
sige
case
top
three
allergen
dust
mite
dog
hair
mold
also
found
highest
posit
rate
children
suffer
nose
eye
diseas
especi
inpati
hsp
children
coinfect
lower
respiratori
tract
infect
lri
posit
rate
increas
hsp
hsplri
p
like
lead
appear
multipl
sensit
therefor
necessari
keep
watch
variat
sensit
state
pay
greater
attent
interpret
test
result
enabl
suppli
pediatrician
ration
treatment
prophylact
strategi
allergen
avoid
oxid
stress
postul
play
import
role
pathogenesi
allerg
airway
inflamm
involv
transcript
regul
mani
antioxid
gene
present
studi
investig
role
experiment
model
ovalbumin
ova
sensit
challeng
allerg
airway
inflamm
balbc
mice
mice
use
balbc
mice
allerg
airway
inflamm
gener
mice
intraperiton
sensit
ovaalum
day
mice
challeng
ova
intranas
day
ova
challeng
twentyfour
hour
examin
cell
popul
bronchoalveolar
lavag
bal
fluid
ige
level
serum
airway
hyperrespons
ahr
assess
wholebodi
plethysmographi
freemov
applic
number
total
cell
macrophag
eosinophil
bal
fluid
decreas
compar
mice
also
case
ahr
chang
balbc
mice
number
neutrophil
bal
fluid
ige
level
serum
significantli
increas
compar
balbc
mice
contrast
significantli
differ
mice
conclus
role
gener
allerg
airway
inflamm
differ
markedli
mous
strain
result
suggest
may
play
key
role
develop
allerg
airway
inflamm
relat
neutrophil
balbc
mice
background
neutrophil
play
import
role
develop
persist
airflow
limit
asthma
particularli
patient
show
poor
respons
corticosteroid
human
mesenchym
stem
cell
hmsc
emerg
new
treatment
option
due
immunomodulatori
effect
howev
role
hmsc
neutrophil
asthma
yet
understood
method
balbc
mice
expos
ovalbumin
poli
ic
induc
neutrophil
airway
inflamm
hmsc
administ
intraven
bronchoalveolarlavag
bal
done
evalu
differenti
cell
count
measur
inflammatori
cytokin
includ
ifngamma
also
measur
cytokin
includ
ifngamma
releas
lymphocyt
pulmonari
lymph
node
addit
lung
histopatholog
done
show
peribronchi
perivascular
inflamm
result
hmsc
treatment
decreas
bal
total
cell
count
p
neutrophil
p
lymphocyt
p
bal
fluid
decreas
hmsc
treatment
group
p
howev
ifngamma
show
differ
compar
wild
type
releas
lymphocyt
pulmonari
lymph
node
significantli
decreas
p
histopatholog
examin
reveal
peribronchi
inflamm
dramat
decreas
hmsc
treatment
group
conclus
hmsc
inhibit
airway
inflamm
poli
ic
induc
neutrophil
asthma
model
mechan
underli
immunomodulatori
effect
might
associ
regul
key
role
mediat
inflamm
background
although
sever
studi
claim
mesenchym
stem
cell
msc
deriv
human
tissu
amelior
allerg
airway
inflamm
immunomodulatori
mechan
msc
remain
unclear
object
aim
determin
effect
underli
mechan
tonsil
deriv
msc
tmsc
allerg
inflamm
compar
adipos
tissu
deriv
stem
cell
asc
mous
model
allerg
rhiniti
ar
method
msc
isol
human
palatin
tonsil
tmsc
adipos
tissu
asc
surfac
marker
analyz
effect
tmsc
evalu
balbc
mice
randomli
divid
group
neg
control
group
posit
control
group
tmsc
group
asc
group
msc
administ
intraven
ovasensit
mice
tmsc
asc
group
day
subsequ
ova
challeng
conduct
daili
day
sever
paramet
allerg
inflamm
assess
result
tmsc
asc
similar
characterist
surfac
marker
intraven
inject
tmsc
significantli
reduc
allerg
symptom
eosinophil
infiltr
serum
total
ova
specificig
nasal
system
cytokin
profil
analysi
reveal
nasal
innat
cytokin
chemokin
induct
suppress
tmsc
inject
group
explain
underli
mechan
addit
tmsc
group
inhibit
allerg
inflamm
asc
group
might
attribut
prolif
activ
tmsc
conclus
administr
tmsc
effect
reduc
allerg
symptom
inflammatori
paramet
mous
model
ar
tmsc
treatment
reduc
cytokin
ova
specif
ige
secret
b
cell
addit
innat
cytokin
express
eotaxin
mrna
express
inhibit
nasal
mucosa
suggest
mechan
reduc
allerg
inflamm
therefor
tmsc
treatment
potenti
altern
therapeut
modal
ar
object
allerg
rhiniti
ar
asthma
major
global
health
problem
develop
develop
countri
like
india
diseas
advers
impact
patient
qualiti
life
qol
also
pose
big
socioeconom
burden
yoga
shown
benefici
effect
improv
sleep
qualiti
lung
function
qualiti
life
patient
asthma
scientif
studi
effect
yoga
airway
resist
patient
ar
aim
studi
assess
subject
object
effect
yoga
also
see
yoga
adapt
cost
cut
intervent
better
control
asthma
ar
method
present
studi
conduct
adult
subject
mildmoder
persist
ar
without
asthma
patient
train
specif
hatha
yogasana
known
improv
respiratori
function
particip
practis
asana
week
subject
object
outcom
measur
assess
baselin
day
week
post
yoga
use
rhinomanometri
spirometri
sino
nasal
outcom
test
questionnair
qol
short
form
result
signific
reduct
total
nasal
resist
tnr
paml
p
signific
increas
total
nasal
airflow
paml
p
yoga
compar
correspond
baselin
valu
day
indic
pulmonari
function
fvc
p
p
forc
midexpiratori
flow
fvc
fef
p
pefr
p
show
signific
improv
qol
questionnair
short
form
show
highli
signific
improv
physic
p
mental
p
composit
score
along
signific
reduct
sino
nasal
outcom
test
score
p
post
yoga
compar
correspond
baselin
valu
conclus
direct
cost
treatment
medic
hospit
visit
etc
well
indirect
cost
due
loss
product
significantli
high
patient
ar
asthma
result
present
studi
conclud
practic
yoga
offer
signific
advantag
patient
ar
reduc
nasal
resist
increas
nasal
airflow
improv
lung
function
qualiti
life
studi
need
analyz
immunologc
mechan
involv
form
therapi
impact
acut
exacerb
need
rescu
medic
long
term
effect
yoga
true
patientphysician
partnership
empow
patient
complianc
adher
therebi
function
health
background
object
chronic
urticaria
cu
common
skin
disord
character
hive
itch
least
week
qol
cu
substanti
impair
due
unpredict
symptom
longterm
natur
studi
aim
evalu
impact
cu
qol
use
cuspecif
qol
measur
previous
valid
korea
identifi
predictor
qol
cu
patient
method
enrol
adult
patient
chronic
spontan
urticaria
follow
allergi
clinic
immunolog
clinic
ajou
univers
hospit
march
decemb
cuqol
questionnair
urticaria
activ
score
ua
presenc
angioedema
serum
total
ige
level
investig
result
averag
cuqol
score
point
cuqol
score
significantli
correl
ua
particularli
ua
coeffici
p
ua
p
total
cuqol
score
significantli
decreas
patient
sever
cu
nonsever
cu
vs
p
case
angioedema
urticaria
symptom
domain
score
significantli
decreas
vs
p
urticaria
multivari
analysi
show
sever
cu
high
log
total
ige
presenc
angioedema
signific
predictor
cuqol
impair
point
conclus
import
consid
qol
impair
sever
cu
log
total
ige
presenc
angioedema
signific
cuqol
predictor
korean
patient
cu
background
hous
dust
mite
hdm
allerg
asthma
symptom
occur
due
airway
eosinophilia
cell
activ
budesonid
use
treat
airway
inflamm
hyperrespons
show
dietari
nondigest
galactooligosaccharid
go
suppress
symptom
murin
model
hdminduc
asthma
aim
studi
combin
dietari
go
budesonid
treatment
allerg
asthma
mice
method
balbc
mice
intranas
sensit
pb
presenc
absenc
hdm
challeng
pb
hdm
day
till
fed
diet
contain
ww
go
day
budesonid
either
instil
oropharyng
day
airway
resist
metacholin
inflamm
determin
leukocyt
subtyp
analyz
bronchoalveolar
lavag
bal
lung
cell
suspens
mucos
mast
cell
measur
serum
cytokin
lung
homogen
result
hdmallergi
significantli
increas
airway
respons
bal
leukocyt
number
budesonid
treatment
suppress
reach
signific
mice
fed
go
budesonid
reduc
number
lymphocyt
eosinophil
bal
feed
go
absenc
budesonid
treatment
reduc
number
eosinophil
well
addit
go
well
budesonid
reduc
serum
concentr
interestingli
go
fed
mice
budesonid
treatment
reduc
concentr
frequenc
cell
lung
conclus
dietari
intervent
use
go
may
novel
way
improv
effect
antiinflammatori
drug
therapi
asthma
studi
perform
within
framework
carbohydr
compet
center
background
american
cockroach
periplaneta
americana
major
sourc
indoor
allergen
tropic
subtrop
region
frequent
caus
allerg
reaction
asthma
sinc
domin
major
allergen
exist
sourc
compon
resolv
diagnosi
crd
requir
determin
patient
sensit
point
treatment
option
therefor
eranet
new
indigo
project
genal
genet
engin
allergen
componentresolv
diagnosi
immunotherapi
airway
allergi
aim
produc
set
wellcharacter
recombin
periplaneta
americana
allergen
establish
crd
method
per
residu
microvillar
membran
associ
protein
homologu
per
unusu
aspart
proteas
ctermin
domain
per
residu
hemocyanin
produc
recombinantli
ecoli
primari
sequenc
purifi
protein
confirm
amino
acid
analysi
aaa
mass
spectrometri
ms
secondari
structur
element
determin
circular
dichroism
spectroscopi
cd
protein
analyz
aggreg
behavior
model
protein
gener
swissmodel
use
homologu
blattella
germanica
allergen
templat
sera
cockroach
allerg
patient
india
south
korea
use
test
ige
sensit
protein
elisa
result
ident
three
purifi
protein
confirm
ms
concentr
rang
mgml
determin
aaa
cd
reveal
partial
intact
secondari
structur
element
protein
resembl
model
structur
per
per
sensit
frequenc
observ
elisa
experi
reactiv
per
limit
test
patient
cohort
conclus
purifi
recombin
per
per
per
physicochem
character
abil
bind
ige
shown
includ
current
describ
periplaneta
americana
allergen
test
divers
patient
cohort
europ
asia
america
sensit
pattern
allergen
elucid
background
hand
eczema
common
inflammatori
dermatosi
influenc
qualiti
life
especi
come
accompani
itch
howev
research
regard
characterist
itch
neurolog
associ
hand
eczema
far
perform
studi
objectifi
influenc
qualiti
life
patient
hand
eczema
investig
associ
cutan
nerv
b
method
conduct
hand
eczema
sever
score
use
hecsi
score
questionnair
contain
leuvin
itch
scale
dermatolog
life
qualiti
index
dlqi
neurolog
exam
use
vonfrey
filament
neuromet
c
result
fortyfour
patient
enrol
studi
patient
also
done
neurolog
examin
itch
occur
least
daili
studi
patient
finger
palm
commonli
affect
itch
area
leuvin
itch
scale
directli
proport
hecsi
score
dlqi
invers
proport
sensori
threshold
forc
measur
vonfrey
filament
significantli
higher
lesion
normal
skin
p
pain
threshold
use
neuromet
also
significantli
decreas
lesion
p
conclus
studi
uniqu
trial
describ
characterist
itch
experienc
hand
eczema
investig
relationship
hand
eczema
cutan
nerv
thought
could
good
basi
develop
futur
therapeut
modal
neurotransmitt
hand
eczema
druginduc
anaphylaxi
big
pitfal
patient
receiv
antineoplast
chemotherapi
report
case
lung
cancer
patient
experienc
two
nearfat
anaphylact
reaction
result
paclitaxel
multivitamin
separ
recurr
sever
reaction
differ
agent
led
investig
materi
patient
hypersensit
skin
prick
test
reveal
sensit
cremophor
commonli
use
emulsifi
agent
case
emphas
import
correctli
identifi
culprit
drug
anaphylaxi
avoid
potenti
fatal
reaction
background
aim
describ
epidemiolog
trigger
anaphylaxi
relat
emerg
depart
visit
children
adult
singapor
method
perform
prospect
studi
patient
visit
emerg
depart
ed
anaphylaxi
collect
data
emerg
depart
three
major
tertiari
hospit
april
march
electron
record
patient
diagnos
allergi
angioedema
urticaria
anaphylaxi
icd
code
obtain
result
case
anaphylaxi
identifi
make
ed
visit
allergyrel
symptom
median
age
year
rang
year
children
year
made
cohort
male
patient
ethnic
includ
chines
case
malay
indian
other
common
trigger
food
follow
drug
sting
insect
trigger
could
identifi
initi
present
case
common
food
allergen
shellfish
follow
peanut
nut
new
case
galactooligosaccharid
allergi
confirm
followup
age
distribut
vari
trigger
factor
druginduc
anaphylaxi
older
food
allergi
mean
age
vs
year
p
case
insectrel
anaphylaxi
occur
adult
age
rang
year
case
shellfish
anaphylaxi
older
peanuttreenut
anaphylaxi
mean
year
rang
sd
year
vs
mean
year
rang
sd
year
p
hospit
rate
univari
multipl
regress
analysi
signific
factor
associ
hospit
age
patient
spearman
correl
coeffici
conclus
food
drug
allergi
common
caus
anaphylaxi
shellfish
common
food
allergen
anaphylaxi
caus
drug
sting
insect
shellfish
common
adult
whilst
anaphylaxi
caus
peanut
tree
nut
common
children
background
atop
dermat
ad
chronic
relaps
inflammatori
skin
diseas
character
dri
skin
sever
itch
children
ad
caregiv
report
diseas
associ
sleep
disrupt
irrit
anxieti
behavior
problem
moreov
ad
place
signific
econom
burden
patient
famili
societi
integr
health
care
servic
use
comprehens
evalu
trigger
respons
treatment
address
confound
factor
includ
psycholog
problem
educ
patient
famili
method
studi
design
evalu
effect
integr
health
care
servic
children
ad
accord
qualiti
life
clinic
symptom
score
children
refer
local
health
care
offic
seoul
medic
center
manag
ad
juli
decemb
questionnair
develop
atopi
free
seoul
research
project
use
qualiti
life
qol
survey
score
atop
dermat
scorad
done
visit
result
studi
target
children
averag
age
year
ad
visit
hospit
time
averag
found
qol
score
patient
particip
integr
health
care
servic
reduc
treatment
compar
intervent
p
children
among
scorad
also
averag
decreas
treatment
p
moreov
posit
correl
chang
score
qol
scorad
patient
p
satisfi
improv
degre
symptom
integr
health
care
servic
satisfi
improv
degre
daili
life
conclus
integr
health
care
servic
children
ad
improv
diseas
sever
qualiti
life
result
multidisciplinari
approach
support
need
feasibl
integr
care
children
ad
famili
background
substanti
proport
patient
chronic
urticaria
cu
refractori
antihistamin
remain
unknown
identifi
subpopul
whose
urticaria
complet
control
antihistamin
autolog
serum
skin
test
asst
respons
suggest
potenti
predictor
urticaria
control
sought
identifi
protein
differenti
express
sera
patient
posit
neg
asst
method
proteom
analysi
perform
use
sera
patient
posit
result
asst
compar
neg
asst
seven
upregul
downregul
protein
identifi
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
posit
asst
group
compar
neg
asst
group
result
protein
differenti
express
accord
asst
result
cu
patient
classifi
group
apolipoprotein
glycoprotein
modifi
albumin
haptoglobulin
plectin
among
apolipoprotein
j
clusterin
valid
use
elisa
clusterin
level
asst
posit
patient
significantli
higher
asst
neg
patient
healthi
control
median
minmax
vs
vs
p
furthermor
differ
significantli
patient
well
respons
refractori
antihistamin
treatment
within
month
vs
p
receiveroper
characterist
roc
curv
analysi
yield
ugml
serum
clusterin
optim
cutoff
discrimin
respons
antihistamin
csu
patient
auc
ci
p
criteria
combin
asst
result
serum
clusterin
level
predict
cu
patient
whose
urticaria
would
refractori
antihistamin
conclus
consid
clusterin
abl
modul
complement
function
suggest
serum
clusterin
prognost
marker
determin
respons
antihistamin
treatment
patient
cu
work
support
grant
nation
research
foundat
korea
fund
korean
govern
msip
sever
biomark
develop
address
airway
inflamm
bronchial
asthma
ba
includ
exhal
nitric
oxid
sputum
eosinophil
howev
challeng
sometim
consid
rather
invas
appropri
obtain
biomark
young
children
sinc
urin
noninvas
easytoobtain
sampl
children
urinari
leukotrien
one
potent
biomark
address
airway
inflamm
infant
ask
whether
use
diagnosi
ba
young
children
determin
concentr
wheez
children
total
patient
outpati
clinic
saitama
prefectur
japan
wheez
februari
august
particip
studi
urin
sampl
collect
immedi
frozen
use
collect
antibodi
concentr
determin
elisa
urin
creatinin
ucr
level
also
determin
sinc
ucr
level
differ
among
differ
age
first
correct
ucr
valu
correspond
age
normal
agecorrect
ucr
level
patient
consist
first
wheezer
without
famili
histori
ba
first
wheezer
rsv
infect
intermitt
ba
mild
persist
ba
control
fever
wheez
level
first
wheezer
famili
histori
respond
inhal
bronchodil
intermitt
ba
higher
p
control
signific
differ
group
control
result
suggest
marker
allerg
airway
inflamm
young
children
current
follow
clinic
cours
patient
ask
whether
predict
marker
develop
ba
background
oral
ingest
food
protein
normal
result
induct
oral
toler
wherea
allerg
sensit
food
protein
mice
induc
presenc
mucos
adjuv
like
cholera
toxin
ct
ct
therefor
often
use
tool
unravel
mechan
behind
allerg
sensit
although
ct
involv
onset
allerg
sensit
human
mycotoxin
deoxynivalenol
among
frequent
detect
contamin
wheat
wheatbas
product
abl
impair
intestin
barrier
function
hypothes
may
repres
humanrelev
mucos
adjuv
therefor
present
studi
investig
capac
act
mucos
adjuv
mous
model
wheyinduc
food
allergi
method
femal
mice
per
group
oral
expos
plu
whey
week
week
control
mice
receiv
pb
acut
allerg
skin
respons
chang
bodi
temperatur
anaphylact
shock
reaction
measur
upon
wheychalleng
allergenspecif
antibodi
measur
serum
mrna
express
ecadherin
determin
intestin
tissu
measur
serum
singl
oral
donexposur
result
mice
expos
plu
whey
show
wheyspecif
ige
antibodi
serum
acut
allerg
skin
respons
upon
intraderm
whey
challeng
compar
control
mice
furthermor
signific
timedepend
increas
solubl
serum
observ
plu
whey
sensit
mice
compar
control
mice
addit
analysi
intestin
tissu
isol
singl
oral
exposur
reveal
increas
mrna
express
tight
junction
protein
adheren
junction
ecadherin
well
increas
mrna
accompani
increas
solubl
receptor
serum
conclus
togeth
result
demonstr
facilit
allerg
sensit
may
thu
serv
model
adjuv
data
therefor
illustr
possibl
contribut
food
contamin
like
allerg
sensit
human
background
late
evid
show
huge
epidemiolog
burden
chronic
cough
gener
popul
howev
definit
chronic
cough
vari
definit
valid
clinic
relev
examin
exist
epidemiolog
definit
detail
investig
oper
characterist
method
systemat
literatur
review
conduct
epidemiolog
studi
report
preval
chronic
cough
gener
adult
popul
publish
peerreview
journal
year
oper
characterist
common
definit
examin
metaanalys
maletofemal
ratio
chronic
cough
preval
result
systemat
review
includ
studi
common
definit
cough
month
preval
without
specif
phlegm
conflict
criteria
clinic
guidelin
cough
week
metaanalys
conduct
maletofemal
ratio
chronic
cough
among
studi
report
sexspecif
preval
use
common
definit
howev
pool
maletofemal
odd
ratio
confid
interv
signific
heterogen
p
contrast
previou
clinic
observ
femal
predomin
cough
clinic
conclus
studi
indic
two
import
issu
defin
chronic
cough
epidemiolog
studi
conflict
epidemiolog
clinic
definit
durat
criteria
need
resolv
anoth
unexpect
differ
gender
preponder
commun
clinic
warrant
clinic
valid
exist
definit
background
object
studi
investig
physician
approach
asthmat
copd
patient
live
differ
area
turkey
report
baselin
demograph
risk
factor
adher
therapi
asthmat
copd
patient
compar
method
total
newli
diagnos
adult
patient
asthmat
copd
secondari
tertiari
center
differ
geograph
locat
took
part
studi
standard
webbas
questionnair
includ
item
relat
demograph
clinic
laboratori
pharmacolog
paramet
appli
juli
may
result
asthmat
patient
mostli
femal
male
patient
higher
copd
percentag
patient
whose
age
year
significantli
higher
copd
patient
compar
asthmat
patient
respect
p
evalu
diseas
sever
show
nearli
half
asthmat
patient
moder
persist
categori
half
copd
patient
gold
b
half
asthmat
copd
patient
least
one
accompani
diseas
respect
hypertens
seen
diseas
asthmat
copd
patient
respect
p
nearli
half
asthmat
patient
state
asthma
state
copd
famili
histori
nearli
copd
patient
state
copd
state
asthma
evalu
smoke
anamnesi
show
signific
differ
asthmat
copd
patient
mean
current
smoke
statu
percentag
respect
p
found
percentag
copd
patient
expos
dust
ga
andor
vapor
work
place
significantli
higher
asthmat
patient
p
evalu
trigger
factor
show
air
pollut
common
trigger
asthma
copd
group
evalu
adher
studi
visit
show
percentag
patient
come
one
control
visit
higher
asthmat
compar
copd
patient
respect
howev
group
compar
term
followup
visit
adher
low
group
asthma
copd
complianc
treatment
percentag
regular
medic
use
significantli
better
copd
patient
compar
asthmat
patient
conclus
copd
asthma
associ
signific
econom
burden
identif
reduct
exposur
risk
factor
import
treatment
prevent
patient
complianc
may
key
better
diseas
manag
need
new
strategi
improv
adher
patient
background
associ
obes
asthma
adult
children
implic
causal
mechan
especi
relat
respiratori
physiolog
well
understood
report
previous
obes
caus
abnorm
reactanc
valu
lung
physiolog
dissect
link
analyz
chang
pulmonari
function
treatment
obes
children
method
eleven
obes
children
boy
girl
year
age
enrol
studi
hospit
other
outpati
month
eight
asthma
asthma
mild
intermitt
sever
without
need
control
medic
spirometri
two
forc
oscil
techniqu
fot
test
master
screen
perform
assess
lung
function
treatment
obes
diet
exercis
patient
divid
two
group
success
group
failur
group
base
outcom
weight
loss
success
defin
improv
percentag
overweight
pow
observ
period
result
fot
reson
frequenc
fre
reactanc
area
ax
fre
significantli
improv
success
group
failur
group
previous
report
improv
significantli
success
group
counterpart
conclus
respiratori
function
reactanc
resist
paramet
fot
improv
parallel
weight
loss
obes
children
may
implic
function
relationship
obes
asthma
purpos
fraction
concentr
exhal
feno
shown
increas
inflammatori
airway
diseas
includ
bronchial
asthma
ba
allerg
rhiniti
ar
chronic
rhinosinus
recent
sever
report
increas
nasal
feno
patient
ar
present
studi
examin
differ
oral
feno
nasal
feno
level
ar
patient
without
ba
method
crosssect
studi
patient
mildpersist
severeintermitt
ar
patient
ar
patient
ba
normal
subject
enrol
feno
level
measur
use
handheld
electrochem
analyz
bedfont
scientif
ltd
rochest
kent
uk
treatment
one
month
treatment
nasal
feno
level
measur
use
nose
adaptor
patient
measur
serum
total
eosinophil
count
total
ige
allergenspecif
ige
hous
dust
mite
dp
df
alternaria
cat
dander
cockroach
tree
mix
immunocap
skin
prick
test
result
signific
differ
serum
total
eosinophil
count
total
ige
level
ar
patient
ar
patient
ba
oral
feno
level
treatment
show
signific
differ
ar
patient
ar
patient
ba
nasal
feno
level
treatment
significantli
higher
ar
patient
ba
ar
patient
treatment
nasal
feno
level
signific
differ
diseas
group
nasal
feno
level
treatment
significantli
lower
compar
nasal
feno
level
treatment
ar
ar
patient
ba
ar
patient
ar
patient
ba
conclus
treatment
nasal
feno
level
significantli
decreas
ar
patient
without
ba
nasal
feno
measur
ar
patient
suitabl
method
monitor
effect
treatment
modal
introduct
vitamin
defici
infant
recogn
caus
ricket
evid
emerg
link
lower
respiratori
tract
infect
food
allergi
diabet
schizophrenia
variou
extra
skelet
health
effect
exclus
breastf
infant
especi
vulner
vitamin
defici
due
depend
previou
transplacent
transfer
vitamin
mother
dietari
vitamin
breast
milk
cutan
synthesi
vitamin
exposur
sunlight
worldwid
epidem
vitamin
defici
pregnanc
low
content
vitamin
breast
milk
underli
high
risk
defici
exclus
breastf
infant
data
regard
magnitud
vitamin
defici
among
exclus
breastf
infant
kenya
need
inform
supplement
polici
object
studi
aim
determin
preval
vitamin
defici
exclus
breastf
infant
evalu
relationship
pth
popul
studi
design
cross
section
studi
includ
three
six
month
old
exclus
breastf
infant
aga
khan
univers
hospit
nairobi
method
ninetyeight
infant
enrol
studi
serum
oh
calcium
phosphat
pth
measur
data
sunlight
exposur
matern
vitamin
supplement
also
collect
result
preval
vitamin
defici
use
ngml
cutoff
ci
infant
insuffici
level
vitamin
infant
replet
case
secondari
hyperparathyroid
vitamin
level
one
case
elev
pth
vitamin
level
use
presum
normal
cutoff
popul
preval
vitamin
defici
doubl
four
mother
receiv
vitamin
supplement
breastfeed
infant
vitamin
replet
less
studi
popul
skelet
sign
ricket
conclus
preval
vitamin
defici
high
young
popul
despit
abundnc
sunshin
geograph
region
polici
vitamin
supplement
recommend
popul
mitig
impact
vitamin
defici
especi
chronic
noncommunic
diseas
background
total
serum
ige
phadiatoptm
key
test
employ
invitro
screen
atopi
acknowledg
possibl
uniqu
allergen
preval
indian
subcontin
aim
studi
understand
ige
seropreval
common
food
inhal
allergen
indian
adult
popul
suspect
atop
diseas
compar
perform
phadiatoptm
us
version
total
ige
screen
test
method
studi
carri
accredit
privat
medic
laboratori
mumbai
india
involv
retrospect
data
analysi
sera
collect
patient
suspect
allerg
diseas
test
includ
allergen
specif
ige
test
common
food
inhal
allergen
immunocap
ms
thermofisch
phadia
sweden
sera
also
simultan
screen
use
adult
phadiatoptm
immunocap
ms
thermofisch
phadia
sweden
screen
total
ige
immulit
siemen
healthcar
usa
design
group
group
ii
respect
group
similar
age
gender
distribut
result
patient
show
sensit
least
allergen
multisensit
common
seen
sera
preval
allergen
housedust
mite
pternyssinu
cockroach
housedust
mite
farina
shrimp
hous
dust
weed
chenopodium
album
pollen
candida
albican
weed
artemisia
vulgarismugwort
pollen
wheat
use
allergen
specif
ige
standard
cut
kual
sensit
specif
phadiatop
group
respect
phadiatop
sensit
increas
allergen
specif
ige
valu
kual
consid
ie
like
involv
symptomat
allerg
diseas
phadiatop
miss
cockroach
shrimp
posit
sera
though
phadiatop
intend
screen
food
allergi
cross
reactiv
certain
pollen
food
yield
posit
screen
result
sensit
specif
total
ige
group
ii
respect
total
ige
miss
low
level
sensit
also
miss
sera
high
posit
allergen
specif
ige
result
conclus
phadiatoptm
found
satisfactori
screen
test
atopi
outperform
serum
total
ige
look
trend
inhal
food
allergen
seropreval
current
studi
abl
establish
preliminari
list
allergen
relev
indian
context
could
test
addit
phadiatop
followon
neg
phadiatoptm
event
strong
clinic
histori
allerg
diseas
background
previous
report
skin
prick
test
sensit
serum
specif
ige
test
specif
predict
posit
airway
respons
hous
dust
mite
hdm
asthma
nose
bronchu
one
airway
nasal
provoc
test
would
specif
skin
test
predict
bronchial
respons
hdm
method
allergi
skin
prick
test
nasal
bronchial
provoc
test
use
hdm
dermatophagoid
farina
done
young
men
yearsold
want
militari
certif
asthma
nasal
respons
hdm
score
accord
sever
nose
symptom
rhinorrhea
sneez
nose
itch
result
preval
posit
skin
test
hdm
significantli
differ
patient
without
posit
respons
earli
late
bronchial
challeng
vs
howev
nasal
respons
score
significantli
higher
respond
other
vs
concord
posit
respons
skin
test
nasal
test
cutoff
score
signific
posit
bronchial
respons
diagnost
sensit
nasal
test
lower
specif
respect
higher
skin
test
sensit
specif
conclus
skin
test
sensit
wherea
nasal
test
specif
predict
posit
bronchial
respons
hdm
asthma
background
recurr
wheez
preschool
age
consist
sever
phenotyp
may
repres
differ
underli
patholog
differenti
respons
treatment
howev
phenotypebas
recommend
treatment
establish
sinc
clinic
trial
target
broad
rang
phenotyp
specif
phenotyp
order
identifi
novel
clue
drug
choic
preschool
wheez
investig
possibl
util
biomark
compar
efficaci
treatment
option
specif
biomarkerdefin
subgroup
serum
eosinophilderiv
neurotoxin
edn
sensit
hous
dust
mite
hdm
employ
biomark
studi
method
children
year
old
episod
recurr
wheez
document
revers
enrol
studi
test
specif
ige
hdm
serum
edn
entri
random
receiv
budesonid
montelukast
week
hdsensit
high
serum
edn
ngml
symptomat
runin
period
primari
outcom
asthma
control
day
acd
nonelig
patient
also
follow
period
administr
montelukast
result
ninetyeight
subject
enrol
studi
elig
random
group
respond
well
treatment
differ
acd
group
howev
serum
edn
level
significantli
decreas
montelulast
group
budesonid
group
serum
edn
level
nonelig
group
treat
montelukast
also
significantli
decreas
conclus
budesonid
montelukast
efficaci
hdmsensit
high
edn
subgroup
preschool
wheez
biomark
repres
differenti
respons
treatment
option
edn
reduc
effect
montelukast
howev
warrant
investig
background
antituberculosi
drug
atd
major
caus
drug
induc
liver
injuri
dili
around
world
compar
gener
popul
patient
connect
tissu
diseas
ctd
suspect
higher
risk
dili
sinc
frequent
expos
variou
medic
includ
immunosuppress
agent
aim
assess
incid
sever
dili
ctd
patient
comparison
nonctd
patient
method
retrospect
case
control
studi
enrol
patient
newli
diagnos
tuberculosi
treat
first
line
atd
two
year
univers
hospit
dili
defin
increas
serum
aspart
aminotransferas
ast
andor
alanin
aminotransferas
alt
greater
threefold
upper
limit
normal
uln
result
total
enrol
patient
patient
ctd
rheumatoid
arthriti
n
system
lupu
erythematosu
n
ankylos
spondyl
n
frequenc
dili
caus
atd
ctd
patient
significantli
differ
nonctd
patient
vs
p
sever
dili
astalt
x
uln
observ
frequent
ctd
control
statist
signific
vs
p
conclus
frequenc
dili
patient
ctd
significantli
differ
nonctd
patient
find
suggest
ctd
signific
risk
factor
dili
induc
atd
background
japanes
cedar
pollinosi
diseas
varieti
symptom
particular
ocular
nasal
symptom
occur
frequent
incid
cedar
pollinosi
symptom
reportedli
differ
year
year
due
larg
amount
japanes
cedar
pollen
dispers
japan
often
sever
symptom
season
allerg
rhiniti
europ
unit
state
although
pollen
allergi
preval
symptom
europ
canonica
et
al
unit
state
schatz
report
preval
ocular
symptom
due
cedar
pollinosi
japan
yet
determin
method
use
japanes
rhinoconjunct
qualiti
life
questionnair
examin
symptom
qualiti
life
patient
consult
hospit
ear
nose
throat
clinic
peak
cedar
pollen
season
receiv
previou
treatment
result
ocular
symptom
seen
patient
itchi
eye
preval
wateri
eye
patient
experienc
itchi
eye
wateri
eye
even
year
low
pollen
dispers
respons
occurr
nasal
ocular
symptom
indic
sever
score
nasal
symptom
correl
better
eye
symptom
comparison
annual
pollen
count
reveal
correl
worsen
itchi
eye
increas
pollen
count
howev
sever
wateri
eye
symptom
differ
significantli
year
small
moder
pollen
level
indic
wateri
eye
develop
amount
pollen
high
conclus
studi
reveal
ocular
symptom
japanes
cedar
pollinosi
preval
even
year
low
cedar
pollen
dispers
pollinosi
patient
ocular
symptom
like
sever
nasal
symptom
refer
canonica
gw
bousquet
j
mullol
j
scad
gk
virchow
jc
survey
burden
allerg
rhiniti
europ
allergi
suppl
schatz
survey
burden
allerg
rhiniti
usa
allergi
suppl
background
advers
drug
reaction
adr
increas
inhospit
stay
cost
care
even
mortal
prevent
adr
lead
mark
socioeconom
benefit
perform
studi
investig
incid
actual
report
statu
clinic
featur
adr
improv
adr
report
system
prevent
recurr
adr
method
retrospect
studi
perform
region
univers
hospit
locat
jeju
korea
adr
case
recruit
review
medic
record
adr
event
defin
either
adrrel
diagnosi
patient
adr
report
inhospit
adr
report
system
incid
culprit
drug
clinic
manifest
sourc
report
sever
treatment
recurr
rate
assess
result
patient
adr
event
enrol
estim
total
patientvisit
studi
period
diagnost
contrast
agent
common
culprit
drug
follow
antibiot
nonsteroid
antiinflammatori
drug
opioid
cutan
involv
rash
hive
frequent
observ
manifest
two
third
adr
case
addit
medic
attent
note
sever
categor
sever
adr
nineteen
experienc
reexposur
culprit
drug
result
recurr
adr
die
adr
physician
frequent
adr
report
use
inhospit
adr
report
system
conclus
larg
proport
adr
event
might
omit
medic
record
report
system
adr
due
reexposur
culprit
drug
rare
prevent
avoid
adr
effect
report
alert
system
necessari
object
determin
allergen
import
diagnosi
manag
allerg
diseas
skin
prick
test
spt
wide
use
identifi
allergen
skin
sensit
allergen
chang
due
chang
lifestyl
outdoor
environ
littl
known
chang
allergen
sensit
young
children
method
allerg
rhiniti
cohort
studi
kid
arcokid
consecut
pediatr
patient
rhiniti
symptom
underw
skin
prick
test
spt
children
assess
allergen
sensit
spt
perform
inhal
allergen
initi
survey
reperform
followup
survey
result
children
fulfil
followup
spt
initi
children
neg
spt
develop
skin
sensit
studi
among
children
newli
sensit
hous
dust
mite
hdm
sensit
hdm
initi
survey
sensit
hdm
followup
survey
skin
sensit
cat
dog
tree
grass
fungu
also
increas
studi
children
sensit
hdm
follow
newli
sensit
antigen
cat
dog
tree
conclus
studi
show
chang
skin
sensit
inhal
allergen
year
schoolag
children
skin
sensit
increas
nonsensit
monosensit
hdm
background
analyz
relat
risk
factor
featur
food
allergi
korea
children
cross
section
survey
method
use
stratifi
cluster
sampl
design
chosen
random
sampl
primari
middl
school
south
korea
octob
novemb
total
children
age
year
year
involv
acquir
inform
food
allergi
questionnair
analyz
mean
valu
continu
variabl
total
ig
e
eosinophil
count
risk
factor
associ
food
allergi
use
multivari
logist
regress
result
preval
food
allergi
studi
mean
age
begin
first
allerg
symptom
month
common
food
caus
allerg
symptom
egg
follow
order
common
caus
food
allergi
symptom
fruit
shellfish
milk
sequenc
mean
total
ig
e
level
eosinophil
count
higher
food
allergi
group
iuml
food
allergi
group
p
risk
factor
food
allergi
multivari
logist
regress
asthma
histori
ci
atop
dermat
histori
father
mother
food
allergi
histori
breast
milk
feed
month
conclus
preval
food
allergi
korean
children
risk
factor
food
allergi
present
asthma
histori
atop
dermat
parent
food
allergi
breast
milk
feed
month
background
asthma
chronic
inflammatori
disord
airway
subsequ
lead
characterist
airway
hyperresponsivenss
ahr
measur
prove
exist
ahr
mainstay
diagnosi
korea
airway
provoc
test
methacholin
direct
test
use
clinic
practic
recent
offici
object
kfda
instead
airway
provoc
test
mannitol
use
indirect
test
show
lower
sensit
consum
longer
testtim
compar
methacholin
despit
higher
specif
diagnosi
asthma
overcom
demerit
sequenti
indirectdirect
provoc
test
design
method
prospect
observ
studi
conduct
asthmasuspici
subject
indirect
test
perform
skip
dose
mg
accumul
methacholin
inhal
tidal
breath
method
appli
thereaft
subject
show
neg
mg
mannitol
regardless
result
end
test
bronchodil
appli
ahr
posit
defin
either
mg
mannitol
methacholin
increment
bronchodil
result
twenti
four
asthmasuspici
subject
median
age
male
enrol
testtim
test
theoret
shorten
least
min
compar
suggest
indirect
test
ahr
two
subject
show
posit
mannitol
provoc
five
show
posit
methacholin
provoc
compar
baselin
compar
mannitol
four
show
posit
bronchodil
overal
subject
show
ahr
posit
among
neg
indirect
test
advers
reaction
except
cough
inhal
mannitol
identifi
conclus
sequenti
indirectdirect
provoc
facilit
detect
ahr
higher
sensit
shorter
testtim
confirm
test
asthma
clinic
practic
appli
effect
modif
verif
background
recent
studi
describ
associ
vitamin
allerg
rhiniti
hypothes
gene
encod
compon
vitamin
pathway
may
candid
gene
suscept
allerg
rhiniti
studi
sought
evalu
whether
genet
variant
vitamin
pathwayrel
gene
associ
allerg
rhiniti
han
chines
popul
b
method
hospitalbas
casecontrol
studi
consist
patient
mitesensit
persist
allerg
rhiniti
per
healthi
control
conduct
five
singl
nucleotid
polymorph
snp
vdr
select
genotyp
c
result
ct
genotyp
vdr
exhibit
significantli
decreas
risk
adjust
ci
aa
genotyp
exhibit
significantli
increas
risk
adjust
ci
per
juvenil
subgroup
year
old
ag
aggg
genotyp
vdr
exhibit
significantli
decreas
risk
ag
adjust
ci
aggg
adjust
ci
per
femal
subgroup
analysi
locuslocu
interact
vdr
reveal
two
model
statist
signific
p
conclus
age
gender
may
impact
associ
three
snp
gene
vitamin
pathway
risk
mitesensit
per
han
chines
popul
vdr
polymorph
may
involv
genet
interact
pathogenesi
allerg
rhiniti
background
wherea
obes
suggest
link
asthma
epidemiolog
associ
metabol
syndrom
asthma
poorli
demonstr
object
aim
explor
relationship
metabol
syndrom
asthma
atopi
korean
adult
popul
method
use
data
korean
nation
health
nutrit
examin
survey
knhane
studi
popul
age
older
divid
subject
without
metabol
syndrom
metabol
syndrom
defin
criteria
intern
diabet
feder
result
preval
rate
asthma
determin
selfreport
current
wheez
subject
without
metabol
syndrom
metabol
syndrom
respect
multivari
logist
regress
analysi
adjust
age
gender
smoke
statu
found
metabol
syndrom
significantli
associ
asthma
adjust
ci
p
signific
relationship
metabol
syndrom
atopi
determin
serum
level
specif
ige
dermatophagoid
farina
cockroach
dog
conclus
gener
popul
korea
subject
metabol
syndrom
increas
risk
asthma
studi
ege
eosinophil
gastroenter
pediatr
patient
due
low
preval
review
medic
record
suspect
patient
retrospect
patient
confirm
ege
mean
age
diagnosi
year
patient
leukocytosi
peripher
eosinophilia
gastrointestin
symptom
diarrhea
abdomin
pain
eighteen
patient
classifi
mucos
layer
diseas
five
patient
show
subseros
eosinophil
infiltr
eosinophilia
ascit
surgic
biopsi
patient
muscular
eosinophil
infiltr
reveal
surgic
biopsi
total
three
patient
surgeri
diagnos
treat
ege
three
patient
show
gastroduoden
ulcer
endoscop
find
patient
proteinlos
enteropathi
anemia
patient
five
patient
improv
conserv
manag
hypoallergen
diet
food
restrict
patient
need
steroid
patient
show
improv
final
ege
relaps
patient
patient
symptom
steadili
despit
steroid
treatment
associ
steroid
depend
resist
gastroduoden
ulcer
statist
signific
diagnos
ege
suspici
pediatr
patient
peripher
eosinophilia
gastrointestin
symptom
endoscop
surgic
biopsi
patient
improv
conserv
manag
steroid
howev
patient
steroid
depend
resist
associ
gastroduoden
ulcer
background
use
allergen
compon
detect
technolog
studi
sensit
model
correl
bermuda
timothi
grass
pollen
allergen
respiratori
allerg
patient
southern
china
method
case
patient
allerg
diseas
includ
asthma
patient
allerg
rhiniti
patient
rhiniti
asthma
children
adult
serum
sige
bermuda
timothi
detect
bermudasig
posit
sige
cyn
phl
p
phl
p
peanut
ara
h
ara
h
birch
bet
v
ccd
test
result
patient
sigeposit
bermuda
sigeposit
timothi
posit
rate
bermuda
timothi
signific
differ
children
adult
male
femal
group
p
bermuda
sigeposit
patient
sensit
cyn
concentr
sige
bermuda
cyn
posit
patient
significantli
higher
cyn
neg
level
bermuda
sigeposit
patient
patient
timothi
sigeposit
concentr
sige
bermuda
timothi
posit
patient
significantli
higher
timothi
neg
timothyposit
patient
sensit
phl
p
posit
phl
p
bermudaposit
patient
sensit
peanut
ara
h
posit
patient
peanutsig
higher
sensit
ara
h
sensit
birch
case
birchposit
sensit
bet
v
sensit
ara
simultan
bermudaposit
patient
ccd
sensit
ccd
sige
level
good
correl
bermuda
cyn
peanut
birch
timothi
phl
p
p
conclus
patient
sigeposit
bermuda
grass
sigeposit
timothi
grass
southern
china
bermuda
sigeposit
patient
sensit
timothi
grass
peanut
ccd
birch
relat
compon
differ
degre
bermudaposit
patient
sensit
cyn
higher
bermuda
sige
level
like
sensit
cyn
timothyposit
patient
sensit
phl
p
sensit
phl
p
peanut
sensit
patient
sensit
ara
h
react
ara
h
birchposit
patient
sensit
bet
v
ccd
good
correl
grass
pollen
peanut
birch
allergen
indic
wide
crossreact
caus
carbohydr
crossreact
determin
background
allergi
march
postul
progress
allerg
diseas
infant
food
allergi
associ
atop
dermat
ad
subsequ
develop
asthma
allerg
rhiniti
ar
evid
mostli
european
countri
unclear
present
chines
children
pilot
studi
aim
investig
preval
allerg
diseas
previou
ad
infant
assess
children
sensit
profil
inhal
food
allergen
preschool
age
method
year
infant
diagnos
food
protein
allergi
fpa
associ
ad
beij
children
hospit
clinic
followup
subject
perform
preschool
age
medic
histori
relat
allergi
toddler
preschool
age
acquir
questionnair
serum
specif
ige
level
test
food
aeroallergen
skin
prick
test
aeroallergen
also
perform
result
overal
followup
rate
preschool
year
children
preval
physician
diagnos
ad
infanc
also
identifi
persist
ad
preval
physician
diagnos
ar
asthma
respect
thirti
two
children
accept
serum
ige
level
test
although
subject
show
posit
test
result
food
allergen
infanc
remain
sensit
food
preschool
year
twenti
six
subject
receiv
screen
test
aeroallergen
infanc
prove
neg
result
preschool
followup
follow
subject
sensit
aeroallergen
twenti
nine
children
accept
skin
prick
test
inhal
allergen
posit
rate
respiratori
allerg
diseas
significantli
preval
children
intermedi
sever
aeroallergen
sensit
other
multivari
logist
regress
analysi
show
persist
ad
independ
risk
factor
airway
allergi
ci
conclus
consider
proport
fpa
associ
ad
infant
develop
ar
asthma
preschool
age
food
sensit
infant
outgrow
year
later
tend
evolv
aeroallergen
sensit
usual
neg
result
infanc
preschool
year
children
moder
sever
sensit
aeroallergen
vulner
respiratori
allerg
diseas
other
persist
ad
might
independ
risk
factor
develop
ar
asthma
background
function
innat
receptor
includ
toll
like
receptor
tlr
convent
recogn
antimicrobi
effect
recent
extend
includ
epitheli
barrier
regul
tlr
activ
shown
aid
tight
junction
tj
repair
atop
dermat
ad
howev
role
tlr
modul
epiderm
barrier
vitro
vivo
remain
poorli
understood
investig
chang
tj
protein
follow
activ
tlr
hous
dust
mite
hdm
method
firstli
mrna
level
tlr
tj
element
assay
use
realtim
rcr
epiderm
keratinocyt
murin
model
adlik
lesion
activ
hdm
allergen
associ
specif
tlr
activ
chang
certain
tj
protein
studi
tlr
defici
mice
result
vitro
vivo
hdm
activ
tlr
tlr
addit
hdm
induc
increas
gene
express
tj
protein
includ
occludin
result
provid
evid
hdm
trigger
activ
pattern
recognit
receptor
tlr
tlr
thu
stimul
modul
tj
protein
moreov
gene
express
tj
protein
includ
occludin
increas
knockout
mice
conclus
data
demonstr
innat
immun
activ
keratinocyt
hdm
allergen
may
lead
preserv
tj
integr
rational
requir
ema
us
fda
pivot
trial
involv
allergen
immunotherapi
ait
product
clinic
efficaci
assess
current
base
dbpc
field
studi
natur
allergen
exposur
problem
field
studi
includ
variabl
allergen
exposur
differ
trial
site
uncertainti
time
exposur
confound
environment
factor
novel
mobil
allergen
exposur
chamber
design
oper
stabl
reproduc
allergen
exposur
standard
environment
condit
accept
appropri
altern
natur
allergen
exposur
clinic
trial
clinic
valid
exposur
chamber
must
document
symptom
provok
chamber
reflect
kind
sever
symptom
reallif
method
determin
polleninduc
allerg
nasal
eye
bronchial
symptom
sever
real
life
use
data
patient
suffer
rhiniti
report
use
electron
patient
hayfev
diari
phd
sinc
public
app
pollen
app
organ
symptom
sever
score
possibl
result
total
symptom
score
tss
also
comparison
symptom
pollen
concentr
surround
lead
symptom
load
index
sli
use
defin
sever
reallif
symptomatolog
pollen
allerg
patient
chamber
birch
grass
pollen
allerg
adult
expos
differ
birch
grass
pollen
load
min
outsid
pollen
season
spirometri
feno
nasal
secret
measur
exposur
nasal
conjunctiv
bronchial
symptom
record
min
peakflow
peak
nasal
inspiratori
flow
everi
min
result
use
data
set
phd
user
mean
tss
germani
calcul
birch
season
grass
season
sli
tss
calcul
total
data
entri
rang
birch
season
grass
season
point
repeat
exposur
birch
grass
pollen
elicit
reproduc
symptom
organ
signific
differ
placebo
verum
pollen
exposur
gener
symptom
start
occur
min
reach
plateau
follow
min
continu
exposur
tss
birch
pollen
reach
averag
grass
point
conclus
exposur
birch
grass
pollen
mobil
exposur
chamber
allow
induc
clinic
symptom
kind
sever
patient
allerg
rhiniti
due
pollen
experi
reallif
therefor
altern
natur
allergen
exposur
background
contact
eczema
complex
polymorph
skin
erupt
diseas
form
inflammatori
aris
skin
contact
irrit
allergen
substanti
proport
patient
exist
also
contact
allergi
howev
less
sensit
inhal
food
allergen
aim
studi
epidemiolog
analysi
determin
frequenc
contact
inhal
food
allergi
patient
contact
eczema
method
main
research
method
studi
retrospect
analysi
medic
record
patient
januari
decemb
regist
allergi
clinic
diagnos
skin
chang
character
contact
eczema
analysi
includ
patient
underw
patch
test
result
studi
analyz
histori
patient
contact
eczema
women
age
year
mean
age
year
men
age
year
mean
age
year
common
locat
contact
eczema
hand
n
face
n
posit
patch
test
result
obtain
patient
major
patient
hand
n
face
n
contact
eczema
common
sensit
hapten
nickel
sulfat
n
paraphenylenediamin
n
potassium
dichrom
n
prick
test
inhal
allergen
perform
patient
food
allergen
perform
patient
patient
regist
posit
skin
prick
test
result
inhal
allergen
major
patient
hand
n
face
n
upper
limb
n
contact
eczema
food
allergi
diagnos
patient
patient
hand
face
feet
contact
eczema
among
inhal
allergen
sensit
farina
pteronyssimu
grass
sensit
food
allergen
celeri
pepper
flour
conclus
hand
face
common
locat
contact
eczema
larg
proport
patient
contact
eczema
occur
contact
allergi
especi
metal
paraphenylenediamin
signific
problem
patient
contact
eczema
coexist
inhal
food
allergi
high
incid
allergi
patient
contact
eczema
diagnosi
diseas
complic
fact
variou
clinic
chronic
profil
diseas
may
decreas
qualiti
life
patient
rational
fungal
exposur
trigger
asthma
exacerb
report
suggest
fungal
sensit
asthma
sever
associ
object
investig
effect
fungal
sensit
sever
asthmat
patient
method
collect
data
patient
sever
asthma
analysi
follow
variabl
asthma
control
test
act
score
pulmonari
function
fraction
exhal
nitric
oxid
feno
sensit
fungi
aspergillu
alternaria
cladosporium
penicillium
trichophyton
schizophyllum
commun
nonfung
antigen
sourc
hous
dust
mite
dog
cat
cockroach
moth
chironomid
fungal
sensit
diagnos
increas
serum
ige
level
specif
allergen
detect
result
eightyseven
patient
sensit
one
antigen
sensit
fungal
allergen
common
aspergillu
patient
trichophyton
patient
patient
six
sensit
fungu
group
f
nonfung
allergen
group
n
fungal
nonfung
antigen
group
f
n
sex
distribut
pulmonari
function
dose
inhal
corticosteroid
significantli
differ
three
group
howev
act
score
significantli
lower
group
f
n
group
feno
ratio
subject
depend
oral
steroid
therapi
higher
group
f
n
group
n
conclus
fungal
sensit
addit
nonfung
sensit
associ
poor
control
asthma
patient
sever
asthma
background
administr
subcutan
immunoglobulin
scig
safe
conveni
altern
intraven
immunoglobulin
ivig
therapi
administr
scig
occur
via
infus
pump
rapid
push
techniqu
base
patient
canadian
site
patient
present
decis
direct
cost
differ
patient
explain
ourexperi
shown
pump
overwhelm
higher
prefer
amongst
patient
method
chart
review
immun
defici
patient
privat
clinic
initi
treatment
scig
therapi
januari
april
patient
given
option
choos
method
desir
shown
techniqu
determin
differ
cost
method
dosag
amount
confirm
shown
amount
time
would
take
infus
via
pump
versu
rapid
push
result
chart
first
patient
male
femal
rang
age
review
fifteen
patient
chose
pump
patient
chose
push
method
patient
patient
cover
insur
patient
chose
push
method
pay
pocket
remain
patient
either
lost
follow
switch
back
ivig
dosag
amount
vari
method
deliveri
conclus
result
clearli
show
immun
defici
patient
higher
prefer
administ
scig
pump
rather
push
hand
relat
time
spent
overal
cost
freedom
grant
patient
may
result
immun
defici
patient
diagnos
within
age
popul
particularli
secondari
immun
defici
introduct
fix
drug
erupt
fde
drug
reaction
character
erythema
edema
sometim
bulla
appear
skin
mucos
region
due
repeat
intak
drug
commonli
caus
drug
sulfonamid
barbitur
nonsteroid
antiinflamatori
drug
herebi
fde
develop
due
intak
ornidazol
treatment
vagin
case
present
case
year
old
woman
appli
clinic
complaint
purpleviolet
colour
symmetr
regular
border
itchi
macular
erythemat
lesion
cm
diamet
dorsum
hand
oral
lesion
medic
histori
reveal
intak
mixovul
ornidazol
one
day
prior
onset
complaint
patient
also
experienc
similar
lezion
skin
oral
mucosa
month
ago
hour
take
ornidazol
patient
similar
symptom
skin
oral
mucosa
also
intak
diclofenac
method
ornidazol
skin
prick
test
found
neg
ornidazol
patch
test
similarli
neg
prick
test
patch
test
diclofenac
found
neg
well
amoxicillin
claculon
acid
prick
test
done
order
determin
altern
safe
antibiot
found
neg
oral
provoc
test
reveal
earli
late
onset
allerg
reaction
either
prick
test
oral
provoc
test
meloxicam
done
order
find
altern
analges
neg
result
case
want
point
ornidazol
commonli
use
antiinfect
agent
caus
fix
drug
erupt
case
also
note
fix
drug
erupt
occur
multipl
drug
patient
background
atop
dermat
ad
character
skin
barrier
dysfunct
studi
use
noninvas
skin
measur
techniqu
measur
epidermi
function
asymptomat
neonat
therefor
conduct
posthoc
analysi
determin
whether
skin
barrier
function
first
week
life
predict
ad
develop
allergen
sensitizationbi
age
week
method
data
infant
collect
previou
random
control
studi
analyz
skin
barrier
function
measur
transepiderm
water
loss
tewl
stratum
corneum
hydrat
sch
ph
studi
particip
divid
group
base
result
cox
regress
analys
skin
measur
valu
cumul
ad
incid
week
age
analysi
test
use
analyz
skin
barrier
function
cumul
ad
incid
allerg
sensit
base
ige
level
egg
white
ovomucoid
week
age
assess
test
result
tewl
optim
cutoff
level
measur
forehead
within
first
week
life
show
lower
pvalu
tewl
measur
lower
leg
sch
ph
measur
found
signific
differ
cumul
ad
incid
high
low
tewl
group
p
moreov
high
tewl
group
exhibit
higher
statist
signific
rate
sensit
ovomucoid
p
conclus
tewl
measur
forehead
first
week
life
associ
ad
develop
background
inhal
allergen
indoor
environ
associ
sensit
asthma
symptom
exacerb
children
soft
toy
harbor
allergen
purpos
studi
review
literatur
regard
inhal
allergen
soft
toy
method
major
data
base
search
term
allergen
toy
exclud
articl
deal
fragranc
contact
allergen
result
present
six
publish
studi
present
allergen
level
soft
toy
allergen
hous
dust
mite
der
p
der
f
measur
wide
differ
level
lower
level
found
soft
toy
child
centr
two
studi
present
dog
f
cat
fel
allergen
level
one
studi
find
dog
cat
home
result
higher
level
f
fel
one
present
cockroach
allergen
bla
g
bla
g
level
albeit
low
level
factor
associ
allergen
level
soft
toy
includ
age
toy
locat
clean
activ
presenc
pet
conclus
given
wide
spread
use
infant
soft
toy
import
sourc
inhal
allergen
exposur
need
taken
account
epidemiolog
studi
research
requir
find
exposur
reduct
techniqu
background
fraction
exhal
nitric
oxid
feno
increasingli
use
noninvas
assess
airway
inflamm
littl
known
regard
eno
determin
elderli
studi
assess
eno
atopi
elderli
asthmat
method
fifti
elderli
asthmat
femal
male
age
year
mean
consecut
recruit
respiratori
outpati
clinic
inhal
steroid
eno
measur
niox
mino
analyz
specif
ige
sige
inhal
food
allergen
measur
blood
fluoresc
enzym
immunoassay
phadia
atopi
defin
sige
kul
result
present
geometr
mean
level
confid
interv
ci
comparison
mannwhitney
utest
signific
set
p
level
result
twenti
subject
atop
atop
hous
dust
mite
hdm
geometr
mean
feno
level
ci
subject
ppb
ci
signific
differ
femal
male
feno
level
significantli
higher
atop
vs
nonatop
subject
ppb
ci
vs
ci
feno
geometr
mean
level
hdmsensit
subject
ppb
ci
nonhdm
sensit
atop
ppb
ci
conclus
atopi
elderli
asthmat
taiwan
associ
significantli
higher
feno
level
predominantli
driven
sensit
hdm
background
juhlin
attempt
estim
incid
urticaria
swedish
popul
come
estim
incid
base
examin
person
goodman
et
al
report
urticaria
trigger
food
preserv
butyl
hydroxyanisol
bha
butyl
hydroxytoluen
bht
mani
report
made
regard
dye
reaction
therefor
subset
urticaria
suffer
thought
trigger
exposur
dye
preserv
commonli
use
food
beverag
method
sinc
allerg
diseas
clinic
laboratori
computer
creat
searchabl
databas
laboratori
patient
investig
perform
placebocontrol
dye
preserv
challeng
individu
patient
adult
children
present
primarili
urticaria
angioedema
mealrel
gastrointestin
symptom
challeng
carri
first
present
seri
blind
liquid
dose
contain
mixtur
fd
c
blue
blue
red
red
yellow
initi
dye
dose
solut
neg
solut
present
reaction
dye
solut
placebo
administ
mixtur
preserv
compound
sodium
benzoat
phydroxybenzo
acid
butyl
hydroxyanisol
butyl
hydroxytoluen
placebo
capsul
form
earli
dose
capsul
mg
preserv
mix
later
dose
capsul
mg
preserv
mix
result
document
posit
challeng
seri
two
reproduc
repeat
challeng
conduct
subsequ
day
placebo
respond
three
four
posit
appear
relat
dye
one
dyereactor
reproduc
caus
dye
appear
one
two
blue
dye
conclus
conclud
taken
togeth
dye
preserv
frequent
suspect
rare
actual
particip
trigger
urticaria
angioedema
background
object
allerg
diseas
children
divers
characterist
sensit
age
allergen
pathophysiolog
immunolog
differ
report
regard
chang
allerg
sensit
age
children
south
korea
aim
find
chang
cap
test
materi
method
total
children
boy
girl
mean
year
rang
month
year
allerg
rhiniti
subject
studi
classifi
age
group
yearold
children
underw
cap
test
fluoroenzym
immunoassay
two
subtyp
hous
dust
mite
pteronyssinu
farina
cat
dog
tree
mixtur
weed
mixtur
allergen
addit
allergen
classifi
indoor
outdoor
analyz
agebas
differ
accord
type
allergen
also
analyz
total
ige
result
cap
test
analysi
allerg
rhiniti
patient
children
show
age
group
higher
titer
hous
dust
mite
allergen
dp
uml
df
group
highest
degre
posit
reaction
multipl
allergen
p
age
group
reveal
signific
differ
pteronyssinu
ige
titer
among
group
p
age
group
show
differ
age
yearold
group
p
differ
kruskalw
test
posthoc
tukey
test
result
obtain
farina
test
sensit
ratio
weed
tree
allergen
tend
increas
age
sensit
ratio
cat
dog
present
signific
differ
accord
age
certain
tendenc
depend
type
allergen
found
sensit
indoor
allergen
high
indic
agebas
differ
sensit
outdoor
allergen
tend
grow
age
addit
total
lge
present
differ
age
group
age
group
statist
signific
p
increas
age
gener
boy
show
significantli
higher
lge
titer
girl
p
conclus
sensit
children
allerg
rhiniti
chang
age
allergen
cap
test
background
recent
report
substanti
percentag
milk
allergi
children
toler
bake
milk
product
howev
littl
known
role
milk
componentspecif
ige
toler
bake
milk
method
milk
casein
alphalactoalbumin
betalactoglobulinspecif
ige
antibodi
measur
allastat
system
milk
allergi
children
perform
oral
bake
milk
challeng
result
children
age
year
old
toler
bake
milk
product
contain
muffin
react
signific
differ
mean
age
gender
histori
milkinduc
anaphylaxi
two
group
children
toler
bake
milk
specif
ige
titer
milk
casein
alphalactoalbumin
significantli
lower
betalactoglobulin
furthermor
componentspecif
ratio
significantli
lower
compar
children
reactiv
bake
milk
conclus
approxim
half
milk
allergi
children
toler
bake
milk
product
componentspecif
ige
titer
could
use
predictor
toler
bake
milk
background
spd
hydrophil
lectin
involv
host
defens
mechan
respiratori
pathogen
modul
immun
respons
bacteria
allergen
purpos
aim
studi
evalu
serum
spd
level
potenti
biomark
aspirinexacerb
respiratori
diseas
aerd
compar
aspirin
toler
asthma
ata
patient
subject
method
ninetythre
subject
aerd
ata
healthi
control
enrol
ajou
univers
hospit
suwon
korea
serum
spd
level
measur
use
commerci
avail
elisa
kit
result
spd
level
sera
aerd
patient
significantli
lower
ata
control
group
roc
curv
indic
spd
optim
cutoff
valu
predict
phenotyp
aerd
sensit
specif
associ
found
clinic
paramet
atopi
chronic
rhinosinus
eosinophilicneutrophil
asthma
severenonsever
asthma
signific
neg
correl
found
serum
spd
level
fall
inhal
lysineasa
asthmat
patient
conclus
find
suggest
spd
may
involv
proinflammatori
respons
airway
mucosa
contribut
bronchoconstrict
respons
inhal
asa
aerd
patient
background
incid
anaphylaxi
increas
western
countri
although
anaphylaxi
recogn
import
lifethreaten
condit
nationwid
report
yet
investig
clinic
featur
anaphylaxi
korean
children
object
sought
investig
clinic
featur
anaphylaxi
korean
children
method
retrospect
medic
record
review
perform
children
patient
diagnos
anaphylaxi
tertiari
hospit
south
korea
result
total
case
male
mean
age
report
year
age
common
past
medic
histori
food
allergi
previou
reaction
allergen
report
cutan
symptom
common
symptom
follow
respiratori
gastrointestin
neurolog
cardiovascular
although
cardiovascular
symptom
anaphylaxi
rare
young
children
cardiovascular
symptom
increas
age
cardiovascular
symptom
common
reaction
caus
insect
sting
mainstay
firstlin
treatment
hospit
includ
antihistamin
corticosteroid
epinephrin
epinephrin
autoinjector
prescrib
conclus
identifi
differ
symptom
anaphylaxi
accord
age
trigger
rate
use
epinephrin
firstaid
medic
low
prescript
rate
adrenalin
autoinjector
low
regardless
age
patient
background
manag
patient
sever
atop
dermat
ad
frequent
difficult
patient
physician
previous
report
repeat
intramuscular
inject
autolog
immunoglobulin
autolog
immunoglobulin
therapi
induc
signific
clinic
improv
patient
sever
ad
evalu
therapeut
mechan
autolog
immunoglobulin
therapi
analyz
chang
serum
concentr
total
ige
allergenspecif
ige
patient
sever
ad
treatment
method
sixteen
adult
patient
sever
ad
sensit
hous
dust
hdm
mite
treat
intramuscular
inject
mg
autolog
immunoglobulin
mainli
igg
puriti
twice
week
week
autolog
immunoglobulin
purifi
autolog
plasma
affin
chromatographi
use
protein
serum
concentr
total
ige
specif
ige
dermatophagoid
farina
farina
specif
ige
recombin
der
f
rder
f
baselin
week
measur
use
enzymelink
immunosorb
assay
result
serum
concentr
total
ige
significantli
decreas
kul
mean
sd
baselin
kul
week
kul
week
kul
week
wilcoxon
signedrank
test
p
serum
concentr
specif
ige
farina
significantli
decreas
kul
baselin
kul
week
kul
week
kul
week
p
serum
concentr
specif
ige
rder
f
significantli
decreas
kul
baselin
kul
week
kul
week
p
conclus
repeat
intramuscular
inject
autolog
immunoglobulin
significantli
decreas
serum
concentr
total
ige
allergenspecif
ige
antibodi
patient
sever
ad
refer
nahm
dh
cho
sm
kim
kim
yj
jeon
sy
autolog
immunoglobulin
therapi
patient
sever
recalcitr
atop
dermat
preliminari
report
allergi
asthma
immunol
re
background
asthma
chronic
obstruct
pulmonari
diseas
copd
common
airway
diseas
diseas
share
clinic
featur
diseas
show
phenotyp
heterogen
even
patient
rel
preserv
lung
function
experi
frequent
exacerb
link
poor
qualiti
life
aim
studi
identifi
subtyp
patient
mild
moder
airflow
limit
evalu
clinic
socioeconom
implic
method
analyz
data
fourth
korean
nation
health
nutrit
examin
survey
nation
health
insur
claim
subject
year
old
forc
expiratori
volum
second
predict
ratio
forc
vital
capac
fvc
includ
kmean
cluster
perform
explor
subtyp
cluster
analysi
six
key
input
variabl
age
bodi
mass
index
bmi
predict
presenc
absenc
selfreport
wheez
smoke
statu
packyear
smoke
select
result
among
total
subject
five
subgroup
identifi
kmean
cluster
includ
put
nearnorm
asthmat
copd
asthmaoverlap
copdoverlap
subtyp
among
five
subgropu
nearnorm
subgroup
show
oldest
mean
age
year
highest
predict
asthmat
subgroup
youngest
year
asthmaoverlap
subgroup
lowest
predict
copd
copdoverlap
subgroup
malepredomin
respect
current
exsmok
appli
lower
limit
normal
criterion
airway
obstruct
asthma
group
show
highest
preval
airway
obstruct
copd
asthmaoverlap
copdoverlap
subgroup
show
high
prescript
rate
respiratori
medicin
asthmat
subgroup
lowest
prescript
rate
despit
highest
proport
selfreport
wheez
except
asthmat
subgroup
comorbid
hypertens
diabet
mellitu
hyperlipidemia
coronari
arteri
diseas
frequent
observ
although
copd
subgroup
repres
total
subject
show
highest
mean
medic
cost
health
util
compris
total
cost
calcul
ratio
total
medic
expens
household
incom
mean
ratio
highest
copd
subgroup
conclus
subject
mild
moder
airflow
limit
exhibit
clinic
epidemiolog
heterogen
subgroup
may
differ
level
demand
health
resourc
boy
acut
osteomyel
right
distal
tibia
treat
combin
intraven
iv
vancomycin
cefotaxim
toler
given
treatment
rapidli
improv
persist
fever
occur
day
prurit
maculopapular
rash
day
laboratori
test
perform
day
reveal
mark
eosinophilia
suspicion
dress
syndrom
iv
antibiot
stop
oral
prednisolon
given
three
day
cessat
antibiot
fever
skin
manifest
rapidli
improv
howev
soon
retri
iv
cefotaxim
skin
manifest
immedi
flare
intraderm
test
perform
week
completerecoveri
posit
cefotaxim
purpos
asthma
atop
dermat
common
chronic
diseas
depress
import
comorbid
allerg
diseas
howev
littl
known
associ
matern
depress
child
allerg
diseas
studi
perform
find
associ
matern
depress
child
allerg
diseas
method
data
acquir
famili
particip
fifth
korea
nation
health
nutrit
examin
survey
knhane
conduct
result
preval
childhood
asthma
childhood
atop
dermat
preval
matern
depress
univari
analysi
matern
depress
associ
singl
mother
low
econom
state
matern
asthma
atop
dermat
children
asthma
p
sex
age
educ
statu
smoke
associ
presenc
matern
depress
adjust
matern
depress
associ
lower
hous
incom
matern
asthma
matern
atop
dermat
children
asthma
conclus
present
studi
show
matern
depress
associ
children
asthma
children
atop
dermat
result
warrant
futur
studi
explor
mechan
respons
associ
matern
depress
children
asthma
purpos
childhood
asthma
common
reason
hospit
deterior
asthma
accompani
respiratori
infect
burden
treatment
asthma
high
around
globe
also
asia
assess
asthma
exacerb
children
difficult
limit
aim
investig
factor
associ
hospit
period
inpati
pediatr
asthma
method
conduct
chart
review
subject
admit
asthma
exacerb
retrospect
subject
consist
patient
age
year
visit
singl
tertiari
hospit
investig
characterist
patient
includ
clinic
symptom
laboratori
test
serum
total
immunoglobulin
ig
e
eosinophil
count
assess
sever
asthma
pulmonari
score
ps
assess
durat
hospit
relat
factor
use
bivari
correl
analysi
multipl
linear
regress
analysi
use
spss
result
total
subject
boy
median
age
year
old
mean
hospit
period
day
rate
total
ige
iuml
eosinophil
count
mean
ps
day
infiltr
chest
radiographi
case
bodi
temperatur
durat
hospit
correl
age
simpl
linear
regress
ps
score
posit
relat
durat
hospit
signific
multipl
linear
regress
model
durat
hospit
posit
relat
infiltr
find
chest
radiographi
age
independ
fever
creactiv
protein
ps
past
histori
allergi
famili
histori
allergi
elev
ige
eosinophil
count
multipl
allergen
sensit
past
histori
visit
admitt
asthma
exacerb
conclus
hospit
period
pediatr
asthma
patient
posit
correl
infiltr
find
chest
radiographi
associ
ps
total
ige
eosinophil
count
could
impli
predict
morbid
asthma
exacerb
children
includ
find
chest
radiographi
present
respiratori
infect
also
new
asthma
sever
score
system
hospit
pediatr
asthma
patient
would
need
acut
eosinophil
pneumonia
aep
rare
diseas
character
acut
febril
respiratori
insuffici
mark
eosinophilia
bronchoalveolar
lavag
fluid
balf
diffus
bilater
thicken
interlobular
septa
chest
radiograph
find
pathogenesi
well
understood
howev
direct
indirect
exposur
smoke
repeatedli
report
caus
aep
present
case
boy
develop
idiopath
aep
peripher
eosinophilia
mark
eosinophilia
balf
decreas
dlco
typic
radiolog
find
dramat
improv
corticosteroid
treatment
without
use
antibiot
despit
best
effort
evid
infect
found
although
initi
deni
current
smoke
repeatedli
ask
previou
histori
smoke
cigarett
final
told
truth
start
smoke
day
hospit
enclos
area
friend
gradual
increas
smokingdos
conclus
suggest
peripher
eosinophilia
exclud
aep
clinic
suspicion
exact
histori
take
radiolog
find
earli
balf
exam
best
approach
avoid
use
unnecessari
antibiot
proper
manag
leukotrien
receptor
antagonist
increasingli
use
treatment
varieti
allerg
diseas
asthma
allerg
rhiniti
chronic
urticaria
other
gener
consid
safe
drug
advers
drug
reaction
type
hypersensit
montelukast
rare
report
hand
anaphylaxi
case
report
worldwid
lack
inform
sever
advers
drug
reaction
associ
pranlukast
experienc
extrem
rare
case
sever
hypersensit
reaction
associ
pranlukast
woman
develop
anaphylact
shock
present
gener
urticaria
angioedema
collaps
loss
conscious
take
pranlukast
confirm
oral
challeng
test
skin
prick
test
present
case
remind
pranlukast
induc
anaphylaxi
mediat
igedepend
pathway
background
obes
known
risk
factor
develop
asthma
obes
asthmat
prone
sever
poorli
control
obes
also
associ
increas
risk
variou
metabol
diseas
recent
studi
suggest
obes
subject
increas
risk
diseas
metabol
healthi
obes
mho
phenotyp
may
exist
absenc
metabol
abnorm
due
pauciti
data
regard
asthmarel
outcom
obes
asthmat
accord
metabol
statu
aim
investig
differ
mho
metabol
unhealthi
obes
muo
asthmat
term
asthmarel
clinic
outcom
materi
method
total
patient
diagnos
asthma
asan
medic
center
asthma
cohort
june
mar
subject
analysi
sort
patient
whose
bmi
divid
patient
two
group
mho
asthmat
muo
asthmat
refer
ncep
atp
iii
identif
metabol
syndrom
compar
asthmarel
clinic
characterist
two
group
result
patient
muo
asthma
group
older
age
vs
pvalu
lower
predict
vs
pvalu
compar
mho
asthmat
also
muo
asthmat
higher
frequenc
develop
sever
persist
asthma
vs
pvalu
moreov
muo
asthma
group
show
lower
mean
predict
valu
followup
enrol
use
higher
mean
ic
dosag
compar
year
enrol
conclus
obes
asthmat
demonstr
differ
clinic
characterist
accord
metabol
statu
muo
asthmat
older
lower
pulmonari
function
higher
tendenc
develop
sever
asthma
enrol
longitudin
followup
studi
suggest
differ
therapeut
approach
implement
obes
asthma
patient
accord
subtyp
obes
background
aim
identifi
risk
factor
associ
longer
length
hospit
stay
lo
infant
respiratori
syncyti
viru
rsv
bronchiol
method
conduct
observ
studi
infant
age
hospit
first
episod
rsv
bronchiol
novemb
februari
retrospect
demograph
clinic
characterist
collect
includ
doctor
diagnos
atop
dermat
day
ill
hospit
vitamin
oh
modifiedt
score
rsv
genom
load
present
lo
comprehens
review
medic
record
kaplanmei
estim
surviv
analysi
cox
proport
hazard
analysi
use
identifi
risk
factor
longer
lo
result
total
infant
identifi
extrem
prematur
birth
congenit
heart
diseas
exclud
age
month
distribut
month
age
median
median
lo
hour
rang
hour
modifiedt
score
point
rang
higher
rsv
genom
load
threshold
cycl
associ
longer
lo
lower
oh
mgdl
higher
cumul
incid
longer
lo
hour
hour
adjust
hazard
ratio
lower
oh
ci
mode
deliveri
exclus
breastmilk
feed
sex
coinfect
doctor
diagnos
atop
dermat
modifi
talscor
associ
longer
lo
conclus
concurr
hypovitaminosi
infant
first
episod
rsv
bronchiol
rather
rsv
viral
load
higher
risk
longer
lo
background
increas
level
mastcellderiv
eicosanoid
prostaglandin
pg
cysteinyl
leukotrien
cyslt
report
patient
exerciseinduc
bronchoconstrict
eib
suggest
mast
cell
activ
involv
mechan
eib
howev
still
controversi
sinc
result
reproduc
studi
aim
studi
evalu
role
adult
asthma
eib
measur
urinari
level
metabolit
exercis
challeng
test
method
eight
patient
asthma
eib
five
normal
control
without
eib
enrol
exercis
challeng
test
compris
min
treadmil
exercis
free
run
perform
studi
subject
urin
sampl
h
challeng
collect
urinari
level
measur
enzym
immunoassay
result
signific
differ
observ
level
beforeaft
exercis
challeng
patient
eib
normal
control
signific
increas
urinari
level
detect
exercis
challeng
patient
eib
normal
control
signific
correl
observ
percent
decreas
forc
expiratori
volum
second
percent
chang
level
exercis
challeng
conclus
urinari
level
increas
exercis
challeng
patient
eib
suggest
urinari
excret
may
good
marker
mast
cell
activ
patient
eib
studi
support
grant
basic
scienc
research
program
nation
research
foundat
korea
nrf
fund
ministri
educ
scienc
technolog
background
ambient
compon
aeroallergen
particul
matter
affect
respiratori
diseas
composit
differ
depend
region
investig
aeroallergen
sensit
pattern
effect
airway
hyperrespons
ahr
airway
inflamm
consid
particul
matter
meteorolog
factor
busan
face
sea
unlik
metropolitan
citi
korea
method
review
retrospect
clinic
data
subject
underw
skin
prick
test
aeroallergen
induc
sputum
analysi
methacholin
bronchial
provoc
test
februari
august
evalu
respiratori
symptom
age
categor
group
yr
group
ii
yr
result
total
subject
analyz
mean
age
femal
ahr
demonstr
sputum
eosinophilia
sensit
least
one
aeroallergen
skin
test
diagnos
asthma
allerg
rhiniti
nonallerg
rhiniti
chronic
rhinosinus
eosinophil
bronchiti
chronic
obstruct
pulmonari
diseas
commonli
sensit
allergen
hous
dust
mite
dermatophagoid
pteronyssinu
dermatophagoid
farina
follow
earli
blossom
tree
pollen
mix
late
blossom
tree
pollen
mix
ahr
associ
sensit
dermatophagoid
pteronyssinu
dermatophagoid
farina
earli
blossom
tree
pollen
mix
late
blossom
tree
pollen
mix
adjust
age
gender
daili
particul
matter
level
meteorolog
factor
howev
subgroup
analysi
accord
age
group
ii
show
associ
ahr
aeroallergen
associ
airway
eosinophil
inflamm
sensit
aeroallergen
conclus
busan
sensit
hous
dust
mite
tree
pollen
common
significantli
affect
airway
hyperrepons
background
effect
manag
atop
dermat
ad
adjust
individu
clinic
cours
demand
challeng
patient
physician
understand
actual
situat
experienc
perceiv
patient
ad
caregiv
essenti
improv
clinic
outcom
satisfact
real
practic
method
multicent
survey
conduct
patient
ad
caregiv
center
questionnair
diagnosi
manag
ad
result
total
patient
caregiv
particip
studi
initi
diagnosi
ad
mostli
made
physician
follow
selfdiagnosi
patient
caregiv
believ
allerg
substanc
hous
dust
mite
food
pollut
respons
ad
develop
allergi
test
perform
patient
allergen
avoid
strategi
instruct
subject
regard
measur
ad
manag
thought
moistur
environment
control
improv
bodi
constitut
import
major
topic
medic
steroid
topic
immunomodul
system
medic
includ
system
steroid
antihistamin
cyclosporin
subject
tri
complementari
altern
medicin
includ
orient
medicin
mani
subject
wish
person
manag
use
special
institut
ad
evidencebas
effect
sustain
treatment
incorpor
session
conclus
find
suggest
still
unmet
healthcar
need
patient
ad
real
practic
custom
evidencebas
multidisciplinari
approach
includ
therapeut
patient
educ
implement
achiev
best
possibl
outcom
background
evalu
ige
reactiv
profil
purifi
hous
dust
mite
hdm
allergen
molecul
ie
nder
p
rder
p
rder
p
korean
allerg
rhiniti
ar
patient
also
symptomat
serolog
chang
sublingu
immunotherapi
slit
analyz
accord
posit
ige
profil
b
method
sixti
ar
patient
alreadi
diagnos
hdm
allergi
analyz
presenc
ige
antibodi
nder
p
rder
p
rder
p
nativ
dermatophagoid
pteronyssinu
dp
symptom
score
laboratori
test
followedup
slit
c
result
preval
rate
ige
dp
der
p
der
p
der
p
respect
one
year
slit
symptom
score
laboratori
find
improv
show
signific
differ
der
p
neg
patient
conclus
korean
ar
patient
specif
ige
der
p
der
p
present
dpallerg
patient
reactiv
der
p
low
chang
symptom
serolog
slit
contain
allergen
der
p
differ
much
der
p
neg
patient
background
histori
betalactam
bl
hypersensit
one
encount
problem
clinic
practic
limit
use
determin
whether
patient
bl
allergi
could
safe
receiv
betalactam
difficult
task
summar
data
patient
presum
allerg
histori
bl
underw
drug
allergi
verif
report
actual
allerg
rate
method
patient
histori
immedi
reaction
undetermin
allerg
onset
betalactam
underw
bl
hypersensit
evalu
king
chulalongkorn
memori
hospit
bangkok
retrospect
review
verif
process
conduct
accord
updat
paramet
drug
allergi
includ
skin
test
major
minor
determin
penicillin
amoxicillin
clavulan
andor
culprit
bl
intraderm
test
idt
perform
neg
skin
prick
test
spt
oral
challeng
test
oct
carri
patient
gave
inform
consent
serum
penicilloyl
amoxycilloyl
specif
ige
level
also
evalu
result
total
patient
mean
age
year
includ
fortyeight
patient
femal
patient
underli
medic
ill
patient
allerg
histori
penicillin
amoxicillin
sixti
percent
patient
develop
symptom
within
hour
major
experienc
skin
symptom
urticari
rash
angioedema
maculopapular
rash
patient
report
anaphylaxi
bl
allergi
confirm
patient
identifi
posit
skin
test
patient
posit
specif
ige
level
patient
posit
oct
patient
posit
skin
test
one
posit
spt
neg
ige
level
anoth
one
posit
result
idt
specif
ige
level
sixti
patient
underw
oct
patient
demonstr
neg
challeng
serum
specif
ige
level
determin
patient
show
neg
result
mild
nonimmedi
reaction
develop
patient
upon
oct
neg
skin
test
conclus
reliabl
selfreport
bl
allergi
low
question
skin
test
specif
ige
determin
safe
diagnos
patient
immedi
reaction
betalactam
drug
allergi
delabel
need
distinguish
true
allerg
patient
nonallerg
case
particularli
certain
circumst
altern
antibiot
avail
appropri
background
investig
protect
role
sonic
hedgehog
shh
signal
associ
lipopolysaccharid
lp
induc
acut
lung
injuri
ali
mous
model
method
male
balbc
mice
randomli
divid
three
group
control
lp
lpsc
group
ali
induc
lp
ip
inject
mgkg
sonic
hedgehog
inhibitor
cyclopamin
given
lpsc
group
mgkg
min
lp
inject
lung
injuri
observ
histolog
hematoxylin
eosin
stain
tissu
section
semiquantifi
lung
tissu
injuri
score
lung
tissu
mass
alter
measur
wet
dri
weight
ratio
wd
mrna
level
shh
patch
ptc
lung
tissu
studi
real
time
quantit
pcr
rtpcr
protein
express
shh
determin
western
blot
analysi
result
lung
tissu
injuri
score
wd
mrna
express
level
significantli
higher
ali
mice
normal
mice
p
mrna
level
shh
ptc
ali
mice
significantli
higher
lp
inject
time
point
protein
product
shh
lung
ali
mice
significantli
increas
timedepend
manner
compar
normal
mice
cyclopamin
intervent
ali
mice
led
reduct
mrna
level
shh
ptc
well
shh
protein
level
meanwhil
patholog
injuri
score
lung
tissu
wd
mrna
express
level
increas
compar
mice
receiv
lp
conclus
shh
signal
pathway
activ
respons
lpsinduc
ali
upregul
shh
express
could
allevi
lung
injuri
involv
repair
injur
lung
tissu
background
knowledg
skill
requir
use
adrenalin
autoinjector
aai
lack
school
set
caus
consider
uneasi
among
teach
staff
administ
aai
student
object
studi
aim
elucid
factor
behind
neg
attitud
toward
administr
aai
school
set
method
lectur
present
emerg
treatment
food
allergi
organ
region
school
board
hyogo
prefectur
conduct
questionnair
survey
among
particip
analyz
answer
receiv
particip
use
logist
regress
model
investig
independ
factor
associ
neg
attitud
toward
administr
aai
result
respond
compris
nurs
teacher
gener
educ
teacher
nutrit
teacher
assist
princip
princip
neg
administ
aai
student
account
total
percentag
differ
significantli
differ
specialtiesposit
nutrit
teacher
highest
percentag
follow
gener
educ
teacher
nurs
teacher
assist
princip
princip
frequent
factor
behind
uneasi
use
aai
time
aai
administr
teach
specialtyposit
greater
number
nurs
teacher
concern
collabor
within
school
collabor
hospit
teacher
specialtiesposit
compar
group
neg
attitud
group
posit
attitud
toward
aai
administr
former
significantli
worri
use
aai
odd
ratio
time
aai
administr
collabor
parent
act
inject
violat
law
conclus
factor
behind
neg
attitud
toward
administr
aai
school
set
associ
technic
concern
background
relationship
atop
dermat
ad
low
vitamin
level
studi
emerg
evid
implic
vitamin
critic
regul
immun
play
role
innat
cellmedi
immun
system
howev
effect
vitamin
hous
dust
mite
hdm
sensit
patient
ad
establish
investig
associ
vitamin
level
hdm
sensit
accord
ad
sever
method
total
patient
men
women
ad
includ
classifi
ad
sever
use
rajka
langeland
score
laboratori
test
includ
serum
total
immunoglobulin
e
ige
specif
ige
antibodi
titer
dermatophagoid
farina
pteronyssinu
result
differ
vitamin
level
mild
moder
ad
sever
ad
group
sever
ad
group
high
hdm
sensit
group
lower
serum
vitamin
level
compar
low
hdm
sensit
group
statist
signific
addit
signific
neg
correl
found
vitamin
level
hdm
sensit
sever
ad
group
result
depend
type
hdm
farina
pteronyssinu
conclus
result
demonstr
low
vitamin
level
may
link
high
hdm
sensit
patient
sever
ad
elucid
role
vitamin
hdm
sensit
may
hold
profound
implic
prevent
treatment
ad
object
investig
effect
copd
skelet
muscl
particularli
patient
limb
muscl
dysfunct
appendicular
skelet
muscl
mass
index
asmi
index
sarcopenia
recent
limelight
index
limb
muscl
mass
consid
use
predict
skelet
muscl
abnorm
copd
patient
thu
relationship
examin
method
research
conduct
use
data
korea
nation
health
nutrit
examin
survey
knhane
conduct
subject
dualenergi
xray
absorptiometri
dxa
perform
confirm
bodi
composit
copd
patient
age
year
show
copd
classifi
three
group
mild
moder
sever
accord
airflow
limit
studi
subject
mild
copd
moder
sever
criteria
sarcopenia
recommend
criteria
european
work
group
sarcopenia
older
peopl
ewgsop
asia
work
group
sarcopenia
awg
use
result
asmi
group
categor
accord
copd
sever
respect
thu
differ
group
higher
sever
lower
result
p
sarcopenia
classif
ewgsop
accord
asmi
appli
group
l
respect
case
class
ii
sarcopenia
lower
normal
case
case
class
sarcopenia
sarcopenia
criteria
awg
appli
l
pulmonari
function
sarcopenia
group
low
p
correl
l
asmi
analyz
higher
bmi
ffmi
p
regress
analysi
also
confirm
asmi
higher
standard
regress
coeffici
bmi
ffmi
skelet
muscl
mass
index
smi
p
found
asmi
use
sarcopenia
risk
increas
case
criteria
recommend
ewgsop
awg
use
criteria
awg
use
moder
sever
stage
show
odd
ratio
cl
p
cl
p
respect
compar
mild
stage
conclus
asmi
fast
accur
predictor
skelet
muscl
abnorm
caus
increas
sever
airflow
limit
copd
patient
background
oral
allergi
syndrom
oa
defin
symptom
igemedi
immedi
allergi
local
oral
mucosa
characterist
depend
labil
antigen
oa
regard
uncommon
manifest
pediatr
popul
studi
focus
allergen
relationship
pollen
food
allergen
oral
allergi
syndrom
korean
children
method
studi
base
data
analysi
patient
diagnos
oral
allergi
syndrom
ajou
univers
hospit
sever
children
hospit
kangnam
sever
hospit
januari
decemb
clinic
detail
collect
medic
histori
telephon
survey
result
subject
male
femal
median
age
year
children
oral
allergi
syndrom
common
caus
food
allergi
syndrom
appl
pollen
highest
rate
posit
respons
birch
children
oral
allergi
syndrom
children
sensit
birch
high
risk
reaction
appl
youngest
patient
oral
allergi
syndrom
year
old
girl
children
reaction
food
conclus
oral
allergi
syndrom
may
commonli
affect
children
allerg
pollen
children
oral
allergi
syndrom
knowledg
specif
sensit
pattern
consequ
dietari
manag
background
numer
epidemiolog
studi
shown
advers
associ
increas
outdoor
air
pollut
health
outcom
major
studi
focus
daili
concentr
air
pollut
smallscal
variat
daili
averag
peak
concentr
abl
character
investig
season
associ
diurnal
variat
trafficrel
air
pollut
exacerb
asthma
symptom
among
middleag
elderli
urban
set
method
address
health
effect
diurnal
variat
trafficrel
air
pollut
asthmarel
emerg
depart
ed
visit
appli
gener
linear
model
dispers
poison
distribut
daili
asthmarel
ed
visit
seoul
korea
indic
variabl
diurnal
variat
trafficrel
air
pollut
diurnal
rang
adopt
defin
differ
level
morn
statist
analysi
conduct
estim
effect
adjust
temperatur
rel
humid
air
pressur
influenza
epidem
indic
day
week
time
trend
agespecif
effect
season
test
agespecif
group
defin
middleag
age
elderli
age
result
among
total
asthmarel
ed
visit
studi
period
recruit
middleag
elderli
increas
overal
risk
suggest
rel
risk
percent
chang
confid
interv
ci
middleag
ci
elderli
ci
interquartil
rang
iqr
increas
season
specif
effect
middleag
ci
ci
ci
ci
elderli
ci
ci
ci
ci
spring
march
may
summer
june
august
fall
septemb
novemb
winter
decemb
februari
respect
among
middleag
group
estim
effect
winter
detect
ci
ci
ci
ci
winter
studi
suggest
advers
relationship
ambient
risk
asthmarel
ed
visit
level
relat
asthma
exacerb
especi
spring
winter
period
delay
effect
vari
agegroup
conclus
provid
evid
heavili
increas
level
trafficrel
pollut
associ
poorli
control
asthma
among
adult
cold
period
background
although
anaphylaxi
recogn
import
lifethreaten
condit
data
limit
regard
characterist
korean
children
object
sought
estim
trigger
anaphylaxi
age
group
korean
children
method
retrospect
medic
record
review
perform
children
patient
diagnos
anaphylaxi
tertiari
hospit
south
korea
result
total
case
male
mean
age
report
year
age
food
common
caus
follow
drug
radiocontrast
media
idiopath
exercis
common
offend
food
allergen
milk
follow
egg
white
walnut
wheat
buckwheat
peanut
milk
common
trigger
anaphylaxi
young
children
older
children
seafood
common
trigger
anaphylaxi
rate
drug
trigger
anaphylaxi
increas
age
conclus
food
commonest
trigger
anaphylaxi
korean
children
common
trigger
food
induc
anaphylaxi
chang
time
korean
children
background
acut
bronchiol
common
caus
hospit
children
identifi
risk
factor
respiratori
failur
young
infant
studi
determin
sever
acut
bronchiol
may
help
initi
assess
infant
method
retrospect
chart
review
infant
hospit
singl
tertiari
hospit
decemb
april
done
exclus
criteria
atop
dermat
preterm
congenit
heart
diseas
congenit
anomali
metabol
diseas
bronchiol
sever
score
bss
gener
appear
lung
sound
dyspnea
respir
rate
oxygen
satur
puls
oxymetri
evalu
admiss
within
hr
admiss
outcom
measur
includ
feed
pattern
allergi
histori
parent
viru
initi
bodi
weight
current
bodi
weight
height
result
enrol
hospit
infant
month
old
month
age
male
mean
bodi
weight
admiss
kg
mean
durat
hospit
day
posit
relat
bss
p
signific
associ
bss
matern
allergi
height
age
p
howev
signific
associ
observ
bss
bodi
weight
amount
increas
weight
birth
infect
viru
conclus
matern
allergi
age
height
infant
found
signific
factor
sever
acut
bronchiol
infant
studi
need
determin
matern
allergi
allow
predict
long
term
respiratori
outcom
asthma
follow
bronchiol
infant
sever
bronchiol
like
famili
atop
predisposit
may
partli
explain
subsequ
increas
asthma
risk
keyword
allergi
pediatr
background
refractori
asthma
character
poor
respons
corticosteroid
treatment
follow
increas
burden
diseas
therefor
develop
endotyp
relat
refractori
asthma
import
diagnosi
treatment
aim
studi
determin
level
inflammatori
mediat
sputum
evalu
use
protein
profil
endotyp
refractori
asthma
method
total
asthmat
never
smoker
exsmok
less
pack
year
enrol
sputum
induc
use
isoton
salin
contain
shortact
bronchodil
differenti
cell
count
perform
concentr
determin
use
elisa
normal
total
protein
supernat
sputum
statist
analys
cluster
decis
tree
analysi
perform
use
spss
result
posit
correl
level
p
level
invers
correl
subject
cluster
four
major
group
accord
sputum
level
cytokin
subject
high
level
group
rel
low
level
cytokin
modest
increas
group
high
group
highest
moder
increas
group
clinic
featur
group
younger
high
airway
hyperreact
increas
number
wbc
blood
group
show
highest
eosinophil
low
neutrophil
sputum
group
show
highest
neutrophil
group
show
highest
neutrophil
sputum
old
age
rel
normal
airway
hyperreact
howev
lung
function
exacerb
statu
compar
group
decis
tree
analysi
exacerb
patient
classifi
three
group
accord
level
cytokin
group
lower
level
pgug
group
higher
pgug
low
pgug
level
group
higher
level
patient
group
oldag
greatest
pack
year
smoke
show
significantli
higher
serum
level
total
ige
neutrophil
sputum
group
lung
function
group
lowest
spite
treatment
highest
dose
inhal
corticosteroid
patient
group
show
significantli
frequent
exacerb
per
year
p
conclus
level
sputum
may
surrog
set
marker
predict
treatment
outcom
asthmat
endotyp
refractori
asthma
background
autophagi
investig
involv
mani
inflammatori
diseas
express
clinic
signific
asthma
rare
studi
aim
studi
evalu
role
autophagi
therapeut
potenti
ovaspecif
mous
model
sever
allerg
asthma
method
balbc
mice
sensit
intraperiton
inject
ovalbumin
ova
day
follow
aerosol
primari
ova
challeng
day
two
week
primari
allergen
challeng
mice
receiv
secondari
allergen
challeng
two
differ
concentr
ova
solut
day
forti
eight
hour
last
ova
challeng
mice
assess
airway
respons
ahr
inhal
methacholin
cell
composit
cytokin
level
bronchoalveolar
lavag
bal
fluid
express
lung
homogen
measur
western
blot
evalu
develop
autophagi
final
knockdown
appli
investig
potenti
role
autophagi
sever
allerg
asthma
mice
result
ahr
total
airway
inflammatori
cell
number
eosinophilia
bal
fluid
significantli
higher
ova
challeng
mice
compar
ova
challeng
mice
p
p
respect
indic
ova
challeng
could
induc
mous
model
present
sever
eosinophil
asthma
sever
allerg
asthma
mice
show
signific
higher
express
compar
mild
asthma
mice
addit
promin
autophagosom
note
cytoplasm
eosinophili
inhibit
autophagi
treatment
knockdown
could
induc
signific
improv
ahr
eosinophilia
level
bal
fluid
airway
inflamm
histolog
antibodi
treatment
significantli
reduc
eosinophil
count
level
bal
fluid
well
express
lung
tissu
homogen
conclus
find
suggest
express
autophagi
correl
sever
asthma
eosinophil
inflamm
autophagi
inhibit
may
provid
novel
therapeut
target
treatment
sever
allerg
asthma
background
possibl
role
proinflammatori
cytokin
member
cytokin
famili
pediatr
asthma
studi
perform
measur
serum
level
pediatr
patient
asthma
method
studi
patient
asthma
healthi
age
sex
match
subject
enrol
serum
level
measur
asthmat
patient
healthi
subject
sandwich
elisa
result
serum
level
significantli
higher
patient
group
compar
control
addit
patient
sever
asthma
significantli
higher
serum
level
compar
control
p
mean
serum
level
asthmat
children
also
significantli
higher
control
also
show
statist
signific
associ
sever
diseas
conclus
elev
serum
level
found
associ
pediatr
asthma
diseas
sever
background
epinephrin
first
treatment
anaphylaxi
investig
clinic
featur
pediatr
anaphylaxi
includ
rate
use
epinephrin
prescrib
epinephrin
autoinjector
method
perform
retrospect
studi
inpati
outpati
emerg
depart
visitor
year
old
soonchunhyang
univers
hospit
cheonan
korea
jan
dec
total
patient
diagnos
anaphylaxi
criteria
time
result
caus
anaphylaxi
food
drug
idiopath
involv
organ
cutan
respiratori
cardiovascular
gastrointestin
tract
patient
treat
system
steroid
antihistamin
epinephrin
patient
revisit
pediatr
allergi
clinic
epinephrin
autoinjector
prescrib
patient
conclus
epinephrin
use
epinephrin
autoinjector
prescrib
pediatr
anaphylaxi
patent
physician
make
effort
use
epinephrin
initi
treatment
anaphylaxi
prescrib
epinephrin
autoinjector
background
oral
immunotherapi
oit
novel
therapeut
approach
food
allergi
appear
effect
increas
threshold
clinic
reactiv
food
aim
studi
assess
risk
factor
associ
rush
oit
roit
treat
anaphylaxi
induc
allergi
hen
egg
cow
milk
cm
wheat
w
peanut
p
method
cm
w
anaphylaxi
depart
confirm
posit
doubleblind
placebocontrol
food
challeng
test
receiv
follow
treatment
roit
patient
treat
combin
rush
phase
follow
slow
buildup
mainten
dose
patient
ingest
trial
food
heatedwhol
egg
g
cm
ml
w
udon
noodl
g
p
peanut
powder
g
without
symptom
sever
month
underw
final
oral
food
challeng
ofc
allergen
avoid
week
confirm
develop
clinic
toler
chang
antigen
specif
ige
level
oit
treatment
document
result
total
subject
n
cm
n
w
n
p
n
averag
age
year
receiv
roit
year
enrol
studi
one
half
year
later
subject
pass
final
ofc
tent
toler
group
cm
w
p
wherea
subject
react
trial
food
allerg
group
year
roit
median
antigenspecif
ige
level
kul
significantli
decreas
compar
level
prior
oit
egg
white
vs
ovomucoid
vs
milk
vs
casein
vs
wheat
vs
gliadin
vs
peanut
vs
ara
h
vs
p
wherea
antigen
specif
increas
significantli
vs
egg
white
vs
casein
p
tent
toler
group
cmroit
initi
antigenspecif
ige
level
significantli
lower
allerg
group
tent
toler
group
vs
allerg
group
egg
white
vs
ovomucoid
vs
milk
vs
casein
vs
p
signific
differ
found
patient
allerg
w
p
conclus
studi
roit
induc
signific
decreas
antigen
specif
ige
level
cm
anaphylaxi
patient
rel
low
antigenspecif
ige
begin
roit
appear
respond
better
roit
within
year
background
atpbind
cassett
subfamili
c
member
proteincod
gene
code
transmembran
protein
protein
transport
variou
molecul
across
extra
intracellullar
membran
includ
camp
studi
report
camp
play
import
role
regul
immun
respons
airway
inflamm
studi
investig
associ
gene
polymorph
clinic
characterist
asthmat
patient
understand
role
asthma
pathogenesi
method
asthma
patient
normal
healthi
control
enrol
studi
two
singl
nucleotid
polymorph
snp
c
g
region
genotyp
taqman
allel
discrimin
assay
function
variabl
promot
polymorph
analyz
gene
report
assay
inflammatori
cytokin
level
serum
measur
elisa
result
signific
differ
genotyp
frequenc
two
studi
group
asthmat
patient
carri
g
allel
g
significantli
higher
periostin
level
sera
lower
methacholin
level
compar
noncarri
signific
differ
note
sputum
eosinophil
count
accord
genotyp
gene
report
assay
show
promot
snp
tag
allel
confer
significantli
higher
promot
activ
p
compar
allel
cell
line
conclus
find
suggest
gene
polymorph
g
may
enhanc
periostin
product
could
involv
eosinophil
asthma
introduct
birth
cohort
risk
asian
infant
prospect
investig
role
earli
onset
allergen
sensit
clinic
phenotyp
risk
factor
atop
disord
age
year
method
studi
recruit
famili
histori
allerg
diseas
first
degre
rel
antenat
clinic
singapor
children
follow
prospect
assess
clinic
outcom
skin
prick
test
perform
year
age
result
clinic
phenotyp
alon
year
age
associ
increas
risk
atop
disord
year
risk
increas
presenc
concomit
allergen
sensit
food
andor
hous
dust
mite
eczema
eczema
alon
year
old
increas
risk
eczema
year
adjor
ci
risk
increas
presenc
allergen
sensit
adjor
ci
wheez
wheez
alon
year
increas
risk
wheez
year
adjor
ci
risk
tripl
concomit
presenc
allergen
sensit
eczema
adjor
ci
rhiniti
symptom
appar
age
year
allergen
sensit
alon
year
without
rhiniti
phenotyp
increas
risk
rhiniti
year
adjor
ci
howev
eczema
phenotyp
year
alon
also
increas
risk
rhiniti
year
adjor
ci
conclus
asian
birth
cohort
clinic
phenotyp
alon
concomit
allergen
sensit
predictor
eczema
wheez
year
except
rhiniti
outcom
allergen
sensit
alon
year
could
predict
atop
clinic
outcom
year
background
korean
red
ginseng
krg
report
antiallerg
properti
includ
benefici
effect
asthma
atop
dermat
howev
effect
allerg
rhiniti
rhinoviru
infect
studi
extens
studi
examin
whether
krg
affect
rhinoviru
infect
human
nasal
epitheli
cell
method
primari
human
nasal
epitheli
cell
obtain
digest
inferior
turbin
mucosa
remov
patient
turbinoplasti
nasal
epitheli
cell
cultur
cell
infect
rhinoviru
serotyp
confirm
prevent
therapeut
effect
krg
rhinoviru
infect
krg
administ
cultur
nasal
epitheli
cell
rhinoviru
infect
provok
morpholog
nasal
epitherli
cell
check
result
morpholog
nasal
epitheli
cell
chang
rhinoviru
infect
degre
morpholog
chang
decreas
krg
treatment
group
treatment
rhinoviru
infect
howev
nasal
epitheli
cell
less
chang
krg
administr
rhinoviru
infect
conclus
krg
prevent
therapeut
effect
human
nasal
epitheli
cell
introduct
korean
red
ginseng
tradit
use
korea
health
improv
howev
clinic
effect
krg
intak
symptom
allerg
rhiniti
patient
remain
unknown
studi
perform
identifi
clinic
effect
krg
allerg
rhiniti
patient
examin
effect
krg
allerg
inflammatori
reaction
patient
method
evalu
allerg
rhiniti
patient
treat
week
patient
divid
three
group
accord
medic
twenti
patient
treat
krg
patient
placebo
patient
antihistamin
patient
record
symptom
daili
symptom
diari
card
patient
check
peak
inspiratori
flow
pnif
rate
two
time
day
morn
even
medic
period
total
serum
ige
serum
specif
ige
dp
df
measur
immunocap
method
week
medic
cytokin
check
serum
treatment
use
elisa
method
eosinophil
count
nasal
smear
check
treatment
result
krg
group
demonstr
signific
improv
allerg
symptom
except
smell
difficulti
categori
pnif
demonstr
differ
period
treatment
either
krg
group
antihistamin
treatment
group
antihistamin
krg
group
show
signific
decreas
total
ige
level
end
treatment
serum
level
eosinophil
count
nasal
smear
significantli
decreas
antihistamin
krg
group
conclus
krg
might
use
treatment
modal
allerg
rhiniti
patient
howev
need
better
understand
longterm
effect
krg
studi
background
screen
system
commonli
use
allergenspecif
ige
detect
system
korea
high
sensit
low
specif
use
screen
system
howev
correl
rate
system
skin
prick
test
rel
lower
food
allergen
inhal
allergen
purpos
valid
new
allergenspecif
ige
detect
system
b
comparison
system
method
evalu
korean
atop
dermat
ad
patient
result
newli
develop
b
also
compar
correl
coeffici
immunocaptest
goldstandard
diagnost
tool
extrins
ad
result
compar
correl
coeffici
immunocaptest
antigen
includ
dfarina
dpteronyssinu
soyben
cow
milk
white
egg
result
cow
milk
dfarina
dpteronyssinu
antigen
significantli
match
moder
strength
agreement
found
egg
white
fair
agreement
observ
wheat
howev
dfarina
dpteronyssinusresult
b
show
signific
agreement
strength
captest
antigen
slight
agreement
conclus
overal
accur
result
observ
new
screen
system
b
compar
studi
perform
analyz
result
antigen
background
object
assess
symptom
sever
allerg
rhiniti
patient
sensit
multipl
allergen
compar
singl
hous
dust
mite
allergen
subject
method
total
allerg
rhiniti
patient
classifi
group
multipl
allergen
group
defin
patient
sensit
multipl
allergen
includ
hous
dust
mite
singl
allergen
group
defin
sensit
hous
dust
mite
skin
prick
test
sever
allerg
rhiniti
evalu
accord
visual
analogu
scale
va
follow
nasal
symptom
vitro
test
total
ige
blood
eosinophil
count
analys
result
total
allerg
rhiniti
patient
classifi
multipl
allergen
singl
hous
dust
mite
sensit
group
visual
analogu
scale
nasal
symptom
differ
two
group
vitro
test
total
ige
blood
eosinophil
count
conclus
subject
symptom
sever
allerg
rhiniti
patient
sensit
multipl
allergen
show
differ
rather
singl
hous
dust
mite
purpos
asthma
major
public
health
problem
mani
studi
shown
diurnal
temperatur
chang
dtr
associ
asthma
mortal
emerg
depart
ed
visit
asthma
morbid
studi
repres
dtr
asthma
ed
visit
show
nonlinear
relationship
lag
effect
day
howev
studi
consid
two
characterist
simultan
studi
aim
find
associ
dtr
asthma
ed
visit
includ
nonlinear
lag
effect
method
ed
data
korean
citi
seoul
busan
daejeon
daegu
gwangju
incheon
collect
januari
decemb
nation
emerg
depart
inform
system
nedi
nation
emerg
medic
center
appli
stage
distribut
lag
nonlinear
model
dlnm
lag
day
allow
overdispers
adjust
meteorolog
condit
time
trend
result
stage
analysi
found
dtr
advers
associ
asthmarel
ed
visit
korea
dtr
increas
risk
ed
visit
rel
risk
asthmarel
ed
visit
estim
midhigh
percentil
versu
minimum
mortal
dtr
high
percentil
versu
minimum
mortal
dtr
extrem
high
percentil
versu
minimum
mortal
dtr
rel
risk
ci
midhigh
condit
high
extrem
high
conclus
found
dtr
advers
effect
ed
visit
korea
effect
dtr
show
nonlinear
relationship
signific
day
therefor
dtr
increas
vulner
peopl
public
health
author
pay
special
attent
acut
exacerb
asthma
backround
mannanbind
lectin
mbl
serum
protein
involv
opson
complement
activ
contain
lectin
collagen
domain
synthes
liver
mbl
bind
nacetylglucosamineand
mannan
structur
thesurfac
bacteria
fungi
virus
protozoa
lead
opson
phagocytosi
activ
ofcompl
system
lectin
pathway
independ
antibodi
allerg
diseas
domin
preferenti
develop
specif
type
adapt
immun
respons
innocu
antigen
atop
individu
low
level
serum
mbl
associ
increas
suscept
infectionsand
high
risk
allerg
autoimmun
diseas
recent
assign
role
mbl
inflammatori
diseas
due
increas
complement
activ
stimul
research
contribut
mbl
associ
complement
activ
asthma
respiratori
allergi
purpos
main
aim
studi
determin
theprofil
mbl
serum
level
mongolian
atop
subject
method
blood
sampl
collect
mongolian
individu
allerg
rhiniti
male
femal
differ
age
group
mean
age
year
subject
posit
reaction
skin
prick
test
one
inhal
allergen
analyz
mbl
level
serum
use
doubleantibodi
sandwich
elisa
method
result
mean
median
serum
level
mbl
ngml
ngml
mbl
level
male
ngml
femal
ngml
associ
observ
sex
mbl
concentr
serum
year
age
year
year
year
signific
differ
mean
concentr
mbl
among
differ
age
group
conclus
mbl
serum
levelof
mongolian
allerg
patient
compar
higher
report
studi
background
preval
atop
eczema
increas
worldwid
past
decad
howev
countri
remain
stabl
even
decreas
aim
studi
estim
preval
atop
eczema
korea
method
investig
preval
atop
eczema
analyz
nationwid
databas
nation
health
insur
corpor
includ
healthcar
record
million
individu
januari
decemb
result
preval
atop
eczema
korea
show
decreas
tendenc
also
child
group
decreas
year
old
age
group
decreas
year
group
howev
adolesc
adult
age
group
increas
year
group
year
group
year
group
year
group
year
group
year
group
year
group
conclus
preval
atop
eczema
korea
show
decreas
tendenc
howev
increas
adult
age
group
interestingli
year
old
age
group
show
abruptli
decreas
pattern
endem
influenza
infecion
studi
need
object
recurr
wheez
one
predict
marker
asthma
preschool
children
aim
studi
investig
airway
inflamm
lung
function
airway
hyperrespons
ahr
preval
allerg
rhiniti
ar
atop
dermat
ad
preschool
children
accord
recurr
wheez
method
perform
populationbas
crosssect
studi
children
age
year
total
children
complet
modifi
intern
studi
asthma
allergi
childhood
questionnair
elig
studi
measur
exhal
nitric
oxid
eno
spirometri
methacholin
bronchial
provoc
impuls
oscillometri
recurr
wheez
defin
lifetim
wheez
time
result
preval
recurr
wheez
children
recurr
wheez
show
higher
preval
lifetim
current
ar
lifetim
ad
current
ad
recurr
wheez
associ
lifetim
emerg
room
visit
time
histori
one
admiss
within
month
due
wheez
episod
high
eno
postbronchodil
chang
blood
eosinophil
well
low
associ
recurr
wheez
howev
dose
respons
slope
methacholin
test
preval
atopi
ahr
serum
ige
level
show
signific
differ
two
group
conclus
recurr
wheez
preschool
children
may
associ
lower
lung
function
airway
inflamm
ahr
atopi
backround
mannosebind
lectin
mbl
protein
contain
lectin
collagen
domain
synthes
liver
mbl
bind
n
acetylglucosamin
mannan
structur
surfac
bacteria
fungi
virus
protozoa
lead
opson
phagocytosi
activ
complement
system
lectin
pathway
independ
antibodi
mbl
vital
protein
innat
immun
system
two
critic
function
complement
activ
lectin
pathway
opson
low
level
serum
mbl
associ
increas
suscept
infect
high
risk
allerg
autoimmun
diseas
purpos
purpos
studi
determin
profil
mbl
serum
level
mongolian
healthi
popul
first
time
method
collect
serum
mongolian
healthi
adult
blood
donor
male
femal
differ
age
group
mean
age
year
analyz
mbl
level
serum
use
doubleantibodi
sandwich
elisa
method
result
mean
median
serum
level
mbl
ngml
ngml
mbl
level
male
ngml
femal
ngml
associ
observ
sex
mbl
concentr
ngml
year
age
ngml
year
ngml
year
ngml
year
signific
differ
mean
concentr
mbl
among
differ
age
group
conclus
mbl
serum
level
mongolian
healthi
popul
compar
higher
nation
popul
mbl
valu
studi
use
normal
refer
rang
futur
studi
mongolian
popul
background
mani
suffer
bronchial
asthma
copd
need
nebulis
therapi
acut
conditionsth
rotahal
wih
rotacap
deliv
drug
quit
subject
use
rotahal
properli
inspit
adequ
train
acut
exacerb
plight
wors
henc
proper
drug
deliveri
acut
condit
rotacap
rotahal
may
adequ
henc
attempt
made
effect
deliveri
entir
salbutamol
mechan
nebulis
market
electron
oper
nebulis
availableth
cost
still
prohibit
urban
rural
area
regular
power
suppli
even
hospit
nebulis
far
conamin
distinct
possibl
ward
icu
set
also
lot
wastag
side
stream
electron
nebulis
take
atleast
min
entir
medicin
nebulis
henc
air
pump
driven
mechan
nebulis
develop
materi
method
air
pump
made
pvc
weigh
fabric
devicethi
cylindr
chamber
slide
steel
rod
inbuilt
posterior
anterior
apertur
draw
propel
air
pressur
pedal
mount
chamberth
whole
unit
rest
metal
frame
nylon
line
slide
cylind
inner
axial
rod
greas
appli
cylindr
chamber
slide
axial
rod
anterior
end
attach
nebulis
unit
availab
market
rotacap
contain
salbutamol
open
nebulis
chamber
charg
salbutamol
rotacap
powder
dissolv
one
two
ml
normal
salin
user
connect
mask
face
end
anterior
end
air
pump
nozzl
pedal
pump
mist
releas
side
stream
avoid
wastagethu
self
oper
one
requir
helper
may
pedal
pump
result
one
hundr
adult
patient
suffer
bronchial
asthma
treat
devic
use
salbutamol
rotacap
powder
normal
salin
solvent
apart
subject
asses
improv
measur
mini
wright
peak
flow
meter
pefr
averg
pefr
lit
per
min
lit
per
min
rota
nebulis
twenti
five
subject
similar
complaint
taken
controlthey
asses
salbutamol
inhal
attach
spacer
reves
airway
obstruct
better
devic
entir
salbutamol
deliv
properli
contrast
drug
deliveri
inhal
attach
spacer
suppos
user
prefer
devic
inspiratori
effort
advantag
electr
last
rotacap
powder
instead
costli
inhal
background
explor
level
serum
interleukin
children
asthma
method
casecontrol
studi
asthmat
children
asthma
clinic
children
hospit
surgic
noninfecti
elect
surgeri
came
affili
children
hospit
capit
institut
pediatr
march
decemb
enrol
studi
boy
girl
age
year
old
mean
age
year
month
level
serum
measur
enzymelink
immunosorb
assay
elisa
method
materi
histori
blood
test
lung
function
test
concentr
fraction
exhal
nitric
oxid
feno
vitro
allergern
test
asthmat
children
reserv
result
level
serum
asthmat
significantli
higher
control
p
posit
relationship
level
serum
sever
asthma
p
level
serum
control
chronic
persist
control
exacerb
chronic
persist
exacerb
significantli
differ
p
level
serum
allerg
asthmat
nonallerg
asthmat
significantli
differ
p
differ
level
serum
p
posit
relationship
level
serum
neutrophil
asthmat
children
posit
relationship
level
serum
sige
inhal
allergen
p
relationship
level
serum
lung
function
feno
sever
asthmat
children
posit
relationship
level
serum
level
serum
p
conclus
level
serum
asthmat
children
higher
control
posit
relationship
serum
sever
asthmat
children
posit
relationship
level
serum
neutrophil
asthmat
children
posit
relationship
serum
sige
sever
asthmat
children
posit
relationship
level
serum
level
serum
purpos
vitamin
one
essenti
nutrient
immun
modul
effector
recent
epidemiolog
studi
shown
lack
vitamin
level
may
associ
high
asthma
preval
purpos
studi
examin
associ
serum
vitamin
level
preval
pediatr
asthma
korea
method
studi
conduct
asthmat
children
healthi
control
age
year
serum
vitamin
vitamin
level
measur
compar
two
group
moreov
relationship
serum
vitamin
level
pulmonari
function
test
environment
factor
sunshin
examin
asthmat
patient
result
serum
vitamin
level
asthmat
patient
ngml
significantli
p
lower
healthi
control
ngml
also
found
serum
vitamin
level
ngml
decreas
preval
asthma
increas
ci
p
howev
associ
vitamin
level
pulmonari
function
sunshin
relat
factor
hous
type
live
floor
indooroutdoor
activ
time
conclus
result
suggest
serum
vitamin
level
associ
pediatr
asthma
korea
prevent
treatment
asthma
intervent
studi
asthmat
children
low
serum
vitamin
level
vitamin
studi
assess
optim
deliveri
safeti
supplement
need
background
great
interest
develop
valid
noninvas
method
local
measur
ige
howev
challeng
ige
least
abund
immunoglobulin
isotyp
present
low
concentr
aim
compar
three
method
collect
ns
local
measur
ige
filter
disk
fd
sinu
pack
sp
ear
pack
ep
furthermor
evalu
suitabl
use
fix
dilut
instead
fix
volum
process
method
ns
collect
fd
sp
hous
dust
mite
hdm
allerg
rhiniti
ar
patient
control
process
salin
solut
ad
order
mobil
ns
sampl
volum
ad
calcul
base
weight
collect
ns
order
obtain
fix
dilut
second
experi
ns
collect
two
hdm
ar
patient
rerecruit
first
experi
fd
sp
consecut
day
experi
perform
fix
volum
fix
dilut
third
experi
ns
collect
fd
ep
sp
hdm
ar
patient
rerecruit
first
experi
process
fix
volum
salin
solut
ad
ml
fd
ml
ep
ml
sp
total
ige
measur
unicap
system
result
experi
fix
dilut
level
total
ige
hdm
ige
significantli
higher
hdm
ar
patient
compar
control
fd
total
ige
hdm
ige
detect
limit
bdl
resp
ar
patient
sp
total
ige
hdm
ige
bdl
resp
patient
compar
fd
sp
consecut
day
reproduc
measur
ige
level
better
sp
third
experi
fix
volum
total
ige
hdm
ige
bdl
resp
ar
patient
use
fd
ep
sp
total
ige
hdm
ige
level
bdl
resp
patient
discuss
method
advantag
disadvantag
sp
method
seem
reproduc
fd
method
make
suitabl
repeat
measur
monitor
howev
sp
unsuit
serial
measur
day
caus
stimul
nasal
mucosa
set
fd
prefer
ep
intermedi
size
fd
sp
could
interest
pediatr
set
compar
fix
volum
fix
dilut
process
latter
time
consum
prone
error
howev
fix
dilut
advantag
fix
detect
limit
sampl
therefor
method
recommend
measur
ige
mediat
present
low
concentr
thu
often
bdl
abstract
background
tight
junction
tj
protein
claudin
critic
control
endotheli
cellular
polar
pericellular
permeabilityin
past
role
asthma
limit
attent
object
aim
studi
identifi
express
cldn
respons
steroid
treatment
mous
model
asthma
ie
ovalbumin
ova
induc
allerg
lung
inflamm
human
lung
microvascular
endotheli
cell
hlmvec
normal
human
bronchial
epitheli
nhbe
cell
method
mice
treat
salin
sham
ova
sensit
challeng
ova
ova
dexamethason
lung
level
assess
qrtpcr
elisa
immunoblot
immunohistochem
stain
confoc
imag
hlmvec
treat
host
dust
mite
peptidas
der
interleukin
mrna
transmembran
endotheli
electr
resist
teer
measur
result
airway
inflamm
hyperrespons
cytokin
transcript
protein
increas
ova
sensitizedchalleng
mice
respons
reduc
dexamethason
treatment
pathway
involv
protein
express
der
increas
protein
express
hlmvec
nhbe
cell
decreas
transendotheli
electr
resist
also
increas
hlmvec
decreas
teer
effect
inhibit
dexamethason
conclus
implic
pathogenesi
bronchial
asthma
repres
potenti
target
therapeut
intervent
keyword
tight
junction
claudin
bronchial
asthma
abstract
background
dysfunct
airway
barrier
contribut
develop
andor
exacerb
allerg
airway
inflamm
major
irrit
smoke
acrolein
affect
bronchial
asthma
alter
tight
junction
protein
impact
acrolein
asthma
remain
poorli
understood
object
aim
studi
identifi
express
claudin
impact
acrolein
mous
model
allerg
asthma
method
use
mice
sensit
ovalbumin
ova
ova
challeng
ova
sensitizedchalleng
mice
well
mice
treat
salin
challeng
air
mice
expos
acrolein
day
effect
acrolein
estim
use
qrtpcr
elisa
immunoblot
immunohistochem
stain
confoc
imag
result
lung
transcript
protein
significantli
increas
ova
mice
sham
mice
acrolein
exposur
reduc
increas
inflammatori
cytokin
level
airway
inflamm
bronchial
hyperrespons
ova
mice
increas
lung
transcript
protein
ova
mice
decreas
acrolein
expos
mice
conclus
result
indic
might
involv
protect
role
pathogenesi
bronchial
asthma
acrolein
dysregul
research
support
basic
scienc
research
program
nation
research
foundat
korea
nrf
fund
ministri
educ
keyword
tight
junction
acrolein
bronchial
asthma
background
studi
investig
efficaci
safeti
sublingu
immunotherapi
slit
hous
dust
mite
hous
dust
mite
sensit
children
allerg
rhiniti
method
children
sensit
hous
dust
mite
treat
slit
enrol
august
juli
nasal
symptom
rhinorrhea
sneez
nasal
obstruct
nasal
itch
sleep
disturb
antiallerg
medic
use
presenc
advers
event
assess
month
month
visit
thereaft
everi
month
visit
result
symtom
allerg
rhiniti
start
improv
month
slit
significantli
improv
month
slit
p
antiallerg
medic
use
decreas
significantli
time
p
incid
advers
event
occur
within
first
month
slit
disappear
time
sever
advers
event
conclus
slit
hous
dust
mite
effect
safe
hous
dust
mite
sensit
children
allerg
rhiniti
background
aim
studi
evalu
whether
low
vitamin
level
associ
skelet
muscl
dysfunct
copd
method
cross
section
analysi
includ
copd
particip
age
year
korea
nation
health
nutrit
examin
survey
conduct
bodi
composit
measur
dualenergi
xray
absorptiometri
dxa
serum
oh
parathyroid
hormon
pth
level
measur
criteria
sarcopenia
recommend
criteria
european
work
group
sarcopenia
older
peopl
ewgsop
asia
work
group
sarcopenia
awg
use
divid
subject
thee
group
accord
oh
level
defici
ngml
insuffici
ngml
suffici
ngml
result
vitamin
level
posit
correl
fat
free
mass
index
ffmi
skelet
muscl
mass
index
smi
appendicular
skelet
muscl
mass
index
asmi
copd
p
howev
pth
show
correl
asmi
p
logist
regress
vitamin
level
reveal
associ
ffmi
smi
asmi
show
lowest
p
valu
asmi
p
classifi
accord
vitamin
level
defici
group
preval
sarcopenia
higher
trend
accord
vitamin
level
p
use
multivari
logist
regress
analys
defici
group
sarcopenia
risk
increas
criteria
recommend
ewgsop
awg
asmi
p
p
conclus
find
suggest
low
vitamin
level
associ
decreas
skelet
muscl
mass
particularli
limb
muscl
dysfunct
may
risk
factor
sarcopenia
copd
purpos
recent
experiment
evid
show
extracellular
vesicl
ev
indoor
dust
induc
neurtrophil
pulmonari
inflamm
addit
igg
sensit
indoor
dust
ev
appear
correl
develop
asthma
copd
lung
cancer
irrespect
cigarett
smoke
studi
analyz
indoor
dust
dust
extracellular
vesicl
ev
microbiom
apart
hospit
also
evalu
whether
igg
sensit
bacteria
devriv
ev
risk
develop
asthma
copd
lung
cancer
method
apart
hospit
collect
summer
winter
dust
genom
dna
extract
dust
dust
ev
ribosom
dna
amplifi
use
univers
primer
sequenc
next
gener
sequenc
sequenc
data
analyz
use
bioinformat
serum
igg
antibodi
major
bacteria
deriv
ev
dust
measur
healthi
control
subject
asthma
copd
lung
cancer
patient
result
bacteria
bacteria
deriv
ev
differ
divers
commun
composit
data
suggest
composit
major
dust
microbiom
includ
pseudomona
acinetobact
enterococcu
staphylococcu
result
compar
bacteri
composit
pseudomona
domin
apart
summer
acinetobact
domin
hospit
winter
especi
winter
hospit
acinetobact
increas
remarl
divers
reduc
result
serum
igg
antibodi
major
bacteria
deriv
ev
dust
adjust
multipl
logist
regress
reveal
sensit
bacteria
deriv
ev
dust
independ
risk
factor
asthma
copd
lung
cancer
conclus
dust
microbiom
bacteria
bacteria
deriv
ev
mostli
compos
pseudomona
acinetobact
enterococcu
staphylococcu
igg
sensit
bacteria
deriv
ev
indoor
dust
appear
major
risk
develop
asthma
copd
lung
cancer
background
asthma
common
chronic
diseas
childhood
common
caus
hospit
children
samitivej
intern
children
hospit
smich
asthmat
children
age
less
year
old
hospit
due
acut
asthma
exacerb
one
need
picu
none
dead
clinic
care
program
deliv
integr
multidisciplinari
organ
care
plan
continu
qualiti
improv
hospit
system
consid
standard
care
asthmat
children
method
core
team
childhood
asthma
framework
set
includ
pediatr
allergist
pediatr
pulmonologist
gener
pediatrician
pediatr
nurs
opd
er
ward
includ
picu
pharmacist
smich
aim
provid
comprehens
clinic
care
program
childhood
asthma
ccpchildhood
asthma
enrol
children
diagnosi
asthma
acut
wheez
opder
evalu
consid
diagnosi
asthma
start
treatment
reevalu
clinic
asthma
control
everi
month
gina
guidelin
children
gener
pediatrician
pediatr
nurs
opd
er
ward
train
implement
clinic
pathway
initi
childhood
asthma
camp
provid
educ
diseas
parent
caregiv
togeth
workshop
inhal
medicin
use
self
assess
asthma
action
plan
environment
allergen
avoid
perform
measur
includ
administr
system
corticosteroid
hospit
within
hour
evalu
inhal
medicin
techniqu
use
correctli
visit
pulmonari
function
test
children
older
year
old
influenza
vaccin
annual
data
collect
analyz
yearli
result
patient
ccpchildhood
asthma
smich
enrol
children
year
children
year
number
hospit
asthma
exacerb
decreas
patient
year
patient
year
respect
patient
ccpchildhood
asthma
receiv
system
corticosteroid
within
hour
hospit
patient
admit
picu
patient
could
demonstr
inhal
drug
use
correctli
receiv
pulmonari
function
test
yearli
influenza
vaccin
rate
asthmat
children
increas
year
year
respect
ccpchildhood
asthma
accredit
joint
commiss
intern
jci
usa
august
first
clinic
care
program
outsid
usa
certifi
jci
conclus
care
children
asthma
chronic
diseas
burden
famili
need
comprehens
multidisciplinari
team
care
help
improv
qualiti
care
childhood
asthma
background
b
cell
interact
activ
helper
th
cell
stimul
small
b
cell
manner
direct
physiolog
contact
ligand
molecul
express
surfac
membran
activ
th
cell
stimul
b
cell
bind
bind
b
cell
activ
b
cell
prolifer
differenti
secret
immunoglobulin
igm
ige
presenc
lymphokin
method
femal
balbc
cbaj
mice
use
week
age
plasma
membran
prepar
mrna
transfect
baculoviru
cell
b
cell
incub
plasma
membran
variou
cytokin
round
bottom
well
plate
variou
period
time
b
cell
puls
harvest
check
dna
synthesi
b
cell
b
cell
cultur
supernat
assay
igm
ige
use
isotyp
specif
sandwich
elisa
result
kinet
b
cell
prolifer
b
cell
prolifer
peak
day
presenc
interleukin
il
immunoglobulin
synthesi
plasma
membran
activ
b
cell
secret
igm
ige
serial
presenc
type
lymphokin
igm
produc
second
day
third
day
ige
fifth
day
cultur
conclus
molecul
play
major
role
activ
b
cell
b
cell
interact
requir
prolifer
b
cell
induc
igm
isotyp
switch
secret
ige
dose
durat
reaction
antigen
cytokin
play
import
role
b
cell
prolifer
differenti
background
known
particip
induct
allerg
respons
purpos
studi
investig
effect
allergen
specif
immunotherapi
mous
model
allerg
rhiniti
method
sixweekold
femal
balbc
mice
divid
group
control
group
allerg
rhiniti
ar
group
immunotherapi
group
antibodi
ab
group
mice
except
control
group
sensit
ovalbumin
ova
aluminum
hydroxid
two
week
consecut
two
week
mice
except
control
group
ar
group
underw
immunotherapi
feed
ova
immunotherapi
mice
ab
group
inject
purifi
antimous
antibodi
sensit
mice
challeng
intranas
ova
allerg
symptom
eosinophil
nasal
mucosa
interleukin
il
tbet
ror
mrna
express
nasal
mucosa
serum
ovaspecif
ige
measur
result
serum
ovaspecif
ige
eosinophil
count
significantli
decreas
ab
group
compar
group
p
level
mrna
express
significantli
decreas
ab
group
compar
group
p
level
mrna
express
significantli
increas
ab
group
compar
group
p
level
mrna
express
significantli
increas
ab
group
compar
group
p
conclus
administr
antibodi
increas
induct
toler
mous
model
allerg
rhiniti
result
suggest
antibodi
immunomodulatori
effect
immun
toler
claim
applic
properti
enhanc
effici
allergenspecif
immunotherapi
object
fraction
concentr
exhal
nitric
oxid
feno
known
marker
airway
inflamm
aim
studi
evalu
feno
impuls
oscillometri
io
spirometri
preschool
children
investig
relationship
wheez
airway
hyperrespons
ahr
method
perform
populationbas
crosssect
studi
children
age
year
total
children
complet
modifi
intern
studi
asthma
allergi
childhood
isaac
questionnair
elig
studi
measur
feno
spirometri
methacholin
bronchial
provoc
io
ahr
defin
induct
decreas
methacholin
concentr
mgdl
result
children
wheez
ahr
higher
feno
level
children
without
symptom
howev
neither
io
spirometri
paramet
show
signific
differ
children
wheez
ahr
without
feno
associ
ahr
wherea
io
spirometri
paramet
show
associ
mean
feno
level
posit
correl
doserespons
slope
methacholin
neither
io
spirometri
paramet
show
signific
correl
conclus
feno
sensit
measur
ahr
wheez
spirometri
io
preschool
children
back
ground
hand
eczema
commonest
disord
afflict
hand
variou
morpholog
form
variabl
sever
emolli
barrier
cream
topic
steroid
known
effect
major
form
mainstay
treatment
sever
case
acut
phase
hand
eczema
system
treatment
help
among
system
therapi
cyclosporin
known
effect
respons
rate
remiss
period
recurr
rate
well
known
object
evalu
efficaci
system
cyclosporin
hand
eczema
patient
refractori
convent
therapi
method
patient
hand
eczema
chosen
among
patient
neg
patch
test
result
patient
never
diagnos
psoriasi
biopsi
patient
contraind
use
cyclosporin
exclud
respons
rate
evalu
patient
satisfact
dlqi
examin
physician
pga
observ
score
use
total
hand
eczema
sever
index
hecsi
result
total
patient
enrol
among
male
femal
averag
age
averag
diseas
durat
year
patient
hyperkeratot
subtyp
fissur
subtyp
pompholyx
subtyp
patient
finish
studi
medic
side
effect
dizzi
averag
initi
treatment
period
week
patient
clinic
subject
improv
week
initi
treatment
improv
dlqi
improv
pga
improv
hecsi
recur
occur
patient
within
month
discontinu
medic
averag
month
recur
rate
conclus
system
cyclosporin
effect
rel
safe
treatment
option
hand
eczema
patient
refractori
treatment
although
recur
quit
common
background
atop
dermat
ad
chronic
prurit
recurr
inflammatori
skin
disord
signific
caus
morbid
obes
shown
proinflammatori
immun
respons
leptin
adipokin
obes
gene
product
secret
adiposit
preval
childhood
obes
ad
increas
past
decad
associ
obes
ad
well
establish
method
total
subject
defin
ad
base
questionnair
survey
nineti
ad
children
age
year
complet
score
sever
ad
scorad
blood
test
serum
total
ige
blood
eosinophil
count
serum
eosinophil
cation
protein
ecp
lipid
profil
serum
level
adipokin
adiponectin
leptin
measur
result
signific
differ
term
age
bmi
percentag
breast
milk
feed
mode
deliveri
preval
atopi
boy
girl
atop
subject
nonatop
subject
lipid
profil
differ
boy
girl
atop
subject
nonatop
subject
regard
adipokin
serum
leptin
level
significantli
higher
girl
ngml
compar
boy
atop
subject
ngml
compar
nonatop
subject
signific
correl
scorad
index
serum
adiponectin
leptin
concentr
conclus
although
serum
leptin
level
significantli
higher
girl
nonatop
subject
scorad
index
correl
serum
lipid
profil
adipokin
level
lipid
profil
serum
adipokin
level
influenc
sever
ad
preadolesc
elementari
school
children
south
korea
background
object
antihistamin
leukotrien
receptor
antagonist
ltra
approv
treatment
allerg
rhiniti
base
allerg
rhiniti
impact
asthma
aria
guidelin
recent
studi
shown
combin
second
gener
antihistamin
montelukast
signific
improv
nasal
symptom
qualiti
life
patient
persist
allerg
rhiniti
recent
montelukast
levocetirin
combin
made
avail
singl
tablet
form
evalu
compar
individu
prepar
efficaci
control
symptom
patient
allerg
rhiniti
studi
aim
evalu
efficaci
levocetirizin
montelukast
combin
tablet
versu
individu
tablet
allevi
symptom
patient
moder
sever
persist
allerg
rhiniti
method
random
doubleblind
parallel
studi
patient
assign
arm
receiv
levocetirizin
mg
montelukast
mg
individu
tablet
receiv
levocetirizin
mg
plu
montelukast
mg
combin
tablet
symptom
score
use
specif
immunotherapi
questionnair
sitq
obtain
baselin
week
week
week
thereaft
treatment
result
patient
levocetirizin
montelukast
combin
tablet
signific
improv
nasal
symptom
score
eye
symptom
score
total
symptom
score
week
week
treatment
p
patient
given
levocetirizin
montelukast
individu
tablet
nasal
symptom
significantli
improv
week
treatment
howev
eye
symptom
score
total
symptom
score
significantli
improv
p
week
week
treatment
qualiti
life
qol
score
two
group
significantli
differ
week
treatment
given
combin
tablet
signific
improv
qol
baselin
p
compar
given
individu
tablet
mean
differ
symptom
score
individu
tablet
combin
tablet
montelukast
levocetirizin
show
signific
differ
p
conclus
treatment
combin
tablet
levocetirizin
montelukast
equal
efficaci
individu
prepar
control
nasal
symptom
eye
symptom
total
symptom
patient
moder
sever
persist
allerg
rhiniti
qualiti
life
score
howev
show
signific
improv
week
treatment
individu
tablet
despit
result
show
signific
mean
differ
compar
chang
qol
score
individu
prepar
levocetirizin
montelukast
background
lower
respiratori
tract
infect
children
often
accompani
wheez
treat
accord
bronchial
asthma
makyokansekito
herbal
cough
medicin
especi
children
asthma
common
among
pediatrician
japan
aim
studi
evalu
efficaci
makyokansekito
lower
respiratori
tract
infect
children
method
subject
sixtyeight
patient
boy
girl
hospit
wheez
lower
respiratori
tract
infect
bronchiti
bronchiol
pneumonia
april
march
median
age
subject
month
patient
treat
tsumura
makyokansekito
compar
patient
treat
without
retrospect
comparison
made
appropri
valu
p
consid
signific
result
makyokansekito
significantli
decreas
number
day
persist
wheez
median
vs
day
feed
humidifi
oxygen
median
vs
day
compar
control
differ
length
hospit
stay
side
effect
admit
conclus
makyokansekito
use
treatment
wheez
lower
respiratori
tract
infect
children
background
allerg
rhiniti
increas
steadili
recent
day
specif
marker
predict
risk
allerg
sensit
individu
serum
eosinophil
eosinophil
cation
protein
ecp
total
ige
tige
known
increas
patient
allerg
diseas
howev
clinic
signific
serolog
result
well
evalu
aim
investig
whether
serum
eosinophil
ecp
tige
associ
increas
risk
allerg
sensit
allerg
symptom
basi
year
followup
studi
method
serum
eosinophil
ecp
tige
measur
grade
student
elementari
school
skin
prick
test
perform
aeroallergen
commonli
found
korea
presenc
allerg
symptom
past
month
check
use
questionnair
studi
perform
grade
student
attend
school
cut
valu
use
serolog
marker
serum
eosinophil
ecp
tige
calcul
use
receiv
oper
characterist
curv
result
serum
eosinophil
fraction
cut
valu
associ
newli
develop
allerg
symptom
sensit
specif
odd
ratio
p
higher
serum
total
ige
cut
valu
iuml
also
associ
risk
allerg
sensit
sensit
specif
odd
ratio
p
conclus
serum
eosinophilia
total
ige
associ
futur
risk
allerg
symptom
allerg
sensit
respect
studi
need
elucid
predict
serum
eosinophil
tige
consid
futur
risk
allergi
background
mongolia
speci
plant
caus
allergi
speci
plant
identifi
allergen
famili
amaranthacea
chenopodiacea
sever
annual
speci
genu
salsola
notori
tumbleweedssalsola
tragu
socal
russian
thistl
last
year
mongolia
spread
allerg
diseas
among
adult
children
increas
notic
plant
russian
thistl
pollen
allergi
increas
sensit
russian
thistl
found
mani
countri
led
carri
studi
studi
made
depart
cell
biolog
biochemistri
school
pharmaci
biomedicin
mnum
effect
allergi
asthma
clinic
use
method
skin
prick
test
allergen
russian
thistl
allergi
laboratori
inc
usa
wheal
size
measur
mean
extrem
diamet
minut
prick
reaction
consid
posit
wheal
larger
neg
control
mm
basi
analysi
sensit
rate
russian
thistl
result
test
specif
activ
russian
thistl
kind
allergen
case
respiratori
allerg
anamnesi
allergi
case
case
age
rang
year
old
women
mensever
allergen
sensit
done
compar
averag
diamet
wheal
posit
result
result
divid
group
follow
mm
weak
middl
sever
sever
mean
diamet
wheal
sensit
russian
thistl
histamin
hydrochlorid
posit
control
skin
prick
test
calcul
peopl
sex
along
averag
diamet
wheal
allergen
sensit
russian
thistl
pollen
peopl
age
sever
sensit
sensit
sever
conclus
sensit
russian
thistl
mild
among
adult
subject
season
allerg
rhiniti
mongolia
background
preval
asthma
among
popul
differ
countri
world
mongolia
preval
asthma
ulaanbaatar
countrysid
villagesin
also
defin
preval
asthma
among
adult
popul
ulaanbaatarin
level
air
pollut
co
significantli
increas
air
ulaanbaatar
citi
last
decad
depend
cold
season
purpos
aim
studi
defin
associ
level
air
pollut
sensit
inhal
allergen
airway
hyperrespons
method
interview
questionnair
subject
use
skin
prick
test
differ
inhal
allergen
allergylab
usa
detect
allergen
specificig
immunoblot
rida
screen
rbiopharma
germani
lung
ventil
function
defin
fvc
pef
paramet
spiromet
test
spirostar
usb
medikro
oy
finland
metacholin
challeng
test
mct
done
step
nebul
spira
electro
dosimet
finland
mgml
methacholin
result
interview
averag
age
age
subject
asthma
symptom
normal
lung
function
spiromet
ci
subject
posit
result
mct
winter
season
air
pollut
co
patient
posit
result
mct
sever
moder
mild
chang
respect
subject
airway
hyperrespons
sensit
aeroallergen
strongli
sensit
mugwort
mean
size
wheal
weakli
sensit
dust
mite
anim
dander
mean
size
wheal
subject
high
level
allergenspecif
ige
mean
level
sera
peripher
blood
immunoblot
rida
screen
rbiopharma
germani
conclus
winter
season
coldest
highest
air
pollut
period
time
co
ulaanbaatar
becom
strongli
risk
factor
airway
hyperrespons
sensit
mugwort
grass
aeroallergen
level
pollut
relat
impact
lung
function
disord
airway
hyperrespons
background
asthma
heterogen
diseas
clinic
express
cours
also
respons
treatment
patient
clinic
stabl
current
therapi
substanti
part
asthma
popul
develop
exacerb
grass
pollen
season
purpos
studi
document
impact
grass
allergi
immunotherapi
tablet
ait
symptom
sever
patient
sever
allerg
rhiniti
sar
persist
allerg
asthma
paa
method
studi
includ
adult
age
yr
paa
sar
met
follow
inclus
two
sever
asthma
exacerb
requir
oral
corticosteroid
receiv
high
dose
ic
ug
beclomethazon
daili
equival
addit
control
medic
long
act
agonist
one
year
prior
screen
patient
examin
baselin
receiv
tablet
alk
sa
approxim
month
expect
start
grass
pollen
season
island
throughout
season
novemb
novemb
result
ait
significantli
reduc
score
baselin
ocular
nasal
symptom
reduct
also
seen
asthmat
score
improv
p
predict
valu
breathless
score
asthma
qualityoflif
aqlq
questionnair
score
improv
baselin
ait
final
visit
daili
activ
impair
sleep
impair
conclus
precoseason
treatment
ait
show
effect
symptom
control
sever
persist
allerg
asthma
symptom
comorbid
rhiniti
conjunct
decreas
object
obtain
peak
expiratori
flow
meter
rate
pefr
normal
valu
healthi
children
year
old
beij
urban
area
establish
predict
equat
pefr
children
also
compar
valu
pefr
measur
mini
wright
peak
flow
meter
peak
expiratori
flow
pef
measur
spirometri
method
healthi
school
children
boy
girl
age
year
old
chosen
kindergarten
primari
middl
school
beij
urban
area
use
peak
flow
meter
mini
wright
af
pari
compani
german
measur
peak
expiratori
flow
rate
record
gender
age
height
weight
physic
paramet
flowvolum
curv
carri
use
jaeger
spirometri
instrument
peak
expiratori
flow
pef
valu
adopt
differ
peak
expiratori
flow
valu
two
measur
compar
use
statist
softwar
stepwis
multipl
linear
regress
use
deriv
regress
equat
result
valu
pefr
increas
along
age
among
children
statist
signific
differ
differ
age
group
p
pefr
valu
boy
higher
girl
differ
male
femal
reach
signific
level
age
p
either
boy
girl
pefr
significantli
correl
age
height
weight
high
degre
correl
exist
height
age
weight
predict
equat
pefr
refer
valu
establish
children
year
old
live
beij
urban
area
follow
pefr
lmin
boy
pefr
lmin
girl
respect
pefr
valu
measur
peak
flow
meter
lmin
higher
measur
spirometri
lmin
differ
statist
signific
p
conclus
new
refer
valu
peak
expiratori
flow
rate
determin
predict
equat
built
children
year
old
beij
urban
area
provid
evid
clinic
manag
respiratori
diseas
background
fooddepend
exerciseinduc
anaphylaxi
fdeia
disord
exercis
follow
allergen
ingest
trigger
anaphylaxi
although
exercis
allergen
exposur
independ
toler
increas
number
report
case
anaphylaxi
due
soybean
fdeia
due
soybean
rare
disord
method
character
clinic
featur
year
old
boy
histori
walnut
allergi
develop
fdeia
due
tofu
soybean
product
patient
develop
anaphylaxi
run
physic
exercis
class
eat
tofu
present
symptom
cough
nasal
obstruct
gener
urticaria
loss
activ
cyanosi
symptom
improv
hour
treatment
loratadin
administ
epinephrin
order
detect
caus
allergen
food
cofactor
induc
symptom
fdeia
perform
specif
ige
test
skin
prick
test
isac
immunoblot
analysi
soybean
soybean
product
use
patient
serum
also
perform
provoc
test
ingest
tofu
follow
exercis
also
schedul
done
confirm
diagnosi
result
skin
prick
test
raw
soybean
product
tofu
fri
tofu
soy
milk
strongli
posit
level
serum
specif
ige
soybean
uaml
isac
phadia
uppsala
sweden
result
reveal
gli
gli
gli
isu
respect
year
half
later
specif
ige
soybean
gli
gli
gli
uaml
respect
patient
well
toler
soybean
product
absenc
exercis
follow
intak
soybean
product
immunoblot
analysi
soy
powder
patient
serum
show
posit
band
kilo
dalton
indic
presenc
specif
ige
storag
protein
gli
gli
conclus
result
suggest
strong
possibl
storag
protein
gli
gli
caus
allergen
fdeia
induc
soybean
tofu
background
preval
allerg
diseas
risen
last
year
mongolia
artemisia
speci
anemophil
genu
includ
composita
famili
wide
spread
mongolian
temper
climat
zone
pollen
variou
artemisia
vulgari
mugwort
one
main
caus
allerg
rhiniti
late
summer
autumn
mongolia
frequenc
sensit
approxim
adult
patient
sensit
plant
pollen
aim
determin
sensit
pollen
allergi
mugwort
lamb
quarter
method
research
done
depart
cellular
biolog
biochemistri
pharmaci
medicin
school
mnum
help
effect
allergi
asthma
hospit
studi
research
one
period
descript
research
done
studi
select
patient
diagnos
posit
pollen
allergen
skin
prick
test
group
chosen
airborn
allerg
patient
effect
allergi
asthma
hospit
censu
result
chosen
subject
sensit
pollen
allergen
case
age
rang
year
old
sex
ratio
women
men
ci
total
subject
sensit
allergen
differ
plant
pollen
averag
diamet
wheal
sensit
mugwort
artemisia
vulgari
lamb
quarter
posit
control
histamin
hydrochlorid
conclus
sensit
level
mugwort
increas
last
year
wheal
size
increas
year
year
allerg
rhiniti
ar
airway
hyperrespons
ahr
mucos
inflamm
diseas
mediat
igeassoci
process
characteris
sneez
nasal
congest
rhinorrhea
imbal
immun
respons
consid
contribut
allerg
diseas
howev
interv
inflamm
ahr
remain
unclear
grow
inform
illustr
nerv
growth
factor
ngf
neurotrophin
play
import
role
neuroimmun
interact
augment
exist
immun
respons
sinc
probiot
biocompat
watersolubl
chitosan
wsc
demonstr
antiinflammatori
properti
could
inhibit
develop
allerg
respons
aim
assess
effect
wsc
probiot
extract
ngf
dermatophagoid
pteronyssinu
der
p
induc
ar
murin
model
intranas
administr
wsc
probiot
extract
attenu
ahr
der
pchalleng
mice
due
lower
respiratori
resist
improv
nasal
congest
manifest
higher
respir
rate
nontreat
mice
manag
wsc
probiot
extract
thick
nasal
respiratori
epithelium
reduc
microscopi
wsc
probiot
extract
treatment
moder
allerg
inflamm
includ
decreas
level
total
der
pspecif
ige
serum
lower
express
nasal
lavag
fluid
well
less
eosinphil
infiltr
nasal
caviti
particular
therapeut
treatment
reduc
ngf
perform
nasal
lavag
fluid
along
receptor
trka
respiratori
epithelium
nasal
mucosa
der
pstimul
mice
suggest
reduc
ngf
receptor
level
may
correspond
decreas
ahr
mucosa
inflamm
wsc
probiot
extract
treatment
background
mimotop
short
peptid
mimick
epitop
potenti
mimotop
treatment
allergi
diseas
investig
method
mimotop
specif
epitop
major
shellfish
allergen
tropomyosin
identifi
screen
onebeadonecompound
oboc
peptid
librari
oboc
librari
chemic
synthet
librari
allow
high
throughput
screen
mimotop
quantit
estim
bind
affin
method
advantag
convent
phagedisplay
librari
allow
use
polyclon
antibodi
even
untreat
serum
sampl
mimicri
potenti
mimotop
valid
silico
vivo
analysi
investig
therapeut
potenti
mimotop
allergi
diseas
use
mous
model
shrimp
allergi
intragastr
gavag
tropomyosin
cholera
toxin
adjuv
follow
oral
challeng
splenocyt
prolifer
local
cytokin
express
jejunum
analyz
elucid
possibl
mechan
therapeut
effect
mimotop
result
twentyf
mimotop
specif
shrimp
tropomyosin
identifi
screen
oboc
peptid
librari
silico
analysi
reveal
six
cluster
mimotop
mimotop
cluster
share
least
three
ident
amino
acid
residu
posit
autom
epitop
map
tool
episearch
six
cluster
mimotop
could
map
six
epitop
region
shrimp
tropomyosin
five
ident
previou
report
epitop
one
mimotop
cluster
synthes
conjug
carrier
protein
keyhol
limpet
hemocyanin
klh
vivo
analysi
balbc
mice
immun
mimotopeklh
conjug
found
elev
level
tropomyosinspecif
igg
mice
immun
klh
alon
irrelev
mimotop
therapeut
potenti
mimotop
investig
use
balbc
mous
model
shrimp
allergi
sensit
mice
inject
mixtur
six
mimotopeklh
conjug
one
cluster
receiv
subsequ
oral
challeng
compar
control
mice
receiv
klh
alon
mimotopestr
mice
demonstr
suppress
splenocyt
prolifer
respons
tropomyosin
reduc
express
cytokin
jejunum
conclus
oboc
peptid
librari
use
tool
identifi
mimotop
allergen
multipl
epitop
mimotop
specif
tropomyosin
identifi
screen
oboc
librari
valid
silico
vivo
experi
mimotop
could
potenti
therapeut
candid
allergi
diseas
present
work
support
grant
research
grant
council
cuhk
health
medic
research
fund
hksar
govern
food
allergi
anaphylaxi
network
background
therapeut
educ
import
success
manag
atop
dermat
ad
provid
effect
therapeut
educ
common
misunderstand
demand
ad
among
patient
caregiv
need
review
method
questionnair
survey
cours
etiolog
manag
ad
conduct
patient
caregiv
visit
depart
dermatolog
seoul
nation
univers
hospit
seoul
korea
result
total
subject
particip
studi
subject
understood
natur
cours
ad
subject
awar
natur
cours
ad
usual
improv
age
mani
subject
misunderstood
relaps
ad
symptom
develop
toler
topic
steroid
subject
believ
enhanc
patient
immun
system
improv
symptom
ad
dietari
restrict
consid
essenti
manag
strategi
mani
agre
postpon
begin
wean
food
patient
ad
food
thought
associ
aggrav
ad
follow
order
instant
food
snack
egg
wheat
respect
subject
accur
inform
cleans
particular
subject
report
use
water
without
cleanser
agre
soap
made
natur
ingredi
use
avoid
harm
effect
chemic
substanc
subject
obtain
inform
ad
medic
doctor
consid
reliabl
sourc
subject
prefer
print
materi
seminar
videoclip
obtain
educ
content
conclus
studi
found
patient
caregiv
lot
misunderstand
ad
therapeut
educ
cours
etiolog
manag
ad
print
materi
made
physician
valuabl
effect
manag
ad
background
recommend
use
puff
puff
ug
salbutamol
bronchodil
respons
bdr
test
aim
compar
differ
two
dosag
regard
small
airway
dysfunct
method
subject
never
diagnos
asthma
consecut
enrol
june
novemb
base
subject
past
famili
histori
evalu
possibl
asthma
score
subject
scale
pre
asthma
score
subject
randomli
assign
bronchodil
test
two
dosag
without
physician
knowledg
perform
bdr
test
use
spirometr
impuls
oscillometr
lung
function
asthma
diagnosi
post
asthma
score
later
reevalu
bdr
test
result
total
subject
particip
studi
mean
age
year
number
particip
assign
puff
puff
respect
mean
age
puff
group
older
puff
group
bdr
test
statist
differ
pre
asthma
score
two
group
puff
vs
puff
bdr
test
post
asthma
score
two
group
respect
also
show
statist
signific
differ
two
group
pre
asthma
score
significantli
correl
forc
expiratori
volum
secforc
vital
capac
forc
expiratori
flow
fvc
reactanc
hz
z
score
howev
signific
differ
spirometr
paramet
resist
hz
impuls
oscillometri
system
io
valu
puff
group
puff
group
conclus
signific
relationship
amount
bronchodil
administ
small
airway
dysfunct
children
howev
show
signific
correl
physician
asthma
predict
score
object
studi
effect
natur
killert
nkt
lymphocyt
nkt
lymphocyt
level
peripher
blood
onset
children
asthma
method
asthmat
children
diagnos
treat
pediatr
depart
renmin
hospit
affili
wuhan
univers
jan
dec
select
asthmat
group
healthi
children
select
control
group
peripher
blood
mononuclear
cell
collect
use
densiti
gradient
centrifug
method
ratio
peripher
blood
nkt
cell
nkt
cell
measur
immunofluoresc
flow
cytometri
assay
relationship
nkt
cell
number
nkt
cell
total
ige
level
observ
level
peripher
blood
detect
enzymelink
immunosorb
assay
prolifer
respons
result
compar
control
group
ratio
nkt
cell
nkt
cell
peripher
blood
asthmat
group
significantli
decreas
p
p
signific
correl
nkt
cell
nkt
cell
total
ige
p
p
level
asthmat
group
higher
control
group
p
p
signific
differ
level
two
group
p
conclus
dysfunct
nkt
cell
nkt
cell
function
chang
cytokin
may
play
import
role
pathogenesi
asthma
background
nonsteroid
antiinflammatori
drug
nsaid
frequent
prescrib
class
drug
easili
access
overthecount
antiinflammatori
drug
singapor
nsaid
hypersensit
second
common
referr
allergi
clinic
tertiari
referr
centr
method
refer
patient
histori
nsaidinduc
urticari
angioedema
anaphylaxi
underw
open
challeng
put
nsaid
confirm
diagnosi
aspirin
determin
crossreact
select
inhibitor
identifi
suitabl
altern
data
analys
retrospect
result
period
patient
mean
sd
age
year
underw
total
openlabel
label
nsaid
oral
provoc
test
opt
patient
demograph
consist
femal
major
chines
ethnic
group
diclofenac
naproxen
two
commonest
report
culprit
nsaid
patient
elicit
nsaid
record
caus
hypersensit
reaction
howev
patient
report
toler
differ
group
nsaid
concomit
intoler
acetaminophen
urticaria
andor
angioedema
frequent
report
symptom
among
isol
periorbit
angioedema
reaction
involv
airway
ie
asthma
without
nasooccular
symptom
rare
anaphylaxi
report
patient
togeth
concomit
drug
breakdown
challeng
follow
put
nsaid
challeng
aspirin
challeng
select
inhibitor
challeng
overal
posit
challeng
rate
despit
clinic
relev
histori
caus
posit
opt
put
nsaid
aspirin
challeng
result
posit
challeng
henc
confirm
diagnosi
nsaid
intoler
use
select
inhibitor
challeng
found
posit
challeng
anaphylaxi
case
cautiou
opt
put
nsaid
done
patient
reaction
found
conclus
without
valid
skin
test
opt
help
evalu
nsaid
hypersensit
patient
patient
cohort
posit
opt
rate
confirm
diagnosi
nsaid
hypersensit
low
posit
opt
rate
select
inhibitor
use
altern
patient
purpos
bronchial
hyperrespons
bhr
key
featur
asthma
natur
cours
bhr
heterogen
divid
bhr
chang
pattern
differ
phenotyp
investig
characterist
risk
factor
longitudin
studi
method
total
male
femal
elementari
school
children
includ
cheer
children
health
environ
research
studi
issac
questionnair
serum
total
ige
level
blood
eosinophil
percentag
skin
prick
test
pulmonari
function
test
methacholin
challeng
test
done
age
baselin
age
year
follow
bhr
defin
provoc
concentr
decreas
mgm
divid
differ
phenotyp
bhr
chang
pattern
bhr
never
bhr
remiss
bhr
new
bhr
persist
multinomi
logist
regress
analysi
done
evalu
risk
factor
type
result
four
phenotyp
bhr
compos
bhr
never
bhr
remiss
bhr
new
bhr
persist
respect
parent
allerg
diseas
ci
asthma
ci
histori
age
year
risk
factor
bhr
remiss
group
atop
sensit
ci
age
year
risk
factor
bhr
new
group
eosinophil
percent
ci
logig
ci
atop
sensit
ci
age
year
risk
factor
bhr
persist
group
dp
sensit
risk
factor
bhr
new
group
age
year
ci
dp
df
sensit
risk
factor
bhr
persist
group
age
year
ci
ci
dfwa
addit
sensit
allergen
risk
factor
bhr
new
group
year
ci
grass
pollen
bhr
persist
group
year
ci
conclus
children
bhr
remiss
associ
famili
histori
asthma
low
sensit
age
year
children
bhr
new
show
high
sensit
normal
lung
function
low
eosinophil
age
yr
children
bhr
persist
associ
high
atop
condit
includ
high
eosinophil
high
ige
high
sensit
low
lung
function
age
yr
find
suggest
natur
cours
childhood
bhr
differ
phenotyp
predict
futur
prognosi
bhr
phenotyp
background
allerg
rhiniti
usual
thought
minor
irrit
diseas
caus
signific
morbid
rhiniti
character
chronic
recurr
sneez
runni
block
nose
pollen
fungi
anim
dander
hous
dust
mite
domest
pet
insect
particular
import
trigger
factor
object
studi
design
determin
whether
sensit
spectrum
allergen
use
skinprick
test
correl
symptom
sever
allerg
rhiniti
asthma
patient
materi
method
detail
histori
take
clinic
examin
carri
patient
ie
satisfi
inclus
criteria
includ
diagnost
nasal
smear
skin
prick
test
spt
allergen
select
spt
base
refer
pollen
calendar
bangalor
citi
creat
us
clue
patient
exposur
probabl
allergen
surround
result
studi
total
patient
overal
rate
sensitis
allergen
common
allergen
hous
dust
mite
hdm
preval
hous
dust
mite
found
mite
dpteronyssinu
sensit
toward
pollen
fungal
spore
respect
allerg
rhiniti
patient
persist
allerg
rhiniti
moderatesever
grade
intermitt
allerg
rhiniti
moderatesever
conclus
light
find
present
studi
conclud
appropri
prevent
strategi
decreas
cost
morbid
therapeut
measur
represent
spt
reactiv
hous
dust
mite
allergen
may
use
refer
counsel
patient
allerg
rhiniti
backgroud
object
asthma
common
chronic
diseas
childhood
well
known
associ
risk
factor
asthma
progress
children
wheez
aim
present
studi
investig
preval
wheez
risk
factor
predict
asthma
young
children
method
green
breath
children
gbc
korean
children
chungbuk
provinc
recruit
preschool
children
yr
age
annual
sinc
physic
examin
questionnair
allerg
respiratori
diseas
skin
prick
test
perform
result
among
children
complet
respons
questionnair
complet
data
avail
children
wheez
medic
histori
skin
prick
test
preval
wheez
found
incid
current
wheez
ill
within
one
year
declin
incid
aeroallergen
sensit
increas
age
year
old
year
old
two
hundr
sixti
nine
children
wheez
episod
among
children
year
old
among
children
current
wheez
ill
within
year
sensit
ah
ratio
grade
allerg
rhiniti
parent
asthma
significantli
higher
children
current
wheez
ill
diagnosi
allerg
rhiniti
parent
asthma
also
significantli
associ
logist
regress
conclus
high
preval
wheez
presenc
risk
factor
asthma
progress
especi
higher
sensit
rate
atop
dermat
preschool
children
need
quantit
measur
atop
statu
biolog
marker
monitor
discrimin
children
asthma
progress
among
preschool
children
wheez
primari
immunodefici
diseas
pid
heterogen
group
inherit
disord
character
defect
one
compon
immun
system
lead
varieti
clinic
manifest
particularli
recurr
sever
infect
autoimmun
lymphoprolifer
malign
pid
usual
present
one
follow
eight
characterist
clinic
present
recurr
upper
lower
respiratori
tract
infect
failur
thrive
ftt
earli
infanc
recurr
pyogen
infect
unusu
sever
infect
recurr
infect
type
pathogen
autoimmun
chronic
inflammatori
diseas
andor
lymphoprolifer
characterist
combin
clinic
featur
eponym
syndrom
number
characterist
present
angioedema
first
step
diagnost
process
start
clinic
screen
suspici
number
certain
pid
could
made
accord
clinic
phenotyp
use
limit
set
test
avail
hospit
includ
complet
blood
count
differenti
first
screen
pid
reliabl
perform
meanwhil
screen
laboratori
test
categori
defect
immun
system
need
consid
characterist
clinic
present
eg
immunoglobulin
assay
antibodi
defici
ap
ah
assay
complement
defici
recurr
sinopulmonari
infect
encapsul
organ
b
lymphocyt
subset
enumer
combin
immunodefici
ftt
earli
onset
sever
infect
chemotaxi
nitroblu
tetrazolium
nbt
dye
reduct
test
dihydrorhodamin
dhr
oxid
test
phagocyt
defect
recurr
pyogen
infect
note
elabor
test
includ
specif
antibodi
respons
protein
polysaccharid
antigen
lymphocyt
prolifer
test
advanc
immunophenotyp
random
migrat
phagocytosi
intracellular
microbi
kill
phagocyt
chemiluminesc
assay
perform
immunolog
laboratori
meanwhil
definit
diagnosi
pid
reli
genet
test
effect
helicobact
pylori
infect
atop
individu
background
role
helicobact
pylori
h
pylori
infect
aetiolog
atopi
remain
unclear
although
possibl
protect
role
hypothes
object
aim
studi
evalu
preval
h
pylori
atop
individu
method
conduct
retrospect
observ
crosssect
studi
includ
patient
age
year
total
serum
ige
immag
beckman
coulter
ireland
hpylori
igg
diapro
itali
measur
particip
use
nephelometr
method
elisa
respect
result
one
hundr
four
patient
includ
studi
avarag
age
patient
femal
averag
ige
measur
iuml
fiftytwo
patient
diagnos
allerg
diseas
accord
anamnesi
laboratori
result
skin
prick
test
h
pylori
infect
found
patient
allerg
diseas
hpylori
frequent
patient
allergi
unless
differ
statist
signific
chi
conclus
preval
allerg
disord
includ
asthma
atop
dermat
urticar
allerg
rhiniti
increas
preval
h
pylori
infect
decreas
previou
studi
invers
associ
observ
h
pylori
infect
mani
allerg
diseas
recent
wheez
allerg
rhiniti
dermat
eczema
rash
studi
hpylori
found
frequent
unless
differ
statist
signific
chi
background
chronic
urticaria
cu
last
week
longer
classifi
chronic
spontan
urticaria
csu
urticari
vascul
induc
physic
urticaria
caus
csu
identifi
approxim
patient
thirti
percent
adult
cu
achiev
remiss
year
onset
studi
investig
clinic
spectrum
natur
cours
cu
chines
children
identifi
possibl
predictor
diseas
remiss
method
singlecentr
retrospect
studi
identifi
patient
csu
year
age
follow
allergi
clinic
month
diseaserel
factor
occurr
urticaria
angioedema
anaphylaxi
well
famili
histori
environment
exposur
comorbid
allergi
immunolog
investig
drug
treatment
retriev
medic
record
patient
consid
remiss
symptomfre
month
natur
histori
cu
delin
kaplanmei
analysi
factor
associ
diseas
remiss
analys
logrank
statist
result
mean
sd
age
patient
baselin
year
male
follow
median
year
coexist
asthma
rhiniti
eczema
affect
patient
sixtyseven
percent
patient
atop
fortyseven
patient
urticari
episod
least
weekli
patient
urticaria
angioedema
patient
develop
anaphylaxi
one
respiratori
one
cardiorespiratori
persist
diseas
seventynin
patient
concomit
induc
urticaria
laboratori
investig
reveal
posit
antinuclear
antibodi
none
antithyroid
antibodi
circul
eosinophilia
increas
serum
total
ige
low
plasma
andor
level
fiftysix
patient
treat
nonsed
antihistamin
alon
combin
nonsed
antihistamin
antagonist
sixti
patient
remiss
median
year
diseas
onset
none
clinic
laboratori
paramet
associ
diseas
remiss
conclus
childhood
cu
gener
favour
prognosi
twothird
achiev
diseas
remiss
studi
identifi
clinic
laboratori
factor
resolut
cu
fund
direct
grant
research
cuhk
background
allerg
rhiniti
ar
preval
allerg
diseas
aeroallergen
play
major
role
pathogenesi
respiratori
allerg
diseas
like
ar
asthma
pollen
fungi
anim
dander
hous
dust
mite
domest
pet
insect
particular
import
common
trigger
object
main
object
studi
assess
sensit
common
pollen
allergen
patient
allerg
rhiniti
ar
patient
visit
ent
allergi
clinic
tertiari
care
hospit
urban
bangalor
materi
method
detail
histori
symptom
ar
clinic
examin
carri
patient
aria
classif
use
elucid
sever
ar
also
perform
nasal
smear
test
eosinophilia
skin
prick
test
result
patient
ar
patient
persist
ar
moderatesever
persist
ar
overal
rate
sensitis
allergen
preval
aeroallergen
sensit
found
parthenium
hysterophoru
amaranthu
spinosu
eucalyptu
cynodan
dactylon
follow
casuarina
equisetifolia
conclus
bangalor
high
preval
ar
success
treatment
condit
need
appropri
diagnosi
therefor
better
understand
aeroallergen
spectrum
sensit
pattern
background
season
variat
asthmarel
hospit
long
recogn
howev
littl
known
asthmarel
icu
admiss
identifi
season
trend
asthmarel
hospit
icu
admiss
may
allow
prevent
strategi
develop
method
analyz
nation
emerg
depart
inform
system
nedi
record
emerg
room
korea
patient
age
year
asthma
six
year
data
tabul
graph
show
season
trend
monthli
number
ed
visit
gener
ward
gw
icu
admiss
asthma
result
total
subject
found
male
femal
ratio
gw
admiss
percent
ed
visit
icu
admiss
monthli
number
ed
visit
gw
admiss
asthma
show
season
variabl
high
peak
fall
septemb
novemb
low
rate
summer
june
august
icu
admiss
howev
show
differ
peak
year
despit
find
icu
admiss
minimum
fall
percent
gener
ward
admiss
conclus
import
differ
season
pattern
ed
visit
gener
ward
gw
icu
admiss
asthma
combin
analysi
three
data
set
provid
new
perspect
epidemiolog
asthma
background
aim
studi
investig
preval
sever
atop
dermat
ad
analyz
associ
risk
factor
total
children
boy
girl
elementari
school
within
gyeonggido
south
korea
method
conduct
questionnair
survey
use
korean
version
intern
studi
asthma
allergi
childhood
isaac
questionnair
anthropometr
evalu
octob
novemb
ad
defin
exist
chronic
eczema
month
base
isaac
questionnair
scorad
score
atop
dermat
index
evalu
children
ad
children
divid
group
accord
scorad
index
mildtomoder
ad
scorad
index
sever
ad
scorad
index
skin
prick
test
allergen
blood
test
complet
children
ad
result
among
children
children
design
ad
one
hundr
nineti
children
mildtomoder
ad
children
sever
ad
preval
obes
bmi
ad
group
significantli
higher
nonad
group
proport
children
experienc
breast
milk
feed
month
ad
group
significantli
higher
nonad
group
signific
differ
ad
group
nonad
group
term
sex
age
bmi
histori
breast
milk
feed
ever
mode
deliveri
geometr
mean
rang
sd
blood
eosinophil
percentag
serum
eosinophil
cation
protein
concentr
sever
ad
group
significantli
higher
mildtomoder
ad
group
signific
differ
mildtomoder
ad
group
sever
ad
group
term
age
bmi
birth
weight
obes
mode
deliveri
histori
breast
milk
feed
ever
serum
hemoglobin
total
ige
concentr
risk
factor
ad
male
sex
aor
obes
aor
histori
breast
milk
feed
month
aor
atopi
skin
prick
test
allergen
observ
ad
group
children
major
children
reactiv
hous
dust
mite
follow
pollen
anim
dander
mold
food
allergen
conclus
preval
ad
gyeonggido
south
korea
similar
preval
recent
korean
nationwid
studi
male
sex
obes
histori
breast
milk
feed
month
independ
increas
risk
ad
background
recent
sever
clinic
trial
report
intralymphat
immunotherapi
ilit
allergen
includ
cat
dander
birch
grass
pollen
induc
toler
faster
convent
subcutan
immunotherapi
compar
durat
effect
inject
without
seriou
local
system
reaction
howev
efficaci
safeti
ilit
variou
allergen
allerg
rhiniti
still
remain
investig
evalu
efficaci
advers
effect
ilit
hous
dust
mite
cat
dog
allergi
patient
allerg
rhiniti
method
total
subject
allerg
rhiniti
sensit
dermatophagoid
farina
dermatophagoid
pteronyssinu
cat
andor
dog
allergen
treat
intralymphat
inguin
inject
causal
allergen
extract
hollistersti
new
orlean
usa
rhinoconjunct
qualiti
life
questionnair
rqlq
sinonas
outcom
test
rhiniti
symptom
exposur
causal
allergen
evalu
month
inject
ilit
result
rqlq
significantli
improv
month
ilit
rang
rang
rang
rang
respect
p
allergi
symptom
exposur
causal
allergen
includ
rhinorrhea
sneez
nasal
obstruct
itch
sensat
eye
nose
contact
skin
also
significantli
reduc
p
respect
five
subject
visit
hospit
month
inject
ilit
rhinorrhea
sneez
nasal
obstruct
exposur
causal
allergen
remain
allevi
also
p
observ
two
case
anaphylaxi
one
case
sever
cutan
erythema
edema
inject
site
ilit
conclus
ilit
rapidli
improv
allergi
symptom
daili
life
especi
provok
allergen
exposur
effect
last
year
howev
ilit
also
caus
sever
system
local
hypersensit
reaction
acknowledg
work
support
gachon
univers
gil
medic
center
grant
number
thank
thermofish
scientif
korea
support
measur
serum
total
allergenspecif
provid
allergen
extract
use
npt
also
appreci
research
center
standard
allerg
diseas
rcsad
yonsei
univers
support
grant
korea
healthcar
technolog
r
project
ministri
health
welfar
famili
affair
republ
korea
background
recent
studi
human
shown
product
induc
lung
rhinoviru
infect
jackson
howev
avail
data
character
express
infect
respiratori
virus
cell
type
produc
cytokin
aim
studi
evalu
effect
respiratori
syncyti
viru
rsv
infect
express
vivo
method
femal
balbc
mice
age
week
divid
group
first
group
intranas
infect
rsv
strain
second
group
receiv
uvinactiv
rsv
third
group
treat
pb
day
infect
airway
hyperrespons
ahr
methacholin
measur
wholebodi
plethysmographi
left
lung
remov
histolog
analysi
one
lobe
right
lung
taken
viral
rna
vrna
evalu
qpcr
lobe
use
prepar
cell
suspens
collagenas
digest
cell
suspens
stain
fluorophor
label
antibodi
determin
intracellular
express
cell
b
cell
cell
epitheli
cell
flow
cytometri
result
vrna
copi
number
lung
tissu
rsvinfect
anim
higher
mice
treat
inactiv
viru
ahr
inhal
methacholin
rsvinfect
anim
increas
compar
mice
treat
inactiv
viru
pb
histolog
analysi
reveal
presenc
inflamm
character
infiltr
lymphocyt
lung
tissu
rsvinfect
anim
data
indic
rsv
infect
mous
lung
express
lung
upregul
upon
rsv
infect
flow
cytometri
analysi
reveal
increas
percent
tcell
cell
respect
found
rsv
increas
fold
mean
fluoresc
intens
bcell
popul
addit
intracellular
protein
express
slightli
increas
epitheli
cell
conclus
result
provid
evid
upregul
b
rsvinfect
murin
lung
may
indic
import
role
virusinduc
lung
infect
studi
support
rsf
grant
background
preval
food
allergi
increas
worldwid
malaysia
food
allergi
preval
never
studi
preval
data
import
assess
burden
food
allergi
order
establish
requir
allergi
servic
object
aim
determin
preval
parentperceiv
food
hypersensit
malaysian
paediatr
popul
evalu
spectrum
clinic
manifest
allergen
involv
method
conduct
crosssect
parentquestionnair
survey
among
preschool
children
attend
outpati
gener
paediatr
clinic
evalu
associ
factor
hypersensit
reaction
food
result
total
children
includ
studi
eighti
parent
report
children
ever
hypersensit
reaction
food
major
food
allergen
shellfish
egg
cow
milk
dairi
product
peanut
reaction
multipl
food
report
children
commonli
report
symptom
hive
itchi
eczemat
skin
rash
chest
tight
wheez
signific
factor
associ
parentreport
food
hypersensit
histori
eczema
ci
allerg
conjunct
ci
children
sibl
food
allergi
ci
conclus
parent
percept
food
hypersensit
reaction
common
preschool
children
studi
larger
sampl
size
longer
durat
requir
determin
preval
food
allergi
malaysia
background
chitin
polym
nacetylbdglucosamin
found
variou
organ
hous
dust
mite
gener
chitin
appli
medic
materi
known
induc
immun
respons
howev
accord
recent
report
chitin
induc
innat
adapt
immun
respons
point
postul
hdm
chitin
induc
immun
respons
exact
effect
mechan
unknown
object
evalu
immunolog
side
develop
airway
inflamm
induc
sensit
allergen
plu
hous
dust
mite
deriv
chitin
method
induc
airway
inflamm
hdm
deriv
chitin
weeksold
mice
administr
intranas
four
time
ovalbomin
ova
hdm
chitin
challeng
intranas
time
ova
day
lung
inflamm
immunolog
paramet
evalu
h
final
allergen
challeng
h
allergen
challeng
day
respect
result
intranas
administr
hdm
hous
dust
mite
induc
domin
mix
airway
inflamm
chitinas
treatment
induc
downregul
immun
respons
refin
hdm
chitin
allergen
sensit
upregul
product
cytokin
dominantli
chitinas
treatment
show
similar
manner
hdm
treatment
result
immun
respons
mediat
known
receptor
chitin
recognit
macrophag
deriv
tnfa
nkt
cell
conclus
find
indic
airway
inflamm
sensit
hdm
deriv
chitin
induc
domin
immun
respons
mainli
depend
tnfa
produc
macrophag
cell
nkt
cell
background
inhal
allergen
sensit
major
risk
factor
allerg
diseas
larg
influenc
live
environ
despit
substanti
geograph
variat
allergen
sensit
literatur
comprehens
studi
still
lack
korean
adult
object
aim
investig
recent
pattern
inhal
allergen
sensit
among
korean
adult
patient
suspect
histori
respiratori
allergi
also
examin
geograph
variat
sensit
profil
korea
method
total
patient
record
retriev
retrospect
analysi
referr
allergist
clinic
differ
region
inclus
criteria
korean
adult
year
old
underw
inhal
allergen
skin
prick
test
suspect
histori
respiratori
allergi
primari
outcom
detail
profil
inhal
allergen
sensit
sensit
allergen
defin
allergentohistamin
wheal
ratio
demograph
clinic
inform
residenti
area
particip
also
collect
region
sensit
profil
individu
allergen
calcul
adjust
age
sex
metaanalyz
region
sensit
profil
estim
overal
atopi
individu
allergen
sensit
profil
gener
geograph
variat
sensit
allergen
group
statist
compar
use
cochran
q
result
overal
preval
atopi
ci
overal
der
f
der
p
commonli
sensit
allergen
respect
follow
cat
birch
hazel
alder
mugwort
beech
oak
tyrophagu
putrescentia
ten
common
inhal
allergen
similar
region
howev
jeju
among
common
allergen
differ
region
sensit
japanes
cedar
rye
velvet
kentucki
timothi
vernal
grass
preval
jeju
accord
allergen
group
geograph
heterogen
highest
outdoor
mold
cockroach
sensit
anim
weed
mite
show
less
depend
locat
sensit
pollen
earli
midbloom
tree
significantli
high
gangwon
gyeongbuk
busan
conclus
overal
common
inhal
allergen
der
p
der
f
cat
birch
hazel
alder
mugwort
beech
oak
tyrophagu
putrescentia
sensit
inhal
allergen
show
geograph
variat
particularli
jeju
studi
largest
scale
conduct
far
aeroallergen
sensit
korean
adult
hope
find
could
contribut
establish
skin
prick
test
panel
use
clinic
practic
epidemiolog
survey
background
purpos
studi
develop
mous
model
asthma
mma
use
hous
dust
mite
dermatophagoid
pteronyssinu
der
p
extract
method
balbc
mice
ip
immun
differ
dose
der
p
lyophil
extract
three
time
three
week
interv
mixtur
al
oh
week
final
immun
mice
challeng
der
p
five
consecut
day
intranas
applic
ina
aerosol
administr
aa
mice
divid
experiment
group
group
immun
der
p
protein
equival
mixtur
mgmous
al
oh
challeng
ina
group
immun
way
challeng
aa
group
immun
der
p
mixtur
mgmous
al
oh
challeng
ina
group
immun
way
challeng
aa
group
neg
control
immun
challeng
salin
hour
last
challeng
airway
hyperrespons
ahr
differ
concentr
methacholin
evalu
group
wholebodi
plethysmographi
hour
last
challeng
group
blood
collect
differenti
cell
count
brochoalveolar
lavag
fluid
balf
sampl
determin
inflammatori
cell
lung
remov
histolog
analysi
histopatholog
chang
grade
accord
semiquantit
score
system
serum
antid
p
ige
antibodi
detect
elisa
seven
day
last
immun
hour
challeng
result
highest
level
serum
der
pspecif
ige
antibodi
observ
group
level
der
pspecif
serum
antibodi
group
significantli
higher
experiment
group
maximum
ahr
observ
group
challeng
ina
analysi
cell
composit
balf
demonstr
elev
number
basophil
group
comparison
experiment
group
signific
differ
peripher
blood
cell
count
observ
among
experiment
group
histolog
pictur
allerg
inflamm
lung
peribronchi
perivascular
infiltr
inflammatori
cell
express
accord
score
system
group
comparison
experiment
group
conclus
data
obtain
indic
sensit
der
p
dose
togeth
al
oh
challeng
der
p
ina
suitabl
approach
model
mous
allerg
asthma
background
pneumonia
one
common
caus
communityacquir
pneumonia
children
clinic
cours
small
portion
seriou
mechan
sever
pulmonari
complic
pneumonia
pneumonia
clear
exagger
immun
reaction
may
play
major
role
destruct
lung
tissu
method
two
patient
sever
respiratori
symptom
sign
high
fever
blood
test
inflammatori
reactant
test
serolog
test
perform
mycoplasma
pneumonia
confirm
posit
igm
also
rise
titer
igg
antibodi
pneumonia
cold
agglutinin
four
time
later
chest
radiograph
comput
tomographi
ct
scan
check
serial
result
one
case
necrot
pneumonia
protract
clinic
cours
high
fever
moder
respiratori
distress
despit
appropri
antibiot
therapi
chest
ct
scan
reveal
profound
lung
tissu
destruct
right
middl
lobe
month
intens
antibiot
therapi
final
recov
complet
without
sequela
case
bronchiol
obliter
show
patch
infiltr
right
middl
lobe
mycoplasma
pneumonia
effect
treat
appropri
antibiot
month
discharg
chest
ct
scan
show
segment
consolid
right
middl
lobe
bronchial
wall
thicken
hyperluc
recurr
pneumonia
clinic
right
lung
lesion
progress
collaps
total
call
destroy
lung
till
year
infect
year
follow
chest
ct
scan
stationari
without
clinic
problem
conclus
report
two
case
necrot
pneumonia
bronchiol
obliter
follow
destroy
lung
mycoplasma
pneumonia
pneumonia
background
effect
educ
tool
implement
strategi
import
dissemin
guidelin
develop
computerbas
interact
educ
program
asthma
guidelin
name
virtual
learn
center
asthma
manag
evalu
use
term
improv
awar
user
satisfact
method
physician
enrol
six
tertiari
hospit
util
interact
educ
program
learn
asthma
manag
guidelin
compar
awar
asthma
guidelin
util
program
investig
user
satisfact
questionnair
survey
result
mean
age
studi
subject
subject
male
total
score
awar
asthma
guidelin
significantli
improv
p
categori
awar
includ
knowledg
attitud
practic
improv
significantli
learn
program
p
satisfact
user
high
aspect
use
conveni
interest
improv
understand
guidelin
elev
confid
use
section
program
virtual
cyber
manag
asthma
patient
conclus
interact
educ
program
use
effect
tool
dissemin
asthma
guidelin
background
hous
dust
mite
hdm
well
known
organ
sourc
major
allergen
besid
hdm
also
possess
bacteria
digest
system
also
found
fece
hdm
accord
recent
studi
bacteria
abl
secret
small
circular
vesicl
contain
divers
molecul
origin
bacteria
addit
administr
vesicl
specif
bacteria
induc
airway
inflamm
tissu
destruct
point
hypothes
hdm
deriv
vesicl
play
import
role
develop
airway
inflamm
object
evalu
role
hdm
deriv
vesicl
develop
airway
inflamm
defin
origin
method
induc
airway
inflamm
hdm
weeksold
mice
administr
intranas
four
time
hdm
challeng
intranas
time
day
lung
inflamm
immunolog
paramet
evalu
h
final
allergen
challeng
h
allergen
challeng
day
respect
case
hdm
deriv
ev
administr
weeksold
mice
administr
intranas
four
time
ovalbomin
ova
hdm
ev
challeng
intranas
time
ova
day
especi
polymyxyn
b
treatment
done
simultan
intranas
sensit
result
hdm
induc
domin
mix
inflamm
airway
contain
bacteria
addit
vesicl
also
identifi
hdm
possibl
induc
immun
respons
macrophag
epitheli
cell
side
abil
induc
inflamm
hdm
deriv
vesicl
induc
airway
inflamm
potenti
compar
free
lp
solubl
portion
immun
respons
mediat
lp
recognit
sourc
gram
neg
bacteria
hdm
conclus
find
show
hdm
deriv
vesicl
induc
airway
inflamm
potenti
via
recognit
lp
deriv
gram
neg
bacteria
dust
mite
background
studi
evalu
whether
allergi
patient
chang
recognit
causal
allergen
avoid
allergen
specif
immunotherapi
sit
diagnosi
treatment
diseas
rel
rare
object
studi
evalu
chang
skin
prick
test
intraderm
test
sptidt
nasal
provoc
test
npt
allergenspecif
intralymphat
immunotherapi
ilit
causal
allergen
among
patient
allerg
rhiniti
method
inform
consent
nine
subject
allerg
rhiniti
allergen
includ
farina
pteronyssinu
cat
hair
dog
hairdand
proven
provok
rhiniti
symptom
histori
take
skin
prick
test
measur
serum
specif
ige
ask
respond
follow
question
agre
allergen
provok
allerg
symptom
daili
life
agre
allergen
avoid
reduc
allerg
symptom
agre
allergen
specif
immunotherapi
reduc
allerg
symptom
thereaft
underw
sptidt
npt
ilit
causal
allergen
repeatedli
ask
respond
question
immedi
sptidt
npt
well
month
ilit
result
agreement
allergen
provok
allerg
symptom
daili
life
chang
sptidt
npt
month
ilit
month
ilit
agreement
allergen
avoid
reduc
allerg
symptom
chang
sptidt
npt
month
ilit
month
ilit
agreement
allergen
specif
immunotherapi
reduc
allerg
symptom
chang
sptidt
npt
month
ilit
month
ilit
conclus
allergi
skin
test
nasal
provoc
sit
intensifi
patient
recognit
causal
allergen
avoid
allergenspecif
immunotherapi
acknowledg
work
support
gachon
univers
gil
medic
center
grant
number
thank
thermofish
scientif
korea
support
measur
serum
total
allergenspecif
provid
allergen
extract
use
npt
also
appreci
research
center
standard
allerg
diseas
rcsad
yonsei
univers
support
grant
korea
healthcar
technolog
r
project
ministri
health
welfar
famili
affair
republ
korea
introduct
diagnosi
staphylococc
sensit
wide
use
immunolog
reaction
reaction
leucocytoli
rll
reaction
inhibit
leucocyt
migrat
riml
reaction
blast
transform
lymphocyt
rbtl
etc
howev
method
timeconsum
riml
rbtl
insuffici
inform
rll
object
develop
simpl
reliabl
method
diagnosi
staphylococc
sensit
vitro
materi
total
survey
patient
odontogen
urolog
staphylococc
infect
confirm
bacteriolog
analysi
control
group
consist
healthi
person
identifi
staphylococc
infect
month
diagnost
staphylococcu
sensit
use
authori
methodolog
get
name
mesr
test
blood
inspect
mix
staphylococcu
antigen
standard
capillari
panchenkov
incub
hour
room
temperatur
increas
result
reaction
higher
comparison
control
reaction
mesr
without
antigen
diagnos
bacteri
sensit
result
discuss
result
mesr
compar
result
riml
posit
result
mesr
riml
detect
respect
control
group
posit
result
observ
conclus
propos
simpl
reliabl
method
laboratori
diagnost
use
detect
sensit
staphylococc
infect
oral
maxillofaci
surgeri
otolaryngolog
urolog
other
background
although
peripher
blood
neutrophil
recent
shown
increas
allerg
asthmat
subject
mediat
mechan
regul
increas
neutrophil
deriv
asthma
properli
investig
along
cytokin
import
promot
cell
differenti
toward
cell
lineag
releas
cytokin
studi
explor
possibl
cytokin
may
activ
peripher
blood
neutrophil
asthmat
patient
releas
cytokin
postul
respons
stimul
could
differ
neutrophil
nonasthmat
subject
method
peripher
blood
neutrophil
isol
asthmat
well
healthi
control
stimul
cytokin
level
gene
well
protein
express
cytokin
determin
use
rtpcr
flow
cytometri
respect
addit
investig
mechan
induc
releas
level
phosphoryl
neutrophil
determin
follow
stimul
cytokin
result
induc
product
cytokin
within
peripher
blood
neutrophil
interestingli
level
induc
cytokin
significantli
higher
asthmat
compar
healthi
control
neutrophil
phosphoryl
requir
induct
within
neutrophil
suggest
pathway
involv
critic
regul
induc
product
neutrophil
conclus
regulatori
cytokin
induc
product
proinflammatori
cytokin
neutrophil
much
higher
level
asthma
environ
high
level
could
stimul
neutrophil
produc
highli
reactiv
oxygen
radic
would
exacerb
airway
inflammatori
respons
asthma
via
cytotox
tissuedestruct
activ
object
avoid
trigger
allergen
major
treatment
allerg
rhiniti
evalu
trigger
allergen
import
treatment
prevent
allergi
howev
correl
clinic
symptom
mast
total
ige
clearli
identifi
studi
compar
serum
total
ige
mast
allerg
symptom
allerg
patient
analyz
diagnost
valu
serum
total
ige
also
analyz
cut
valu
serum
total
ige
predict
posit
allergen
specif
ige
use
sum
squar
estim
recent
propos
froud
et
al
method
total
patient
allerg
symptom
underw
mast
serum
total
ige
test
panel
evalu
mast
allergen
result
greater
class
iuml
consid
posit
analyz
result
serum
total
ige
clinic
symptom
total
nasal
score
tn
evalu
sum
nasal
symptom
rhinorrhea
nasal
obstruct
sneez
itch
sens
patient
divid
high
iuml
low
iuml
group
total
serum
ige
level
posit
rate
number
posit
allergen
specif
ige
evalu
group
furthermor
calcul
cut
valu
serum
total
ige
predict
posit
allergen
specif
ige
result
nasal
obstruct
turn
common
symptom
total
score
tn
show
signific
correl
serum
total
ige
quantiti
high
total
serum
ige
group
show
significantli
higher
posit
rate
number
posit
allergen
specif
ige
mast
p
number
allergen
specif
ige
show
good
correl
serum
total
ige
p
use
roc
curv
cut
valu
serum
total
ige
comput
iuml
sensit
specif
due
low
sensit
analyz
posit
predict
valu
serum
total
ige
divid
group
suggest
iuml
predict
conclus
serum
total
ige
appear
use
predict
posit
result
allergen
specif
ige
mast
also
serum
total
ige
level
iuml
turn
reliabl
recommend
mast
background
respons
bronchodil
asthma
diagnosi
gener
defin
increas
ml
baselin
bronchodil
howev
increas
fvc
ml
baselin
due
increas
expiratori
time
bronchodil
could
also
mean
bronchodil
evalu
diagnost
valu
andor
fvc
bronchodil
respons
method
patient
perform
methacholin
challeng
test
pulmonari
function
test
bronchodil
suspect
asthma
select
result
test
order
commun
system
review
diagnost
criteria
asthma
defin
one
follow
provoc
concentr
methacholin
caus
fall
baselin
extrapol
equal
mgml
criterion
increas
ml
baselin
salbutamol
criterion
increas
ml
baselin
antiinflammatori
treatment
variat
ml
visit
within
year
least
criterion
andor
fvc
bronchodil
respons
defin
increas
andor
fvc
ml
baselin
salbutamol
sensit
specif
andor
fvc
bronchodil
respons
asthma
diagnosi
calcul
result
total
pulmonari
function
test
salbutamol
methacholin
challeng
test
patient
year
old
analyz
diagnost
criteria
asthma
satisfi
patient
among
number
patient
met
criterion
criterion
criterion
criterion
among
pulmonari
function
test
asthma
patient
sensit
test
show
posit
andor
fvc
bronchodil
respons
sensit
test
show
posit
bronchodil
respons
fals
posit
result
andor
fvc
bronchodil
respons
shown
pulmonari
function
test
patient
without
asthma
specif
fals
posit
result
shown
differ
patient
among
patient
real
asthma
patient
accord
result
pulmonari
function
test
evalu
studi
patient
histori
asthma
conclus
increas
andor
fvc
ml
baselin
bronchodil
could
also
diagnost
valu
asthma
background
aim
present
studi
see
whether
measur
bronchodil
respons
bdr
fraction
exhal
nitric
oxid
feno
combin
inform
upcom
loss
asthma
control
among
children
atop
asthma
method
two
hundr
one
patient
age
year
atop
asthma
recruit
pulmonari
function
test
includ
bdr
feno
serial
measur
time
year
subject
receiv
control
medic
complet
monitor
observ
loss
asthma
control
perform
result
least
posit
bdr
improv
respons
inhal
shortact
high
maximum
feno
mfeno
part
per
billion
ppb
confirm
observ
period
studi
particip
differ
feno
level
individu
posit
neg
bdr
risk
asthma
control
loss
increas
patient
mfeno
ppb
hazard
ratio
hr
p
posit
bdr
hr
p
risk
asthma
control
loss
greatest
patient
either
hr
p
posit
bdr
mfeno
ppb
hr
p
conclus
high
feno
better
abl
predict
upcom
loss
asthma
control
bdr
use
marker
togeth
provid
better
indic
asthma
control
loss
purpos
iga
antibodi
massiv
produc
intestin
peyer
patch
secretori
iga
siga
play
import
role
immun
respons
consid
siga
regul
caus
allerg
reaction
relationship
iga
level
allerg
reaction
fulli
understood
studi
siga
level
antigenspecif
iga
level
allerg
children
studi
relationship
allergi
symptom
method
retrospect
studi
use
medic
record
infant
month
year
old
present
hospit
evalu
allergi
classifi
group
accord
result
physic
examin
without
allerg
symptom
eczema
wheez
food
allergi
addit
investig
white
blood
cell
count
eosinophil
basophil
serum
level
total
ige
antigenspecif
ige
total
iga
siga
antigenspecif
iga
result
children
low
level
siga
past
histori
atop
dermat
serum
level
antigenspecif
ige
significantli
higher
serum
iga
level
significantli
lower
compar
children
allerg
symptom
serum
level
antigenspecif
iga
significantli
lower
allerg
children
especi
ovomucoid
specif
iga
level
low
children
ovalbumin
allergi
conclus
secretori
iga
level
import
onset
allerg
reaction
antigenspecif
iga
might
play
import
role
allerg
reaction
ige
antibodi
contribut
immedi
type
allerg
reaction
presenc
specif
antibodi
evid
diagnosi
allerg
reaction
moreov
suggest
measur
siga
antigenspecif
iga
also
use
predict
allerg
reaction
background
anaphylact
shock
life
threaten
circumst
requir
urgent
proper
medic
manag
epinephrin
firstlin
lifesav
medic
acut
manag
delay
make
accur
diagnosi
initi
appropri
treatment
inappropri
use
epinephrin
lead
death
object
studi
design
evalu
emphas
paramount
import
traine
knowledg
anaphylaxi
treatment
method
lifesav
medic
rout
administr
dosag
aim
bridg
gap
knowledg
real
life
practic
enabl
traine
act
undoubt
face
patient
anaphylaxi
method
crosssect
two
phase
questionnair
base
survey
hamad
gener
hospit
pediatr
depart
tertiari
hospit
qatar
result
phase
questionnair
distribut
traine
respons
respons
femal
male
traine
report
know
treat
total
claim
train
epinephrin
select
life
save
drug
im
rout
administr
select
correct
epinephrin
concentr
known
phase
questionnair
distribut
traine
respond
stage
respons
rate
claim
heard
epinephrin
autoinjector
fellow
claim
never
heard
claim
know
use
know
fellow
anaphylaxi
case
use
know
right
locat
method
inject
sub
cutan
inject
select
conclus
although
prompt
treatment
epinephrin
deem
critic
import
surviv
anaphylaxi
huge
gap
theoret
knowledg
epinephrin
concentr
site
administr
epinephrin
fundament
practic
among
pediatr
traine
analysi
data
necessit
urgent
need
concret
program
teach
traine
especi
pediatr
fellow
solidifi
knowledg
anaphylaxi
import
practic
guidelin
site
administr
concentr
act
fast
face
anaphylaxi
need
taught
current
futur
traine
background
evid
demonstr
exist
local
allerg
rhiniti
lar
nonatop
patient
although
preval
rhiniti
popul
remain
unknown
children
aim
studi
evalu
preval
clinic
characterist
sever
lar
children
compar
patient
classic
allerg
rhiniti
ar
system
atopi
nonallerg
rhiniti
nar
sensit
inhal
allergen
test
method
two
hundredeighteen
children
month
year
old
enrol
divid
group
ar
children
nar
healthi
control
clinic
questionnair
skin
prick
test
spt
evalu
nasal
allergen
provoc
test
npt
dermatophagoid
pteronyssinu
perform
subject
sever
ocular
nasal
symptom
record
visual
analogu
scale
va
cm
symptom
categor
mild
va
cm
moder
va
cm
sever
va
cm
result
ar
group
patient
present
posit
respons
npt
nar
group
patient
posit
respons
npt
npt
neg
healthi
control
major
rhiniti
patient
nasal
symptom
lar
ar
subject
similar
pattern
nasal
symptom
frequenc
sever
howev
signific
differ
detect
lar
nar
conclus
local
allerg
rhiniti
preval
entiti
patient
evalu
rhiniti
lar
ar
subject
similar
pattern
nasal
symptom
frequenc
sever
convent
skin
test
significantli
well
correl
nasal
provoc
test
background
role
allergen
immunotherapi
ait
treatment
patient
atop
dermat
ad
quit
controversi
sinc
efficaci
poorli
investig
past
year
eczema
exacerb
report
follow
ait
investig
toler
hypoallergen
ait
benefit
eczema
influenc
progress
allerg
diseas
method
studi
includ
patient
sever
ad
scorad
monosensit
hous
dust
mite
hdm
without
diagnost
criteria
rhiniti
asthma
food
allergi
baselin
subject
treat
continu
way
year
sublingu
tablet
carbamyl
monomer
allergoid
extract
hdm
auweek
compar
subject
treat
cetirizin
daili
topic
short
cours
oral
steroid
demand
allow
count
main
endpoint
chang
scorad
score
differ
timepoint
year
ait
discontinu
addit
assess
diseas
progress
data
respiratori
symptom
relat
medic
collect
mite
exposit
period
lung
function
bronchial
hypereact
nasal
eosinophil
onset
new
sensit
occurr
local
system
advers
reaction
regist
result
system
seriou
reaction
occur
year
adher
ait
regimen
good
till
end
treatment
period
subject
ait
group
control
group
reach
final
observ
year
baselin
mean
scorad
index
ait
group
decreas
control
group
use
topic
corticosteroid
halv
ait
group
vs
control
group
use
oral
corticosteroid
decreas
ait
group
patient
ait
group
develop
rhiniti
asthma
control
group
develop
rhiniti
asthma
requir
regular
pharmacotherapi
patient
ait
group
develop
new
sensit
wherea
control
result
polysensit
conclus
ait
tablet
hdm
carbamyl
monomer
allergoid
well
toler
provid
sustain
long
last
partial
improv
sever
atop
eczema
remark
reduct
use
corticosteroid
prevent
effect
progress
respiratori
allergi
onset
new
allerg
sensit
object
explor
level
correl
food
sigg
antibodi
serum
patient
allerg
diseas
method
use
elisa
detect
kind
sigg
antibodi
patient
allerg
diseas
first
affili
hospit
guangzhou
medic
univers
diagnosi
differenti
diagnosi
data
analyz
statist
softwar
result
posit
rate
ten
kind
food
sigg
antibodi
high
low
milk
dairi
product
crustacean
meat
egg
legum
fish
other
veget
nut
oilse
cereal
lowest
fruit
highest
posit
rate
food
egg
follow
white
soft
chees
cow
milk
year
old
group
lead
kind
posit
rate
food
milk
dairi
product
decreas
age
year
old
group
posit
rate
biggest
chang
ten
categori
food
accord
age
except
year
old
group
posit
rate
cow
milk
sigg
higher
goat
milk
sigg
p
posit
tate
crustacean
increas
age
group
scallop
lead
food
crustacean
old
group
posit
rate
respect
lead
food
cereal
sesam
group
other
food
lea
food
sugar
posit
rate
old
old
old
group
lead
food
coffe
year
old
group
lead
food
tobacco
year
old
group
posit
rate
sigg
antibodi
differ
categori
food
statist
differ
gender
year
old
group
posit
rate
cereal
fruit
veget
male
higher
femal
year
old
group
posit
rate
veget
crustacean
male
higher
femal
year
old
group
posit
rate
veget
femal
higher
male
old
group
posit
rate
cereal
nut
oilse
veget
milk
dairi
product
fish
male
higher
femal
lot
food
sigg
antibodi
level
associ
coupl
food
highli
correl
includ
coupl
veget
coupl
fruit
veget
conclus
certain
distribut
characterist
kind
food
sigg
antibodi
differ
age
gender
clinic
diagnosi
combin
sex
dietari
habit
factor
make
guidanc
reason
patient
diet
adjust
background
osteopontin
opn
pleomorph
cytokin
known
influenc
rang
immun
cell
includ
macrophag
neutrophil
dendrit
cell
b
cell
high
opn
level
associ
significantli
increas
risk
autoimmun
lymphoprolif
syndrom
multipl
sclerosi
system
lupu
erythematosu
suggest
opn
candid
biomark
condit
present
crosssect
studi
aim
verifi
serum
level
opn
may
qualifi
biomark
activ
immun
respons
allerg
patient
b
method
serum
opn
level
measur
enzymelink
immunosorb
assay
elisa
human
osteopontin
duoset
r
system
seri
adult
patient
median
age
femal
year
male
year
differ
allerg
diseas
studi
patient
allerg
rhinoconjunct
asthma
hymenoptera
venom
allergi
allerg
contact
dermat
food
allergi
igemedi
hypersensit
betalactam
healthi
subject
similar
demograph
characterist
serv
control
data
analyz
compar
case
control
well
look
subgroup
differ
within
group
allerg
patient
c
result
opn
serum
level
significantli
higher
case
comparison
control
median
pgml
interquartil
rang
pgml
vs
pgml
interquartil
rang
pgml
p
mannwhitney
test
highest
serum
opn
level
observ
among
patient
asthma
median
pgml
p
follow
observ
hymenoptera
venom
allergi
group
median
pgml
p
lower
valu
opn
detect
group
patient
rhinoconjunct
median
pgml
p
allerg
contact
dermat
median
pgml
food
allergi
median
pgml
patient
igemedi
sensit
betalactam
heterogen
valu
statist
differ
comparison
control
conclus
serum
opn
level
may
repres
novel
potenti
use
biomark
allerg
respiratori
diseas
hymenoptera
venom
allergi
consider
given
explor
clinic
correl
high
opn
level
condit
background
sequenti
develop
allerg
diseas
begin
food
allergi
atop
dermat
follow
asthma
allerg
rhiniti
ar
earli
childhood
often
refer
allergi
march
recent
number
schoolag
children
ar
shown
increas
japan
earli
onset
ar
poorli
describ
remain
unknown
preval
allerg
rhiniti
young
children
object
aim
evalu
preval
clinic
characterist
treatment
ar
popul
preschool
children
chiba
citi
urban
area
japan
method
total
children
age
year
kindergarten
chiba
citi
japan
survey
preval
symptom
allerg
rhiniti
assess
use
modifi
version
intern
studi
asthma
allergi
childhood
isaac
questionnair
result
total
questionnair
return
evalu
sex
male
femal
age
preval
lifetim
current
physiciandiagnos
allerg
rhiniti
respect
preval
ar
higher
male
femal
cf
physiciandiagnos
ar
vs
p
increas
age
cf
physiciandiagnos
ar
mani
children
show
ar
symptom
septemb
april
especi
februari
march
cedar
pollen
allergi
season
children
ar
visit
clinic
hospit
half
dissatisfi
treatment
conclus
preval
ar
symptom
high
start
earli
life
background
short
act
agonist
saba
system
corticosteroid
oxygen
primari
therapi
asthma
attack
repeat
use
system
corticosteroid
risk
system
side
effect
inhal
corticosteroid
offer
potenti
benefit
direct
effect
airway
lower
system
side
effect
object
compar
efficaci
combin
nebul
salbutamol
fluticason
propion
nebul
salbutamol
children
mild
moder
asthma
attack
method
thirti
children
age
year
mild
moder
asthma
attack
outpati
clinic
emerg
depart
soetomo
hospit
investig
open
label
random
control
trial
studi
subject
divid
treatment
group
combin
salbutamol
fluticason
propion
control
group
salbutamol
children
pulmonari
score
side
effect
tachycardia
tremor
evalu
nebul
minut
statist
analysi
use
test
mann
whitney
test
wilcoxon
sign
rank
test
accord
type
data
result
decreas
pulmonari
score
time
evalu
signific
nebul
group
p
decreas
pulmonari
score
treatment
group
greater
control
group
p
side
effect
tachycardia
group
significantli
differ
p
tremor
obtain
group
conclus
combin
nebul
salbutamol
fluticason
propion
better
efficaci
nebul
salbutamol
children
mild
moder
asthma
attack
background
asthma
chronic
airway
diseas
larg
control
proper
primari
care
need
hospit
usual
prevent
method
retrospect
studi
explor
clinic
characterist
children
hospit
asthma
conduct
depart
child
health
west
nusa
tenggara
gener
hospit
mataram
indonesia
data
medic
histori
physic
examin
got
pediatr
asthma
registri
pediatr
asthma
registri
pediatr
respirolog
divis
start
octob
present
characterist
children
hospit
asthma
octob
april
also
taken
number
children
admit
asthma
emerg
depart
outpati
clinic
period
addit
inform
present
characterist
studi
subject
tabl
chart
result
fourteen
children
hospit
asthma
enrol
studi
octob
april
ten
admit
emerg
depart
outpati
clinic
number
children
asthma
visit
period
visit
emerg
depart
visit
outpati
clinic
found
moder
exacerb
mild
exacerb
seven
refer
sever
exacerb
emerg
depart
reassess
moder
exacerb
moder
exacerb
frequent
asthma
case
subject
male
age
year
old
normal
nutrit
statu
first
asthma
diagnosi
year
old
case
histori
hospit
use
control
histori
atop
histori
asthma
famili
allerg
diseas
feather
pet
cigarett
smoke
trigger
asthma
exacerb
exercis
respiratori
infect
cold
weather
hous
dust
food
conclus
studi
show
children
hospit
asthma
set
moder
exacerb
frequent
asthma
male
age
year
old
first
diagnos
year
old
histori
hospit
normal
nutrit
statu
histori
atop
famili
cigarett
smoke
expos
keyword
asthma
children
hospit
characterist
background
allerg
bronchopulmonari
aspergillosi
abpa
known
type
iii
allerg
diseas
aspergillu
clinic
present
abpa
rang
asymptomat
mucu
plug
sever
asthmat
symptom
destruct
fibrot
lung
diseas
heterogen
may
reflect
differ
clinic
stage
diseas
also
differ
phenotyp
herein
attempt
identifi
phenotyp
abpa
use
cluster
analysi
method
analyz
data
patient
possibl
abpa
nationalwid
survey
japan
execut
definit
possibl
abpa
posit
skin
test
specif
ige
aspergillu
either
posit
precipit
igg
antibodi
aspergillu
b
mucoid
impact
bronchiectasi
chest
comput
tomographi
nonhierarch
cluster
analysi
use
kmean
method
perform
result
three
cluster
identifi
cluster
includ
patient
later
age
onset
mean
age
year
femaledomin
less
frequent
preval
asthma
patient
cluster
middl
age
onset
year
femaledomin
show
lower
valu
total
serum
ige
cluster
character
earlyonset
year
maledomin
frequent
recurr
conclus
three
distinct
clinic
phenotyp
identifi
character
age
onset
gender
asthma
preval
total
serum
ige
level
frequenc
recurr
background
chronic
rhinosinus
cr
one
frequent
chronic
diseas
littl
understood
pathogenesi
eosinophil
consid
play
major
role
patholog
still
know
littl
caus
chronic
immun
activ
persist
eosinophil
inflamm
cr
recent
type
innat
lymphoid
cell
lineag
identifi
candid
produc
highli
level
cytokin
activ
eosinophil
hypothes
enrich
blood
nasal
polyp
patient
eosinophil
cr
ecr
associ
patholog
method
fthe
patient
cr
pituitari
adenoma
normal
sinu
underw
endoscop
sinu
surgeri
ess
jikei
univers
hospit
enrol
use
pbmc
nasal
polyp
np
patient
cr
normal
subject
analyz
amount
flow
cytometri
also
investig
distribut
np
immunohistochemistri
edn
cytokin
np
measur
elisa
investig
correl
lineag
neg
cell
nasal
polyp
cultur
vitro
orand
investig
amount
cytokin
produc
result
edn
cytokin
significantli
higher
ecr
noneosinophil
cr
necr
edn
strongli
correl
number
np
count
np
significantli
higher
ecr
necr
immunostain
show
accumul
nasal
polyp
ecr
necr
normal
subject
surfac
express
pbmc
significantli
higher
ecr
necr
surfac
express
np
significantli
higher
necr
ecr
lineag
neg
cell
ecr
np
necr
produc
stimul
conclus
consid
candid
command
ecr
strongli
induc
inflamm
possibl
sever
subtyp
characterist
differ
environ
introduct
esfahan
famou
histor
citi
million
citizen
one
million
vehicl
uniqu
geograph
posit
take
place
main
industri
center
iran
air
pollut
esfahan
complex
problem
effect
children
respiratori
qualiti
main
goal
research
materi
method
cross
section
studi
conveni
sampl
winter
total
girl
esfahan
cbd
citi
tiran
small
calm
citi
km
west
esfahan
nearli
climat
everi
particip
complet
questionnair
anthropomorph
valu
past
year
respiratori
symptom
spirometri
evalu
use
spirolab
analyz
spss
version
result
esfahan
tiran
girl
age
height
weight
bmi
near
main
respiratori
symptom
cough
dyspnea
wheez
person
zero
spirometri
index
vital
capac
vc
percent
fvc
fef
p
valu
conclus
qualiti
respiratori
air
differ
normal
physiolog
index
even
childhood
probabl
compensatori
like
vc
other
capabl
limit
normal
activ
step
step
rational
mannan
deriv
saccharomyc
cerevisia
scmn
modul
allerg
asthma
pathogenesi
mous
model
purpos
studi
explor
downstream
transcript
factor
involv
scmn
benefici
effect
asthma
klf
import
transcript
factor
epitheli
surviv
modul
epitheli
mesenchym
transit
smooth
muscl
prolifer
highli
express
lung
hypothes
scmn
induc
klf
lung
cell
method
primari
normal
human
epitheli
cell
nhbec
bronchial
smooth
muscl
cell
incub
scmn
examin
level
phosphoryl
time
cours
western
blot
wb
normal
human
bronchial
smooth
muscl
cell
analyz
level
wb
alphaisoactin
indirect
immunofluoresc
stain
result
follow
exposur
scmn
protein
level
increas
nhbec
nhbsm
cell
subsequ
h
bronchial
smooth
muscl
cell
nhbec
show
biphas
activ
min
h
known
lead
klf
phosphoryl
vascular
smooth
muscl
cell
addit
scmn
increas
smoooth
muscl
specif
alphaisoactin
hr
consist
phenotyp
chang
conclus
scmn
induc
transcript
factor
import
epitheli
surviv
regul
smooth
muscl
prolifer
background
proper
asthma
manag
inform
exact
distribut
asthma
sever
fundament
develop
korean
pediatr
asthma
guidelin
baselin
data
sever
distribut
prescript
pattern
korean
asthmat
children
avail
method
request
pediatr
allergist
review
medic
record
asthmat
children
visit
clinic
recent
month
base
subject
symptom
sign
medic
maintain
control
asthma
sever
assess
accord
global
initi
asthma
gina
criteria
japanes
pediatr
guidelin
treatment
manag
bronchial
asthma
jpgl
criteria
result
total
case
year
year
year
review
criteria
reveal
asthmat
children
intermitt
asthma
wherea
subject
sever
persist
asthma
pattern
prescrib
control
vari
wide
match
asthma
sever
classif
either
gina
jpgl
criteria
confin
sever
assess
criterion
differ
conclus
korea
distinct
pattern
distribut
asthma
sever
especi
preval
sever
asthma
low
practic
pattern
prescript
match
recommend
modal
accord
sever
assess
either
gina
jpgl
result
provid
evid
current
state
korean
asthma
practic
develop
new
practic
guidelin
suitabl
korean
asthmat
children
background
autism
spectrum
disord
food
allergi
condit
increas
preval
studi
investig
link
intak
certain
food
among
asd
patient
onset
advers
reaction
result
studi
vari
conflict
first
local
studi
preval
food
allergi
among
patient
studi
aim
determin
preval
food
sensit
igemedi
nonigemedi
food
allergi
among
pediatr
asd
patient
also
aim
determin
preval
perceiv
food
allergi
trigger
type
reaction
perceiv
food
allergi
open
food
challeng
b
method
crosssect
prospect
studi
pediatr
patient
diagnos
autism
spectrum
disord
enrol
studi
exclud
children
uncontrol
asthma
recent
anaphylact
reaction
chronic
high
dose
steroid
therapi
requir
sampl
size
complet
histori
pe
obtain
previou
reaction
food
suspect
allergen
duli
note
patient
underw
skin
prick
test
spt
cow
milk
wheat
soy
perceiv
food
allergen
perceiv
food
allergi
underw
open
food
challeng
specif
food
allergen
frequenc
proport
determin
analyz
differ
variabl
c
result
data
gather
patient
diagnos
asd
perceiv
food
allergi
mostli
milk
chocol
egg
commonli
perceiv
allerg
reaction
food
allergen
hyperact
loos
stool
pruritu
wheal
total
patient
skin
prick
test
result
henc
food
sensit
least
food
allergen
mostli
soy
milk
patient
perceiv
food
allergi
patient
underw
open
food
challeng
result
conclus
preval
perceiv
food
allergi
food
sensit
higher
among
asd
patient
studi
compar
gener
popul
common
perceiv
food
allergen
similar
children
notabl
common
perceiv
allerg
reaction
food
behavior
gastrointestin
symptom
may
nonig
mediat
food
allergi
henc
asd
patient
advers
food
reaction
recommend
undergo
complet
systemat
evalu
possibl
restrict
diet
base
welldocu
food
allergi
background
littl
known
data
componentresolv
diagnosi
crd
allergi
dermatophagoid
pteronyssinu
der
p
chines
popul
aim
measur
preval
sensit
der
p
allergen
compon
among
patient
southern
china
method
der
pposit
der
pneg
subject
test
serum
immunoglobulin
e
sige
der
p
der
p
der
p
use
immunocap
polysensit
patient
examin
immunocap
immuno
solidphas
allergen
chip
isac
der
p
subject
test
sige
crude
extract
cockroach
moth
shrimp
result
patient
sensit
der
p
andor
der
p
der
pposit
patient
sensit
der
p
posit
proport
median
level
sige
der
p
higher
children
adult
der
p
der
correl
der
p
sige
level
p
immunocap
isac
demonstr
specif
sensit
detect
der
p
p
p
compar
immunocap
accord
immunocap
isac
der
p
patient
tripl
posit
patient
tripl
neg
pen
bla
g
ani
one
sole
posit
pen
sensit
der
p
correl
well
sige
shrimp
moth
cockroach
pen
bla
g
ani
conclus
detect
der
p
der
p
well
reflect
atopi
der
p
chines
cohort
sensit
der
p
may
result
crossreact
seafood
cockroach
coastal
southern
china
immunocap
isac
may
offer
use
tool
crd
perform
compar
immunocap
background
local
especi
system
reaction
import
problem
subcutan
immunotherapi
scit
local
reaction
develop
inject
system
reaction
develop
current
studi
aim
evalu
frequenc
risk
factor
reaction
develop
patient
undergo
scit
method
local
system
reaction
develop
inject
retrospect
evalu
current
studi
grade
system
system
reaction
recommend
world
allergi
organ
wao
use
type
allerg
diseas
allergen
produc
sensit
vaccin
content
adjuv
content
effect
treatment
phase
frequenc
advers
effect
investig
result
patient
includ
local
reaction
larg
local
reaction
system
reaction
local
reaction
observ
inject
wherea
system
reaction
observ
inject
local
reaction
frequent
initi
phase
system
reaction
frequent
mainten
phase
advers
reaction
common
patient
vaccin
scit
multipl
allergen
housedustmit
statist
signific
differ
found
content
adjuv
frequenc
advers
effect
conclus
frequenc
local
wide
local
reaction
subcutan
immunotherapi
lower
expect
although
system
reaction
frequent
seen
fatal
reaction
observ
current
studi
mite
immunotherapi
multipl
allergen
use
increas
risk
reaction
background
cyclic
anaphylaxi
rare
reaction
occur
luteal
phase
menstruat
present
may
includ
dyspnea
respiratori
distress
cutan
gastrointestin
symptom
previou
success
treatment
option
condit
limit
medic
surgic
ovulatori
suppress
present
use
igeinhibit
drug
omalizumab
shown
success
multipl
individu
make
favor
treatment
oophorectomi
women
look
conceiv
report
first
success
case
seri
four
patient
treat
omalizumab
cyclic
anaphylaxi
method
literatur
review
conduct
publish
data
pertain
cyclic
anaphylaxi
luteal
phase
menstruat
inform
summar
four
patient
center
includ
summari
result
omalizumab
result
symptom
resolut
signific
reduct
symptom
four
patient
consist
literatur
definit
cyclic
anaphylaxi
nomenclatur
similar
andor
overlap
condit
make
uniform
treatment
decis
challeng
make
consensu
recommend
cyclic
urticaria
anaphylaxi
omalizumab
repres
safer
prefer
treatment
option
rare
condit
conclus
evalu
data
regard
use
omalizumab
note
prefer
treatment
cyclic
anaphylaxi
women
would
like
maintain
option
concept
later
life
continu
research
necessari
order
fulli
understand
generaliz
reliabl
studi
data
popul
also
propos
systemat
classif
relat
condit
better
direct
futur
research
acut
lung
injuri
alt
associ
high
mortal
morbid
infant
adult
caus
sever
lung
inflamm
result
varieti
local
system
infect
sepsi
pneumonia
accord
diseas
process
three
stage
exud
format
prolifer
fibrosi
idiopath
pulmonari
fibrosi
ipf
anoth
chronic
progress
lethal
fibrot
lung
diseas
etiolog
ipf
still
unknown
howev
diseas
similar
hallmark
hypoxemia
respiratori
failur
surfact
protein
spd
ctype
lectin
produc
alveolar
type
ii
cell
import
respiratori
innat
immun
antiinflamm
action
spd
diseas
still
unrev
studi
use
bleomycin
induc
anim
model
ali
ipf
bleomycin
chemotherapeut
antibiot
drug
clinic
use
lymphoma
squamou
cell
carcinoma
follow
overproduct
reactiv
oxygen
lead
irrevers
lung
injuri
anim
model
found
group
present
sever
resist
poorest
elast
lung
tissu
addit
proinflammatori
cytokin
tumor
necrosi
nitric
oxid
follow
increas
express
profibrot
cytokin
transform
growth
histolog
alter
caus
bleomycin
mural
incorpor
collagen
obliter
alveolar
space
similar
human
ipf
ex
vivo
studi
pretreat
recombin
human
spd
nativ
spd
significantli
decreas
product
proinflammatori
cytokin
vivo
studi
treatment
nativ
spd
bleomycininduc
lung
fibrosi
mice
also
show
signific
bodi
weight
increas
recoveri
lung
function
declin
product
transform
growth
nitric
oxid
therefor
conclud
spd
may
promin
antiinflammatori
antifibrot
effect
ali
ipf
also
potenti
becom
novel
treatment
ali
ipf
near
futur
previous
demonstr
releas
activ
endotheli
cell
lead
convers
prekallikrein
kallikrein
prekallikrein
bound
hk
kallikrein
format
therefor
stoichiometr
occur
absenc
factor
xii
sinc
kallikrein
activ
factor
xii
theoriz
endotheli
cell
activ
might
first
gener
kallikrein
recruit
factor
xii
demonstr
estrogen
interleukin
lesser
degre
tnfa
activ
endotheli
cell
releas
dose
rang
test
ngml
doserespons
estrogen
maxim
ngml
dose
tnfa
best
ngml
time
cours
hr
incub
reveal
maxim
secret
min
signific
increas
note
min
observ
particularli
relev
type
ii
hae
inhibitor
defici
estrogen
inflamm
known
trigger
angioedema
event
hae
normal
inhibitor
haen
estrogen
exposur
key
precipit
latter
studi
endotheli
cell
releas
urokinas
tissu
plasminogen
activ
progress
given
recent
observ
regard
inhibitor
fibrinolysi
background
period
septemb
march
home
children
northern
moravia
czech
republ
sunni
day
day
limit
dust
polyaromat
hydrocarbon
overthrown
medic
profession
institut
metylovic
locat
meter
sea
level
found
highland
stay
treatment
vitamin
investig
effect
climat
paramet
bronchial
asthma
chang
physic
paramet
modifi
test
asthmat
children
main
goal
studi
assess
effect
benefit
stay
describ
treatment
b
method
period
children
patient
underw
long
term
stay
medic
treatment
medic
institut
metylovic
total
girl
boy
age
bronchial
asthma
fulfil
inclus
criterion
gina
includ
studi
patient
atop
statu
evalu
skin
prick
test
use
common
allergen
extract
grass
tree
pollen
hous
dust
mite
mould
catdog
extract
patient
blood
eosinophil
leukocyt
count
level
total
sesrum
imunoglobulin
e
serum
eosinophil
cation
protein
exhal
nitric
oxid
level
determineddaili
patient
receiv
iu
vitamin
oral
c
result
object
evalu
effect
benefit
long
term
stay
asthmat
children
continu
treatment
vitamin
physic
exercisesth
evalu
done
comparison
laboratori
examin
blood
physic
paramet
begin
stay
end
stay
determin
hypothesi
long
term
stay
signific
posit
effect
level
vitamin
mmoll
begin
stay
vs
mmoll
p
paramet
physic
fit
children
studi
done
modifi
cooper
stest
test
abdomin
muscl
pull
smin
vs
pullsmin
p
conclus
climat
stay
exclus
neg
influenc
environ
activ
vitamin
led
stabilis
asthma
without
need
treatment
salbutamol
spray
subsequ
higher
intens
rehabilit
exercis
increas
muscl
strength
improv
qualiti
breath
background
chronic
inflammatori
diseas
asthma
accompani
mani
diseas
astmat
patient
comparison
vitamin
group
due
sever
asthma
replac
treatment
case
lack
extrem
import
method
respiratori
fuction
test
conduct
patient
male
total
age
group
appli
chest
diseas
polyclin
januarymay
patient
classifi
mild
moder
sever
due
gina
criteria
vitamin
vitamin
vitamin
e
folic
acid
vitamin
level
investig
statist
mann
whitney
u
kruskal
wallish
posthoc
test
appli
result
age
group
vitamin
vitamin
valu
femal
significantli
lower
male
p
patient
age
lower
folic
acid
valu
significantli
low
due
vitamin
vitamin
vitamin
e
vitamin
folic
acid
statist
signific
differ
detect
among
astmat
level
patient
enrol
studi
p
conclus
besid
physiopatholog
chang
astma
evid
free
oxygen
radic
releas
inflammatori
cell
decreas
antioxid
level
give
impress
oxidantantioxid
disequilibrium
role
astmat
pathogenesi
defenc
mechan
bodi
oxyd
stress
outsourc
vitamin
therefor
essenti
low
valu
vitamin
vitamin
valu
astmat
patient
encourag
astmat
symptom
sever
addit
exhaust
fatigu
bone
ach
eye
diseas
reinforc
vitamin
nutrit
medic
believ
use
treatment
asthma
purpos
recent
epidemiolog
data
regard
allerg
sensit
atop
dermat
ad
korea
aim
studi
investig
pattern
sensit
children
ad
method
retrospect
studi
includ
pediatr
patient
year
old
ad
visit
samsung
medic
center
serum
specif
ige
sige
level
egg
white
ew
cow
milk
cm
peanut
wheat
soy
buckwheat
tree
nut
crustacean
meat
hous
dust
mite
hdm
review
sige
level
kul
regard
posit
ad
categor
extrins
type
ade
intrins
type
adi
accord
presenc
absenc
posit
sige
compar
proport
sensit
children
accord
age
use
chisquar
test
preval
immediatetyp
egg
cm
allergi
also
evalu
base
previous
report
diagnost
decis
point
ddp
result
data
collect
total
children
boy
girl
identifi
children
ade
type
adi
type
differ
proport
sensit
patient
accord
age
p
valu
ratio
posit
sige
among
individu
food
item
highest
ew
follow
cm
peanut
wheat
soy
buckwheat
among
food
group
tree
nut
common
allergen
sensit
dermatophagoid
farina
pteronyssinu
found
respect
addit
show
higher
level
sige
ew
cm
previous
report
ddp
conclus
frequenc
ade
among
children
ad
frequent
sensit
food
allergen
ew
follow
cm
peanut
refer
allergi
asthma
immunol
re
background
pathogenesi
asthmachron
obstruct
pulmonari
diseas
overlap
syndrom
aco
suppos
multifactori
unclear
recent
evid
suggest
staphylococc
enterotoxin
ige
sensit
seig
risk
factor
asthma
sever
adult
includ
elderli
hypothes
se
sensit
contribut
develop
fix
airway
obstruct
asthma
lead
aco
phenotyp
present
studi
aim
examin
associ
seig
sensit
fix
airway
obstruct
elderli
asthma
patient
method
compar
baselin
characterist
elderli
control
asthma
aco
patient
year
baselin
assess
includ
demograph
lung
function
comorbid
serum
total
ige
seig
level
seig
sensit
classifi
neg
kul
moder
kul
high
kul
seig
sensit
defin
posit
kul
lung
function
serial
check
everi
month
two
year
elderli
asthma
patient
best
ratio
use
defin
fix
airway
obstruct
persist
asthma
manag
exacerb
frequenc
assess
prospect
followup
result
total
elderli
subject
analyz
control
asthma
aco
serum
seig
level
higher
among
elderli
aco
asthma
patient
compar
control
respect
seig
sensit
rate
significantli
differ
group
high
seig
sensit
aco
asthma
control
p
presenc
fix
airway
obstruct
show
relationship
male
sex
smoke
histori
chronic
rhinosinus
cr
seig
sensit
multivari
analys
smoke
histori
high
seig
sensit
independ
relationship
fix
airway
obstruct
asthma
aco
group
seig
level
show
signific
correl
exacerb
frequenc
conclus
staphyloccoc
enterotoxin
could
pathogen
role
develop
copd
overlap
lateonset
elderli
asthma
find
warrant
investig
mechan
se
mediat
airway
remodel
probiot
normal
inhabit
gastrointestin
tract
man
wide
consid
exert
number
benefici
role
includ
immunomodul
interfer
enter
pathogen
mainten
healthi
intestin
microflora
recent
year
studi
probiot
also
confirm
extraintestin
effect
particularli
prevent
allerg
diseas
howev
antiallergi
mechan
probiot
still
unclear
first
part
studi
found
continu
feed
lactobacillu
gasseri
l
gasseri
ml
ml
week
der
psensit
challeng
mice
could
prevent
allergeninduc
airway
inflamm
also
signific
chang
airway
hypersensit
cytokin
pattern
lymphocyt
prolifer
immunoglobulin
product
l
gasseri
treat
nontreat
mice
second
part
studi
appli
microarray
analysi
lung
drain
lymph
node
mesenter
lymph
node
mice
detect
gene
express
signal
pathway
genet
profil
immunolog
toler
induc
l
gasseri
play
essenti
role
prevent
therapeut
allerg
asthma
found
significantli
decreas
inflammatori
chemokin
gene
express
increas
carbohydr
lipid
metabol
gene
express
l
gasseritr
mice
compar
nontreat
sensit
challeng
mice
thirdli
pick
one
candid
target
gene
peroxisom
proliferatoractiv
receptor
studi
benefici
effect
probiot
allerg
induc
airway
inflamm
previous
report
member
nuclear
hormon
receptor
famili
promin
involv
adipogenesi
metabol
regul
also
exert
pleiotrop
antiinflammatori
effect
lung
hypothes
may
play
import
role
allergeninduc
airway
inflamm
allergensensit
effect
murin
model
asthma
appli
mutant
mice
evalu
ahr
total
number
inflammatori
cell
cytokin
secret
bronchoalveolar
fluid
balf
lung
inflamm
mite
allergen
sensit
challeng
moreov
probiot
treatment
mutant
mice
wide
type
mice
administr
allergensensit
mice
summari
result
show
play
import
role
inhibitori
effect
allergeninduc
airway
inflamm
mice
antiallerg
effect
l
gasseri
may
activ
allevi
airway
inflamm
allergensensit
murin
model
asthma
background
adrenalin
autoinjector
aai
key
immedi
hospit
manag
anaphylaxi
mani
studi
focus
poor
util
patient
howev
paper
address
ideal
featur
aai
neglect
patient
view
prefer
object
explor
view
adult
patient
aai
design
method
themat
analysi
semistructur
interview
adult
patient
prescrib
aai
discuss
facilit
varieti
aai
model
commerci
avail
prototyp
result
particip
spoke
spontan
size
devic
want
portabl
without
need
bag
mani
favour
smaller
devic
other
toler
bulki
design
inconveni
associ
lifesav
characterist
aai
increas
size
recent
product
market
welcom
howev
significantli
smaller
design
necessarli
perceiv
prefer
potenti
difficulti
locat
emerg
argu
greater
visibl
achiev
bright
colour
other
found
bright
colour
frighten
attract
unwant
attent
fact
carri
aai
grey
consid
undesir
colour
grey
quit
depress
patient
want
instruct
brief
simpl
made
full
use
illustr
middl
age
respond
comment
need
adequ
font
size
younger
peopl
recognis
without
read
glass
bystand
assist
could
impair
exist
present
style
integr
instruct
devic
intuit
use
fiddli
need
prioritis
consist
request
recognis
differ
way
highlight
safeti
cap
devic
needl
end
other
potenti
confus
strong
resili
protect
case
thought
mandatori
sever
respond
describ
case
deterior
aai
expiri
date
sever
novel
design
featur
suggest
patient
base
mani
year
experi
conclus
size
aesthet
two
import
aai
design
issu
patient
greater
involv
patient
develop
new
aai
patient
center
design
could
potenti
increas
carriag
devic
import
howev
good
ballist
characterist
devic
patient
benefit
technolog
unless
aai
carri
utilis
need
background
allerg
asthma
chronic
pulmonari
diseas
character
inflammatori
respons
immun
respons
known
play
key
role
pathogenesi
allerg
asthma
particular
macrophag
deriv
chemokin
directli
implic
inflammatori
reaction
studi
investig
immun
modul
use
mirna
would
induc
therapeut
effect
ovalbuminsensit
challeng
asthmat
mice
method
recombin
strain
salmonella
typhimurium
express
mirna
prepar
vivo
knockdown
use
ovalbumininduc
asthma
model
mice
sensit
challeng
treat
result
construct
recombin
strain
salmonella
typhimurium
express
mirna
vivo
knockdown
treatment
mice
establish
allergi
led
attenu
eosinophilia
cytokin
airway
hyperrespons
treatment
also
induc
increas
ovaspecif
level
frequenc
lung
inflammatori
monocyt
conclus
research
microrna
treat
modul
imbal
diseas
mirna
reduc
immun
respons
induc
therapeut
effect
ovainduc
mous
model
asthma
result
suggest
mirna
could
potenti
use
effect
therapeut
agent
treat
asthma
background
head
neck
dermat
hnd
uniqu
subtyp
atop
dermat
ad
commonli
manifest
late
adolesc
adulthood
hnd
often
refractori
therapi
affect
patient
qualiti
life
greatli
howev
presenc
hnd
often
underappreci
clinic
detail
studi
characterist
limit
method
studi
sought
analyz
clinic
histolog
characterist
hnd
patient
grow
number
ad
studi
focus
role
skin
microbiom
diseas
pathogenesi
microbiom
analysi
hnd
patient
comparison
nonhnd
nhnd
ad
normal
nl
subject
perform
result
result
show
hnd
patient
compris
approxim
ad
patient
outpati
clinic
set
compar
nhnd
patient
hnd
initi
present
sever
diseas
statu
elev
serum
total
ige
serum
specif
ige
eactiv
dermatophagoid
farina
histolog
hnd
specimen
show
thicken
epidermi
increas
vascular
compon
dermal
inflammatori
infiltr
stain
posit
proinflammatori
cytokin
chemokin
lastli
microbiom
analysi
hnd
comparison
nhnd
ad
nl
subject
reveal
presenc
divers
commun
present
skin
conclus
find
reaffirm
hnd
clinic
subtyp
ad
need
distinct
classic
ad
futur
investig
skin
microbiom
inflammatori
factor
involv
vasculatur
facial
lesion
ad
lead
develop
potenti
therapeut
target
background
microrna
mirna
modul
gene
transcript
respons
environment
stressor
stimuli
role
mirna
inflamm
immun
demonstr
evid
suggest
mirna
also
play
role
atop
dermat
studi
hypothes
immun
suppress
use
would
induc
therapeut
effect
atop
diseas
method
ige
interferong
ifng
examin
treatment
mirna
murin
atop
model
addit
atop
patient
blood
sampl
collect
examin
mirna
express
result
reduc
chemokin
gene
activ
lymphocyt
mice
cutan
diseas
similar
atop
dermat
inhibit
induc
treatment
furthermor
level
suppress
atop
patient
conclus
suppress
immun
respons
induc
therapeut
effect
atop
mous
model
background
crossreact
food
inhal
allergen
usual
show
mild
symptom
howev
sever
asthma
symptom
exerciseinduc
anaphylaxi
urticaria
recal
urticaria
site
immunotherapi
inject
may
occur
ingest
snail
patient
allerg
hous
dust
mite
b
method
report
case
old
woman
suffer
acut
sever
asthma
attack
complic
asphyx
evolut
lead
cardiopulmonari
arrest
cardiopulmonari
resuscit
success
subcutan
emphysema
occur
left
pneumothorax
treat
chest
tube
clinic
cours
benign
patient
return
hospit
home
day
complic
medic
histori
reveal
asthma
year
allergi
inhal
allergen
grass
pollen
hous
dust
mite
pet
dander
treat
year
earlier
subcutan
specif
immunotherapi
hous
dust
mite
year
medic
taken
includ
albuterol
beclomethason
salmeterol
montelukast
ate
norway
lobster
snail
hour
begin
acut
sever
asthma
attack
sexual
intercours
condom
hour
c
result
skin
prick
test
spt
diamet
wheal
flare
mm
serum
specif
ig
e
ssig
e
pharmacia
unicap
confirm
sensit
snail
spt
ssig
e
kuil
norway
lobster
spt
ssig
e
kuil
human
semin
fluid
spt
ssig
e
kuil
ig
e
sensit
later
found
prawn
hous
dust
mite
tropomyosin
rpen
kuil
pharmacia
unicap
rder
p
kuil
phadia
immunocap
sever
asthma
attack
occur
thirteen
year
begin
evict
diet
continu
asthma
treatment
case
allerg
symptom
consumpt
snail
among
patient
allerg
hous
dust
mite
publish
allerg
symptom
may
occur
first
ever
ingest
snail
may
lifethreaten
begin
usual
minut
rare
hour
ingest
snail
crosssensit
snail
hous
dust
mite
probabl
due
common
epitop
haemocyanin
conclus
allerg
patient
hous
dust
mite
inform
possibl
sever
crossallergi
symptom
eat
snail
refer
van
ree
r
et
al
asthma
consumpt
snail
housedustmiteallerg
patient
case
ige
crossreact
allergi
jun
de
maatbleek
f
et
al
vineyard
snail
allergi
possibl
induc
sensit
housedust
mite
dermatophagoid
pteronyssinu
allergi
may
background
distinct
pattern
divers
earli
intestin
colonis
shown
influenc
immun
matur
potenti
develop
allerg
diseas
recent
demonstr
prenat
supplement
lactobacillu
rhamnosu
gg
lgg
late
pregnanc
influenc
infant
gut
colonis
particular
bifidobacterium
speci
direct
toward
healthi
infanttyp
microbiota
investig
whether
earlylif
gut
colonis
bifidobacterium
speci
associ
system
immun
respons
month
age
method
faecal
sampl
collect
infant
first
month
life
bacteri
dna
extract
faecal
sampl
bifidobacterium
longum
b
lacti
b
breve
b
angulatum
b
adolescenti
b
catenulatum
detect
real
time
pcr
infant
peripher
blood
mononuclear
cell
month
stimul
ovalbumin
ova
heatkil
lgg
hkl
probiot
use
origin
studi
tetanu
toxoid
tt
without
stimulu
cell
analys
flow
cytometri
marker
dendrit
cell
phenotyp
regulatori
cell
treg
number
cultur
supernat
analys
multiplex
elisa
measur
use
elisa
result
colonis
b
longum
day
life
associ
significantli
higher
p
level
cytokin
proinflammatori
cytokin
increas
p
secret
regulatori
cytokin
infant
month
howev
colonis
b
adolescenti
day
associ
higher
secret
cytokin
significantli
increas
number
treg
observ
infant
colonis
b
adolescenti
day
age
conclus
colonis
specif
bifidobacterium
speci
earli
life
influenc
cellular
immun
function
name
cytokin
profil
treg
later
month
suggest
probiot
treatment
pregnanc
may
modul
infant
immun
function
late
month
age
feasibl
mediat
modul
infant
microbiota
howev
immun
mechan
might
protect
allerg
diseas
still
unclear
background
curri
spice
allergi
children
extrem
rare
japan
addit
fooddepend
exerciseinduc
anaphylaxi
feian
manifest
spice
allergi
curri
powder
quit
uncommon
method
report
case
feian
due
curri
spice
allergi
boy
boy
histori
sever
episod
exerciseinduc
anaphylaxi
sinc
age
year
suspect
feian
develop
pollinosi
spring
autumn
increas
level
specif
ige
antibodi
mani
differ
kind
allergen
food
pollen
includ
celeri
white
birch
mugwort
among
sever
differ
food
consum
last
three
episod
anaphylaxi
found
curri
powder
common
ingredi
sinc
curri
powder
induc
symptom
without
exercis
suspect
feian
caus
curri
spice
result
result
exercis
challeng
test
conduct
ingest
curri
posit
accompani
skin
flare
itch
urticaria
bulbar
conjunctiv
hyperemia
record
decreas
forc
vital
capac
decreas
forc
expiratori
volum
respiratori
function
test
patient
diagnos
feian
respons
curri
powder
patient
found
sensit
coriand
curri
powder
ingredi
immnocap
sensit
sever
spice
also
detect
skinprick
test
patient
instruct
refrain
exercis
h
ingest
curri
powder
shown
symptom
sinc
conclus
base
histori
investig
result
suspect
celerybirchmugwortspic
syndrom
caus
ige
crossreact
pollen
spice
background
atop
dermat
ad
chronic
relaps
inflammatori
skin
disord
character
multifactori
pathophysiolog
aspect
pruritu
sleep
disturb
cardin
symptom
atop
dermat
sever
score
system
avail
eczema
area
sever
index
easi
tool
commonli
use
measur
sever
atop
dermat
correl
visual
analogu
scale
va
pruritu
loss
sleep
lo
easi
score
fulli
investig
yet
object
studi
design
evalu
associ
pruritu
sleep
disturb
atop
dermat
object
diseas
sever
laboratori
paramet
method
assess
easi
score
object
diseas
sever
va
pruritu
lo
point
sever
pruritu
sleep
disturb
ad
patient
dermatolog
clinic
also
measur
eosinophil
count
total
ige
specif
ige
peripher
blood
correl
prurirut
sleep
disturb
diseas
sever
laboratori
paramet
determin
pearson
correl
analysi
use
spss
version
result
mean
va
pruritu
lo
mean
sd
mean
easi
score
studi
reveal
easi
score
show
weak
statist
signific
va
pruritu
lo
easi
vs
va
pruritu
r
easi
vs
va
lo
r
eosinophil
count
reveal
weak
statist
signific
va
pruritu
lo
va
pruritu
r
va
lo
r
total
ige
level
show
statist
signific
va
pruritu
lo
specif
ige
titer
dermatophagoid
farina
show
weak
statist
signific
va
pruritu
lo
va
pruritu
r
va
lo
r
conclus
result
demonstr
easi
score
weakli
reflect
subject
sever
pruritu
lo
sinc
sever
pruritu
lo
affect
qualiti
life
atop
dermtaitti
patient
strongli
correl
diseas
sever
measur
dermatologist
dermatologist
awar
subject
symptom
patient
consid
manag
subject
symptom
togeth
object
symptom
refer
chrostowskaplak
salomon
j
reich
szepietowski
jc
clinic
aspect
itch
adult
atop
dermat
patient
acta
derm
venereol
hanifin
jm
diagnost
criteria
atop
dermat
consid
context
arch
dermatol
background
hereditari
factor
atop
dermat
ad
emphas
recent
adrel
gene
mutat
vari
significantli
across
ethnic
tri
find
mutat
flg
gene
korean
ad
patient
aim
develop
revers
blot
hybrid
assay
reba
appli
adrel
gene
first
time
method
divid
ad
subject
moder
sever
ad
mild
ad
group
also
divid
extrins
intrins
ad
group
check
gene
mutat
use
reba
ad
nonatopi
control
subject
result
mutant
type
mt
significantli
frequent
ad
subject
control
higher
moder
sever
group
compar
mild
group
mt
frequenc
differ
intrins
extrins
ad
group
ad
subject
frequent
mix
type
mt
c
compar
control
differ
intrins
extrins
ad
among
ad
subject
moder
sever
ad
group
gene
mutat
compar
mild
group
conclus
found
correl
mutat
mutat
c
ad
report
asian
includ
korean
thing
verifi
reba
appli
detect
multipl
barrierrel
gene
mutat
ad
easili
simpli
accur
background
diagnost
workup
patient
suffer
lifethreaten
drug
anaphylaxi
difficult
clinic
practic
owe
low
sensit
laboratori
test
risk
anaphylaxi
use
vivo
test
flow
cytometryassist
basophil
activ
test
bat
suggest
safe
diagnost
method
although
expens
technic
challeng
compar
convent
vitro
vivo
test
sought
evalu
diagnost
util
test
clinic
practic
method
nineteen
patient
druginduc
anaphylaxi
recruit
basophil
activ
test
skin
test
measur
commerci
avail
specif
ige
drug
perform
diagnost
evalu
stimul
absolut
activ
basophil
consid
posit
respons
bat
result
patient
met
faanniaid
criteria
anaphylaxi
causal
assess
use
whoumc
classifi
categori
certain
probabl
male
femal
ratio
mean
age
yr
five
patient
present
sever
anaphyalxi
hypotens
hypoxia
loss
conscious
other
moder
sever
involv
drug
cephalosporin
antibiot
patient
eperison
ranitidin
aminoglycosid
glimepirid
humalog
insulin
paclitaxel
tradamol
propofol
one
patient
bat
use
cd
marker
posit
neg
patient
wherea
bat
use
posit
neg
patient
marker
appli
patient
show
posit
bat
skin
test
posit
neg
nonapplic
two
patient
conclus
bat
prove
use
diagnost
tool
druginduc
anaphyalxi
addit
test
identifi
caus
drug
patient
neg
skin
test
unavail
sige
measur
background
bacteri
colon
infant
gut
begin
birth
gut
microbiota
infant
unstabl
initi
gut
microbiota
play
import
role
develop
immnu
system
disrupt
gut
microbiota
link
develop
allerg
diseas
especi
feed
method
signific
impact
allerg
diseas
object
investig
composit
gut
microbiota
accord
feed
method
associ
serum
ige
infant
materi
method
fecal
sampl
collect
month
infant
cocoa
birth
cohort
microbiota
character
perform
use
rrna
shotgun
sequenc
result
speci
rich
alphadivers
differ
accord
feed
method
signific
higher
level
firmicut
lower
level
actinobacteria
detect
mix
milk
breast
formula
milk
feed
infant
breast
milk
feed
infant
phylum
level
proport
bifidobacterium
significantli
reduc
clostridium
highli
enrich
mix
milk
feed
infant
breast
milk
feed
infant
genu
level
level
escherichiaposit
correl
total
serum
ige
age
year
mix
milk
feed
infant
breast
milk
feed
infant
conclus
feed
method
affect
divers
gut
microbiota
howev
shape
composit
specif
bacteria
escherichiaaffect
develop
atopi
research
support
basic
scienc
research
program
nation
research
foundat
korea
nrf
fund
ministri
scienc
ict
futur
plan
background
transform
growth
play
crucial
regulatori
role
cellmedi
contact
hypersensit
ch
canon
signal
pathway
mediat
receptorregul
smad
rsmad
common
smad
howev
precis
signal
mechan
wherebi
regul
cell
ch
fulli
understood
object
sought
determin
mechan
signal
regul
pathogen
effector
cell
subset
ch
method
use
system
delet
cellspecif
manner
mice
immun
sensit
dnfb
result
found
cellspecif
delet
exacerb
dnfbinduc
ch
signific
expans
infiltr
cell
drain
lymph
node
skin
lesion
defici
cell
upregul
differenti
regardless
genotyp
cell
combin
suppress
express
tbox
transcript
factor
eomesodermin
eom
cell
express
eom
cytotox
molecul
cell
earli
phase
sensit
significantli
upregul
mice
compar
control
mice
cytolyt
molecul
cell
upregul
delet
induc
cell
apoptosi
result
increas
conclus
data
highlight
cellintrins
crucial
regul
effector
cell
subset
ch
background
gastrointestin
tract
primari
site
interact
host
immun
system
microorgan
studi
suggest
select
microbi
target
may
influenc
develop
allerg
diseas
differ
function
gene
composit
remain
unknown
aim
assess
structur
function
gene
composit
stool
microbiota
infant
eczema
match
age
gender
mode
deliveri
feed
control
age
month
method
twelv
children
eczema
control
select
placebo
arm
birth
cohort
atrisk
infant
particip
random
doubleblind
trial
protect
effect
supplement
probiot
earli
life
allerg
outcom
four
caesarean
deliveri
follow
formula
feed
eczema
healthi
control
eight
vagin
deliveri
follow
partial
breast
feed
mix
formula
feed
eczema
healthi
control
bacteri
genom
dna
extract
fecal
sampl
prepar
illumina
miseq
hiseq
sequenc
data
analysi
sequenc
qualiti
check
contig
assembl
gene
annot
carri
dna
sequenc
obtain
miseq
hiseq
sequenc
result
phylogenet
analysi
metagenom
sequenc
reveal
four
phyla
domin
microbi
commun
proteobacteria
healthi
eczema
commun
respect
firmicut
actinobacteria
bacteroidet
compar
metagenom
analysi
show
immuneregulatori
tcaagcttga
motif
significantli
enrich
healthi
commun
mani
encod
bifidobacterium
total
motif
healthi
commun
draft
genom
five
bifidobacterium
speci
b
longum
b
bifidum
b
breve
b
dentium
b
pseudocatenulatum
recov
metagenom
dataset
b
longum
genom
encod
tcaagcttga
motif
copi
per
million
genom
sequenc
bifidobacterium
genom
significantli
overrepres
p
healthi
commun
conclus
result
report
distinct
immunemodulatori
genom
properti
gut
microbiota
healthi
infant
compar
children
eczema
provid
new
insight
potenti
role
gut
microbiota
affect
human
immun
homeostasi
object
allerg
rhiniti
occur
world
popul
caus
runni
nose
sneez
itch
qualit
degrad
sleep
disord
caus
failur
social
life
allerg
rhiniti
associ
patient
obstruct
sleep
apnea
aim
studi
investig
impact
allerg
rhiniti
obstruct
sleep
apnea
chang
symptom
obstruct
sleep
apnea
allerg
rhiniti
treatment
method
examin
patient
diagnos
obstruct
sleep
apnea
use
polysomnographi
sleep
clinic
patient
examin
allergi
skin
test
diagnos
allerg
rhiniti
patient
group
osa
ar
allerg
rhiniti
medic
treatment
week
osa
treatment
survey
visual
analogu
scale
epworth
sleepi
scale
chalder
fatigu
scale
daili
hassl
scale
connerdavidson
resili
scale
rhinoconjunct
qualiti
life
questionnair
allerg
rhiniti
treatment
result
osaar
group
pateint
age
rang
year
old
mean
age
prior
treatment
osaar
group
score
less
averag
va
sleep
time
wake
time
ess
cf
dh
cdrisc
rqlq
examin
tnss
associ
rhiniti
rqlq
show
less
averag
except
nasal
obstruct
osaar
va
sleep
time
wake
time
rqlq
patient
underw
medic
treatment
show
statist
signific
differ
treatment
sleep
time
p
wake
time
p
rqlq
averag
score
ess
cf
dh
cdrisc
rqlq
tnss
lower
signific
differ
treatment
treatment
conclus
could
find
allerg
rhiniti
treatment
contribut
improv
subject
symptom
qol
patient
osaar
treatment
patient
consid
lower
number
subject
investig
perform
differenti
acut
gener
exanthemat
pustulosi
agep
gener
pustular
psoriasi
gpp
extrem
difficult
present
erythemat
pustular
erupt
woman
present
emerg
depart
gener
erythemat
pustular
erupt
gener
edema
fever
treat
drug
erupt
herbal
remedi
dermatolog
depart
week
one
week
visit
ed
receiv
dapson
zaltoprofen
anoth
hospit
bodi
temperatur
measur
blood
neutrophil
total
leukocyt
base
clinic
laboratori
find
diagnos
agep
dapson
nsaid
medic
discontinu
treatment
system
steroid
day
fever
skin
lesion
improv
howev
new
pustular
lesion
develop
immedi
dose
reduct
steroid
rapidli
aggrav
result
skin
biopsi
compat
gpp
rather
agep
acitretin
start
steroid
slowli
taper
pustular
lesion
scale
improv
report
patient
pustular
erupt
initi
diagnos
agep
diagnosi
chang
gpp
case
highlight
import
differenti
diagnos
order
treat
condit
appropri
gelatin
allergi
well
describ
type
hypersensit
reaction
vaccin
case
report
publish
anaphylaxi
associ
food
report
year
old
boy
develop
anaphylaxi
eat
gummi
bear
refer
evalu
episod
anaphylaxi
ingest
gummi
product
first
episod
occur
within
minut
consum
packag
haribo
gold
bear
candi
develop
diffus
urticaria
gener
rash
angioedema
pruritu
wheez
approxim
month
later
second
episod
occur
ingest
mygummi
fruit
snack
packag
ten
minut
ingest
gener
urticaria
erythema
resolv
receiv
antihistamin
prick
prick
skin
test
gelatincontain
gum
haribo
mygummi
soak
water
porcin
gelatin
posit
reaction
addit
intraderm
test
gelatin
strongli
reactiv
immunocap
test
show
increasd
ige
level
bovin
gelatin
kual
porcin
gelatin
avail
korea
mammalian
gelatin
well
known
crossreact
doubleblind
placebocontrol
food
challeng
gold
standard
diagnosi
food
allergi
howev
conduct
patient
alreadi
sever
reaction
food
contain
gelatin
includ
anaphylact
reaction
evid
specif
ige
gelatin
skin
test
intraderm
test
patent
advis
avoid
gelatincontain
food
medic
vaccin
background
asthma
chronic
inflammatori
diseas
airway
progress
undergo
structur
chang
collect
term
airway
remodel
sever
refractori
bronchospasm
elicit
mechan
stress
bronchial
wall
respons
airway
inflamm
remodel
studi
plan
examin
relationship
asthmat
lung
function
serum
folliculin
level
folliculin
releas
bronchial
epitheli
cell
respons
compress
stress
mimick
bronchospasm
materi
method
folliculin
level
serum
measur
elisa
asthma
patient
visit
asthma
center
tertiari
referr
hospit
may
decemb
healthi
control
visit
health
examin
center
hospit
folliculin
level
compar
two
group
investig
level
folliculin
correl
lung
function
clinic
variabl
within
group
asthma
patient
whose
folliculin
level
defin
high
follicullin
group
sought
find
clinic
characterist
high
folliculin
phenotyp
result
serum
concentr
folliculin
significantli
higher
asthmat
vs
pgml
p
healthi
control
found
neg
correl
serum
folliculin
level
post
bronchodil
p
post
bronchodil
p
highfolliculin
group
older
onset
asthma
vs
month
p
heavier
histori
smoke
vs
packyear
p
present
frequent
exacerb
vs
show
lower
predict
vs
conclus
result
demonstr
serum
folliculin
concentr
higher
asthmat
associ
lower
lung
function
thu
follucilin
novel
biomark
asthma
background
asthma
patient
chronic
rhinosinus
nasal
polyp
tend
high
recurr
rate
surgeri
get
better
wors
along
clinic
cours
asthma
oral
steroid
treatment
often
use
case
poor
effect
local
nasal
steroid
treatment
side
effect
longterm
oral
steroid
consid
seriou
concern
physician
offlabel
use
budesonid
nasal
irrig
introduc
recent
post
oper
manag
patient
chronic
rhinosinus
safeti
effect
budesonid
nasal
irrig
accept
mani
physician
object
studi
evalu
efficaci
postop
steroid
irrig
asthma
patient
method
prospect
studi
done
chronic
rhinosinus
patient
nasal
polyp
asthma
use
oral
steroid
treatment
due
recur
worsen
diseas
sinonas
outcom
test
lundkennedi
endoscopi
score
perform
nasal
budesonid
irrig
month
irrig
result
subject
male
femal
patient
mean
age
patient
score
irrig
follow
month
month
month
month
irrig
score
significantli
improv
irrig
endoscopi
score
irrig
follow
month
month
month
month
score
significantli
improv
irrig
p
conclus
nasal
irrig
budesonid
consid
effect
post
oper
treatment
chronic
rhinosinus
patient
asthma
recur
frequent
reduc
use
oral
steroid
intak
background
atop
dermat
ad
chronic
relaps
inflammatori
skin
diseas
character
sever
itch
dysfunct
skin
homeostasi
previous
new
ad
model
establish
capsaicin
inject
neonat
rat
display
itch
behavior
skin
inflamm
week
inject
method
rat
inject
capsaicin
ad
skin
analyz
use
immunohistochemistri
rtpcr
immunoblot
analysi
result
show
alter
filaggrin
corneodesmosin
cdsn
proteolyt
process
corel
ad
develop
newborn
rat
show
welldevelop
epidermi
becam
thinner
till
weekag
hair
began
grow
epiderm
thick
gradual
increas
corel
express
epiderm
differenti
marker
suggest
ushap
epiderm
develop
investig
relationship
ad
epiderm
develop
neonat
weekag
rat
inject
capsaicin
ad
symptom
monitor
late
inject
produc
earlier
develop
ad
ad
symptom
less
sever
shorter
durat
suggest
stimul
neonat
period
potenti
ad
symptom
subsequ
immunohistochem
stain
show
increas
express
known
epiderm
stem
cell
marker
conclus
result
suggest
postnat
epiderm
develop
may
influenc
ad
develop
abstract
background
littl
known
regard
possibl
associ
lung
clearanc
index
lci
monitor
lung
heterogen
asthma
control
exacerb
aim
studi
determin
relationship
lci
level
asthma
control
cact
childhood
asthma
control
test
score
asthma
patient
method
studi
includ
patient
visit
outpati
depart
admit
depart
pediatr
cha
bundang
medic
center
cha
univers
octob
decemb
due
asthma
control
exacerb
level
asthma
control
classifi
accord
gina
guidelin
asthma
exacerb
appli
asthma
patient
hospit
measur
baselin
io
impuls
oscillometri
system
feno
fraction
exhal
nitric
oxid
spirometri
lci
evalu
cact
score
subject
result
subject
number
patient
asthma
control
group
partli
control
group
uncontrol
group
asthma
exacerb
group
respect
mean
age
group
year
statist
differ
across
group
spearman
correl
coeffici
reveal
signific
correl
cact
lci
scond
vt
signific
correl
cact
z
score
feno
signific
differ
lci
p
scondvt
p
p
differ
control
group
uncontrol
group
conclus
lci
scond
vt
close
correl
cact
score
good
paramet
differenti
level
asthma
control
background
chronic
inflamm
airway
airway
hyperrespons
ahr
key
patholog
featur
asthma
fraction
exhal
nitric
oxid
feno
close
relat
eosinophil
airway
inflamm
corticosteroid
respons
ahr
use
indirect
marker
degre
airway
inflamm
ahr
mannitol
close
relat
airway
inflamm
compar
ahr
methacholin
sought
evalu
associ
feno
ahr
adult
without
asthma
method
patient
symptom
suggest
asthma
feno
ahr
mannitol
methacholin
measur
total
underw
test
analyz
divid
four
group
low
high
feno
without
ahr
result
feno
respons
mannitol
measur
patient
feno
respons
methacholin
groupii
current
asthma
diagnos
groupii
nonasthmat
low
fenoahr
low
fenoahr
high
fenoahr
high
fenoahr
group
groupii
asthmat
groupii
neither
show
signific
differ
atopi
durat
asthma
use
inhal
corticosteroid
blood
sputum
eosinohil
regard
distribut
feno
ahr
except
signific
correl
observ
log
feno
log
responsedos
rate
rdr
mannitol
also
log
feno
log
rdr
methacholin
asthma
patient
conclus
asthma
patient
associ
feno
ahr
stronger
mannitol
methacholin
howev
signific
proport
patient
high
feno
ahr
mannitol
low
feno
ahr
methacholin
background
well
known
preval
allerg
diseas
increas
recent
decad
industri
countri
consid
rel
short
period
time
environment
factor
involv
phenomenon
studi
aim
evalu
correl
allerg
rhiniti
air
pollut
metropolitan
citi
incheon
seoul
korea
method
number
patient
visit
physician
allerg
rhiniti
incheon
seoul
obtain
medic
data
nation
health
insur
corpor
data
air
pollut
obtain
air
pollut
measur
system
measur
hour
interv
air
pollut
measur
co
ppm
ppm
ppm
ppm
level
air
pollut
district
interpol
krige
estim
geograph
inform
system
measur
data
air
pollut
adjust
age
annual
number
automobil
registr
ridg
regress
model
use
determin
correl
preval
allerg
rhiniti
annual
averag
concentr
air
pollut
result
preval
allerg
rhiniti
children
adolesc
respect
air
pollut
show
signific
correl
preval
allerg
rhiniti
adjust
ozon
yr
age
ozon
yr
yr
conclus
conclus
ozon
may
contribut
increas
risk
allerg
rhiniti
therefor
consid
monitor
air
pollut
preval
allerg
rhiniti
continu
clarifi
effect
air
pollut
allerg
rhiniti
korea
background
fraction
concentr
exhal
breath
feno
mainli
use
evalu
eosinophil
inflamm
asthma
also
propos
index
evalu
atop
diseas
allerg
rhiniti
mani
studi
suggest
use
feno
allerg
rhiniti
level
feno
may
differ
depend
race
age
environment
factor
studi
feno
korean
children
allerg
rhiniti
aim
studi
investig
use
feno
korean
children
allerg
rhiniti
b
method
children
age
enrol
subject
underw
skin
prick
test
pulmonari
function
test
methacholin
challeng
test
subject
classifi
group
children
allerg
rhiniti
ar
children
nonallerg
rhiniti
nar
children
asthma
children
ar
asthma
control
subject
feno
measur
subject
c
result
mean
level
feno
ar
ppb
asthma
ppb
arasthma
group
ppb
significantli
higher
compar
nar
ppb
control
group
ppb
p
signific
differ
feno
level
among
ar
asthma
arasthma
group
signific
differ
feno
level
ar
group
bhr
ar
group
without
bhr
skin
prick
test
mean
level
feno
greater
equal
group
ppb
significantli
higher
group
ppb
p
roc
curv
analysi
predict
ar
show
posit
predict
valu
cutoff
level
feno
ppb
conclus
level
feno
signific
correl
allerg
rhiniti
result
suggest
measur
feno
may
use
diagnosi
allerg
rhiniti
also
suggest
relationship
allerg
rhiniti
eosinophil
inflamm
like
asthma
although
express
system
eosinophil
reaction
bronchial
hyper
reactiv
object
explor
relationship
childhood
bronchial
asthma
allerg
rhiniti
calcul
incid
allerg
rhiniti
patient
bronchial
asthma
analys
correlationship
allerg
rhiniti
bronchial
asthma
clinic
perform
method
investig
case
children
bronchial
asthma
year
old
shinan
district
qingdao
questionnair
survey
includ
children
simpl
asthma
group
children
asthma
complic
allerg
rhiniti
group
ii
control
group
select
healthi
children
group
iii
answer
parent
comprehend
relev
circumst
concomit
diseas
allergi
histori
famili
histori
onset
schedul
establish
correspond
individu
databas
file
analyz
databi
statist
method
result
children
person
drug
allergi
histori
famili
allergi
histori
group
group
ii
significantli
higher
group
iii
p
chilaren
digest
skin
allergi
histori
significantli
higher
group
p
conclus
asthma
allerg
rhiniti
allerg
airway
diseas
close
correlationship
morbilliform
drug
erupt
common
form
cutan
advers
drug
reaction
account
entir
skin
side
effect
everi
drug
theoret
potenti
induc
drug
erupt
despit
frequenc
differ
trimebutin
wide
use
treatment
gastroenter
gastroesophag
reflux
diseas
irrit
bowel
syndrom
common
use
howev
report
dermatolog
side
effect
surprisingli
scarc
report
case
woman
prurit
morbilliform
skin
erupt
take
trimebutin
visit
clinic
year
ago
similar
skin
lesion
take
medic
contain
trimebutin
patient
underw
oral
provoc
test
develop
similar
gener
morbilliform
skin
erupt
hour
later
knowledg
first
case
report
trimebutineinduc
morbilliform
skin
erupt
background
bronchial
hyperrespons
bhr
assess
perform
bronchial
provoc
test
bpt
direct
stimuli
methacholin
indirect
stimuli
mannitol
aim
studi
examin
diagnost
properti
methacholin
mannitol
challeng
predict
exerciseinduc
bronchoconstrict
eib
athmat
children
method
eightynin
asthmat
children
year
old
enrol
exercis
challeng
conduct
subject
subject
underw
methacholin
bpt
subject
underw
mannitol
bpt
subject
underw
mannitol
methacholin
bpt
bhr
exercis
defin
fall
exercis
methacholin
mgml
mannitol
fall
mg
result
thirtyseven
subject
asthma
posit
exercis
challang
test
maximum
decreas
exercis
posit
correl
mannitol
correl
methacholin
asthmat
eib
sensit
methacholin
identifi
eib
specif
sensit
mannitol
specif
conclus
maximum
decreas
exercis
significantli
correl
mannito
methacholin
howev
methacholin
sensit
mannitol
identifi
eib
asthmat
children
background
human
metapneumoviru
hmpv
respiratori
syncyti
viru
rsv
share
epidemiolog
clinic
characterist
howev
studi
examin
whether
virus
induc
similar
cytokin
respons
studi
compar
cytokin
profil
hmpv
rsv
patient
investig
inflammatori
pathway
method
nasopharyng
aspir
specimen
collect
pediatr
patient
hospit
acut
respiratori
infect
includ
wheez
test
common
respiratori
virus
divid
hmpv
rsv
group
cytokin
profil
analyz
result
level
group
statist
similar
level
significantli
higher
rsv
compar
hmpv
group
p
level
group
detect
level
level
significantli
higher
hmpv
compar
rsv
group
p
conclus
result
suggest
hmpv
rsv
differ
inflammatori
mechan
hmpv
induc
airway
inflamm
pathway
releas
wherea
rsv
act
pathway
background
asthma
chronic
inflammatori
diseas
airway
potenti
link
microbi
infect
asthma
thought
environ
immun
genet
factor
potenti
role
bacteri
colon
infect
bronchial
mucosa
pathogenesi
asthma
rais
sever
recent
report
aim
studi
examin
alter
airway
microbiota
among
asthma
phenotyp
chines
adult
patient
method
induc
sputum
sampl
obtain
nonsmok
patient
stabl
asthma
healthi
subject
total
dna
amplifi
use
primer
specif
hypervari
region
bacteri
rrna
sampl
barcod
sequenc
gs
flx
sequenc
sequenc
assign
bacteri
taxa
compar
rrna
sequenc
ribosom
databas
project
result
asthmat
lower
predict
vs
p
higher
sputum
eosinophil
vs
p
compar
healthi
control
statist
differ
otu
number
divers
score
asthmat
nonasthmat
subject
phylum
level
differ
otu
rel
abund
remain
nonsignific
subject
eosinopihil
asthma
ea
older
shorter
durat
asthma
vs
year
well
lower
vs
p
compar
subject
noneosinopihil
asthma
nea
highest
otu
number
vs
vs
divers
score
includ
chao
index
vs
vs
ace
index
vs
vs
found
nea
group
follow
healthi
ea
group
phylum
level
ea
subject
higher
abund
firmicut
vs
lower
proteobacteria
vs
compar
nea
subject
although
differ
signific
conclus
patient
eosinophil
asthma
alter
microbi
composit
respiratori
tract
compar
subject
noneosinophil
asthma
correspond
biolog
effect
airway
inflamm
remain
determin
introduct
staphylococcu
aureu
sa
colonizationinfect
import
pathophysiolog
childhood
atop
dermat
ad
studi
evalu
clinic
featur
may
predict
presenc
sa
colonizationinfect
review
antimicrobi
sensit
sa
patient
ad
method
associ
bacteriolog
cultur
result
skin
swab
taken
sever
affect
area
antecubit
fossa
scoringatopicdermat
scorad
skin
hydrat
transepiderm
water
loss
tewl
qualiti
life
evalu
result
moderatetoheavi
growth
sa
present
swab
sever
area
flexur
antecubit
fossa
area
ad
patient
year
binomi
logist
regress
show
moderatetoheavi
growth
sa
associ
object
scorad
lesion
intens
erythema
lichenif
sever
area
excori
tewl
antecubit
fossa
rel
risk
isol
moderatetoheavi
growth
sa
affect
area
patient
sever
diseas
object
scorad
p
growth
sa
either
swab
site
associ
object
scorad
lesion
intens
sa
associ
qualiti
life
clinic
paramet
specimen
methicillinsensit
sa
sensit
cloxacillin
methicillinresist
sa
sensit
cotrimoxazol
fusid
acid
conclus
clinic
featur
especi
sever
lesion
intens
use
predict
presenc
sa
colonizationinfect
ad
patient
cloxacillin
favour
sensit
profil
methicillinsensitivesa
cotrimoxazol
fusid
acid
methicillinresistantsa
find
facilit
manag
patient
bacteriolog
result
becom
avail
background
vascular
endotheli
growth
factor
vegf
transform
growth
factor
tgf
platelet
deriv
growth
factor
pdgf
known
involv
pathogenesi
inflamm
remodel
asthmat
airway
chitinaselik
protein
clusterin
report
biomark
sever
asthma
examin
serum
level
growth
factor
clusterin
acut
asthma
stabl
asthma
investig
correl
clinic
find
lung
function
paramet
method
fortyon
children
age
asthma
enrol
group
defin
patient
admit
asthma
exacerb
patient
stabl
asthma
serum
level
vegf
pdgfbb
clusterin
measur
use
elisa
assess
relat
clinic
spirometr
paramet
fifteen
agematch
control
also
studi
result
vegf
level
children
acut
asthma
significantli
elev
compar
control
vegf
level
stabl
asthma
group
higher
control
differ
acut
asthma
group
vegf
level
acut
asthma
group
correl
significantli
asthma
sever
level
stabl
asthma
group
show
signific
invers
correl
relationship
clinic
spirometr
paramet
conclus
studi
suggest
increas
vegf
might
affect
asthmat
airway
acut
exacerb
also
stabl
state
also
suggest
serum
might
biomark
airway
obstruct
children
asthma
background
asthma
character
chronic
inflamm
associ
airway
hyperrespons
ahr
measur
use
bronchial
challeng
test
mannitol
indirect
challeng
show
better
reflect
complex
effect
inflamm
compar
direct
challeng
simpl
safe
practic
use
follow
airway
hyperreact
may
use
strategi
asthma
manag
hyperreact
may
abnorm
even
patient
mild
asthma
normal
lung
function
airway
hyperreact
may
better
reflect
airway
inflamm
risk
deterior
dose
lung
function
asthma
symptom
investig
analyz
followup
result
mannitol
challeng
test
asthma
patient
method
total
asthmat
repeat
mannitol
test
donga
univers
hospit
may
februari
compar
clinic
characterist
neg
convers
persist
ahr
group
result
fiftythre
show
ahr
mannitol
initi
test
ahr
neg
convers
groupi
persist
ahr
group
ii
followup
test
six
ahr
initi
test
respons
mannitol
followup
test
signific
differ
sex
age
smoke
habit
level
eosinophil
serum
sputum
baselin
lung
function
longer
durat
asthma
high
frequenc
asthma
exacerb
observ
group
iithan
group
proport
atopi
patient
higher
group
total
ige
sputum
eosinophil
much
decreas
group
compar
group
ii
conclus
studi
asthma
patient
show
persist
ahr
mannitol
neg
convers
group
ahr
may
associ
atopi
histori
ic
use
improv
eosinophil
inflamm
background
report
oral
food
challeng
ofc
test
walnut
object
purpos
studi
clarifi
risk
factor
predict
posit
result
walnut
ofc
subject
retrospect
analyz
patient
undergon
walnut
ofc
may
august
sagamihara
nation
hospit
method
open
ofc
perform
greater
walnut
measur
patient
walnut
specif
ige
within
year
ofc
furthermor
also
randomli
measur
subject
allergen
compon
eg
jug
r
jug
r
total
subject
judg
posit
patient
obviou
object
symptom
symptom
walnut
ofc
uncertain
encourag
take
quantiti
walnut
home
made
final
conclus
check
reproduc
next
visit
outpati
result
among
patient
patient
male
median
patient
age
rang
year
old
reason
elimin
walnut
follow
posit
specif
ige
histori
immedi
reaction
walnut
anxieti
etc
forti
eight
patient
atop
dermat
patient
asthma
patient
allerg
rhiniti
patient
allerg
conjunct
twenti
four
patient
histori
immedi
reaction
peanut
patient
histori
immedi
reaction
nut
ofc
posit
patient
five
patient
experienc
anaphylaxi
twenti
four
case
cutan
symptom
case
respiratori
symptom
case
gastrointestin
symptom
case
mucos
symptom
case
neurolog
symptom
twenti
five
patient
treat
antihistamin
patient
stimul
inhal
patient
steroid
drug
patient
adrenalin
compar
posit
patient
neg
patient
ofc
posit
patient
frequent
histori
immedi
reaction
walnut
vs
walnut
specif
ige
titer
posit
higher
neg
median
specif
ige
uaml
vs
uaml
twelv
patient
posit
jug
r
posit
ofc
conclus
healthcar
provid
prepar
high
posit
reaction
walnut
ofc
possibl
anaphylaxi
risk
factor
predict
posit
reaction
walnut
ofc
past
histori
immedi
reaction
walnut
high
titer
walnut
specif
ige
posit
jug
r
background
allerg
diseas
constitut
great
threat
human
health
studi
shown
seizur
progress
allerg
diseas
relat
indoor
environ
recent
year
environment
control
begun
adopt
world
object
order
probe
cur
effect
allerg
rhiniti
thought
air
filter
test
pm
includ
use
method
total
year
old
clinic
confirm
allerg
rhiniti
patient
select
use
air
filter
three
month
use
air
filter
everi
month
indoor
outdoor
pm
content
subject
test
chang
pm
valu
shown
pm
indoorpm
outdoor
addit
base
intern
studi
asthma
allergi
childhood
swedish
dbh
household
questionnair
rhinoconjunct
qualiti
life
questionnair
rqlq
combin
epidemiolog
characterist
guangzhou
allerg
diseas
observ
made
symptom
seizur
frequenc
anaphylact
diseas
patient
also
cur
effect
air
filter
base
environment
control
mean
allerg
diseas
evalu
questionnair
cover
famili
allerg
histori
allerg
histori
way
life
live
environ
symptom
ar
seizur
seizur
frequenc
etc
statist
softwar
use
inform
input
analysi
descript
statist
measur
data
nonparametr
test
repeat
measur
anova
use
comparison
among
group
p
differ
statist
signific
result
ratio
declin
p
applic
air
filter
statist
signific
ratio
differ
p
second
month
follow
applic
air
filter
time
prior
use
air
filter
accord
rqlq
result
subject
saw
signific
drop
nose
eye
emot
score
one
month
applic
air
filter
conclus
applic
air
filter
comprehens
enhanc
indoor
air
qualiti
improv
allerg
rhiniti
patient
qualiti
life
aim
relationship
airway
hyperrespons
ahr
atopi
previous
investig
still
issu
clarifi
aim
studi
assess
link
ahr
mannitol
atopi
asthmat
children
method
evalu
children
asthma
age
six
use
skin
prick
test
spt
serum
total
specif
immunoglobulin
e
ige
level
pulmonari
function
tet
perform
baselin
postbronchodil
inhal
mannitol
inhal
respons
mannitol
express
dose
caus
decreas
forc
expiratori
volum
one
second
atopi
presenc
least
one
posit
allergenspecif
ige
test
result
ige
kul
find
spt
result
subject
asthma
show
posit
result
mannitol
bronchial
provoc
test
bpt
mannitol
bptposit
group
subject
diagnos
atopi
mannitol
bptneg
group
subject
diagnos
atopi
signific
differ
atopi
preval
mannitol
bptposit
bptneg
group
found
correl
mannitol
serum
total
ige
r
conclus
children
pediatr
asthma
could
find
signific
correl
ahr
mannitol
atopi
preval
acetaminopen
one
drug
commonli
use
intent
selfpoison
nacetylcystein
nac
effect
antidot
acetaminophen
overdos
usual
given
intraven
hour
use
intraven
nac
caus
anaphylactoid
reaction
advers
reaction
cutan
manifest
involv
flush
pruritu
rash
urticaria
howev
system
reaction
bronchospasm
hypotens
etiolog
anaphylactoid
reaction
entir
understood
data
conflict
studi
conduct
evalu
ige
respons
rule
true
anaphylact
reaction
intraven
nac
typic
occur
within
minut
nac
infus
appear
dose
relat
rather
true
anaphylaxi
report
case
anaphylactoid
reaction
nac
yet
report
korea
femal
admit
via
emerg
depart
histori
depress
ingest
tablet
isoporylantipyrin
acetaminophen
suicid
attempt
precipit
famili
quarrel
suffer
dizzi
vomit
gastric
lavag
done
immedi
treat
nac
standard
regimen
consist
intraven
infus
nac
mgkg
bolu
mgkg
repeat
infus
mgkg
three
consecut
recov
valu
inr
demonstr
immedi
infus
nac
develop
gener
urticaria
nausea
vomit
chest
tight
dyspnea
hypotens
administr
nac
stop
epinephrin
antihistamin
administ
addit
activ
charcoal
use
prevent
drug
absorpt
laboratori
abnorm
seen
includ
serum
tryptas
recov
complet
without
sequela
within
acknowledg
research
support
grant
ministri
food
drug
safeti
oper
region
pharmacovigil
center
background
recent
found
prenat
matern
depress
anxieti
relat
offspr
respiratori
infect
atop
dermat
infanc
psycholog
stress
consid
import
program
factor
wheez
lung
develop
earli
life
moreov
genet
suscept
influenc
effect
offspr
health
matern
prenat
distress
object
investig
whether
prenat
matern
distress
associ
offspr
recurr
wheez
rw
gsdmb
polymorph
influenc
relationship
earli
childhood
method
studi
popul
consist
mother
babi
dyad
recruit
cocoa
birth
cohort
studi
prenat
matern
distress
evalu
selfreport
questionnair
week
pregnanc
center
epidemiolog
statetrait
anxieti
inventorytrait
subscal
stait
use
measur
matern
depress
anxieti
respect
genotyp
gsdmb
perform
taqman
assay
diagnosi
rw
assess
parent
report
physician
diagnosi
month
year
age
rw
defin
report
wheez
first
year
life
also
use
cox
regress
estim
associ
prenat
matern
distress
offspr
rw
result
cumul
incid
ci
rw
age
prenat
matern
depress
aor
ci
anxieti
aor
ci
increas
offspr
rw
age
hazard
ratio
hr
rw
year
followup
ci
depress
ci
anxieti
furthermor
ga
aa
genotyp
gsdmb
associ
higher
risk
rw
gsdmb
ga
aa
genotyp
prenat
matern
depress
aor
ci
p
interact
anxieti
aor
ci
p
interact
increas
risk
offspr
rw
conclus
prenat
matern
depress
anxieti
increas
risk
rw
earli
childhood
addit
prenat
matern
depress
comorbid
anxieti
associ
higher
risk
offspr
rw
effect
matern
prenat
distress
develop
rw
may
modifi
gsdmb
polymorph
although
signific
interact
found
prenat
distress
gsdmb
find
suggest
prevent
strategi
reduct
prenat
distress
may
improv
risk
rw
offspr
fund
sourc
research
support
fund
research
korea
center
diseas
control
prevent
introduct
vitamin
emerg
play
key
role
allerg
diseas
influenc
immun
system
studi
suggest
relationship
vitamin
statu
allerg
rhiniti
other
aim
systemat
review
observ
studi
investig
level
vitamin
preval
current
allerg
rhiniti
ar
develop
ar
method
use
standard
cochran
systemat
review
methodolog
search
medlin
embas
cochran
librari
koream
februari
put
restrict
languag
year
public
search
two
review
complet
duplic
independ
studi
select
data
abstract
assess
risk
bia
select
studi
current
level
preval
current
ar
level
cold
blood
previous
sampl
serum
develop
ar
result
select
crosssect
studi
current
level
preval
current
ar
prospect
studi
develop
ar
relat
previou
level
metaanalysi
perform
pool
odd
ratio
crosssect
studi
odd
ratio
top
vs
bottom
categori
prospect
studi
top
vs
bottom
categori
prospect
studi
analyz
addit
adjust
gener
epidemiolog
characterist
metaanalysi
perform
pool
adjust
odd
ratio
aor
prospect
studi
aor
top
vs
bottom
categori
discuss
avail
evid
metaanalysi
suggest
level
may
relat
neither
preval
current
ar
develop
ar
sinc
studi
heterogen
retrospect
observ
cohort
studi
larg
random
control
trial
need
determin
whether
vitamin
supplement
may
benefici
prevent
ar
background
impuls
oscillometri
io
develop
noninvas
method
evalu
lung
function
measur
respiratori
resist
reactanc
respiratori
resist
reactanc
measur
tidal
breath
wholebreath
analysi
measur
separ
inspir
expir
inspiratoryexpiratori
analysi
known
reactanc
inspiratoryexpiratori
analysi
detect
expiratori
flow
limit
investig
characterist
inspiratoryexpiratori
measur
obtain
io
children
asthma
method
enrol
children
asthma
male
healthi
control
male
age
yr
children
asthma
diagnos
accord
atser
guidelin
spirometri
wholebreath
inspiratoryexpiratori
impuls
oscillometri
perform
enrol
children
measur
assess
asthmat
children
compar
control
subject
result
wholebreath
io
analys
asthmat
children
increas
resist
vs
kpal
p
increas
vs
kpal
decreas
reactanc
hz
kpal
p
increas
reactanc
area
ax
vs
kpal
p
control
subject
inspiratoryexpiratori
io
analysi
expiratori
ax
higher
inspiratori
ax
asthmat
children
vs
kpal
p
control
subject
vs
kpal
p
chang
ax
expir
inspir
larger
asthmat
children
compar
control
subject
kpal
vs
kpal
p
wherea
chang
expir
inspir
signific
asthmat
children
control
subject
kpal
p
conclus
children
asthma
significantli
differ
healthi
control
wholebreath
impuls
oscillometri
larger
inspiratoryexpiratori
variat
ax
analysi
asthmat
children
control
subject
could
reflect
airway
narrow
expir
childhood
asthma
keyword
impuls
oscil
system
asthma
wholebreath
analysi
inspiratoryexpiratori
analysi
object
diagnosi
asthma
challeng
preschool
children
wheez
asthma
predict
index
api
use
tool
predict
asthma
decid
whether
initi
control
therapi
preschool
children
aim
studi
investig
whether
api
associ
doctor
diagnosi
asthma
preschool
children
recurr
wheez
find
relev
criteria
asthma
method
perform
populationbas
crosssect
studi
children
age
year
total
children
complet
modifi
intern
studi
asthma
allergi
childhood
questionnair
children
recurr
wheez
enrol
recurr
wheez
defin
lifetim
wheez
time
result
preval
doctor
diagnosi
asthma
percentag
children
met
api
major
minor
posit
api
show
tendenc
associ
doctor
diagnosi
asthma
preschool
children
recurr
wheez
ci
among
api
criteria
doctor
diagnosi
allerg
rhiniti
ar
significantli
associ
asthma
ci
conclus
doctor
diagnosi
ar
like
highest
associ
asthma
among
criteria
api
preschool
children
recurr
wheez
background
respiratori
syncyti
viru
rsv
common
caus
lower
respiratori
ill
lri
infanc
earli
childhood
rsv
report
induc
immun
respons
increas
ige
product
acut
infect
aim
investig
relationship
serum
total
ige
level
clinic
characterist
children
rsvassoci
lri
rsvlri
method
one
hundr
seven
children
year
age
admit
rsvlri
bronchiol
andor
pneumonia
enrol
patient
divid
group
accord
total
serum
ige
level
admiss
high
ige
group
normal
ige
group
high
ige
level
defin
valu
higher
standard
deviat
sd
agematch
mean
valu
medic
record
patient
investig
determin
differ
demograph
characterist
clinic
laboratori
find
admiss
recurr
wheez
within
year
discharg
group
among
patient
lri
first
time
live
reanalyz
data
relat
ige
level
addit
differ
children
isol
rsv
infect
mix
infect
virus
examin
result
median
age
month
high
ige
group
month
normal
ige
group
p
male
preponder
observ
high
ige
group
p
frequenc
durat
fever
sever
symptom
concurr
respiratori
difficulti
significantli
higher
high
normal
ige
group
p
differ
admiss
day
parent
allerg
diseas
nearli
find
observ
reanalysi
data
patient
rsvlri
recurr
wheez
discharg
significantli
higher
high
ige
group
p
children
isol
rsv
infect
show
frequent
prolong
wheez
mix
infect
conclus
studi
children
present
high
serum
ige
level
rsvlri
sever
symptom
compar
normal
ige
level
result
suggest
increas
immun
respons
induc
acut
rsv
infect
might
associ
sever
clinic
present
lri
pollen
close
relat
health
issu
allergen
rhiniti
asthma
well
intensifi
atop
syndrom
inform
current
futur
spatiotempor
distribut
allergen
pollen
need
address
issu
studi
asian
dust
aerosol
model
util
base
model
system
forecast
pollen
dispers
oak
tree
pollen
emiss
one
import
part
dispers
model
system
areal
emiss
factor
determin
grid
areal
fraction
oak
tree
produc
analysi
tree
type
map
obtain
korea
forest
servic
daili
total
pollen
product
estim
robust
multipl
regress
model
weather
condit
pollen
concentr
hourli
emiss
factor
determin
wind
speed
friction
veloc
hourli
pollen
emiss
calcul
multipli
areal
emiss
factor
daili
total
pollen
product
hourli
emiss
factor
forecast
data
um
ldap
unifi
model
local
data
assimil
predict
system
util
input
verif
model
daili
observ
pollen
concentr
site
korea
pollen
season
although
model
show
tendenc
overestim
term
season
daili
mean
concentr
overal
concentr
similar
observ
comparison
hourli
output
show
distinct
delay
peak
hour
model
pocheon
site
specul
constant
releas
hourli
number
pollen
model
framework
caus
delay
background
object
studi
investig
shortterm
effect
meteorolog
factor
air
pollut
sever
persist
atop
dermat
ad
symptom
infant
young
children
method
present
studi
infant
young
children
ad
age
year
live
seoul
metropolitan
area
korea
enrol
follow
month
august
decemb
ad
symptom
describ
degre
scale
itch
sleep
disturb
erythema
dryness
ooz
edema
record
daili
basi
gener
linear
mix
model
glmm
binomi
distribut
error
use
estim
effect
meteorolog
factor
daili
mean
temperatur
rel
humid
diurnal
temperatur
rang
dtr
air
pollut
nitrogen
dioxid
ozon
ad
symptom
potenti
confound
factor
includ
age
sex
symptom
sever
scorad
initi
visit
presenc
fever
day
week
control
move
averag
previou
consecut
day
use
repres
lag
effect
meteorolog
variabl
air
qualiti
ad
symptom
result
personday
rate
posit
ad
symptom
studi
period
increas
daili
mean
temperatur
rel
humid
significantli
associ
ci
ci
decreas
ad
symptom
respect
particularli
spring
increas
dtr
relat
ci
increas
ad
symptom
effect
move
averag
day
previou
three
consecut
day
estim
increas
concentr
increas
ad
symptom
ci
increas
concentr
ppb
ozon
associ
increas
ad
symptom
ci
ci
respect
hazard
effect
ad
symptom
note
significantli
spring
ozon
found
winter
conclus
shortterm
exposur
temperatur
humid
air
pollut
strongli
associ
ad
symptom
clean
air
qualiti
essenti
appropri
manag
ad
symptom
children
background
pulmonari
fibrosi
lung
diseas
hardli
cure
high
mortal
rate
recent
studi
suggest
play
central
role
pathogenesi
pulmonari
fibrosi
compound
v
isol
natur
sourc
use
antioxid
howev
find
compound
suppress
express
collagen
treat
lung
fibroblast
cell
line
therefor
would
like
realiz
influenc
compound
lung
fibrosi
anim
model
method
establish
pulmonari
fibrosi
anim
model
treat
mice
bleomycin
day
intratrach
inject
treat
compound
v
oral
daili
day
day
collect
mice
bronchoalveolar
lavag
fluid
spleen
lung
section
observ
effect
compound
v
pulmonari
fibrosi
anim
model
elisa
histolog
scireq
machin
detect
mice
lung
function
result
compound
v
improv
lung
fibrosi
physiolog
significantli
scireq
collagen
express
lung
section
also
decreas
appar
conclus
find
indic
compound
v
reduc
collagen
express
bleomycininduc
pulmonari
fibrosi
anim
model
figur
mechan
compound
v
pulmonari
fibrosi
object
explor
vitamin
vit
level
analys
correl
immunoglobulin
e
ige
children
allerg
respiratori
diseas
guangzhou
china
method
children
patient
allerg
respiratori
diseas
jun
august
experiment
group
detect
kind
serum
specif
ige
total
ige
antibodi
health
children
control
group
use
elecsi
detect
vit
concentr
result
vit
averag
concentr
experiment
group
male
ngml
control
group
ngml
male
ngml
ngml
signific
differ
two
group
sex
age
vit
concentr
neg
correl
experiment
group
control
group
experiment
group
level
total
dp
specif
ige
neg
correl
serum
concentr
vitamin
rs
respect
level
cow
milk
specif
ige
posit
correl
serum
concentr
vitamin
use
multivari
linear
regress
analysi
adjust
sex
age
signific
associ
total
ige
serum
vitamin
b
ci
children
allerg
respiratori
diseas
also
signific
associ
total
dp
specif
ige
serum
vitamin
b
ci
b
ci
respect
children
dp
sensit
conclus
serum
vit
level
could
associ
increas
risk
allerg
diseas
develop
introduct
eosinophil
gastroenter
eg
rare
diseas
variou
gastrointestin
symptom
character
promin
eosinophil
infiltr
eg
heterogen
clinic
manifest
etiolog
remain
unknown
describ
two
case
eg
associ
allerg
diseas
case
first
case
man
visit
emerg
room
complain
abdomin
pain
diarrhea
nausea
last
day
upper
respiratori
infect
experi
treat
eg
pancreat
asciti
year
ago
laboratori
find
peripher
wbc
count
eosinophilia
endoscop
studi
abdomin
comput
tomographi
diagnos
eg
refer
allerg
clinic
complain
food
relat
allergi
symptom
except
intermitt
mild
rhiniti
symptom
cough
exhibit
elev
serum
total
ige
level
posit
respons
hous
dust
mite
japanes
hop
pollen
skin
prick
test
lung
function
test
show
obstruct
pattern
posit
respons
bronchodil
final
diagnos
eg
allerg
rhiniti
bronchial
asthma
treat
prednisolon
therapi
eg
recommend
take
antiallerg
medic
well
second
case
femal
nausea
indigest
sever
month
treat
eosinophil
gastriti
endoscop
one
month
anoth
hospit
symptom
persist
aggrav
milk
ingest
moreov
urticari
newli
develop
form
week
ago
wbc
count
eosinophilia
skin
prick
test
show
posit
respons
hous
dust
mite
grass
pollen
high
serum
specif
ige
level
milk
note
diagnos
eg
food
allergi
urticaria
recommend
avoid
milk
oral
antihistamin
therapi
three
month
food
restrict
medic
symptom
improv
endoscop
studi
normal
conclus
report
two
case
eg
associ
respiratori
food
allergi
respect
although
eg
variou
clinic
manifest
report
suggest
possibl
coexist
eg
allerg
diseas
consid
background
mani
studi
investig
genet
factor
caus
predisposit
drug
hypersensit
howev
studi
focus
specif
phenotyp
drug
thu
plan
perform
genomewid
associ
gwa
studi
discov
common
genet
marker
associ
immedi
delay
drug
hypersensit
reaction
method
studi
patient
diagnos
drug
hypersensit
tertiari
referr
hospit
control
subject
divid
patient
group
immediatetyp
hypersensit
reaction
delayedtyp
hypersensit
reaction
accord
type
drug
hypersensit
genomewid
snp
genotyp
patient
perform
use
genom
dna
peripher
blood
lymphocyt
result
immediatetyp
hypersensit
reaction
group
found
signif
associ
total
gene
wherea
five
gene
show
signif
associ
delayedtyp
hypersensit
reaction
group
top
snp
immediatetyp
hypersensit
group
well
also
identifi
delayedtyp
hypersensit
group
interestingli
two
gene
overlap
two
group
name
lipopolysacchariderespons
beigelik
anchor
lrba
gene
methionin
adenosyltransferas
beta
gene
associ
snp
gene
commonli
found
immedi
delay
type
hypersensit
reaction
lrba
p
x
p
x
respect
p
x
p
x
respect
conclus
genet
variant
lrba
gene
might
signific
genet
marker
drug
hypersensit
reaction
replic
studi
also
need
confirm
find
background
clinic
cours
atop
dermat
ad
highli
divers
previou
epidemiolog
studi
preval
diseas
sever
ad
show
condit
certain
time
point
patient
develop
questionnair
secular
chang
ad
sever
perform
webbas
studi
patient
ad
japan
b
method
first
creat
pilot
questionnair
consist
nine
basic
pattern
space
free
draw
secular
chang
ad
birth
analysi
answer
patient
ad
visit
depart
dermatolog
hiroshima
univers
reveal
subject
clinic
cours
patient
fell
one
basic
pattern
next
complet
questionnair
patient
choos
one
nine
basic
pattern
applic
na
use
webbas
epidemiolog
studi
use
macromil
onlin
research
system
macromil
inc
tokyo
japan
first
studi
conduct
particip
year
age
march
total
individu
declar
ever
diagnos
ad
among
subject
ad
histori
ad
individu
chose
one
present
nine
pattern
individu
chose
na
ad
option
choic
ad
develop
word
prompt
subject
avoid
na
perform
anoth
survey
use
revis
questionnair
subject
ad
februari
c
result
latest
studi
show
individu
chose
na
individu
chose
ad
develop
chose
secular
chang
ad
classifi
one
nine
repres
pattern
interestingli
chose
improv
curv
chose
nearli
flat
curv
chose
exacerb
curv
chose
curv
repres
improv
exacerb
curv
chose
curv
repres
exacerb
improv
conclus
epidemiolog
survey
use
new
questionnair
give
us
new
clinic
aspect
ad
secular
chang
diseas
sever
may
influenc
acquir
condit
includ
treatment
environment
factor
epidemiolog
studi
correl
secular
chang
treatment
patient
characterist
includ
medic
phobia
may
give
us
new
insight
manag
ad
background
adher
start
questionnair
investig
caus
decreas
medic
adher
purpos
studi
investig
inhal
drug
adher
statu
asthma
patient
subject
seventyfour
patient
bronchial
asthma
whose
symptom
rel
stabl
mean
age
yearold
male
femal
use
inhal
drug
method
analyz
evalu
item
point
point
order
heavi
degre
among
five
choic
answer
base
describ
inhal
drug
subject
result
lifestyl
ratio
point
attitud
belief
ratio
point
help
other
ratio
point
talk
healthcar
team
ratio
point
talk
medicin
ratio
point
ratio
point
conclus
result
patient
sometim
forget
medicin
half
ratio
patient
consult
drug
elimin
noteworthi
patient
like
inhal
twice
day
result
patient
wrong
number
amount
take
medicin
result
patient
medicin
specifi
time
result
consider
consid
adher
increas
could
switch
inhal
drug
day
approxim
patient
thought
troublesom
twice
inhal
day
background
studi
perform
investig
epidemiolog
clinic
featur
human
metapneumoviru
hmpv
method
perform
realtim
rtpcr
nasopharyng
sampl
children
hospit
acut
respiratori
infect
medic
record
children
diagnos
hmpv
respiratori
infect
analyz
retrospect
compar
epidemiolog
data
respiratori
viru
infect
report
korea
center
diseas
control
prevent
result
detect
hmpvposit
case
virusposit
specimen
prevail
mostli
spring
march
may
respiratori
infect
hmpv
common
femal
popul
age
distribut
hpmv
infect
month
year
year
year
year
age
show
hpmv
preval
among
children
age
year
coinfect
respiratori
virus
observ
patient
hmpvposit
case
rhinoviru
adenoviru
bocaviru
rsv
parainfluenza
coronaviru
outbreak
hmpv
infect
found
among
hmpvposit
patient
recent
year
patient
diagnos
hmpv
detect
rate
among
virusposit
case
influenza
viru
infect
preval
mainli
januari
march
hmpv
infect
start
appear
end
influenza
viru
outbreak
hpmv
infect
mostli
present
pneumonia
common
younger
children
compar
hmpv
infect
mean
age
vs
conclus
infect
hpmv
preval
among
children
year
age
hmpv
common
caus
organ
viral
pneumonia
spring
season
korean
children
hmpv
infect
pandem
observ
clinic
import
hmpv
increas
recent
therefor
addit
studi
requir
defin
epidemiolog
diseas
characterist
caus
hmpv
caus
recent
outbreak
intraven
immunoglobulin
ivig
use
immunomodulatori
agent
variou
autoimmun
diseas
gener
consid
safe
therapi
advers
effect
ae
associ
ivig
administr
mild
transient
immedi
ae
includ
headach
flush
fever
anaphylact
reaction
especi
igadefici
patient
late
ae
rare
includ
acut
renal
failur
thromboembol
event
asept
mening
neutropenia
patient
antibodi
defici
prone
develop
acut
netropen
episod
even
ivig
replac
iviginduc
neutropenia
transient
mild
moder
sever
infecti
complic
report
report
case
neutropenia
patient
guiilianbarr
syndrom
gb
infus
ivig
femal
present
histori
quadriparesi
previou
medic
histori
develop
myalgia
progress
descend
weak
involv
upper
lower
extrem
electrophysiolog
studi
show
motor
domin
neuropathi
abnorm
find
brain
magnet
reson
imag
rais
protein
concentr
normal
cell
count
observ
cerebrospin
fluid
csf
virusspecif
antibodi
bacteria
fungi
detect
csf
blood
urin
administr
ivig
daili
gb
gradual
recov
strength
extrem
day
day
administr
ivig
sever
neutropenia
absolut
neutrophil
count
occur
tue
infus
ivig
stop
howev
neutropenia
last
day
develop
fever
given
granulocyt
colonystimul
factor
improv
discharg
infecti
neurolog
complic
hospit
day
acknowledg
research
support
grant
ministri
food
drug
safeti
oper
region
pharmacovigil
center
introduct
lymphocyt
interstiti
pneumon
lip
uncommon
histopatholog
entiti
character
infiltr
interstitium
alveolar
space
lung
lymphocyt
plasma
cell
lymphoreticular
element
lip
children
commonli
associ
human
immunodefici
viru
hiv
infect
report
first
case
lip
hivneg
healthi
adolesc
case
report
boy
repres
pneumonia
chest
xray
routin
health
examin
respiratori
symptom
abnorm
find
physic
examin
chest
ct
show
multipl
ill
defin
centrilobular
nodul
peribronchi
air
space
nodul
mild
volum
loss
rll
increas
igg
mycoplasma
pneumonia
antibodi
titer
serial
test
day
interv
tuberculin
skin
test
tbc
specif
antigen
induc
interferongamma
igra
test
neg
chest
xray
regular
interv
month
show
improv
pneumon
consolid
new
pneumon
consolid
site
therefor
open
lung
biopsi
perform
show
diffus
interstiti
lymphocyt
infiltr
lung
tissu
neg
ebv
dnapcr
ebv
serolog
show
allneg
serum
immunoglobulin
normal
autoimmun
studi
neg
total
lymphocyt
count
lymphocyt
subset
normal
start
oral
prednison
mgkgday
month
chest
xray
return
normal
taper
oral
prednison
month
followup
chest
ct
show
abnorm
find
follow
month
diagnosi
without
complic
conclus
report
first
case
hivneg
ebvneg
lip
healthi
child
background
epidemiolog
data
cohort
studi
indic
associ
caesarean
section
develop
allergi
infant
besid
delay
colon
commens
bacteria
turn
affect
immun
system
develop
cytokin
profil
csection
deliv
infant
could
differ
may
implic
infant
immun
method
clinic
studi
conduct
kk
women
children
hospit
cord
blood
sampl
caesarean
sectiondeliv
infant
collect
evalu
respons
allergen
cord
blood
cell
freshli
isol
cordblood
mononuclear
cell
cbmc
cultur
plate
cell
per
well
triplic
per
condit
stimul
extract
either
one
major
hous
dust
mite
speci
blomia
tropicali
blot
dermatophagoid
pteronyssinu
derp
phytohemagglutinin
pha
lipopolysaccharid
lp
use
posit
control
supernat
cutur
harvest
stimul
analyz
use
bioplex
protm
human
cytokin
assay
product
ifngamma
tnfalpha
allergenstimul
cbmc
analyz
result
derp
stimul
induc
higher
respons
compar
blot
stimul
follow
derp
stimul
median
valu
pgml
pgml
pgml
pgml
ifngamma
pgml
pgml
tnfalpha
pgml
pgml
among
analys
subject
subject
show
higher
express
ifngamma
pgml
lower
express
pgml
subject
display
higher
express
pgml
tnfalpha
level
detect
high
subject
note
correl
strong
product
cytokin
parent
allergi
histori
observ
conclus
observ
strong
product
cytokin
csectiondeliv
infant
upon
derp
stimul
interestingli
infant
histori
parent
allergi
find
might
indic
utero
sensit
infant
cytokin
profil
cord
blood
might
use
earli
sign
atop
manifest
futur
plan
followup
subject
order
monitor
develop
allerg
respons
later
life
drug
reaction
eosinophilia
system
symptom
dress
syndrom
rare
sever
druginduc
hypersensit
syndrom
character
hematolog
abnorm
multiorgan
involv
liver
involv
common
viscer
manifest
howev
renal
failur
rare
describ
common
culprit
drug
anticonvuls
allopurinol
experienc
patient
dress
syndrom
acut
interstiti
nephriti
caus
concomit
administr
quinolon
nonsteroid
antiinflammatori
drug
nsaid
man
present
diffus
erythemat
rash
fever
develop
administr
quinolon
nsaid
month
due
prostat
diagnos
dress
syndrom
skin
rash
fever
eosinophilia
elev
liver
enzym
improv
conserv
treatment
discontinu
caus
drug
howev
deterior
renal
function
occur
day
admiss
level
blood
urea
nitrogen
serum
creatinin
increas
oliguria
proteinuria
urinari
eosinophil
observ
ultrasonographi
show
diffus
renal
enlarg
clinic
featur
compat
acut
interstiti
nephriti
despit
intraven
rehydr
diuret
renal
function
improv
hemodialysi
renal
function
recov
complet
within
week
without
administr
system
corticosteroid
acknowledg
research
support
grant
ministri
food
drug
safeti
oper
region
pharmacovigil
center
background
postul
critic
mediat
contribut
airway
inflamm
hous
dust
mite
hdm
one
common
allergen
howev
role
hdminduc
mous
model
well
understood
object
evalu
role
hdminduc
allerg
asthma
model
particularli
allergen
sensit
period
method
balbc
mice
repeatedli
administ
hdm
intranas
develop
acut
allerg
asthma
model
antibodi
given
hdm
sensit
period
analyz
activ
dc
ldln
last
sensit
addit
evalu
role
bronchial
epithelium
contact
hdm
vitro
cell
experi
done
hdm
stimul
andor
antibodi
treatment
result
antibodi
treatment
allergen
sensit
significantli
diminish
sever
phenotyp
allerg
asthma
particularli
eosinophil
inflamm
airway
hyperrespons
markedli
reduc
bronchoalveolar
lavag
fluid
cytokin
level
significantli
reduc
antibodi
treat
mice
activ
dc
ldln
significantli
reduc
last
sensit
vitro
studi
treatment
prevent
proinflammatori
proallerg
cytokin
respons
hdmstimul
cell
conclus
may
play
signific
role
allerg
asthma
allergen
sensit
period
particularli
may
significantli
involv
allergencontact
epitheli
cell
respons
final
lead
allerg
sensit
background
high
preval
rate
asthma
allerg
rhiniti
recent
shown
south
korea
better
prevent
develop
exacerb
allerg
diseas
secondari
prevent
symptom
atop
dermat
ad
could
effect
aspect
allerg
march
reason
aim
explor
variat
indoor
risk
factor
may
link
chang
symptom
ad
develop
asthma
andor
allerg
rhiniti
method
recruit
home
ad
patient
age
around
month
old
along
score
atop
dermat
scorad
index
greater
environment
health
center
asthma
atop
allergi
total
volatil
organ
compound
tvoc
formaldehyd
hcho
airborn
mold
bacteria
particul
matter
diamet
less
mm
measur
dwell
indoor
outdoor
particularli
level
tvoc
monitor
hr
use
direct
read
instrument
well
result
environment
survey
perform
total
hous
mean
age
standard
deviat
sd
scorad
index
subject
year
old
respect
geometr
mean
gm
concentr
airborn
mold
refer
recommend
level
howev
correspond
valu
airborn
bacteria
korean
standard
guidelin
exposur
level
gaseou
pollut
indoor
tvoc
hcho
rang
respect
outdoor
level
tvoc
hcho
highest
level
tvoc
use
direct
read
instrument
observ
midnight
even
respect
conclus
find
indic
compar
amount
bioaerosol
gaseou
pollut
indoor
observ
patient
dwell
particularli
differ
exposur
pattern
particul
matter
tovc
shown
time
proper
prevent
strategi
prepar
background
peripher
blood
eosinophilia
common
clinic
manifest
draw
medic
attent
howev
littl
report
blood
eosinophilia
elderli
aim
investig
normal
rang
blood
eosinophil
associ
factor
includ
allerg
paramet
use
dataset
communitybas
random
elderli
popul
korea
method
crosssect
analysi
perform
use
databas
korean
longitudin
studi
health
age
communitybas
elderli
cohort
primari
outcom
peripher
blood
eosinophil
count
upper
limit
confid
interv
absolut
count
blood
eosinophil
count
calcul
normal
rang
demograph
socioeconom
metabol
comorbid
allerg
paramet
lung
function
analyz
atopi
defin
skin
test
posit
common
inhal
allergen
allerg
histori
symptom
assess
questionnair
result
cutoff
valu
blood
eosinophilia
less
preval
eosinophilia
hypereosinophilia
respect
univari
analys
blood
eosinophil
count
significantli
relat
male
sex
smoke
statu
howev
multivari
analys
associ
blood
eosinophil
count
male
sex
appear
least
partli
depend
smoke
statu
potenti
determin
p
univari
analys
bodi
mass
index
atopi
current
wheez
physiciandiagnos
asthma
multivari
linear
regress
analys
relationship
blood
eosinophil
count
potenti
determin
factor
examin
conclus
normal
rang
peripher
blood
eosinophil
korean
elderli
upper
percentil
almost
ident
refer
rang
literatur
smoke
major
determin
factor
eosinophilia
explain
associ
eosinophilia
male
sex
determin
factor
bodi
mass
index
atopi
asthma
find
could
suggest
potenti
role
blood
eosinophil
epidemiolog
marker
atopi
asthma
elderli
popul
stevensjohnson
syndrom
sj
sever
acut
mucocutan
bullou
disord
commonli
druginduc
antibiot
common
caus
sj
follow
analges
nonsteroid
antiinflammatori
drug
anticonvuls
antigout
drug
methotrex
folic
acid
antagonist
use
treatment
psoriasi
rheumatoid
arthriti
neoplast
diseas
includ
leukemia
lymphoma
princip
toxic
effect
bone
marrow
suppress
gastrointestin
mucos
hepat
renal
impair
erythemat
rash
sj
report
patient
receiv
intermedi
high
dose
methotrex
whether
epiderm
necrolysi
allerg
doserel
toxic
reaction
still
controversi
report
case
sj
patient
receiv
low
dose
methotrex
psoriasi
male
present
gener
erythemat
rash
eros
sever
oral
ulcer
start
allopurinol
well
toler
year
patient
histori
lowdos
methotrex
treatment
mgday
day
develop
complaint
second
day
methotrex
treatment
erythemat
itchi
edemat
rash
develop
leg
spread
wide
trunk
extrem
subsequ
bullou
format
suffer
aggrav
oropharyng
ulcer
admit
local
hospit
treat
system
corticosteroid
day
skin
lesion
improv
transfer
hospit
persist
pain
ulcer
odynophagia
treat
topic
steroid
skin
lesion
total
parenter
nutrit
start
difficulti
eat
recov
gradual
discharg
support
therapi
without
addit
system
corticosteroid
acknowledg
research
support
grant
ministri
food
drug
safeti
oper
region
pharmacovigil
center
background
asthma
trait
determin
complex
interact
predisposit
gene
environment
influenc
gabriel
consortium
identifi
metaanalysi
genomewid
associ
studi
ten
asthma
loci
nonetheless
relev
loci
longitudin
chang
patient
lung
function
remain
unknown
prospect
cohort
studi
investig
effect
asthma
loci
chang
spirometr
indic
among
chines
asthmat
children
method
chines
asthmat
children
age
year
recruit
paediatr
allergi
clinic
patient
prospect
follow
five
year
prebronchodil
spirometri
record
baselin
monitor
least
annual
spirometr
indic
compar
local
refer
genom
dna
patient
genotyp
singlenucleotid
polymorph
snp
asthma
loci
taqman
genotyp
assay
generalis
estim
equat
use
analys
effect
snp
longitudin
chang
lung
function
paramet
result
mean
sd
age
patient
baselin
year
male
twentyeight
percent
passiv
smoke
ever
receiv
inhal
corticosteroid
ic
treatment
followup
three
quarter
patient
famili
histori
allergi
genotyp
due
unavail
taqman
assay
adjust
age
sex
passiv
smoke
exposur
ic
treatment
presenc
upper
respiratori
infect
within
two
week
significantli
associ
p
fvc
p
p
gsdmb
also
associ
p
six
snp
rora
show
signific
associ
longitudin
chang
spirometr
index
conclus
first
asian
studi
genet
determin
lung
function
growth
appear
candid
gene
longitudin
chang
sever
spirometr
indic
among
chines
children
asthma
larger
cohort
need
replic
find
due
low
frequenc
risk
allel
among
patient
fund
research
grant
council
gener
research
fund
research
committe
group
research
scheme
direct
grant
research
cuhk
background
usual
rhiniti
classifi
simpli
allerg
nonallerg
rhiniti
accord
allerg
reaction
airborn
allergen
ig
inflamm
confirm
posit
skin
test
presenc
specif
ige
posit
result
one
two
test
usual
enough
diagnosi
allerg
rhiniti
interest
diagnost
power
allergen
specif
ig
e
recent
korean
nation
health
nutrit
examin
survey
presenc
rhiniti
specif
ig
e
major
airborn
allergen
check
popul
purpos
studi
evalu
signific
allergen
specif
ig
e
diagnosi
allerg
rhiniti
b
method
data
obtain
korean
nation
hane
crosssect
survey
noninstitution
popul
around
countri
presenc
rhiniti
defin
experi
rhiniti
symptom
diagnos
allerg
rhiniti
doctor
serum
specif
ige
check
dermatophagoid
farina
cockroach
dog
data
obtain
adult
older
posit
predict
valu
ppv
allergen
specif
ige
diagnosi
allerg
rhiniti
calcul
accord
level
specif
ig
e
c
result
specif
ig
e
higher
kul
found
popul
rhiniti
popul
without
rhiniti
ppv
level
kul
level
kul
preval
allerg
rhiniti
increas
increas
level
specif
ige
ppv
also
increas
howev
posit
predict
rate
level
kul
level
kul
conclus
diagnost
power
specif
ige
classif
rhiniti
high
level
specif
ig
e
higher
kul
may
clinic
signific
background
allergen
immunotherapi
ait
current
immunemodifi
treatment
allerg
diseas
clinic
efficaci
ait
treatment
allerg
rhiniti
bronchial
asthma
well
document
howev
mani
factor
includ
inconveni
cost
side
effect
adher
influenc
initi
persist
ait
sought
evalu
ait
practic
pattern
patient
attitud
behavior
ait
method
conduct
retrospect
analysi
medic
record
patient
receiv
ait
compar
clinic
characterist
convent
cit
rush
immunotherapi
rit
total
perform
questionnair
survey
result
patient
treat
cit
rit
signific
differ
allerg
diseas
allergen
immunotherapi
frequenc
system
advers
reaction
buildup
phase
rate
miss
patient
higher
cit
rit
vs
patient
initi
ait
mainli
accord
physician
recommend
cit
vs
rit
patient
rit
person
insur
show
better
treatment
satisfact
cit
concern
advers
event
main
reason
start
cit
frequent
hospit
visit
start
rit
conclus
major
patient
initi
ait
accord
physician
recommend
show
good
treatment
satisfact
rit
may
give
better
clinic
outcom
cit
background
immun
respons
staphylococc
enterotoxin
may
contribut
pathogenesi
asthma
object
investig
role
staphylococc
enterotoxin
b
seb
mous
asthma
model
method
balbc
mice
intranas
sensit
dermatophagoid
pteronyssinu
der
p
andor
seb
develop
acut
asthma
model
mice
group
see
effect
seb
der
p
interact
sensit
challeng
period
outcom
evalu
methacholin
airway
hyperrespons
ahr
lung
inflammatori
cell
lung
cytokin
serum
ige
vitro
der
pstimul
splenocyt
respons
result
intranas
seb
exposur
increas
lung
macrophag
lymphocyt
neutrophil
infiltr
seb
alon
develop
typic
asthmat
phenotyp
effect
seb
asthma
phenotyp
evid
coadminist
der
p
sensit
period
develop
ahr
lung
eosinophil
inflamm
der
p
challeng
serum
der
p
specif
ige
level
also
amplifi
seb
cosensit
vitro
der
p
restimul
experi
respons
also
increas
splenocyt
mice
cosensit
seb
der
p
conclus
present
find
indic
role
seb
der
pinduc
allerg
asthma
particularli
sensit
period
background
drug
reaction
eosinophilia
system
symptom
dress
syndrom
rare
diseas
caus
sever
morbid
mortal
report
dress
syndrom
uncommon
gener
recogn
previou
studi
object
investig
clinic
manifest
dress
syndrom
compar
previou
data
method
total
patient
prospect
collect
octob
march
period
month
compar
data
dress
patient
septemb
august
period
ii
month
result
common
caus
drug
antibiot
follow
anticonvuls
antituberculosi
drug
period
period
vs
period
ii
respect
eosinophilia
peripher
blood
hepat
involv
frequent
note
period
ii
enlarg
lymph
node
period
significantli
mean
latenc
period
day
rang
period
rang
period
ii
longest
latenc
period
note
antituberculosi
drug
follow
anticonvuls
antibiot
period
system
corticosteroid
administ
patient
period
patient
show
complet
recoveri
period
patient
poor
outcom
conclus
clinic
manifest
dress
syndrom
variabl
antibiot
frequent
implic
drug
antituberculosi
drug
long
latenc
period
major
patient
show
good
clinic
outcom
without
administr
system
corticosteroid
acknowledg
research
support
grant
ministri
food
drug
safeti
oper
region
pharmacovigil
center
food
allergi
one
common
allerg
diseas
world
probiot
shown
promot
endogen
host
defens
modul
host
immun
respons
potenti
harm
antigen
studi
first
establish
mous
model
food
allergey
ip
sensit
ova
oral
challeng
protein
allergen
ova
balbc
mice
found
bodi
weight
bodi
temperatur
immedi
food
allergen
challeng
significantli
decreas
compar
control
mice
symptom
food
allergi
level
total
ige
allergenspecif
ige
iga
sera
level
ige
iga
intestin
lavag
fluid
ilf
food
allergen
mice
significantli
increas
compar
control
mice
oral
administr
cfu
lactobacillu
gasseri
l
gasseri
time
food
allergen
sensit
challeng
bodi
temperatur
bodi
weight
level
antigenspecif
iga
sera
concentr
ilf
level
cultur
medium
cellular
number
dendrit
cell
dc
treg
cell
bet
cell
peyer
patch
drain
lymph
node
l
gasseritr
mice
significantli
increas
compar
nontreat
food
allergi
mice
contrast
food
allergi
symptom
level
antigenspecif
ige
sera
level
total
ige
antigenspecif
ige
ilf
concentr
cultur
medium
cellular
number
cell
cell
lymphocyt
prolifer
intestin
inflamm
lgasseritr
mice
food
hypersensit
significantli
decreas
compar
nontreat
control
mice
explor
antiallergi
effect
l
gasseri
dendrit
cell
dc
food
allergi
develop
bone
marrowderiv
dendrit
cell
bmdc
isol
mice
stimul
hr
recombin
l
gasseri
bmdc
collect
adopt
transfer
mice
sensit
challeng
food
allergen
find
suggest
l
gasseri
recombin
protein
antiallergi
effect
mice
sensit
challeng
food
allergen
ova
cow
milk
antiallerg
effect
may
mediat
tolergen
effect
dendrit
cell
enhanc
immuneregulatori
effect
b
lymphocyt
may
clinic
applic
patient
suffer
food
allergi
background
folat
dietari
methyl
donor
known
alter
gene
express
influenc
immun
system
epigenet
modif
howev
relationship
folat
level
risk
allerg
respiratori
diseas
children
still
unknown
object
investig
whether
serum
folat
level
associ
atop
biomark
also
risk
allerg
respiratori
diseas
children
method
data
children
complet
inform
birth
cohort
south
korea
avail
serum
folat
level
analyz
month
age
children
atop
biomark
total
ig
e
eosinophil
count
also
measur
month
inform
matern
demograph
obstetr
characterist
children
allerg
respiratori
outcom
obtain
questionnair
result
serum
folat
level
invers
associ
eosinophil
count
r
p
total
ige
level
eosinophil
count
decreas
significantli
group
whose
serum
folat
median
valu
ngml
compar
counterpart
group
p
p
respect
multivari
logist
regress
analysi
reveal
folat
level
median
valu
ngml
associ
decreas
risk
atop
dermat
ad
adjust
odd
ratio
aor
confid
interv
ci
month
age
howev
signific
associ
observ
serum
folat
level
respiratori
outcom
children
conclus
serum
folat
level
associ
lower
risk
develop
ad
earli
childhood
background
dysregul
mucos
inflamm
chronic
rhinosinus
cr
often
difficult
control
pharmacotherapi
alon
sought
determin
whether
immunomodulatori
properti
vitamin
might
benefici
effect
cr
method
perform
random
placebo
control
trial
adult
subject
meet
research
criteria
cr
low
serum
vitamin
level
ngml
contraind
vitamin
therapi
subject
random
receiv
vitamin
placebo
week
addit
standard
regimen
peripher
blood
mononuclear
cell
pbmc
nasal
epitheli
cell
nec
collect
begin
end
trial
analyz
upregul
molecul
involv
mucos
immun
rtpcr
clinic
respons
analyz
use
result
level
vitamin
serum
elev
vitamin
group
unchang
placebo
group
cathelicidin
human
bdefensin
autophagi
relat
protein
light
chain
alpha
molecul
involv
autophagi
upregul
vitamin
administr
pbmc
similar
result
observ
nec
signific
chang
upregul
mediat
placebo
group
symptomat
chang
observ
score
either
group
side
effect
advers
event
studi
conclus
result
suggest
vitamin
might
modul
mediat
involv
immun
respons
cr
studi
need
clarifi
clinic
efficaci
vitamin
disord
background
system
contact
dermat
scd
inflammatori
skin
diseas
may
occur
person
contact
allergi
expos
allergen
systemat
includ
oral
transcutan
per
rectum
intraves
intraven
inhal
common
caus
scd
drug
use
topic
system
caus
ubiquit
occur
hapten
metal
nickel
cobalt
gold
chromat
aromat
substanc
spice
scd
plant
seen
follow
ingest
variou
rhu
prepar
korea
rhu
use
folk
medicin
cure
gastrointestin
diseas
health
food
common
observ
patient
accident
occup
rhu
dermat
also
scd
caus
ingest
rhu
object
investig
clinic
featur
scd
caus
rhu
method
conduct
retrospect
analysi
patient
scd
caus
rhu
donga
univers
hospit
haeunda
paik
hospit
result
nine
women
averag
age
year
rang
way
rhu
ingest
boil
chicken
rhu
rhu
veget
rhu
sap
patient
experienc
gener
pruritu
erythemat
maculopapular
rash
patient
develop
erythema
multiform
vesiculobul
lesion
urticaria
angioedema
extracutan
symptom
duoden
ischemia
hypotens
fever
oral
mucos
mean
latenc
period
day
rang
mean
recoveri
time
day
rang
system
corticosteroid
administ
day
rang
conclus
scd
ingest
rhu
show
variou
cutan
manifest
mainli
erythemat
maculopapuar
erupt
also
extracutan
symptom
patient
recov
well
treatment
system
corticosteroid
background
atop
dermat
ad
current
regard
allerg
inflammatori
diseas
mani
studi
shown
ad
multipl
caus
activ
complex
immunolog
inflammatori
pathway
howev
aeroallergen
especi
hous
dust
mite
hdm
play
relev
role
elicit
exacerb
eczemat
lesion
mani
ad
patient
accordingli
allergenspecif
immunotherapi
use
ad
patient
aim
redirect
inappropri
immun
respons
sublingu
immunotherapi
slit
especi
prefer
easi
applic
safeti
aim
studi
describ
effect
slit
patient
ad
method
patient
ad
allerg
hdm
evalu
patient
allerg
hdm
treat
slit
effect
patient
clinic
cours
slit
dermatophagoid
pteronyssinu
dermatophagoid
farina
standard
extract
assess
side
effect
slit
record
result
record
patient
male
femal
studi
mean
age
start
slit
year
age
year
median
age
treatment
deem
effect
effect
patient
major
patient
satisfi
treatment
well
toler
seriou
side
effect
except
transient
nausea
abdomin
pain
oral
itch
sensat
first
day
slit
discontinu
patient
exacerb
asthma
dermat
especi
complianc
patient
ad
allerg
rhiniti
better
patient
ad
conclus
slit
reduc
symptom
ad
amount
drug
consumpt
progress
diseas
especi
slit
recommend
patient
ad
allerg
rhiniti
believ
slit
altern
safe
treatment
option
allerg
ad
refractori
longterm
convent
treatment
background
advers
drug
reaction
adr
frequent
occur
hospit
set
seriou
adr
sae
may
threaten
patient
life
lead
poor
clinic
outcom
earli
detect
urgent
medic
intervent
requir
prevent
develop
sae
studi
conduct
investig
clinic
characterist
sae
singl
univers
hospit
method
adr
report
hospit
pharmacovigil
center
collect
jan
dec
case
sae
select
clinic
inform
collect
electron
medic
record
result
total
sae
among
adr
identifi
spontan
report
system
gradual
decreas
tendenc
frequenc
incid
sae
note
sae
report
doctor
nurs
pharmacist
adr
relatedhospit
prolong
exist
hospit
common
caus
sae
medic
import
event
second
caus
sae
develop
inject
po
medic
patch
type
agent
antineoplast
agent
antiinfect
antituberculosi
drug
drug
class
commonli
involv
white
cell
re
disord
frequent
involv
system
organ
class
skin
appendag
disord
next
leukopenia
neutropenia
frequent
note
sae
conclus
antineoplast
agent
antiinfect
antituberculosi
drug
elicit
sae
frequent
decreas
tendenc
develop
sae
note
might
result
least
partli
pharmacovigil
activ
adr
monitor
comprehens
prophylact
approach
requir
prevent
develop
predict
sae
reduc
chanc
unpredict
sae
background
allerg
contact
dermat
common
diagnosi
eyelid
dermat
sensit
metal
preval
eyelid
dermat
color
cosmet
product
frequent
suspect
sourc
metal
exposur
studi
perform
investig
recent
contact
allergen
eyelid
dermat
assess
metal
content
eye
shadow
product
method
data
collect
depart
dermatolog
ewha
woman
univers
hospit
decemb
februari
total
patient
patch
test
period
patient
eyelid
dermat
among
examin
metal
element
color
cosmet
product
eye
randomli
select
eye
shadow
analyz
result
frequent
allergen
metal
thimeros
phenylenediamin
patient
eyelid
dermat
sensit
rate
individu
allergen
significantli
differ
patient
eyelid
dermat
without
eyelid
dermat
eye
shadow
product
contain
ppm
least
one
element
nickel
cobalt
chromium
conclus
metal
toprank
allergen
eyelid
dermat
eye
shadow
product
contain
signific
amount
nickel
cobalt
chromium
elicit
allerg
reaction
patient
eyelid
dermat
metal
allergi
inform
color
eye
makeup
product
elicit
aggrav
symptom
background
recent
studi
suggest
dietari
chang
may
influenc
program
immun
system
favor
develop
allerg
diseas
howev
result
effect
fat
statu
develop
allerg
respiratori
diseas
children
still
conflict
method
total
children
includ
studi
birth
cohort
south
korea
data
regard
children
allerg
respiratori
outcom
obtain
standard
questionnair
complet
mother
serum
total
cholesterol
triglycerid
tg
highdens
cholesterol
hdl
level
measur
children
month
age
atop
biomark
includ
total
ig
e
eosinophil
count
also
measur
month
result
serum
hdl
cholesterol
level
invers
associ
eosinophil
count
count
r
p
total
ige
eosinophil
count
level
increas
significantli
group
whose
serum
hdl
cholesterol
level
median
valu
compar
counterpart
group
p
p
p
respect
howev
associ
lipid
level
risk
respiratori
outcom
ad
month
logist
regress
analysi
conclus
found
hdl
cholesterol
level
associ
lower
atop
biomark
children
month
risk
allerg
respiratori
diseas
background
first
report
induc
tumor
necrosi
proinflammatori
cytokin
involv
variou
chronic
inflammatori
diseas
studi
evalu
relationship
sputum
express
sever
asthma
method
determin
induc
sputum
sampl
patient
asthma
n
use
sandwich
elisa
relationship
among
sputum
airway
obstruct
inflamm
neutrophil
eosinophil
airway
exacerb
frequenc
evalu
result
sputum
level
well
correl
total
studi
subject
p
stabl
asthmat
p
level
differ
use
inhal
steroid
subject
group
two
inflammatori
pattern
eosinophil
neutrophil
level
differ
inflammatori
pattern
level
significantli
increas
subject
experienc
exacerb
compar
experienc
exacerb
p
sputum
level
well
correl
annual
rate
exacerb
total
subject
p
conclus
sputum
may
associ
sever
asthma
regardless
inhal
steroid
treatment
may
surrog
marker
exacerb
risk
asthma
background
chromium
allergi
tradit
caus
occup
skin
contact
cement
relat
construct
materi
involv
hand
commonli
object
investig
clinic
characterist
patient
chromium
allergi
korea
method
patch
test
data
june
januari
retrospect
analyz
patient
show
posit
reaction
potassium
dichrom
chromium
group
show
posit
reaction
allergen
except
potassium
dichrom
other
group
identifi
characterist
group
compar
preval
chromium
allergi
addit
analyz
period
studi
chang
time
result
sensit
rate
potassium
dichrom
women
compris
chromium
group
hand
feet
frequent
affect
chromium
group
occup
dermat
significantli
common
chromium
group
chromium
allergi
preval
patient
preval
chromium
allergi
decreas
conclus
characterist
patient
chromium
allergi
suggest
chromium
exposur
daili
activ
includ
leather
exopsur
relev
occup
exposur
patient
preval
chromium
allergi
decreas
korea
may
effect
voluntari
regul
chromium
extent
cement
manufactur
background
chronic
hand
eczema
che
may
sever
reduc
patient
qualiti
life
che
refractori
topic
corticosteroid
current
limit
treatment
option
suit
chronic
use
demand
safe
new
therapi
oral
alitretinoin
acid
propos
econom
burden
limit
broad
use
acitretin
wellknown
second
gener
vitamin
deriv
wide
use
palmoplantar
psoriasi
less
cost
investig
perform
assess
efficaci
safeti
acitretin
chronic
hand
eczema
patient
b
method
total
patient
diagnos
che
enrol
prospect
openlabel
studi
patient
administ
oral
acitretin
start
dose
twice
daili
taper
daili
week
period
che
sever
evalu
use
hand
eczema
sever
index
physici
global
assess
pga
c
result
sever
hand
eczema
decreas
averag
improv
remark
hyperkeratot
type
type
hand
eczema
p
clinic
respons
defin
clear
almost
clear
achiev
patient
seriou
side
effect
report
except
mild
cheiliti
patient
abdomin
discomfort
patient
conclus
oral
acitretin
welltoler
effect
improv
chronic
hand
eczema
especi
hyperkeratot
type
introduct
laryng
dystonia
rare
potenti
fatal
complic
therapi
atyp
antipsychot
anticholinerg
agent
report
case
laryng
dystonia
due
agent
ascrib
initi
anaphylaxi
case
old
man
present
emerg
depart
progress
develop
sensat
sever
throat
swell
slur
speech
follow
ingest
regular
ziprasidon
intramuscular
adrenalin
given
without
benefit
put
diagnosi
anaphylaxi
symptom
gradual
resolv
hour
mast
cell
tryptas
level
normal
allergenspecif
ige
tempor
relev
allergen
undetect
report
similar
episod
decad
prior
take
risperidon
allergist
review
note
diagnost
criteria
anaphylaxi
lack
ziprasidon
taken
night
excess
alcohol
intak
recurr
atyp
antipsychot
induc
laryng
pharyng
dystonia
manag
success
recommenc
ziprasidon
condit
avoid
excess
alcohol
took
drug
regular
time
case
yearold
man
present
emerg
depart
sensat
throat
tongu
swell
voic
hoars
earlier
selfmed
intramuscular
metoclopramid
intramuscular
prochlorperazin
oral
ondansetron
intract
vomit
due
cyclic
vomit
syndrom
evid
haemodynam
compromis
urticaria
airway
oedema
found
promethazin
intraven
hydrocortison
given
suspect
anaphylaxi
follow
low
dose
midazolam
aim
laryng
relax
symptom
improv
rapidli
thereaft
mast
cell
tryptas
level
normal
event
allergenspecif
ige
tempor
relev
allergen
undetect
similar
episod
year
previous
follow
selfadminist
larg
dose
metoclopramid
case
repres
recurr
laryng
dystonia
respons
larg
dose
metoclopramid
possibl
aggrav
coadministr
prochlorperazin
fortuit
anticholinerg
effect
promethazin
would
help
reliev
dystonia
discuss
previou
report
ziprasidon
induc
laryng
dystonia
follow
intramuscular
use
mellecheruvu
et
al
first
case
first
report
oral
administ
ziprasidon
caus
laryng
pharyng
dystonia
second
case
fourth
report
metoclopramideinduc
laryng
dystonia
given
right
emphasi
first
line
treatment
adrenalin
anaphylaxi
awar
propens
drug
provok
reaction
crucial
time
specif
treatment
anticholinerg
along
increas
suspicion
predispos
factor
youth
male
gender
alcohol
ingest
previou
reaction
present
background
questionnairebas
diagnost
criteria
atop
dermat
ad
limit
low
diagnost
accuraci
individu
level
object
develop
novel
questionnairebas
diagnost
criteria
improv
accuraci
estim
ad
preval
individu
diagnos
childhood
ad
epidemiolog
survey
method
candid
question
questionnair
select
preliminari
survey
reliabl
estim
atop
dermat
childhood
reach
diagnost
criteria
deriv
populationbas
survey
result
thirteen
question
major
minor
criteria
includ
final
version
questionnair
reach
diagnost
criteria
defin
fulfil
two
major
criteria
typic
ad
one
major
plu
four
minor
criteria
atyp
ad
deriv
set
reach
criteria
demonstr
superior
perform
compar
isaac
term
estim
ad
preval
diagnost
accuraci
valid
set
limit
valid
requir
use
moredivers
rang
popul
conclus
propos
comprehens
questionnairebas
reach
diagnost
criteria
use
childhood
ad
epidemiolog
survey
also
context
person
medic
advic
background
oral
allergi
syndrom
oa
may
common
foodrel
allergi
adult
even
oa
pollenfood
allergi
complic
crossreact
protein
immunocap
isac
immuno
solidphas
allergen
chip
allow
detect
specif
ige
molecular
compon
allergen
sourc
new
approach
help
clarifi
molecular
base
primari
sensit
crossreact
phenomena
use
approach
analyz
allergen
compon
comprehens
method
retrospect
analyz
sera
patient
examin
base
suspicion
allergi
depart
dermatolog
osaka
univers
patient
patient
symptom
pruritu
tingl
lip
oral
mucosa
throat
one
patient
symptom
immunocap
isac
use
screen
allergen
compon
compar
test
result
skin
prick
test
specigi
antigen
elisa
western
blot
blood
test
also
perform
result
test
use
cross
reaction
allergi
patient
sensit
larg
number
allergen
grasp
sensit
pattern
common
antigen
younger
patient
lower
number
posit
compon
tick
cat
dog
relat
compon
characterist
patient
dermat
result
exclud
tick
cat
dog
relat
compon
number
posit
compon
patient
ad
eczema
contact
dermat
ppp
higher
dermat
conclus
found
age
dermat
factor
influenc
caus
factor
oa
find
suggest
number
posit
compon
higher
subject
accompani
ad
compar
subject
without
ad
thu
assum
subject
ad
might
highli
suscept
oa
object
allerg
skin
test
commonli
use
test
evalu
immedi
immun
respons
either
skin
prick
test
spt
intraderm
test
spt
wide
use
sever
method
propos
interpret
spt
howev
comparison
studi
intertest
relationship
aim
studi
compar
three
differ
interpret
method
defin
relationship
among
method
examin
spt
patient
visit
allergi
clinic
complain
nasal
symptom
januari
decemb
three
differ
interpret
method
use
defin
posit
spt
interpret
compar
wheal
size
allergen
histamin
biggest
diamet
wheal
size
mm
biggest
diamet
erythema
greater
mm
compar
posit
among
differ
interpret
method
valid
interpret
method
evalu
compar
posit
tnss
result
posit
spt
report
ah
ratio
method
wheal
size
method
erythema
size
method
respect
subject
show
neg
result
ah
ratio
method
posit
result
wheal
size
method
erythema
size
method
respect
subject
show
neg
result
ah
ratio
posit
result
erythema
size
wheal
size
method
significantli
higher
rhinorrhea
nasal
obstruct
tnss
subject
show
neg
result
conclus
compar
tnss
method
tnss
spt
posit
group
higher
neg
group
except
tnss
nasal
obstruct
ah
method
thu
diagnos
allerg
rhiniti
patient
may
consid
wheal
size
method
erythema
size
method
ah
ratio
method
asthma
lead
caus
emerg
depart
ed
visit
hospit
children
develop
countri
studi
determin
variabl
treatment
protocol
associ
hospit
among
children
asthmarel
ed
visit
retrospect
collect
data
clinic
record
children
age
year
diagnos
asthma
treat
ed
referr
tertiari
center
southern
taiwan
june
may
regressionbas
analys
perform
determin
factor
associ
hospit
admiss
investig
whether
administ
intraven
aminophyllin
associ
hospit
admiss
asthmarel
ed
visit
total
patient
includ
analysi
bodi
weight
adjust
odd
ratio
aor
confid
interv
ci
fever
episod
puls
rate
previou
hospit
due
asthma
episod
significantli
associ
hospit
admiss
among
children
asthmarel
ed
visit
whole
studi
period
hospit
admiss
rate
sharpli
increas
children
hospit
admiss
second
time
period
receiv
significantli
less
aminophyllin
treatment
without
hospit
admiss
first
time
period
conclus
found
bodi
weight
fever
episod
puls
rate
previou
hospit
predict
factor
hospit
children
asthma
exacerb
ed
visit
refrain
intraven
aminophyllin
use
may
increas
hospit
admiss
among
children
acut
asthma
purpos
atop
dermat
ad
increas
worldwid
nationwid
howev
well
design
random
nation
epidemiolog
studi
select
data
preval
ad
investig
preval
ad
risk
factor
nationwid
random
children
adolesc
korea
method
conduct
questionnair
survey
children
age
year
old
nationwid
korea
subject
select
stratifi
sampl
method
school
grade
five
region
popul
compos
elementari
school
middl
school
high
school
student
current
ad
defin
recent
ad
symptom
within
month
diagnos
ad
physician
ever
atop
sensit
describ
skin
prick
test
common
allergen
result
preval
current
ad
recent
ad
treatment
within
month
elementari
school
middl
school
high
school
respect
risk
factor
base
multivari
analysi
current
ad
merg
data
includ
household
pet
keep
aor
ci
well
parent
allerg
diseas
aor
ci
mold
exposur
infanc
aor
ci
recent
mold
exposur
within
month
aor
ci
atop
sensit
aor
ci
conclus
nationwid
preval
current
ad
elementari
school
middl
school
high
school
student
respect
risk
factor
current
ad
includ
parent
allerg
diseas
mold
exposur
infanc
recent
mold
exposur
within
month
atop
sensit
household
pet
keep
fund
sourc
studi
support
nation
institut
environment
research
nier
recent
probiot
treatment
becom
new
therapi
allerg
diseas
base
previou
research
lab
discov
enzym
dehydrogenas
major
materi
probiot
extract
want
investig
recombin
enzym
effect
allerg
diseas
use
dermatophagoid
pteronyssinu
der
p
induc
atop
dermat
ad
mous
model
demonstr
effect
probiot
recombin
protein
found
probiot
recombin
protein
could
decreas
mous
serum
total
ige
der
pspecif
ige
hand
probiot
protein
also
could
recov
physiolog
function
skin
decreas
langerhan
cell
infiltr
epiderm
attenu
cytokin
thymic
stromal
lymphopoietin
tslp
product
skin
tissu
next
postul
recombin
protein
could
enhanc
physiolog
function
anatom
barrier
skin
use
wound
heal
model
human
keratinocyt
hacat
cell
pretreat
cell
enzym
wound
format
experi
determin
enzym
promot
wound
heal
faster
untreat
group
result
may
explor
effect
mechan
recombin
dehydrogenas
der
pinduc
ad
model
background
varieti
skin
diseas
known
associ
allerg
inflamm
suffici
data
statu
allerg
sensit
adult
patient
variou
inflammatori
skin
diseas
object
sought
compar
statu
immunoglobulin
e
sensit
variou
inflammatori
skin
diseas
method
serum
specif
immunoglobulin
e
ige
level
common
food
aeroallergen
measur
total
adult
patient
diagnos
allerg
contact
dermat
n
atop
dermat
n
acut
urticaria
n
chronic
urticaria
n
irrit
contact
dermat
n
eczema
n
pruritu
n
sensit
allergen
defin
specif
ige
level
equal
greater
kul
result
statist
signific
differ
number
sensit
allergen
skin
condit
p
sensit
milk
beef
antigen
higher
atop
dermat
allerg
contact
dermat
irrit
contact
dermat
pruritu
compar
other
p
respect
addit
sensit
yeast
cladosporium
candida
significantli
higher
atop
dermat
compar
other
p
respect
howev
statist
signific
differ
rate
sensit
allergen
conclus
overal
statu
allerg
sensit
similar
variou
inflammatori
skin
diseas
howev
sever
allergen
close
associ
specif
skin
condit
good
syndrom
acquir
immunodefici
state
associ
thymoma
character
recurr
infect
autoimmun
diseas
immunolog
abnorm
insuffici
immun
support
intraven
immunoglobulin
ivig
replac
therapi
describ
patient
present
cough
dyspnea
caus
pneumocysti
jiroveci
pneumonia
cytomegaloviru
pneumonia
respect
thymectomi
thymoma
immunolog
studi
reveal
hypogammaglobulinemia
low
bcell
count
consist
good
syndrom
success
treat
trimethoprimsulfamethoxazol
gancyclovir
respect
well
without
addit
infect
regular
ivig
replac
background
recent
report
cigarett
smoke
exposur
allergen
sensit
period
facilit
develop
hous
dust
mite
hdm
sensit
subsequ
allerg
asthma
howev
mechan
remain
elus
sever
research
recent
shown
involv
antigeninduc
airway
inflamm
therefor
hypothes
involv
pathway
object
evalu
role
short
cigarett
smoke
exposureinduc
hdmallerg
asthma
mous
model
method
balbc
mice
expos
hdm
andor
cigarett
smoke
extract
cse
hdm
sensit
period
day
antibodi
given
sensit
period
analyz
sever
asthmat
phenotyp
last
allergen
challeng
addit
also
analyz
chang
dc
activ
ldln
cytokin
profil
last
sensit
result
cse
exposur
sensit
period
promot
develop
hdmallerg
sensit
asthma
phenotyp
proport
innat
lymphoid
type
cell
also
increas
cse
hdm
coexposur
compar
singl
exposur
antibodi
treatment
allergen
sensit
period
significantli
diminish
sever
phenotyp
allerg
asthma
treatment
also
reduc
recruit
innat
lymphoid
type
cell
along
activ
dc
ldln
significantli
reduc
last
sensit
conclus
may
play
signific
role
develop
short
cigarett
smokeinduc
allerg
sensit
asthma
background
outpati
clinic
meet
mani
patient
suffer
allerg
diseas
depart
usual
ask
patient
suffer
allerg
diseas
allerg
rhiniti
take
blood
test
give
inform
consent
calcul
ratio
eosinophil
level
nonspecif
specif
ige
howev
ratio
eosinophil
fluctuat
seem
connect
level
nonspecif
ige
sever
allerg
diseas
studi
retrospect
studi
whether
result
blood
test
associ
relev
allerg
diseas
method
sampl
patient
men
women
visit
depart
took
blood
test
januari
decemb
measur
ratio
eosinophil
level
nonspecif
specif
ige
studi
divid
patient
group
accord
level
nonspecif
ige
less
group
less
group
less
group
group
investig
sever
aspect
result
common
diseas
group
season
allerg
rhiniti
follow
vasomotor
rhiniti
perenni
allerg
rhiniti
group
tendenc
group
season
allerg
rhiniti
vasomotor
rhiniti
perenni
allerg
rhiniti
group
small
number
patient
difficult
calcul
percentag
diseas
group
season
allerg
rhiniti
chronic
sinus
tend
high
relev
next
evalu
relationship
level
nonspecif
ige
relev
diseas
group
relev
chronic
sinus
perenni
allerg
rhiniti
significantli
higher
group
eosinophil
sinus
season
allerg
rhiniti
vasomotor
rhiniti
signific
differ
conclus
nonspecif
ige
level
may
relat
sever
chronic
sinus
perenni
allerg
rhiniti
nonspecif
ige
level
may
also
use
order
estim
futur
relev
sever
nasal
diseas
year
old
work
restaur
complaint
sneez
clog
nose
impair
sensit
smell
post
nasal
drip
sneez
morn
sneez
provoc
exposit
prawn
smell
itch
sensat
nose
nasal
drip
itch
wet
eye
short
breath
pressur
sensat
chest
histori
complaint
fort
last
year
work
kitchen
restaur
serv
sea
product
includ
prawn
larg
shrimp
year
experienc
sneez
post
nasal
drip
itch
sensat
eye
provoc
exposur
smell
prawn
clean
prepar
exposur
prawn
smell
caus
edema
swell
lip
eyelid
suggest
angioedema
prawn
smell
inhal
also
caus
short
breath
pressur
sensat
chest
stridor
medic
histori
also
reveal
angioedema
trigger
intak
appranax
naproxen
laboratori
eosinophil
total
ig
e
iuml
specif
ig
e
mix
food
panel
morino
fish
prawn
shell
tuna
fish
salmon
fish
kul
kul
wchich
indic
strong
posit
resultinasmuch
patient
allerg
rhiniti
skinprick
test
respiratori
allergen
panel
conduct
order
determin
caus
inhalatori
allergen
result
follow
der
p
mm
der
f
mm
bgermenica
mm
neg
control
mm
subject
patient
pricktoprick
test
prawn
mm
strong
posit
neg
control
histamin
mm
ao
year
old
male
patient
complaint
patient
experienc
sensat
itch
mouth
swell
tongu
throat
difficulti
swallow
occur
follow
consumpt
prawn
histori
complaint
none
complaint
occur
age
patient
experienc
symptom
fort
last
year
upon
consumpt
prawn
patient
experienc
swell
tongu
throat
along
itch
sensat
localis
consum
prawn
restaur
experienc
swell
tongu
throat
laryng
edema
accompani
dizzi
sensat
faint
hypotens
suggest
anaphylact
reaction
consum
prawn
restaur
bthe
patient
favour
prawn
lot
quit
consum
prawn
spite
complaint
allerg
episod
appli
clinic
result
patient
issu
adrenalin
autoinject
certif
instruct
auto
inject
techniqu
advic
ever
consum
prawn
also
advic
cautiou
restaur
serv
prawn
sinc
certain
kitchen
equip
might
contamin
prawn
particl
background
increas
preval
allerg
diseas
attribut
part
reduc
microbi
exposur
associ
modern
lifestyl
alter
composit
signatur
reduc
divers
intestin
microbiota
link
develop
allerg
diseas
investig
relationship
domin
bifidobacteriumspeci
stool
earli
postnat
period
subsequ
develop
eczema
igeassoci
eczema
sensitis
first
year
life
method
faecal
sampl
collect
age
week
month
month
infant
high
risk
allerg
diseas
follow
prospect
age
month
bifidobacteriumspeci
analys
quantit
pcr
termin
restrict
fragment
length
polymorph
infant
examin
month
skin
prick
test
perform
month
eczema
diagnos
accord
ukwork
parti
criteria
result
presenc
b
catenulatum
month
associ
higher
risk
develop
eczema
oradj
ci
padj
infant
colonis
b
breve
week
oradj
ci
padj
month
oradj
ci
padj
reduc
risk
develop
eczema
furthermor
presenc
b
breve
month
associ
lower
risk
atop
sensitis
month
oradj
ci
padj
b
brevecolonis
pattern
influenc
matern
allerg
statu
household
pet
number
sibl
conclus
tempor
variat
bifidobacterium
colonis
pattern
earli
life
variat
differenti
modul
later
develop
eczema
andor
atop
sensitis
infant
high
risk
allerg
diseas
modul
earli
microbiota
may
provid
mean
prevent
eczema
high
risk
infant
background
recent
epidemiolog
studi
demonstr
signific
associ
staphylococc
enterotoxin
se
asthma
addit
clinic
studi
suggest
enterotoxin
exposur
could
contribut
develop
fix
airway
obstruct
asthma
lead
copdoverlap
phenotyp
previou
experi
mice
shortterm
exposur
staphylococc
enterotoxin
b
seb
induc
extens
inflammatori
respons
lung
includ
lymphocyt
neutrophil
eosinophil
therefor
hypothes
chronic
repeat
exposur
seb
could
induc
tissu
remodel
lower
airway
object
investig
effect
repeat
seb
exposur
airway
remodel
ovainduc
chronic
allerg
asthma
model
method
balbc
mice
intraperiton
sensit
ovalbumin
ova
aluminum
hydroxid
day
intranas
challeng
ova
andor
seb
next
week
ug
ova
ng
seb
time
per
week
period
total
exposur
week
mice
sacrif
assess
histopatholog
bronchoalveolar
lavag
fluid
balf
cell
count
lung
cytokin
methacholin
airway
hyperrespons
ahr
serum
immunoglobulin
result
ova
sensit
follow
repeat
ova
exposur
result
develop
asthma
inflamm
includ
balf
cell
count
lung
cytokin
histopatholog
ahr
serum
immunoglobulin
howev
repeat
seb
exposur
aggrav
ovainduc
patholog
chang
induc
remark
patholog
chang
administ
alon
serum
total
ige
level
also
influenc
repeat
seb
exposur
rather
chronic
repeat
sebexpos
mice
show
lower
level
lung
inflamm
remodel
higher
level
compar
nonsebexpos
mice
conclus
present
studi
demonstr
unpredict
suppress
effect
chronic
repeat
exposur
seb
allerg
asthma
model
lead
specul
seb
exert
bidirect
effect
depend
time
exposur
mechan
antiinflammatori
effect
warrant
investig
background
allerg
rhiniti
repres
global
health
problem
caus
major
ill
disabl
worldwid
immunotherapi
effect
manag
allerg
rhiniti
skin
prick
test
reliabl
method
diagnos
igemedi
allerg
diseas
uptod
biomark
yet
valid
good
predictor
clinic
respons
allergen
immunotherapi
method
cohort
studi
determin
associ
skin
prick
test
result
allergen
immunotherapi
efficaci
children
allerg
rhiniti
patient
seen
tertiari
hospit
diagnos
allerg
rhiniti
allergen
immunotherapi
includ
studi
skin
prick
test
result
record
total
nasal
symptom
score
tnss
obtain
start
immunotherapi
monthli
six
month
correl
baselin
skin
prick
test
chang
tnss
monthli
endpoint
done
check
associ
baselin
skin
prick
test
efficaci
immunotherapi
measur
improv
tnss
score
result
total
patient
complet
least
six
month
immunotherapi
includ
studi
averag
age
year
old
predominantli
male
averag
skin
prick
test
dfarina
mm
dpteronyssinu
mm
baselin
tnss
subject
median
score
gradual
decreas
median
score
sixth
month
immunotherapi
gener
low
invers
correl
dpteronyssinu
immunotherapi
skin
prick
test
result
first
four
month
immunotherapi
direct
moder
correl
fourth
sixth
month
immunotherapi
howev
statist
signific
low
invers
correl
dfarina
immunotherapi
skin
prick
test
result
first
four
month
immunotherapi
direct
low
correl
fifth
sixth
month
immunotherapi
conclus
larger
size
skin
prick
test
dpteronyssinu
greater
improv
total
nasal
symptom
score
baselin
six
month
immunotherapi
background
chitinas
demonstr
requir
optim
allergen
sensit
inflamm
variou
chronic
inflammatori
diseas
includ
asthma
role
airway
hyperrespons
ahr
induc
respiratori
virus
prove
yet
purpos
studi
figur
relationship
mous
chitinas
protein
respiratori
syncyti
viru
rsv
induc
ahr
method
use
mice
null
mice
mice
inocul
live
rsv
control
pb
methacholin
challeng
test
measur
airway
resist
work
day
inocul
bronchoalveolar
lavag
fluid
balf
sampl
obtain
lung
specimen
also
harvest
day
inocul
assess
lung
inflamm
cytokin
express
product
express
evalu
elisa
rsv
load
assess
cultur
realtim
polymeras
chain
reaction
pcr
histolog
evalu
h
e
pa
stain
use
evalu
inflamm
tissu
remodel
result
level
balf
significantli
increas
wildtyp
wt
mice
rsv
infect
observ
null
mice
inflammatori
chang
induc
rsv
infect
less
mice
rather
wt
mice
wt
mice
rsv
infect
caus
loss
bodi
weight
signific
increas
total
cell
macrophag
neutrophil
balf
exagger
ahr
also
note
wt
mice
rsv
infect
mice
show
decreas
respons
paramet
rsv
infect
group
histolog
tissu
inflamm
also
decreas
mice
conclus
role
earlyonset
wheez
respiratori
viral
infect
childhood
asthma
incept
receiv
attent
rsv
known
signific
risk
factor
asthma
extend
adolesc
adult
mechan
still
investig
studi
express
increas
rsv
infect
mice
inflammatori
chang
ahr
induc
rsv
decreas
null
mice
find
suggest
could
contribut
airway
inflamm
induc
rsv
infect
mice
furthermor
might
consid
therapeut
target
viral
wheez
virusinduc
asthma
background
primari
immunodefici
diseas
pid
adult
often
underrecognis
result
delay
diagnosi
signific
morbid
mortal
review
longterm
outcom
adult
pid
tan
tock
seng
hospit
pid
registri
method
chart
review
adult
pid
onset
age
year
longitudin
followedup
time
diagnosi
jan
may
result
patient
male
femal
eighteen
ethnic
chines
malay
indian
age
diagnosi
year
rang
iui
group
antibodi
defici
common
patient
compris
common
variabl
immunodefici
cvid
select
iga
defici
alon
select
iga
defici
select
defici
alon
hypogammaglobulinaemia
ring
chromosom
ten
patient
pid
name
immunodefici
thymoma
chronic
mucocutan
candidiasi
cmc
hyperig
syndrom
half
patient
alreadi
bronchiectasi
chronic
sinus
diagnosi
pid
seroneg
arthriti
develop
femal
one
year
follow
diagnosi
cmc
coincid
diagnosi
cvid
system
lupu
erythematosu
predat
diagnosi
select
iga
defici
year
one
patient
death
four
bronchiectasi
diagnosi
die
chronic
respiratori
failur
without
pneumonia
despit
regular
adequ
ivig
replac
femal
cvid
irregular
ivig
replac
die
persist
elizabethkingia
meningoseptica
bacteraemia
septic
shock
follow
consumpt
frog
two
patient
die
male
thymoma
immunodefici
one
metastat
thymoma
multipl
infect
associ
cell
defect
cytomegaloviru
coliti
retin
dissemin
candida
esophag
hepat
ocular
toxoplasmosi
conclus
spectrum
adult
pid
patient
manag
centr
report
elsewher
mani
patient
present
late
establish
sinopulmonari
complic
contribut
death
background
breast
feed
recommend
prevent
allerg
diseas
particularli
high
risk
infant
evid
protect
effect
food
sensit
food
allergi
fa
remain
elus
aim
studi
investig
associ
breast
feed
food
sensit
fa
children
year
atop
dermat
method
review
medic
record
children
atop
dermat
year
old
visit
pediatr
allerg
clinic
march
decemb
assess
symptom
fa
durat
breast
feed
histori
parent
allerg
diseas
concomit
allerg
diseas
laboratori
test
includ
serum
total
ige
eosinophil
specif
ige
egg
white
milk
soy
wheat
peanut
measur
basi
sensit
ige
kul
clinic
histori
children
fa
fa
fa
group
divid
sensit
toler
allergicnot
sensit
result
two
hundredforti
male
includ
fa
group
one
hundr
fortyfour
male
includ
nonfa
group
children
fa
higher
blood
total
ige
level
iuml
vs
iuml
eosinophil
vs
frequent
parent
allerg
histori
vs
frequenc
breast
feed
rel
higher
fa
group
nonfa
group
vs
p
subanalysi
children
fa
children
food
sensit
toler
group
show
signific
differ
frequenc
breast
feed
vs
adjust
revers
causat
exclud
children
age
month
parent
allerg
diseas
without
parent
allerg
diseas
alter
result
conclus
breast
feed
increas
risk
food
sensit
affect
fa
children
atop
dermat
effect
immunoadsorpt
procedur
specif
design
remov
ige
foodinduc
anaphylaxi
never
evalu
evalu
effect
ige
remov
allerg
threshold
food
six
yearold
boy
anaphylaxi
multipl
food
steroidresist
unstabl
allerg
asthma
display
serum
ige
level
kul
order
lower
ige
serum
concentr
could
overridden
high
dose
omalizumab
vol
plasma
exchang
apheresi
session
procedur
serum
ige
level
fell
kul
procedur
threshold
reactiv
bake
milk
increas
g
milk
protein
full
toler
first
session
threshold
reactiv
hazelnut
increas
g
protein
first
session
g
sixth
session
immedi
sixth
ige
immunoadsorpt
start
omalizumab
therapi
follow
day
threshold
reactiv
hazelnut
increas
full
toler
asthma
control
obtain
lung
function
improv
treatment
montelukast
stop
fluticason
taper
mcgday
boy
becam
partial
fulli
toler
food
caus
anaphylaxi
qualiti
life
improv
igeimmunoadsorpt
use
establish
start
basi
omalizumab
administr
abl
per
se
increas
toler
threshold
food
background
cigarett
smoke
predomin
risk
factor
develop
chronic
airway
obstruct
global
copd
one
lead
caus
mortal
morbid
purpos
studi
assess
burden
correl
cigarett
smoke
respiratori
airway
obstruct
among
healthi
adult
method
crosssect
studi
includ
healthi
adult
without
respiratori
ill
non
communic
diseas
smoke
inform
collect
use
standard
questionnair
lung
function
test
perform
spiromet
cutoff
point
deriv
gold
guidelin
multivari
logist
regress
analysi
perform
result
male
femal
current
heavi
smoker
among
two
femal
male
smoker
femal
overal
airway
obstruct
male
femal
compar
never
smoker
former
smoker
ci
current
heavi
smoker
ci
p
associ
obstruct
increas
age
associ
increas
obstruct
ci
p
obstruct
associ
short
breath
ci
cough
ci
phlegm
ci
wheez
ci
p
compar
obstruct
smoker
obstruct
associ
phlegm
ci
wheez
ci
refer
smoker
without
obstruct
among
obstruct
sob
ci
phlegm
ci
associ
smoker
refer
nonsmok
conclus
one
four
one
quarter
appar
healthi
adult
cohort
suffer
undiagnos
airway
obstruct
associ
document
cigarett
smoke
develop
airway
obstruct
symptom
background
sputum
eosinophilia
use
biomark
corticosteroid
respons
patient
asthma
chronic
cough
howev
sputum
induct
requir
special
personnel
facil
alway
feasibl
recent
evid
suggest
moder
degre
diagnost
util
less
invas
biomark
blood
eosinophil
predict
sputum
eosinophilia
asthma
howev
none
literatur
examin
diagnost
util
blood
eosinophil
sputum
eosinophilia
patient
nonasthmat
chronic
cough
method
examin
dataset
elderli
asthma
nonasthmat
chronic
cough
recruit
previous
establish
cohort
inclus
criteria
follow
elderli
subject
year
old
current
oral
inhal
corticosteroid
signific
comorbid
sputum
eosinophilia
defin
induc
sputum
diagnost
util
assess
use
receiv
oper
curv
roc
analys
blood
eosinophil
predict
sputum
eosinophilia
result
total
elderli
asthma
nonasthmat
chronic
cough
patient
analyz
signific
differ
demograph
profil
age
gender
smoke
two
group
elderli
asthma
nonasthmat
chronic
cough
patient
sputum
eosinophilia
spearman
test
correl
blood
eosinophil
sputum
eosinophil
signific
eosinophil
asthma
p
nonasthmat
eosinophil
bronchiti
roc
analys
sputum
eosinophilia
blood
eosinophil
show
moder
util
area
roc
curv
auc
asthma
util
auc
nonasthmat
chronic
cough
conclus
unlik
asthma
blood
eosinophil
diagnost
util
sputum
eosinophilia
nonasthmat
chronic
cough
find
could
suggest
differ
pathophysiolog
airway
eosinophil
inflamm
two
entiti
background
complementari
altern
medicin
cam
extens
use
patient
allerg
diseas
worldwid
purpos
studi
investig
actual
situat
cam
practic
treatment
allerg
rhiniti
method
distribut
questionnair
otolaryngologist
facil
japan
subject
particip
studi
includ
children
year
age
adult
year
age
diagnos
allerg
rhiniti
otolaryngologist
survey
perform
period
septemb
august
furthermor
perform
investig
hospit
set
gener
health
examin
questionnair
return
chiba
univers
analyz
result
proport
patient
ever
experi
cam
hospit
survey
children
adult
respect
approxim
adult
patient
thought
treatment
effect
main
reason
cam
use
safeti
conveni
low
price
howev
group
spent
cam
felt
dissatisfact
anxieti
relat
treatment
hospit
situat
cam
practic
consist
instead
influenc
background
subject
conclus
mani
patient
receiv
cam
report
feel
effect
treatment
provid
hospit
insuffici
concern
side
effect
treatment
inform
regard
standard
treatment
describ
guidelin
becom
wide
known
diffus
strong
commun
patient
consid
background
assess
diseas
sever
cours
import
achiev
wellcontrol
statu
asthma
elderli
popul
cognit
physic
impair
note
age
process
may
impact
asthma
control
aim
evalu
impact
cognit
function
assess
asthma
control
elderli
asthmat
method
fifti
mild
moder
asthmat
enrol
year
old
questionnair
includ
act
asthma
specif
qualiti
life
aqol
geriatr
depress
scale
gd
perform
seoul
neuropsycholog
screen
batterydementia
version
snsbd
korean
version
mini
mental
statu
examin
kmmse
seoul
instrument
activ
daili
live
scale
siadl
done
neuropsycholog
assess
result
mean
age
year
thirti
patient
femal
accord
gina
wellcontrol
notcontrol
howev
accord
act
group
group
sensit
specif
act
determin
wellcontrol
asthma
respect
overestim
asthma
control
statu
use
act
compar
gina
regard
neuropsycholog
assess
mild
cognit
impair
dementia
depress
depress
common
patient
uncontrol
asthma
vs
total
snsbd
score
significantli
higher
patient
vs
act
score
significantli
correl
degre
cognit
function
adjust
use
age
sex
educ
gd
conclus
discrep
selfreport
act
physician
decis
gina
assess
asthma
control
elderli
asthma
act
score
affect
cognit
function
elderli
asthmat
higher
cognit
function
achiev
better
asthma
control
background
mani
aspect
relationship
allerg
inflamm
reactiv
oxygen
stress
unclear
aim
elucid
associ
respiratori
syncyti
viru
rsv
infect
reactiv
oxygen
stress
wheez
ill
reactiv
oxygen
stress
method
subject
children
age
year
hospit
rsv
infect
patient
rs
group
bronchial
asthma
without
rsv
patient
ba
group
acut
bronchiti
pharyng
patient
br
group
level
blood
nitric
oxid
nox
high
mobil
group
thioredoxin
eosinophilderiv
neurotoxin
urin
nox
biopyrrin
measur
admiss
day
acut
phase
hospit
day
recoveri
phase
week
discharg
late
phase
studi
approv
ethic
committe
nation
hospit
organ
fukuyama
medic
center
parent
subject
provid
written
inform
consentin
accord
declar
helsinki
result
higher
rs
ba
group
recoveri
late
phase
acut
phase
higher
late
phase
rs
ba
group
br
group
rs
group
recoveryacut
lateacut
ba
group
br
respect
urin
higher
rs
group
ba
br
group
recoveri
late
phase
rs
group
recoveryacut
lateacut
ba
group
br
respect
signific
differ
found
biomark
conclus
young
children
acut
respiratori
tract
ill
wheez
reactiv
oxygen
stress
high
recoveri
late
phase
lower
respiratori
tract
inflamm
might
persist
acut
phase
lead
bronchial
hyperrespons
purpos
effect
allerg
rhiniti
ar
pulmonari
function
risk
factor
ar
controversi
purpos
studi
analys
risk
factor
pulmonari
function
dust
mite
sensit
current
ar
children
never
diagnos
asthma
method
crosssect
studi
children
age
year
korea
conduct
demograph
diseas
relat
inform
obtain
via
detail
questionnair
skin
prick
test
pulmonari
function
test
methacholin
challeng
test
result
total
children
includ
analysi
children
sensit
common
allergen
allerg
diseas
classifi
control
group
children
classifi
current
ar
dust
mite
sensit
group
binari
logist
regress
analysi
evidenc
nonfarm
parent
adjust
odd
ratio
aor
ci
older
sibl
aor
ci
use
antibiot
infanc
aor
ci
helminth
infect
aor
ci
low
incom
aor
ci
pet
ownership
aor
ci
risk
protect
factor
differ
spirometri
control
current
ar
group
none
children
show
bronchodil
respons
howev
methacholin
provoc
concentr
methacholin
caus
fall
forc
expiratori
volum
second
less
less
less
control
group
respect
allerg
rhiniti
group
conclus
might
reduc
preval
dust
mite
sensit
current
ar
control
environment
factor
even
spirometri
seem
normal
bronchial
hyperrespons
occur
frequent
children
dust
mite
sensit
ar
normal
children
background
blomia
tropicali
common
hous
dust
mite
tropic
region
although
predomin
sensit
blomia
allergen
clearli
demonstr
southeast
asian
countri
singapor
malaysia
preval
btropicali
hypersensit
well
identif
major
allergen
remain
elucid
thailand
goal
studi
clone
express
recombin
blo
rblo
allergen
pichia
pastori
method
cdna
encod
matur
blo
amplifi
b
tropicali
total
cdna
templat
use
specif
primer
deriv
allergen
mrna
sequenc
genbank
access
number
cdna
subsequ
clone
ppastori
express
vector
downstream
mate
factor
leader
sequenc
protein
secret
p
pastori
cell
transform
linear
recombin
ablo
plasmid
electropor
rblo
express
subsequ
assay
zeocinresist
coloni
follow
methanol
induct
recombin
allergen
purifi
homogen
anionexchang
gel
filtrat
chromatographi
result
amplifi
cdna
matur
blo
encod
amino
acid
protein
sequenc
align
matur
blo
refer
primari
structur
uniprotkbtrembl
access
number
evidenc
four
point
mutat
also
twenti
amino
acid
insert
multipl
align
show
blo
sequenc
segment
conserv
domain
share
group
mite
allergen
tyr
p
aca
lep
gli
der
p
der
f
matur
rblo
success
express
secret
ppastori
follow
induct
methanol
express
protein
migrat
onto
sdspage
band
differ
predict
molecular
weight
kd
could
attribut
glycan
structur
predict
nglycosyl
site
ntt
aa
conclus
correct
matur
blo
cdna
sequenc
togeth
success
recombin
allergen
product
p
pastori
offer
great
opportun
initi
componentresolv
diagnosi
b
tropicali
allergi
thailand
abstract
use
burkard
volumetr
sampler
survey
airborn
pollen
grain
bangalor
carri
januari
decemb
assess
qualit
quantit
occurr
pollen
grain
differ
month
year
character
pollen
season
domin
pollen
type
atmospher
bangalor
citi
pollen
type
identifi
total
pollen
catch
pollen
bulk
pollen
origin
anemophil
tree
grass
eight
pollen
type
record
annual
total
pollen
catch
peltophorum
pterocarpum
form
major
compon
pollen
spectrum
constitut
total
pollen
catch
follow
signific
pollen
contributor
genera
delonix
regia
parthenium
hysterophoru
samanea
saman
poacea
amaranthu
spinosu
highest
pollen
count
obtain
month
may
lowest
august
pollen
type
record
mark
season
pattern
occurr
atmospher
februarymay
principl
pollen
season
maximum
number
pollen
count
pollen
type
septemb
octob
second
pollen
season
grass
main
sourc
pollen
airborn
pollen
spectrum
reflect
veget
bangalor
citi
signific
neg
correl
found
daili
pollen
count
minimum
temperatur
rel
humid
rainfal
skin
prick
test
perform
patient
allerg
rhiniti
test
perform
eleven
pollen
allergen
extract
peopl
take
outdoor
activ
pollinosi
patient
bronchial
asthma
allerg
conjunct
allerg
rhiniti
increas
pollen
produc
variou
plant
especi
anemophil
pollen
mostli
relat
allerg
diseas
korea
pollinosi
mainli
caus
pollen
tree
spring
weed
fall
respect
oak
birch
cedar
main
tree
speci
gener
allergen
pollen
ragwe
mugwort
humulu
main
weed
speci
nation
institut
meteorolog
research
nimr
korean
academi
pediatr
allergi
respiratori
diseas
jointli
oper
nationwid
pollen
observ
network
current
fourteen
hirst
type
trap
burkard
sevenday
record
volumetr
spore
trap
oper
twelv
citi
airborn
pollen
collect
everi
day
sampler
collect
site
pollen
speci
morpholog
identifi
classifi
size
color
pore
shape
surfac
pattern
observ
pollen
compos
fifteen
tree
speci
includ
pine
nine
weed
speci
base
observ
data
nimr
establish
system
issu
daytoday
warn
allergen
pollen
tree
weed
offer
risk
index
allerg
pollen
dedic
web
page
pollen
risk
index
four
risk
level
mild
moder
sever
danger
base
symptom
level
pollen
allergi
patient
continu
observ
pollen
monitor
network
support
longterm
chang
allergen
plant
improv
daytoday
pollen
forecast
background
associ
serum
vitamin
defici
birth
atop
dermat
ad
uncertain
aim
studi
investig
relationship
cord
serum
oh
develop
ad
prospect
birth
cohort
studi
method
children
age
yr
birth
cohort
cohort
childhood
origin
asthma
allerg
diseas
cocoa
studi
enrol
cord
blood
obtain
birth
oh
dna
cord
blood
measur
specif
ige
antibodi
egg
milk
perform
age
also
skin
prick
test
conduct
age
result
median
cord
serum
oh
ngml
low
cord
serum
oh
ngml
associ
milk
sensit
age
sever
cord
serum
oh
defici
ngml
increas
risk
ad
age
aor
ci
pvalu
age
aor
ci
pvalu
also
found
cord
serum
oh
may
affect
outcom
ad
low
cord
serum
oh
reduc
remiss
ad
aor
ci
pvalu
sever
defici
ngml
associ
newli
develop
ad
aor
ci
pvalu
conclus
cord
serum
oh
associ
milk
sensit
ad
low
cord
serum
oh
reduc
remiss
ad
sever
defici
associ
newli
develop
ad
data
suggest
cord
serum
oh
affect
develop
prognosi
ad
background
mast
cell
origin
canin
mast
cell
tumor
use
tool
investig
kitdepend
independ
prolifer
mast
cell
well
known
gain
function
mutat
ckit
gene
serious
associ
neoplast
prolifer
mast
cell
human
rodent
dog
howev
kitindepend
malign
prolifer
mast
cell
rare
explor
sinc
patient
mast
cell
leukemiasarcoma
patient
cutan
mastocytosi
preserv
wild
type
kit
mutant
kit
attempt
find
kitindepend
mechan
induc
tumorigen
prolifer
mast
cell
b
method
investig
mechan
tumorigenesi
use
wildtyp
kitexpress
canin
mast
cell
line
western
blot
analysi
conduct
detect
kit
phosphoryl
rtpcr
flow
cytometri
analysi
carri
examin
stem
cell
factor
scf
express
inhibitori
effect
scf
neutral
antibodi
rna
interfer
scf
cell
prolifer
also
evalu
scf
product
xenograft
consist
wildtyp
kitexpress
tumor
identifi
c
result
high
express
scf
detect
canin
mast
cell
line
wildtyp
kit
use
studi
cell
kit
spontan
phosphoryl
neutral
scf
well
scf
gene
silenc
inhibit
growth
cell
suggest
scf
autocrineparacrin
action
product
scf
also
observ
sever
mast
cell
line
origin
human
rodent
enhanc
pmaionomycin
stimul
cell
xenograft
markedli
posit
scf
moreov
scf
strongli
detect
sampl
isol
canin
mast
cell
tumor
express
wildtyp
kit
conclus
discuss
result
indic
broad
contribut
scf
autocrineparacrin
neoplast
prolifer
wildtyp
kitexpress
mast
cell
dog
also
human
rodent
suggest
target
scf
product
may
becom
novel
strategi
treatment
mast
cell
malign
background
mite
tablet
monomer
allergoid
develop
sublingu
immunotherapi
patient
suffer
allerg
rhinoconjunct
arc
purpos
trial
determin
efficaci
safeti
four
differ
dose
mite
tablet
compar
placebo
method
patient
recruit
adult
patient
arc
induc
hdm
random
dbpc
phase
ii
studi
eudract
conduct
germani
treatment
consist
either
uad
uad
uad
uad
placebo
cours
week
efficaci
assess
improv
reaction
titrat
conjunctiv
allergen
challeng
safeti
assess
frequenc
type
sever
treatmentrel
advers
event
trae
result
cours
immunotherapi
patient
treat
uad
uad
respect
show
tenfold
improv
threshold
allergen
concentr
compar
placebo
p
neither
treatment
relat
sae
case
anaphylaxi
report
need
use
epinephrin
total
patient
activ
treatment
experienc
local
trae
system
trae
conclus
treatment
mite
monomer
allergoid
welltoler
safe
treatment
patient
suffer
hdm
induc
arc
highest
proport
patient
improv
cpt
threshold
allergen
concentr
found
patient
treat
uad
correspond
approxim
ua
cumul
dose
cours
trial
background
depress
allerg
diseas
report
frequent
comorbid
howev
associ
evalu
comprehens
way
particularli
elderli
object
aim
examin
associ
allerg
paramet
depress
communitybas
elderli
popul
method
present
analys
perform
use
baselin
data
set
korean
longitudin
studi
health
age
consist
elderli
subject
age
randomli
recruit
urban
commun
depress
assess
geriatr
depress
scale
gd
center
epidemiolog
studi
depress
scale
cesd
scale
hamilton
rate
scale
depress
hrsd
allerg
paramet
includ
questionnair
allergen
skin
testsasthma
symptom
histori
defin
structur
questionnair
atopi
defin
inhal
allergen
skin
prick
test
gener
qualiti
life
scale
comorbid
assess
result
preval
asthma
major
depress
disord
respect
preval
depress
symptom
statist
signific
nonasthmat
asthma
group
vs
p
addit
analys
howev
individu
report
symptom
usual
cough
chronic
cough
nocturn
cough
higher
risk
major
depress
lower
adjust
use
age
gender
educ
incom
p
furthermor
rhiniti
atopi
eosinophilia
relat
depress
risk
factor
geriatr
depress
identifi
femal
sex
advanc
age
low
incom
million
month
dementia
solitari
life
comorbid
medic
condit
conclus
conclud
asthma
associ
depress
elderli
comparison
asthma
symptom
profoundli
affect
object
depress
scale
present
studi
indic
appropri
treatment
asthma
control
potenti
decreas
depress
disord
background
allerg
diseas
mainli
mediat
immun
respons
ige
antibodi
specif
allergen
orchestr
variou
immunolog
factor
includ
immun
cell
cytokin
known
level
total
ige
helper
cell
cytokin
associ
allerg
inflamm
diseas
develop
evalu
correl
need
examin
possibl
refer
factor
diagnosi
monitor
allerg
diseas
method
previous
investig
serum
level
total
ige
allergyrel
cytokin
ratio
cell
respect
normal
individu
allerg
patient
factor
compar
normal
allerg
particip
examin
signific
differ
correl
total
ige
immunolog
factor
investig
variou
statist
analysi
use
integr
result
factor
result
serum
level
total
ige
allerg
patient
significantli
higher
normal
subject
vs
kul
p
cell
percentag
also
differ
vs
cell
percentag
ratio
show
signific
differ
normal
allerg
particip
nine
cytokin
analyz
allerg
patient
level
increas
patient
compar
normal
individu
particularli
plateletderiv
growth
factor
bb
pdgfbb
much
higher
allerg
patient
vs
pgml
p
integr
analysi
particip
total
ige
signific
correl
ratio
cell
percentag
respect
conclus
studi
found
cell
percentag
decreas
allerg
patient
support
cell
might
import
role
allerg
respons
result
also
show
pdgfbb
could
respons
allerg
respons
suggest
possibl
refer
factor
allerg
diseas
demonstr
correl
total
ige
ratio
cell
percentag
might
relev
corrobor
immunolog
function
cell
igerel
respons
background
studi
pattern
allerg
diseas
among
militari
servicemen
women
refer
singapor
arm
forc
saf
method
referr
tan
tock
seng
hospit
clinic
immunologyallergi
clinic
jan
may
retrospect
review
demograph
profil
servicemen
type
allergicimmunolog
diseas
definit
therapi
prescrib
studi
result
referr
compris
male
predominantli
activ
fulltim
nation
servicemen
nsf
regular
mean
age
diagnosi
year
compris
chines
malay
indian
common
refer
diagnos
insect
venom
allergi
urticarialangioedema
anaphylaxi
drug
allergi
food
allergi
nonsteroid
antiinflammatori
drug
nsaid
hypersensit
allerg
rhiniti
follow
evalu
allergist
insect
venom
allergi
anaphylaxi
allerg
rhiniti
nsaid
hypersensit
common
condit
servicemen
diagnos
insect
venom
anaphylaxi
underw
allergen
immunotherapi
ait
regular
nsf
receiv
yellow
jacket
paper
wasp
venom
ait
addit
receiv
honey
bee
venom
ait
serviceman
develop
system
reaction
ait
serviceman
complet
year
ait
mean
durat
servicemen
ait
date
year
conclus
insect
venom
allergi
anaphylaxi
allerg
rhiniti
nsaid
hypersensit
common
referr
saf
medic
offic
militari
train
equip
manag
militari
servicemen
condit
primari
care
level
particular
knowledg
anaphylaxi
action
plan
use
epinephrin
autoinjector
knowledg
nsaid
hypersensit
reaction
also
import
especi
sinc
nonselect
nsaid
commonli
use
treatment
musculoskelet
injuri
train
antituberculosi
tb
drug
caus
variou
advers
drug
reaction
adr
includ
hypersensit
syndrom
multipl
drug
concomitantli
administ
detect
culprit
drug
essenti
success
treatment
lymphocyt
activ
test
lat
one
promis
methodolog
evalu
delay
drug
hypersensit
role
antitb
hypersensit
remain
controversi
man
refer
allergi
clinic
high
fever
headach
skin
rash
arm
leg
diagnos
pulmonari
tb
start
combin
antitb
drug
therapi
consist
isoniazid
rifampicin
ethambutol
pyrazinamid
day
bodi
temperatur
erythemat
maculopapular
rash
upper
lower
extrem
sever
tender
lymph
node
palpabl
cervic
area
increas
level
aminotransferas
ast
iul
alanin
transaminas
alt
iul
antitb
drug
ceas
patch
test
show
weak
reaction
rifampin
pyrazinamid
howev
rifampin
strong
posit
lat
test
success
reintroduc
rifampicin
oral
desensit
without
complic
experi
suggest
lat
could
help
determin
culprit
drug
polypharmaci
especi
antitb
drug
background
anaphylaxi
catastroph
system
reaction
drug
respons
anaphylaxi
howev
littl
known
characterist
druginduc
anaphylaxi
korea
aim
studi
investig
causal
drug
clinic
featur
druginduc
anaphylaxi
korean
use
data
advers
drug
reaction
adr
report
system
korea
institut
drug
safeti
risk
manag
kid
method
among
individu
case
safeti
report
icsr
kid
januari
june
case
druginduc
anaphylaxi
select
age
gender
caus
agent
fatal
case
result
death
analyz
result
total
case
identifi
male
mean
age
year
common
causal
drug
antibiot
follow
aspirinnonsteroid
antiinflammatori
drug
nsaid
contrast
media
anticanc
drug
fatal
case
antibiot
case
contrast
media
case
two
common
caus
drug
categori
drug
report
least
two
time
suspect
caus
agent
drug
reflect
anaphylaxi
drug
label
inform
conclus
antibiot
aspirinnsaid
contrast
media
anticanc
drug
caus
drug
among
anaphylaxi
icsr
korea
antibiot
contrast
media
also
main
caus
agent
respons
fatal
drug
induc
anaphylaxi
background
antimit
barrier
cover
manufactur
textil
filtrat
properti
usual
valid
differ
certif
label
although
textil
certif
mandatori
cover
manufactur
use
process
iso
certifi
subject
cover
stringent
qualiti
control
measur
object
studi
evalu
benefit
iso
certif
liabil
final
product
method
studi
six
differ
batch
microwoven
mwc
nonwoven
polyest
polyamid
nwp
textil
went
qualiti
control
process
requir
norm
iso
upon
recept
textil
pore
size
measur
use
optic
microscop
bresser
usa
textil
permeabl
test
use
rotomitest
apparatu
compos
two
compart
separ
sampl
der
allergen
place
compart
apparatu
set
rotat
hour
der
allergen
pass
sampl
compart
measur
der
elisa
kit
citeq
biolog
netherland
valu
express
mean
sem
compar
use
twoway
anova
result
pore
size
found
smaller
mwc
nwp
textil
vs
nwp
fabric
show
irregular
pore
size
batch
pore
size
greater
permeabl
result
show
nwp
fabric
significantli
permeabl
der
allergen
compar
mwc
tissu
vs
thu
iso
qualiti
control
allow
dismiss
batch
unsatisfactori
nwp
textil
conclus
addit
initi
test
textil
medic
devic
higher
class
monitor
manufactur
process
certif
necessari
ensur
qualiti
finish
product
especi
use
nonwoven
fabric
therefor
iso
certif
relev
criteria
antimit
cover
qualiti
thu
effect
subcutan
immunotherapi
effect
treatment
allergi
work
help
rebal
individu
immun
respons
allergen
abil
drive
antibodi
titr
respons
greatli
improv
use
adjuv
common
aluminium
hydroxid
data
preclin
model
localis
kinet
aluminium
subcutan
inject
base
allergi
formul
current
exist
method
albino
rat
crl
wi
han
strain
receiv
singl
subcutan
administr
occas
day
interv
birch
concentr
formul
either
alhydrogel
ltyrosin
repres
depot
adjuv
dose
site
extract
digest
month
final
administr
aluminium
analys
via
icpm
result
signific
proport
aluminium
retain
inject
site
month
post
final
inject
rate
clearanc
aluminium
dose
site
calcul
month
time
period
estim
data
termin
halflif
clearanc
sc
dose
site
would
approx
day
ie
time
taken
remov
half
dose
therefor
estim
time
clear
dose
sc
site
would
take
approx
year
rat
model
conclus
localis
kinet
aluminium
subcutan
inject
base
allergi
formul
investig
rate
clearanc
aluminium
inject
site
calcul
rat
model
granuloma
format
one
common
unwant
advers
reaction
patient
receiv
allergi
subcutan
immunotherapi
result
present
herein
support
current
understand
aluminium
propens
form
focal
accumul
bodi
begin
site
administr
background
periostin
consid
biomark
allerg
inflamm
predictor
airway
eosinophilia
periostin
level
exhal
breath
condens
ebc
athlet
evalu
aim
present
studi
includ
comparison
periostin
level
ebc
athlet
asthmat
healthi
control
hc
assess
effect
exercis
influenc
ambient
condit
ebc
periostin
method
studi
group
consist
competit
athlet
speed
skater
swimmer
age
control
group
compris
mildtomoder
asthmat
age
asthma
control
ac
healthi
nonsmok
subject
age
healthi
control
hc
control
subject
perform
sport
reglar
basi
athlet
assess
two
timepoint
intrain
period
outoftrain
period
depend
individu
train
schedul
treadmil
exercis
challeng
conduct
accord
at
guidelin
ebc
collect
immedi
minut
exercis
periostin
level
ebc
assess
elisa
result
periostin
ebc
level
exercis
challeng
significantli
decreas
athlet
intrain
period
compar
outoftrain
period
vs
ngml
p
ac
subject
vs
ngml
p
exercis
challeng
induc
signific
chang
ebc
periostin
group
athlet
train
period
signific
posit
correl
observ
baselin
ebc
periostin
level
mean
daili
air
temperatur
assess
day
day
mean
temperatur
day
preced
assess
dew
point
temperatur
day
p
mean
dew
point
temperatur
day
preced
assess
asthmat
signific
neg
correl
observ
baselin
ebc
periostin
mean
daili
air
temperatur
day
correl
observ
athlet
offtrain
period
hc
subject
conclus
regular
exercis
may
contribut
decreas
express
airway
periostin
level
ambient
condit
seem
influenc
periostin
releas
airway
asthma
exacerb
exagger
lower
airway
respons
environment
exposur
trigger
asthma
exacerb
includ
viru
infect
allergen
environment
pollut
occup
sensitis
irrit
medicin
aspirin
well
known
respiratori
viral
infect
common
cuas
sever
asthma
exacerb
doublestrand
rna
dsrna
activ
serinethreonin
kinas
r
pkr
well
character
essenti
compon
innat
antivir
respons
moreov
pkr
activ
associ
ige
class
switch
subsequ
induct
igemedi
disord
allergi
asthma
meanwhil
pkr
phosphoryl
one
branch
unfol
protein
respons
upr
convers
endoplasm
reticulum
er
stress
activ
pkr
stimul
variou
inflammatori
signal
pathway
howev
date
littl
inform
role
asthma
exacerb
especi
acut
exacerb
steroidresist
sever
asthma
studi
investig
whether
pkr
activ
involv
induct
asthma
exacerb
use
mous
model
acut
asthma
exacerb
induc
administr
poli
c
found
administr
poli
c
aggrav
sever
asthmat
featur
compar
mice
sensit
ovalbumin
ova
lipopolysaccharid
lp
challeng
ova
ovalpsova
mice
number
airway
inflammatori
cell
bronchioalveolar
lavag
bal
fluid
airway
hyperrespons
express
kc
lung
tissu
interestingli
pkr
express
also
increas
lung
tissu
ovalpsova
mice
treat
poli
c
ovalpsova
mice
moreov
phosphoryl
pkr
primari
cultur
tracheal
epitheli
cell
enhanc
ovalpsova
mice
treat
poli
c
studi
indic
pkr
activ
play
import
role
induct
acut
exacerb
sever
neutrophil
asthma
highlight
therapeut
potenti
pkr
inhibitor
potent
control
acut
asthma
exacerb
sever
asthmat
patient
background
idiopath
hypereosinophil
syndrom
ihe
rare
disord
defin
persist
blood
eosinophilia
absenc
secondari
caus
evid
eosinophilassoci
organ
dysfunct
patient
hypereosinophilia
may
caus
lifethreaten
complic
wherea
patient
refer
hypereosinophila
unknown
signific
us
exhibit
measur
organ
damag
although
clinic
divers
he
recogn
isol
case
report
avail
asia
retrospect
analysi
sought
summar
baselin
demograph
clinic
laboratori
characterist
cohort
patient
he
us
review
respons
treatment
method
clinic
laboratori
data
patient
ihe
us
seen
januari
decemb
hallym
sacr
heart
hospit
collect
retrospect
chart
review
result
total
patient
enrol
patient
diagnos
us
patient
ihe
mean
number
white
blood
cell
peak
total
eosinophil
count
tec
significantli
increas
patient
ihe
compar
us
respect
growth
factor
receptor
mutat
analysi
done
patient
use
situ
hybrid
show
neg
result
patient
ihe
common
clinic
present
symptom
gastrointestin
follow
constitut
symptom
fever
myalgia
weak
weight
loss
pulmonari
patient
receiv
corticosteroid
mgkg
initi
therapi
seven
patient
show
complet
respons
patient
partial
respons
within
month
howev
patient
recur
taper
discontinu
corticosteroid
signific
associ
treatment
respons
laboratori
paramet
includ
peak
tec
total
ige
eosinophil
cation
protein
marrow
eosinophilia
conclus
major
patient
ihe
respond
corticosteroid
therapi
howev
discontinu
corticosteroid
associ
recurr
clinic
laboratori
marker
predict
prognosi
ihe
object
evid
suggest
dexamethason
involv
apoptosi
differenti
cell
apoptosi
neutrophil
delay
neutrophil
asthma
mice
model
investig
effect
dexamethason
cell
involv
mechan
neutrophil
asthma
na
method
na
neutrophil
asthma
dexamethason
intervent
nad
mice
sensit
lp
ova
airway
deliveri
eosinophil
asthma
ea
eosinophil
asthma
dexamethason
intervent
ead
mice
sensit
peritoneum
ova
aluminum
hydroxid
challeng
stage
na
ea
mice
expos
ova
aerosol
aerosol
nad
ead
mice
treat
dexamethason
peritoneum
control
mice
treatment
data
collect
last
exposur
elisa
flowcytometri
quantit
pcr
use
measur
cytokin
cell
subset
intracellular
cytokin
signal
molecul
invas
measur
airway
resist
use
measur
airway
hyperreact
ahr
result
balf
level
nad
group
signific
differ
compar
na
ead
group
higher
control
balf
level
nad
group
signific
differ
compar
na
ead
group
markedli
higher
control
balf
level
nad
group
signific
differ
na
group
markedli
higher
control
express
level
nad
group
markedli
downregul
compar
na
group
signific
differ
ead
group
control
level
nad
group
markedli
upregul
compar
na
control
markedli
downregul
compar
ead
group
express
level
nad
group
markedli
upregul
compar
na
group
markedli
higher
ead
control
level
nad
group
signific
differ
na
group
nad
group
signific
downregul
compar
ead
group
level
nad
group
markedli
decreas
compar
na
group
markedli
higher
ead
control
level
nad
group
markedli
decreas
compar
na
group
markedli
higher
thanin
ead
control
level
nad
group
markedli
decreas
compar
na
group
markedli
lower
ead
group
nad
group
conclus
dexamethason
decreas
differenti
cell
domin
downregul
upregul
na
mice
treat
dexamethason
high
level
inhibit
apoptosi
promot
surviv
cell
connect
domin
signal
pathway
background
preval
allerg
diseas
like
asthma
rhiniti
eczema
gradual
increas
india
knowledg
preval
common
allergen
caus
allerg
asthmarhin
eczema
use
optimum
use
therapeut
modal
like
allergen
avoid
immunotherapi
reduc
burden
diseas
studi
india
base
skin
prick
intra
dermal
test
conduct
non
standard
techniqu
lack
studi
base
measur
specif
ige
antibodi
immunocap
techniqu
recent
introduc
india
therefor
immunocap
specif
serum
ige
antibodi
assay
done
determin
preval
allergen
patient
eczema
allerg
asthmarhin
india
method
studi
conduct
new
delhi
india
six
month
patient
allerg
rhinitisasthma
eczema
recruit
studi
investig
pattern
allergen
preval
use
immunocap
allergen
specif
ige
antibodi
assay
data
analyz
use
spss
result
patient
enrol
studi
show
posit
respons
one
allergen
gender
dust
mite
cockroach
bermuda
grass
ragwe
found
promin
allergen
dust
mite
promin
age
group
year
import
allergen
ragwe
bermuda
grass
johnson
grass
cockroach
also
age
group
dust
mite
import
allergen
follow
cockroach
bermuda
grass
ragwe
cocklebur
patient
asthmarhin
domin
allergen
found
dust
mite
cockroach
bermuda
grass
ragwe
respect
p
patient
eczema
cockroach
promin
follow
dust
mite
wheat
shrimp
preval
p
conclus
india
one
first
studi
kind
use
fda
approv
standard
gold
standard
method
immunocap
specif
ige
assay
estim
preval
differ
allergen
patient
asthmaallerg
rhiniti
eczema
one
allergen
respons
caus
asthmarhin
eczema
preval
increas
india
avoid
known
allergen
specif
immunotherapi
significantli
reduc
need
ongo
expens
pharmacolog
long
term
treatment
enhanc
remiss
background
limit
public
regard
characterist
allerg
rhiniti
children
indonesia
object
aim
investig
clinic
characterist
allerg
rhiniti
ar
children
method
retrospect
crosssect
studi
conduct
pediatr
clinic
tertiari
referr
hospit
cipto
mangunkusmo
hospit
jakarta
indonesia
result
ar
diagnos
patient
boy
common
age
year
old
median
rang
year
old
common
symptom
rhinorrhea
cough
gener
patient
atopi
famili
histori
atopi
durat
ill
mostli
week
base
interview
cold
air
common
trigger
factor
follow
food
dust
common
sign
allerg
shiner
second
gener
antihistamin
intranas
steroid
prescrib
drug
asthma
comorbid
found
rhinosinus
complic
occur
conclus
younger
age
found
case
frequent
type
ar
persist
ar
despit
high
number
atop
histori
small
proport
children
asthma
background
vaccin
allergenspecif
immunotherapi
typic
contain
adjuv
facilit
immun
respons
human
anim
almost
centuri
salt
aluminium
hydroxid
phosphat
approv
adjuv
human
one
major
problem
aluminium
adjuv
biodegrad
typic
stimul
socal
thelper
type
oppos
immun
respons
affect
type
antibodi
respons
produc
goal
new
adjuv
therefor
facilit
recognit
antigenallergen
ii
biodegrad
biocompat
iii
without
toxic
inflammatori
side
effect
iv
trigger
protect
immun
respons
well
allergenneutralis
antibodi
coprecipit
micro
crystallin
tyrosin
mct
protein
suggest
candid
adjuv
allergenspecif
immunotherapi
method
immunogen
test
mctovalbumin
vaccin
balbc
mice
undertaken
three
inject
perform
week
interv
mice
tail
bled
prior
inject
well
differ
time
point
last
inject
obtain
sera
analys
ovaspecif
antibodi
spleen
cell
test
tcell
respons
includ
cytokin
secret
restimul
cell
vitro
ovalbumin
result
mct
good
adjuv
properti
compris
high
adsorpt
power
protein
enhanc
associ
immun
respons
highlight
potenti
action
biodegrad
depot
adjuv
allergenspecif
immunotherapi
mct
natur
metabolis
pharmacokinet
mct
present
halflif
inject
site
hour
particular
benefit
allergi
scit
tradit
long
cours
treatment
minimis
need
accumul
nonbiodegrad
adjuv
conclus
result
preclin
immunogen
mct
modeofact
studi
mice
demonstr
potenti
mct
nontox
biodegrad
altern
convent
adjuv
use
allergen
immunotherapi
background
sinc
report
associ
filaggrin
flg
mutat
atop
dermat
ad
genet
divers
flg
mutat
intens
investig
european
ethnic
popul
howev
except
wellestablish
racial
differ
european
asian
detail
analysi
genet
divers
clinic
implic
flgmutat
east
asian
ancestri
perform
yet
object
studi
geograph
distribut
flg
mutat
east
asia
evalu
clinic
signific
flg
mutat
east
asian
ad
patient
method
summar
data
relat
flg
mutat
across
east
asian
countri
analyz
geograph
distribut
flg
mutat
light
human
migrat
histori
east
asia
final
investig
clinic
signific
flgmutat
east
asian
ad
patient
result
genealog
analysi
genet
divers
found
flg
mutat
across
east
asia
confirm
distribut
flg
mutat
among
east
asian
popul
consist
hypothet
wave
human
migrat
along
southeastern
coast
asia
similar
european
flg
mutat
signific
risk
factor
ad
east
asian
palmar
hyperlinear
use
clinic
marker
screen
carrier
flg
mutat
howev
contrast
european
flg
mutat
increas
risk
concomit
asthma
east
asian
conclus
genet
divers
flg
mutat
across
east
asia
consist
hypothet
wave
human
migrat
along
costal
border
east
asia
european
asian
flg
mutat
similar
differ
background
world
health
organis
recommend
adsorpt
tetanu
diphtheria
toxoid
antigen
aluminium
contain
adjuv
protein
adsorpt
capac
aluminium
calcium
adjuv
well
document
modifi
allergen
tyrosin
adsorbedmonophosphoryl
lipid
matampl
formul
shown
effect
therapeut
allergi
immunotherapi
micro
crystallin
tyrosin
mct
formul
shown
consist
adsorb
allergoid
mpl
manufactur
howev
mct
adsorpt
capac
factor
protein
mpl
measur
direct
comparison
aluminium
calcium
adjuv
method
adsorpt
capac
mct
mpl
protein
calcul
quantit
determin
formul
ga
chromatographi
method
use
determin
mpl
content
bradford
method
use
determin
protein
content
adsorpt
capac
aluminium
calcium
adjuv
calcul
similar
way
direct
comparison
mct
result
mct
demonstr
greater
adsorpt
capac
mpl
aluminium
calcium
adjuv
conclus
abil
mct
readili
adsorb
mpl
compar
aluminium
calcium
adjuv
support
characterist
associ
base
tyrosin
structur
mct
physic
properti
mct
effect
depot
candid
allergi
immunotherapi
formul
vaccin
background
inflammatori
bowel
diseas
ibd
inflammatori
disord
unknown
pathogenesi
recent
studi
show
play
import
role
inflammatori
process
diseas
purpos
casecontrol
studi
explor
associ
gene
polymorph
suscept
ibd
method
patient
healthi
individu
refer
namazi
hospit
shiraz
iran
enter
studi
blood
sampl
collect
genom
dna
extract
restrict
fragment
length
polymorph
polymeras
chain
reaction
pcrrflp
perform
data
analyz
use
chisquar
bonferroni
test
result
frequenc
allel
significantli
greater
allel
significantli
lower
patient
compar
control
p
valu
addit
statist
signific
relationship
aa
genotyp
ibd
p
valu
conclus
first
studi
evalu
iranian
patient
ibd
studi
requir
order
clarifi
exact
role
polymorph
pathogenesi
suscept
inflammatori
bowel
diseas
background
object
sever
studi
demonstr
adiposederiv
stem
cell
asc
amelior
allerg
airway
inflamm
shift
immun
respons
asc
secret
varieti
autocrineparacrin
factor
call
secretom
protect
cell
apoptot
cell
death
modul
immun
system
studi
evalu
effect
ascsderiv
secretom
allerg
airway
inflamm
ovalbumin
ova
induc
asthmat
mous
model
materi
method
mice
sensit
ova
intraperiton
inject
challeng
intranas
ova
evalu
effect
ascsderiv
secretom
allerg
airway
diseas
asc
supernat
administr
intranas
ova
challeng
evalu
airway
hyperrespons
ahr
proport
eosinophil
bronchoalveolar
lavag
fluid
balf
lung
histolog
serum
total
ovaspecif
antibodi
cytokin
profil
balf
lung
drain
lymph
node
lln
cell
popul
lln
result
ascsderiv
secretom
significantli
inhibit
eosinophil
inflamm
lung
ahr
total
immun
cell
eosinophil
balf
mucu
product
significantli
reduc
ascsderiv
secretom
administr
ascsderiv
secretom
significantli
decreas
serum
total
allergenspecif
ige
level
ascsderiv
secretom
significantli
inhibit
cytokin
enhanc
cytokin
regulatori
cytokin
balf
lln
addit
cell
lln
significantli
increas
ascsderiv
secretom
administr
conclus
ascsderiv
secretom
amelior
allerg
airway
inflamm
improv
lung
function
induct
treg
expans
secretom
may
promis
candid
novel
cellfre
therapi
allerg
airway
diseas
mani
advantag
overcom
limit
risk
associ
cellbas
therapeut
alveolar
hemorrhag
antineutrophil
cytoplasm
antibodi
anca
rare
diseas
children
anca
associ
certain
diseas
granulomatosi
polyangi
gpa
microscop
polyangi
mpa
eosinophil
granulomatosi
polyangi
epga
group
diseas
character
necrot
smallvessel
vascul
show
autoantibodi
patient
serum
direct
neutrophil
cytoplasm
constitu
especi
proteinas
myeloperoxidas
mpo
diseas
affect
vessel
chang
focal
necrosi
patholog
find
patient
suffer
pulmonari
cerebr
gastrointestin
hemorrhag
complic
also
renal
dysfunct
repres
crescent
glomerulonephr
previou
healthi
girl
present
acut
onset
dyspnea
cough
hemoptysi
chest
discomfort
fever
hypoxemia
chest
ct
scan
show
diffus
consolid
ground
glass
opac
lung
hemoglobin
hematocrit
diagnos
diffus
alveolar
hemorrhag
bleed
diathes
exclud
laboratori
test
anti
nuclear
antibodi
ana
panca
posit
myeloperoxidaseanca
mpoanca
posit
proteinas
neg
antiglomerular
basement
membran
antibodi
antigbm
neg
urinalysi
show
rbc
creatinin
rbc
cast
protein
patient
diagnos
microscop
hematuria
kidney
function
normal
symptom
anca
associ
vascul
never
appear
patient
alveolar
hemorrhag
recov
immunosuppres
therapi
cyclophopamid
corticosteroid
report
old
girl
case
treat
sever
alveolar
hemorrhag
microscop
hematuria
posit
anca
background
correct
sever
assess
import
treatment
atop
dermat
ad
although
level
serum
thymu
activationregul
chemokin
tarc
well
known
proper
mean
assess
sever
ad
level
tarc
differ
accord
month
age
examin
correl
serum
tarc
level
sever
score
atop
dermat
scorad
index
patient
ad
earli
infanc
method
thirtythre
patient
atop
dermat
boy
girl
age
month
recruit
examin
correl
scorad
index
tarc
level
primari
outcom
well
correl
scorad
index
serum
total
ige
level
peripher
eosinophil
count
serum
lactat
dehydrogenas
ldh
level
secondari
outcom
spearman
rank
correl
coeffici
use
statist
evalu
result
median
scorad
index
patient
rang
also
median
tarc
level
peripher
eosinophil
count
serum
ldh
level
rang
pgdl
rang
rang
iuml
respect
signific
posit
correl
scorad
index
tarc
level
p
well
scorad
index
peripher
eosinophil
count
p
hand
signific
correl
scorad
index
serum
total
ige
level
also
scorad
index
serum
ldh
level
correl
significantli
conclus
serum
tarc
level
peripher
eosinophil
count
may
use
assess
sever
ad
earli
infanc
background
research
filaggrin
flg
mutat
variou
ethnic
group
reveal
nonoverlap
mutat
pattern
addit
japanes
chines
atop
patient
show
somewhat
differ
mutat
ethnic
differ
make
research
korean
patient
mandatori
howev
systemat
research
korean
atop
dermat
patient
perform
object
studi
aim
investig
genet
polymorph
flg
korean
atop
dermat
patient
method
studi
made
three
group
includ
iv
patient
ad
patient
normal
control
ichthyosi
group
incorpor
due
report
associ
flg
mutat
ichthyosi
vulgari
comparison
sequenc
method
overlap
longrang
pcr
use
result
reveal
genet
polymorph
flg
korean
time
discov
new
nonsens
mutat
confirm
previous
report
korean
patient
conclus
use
flg
sequenc
techniqu
confirm
studi
new
mutat
genet
polymorph
ethnic
characterist
would
detect
larger
studi
repeat
number
polymorph
could
perform
background
igemedi
wheat
allergi
affect
around
popul
accept
treatment
complet
food
avoid
howev
accident
exposur
may
occur
frequent
sinc
difficult
avoid
major
food
recent
sever
studi
chang
dilemma
avoid
propos
new
wheat
oral
immunotherapi
oit
protocol
anaphylact
patient
method
children
histori
anaphylaxi
met
inclus
criteria
recruit
studi
patient
uncontrol
asthma
cardiovascular
diseas
signific
system
diseas
poor
compliant
patient
exclud
anaphylaxi
confirm
dbpcfc
patient
ofc
oral
food
challeng
perform
patient
cake
determin
initi
dose
oit
design
step
build
phase
contain
cake
bread
bread
b
accord
ofc
result
patient
start
protocol
reaction
threshold
wheat
protein
would
start
cake
continu
till
gr
beyond
gr
ask
take
bread
contain
protein
gr
flour
amount
bread
increas
twice
week
medic
supervis
reach
gr
chang
full
wheat
bread
gr
protein
gr
flour
risen
gr
finish
build
phase
continu
take
bread
day
mainten
phase
next
month
addit
clinic
measur
immunolog
mechan
desensit
measur
first
day
end
buildup
mainten
phase
result
patient
recruit
studi
finish
protocol
one
accomplish
protocol
recurr
sever
anaphylact
reaction
remain
gr
bread
b
spt
wheal
significantli
reduc
end
mainten
phase
conclus
demonstr
wheat
toler
could
achiev
stepwis
oit
regimen
anaphylact
patient
appar
investig
need
confirm
safeti
effect
wheat
oit
protocol
background
filaggrin
key
protein
involv
skin
barrier
function
mutat
gene
encod
filaggrin
flg
identifi
caus
ichthyosi
vulgari
shown
major
predispos
factor
atop
dermat
ad
object
purpos
studi
investig
clinic
characterist
ad
patient
flg
mutat
determin
differ
ad
patient
without
flgmutat
method
identifi
flgmutat
ad
patient
complet
sequenc
snapshot
method
analyz
data
clinic
characterist
questionnair
respons
result
found
earlier
age
ad
onset
tendenc
respiratori
atopi
sever
ad
clinic
characterist
higher
easi
score
decreas
skin
hydrat
associ
flgrelat
ad
conclus
data
demonstr
flg
mutat
indic
poor
prognosi
ad
predispos
factor
exist
earli
infanc
persist
adulthood
background
aim
project
earli
diagnosi
asthma
allergi
among
children
attend
primari
school
wroclaw
preselect
group
high
risk
asthmaallergi
develop
use
questionnair
confirm
diagnosi
physician
offic
method
studi
carri
year
children
attend
grade
grammar
school
ys
age
poland
enter
studi
prior
diagnosi
asthma
ana
allergi
allergist
care
exclud
first
part
parent
educ
allergi
symptom
prevent
given
special
prepar
screen
questionnair
questionnair
includ
question
concern
famili
histori
earli
exposur
children
differ
allergen
etc
children
medic
histori
infect
symptom
cough
wheez
short
breath
runni
nose
rash
hospit
etc
second
part
children
score
fix
level
questionnair
subject
allergist
checkup
includ
pricktest
spirometri
confirm
deni
possibl
diagnosi
asthma
allergi
result
studi
first
part
involv
children
analysi
questionnair
children
visit
studi
allergist
diagnosi
asthma
allergi
confirm
especi
earli
symptom
select
allergen
exposur
correl
well
final
diagnosi
p
note
exposur
moistur
mold
diagnos
child
asthma
phi
p
allerg
rhiniti
phi
p
atop
dermat
phi
p
food
allergi
phi
p
conclus
questionnair
prove
fast
cheap
reliabl
tool
allergi
detect
introduc
school
standard
use
rational
patient
food
allergi
asthma
increas
risk
anaphylact
reaction
lifethreaten
asthmat
reaction
aim
studi
determin
asthma
impact
characterist
children
food
induc
anaphylaxi
adrenalin
autoinjector
prescrib
method
patient
rang
yearold
food
allergi
adrenalin
autoinjector
prescrib
april
octob
recruit
exclud
case
treat
oral
immunotherapi
evalu
causal
food
symptom
recent
anaphylact
reaction
serum
mitespecif
ige
adrenalin
treatment
anaphylaxi
factor
asthmat
group
asthma
onset
year
treat
inhal
corticosteroid
compar
nonasthmat
group
result
number
adrenalin
treatment
anaphylact
reaction
asthmat
group
higher
nonasthmat
group
significantli
p
signific
differ
mitespecif
ige
symptom
anaphylaxi
asthmat
group
nonasthmat
group
forti
three
anaphylact
reaction
asthmat
group
induc
milk
wheat
egg
higher
nonasthmat
patient
p
contrast
peanut
nut
induc
anaphylact
reaction
nonasthmat
group
frequent
asthmat
group
conclus
asthmat
children
anaphylact
reaction
occur
frequent
accident
ingest
daili
food
exampl
milk
wheat
egg
bronchial
hyperrespons
may
induc
anaphylact
reaction
easili
small
amount
causal
food
background
stevensjohnson
syndrom
sj
toxic
epiderm
necrolysi
ten
immunemedi
disord
lifethreaten
frequent
relat
prior
drug
consumpt
autoimmun
disord
suggest
predispos
effect
sj
sjsten
ten
howev
difficult
decid
whether
erupt
induc
drug
manifest
lupu
object
case
report
present
case
sj
sjsten
system
lupu
erythematosu
sle
case
year
old
femal
came
hospit
chief
complaint
blister
scald
skin
bodi
hand
feet
face
start
day
prior
admiss
consum
herbal
medic
day
addit
symptom
fever
multipl
painless
oral
ulcer
pain
swell
joint
made
patient
unabl
walk
sinc
month
prior
admiss
physic
examin
gener
multipl
discret
round
size
cm
mostli
fine
demarc
rais
mostli
dri
form
erythema
bulla
eros
discoid
pustul
bullou
pustul
discoid
found
ulcer
oral
genit
mucou
blood
examin
perform
hemolyt
anemia
posit
anti
nuclear
antibodi
ana
anti
dsdna
well
proteinuria
observ
patient
diagnos
suffer
sj
sle
case
year
old
femal
came
hospit
chief
complaint
peel
skin
bodi
hand
face
day
prior
admiss
patient
refer
anoth
hospit
cefixim
gentamicin
treatment
histori
physic
examin
fever
scali
lesion
bodi
hand
face
scald
lesion
back
eros
lip
oral
mucou
laboratori
find
pancytopenia
posit
direct
coomb
test
reactiv
ana
high
titer
anti
dsdna
well
proteinuria
patient
diagnos
suffer
sjsten
sle
conclus
patient
present
sj
sjstenlik
pictur
sle
background
becom
difficult
decid
whether
erupt
drug
induc
manifest
lupu
object
mani
report
exist
effect
oral
toler
induct
food
allergi
howev
comprehens
report
exist
effect
wheat
allergi
subject
among
subject
posit
result
oral
food
challeng
test
udon
wheat
noodl
inform
consent
obtain
subject
judg
capabl
start
intak
g
dri
noodl
weight
base
final
dose
induc
symptom
method
oral
toler
induct
perform
randomli
divid
subject
consider
age
follow
two
group
accord
intak
frequenc
frequent
group
intak
six
timesweek
intermitt
group
intak
two
timesweek
six
month
toler
induct
abil
patient
ingest
noodl
target
dose
evalu
result
subject
final
consid
studi
group
subject
intak
could
total
base
intak
diari
abl
maintain
intak
five
timesweek
frequent
group
two
timesweek
intermitt
group
six
month
proport
subject
neg
result
test
target
dose
g
dri
noodl
weight
subject
year
age
g
dri
noodl
weight
year
age
capabl
target
intak
within
six
month
whole
differer
group
conclus
find
suggest
even
intak
frequenc
oral
toler
induct
wheat
reduc
twiceweek
clear
differ
seen
target
dose
six
month
toler
induct
background
aspirin
exacerb
respiratori
diseas
aerd
character
acut
bronchospasm
ingest
aspirin
heavi
infiltr
eosinophil
contribut
alter
synthesi
cycteinyl
leukotrien
although
acquir
respons
appar
reveal
ige
depend
asthma
obviou
aerd
recent
tslp
appear
key
molecul
innat
respons
allerg
inflamm
thu
tri
reveal
relat
innat
molecul
develop
aerd
method
materi
level
tslp
measur
plasma
aspirin
challeng
subject
aerd
ata
use
enzymelink
immunosorb
assay
elisa
normal
plasma
protein
result
plasma
level
tslp
compar
aspirin
challeng
aerd
ata
aspirin
challeng
howev
concentr
robustli
increas
aerd
compar
aspirin
challeng
chang
ata
post
challeng
level
significantli
higher
aerd
ata
pgmg
vs
pgmg
tslp
chang
signific
correl
concentr
aspirin
induc
fall
rate
total
subject
conclus
among
innat
cytokin
tslp
relat
develop
airway
spasm
aspirin
challeng
suggest
may
play
role
pathogenesi
aerd
via
modul
immun
respons
object
allerg
nonallerg
rhiniti
common
diseas
children
howev
littl
known
natur
cours
purpos
evalu
natur
cours
allerg
nonallerg
rhiniti
children
studi
design
individu
cohort
studi
method
analyz
data
snore
child
cohort
children
data
encompass
questionnair
chronic
rhiniti
result
skin
prick
test
spt
inhal
specif
ige
allergen
children
classifi
four
group
name
allerg
rhiniti
rhiniti
plu
posit
spt
nonallerg
rhiniti
rhiniti
plu
neg
spt
sensit
rhiniti
plu
posit
spt
control
rhiniti
plu
neg
spt
result
final
data
children
analyz
among
children
allerg
rhiniti
year
becam
sensit
year
remain
allerg
rhiniti
five
children
nonallerg
rhiniti
year
turn
allerg
rhiniti
year
control
twenti
six
children
sensit
year
remain
year
among
control
children
year
becam
allerg
rhiniti
nonallerg
rhiniti
sensit
year
conclus
statu
chronic
rhiniti
allergen
sensit
changeabl
children
background
psoriasi
juvenil
idiopath
arthriti
psjia
autoimmun
diseas
constitut
small
part
juvenil
idiopath
arthriti
jia
classifi
within
spectrum
jia
psoriat
lesion
onset
often
occur
age
year
occur
year
morbid
leg
discrep
irrevers
joint
damag
contractur
visual
loss
caus
chronic
uveiti
persist
pain
impact
life
qualiti
patient
import
make
earli
precis
diagnosi
give
treatment
soon
possibl
order
make
qualiti
life
patient
optimum
method
six
month
longitudin
case
report
earli
onset
psoriasi
jia
result
treatment
result
present
year
histori
right
knee
swell
accompani
inflam
sign
joint
stiff
dactyl
skin
red
also
white
scale
gener
bodi
first
diagnos
ichtyosi
vulgari
persist
arthriti
week
refer
dermatolog
venereolog
depart
pediatr
immunologyallergi
depart
highli
suspect
jia
born
term
spontan
vagin
deliveri
birth
weight
gram
histori
jia
psoriasi
famili
laboratori
examin
anaemia
small
increas
erythrocyt
sediment
rate
esr
creactiv
protein
crp
liver
kidney
function
within
normal
limit
antinuclear
antibodi
ana
rheumatoid
factor
rf
antidsdna
neg
treatment
patient
look
stiff
could
stand
well
could
move
hand
finger
feet
finger
bent
like
claw
month
therapi
methotrex
nsaid
physiotherapi
also
topic
momethason
furoat
experienc
laboratori
clinic
remiss
arthriti
psoriasi
conclus
goal
therapi
control
pain
inflamm
prevent
joint
damag
preserv
rang
motion
muscl
strength
strive
normal
function
growth
nutrit
physic
psychosoci
develop
control
system
manifest
multidisciplinari
team
approach
essenti
optim
result
physic
occup
therapi
import
patient
methotrex
mtx
recogn
effect
dmard
applic
almost
everi
countri
genet
counsel
educ
diseas
need
everi
parent
affect
child
background
histamin
antagonist
gener
welltoler
sever
hypersensit
reaction
rare
howev
igedepend
mechan
suggest
hypersensit
induc
antagonist
addit
possibl
crossreact
among
antagonist
exist
object
investig
clinic
featur
immedi
hypersensit
induc
antagonist
cross
reactiv
method
retrospect
evalu
clinic
characterist
patient
diagnos
immedi
hypersensit
antagonist
univers
hospit
busan
korea
analyz
data
skin
test
variou
antagonist
result
total
patient
enrol
studi
mean
age
year
rage
patient
femal
common
culprit
drug
ranitidin
follow
cimetidin
nizatidin
half
patient
previous
allerg
reaction
antagonist
diagnos
mean
latent
time
minut
rang
anaphylaxi
common
symptom
follow
local
urticaria
system
urticaria
patient
except
one
posit
reaction
skin
test
prick
test
intraderm
test
crossreact
ranitidin
famotidin
cimetidin
one
patient
posit
reaction
histamin
antagonist
conclus
histamin
antagonist
wide
use
gener
toler
howev
anaphylaxi
common
symptom
histamin
antagonist
induc
immedi
hypersensit
ranitidin
common
caus
drug
addit
data
show
signific
cross
reactiv
drug
background
anaphylaxi
galactooligosaccharid
go
prebiot
entiti
uniqu
asian
region
despit
pure
carbohydr
shown
via
skin
prick
spt
basophil
activ
test
bat
reaction
igemedi
preliminari
studi
use
biotinyl
go
streptavidin
bind
solid
phase
develop
invitrogo
specif
ige
assay
unsuccess
aim
sought
develop
vitro
ige
assay
go
screen
popul
go
sensit
compar
accuraci
bat
method
go
degre
conjug
human
serum
albumin
hsa
mean
maillard
reaction
sera
go
allerg
patient
go
spt
neg
control
studi
addit
sera
go
spt
posit
volunt
underw
oral
go
challeng
result
posit
challeng
includ
sera
preabsorb
hsa
prior
detect
gosspecif
ige
use
go
conjug
hsa
goshsa
elisa
mean
plu
two
standard
deviat
ige
level
go
spt
neg
subject
set
cut
valu
determin
posit
neg
ige
respons
go
among
test
sera
result
go
challeng
cohort
sensit
goshsa
ige
assay
ci
specif
ci
among
patient
present
go
allergi
posit
goshsa
ige
assay
result
give
sensit
ci
contrast
bat
sensit
ci
specif
go
challeng
cohort
patient
strongli
posit
bat
go
concentr
higher
conclus
goshsa
ige
assay
abl
detect
go
specif
ige
howev
bat
assay
superior
assay
term
sensit
specif
purpos
controversi
relationship
vitamin
allerg
diseas
although
grow
interest
vitamin
insuffici
aim
studi
investig
associ
concentr
serum
vitamin
level
recent
symptom
allerg
diseas
elementari
schoolchildren
method
nationwid
crosssect
survey
conduct
first
grade
student
randomli
select
elementari
school
particip
survey
select
use
stratifi
twostag
cluster
sampl
design
preval
atop
dermat
ad
allerg
rhiniti
ar
asthma
obtain
korean
version
intern
studi
asthma
allergi
childhood
questionnair
children
examin
pediatrician
determin
presenc
eczema
neck
flexur
area
arm
serum
oh
measur
chemiluminesc
microparticl
immunoassay
categor
analysi
oh
concentr
use
cutoff
ngml
nmoll
ngml
nmoll
ngml
nmoll
multivari
logist
regress
analysi
appli
adjust
gender
matern
educ
level
allerg
diseas
parent
famili
incom
urban
result
overal
preval
rate
vitamin
insuffici
ngml
defici
ngml
vitamin
level
associ
symptom
ad
ar
asthma
last
month
p
valu
respect
vitamin
level
relat
presenc
treatment
ad
ar
asthma
last
month
p
valu
respect
addit
signific
associ
vitamin
level
presenc
pediatricianconfirm
ad
day
survey
p
valu
conclus
high
preval
vitamin
defici
insuffici
found
korean
elementari
schoolchildren
vitamin
level
associ
recent
symptom
allerg
diseas
background
staphylococcu
aureu
enterotoxin
seig
associ
pathophysiolog
chronic
rhinosinus
cr
aim
studi
determin
import
serum
specif
ige
toxic
shock
syndrom
toxin
type
one
seig
eosinophil
cr
nasal
polyp
np
korean
popul
method
retrospect
review
prospect
collect
data
cr
patient
underw
endoscop
sinu
surgeri
ess
enrol
tissu
microscop
examin
presenc
eosinophilia
power
field
blood
eosinophil
count
serum
level
total
ige
specif
ige
eosinophil
cation
protein
ecp
use
immunocap
analyz
result
fifti
six
cr
without
np
noneosinophil
eosinophil
cr
np
noneosinophil
eosinophil
patient
includ
level
blood
eosinophil
count
total
ige
ecp
significantli
differ
serum
specif
ige
differ
cr
np
without
np
posit
rate
serum
specif
ige
higher
eosinophil
cr
np
cr
without
np
noneosinophil
cr
np
conclus
studi
demonstr
higher
posit
rate
serum
specif
ige
patient
eosinophil
cr
np
noneosinophl
cr
np
preoper
examin
serum
specif
ige
help
predict
eosinophil
np
shown
higher
recurr
rate
ess
background
although
sever
studi
report
rhizospher
clean
effect
pot
indoor
plant
rceip
could
decreas
indoor
pollut
voc
particul
matter
etc
habit
stress
impact
rceip
allerg
rhiniti
ar
fulli
evalu
method
total
student
year
two
newli
built
elementari
school
includ
demograph
data
skin
prick
result
common
inhal
allergen
collect
initi
rceip
pot
indoor
plant
eight
plantspeci
introduc
four
classroom
student
three
month
other
includ
control
process
done
randomli
singl
blind
investig
studi
scheme
kept
complet
ar
symptomquestionnair
aria
base
korean
daili
hassl
scale
children
stressarous
checklist
indoor
attract
scale
survey
introduc
indoor
plant
result
comparison
inhal
allergen
sensit
rate
base
allergi
skin
prick
test
common
inhal
allergen
two
group
plant
introduct
vs
control
insignific
stratifi
propens
score
match
analys
ar
student
suspect
confirm
ar
symptom
chang
rceip
increas
teachersschoollif
relat
stress
suppress
rceip
subject
control
p
indoor
attract
maintain
rceip
decreas
control
p
conclus
threemonthintroduct
indoor
plant
rceip
suppress
school
stress
increas
indoor
attract
aggrav
ar
symptom
student
newli
built
school
work
carri
support
rural
develop
administr
republ
korea
south
korea
food
allergi
defin
advers
health
effect
occur
reproduc
exposur
given
food
food
allergi
classifi
immunoglubulin
e
ige
mediat
nonigemedi
reaction
clinic
manifest
includ
gastrointestin
cutan
respiratori
symptom
ige
mediat
food
allergi
usual
manifest
acut
gastrointestin
hypersensit
pollenfood
allergi
syndrom
acut
urticaria
angioedema
allerg
rhinoconjunct
acut
bronchospasm
diagnosi
made
histori
skin
prick
test
serum
foodspecif
ige
level
although
oral
food
challeng
confirm
diagnosi
manag
food
allergi
food
avoid
treatment
acut
reaction
report
case
multipl
food
allergi
recurr
anaphylaxi
success
control
omalizumb
male
patient
visit
allergi
depart
evalu
chest
tight
throat
swell
dyspnea
minut
ingest
two
strawberri
patient
repeatedli
suffer
multipl
food
allergi
peach
plum
apricot
raspberri
appl
sinc
childhood
present
acut
urticaria
laboratori
test
result
show
elev
blood
eosinophil
count
elev
serum
specif
ige
level
strawberri
measur
thermofish
scientif
uppsala
sweden
system
kul
spirometri
show
normal
rang
assess
food
allergi
strawberri
eosinophilia
thought
result
food
allergi
use
system
corticosteroid
antihistamin
blood
eosinophil
count
decreas
normal
rang
patient
symptom
resolv
five
month
later
complain
acut
urticari
dizzi
dyspnea
ingest
pineappl
celeri
sesam
blood
eosinophil
count
serum
specif
ige
level
pineappl
celeri
sesam
kul
kul
kul
respect
one
month
later
patient
visit
emerg
depart
acut
urticaria
dyspnea
gener
weak
numb
leg
ingest
almond
blood
eosinophil
count
serum
specif
ige
level
almond
kul
recurr
episod
anaphylaxi
due
multipl
food
occur
eosinophilia
food
avoid
strategi
fail
allerg
reaction
unknown
food
furthermor
sesam
wide
use
variou
korean
food
spice
omalizumab
treat
monthli
control
igemedi
food
allergi
treatment
episod
anaphylaxi
patient
perform
daili
task
without
disturb
complet
avoid
food
allergi
imposs
omalizumab
altern
treatment
control
symptom
secondgener
antihistamin
wide
prescrib
control
symptom
allerg
inflamm
itchi
hive
coryza
itchi
eye
rare
circumst
drug
provok
allerg
inflamm
hypersensit
bepotastin
besil
secondgener
antihistamin
never
report
schoolgirl
whose
paroxysm
itchi
hive
control
bepotastin
experienc
aggrav
hive
oral
provoc
test
confirm
hypersensit
bepotastin
crossreact
levocetirizin
show
reaction
chlorpheniramin
ketotifen
olopatadin
among
antihistamin
test
search
antihistamin
control
itchi
hive
found
also
exhibit
crossreact
variou
antihistamin
differ
chemic
structur
bepotastin
predict
accord
chemic
classif
antihistamin
report
case
hypersensit
bepotastin
besil
patient
chronic
spontan
urticaria
background
acut
chronic
exposur
ozon
character
increas
airway
hyperreact
ahr
neutrophil
inflamm
airway
human
recent
meaning
increas
observ
transcriptom
data
ozon
expos
mice
sinc
gene
induc
mucin
gene
intralumin
acidif
airway
suppos
key
molecul
ozon
induc
ahr
neutrophil
inflamm
thu
evalu
role
gene
chronic
ozon
exposur
murin
model
materi
method
old
balbc
femal
mice
expos
filter
air
daili
exposur
time
airway
resist
measur
use
flexi
vent
bronchoalveolar
lavag
fluid
balf
cell
differenti
count
thiocyan
metabolit
produc
measur
bal
fluid
protein
gene
assess
western
blot
immun
stain
realtim
pcr
tetraammonium
administ
ozoneexpos
anim
via
intratrachea
rout
block
effect
result
airway
resist
number
neutrophil
bal
fluid
increas
significantli
ozon
expos
mice
time
depend
manner
thiocyan
amount
gradual
decreas
lung
lysat
balf
ozon
exposur
correl
number
neutrophil
amount
thiocyan
rna
protein
level
increas
pick
ozon
expos
mice
tetraammonium
significantli
suppress
ozon
induc
increas
ahr
inflammatori
cell
particularli
neutrophil
conclus
may
exert
key
role
gene
ozon
exposur
relat
trait
includ
ahr
neutrophil
inflamm
murin
model
background
proteas
common
allergen
eg
cockroach
mold
induc
pathogenesi
allerg
diseas
proteas
activ
receptor
report
trigger
immun
respons
allerg
asthma
aim
studi
aim
investig
effect
proteaseinduc
allerg
inflamm
identifi
mechan
method
administ
intranas
mous
model
asthma
induc
german
cockroach
extract
gce
addit
human
lung
epitheli
cell
cell
treat
gce
nac
confirm
mechan
relat
vivo
result
result
airway
hyperrespons
total
ige
product
pulmonari
inflamm
significantli
suppress
nac
mous
model
tslp
lung
suppress
nac
antagonist
tight
junction
protein
disturb
gce
restor
nac
lung
tslp
show
correl
human
lung
epitheli
cell
two
vitro
conclus
gce
elicit
allerg
inflamm
mediat
disrupt
tight
junction
trigger
gener
ro
background
optim
asthma
symptom
control
alway
achiev
sever
case
due
risk
steroid
resist
lack
respons
betaagonist
therefor
altern
approach
need
achiev
revers
patholog
airway
remodel
steroid
resist
sever
asthma
cytokin
critic
asthma
pathogenesi
modul
ige
synthesi
chemokin
product
airway
eosinophilia
smooth
muscl
hyperplasia
mucu
product
asthma
past
decad
sever
nanoparticl
approach
develop
test
effici
drug
antiinflammatori
agent
deliveri
variou
bodi
site
cancer
chronic
inflammatori
diseas
current
studi
evalu
antiinflammatori
respons
follow
intratrach
instil
function
pegyl
nanocarri
contain
block
antibodi
inflam
lung
asthmat
mous
model
method
load
nanoparticl
administ
intrapulmonari
asthmat
mice
particl
distribut
within
lung
examin
target
specif
inflammatori
cell
investig
use
mri
histolog
analysi
immunohistochemistri
immunofluoresc
multipl
gene
express
studi
rtpcr
flow
cytometri
cytokin
array
luminex
histolog
analys
perform
treat
asthmat
lung
tissu
cell
evalu
antiinflammatori
respons
nanocari
result
target
local
nanocarri
perl
iron
peg
antipeg
antibodi
immunofluoresc
spio
nanocarri
fitc
label
antibodi
confirm
local
lung
inflammatori
cell
follow
treatment
asthmat
mice
nanocarri
signific
decreas
bal
level
gmcsf
mig
observ
compar
ovasensit
mice
bal
level
lymphocyt
neutrophil
eosinophil
decreas
significantli
p
mice
receiv
load
nanocarri
lung
inflamm
significantli
decreas
observ
histolog
analysi
well
gene
express
inflammatori
cytokin
gene
addit
signific
decreas
activ
function
lung
inflammatori
cell
observ
su
fac
analysi
follow
treatment
conclus
treatment
inflam
lung
antiinflammatori
safe
effici
reduc
lung
inflamm
control
asthma
pathogenesi
approach
could
effect
attain
asthma
control
sever
case
altern
approach
steroid
need
background
allergen
specif
immunotherapi
sit
abl
significantli
improv
symptom
well
reduc
need
symptomat
medic
sit
act
basic
immunolog
mechan
potenti
chang
patholog
allerg
immun
respons
immunolog
chang
treatment
achiev
certain
period
time
usual
year
way
patient
present
reduc
allerg
respons
immunotherapi
earli
stage
immunolog
respons
allergen
may
affect
favor
clinic
outcom
year
treatment
method
patient
allerg
airway
diseas
receiv
subcutan
sit
hous
dust
mite
allergen
skin
prick
test
therapi
time
year
period
investig
retrospect
analysi
main
paramet
immunolog
chang
skin
reactiv
wheal
ratio
allergenhistamin
skin
prick
test
hous
dust
mite
ongo
immunotherapi
number
posit
allergen
skin
respons
blood
test
eosinophil
count
total
ige
esr
collect
well
result
total
patient
analys
mean
age
initi
immunotherapi
time
year
old
male
allerg
rhiniti
bronchial
asthma
median
number
strongli
sensit
allergen
among
aeroallergen
two
item
initi
phage
mean
skin
reactiv
target
allergen
year
immunotherapi
respect
skin
reactiv
target
allergen
ongo
immunotherapi
signific
reduc
younger
age
group
year
old
group
small
number
total
allergen
sensit
p
hous
dust
mite
hdm
sensit
rather
mix
hdm
pollen
p
high
reactiv
ah
ratio
target
allergen
p
initi
time
signific
differ
among
initi
immunotherapi
method
rush
convent
underlin
allerg
airway
diseas
eosinophil
count
total
ige
esr
level
conclus
studi
suggest
clinic
factor
associ
favor
allergen
reactiv
chang
may
affect
good
clinic
outcom
earli
phase
immunotherapi
background
acut
reject
ar
kidney
transplant
one
import
caus
reject
iran
world
consid
role
inflammatori
cytokin
process
due
fact
genet
polymorph
alter
function
cytokin
aim
evalu
variou
singl
nucleotid
polymorph
snp
relat
cytokin
gene
method
genom
dna
extract
whole
blood
patient
acut
reject
patient
stabl
graft
function
sgf
polymeras
chain
reaction
sequenc
specif
primer
pcrssp
perform
use
relat
kit
result
analyz
statist
softwar
spss
epiinfo
result
frequenc
g
allel
relat
posit
allel
c
g
posit
relat
show
signific
associ
patient
transplant
kidney
ar
sgf
compar
control
p
valu
data
relat
snp
gg
cg
genotyp
posit
reveal
signific
relationship
ar
healthi
control
addit
result
comparison
sgf
healthi
control
posit
show
signific
correl
haplotyp
analysi
among
studi
group
also
display
statist
signific
associ
conclus
studi
found
associ
gene
polymorph
kidney
graft
reject
surviv
process
studi
greater
sampl
variou
popul
need
order
confirm
find
background
phthalat
wide
use
daili
live
includ
floor
toy
food
wrap
plastic
ware
emulsifi
agent
lotion
shampoo
sever
studi
report
associ
exposur
phthalat
allerg
disord
also
conflict
result
report
whether
atop
dermat
associ
overweight
obes
evalu
associ
phthalat
exposur
overweightobes
atop
dermat
ad
korean
children
adolesc
method
nationwid
repres
survey
conduct
children
adolesc
age
year
korea
inform
atop
dermat
collect
intern
studi
asthma
allergi
childhood
isaac
questionnair
urin
monobenzyl
phthalat
mbzp
mononbutyl
phthalat
mnbp
phthalat
mecpp
phthalat
mehhp
mono
phthalat
meohp
measur
phthalat
metabolit
adjust
urin
creatinin
subject
overweight
obes
defin
bodi
mass
index
percentil
percentil
age
gender
respect
result
preval
ad
diagnosi
current
ad
diagnos
present
symptom
recent
month
respect
proport
subject
overweight
obes
respect
divid
group
accord
urinari
phthalat
level
averag
bmi
normal
overweightobes
subject
overweight
obes
exposur
higher
urinari
mnbp
meohp
mehhp
highest
odd
ratio
compar
group
diagnosi
atop
dermat
ci
mnbp
meohp
mehhp
subject
overweightobes
exposur
higher
urinari
mnbp
mehhp
highest
odd
ratio
compar
group
current
symptom
atop
dermat
ci
mnbp
mehhp
conclus
overweight
obes
exposur
higher
phthalat
especi
mnbp
meohp
mehhp
could
associ
increas
preval
diagnosi
current
symptom
atop
dermat
studi
support
nation
institut
environment
research
nier
background
recent
metaanalys
demonstr
high
global
epidemiolog
burden
chronic
cough
gener
popul
howev
still
lack
nationwid
studi
epidemiolog
cough
gener
korean
popul
object
aim
calcul
nationwid
preval
current
cough
explor
factor
underli
epidemiolog
korean
gener
adult
popul
method
analyz
crosssect
korean
nation
health
nutrit
examin
survey
knhane
databas
survey
presenc
durat
current
cough
defin
structur
questionnair
classifi
acut
week
subacut
week
chronic
week
demograph
clinic
paramet
also
examin
relat
cough
weight
preval
cough
accord
durat
calcul
risk
factor
cough
evalu
use
multivari
logist
regress
result
among
total
adult
current
cough
among
subject
current
cough
proport
acut
subacut
chronic
cough
respect
chronic
cough
cough
longer
year
epidemiolog
cough
significantli
differ
age
group
acut
cough
preval
younger
adult
year
old
wherea
chronic
cough
significantli
preval
elderli
subject
year
old
preval
chronic
cough
increas
age
gender
male
subject
age
year
subject
age
year
subject
age
year
femal
respect
p
trend
adjust
demograph
risk
factor
sever
factor
associ
chronic
cough
independ
age
current
smoke
chest
xray
abnorm
rhiniti
rhinosinus
p
femal
menopaus
estrogen
replac
therapi
also
relat
chronic
cough
p
conclus
present
studi
indic
consider
epidemiolog
burden
cough
korean
gener
adult
popul
epidemiolog
cough
significantli
differ
age
group
find
warrant
elucid
variou
factor
underli
high
burden
chronic
cough
older
adult
introduct
data
airway
cell
subset
wheez
children
wc
avail
found
activ
cell
memori
cell
associ
cell
develop
cell
activ
ige
synthesi
analyz
bal
wc
normal
method
evalu
wc
minimum
episod
wheez
prolong
wheez
month
month
period
bal
wc
subdivid
children
histori
rsv
wcrsv
median
age
month
without
rsv
wcrsv
median
age
month
comparison
made
normal
control
control
median
age
mo
bal
cell
count
differenti
determin
cell
fix
aceton
embed
glycol
methacryl
resin
cell
block
cut
immunohistochem
stain
follow
cell
surfac
marker
coexpress
cell
evalu
imag
analysi
program
sequenti
section
comparison
group
first
made
use
kruskalw
test
case
signific
differ
individu
group
compar
use
mannwhitney
u
test
result
total
number
cell
significantli
elev
wcrsv
compar
control
wcrsv
signific
elev
cell
compar
control
total
number
significantli
elev
wcrsv
compar
wcrsv
control
although
cell
express
greater
wcrsv
wcrsv
elev
statist
signific
compar
control
conclus
find
suggest
specif
cell
profil
exist
wcrsv
differ
wcrsv
control
furthermor
cell
may
play
role
immun
process
wcrsv
background
obes
atop
diseas
two
increasingli
import
popul
health
issu
obes
could
risk
factor
atop
diseas
full
vision
health
condit
patient
obes
atop
diseas
import
pediatrician
make
qualiti
life
qol
questionnair
part
patient
followup
studi
suggest
obes
decreas
qol
children
atop
diseas
asthma
aim
studi
evalu
qol
obes
children
without
atop
diseas
method
crosssect
studi
initi
sampl
children
year
old
recruit
privat
elementari
school
bandung
indonesia
subject
divid
obes
children
without
atop
diseas
normal
weight
children
without
atop
diseas
standard
definit
obes
atop
diseas
children
base
world
health
organ
determin
effect
obes
atop
diseas
qol
pediatr
qualiti
life
appli
subject
also
parent
mannwhitney
test
use
test
signific
categor
data
signific
determin
p
result
patient
studi
male
femal
ratio
mean
age
year
standard
deviat
result
four
scale
evalu
questionnair
physic
emot
social
school
function
show
signific
differ
emot
function
qol
obeseatop
diseas
obesenon
atop
diseas
group
p
signific
differ
scale
conclus
studi
reveal
signific
differ
emot
function
qol
obeseatop
diseas
obesenon
atop
diseas
group
signific
differ
scale
studi
need
understand
relationship
obes
atop
diseas
patient
qol
refer
vant
gent
r
van
der
ent
ck
rover
mm
et
al
excess
bodi
weight
associ
addit
loss
qualiti
life
children
asthma
j
allergi
clin
immunol
vijil
vb
navarro
dr
eslava
ab
mong
jjl
qualiti
life
pediatr
patient
asthma
without
obes
pilot
studi
allergol
et
immunopathol
background
exacerb
asthma
frequent
attribut
upper
lower
airway
infect
respiratori
virus
rhinoviru
influenza
virus
host
cell
protect
viru
via
innat
acquir
immun
respons
microrna
act
key
regulatori
molecul
complic
interact
network
virus
host
howev
studi
perform
mirna
relat
influenza
infect
aim
studi
search
candid
mirna
silico
analysi
valid
relat
mirna
sputum
exacerb
asthma
method
materi
inform
sequenc
matur
human
mirna
obtain
use
mirbas
http
wwwmirbaseorg
appli
whole
genom
sequenc
influenza
virus
http
wwwncbinlmnihgov
search
complementar
viral
rna
mirna
extract
sputum
exacerb
asthmat
use
viral
kit
intron
biotechnolog
seoul
korea
mirneasi
kit
qiagen
ca
usa
respect
rtpcr
realtim
pcr
appli
discoveri
respiratori
virus
adenoviru
human
metapneumoviru
parainfluenza
viru
influenza
ab
viru
respiratori
syncyti
viru
ab
rhinoviru
measur
mirna
respect
result
total
human
mirna
use
analysi
among
predict
match
nucleotid
one
locat
polymeras
basic
protein
mrna
three
locat
haemagglutinin
mrna
influenza
respiratori
virus
identifi
patient
total
patient
patient
infect
influenza
viru
level
much
lower
patient
infect
influenza
rhinoviru
virusinfect
uninfect
patient
level
influenza
ainfect
patient
compar
rhinovirusinfect
subject
conclus
regul
express
may
associ
infect
influenza
viru
might
exert
neg
regulatori
activ
influenza
viru
replic
due
high
frequenc
allerg
diseas
special
grow
rate
among
world
popul
medicin
centuri
call
centuri
allergi
known
allerg
diseas
pollinosi
bronchial
asthma
highest
percentag
come
allergen
aeropolut
repres
mani
plant
herb
form
dust
ragwe
pollen
alder
birch
mapl
walnut
mallow
cotton
plant
etc
sinc
institut
activ
work
direct
gradual
world
allergi
organ
wao
present
apparatu
burkhard
pollen
trap
uk
institut
research
activ
continu
direct
result
publish
period
intern
journal
becam
public
report
scientif
congress
accord
abovement
aim
studi
stage
follow
identif
specif
aeropollut
elabor
annual
calendar
plant
blossom
realiti
imereti
region
studi
involv
patient
differ
age
among
male
femal
allerg
rhiniti
asthma
appli
sr
institut
allergi
asthma
clinic
immunolog
academi
scienc
georgia
tskaltubo
georgia
allegrodiagnost
reveal
increas
level
phadiatop
blood
exist
atop
allergen
inhal
allergen
studi
cover
follow
allegrodiagnost
stage
stage
precis
verif
allergen
patient
blood
serum
examin
particular
specificig
antibodi
modern
autom
system
immuno
cap
phadia
switzerland
ii
stage
monitor
concentr
aeropolu
conduct
use
aeropolinomet
burkard
trap
great
britain
analysi
laboratori
result
obtain
autom
system
immunocap
show
studi
patient
high
titer
specif
ige
weed
ambrosia
plantain
absinth
atriplex
tree
dust
alder
lactariu
piperatu
nut
oak
willow
cereal
festuca
pratensi
lolium
temulentum
timoti
grass
poa
specif
ige
concentr
detect
posit
panel
reveal
concret
allergen
mention
patient
provid
data
aeropolinomet
burkard
trap
annual
calendar
distribut
aeroallergen
reflect
concentr
blossom
planttre
atmospher
aerosol
air
imereti
region
given
period
time
extracorpor
membran
oxygen
ecmo
use
primarili
treat
respiratori
failur
due
acut
respiratori
distress
syndrom
fail
respond
maxim
medic
therapi
use
ecmo
statu
asthmaticu
limit
case
report
present
three
case
patient
nearfat
statu
asthmaticu
reliev
convent
treatment
earli
administr
ecmo
result
good
outcom
case
ecmo
institut
sustain
hypercapnia
respiratori
acidosi
within
hour
initi
mechan
ventil
patient
support
ecmo
hour
intub
sever
hypotens
hypercapnia
lung
statu
patient
rapidli
recov
within
day
extub
hour
day
initi
ecmo
respect
success
wean
ecmo
complet
next
day
extub
patient
signific
complic
relat
ecmo
patient
mechan
ventil
patient
refractori
statu
asthmaticu
deleteri
effect
due
worsen
dynam
hyperinfl
increas
intrathorac
pressur
earli
ecmo
applic
use
treatment
option
patient
fail
convent
therapi
background
previous
report
elev
calcium
bind
protein
protein
sputum
neutrophil
uncontrol
asthmat
compar
stabl
asthmat
annel
allergi
asthma
immunolog
oct
suggest
possibl
role
neutrophil
sever
asthma
aim
studi
valid
role
express
neutrophil
airway
inflamm
ovacfasensitizedchalleng
murin
asthma
model
method
express
mrna
protein
measur
use
rtpcr
western
blot
respect
spatial
express
protein
neutrophil
elastas
visual
use
immunofluorescen
stain
confoc
microscopi
evalu
potenc
neutrophil
inflamm
tempor
chang
neutrophil
infiltr
analyz
lung
tissu
ovacfa
model
mice
intratrach
protein
administr
block
airway
mice
treat
antibodi
via
intranas
rout
hour
challeng
result
start
increas
day
peak
day
number
total
cell
macrophag
neutrophil
significantli
increas
concomit
escal
airway
hyperrespons
ahr
day
neutrophil
elastas
coloc
peribronchi
infiltr
cell
apic
portion
bronchial
epithelium
intratrach
instil
induc
rapid
increas
neutrophil
bal
fluid
hr
peak
thereaft
progress
decreas
till
hr
intranas
administr
antibodi
restor
increas
number
inflammatori
cell
ahr
cfaova
mice
sham
mice
conclus
directli
activ
neutrophil
inflamm
airway
neutrophil
may
major
cell
sourc
protein
suggest
main
role
protein
neutrophil
experiment
asthma
background
atop
dermat
ad
complex
heterogen
diseas
influenc
genet
environment
factor
last
decad
previou
effort
find
ad
associ
loci
identifi
unpreced
amount
associ
loci
howev
previous
report
genet
loci
explain
small
proport
herit
thu
analysi
unrev
genet
compon
requir
solv
miss
herit
problem
context
wholeexom
sequenc
analysi
gather
much
attent
find
function
variant
rel
high
genet
effect
present
studi
perform
wholeexom
sequenc
studi
identifi
function
variant
respons
sever
ad
korean
childhood
method
casecontrol
sampl
sever
ad
patient
normal
individu
recruit
childhood
asthma
atopi
center
asan
medic
center
diagnos
physician
case
control
sequenc
illumina
hiseq
agil
sureselectxt
human
exon
kit
sequenc
align
perform
use
burrowswheel
align
variant
call
use
genom
analysi
toolkit
gatk
identifi
singl
nucleotid
variant
snv
snv
pass
qualiti
control
criteria
hwe
pvalu
miss
rate
minor
allel
count
variant
nonsynonym
snp
chisquar
test
conduct
find
diseaseassoci
variant
result
identifi
three
missens
variant
window
pvalu
pvalu
missens
variant
discov
among
variant
locat
nearbi
previous
report
ad
associ
region
function
enrich
analysi
show
snv
relat
immun
relat
gene
mtr
ttn
conclus
summari
identifi
missens
variant
suscept
ad
replic
previous
report
loci
valid
genet
effect
discov
variant
replic
analysi
independ
cohort
requir
cutan
molluscum
contagiosum
mc
infect
occur
children
may
found
adult
especi
infect
human
immunodefici
viru
hiv
man
present
multipl
peasiz
firm
skincolor
round
papul
first
appear
arm
quickli
spread
whole
bodi
last
month
treat
sever
atop
dermat
system
immunosuppress
therapi
year
screen
test
hiv
neg
lesion
diagnos
mc
base
histopatholog
find
typic
eosinophil
cytoplasm
molluscum
inclus
bodi
acanthot
epidermi
well
dermal
inclus
cyst
unusu
case
widespread
mc
infect
adult
report
hiv
posit
patient
suppos
patient
dissemin
infect
may
relat
combin
perturb
skin
barrier
system
immunosuppress
therapi
sever
atop
condit
background
macadamia
nut
tree
nut
list
major
allergen
label
prepackag
food
global
least
case
macadamia
nut
allergi
report
date
howev
elicit
allergen
protein
identifi
consequ
compon
resolv
diagnosi
develop
studi
aim
identifi
put
allergen
protein
macadamia
nut
combin
patient
ige
recognit
allergenom
approach
challeng
macadamia
nut
genom
sequenc
partial
complet
method
proteom
profil
studi
use
labelfre
shotgun
proteom
approach
genom
sequenc
macadamia
nut
allergen
avail
homolog
known
allergen
affili
protein
famili
determin
result
allergenom
screen
method
use
predict
potenti
allergen
protein
crossreact
plant
particularli
molecular
weight
distribut
protein
determin
gel
electrophoresi
follow
ingel
digest
trypsin
protein
subject
liquid
chromatographi
coupl
tandem
mass
spectrometri
base
share
peptid
evid
identifi
protein
cluster
allergen
protein
identifi
immunoreact
protein
identifi
immunoblot
three
patient
sera
confirm
exhibit
igemedi
reaction
result
peptid
match
sequenc
allergen
protein
belong
differ
protein
famili
seed
storag
protein
conglutin
vicilin
rubber
elong
factor
protein
phosphat
bind
protein
detoxifi
methylglyoxalas
identifi
includ
peptid
sequenc
homolog
conglutin
known
allergen
lupin
angustifoliu
conclus
allergen
protein
confirm
seed
storag
protein
belong
protein
signific
number
peptid
sequenc
homolog
conglutin
lupin
angustifoliu
observ
suggest
may
crossreact
macadamia
lupin
allergen
background
immunoglobulin
e
ige
trigger
multipl
inflammatori
allerg
respons
cytokin
releas
bind
highaffin
ige
fc
receptor
mast
cell
atop
dermat
ad
asthma
antibodi
new
option
treatment
may
block
bind
therefor
may
reduc
inflammatori
cascad
allerg
diseas
howev
potenti
effect
mechan
antibodi
remain
poorli
understood
object
investig
effect
mechan
antibodi
block
combin
antibodi
allerg
march
mice
model
method
develop
mice
model
three
exposur
separ
interv
ovalbumin
ova
salin
follow
ova
inhal
challeng
order
develop
mice
model
day
sacrific
mice
inhal
ova
airway
challeng
antibodi
administ
mice
intraperiton
consecut
day
end
studi
identif
interleukin
il
express
perform
immunohistochemistri
real
time
pcr
skin
lung
specimen
result
antibodi
treat
mice
significantli
decreas
phenotyp
eg
clinic
score
airway
hyperrespons
patholog
ad
allerg
asthma
addit
level
total
ige
ovaspecif
serum
significantli
lower
mice
treat
antibodi
level
prostaglandin
number
mast
cell
skin
also
decreas
antibodi
treat
mice
furthermor
skin
lung
express
reduc
treatment
antibodi
conclus
blockad
antibodi
suppress
igemedi
phenotyp
inflammatori
respons
mechan
may
decreas
via
suppress
mast
cell
activ
background
antithymocyt
globulin
atg
immunosuppress
deriv
hors
rabbitimmun
human
thymu
lymphocyt
commonli
use
prevent
treatment
acut
reject
organ
transplant
aplast
anemia
hypersensit
atg
lifethreaten
mani
clinic
data
real
practic
therefor
studi
aim
investig
clinic
characterist
outcom
atg
hypersensit
method
case
hypersensit
reaction
rabbit
atg
retriev
databas
individu
case
safeti
report
seoul
nation
univers
hospit
clinic
characterist
hypersensit
reaction
analyz
accord
involv
organ
system
sever
assess
accord
common
terminolog
criteria
advers
event
ctcae
version
result
among
patient
male
averag
age
high
fever
frequent
symptom
follow
chill
cutan
symptom
itch
sens
flush
urticaria
rash
follow
major
symptom
gastrointestin
symptom
nausea
vomit
abdomin
pain
diarrhea
mean
sever
ctcae
grade
although
patient
premed
antihistamin
steroid
grade
reaction
includ
case
present
profound
hypotens
develop
atg
hypersensit
patient
abl
continu
follow
atg
infus
increas
dose
antihistamin
steroid
slow
infus
rate
desensit
conclus
atg
hypersensit
reaction
present
sever
form
half
case
report
howev
patient
atg
hypersensit
abl
continu
atg
infus
increas
premed
modifi
infus
protocol
background
total
serum
immunoglobulin
ige
known
essenti
diagnost
tool
atopi
allerg
diseas
differ
accord
host
factor
includ
sex
age
race
evalu
distribut
total
ige
level
korean
children
util
diagnosi
atopi
allerg
diseas
method
nationwid
crosssect
studi
elementari
schoolchildren
yr
old
middl
schoolchildren
yr
old
enrol
total
ige
level
measur
skin
prick
test
perform
common
inhal
allergen
children
parent
answer
intern
studi
asthma
allergi
childhood
isaac
questionnair
analyz
diagnost
valu
total
ige
use
roc
receiv
oper
characterist
curv
compar
total
ige
level
accord
atopi
allerg
diseas
atop
dermat
bronchial
asthma
allerg
rhiniti
result
total
ige
rang
kul
elementari
schoolchildren
kul
middl
schoolchildren
median
total
ige
level
kul
percentil
kul
percentil
kul
percentil
kul
elementari
schoolchildren
kul
percentil
kul
percentil
kul
percentil
kul
middl
schoolchildren
median
total
ige
level
significantli
higher
atop
group
defin
posit
spt
elementari
schoolchildren
kul
p
middl
schoolchildren
kul
p
allerg
diseas
group
elementari
schoolchildren
kul
p
middl
schoolchildren
kul
p
roc
analysi
total
ige
diagnos
atopi
auc
ci
elementari
schoolchildren
ci
middl
schoolchildren
optim
cutoff
valu
kul
elementari
schoolchildren
kul
middl
schoolchildren
sensit
specif
posit
neg
predict
valu
elementari
schoolchildren
middl
schoolchildren
respect
conclus
total
serum
ige
level
higher
children
atopi
allerg
diseas
valu
total
serum
ige
diagnost
test
atopi
limit
due
low
sensit
specif
background
sever
immedi
hypersensit
reaction
ihr
contrast
media
cm
one
legal
problem
hospit
overal
preval
ihr
nonion
cm
order
reduc
immedi
drug
advers
reaction
legal
problem
prescreen
skin
test
administr
antibiot
penicillin
cephalosporin
may
import
avoid
crossreact
agent
select
altern
safe
drug
clinic
valu
cm
prescreen
skin
test
controversi
cm
prescreen
skin
test
might
use
reduc
ihr
aim
evalu
incid
ihr
nonion
cm
twostep
prescreen
skin
test
group
method
retrospect
studi
review
ct
case
perform
jan
dec
patient
perform
skin
test
pend
nonion
cmenhanc
comput
tomogram
ct
skin
test
ct
scan
perform
twostep
process
one
step
skin
test
perform
common
nonion
cm
skin
test
neg
nonion
cmenhanc
comput
tomogram
ct
perform
second
step
skin
test
posit
skin
test
perform
two
nonion
cm
salin
neg
control
skin
test
neg
skin
test
neg
nonion
cmenhanc
ct
perform
test
posit
clinician
gave
patient
premed
enhanc
ct
exchang
altern
radiolog
test
without
cm
result
ihr
note
total
patient
patient
sever
ihr
symptom
ihr
nausevomit
erythemaurticariaprur
dyspnea
chest
tight
angioedema
hypotens
syncop
conclus
nonion
cm
prescreen
skin
test
twostep
process
may
use
reduc
ihr
select
safe
cm
object
evalu
trigger
allergen
import
treatment
prevent
allerg
rhiniti
ar
sever
nationwid
studi
reveal
region
differ
preval
allergi
sensit
individu
allergen
allergen
type
studi
use
mast
cla
evalu
allergen
ar
patient
state
level
gwangju
jeonnam
area
evalu
differ
allerg
sensit
across
level
urban
method
total
patient
gwangjujeonnam
region
allerg
symptom
underw
mast
total
nasal
score
tn
serum
total
ige
evalu
panel
evalu
mast
allergen
result
greater
class
iuml
consid
posit
preval
distribut
allergenspecif
ige
correl
serum
total
ige
tn
analyz
accord
level
urban
age
result
mean
age
studi
popul
year
total
patient
enrol
studi
patient
urban
patient
rural
region
among
studi
popul
posit
test
result
least
allergen
patient
posit
test
result
multipl
allergen
preval
allerg
sensit
differ
significantli
age
younger
patient
tend
posit
test
result
perenni
allergen
howev
older
patient
tend
posit
test
result
season
allergen
differ
posit
test
result
patient
urban
rural
area
conclus
larg
portion
studi
popul
sensit
indoor
outdoor
allergen
howev
overal
preval
sensit
preval
sensit
individu
allergen
allergen
type
show
differenc
accord
level
urban
state
background
english
walnut
juglansregia
one
common
allergen
food
influenc
process
allergen
scarc
known
studi
aim
evalu
relev
walnut
allergen
walnut
allerg
korean
young
children
examin
influenc
differ
cook
method
walnut
protein
method
protein
extract
boil
roast
pickl
walnut
compar
raw
walnut
use
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
raw
walnut
protein
extract
immunoblot
individu
sera
children
level
walnut
specif
ige
higher
immunocap
thermofish
scientif
waltham
mass
addit
produc
peanut
extract
sera
test
enzym
link
immunosorbentassay
inhibit
test
result
least
distinct
protein
band
visibl
raw
walnut
sdspage
jug
r
jug
r
band
stabl
boil
roast
walnut
intens
band
even
enhanc
roast
boil
walnut
wherea
band
slightli
decreas
roast
walnut
meanwhil
jug
r
band
profoundli
disappear
roast
walnut
protein
band
shown
walnut
treat
vinegar
one
month
igeimmunoblot
individu
sera
walnutsensit
children
least
protein
compon
identifi
band
correspond
jug
r
wasreact
patient
band
jug
r
band
jug
r
react
patient
walnut
igeelisa
inhibit
peanut
extract
conclus
studi
indicatesthat
igebind
band
suspect
jug
r
jug
r
jug
r
major
problemat
allergen
walnut
allerg
children
also
amount
compon
weight
reduc
heat
wherea
rel
stabl
background
cholinerg
urticaria
associ
acquir
idiopath
gener
anhidrosi
cuaiga
strongli
impair
qualiti
life
tingl
skin
surfac
increas
bodi
temperatur
gener
fatigu
warm
circumst
pathogenesi
diseas
remain
obscur
object
aim
studi
clarifi
relationship
cholinerg
urticaria
autonom
function
method
clinic
demograph
inform
subject
cuaiga
consult
clinic
summar
retrospect
digit
blood
flow
tissu
blood
flow
blood
volum
flow
veloc
measur
laser
tissu
blood
flow
meter
stand
posit
quantit
sudomotor
axon
reflex
test
qsart
use
measur
sweat
volum
administr
acethylcholin
iontophoresi
result
subject
cuaiga
fail
restor
digit
blood
flow
stand
posit
indic
impair
autonom
nerv
abnorm
result
qsart
show
extrem
decreas
sweat
volum
stimul
acethylcholin
therapeut
intervent
eg
antihistamin
chines
herbal
medicin
steroid
puls
therapi
improv
evalu
item
observ
case
accompani
urticari
symptom
improv
conclus
result
indic
possibl
involv
abnorm
autonom
nervou
function
cholinerg
urticaria
knowledg
possibl
causal
relationship
cuaiga
autonom
nervou
function
may
contribut
formul
novel
therapeut
strategi
diseas
background
interleukin
beta
produc
inflammasom
activ
involv
variou
process
chronic
inflammatori
diseas
recent
although
inflammsom
activ
observ
chronic
inflammatori
airway
diseas
role
asthma
yet
studi
aim
studi
investig
relat
sputum
inflammatori
phenotyp
sever
asthma
method
hyperton
salin
induc
sputum
obtain
asthma
stabl
state
exacerb
state
differenti
cell
count
induc
sputum
done
measur
use
sandwich
elisa
induc
sputum
level
analyz
term
airway
obstruct
inflamm
neutrophil
eosinophil
induc
sputum
exacerb
frequenc
lung
function
year
longer
follow
result
level
significantli
correl
neutrophil
cell
count
induc
sputum
initi
total
asthmat
p
correl
level
neutrophil
eosinophil
observ
stabl
asthmat
exacerb
group
level
invers
correl
long
term
follow
stabl
asthmat
year
level
correl
follow
annual
averag
exacerb
rate
also
well
correl
level
subject
neutrophil
inflamm
sputum
conclus
sputum
may
relat
neutrophilc
inflamm
exacerb
state
long
term
follow
asthma
sputum
may
also
relat
extent
airway
obstruct
data
suggest
may
particip
airway
obsturct
exacerb
frequeci
especi
neutrophil
inflamm
background
neutrophil
airway
inflamm
often
observ
nonatop
adult
asthma
interleukin
potent
proinflammatori
cytokin
recruit
activ
neutrophil
relat
reveal
exacerb
asthma
howev
role
reveal
term
prognosi
asthma
aim
studi
investig
relat
sputum
inflammatori
phenotyp
sever
long
term
prognosi
asthma
materi
method
hyperton
salin
induc
sputum
obtain
asthma
stabl
state
exacerb
differenti
cell
count
done
measur
use
sandwich
elisa
level
analyz
term
airway
obstruct
inflamm
neutrophil
eosinophil
airway
exacerb
frequenc
lung
function
year
longer
follow
result
level
significantli
correl
percentag
neutrophil
neutrophil
count
sputum
invers
level
total
asthmat
correl
level
percentag
neutrophil
also
observ
stabl
asthmat
exacerb
group
level
invers
correl
predict
valu
long
term
follow
year
posit
correl
annual
number
exacerb
conclus
sputum
relat
neutrophilc
inflamm
rather
eosinophilc
inflamm
asthma
long
term
follow
asthma
increas
sputum
may
one
suscept
factor
frequenct
exacerb
background
know
major
solubl
factor
respons
immunomodulatori
effect
adiposederiv
stem
cell
asc
asthmat
mous
evalu
effect
asc
allerg
inflamm
indoleamin
knockout
idoko
mice
mice
treat
prostaglandin
inhibitor
transform
growth
specif
neutral
antibodi
method
asc
inject
intraven
wildtyp
wt
idoko
asthmat
mice
inhibitor
neutral
antibodi
inject
intraperiton
four
consecut
day
approxim
time
asc
inject
investig
immunomodulatori
effect
asc
wt
idoko
mice
wt
mice
treat
without
inhibitor
wt
mice
treat
without
antibodi
respect
result
wt
idoko
asthmat
mice
asc
significantli
reduc
airway
hyperrespons
total
inflammatori
cell
eosinophil
bronchoalveolar
lavag
fluid
balf
eosinophil
inflamm
goblet
cell
hyperplasia
serum
total
allergenspecif
ige
asc
significantli
inhibit
cytokin
enhanc
cytokin
regulatori
cytokin
balf
lung
drain
lymph
node
lln
furthermor
asc
engraft
caus
signific
increas
regulatori
cell
treg
cell
popul
lln
howev
treat
mice
inhibitor
neutral
antibodi
block
idoko
mice
elimin
immunosuppress
effect
asc
allerg
airway
inflamm
conclus
asc
capabl
secret
may
play
role
induc
treg
expans
furthermor
inhibitor
neutral
antibodi
elimin
benefici
effect
asc
treatment
asthmat
mice
suggest
major
solubl
factor
suppress
allerg
airway
inflamm
recent
number
patient
suffer
allerg
diseas
asthma
rhiniti
increas
especi
develop
countri
reason
unclear
mani
studi
demonstr
particl
pollut
diesel
exhaust
sand
dust
may
exacerb
allerg
respons
furthermor
sever
nanomet
micrometers
tini
particul
particul
matter
less
micromet
diamet
could
enter
respiratori
tract
settl
deep
lung
caus
pulmonari
chronic
inflamm
asthma
particul
includ
particl
pollut
consid
function
immun
adjuv
enhanc
allergenspecif
type
respons
howev
basi
adjuvant
particul
mechan
elicit
type
respons
remain
poorli
understood
show
particul
induc
induc
bronchusassoci
lymphoid
tissu
ibalt
lung
consequ
cell
death
alveolar
macrophag
releas
particul
alum
silica
administ
intratrach
instil
analyz
particulateinduc
lung
inflamm
histolog
analysi
show
addit
infiltr
inflammatori
cell
mani
lymphoid
cluster
size
mm
diamet
induc
lung
cluster
mainli
compos
b
cell
character
area
cell
induc
bronchusassoci
lymphoid
tissu
ibalt
cluster
contain
germin
center
gc
b
cell
area
cell
area
gener
cell
plasmablast
indic
aluminduc
ibalt
structur
function
tertiari
lymphoid
organ
lung
alum
instil
induc
releas
lung
alveolar
macrophag
cell
death
number
ibalt
format
clearli
reduc
mice
interestingli
ige
respons
also
attenu
mice
coincid
decreas
number
ibalt
structur
find
suggest
particul
induc
uniqu
immun
respons
lung
cell
death
tertiari
lymphoid
organ
format
axi
may
uniqu
therapeut
target
particulateinduc
allerg
inflamm
background
present
studi
sought
investig
associ
smoke
allerg
diseas
includ
atop
dermat
asthma
allerg
rhiniti
korean
adult
gener
popul
method
crosssect
studi
perform
use
data
subject
age
year
particip
fourth
fifth
korean
nation
health
nutrit
examin
survey
perform
repres
korean
gener
popul
multipl
logist
regress
analys
conduct
estim
odd
ratio
allerg
condit
accord
smoke
statu
adjust
potenti
confound
factor
includ
age
sex
region
resid
level
educ
incom
alcohol
consumpt
result
adjust
potenti
confound
neither
atop
dermat
asthma
associ
smoke
statu
respect
contrast
compar
neversmok
odd
allerg
rhiniti
significantli
lower
current
smoker
odd
ratio
confid
interv
p
higher
exsmok
p
adjust
confound
conclus
present
result
may
suggest
complex
relationship
smoke
allerg
condit
background
previous
report
elev
protein
sputum
neutrophil
sever
uncontrol
asthmat
compar
stabl
asthmat
annal
allergi
asthma
immunolog
oct
suggest
possibl
role
neutrophil
sever
asthma
releas
activ
inflammasom
exert
neutrophil
activ
activ
aim
studi
evalu
tempor
relationship
inflammasom
activ
neutrophilicmurin
mice
model
use
cfaovasensitizationchalleng
method
express
mrna
protein
level
activ
measur
lung
tissu
cfaova
modelus
rtpcr
realtim
pcr
western
blot
spatial
express
protein
inflammasom
relat
protein
visual
immun
fluoresc
stain
evalu
relat
activ
inflammsom
tempor
chang
neutrophil
infiltr
activ
analyz
intratrach
administr
protein
result
activ
start
increas
day
peak
day
earlier
number
total
cell
macrophag
neutrophil
significantli
increas
concomit
increas
airway
resist
day
neutrophil
elastas
activ
coloc
peribronchi
infiltr
cell
apic
portion
bronchial
epitheliumus
confoc
microscopi
intratrach
instil
protein
induc
rapid
increas
activ
lung
tissu
hr
peak
hr
progress
decreas
till
hr
concomitantincreas
neutrophilsin
bal
fluid
conclus
may
induc
neutrophil
inflamm
via
direct
activ
inflammsom
airway
background
asthma
heterogen
diseas
classifi
sever
phenotyp
basi
allerg
inflammatori
clinic
manifest
atop
nonatop
eosinophil
neutrophil
sever
nonsever
subtyp
cluster
analysi
task
group
set
object
way
object
group
similar
group
cluster
analysi
appli
develop
asthma
subphenotyp
demonstr
differ
clinic
respons
treatment
distinct
phenotyp
sever
asthma
cluster
extend
popul
includ
asthma
chronic
obstruct
pulmonari
diseas
cluster
use
addit
paramet
inflammatori
biomark
obes
present
studi
investig
cluster
reflect
prognosi
asthma
term
exacerb
one
year
method
clinic
demograph
data
asthmat
regist
asthma
cohort
korea
analyz
retrospect
ethnic
korean
asthma
diagnos
physician
basi
global
initi
asthma
gina
guidelin
among
subject
regularli
follow
longer
year
includ
analysi
exclud
current
smoker
exsmok
pack
year
baselin
visit
demograph
inform
enrol
age
sex
bmi
asthma
onset
age
asthma
durat
smoke
amount
collect
uniform
cluster
analysi
method
appli
popul
use
twotier
approach
includ
hierarch
cluster
analysi
kmean
cluster
analysi
result
subject
classifi
major
cluster
use
ward
method
age
age
onset
durat
asthma
bmi
atop
statu
robustli
differ
among
cluster
clinic
characterist
cluster
cluster
earlyonset
high
frequenc
atopi
rel
well
preserv
cluster
earlyonset
long
durat
moder
impair
cluster
middl
age
onset
short
durat
sever
impair
cluster
old
age
onset
high
bmi
well
preserv
annual
averag
frequenc
exacerb
significantli
differ
cluster
markedli
higher
cluster
conclus
exacerbationpron
asthma
phenotyp
found
use
cluster
analysi
clinic
characterist
phenotyp
middleag
onset
short
durat
sever
impair
notic
asthma
phenotyp
use
clinic
practic
predict
asthma
exacerb
object
investig
express
cell
treg
mous
model
neutrophil
asthma
effect
inhibit
method
femal
mice
equal
randomli
divid
three
group
na
group
na
treat
naag
group
normal
control
nc
group
mice
treat
fowllow
mice
na
group
naag
group
sensit
mixtur
consist
ovalbumin
ova
grade
v
lipopolysaccharid
lp
via
airway
deliveri
experi
day
besid
naag
mice
inject
intraperiton
dose
three
time
week
case
intervent
encount
sentis
ova
lp
inject
mice
minut
sensitis
airway
diliveri
sensit
stage
finish
mice
na
group
naag
group
challeng
consecut
exposur
ova
aerosol
produc
inhal
deliveri
system
one
hour
day
day
time
hour
last
challeng
mice
dispos
rel
index
measur
time
bronchoalveolar
lavag
fluid
balf
collect
total
white
blood
cell
count
determin
blood
cell
count
plate
classif
proport
determin
optic
microscop
diffquick
stain
lung
tissu
separ
pa
stain
done
obsev
patholog
chang
goblet
cell
hyperplasia
optic
microscop
balf
cytokin
concentr
determin
mean
enzymelinkedimmunosorb
serolog
assay
elisa
percentag
cell
treg
cell
lung
tissu
determin
mean
flow
cytometri
fcm
result
balf
total
cell
count
neutrophil
percentag
eosinophil
percentag
count
naag
group
lower
na
group
p
still
higher
nc
group
p
lung
tissu
patholog
chang
goblet
cell
hyperplasia
markedli
improv
naag
group
compar
na
group
still
signific
chang
compar
nc
group
balf
cytokin
concentr
naag
group
lower
na
group
still
higher
nc
group
p
cell
percentag
lung
naag
group
lower
na
group
still
higher
nc
group
p
treg
cell
percentag
lung
na
group
higher
naag
group
p
conclus
airway
inflamm
mous
model
neutrophil
asthma
improv
earli
treatment
probabl
via
downregul
espress
cell
upregul
espress
treg
background
purpos
studi
character
clinic
present
virusinduc
wheez
bronchiol
patient
younger
year
age
also
aim
verifi
whether
clinic
index
good
associ
diseas
sever
method
retrospect
review
medic
record
hospit
children
younger
year
old
acut
bronchiol
caus
respiratori
viru
april
april
sever
children
hospit
specif
viral
etiolog
detect
nasopharyng
aspir
multiplex
revers
transcript
polymeras
chain
reaction
time
admiss
clinic
sever
score
base
age
respiratori
rate
wheez
chest
wall
retract
percutan
oxygen
satur
admiss
durat
fever
use
oxygen
therapi
inhal
corticosteroid
within
hour
admiss
investig
accord
score
patient
divid
mild
moder
sever
bronchiol
group
host
factor
type
respiratori
virus
compar
among
sever
group
multivari
logist
regress
analys
perform
verifi
risk
factor
sever
bronchiol
result
total
children
studi
singl
viru
identifi
multipl
virus
respiratori
syncyti
viru
rsv
rhinoviru
rv
rsvrv
influenza
virus
flu
human
metapneumoviru
hmpv
parainfluenza
viru
detect
sampl
respect
rsv
rhinoviru
virus
frequent
identifi
mix
infect
differ
age
sever
score
patient
preval
virus
rsv
rv
less
common
infect
patient
coinfect
time
confid
interv
risk
sever
bronchiol
singl
viral
infect
host
factor
associ
sever
bronchiol
includ
younger
age
prematur
chronic
cardiopulmonari
diseas
type
virus
person
famili
histori
allerg
diseas
significantli
associ
bronchiol
sever
conclus
compar
clinic
characterist
respiratori
viral
infect
wheezi
bronchiol
patient
younger
year
old
viral
coinfect
host
factor
includ
younger
age
prematur
chronic
cardiopulmonari
diseas
risk
factor
sever
bronchiol
background
among
patient
serum
total
immunoglobulin
e
tige
higher
suffer
respiratori
diseas
could
found
major
sensit
hous
dust
mite
hdm
aspergillosi
aim
find
correl
tige
among
serum
specif
immunoglobulin
e
sige
hous
dust
mite
along
aspergillosi
patient
method
subject
high
level
tige
test
serum
sigeaf
use
immunocap
result
patient
sensit
hdm
sensit
aspergillosi
patient
could
detect
sige
af
patient
found
sige
af
free
patient
mere
sensit
hdm
sensit
aspergillosi
among
patient
tige
higher
patient
sensit
hdm
significantli
sensit
aspergillosi
p
sigeaf
correl
tige
p
conclus
patient
high
level
tige
complic
respiratori
diseas
like
sensit
hdm
rather
aspergillosi
compar
sige
hdm
sigeaf
contribut
level
tige
detect
sige
hdm
aspergillosi
import
patient
complic
respiratori
high
level
tige
last
decad
preval
metal
contact
allergi
high
among
danish
femal
patient
well
north
american
patient
occurr
metal
sensit
increas
import
metal
exposur
fix
orthodont
applianc
discuss
fix
orthodont
applianc
contain
metal
includ
nickel
chromium
cobalt
mercuri
knowledg
would
first
report
relationship
metal
allergi
orthodont
investig
associ
preval
metal
includ
nickel
chromium
cobalt
mercuri
patch
test
orthodont
applianc
addit
investig
coincid
resin
colophonium
sensit
adhes
materi
orthodont
applianc
patient
orthodont
applianc
total
patient
includ
perform
patch
test
patient
characterist
includ
orthodont
applianc
histori
collect
questionnair
clinic
investig
incid
metal
allergi
significantli
high
patient
experi
orthodont
applianc
especi
nickel
cobalt
allergi
significantli
correl
orthodont
histori
metal
allergi
orthodont
could
import
role
atop
triad
allerg
asthma
allerg
rhiniti
atop
dermat
reach
epidem
proport
epidemiolog
studi
show
world
popul
afflict
allergi
local
set
million
filipino
report
suffer
allerg
diseas
allergi
multifactori
immunolog
disord
involv
genet
environment
factor
develop
chronic
sever
pathogenesi
allerg
diseas
involv
complex
interact
well
character
environment
allergen
poorlyunderstood
genet
factor
addit
declin
number
infecti
stimuli
develop
immun
system
may
contribut
allergi
pathogenesi
paradigm
call
hygien
hypothesi
support
steep
rise
allergi
develop
popul
contrast
effect
environment
allergen
pathogen
nonpathogen
microogan
structur
compon
exert
pressur
immun
system
modul
develop
allerg
respons
furthermor
effect
differ
polymorph
may
play
import
role
individu
predisposit
allerg
diseas
recent
year
find
combin
effect
environment
allergen
genet
polymorph
absenc
infect
environment
factor
start
converg
produc
fascin
result
geneenviron
interact
may
explain
develop
allergi
understand
biochem
natur
allergen
identif
genet
polymorph
implic
allergi
advanc
knowledg
diseas
preval
healthcar
burden
pathogenesi
allergi
elucid
mechan
interact
gene
allergen
involv
pathogenesi
allerg
diseas
help
enhanc
present
medic
armamentarium
diagnosi
therapi
allergi
background
peanut
pn
tree
nut
tn
wellrecogn
major
caus
anaphylaxi
western
countri
inform
avail
korea
purpos
studi
featur
clinic
characterist
anaphylaxi
caus
pn
tn
seed
korean
children
adolesc
method
retrospect
medic
record
review
perform
patient
year
old
diagnos
anaphylaxi
pn
tn
walnut
almond
hazelnut
pine
nut
cashew
nut
pistachio
pecan
macadamia
seed
sunflow
sesam
perilla
fourteen
univers
hospit
korea
result
one
hundr
twentysix
case
anaphylaxi
pn
tn
seed
identifi
male
patient
mean
age
year
year
subject
seven
year
old
number
patient
increas
case
case
pn
account
walnut
wn
account
pine
nut
account
tn
seed
account
common
system
involv
cutan
follow
respiratori
gastrointestin
proport
patient
cardiovascular
symptom
significantli
higher
older
patient
younger
children
p
time
interv
ingest
trigger
food
onset
symptom
immedi
less
two
hour
among
case
serum
level
specif
ige
sige
correspond
allergen
measur
median
valu
sige
pn
wn
pine
nut
kual
kual
kual
respect
among
case
manag
emerg
depart
patient
treat
intramuscular
epinephrin
system
steroid
antihistamin
oxygen
bronchodil
overal
percentag
patient
prescrib
epinephrin
autoinjector
signific
differ
age
group
conclus
among
anaphylaxi
caus
pn
tn
seed
korea
wn
pn
pine
nut
common
trigger
order
kind
tn
seed
also
identifi
trigger
case
children
age
seven
median
level
sige
pn
wn
kual
kual
respect
case
show
remark
low
sige
level
kual
three
subject
studi
done
food
allergi
atop
dermat
studi
group
korean
academi
pediatr
allergi
respiratori
diseas
perilla
perilla
frutescen
seed
also
known
wild
sesam
seed
one
popular
spice
asia
seriou
allerg
reaction
perilla
seed
rare
report
herein
report
two
case
anaphylaxi
caus
perilla
seed
children
boy
present
outpati
clinic
ajou
univers
hospit
previou
experi
urticaria
facial
angioedema
immedi
ingest
soup
contain
perilla
seed
powder
age
month
month
past
histori
asthma
previou
experi
lip
angioedema
ingest
kiwi
first
time
month
old
specif
ige
sige
test
perilla
seed
commerci
avail
sige
sesam
seed
belong
lamial
like
perilla
measur
instead
sige
level
sesam
seed
kual
month
kual
year
age
sige
level
kiwi
kual
multipl
allergosorb
test
chemiluminesc
assay
mast
cla
reveal
remark
sensit
inhal
allergen
confirm
causal
relationship
open
oral
food
challeng
ofc
perilla
seed
powder
perform
year
old
immedi
contact
extrem
small
amount
perilla
seed
powder
around
lip
develop
urticaria
facial
angioedema
cough
rhinorrhea
treat
intramuscular
epinephrin
symptom
resolv
complet
second
patient
boy
present
outpati
clinic
previou
histori
urticaria
lip
angioedema
pruriti
tongu
hoars
immedi
ingest
seawe
soup
contain
perilla
seed
month
past
histori
asthma
allerg
rhiniti
atop
dermat
previous
diagnos
allerg
egg
white
peanut
also
oral
allergi
syndrom
kiwi
fruit
moder
sensit
alder
birch
white
oak
note
mast
cla
sige
level
sesam
seed
egg
white
peanut
kiwi
kual
kual
kual
kual
respect
ofc
test
perilla
seed
perform
patient
initi
symptom
compat
anaphylaxi
etiolog
confirm
enzymelink
immunosorb
assay
elisa
ige
western
blot
crude
extract
perilla
seed
produc
laboratori
progress
patient
best
knowledg
first
report
anaphylaxi
caus
perilla
seed
children
background
particul
matter
pm
associ
wheez
episod
increas
risk
asthma
symptom
respiratori
tract
infect
children
howev
impact
prenat
exposur
indoor
pm
health
children
poorli
understood
yet
tolllik
receptor
play
critic
role
respons
induc
air
pollut
object
investig
whether
prenat
exposur
indoor
fine
particul
matter
affect
suscept
wheez
children
determin
whether
genet
factor
modifi
environment
effect
method
studi
popul
consist
children
indoor
data
birth
cohort
recurr
wheez
determin
wheez
episod
diagnos
physician
first
year
age
indoor
measur
pregnanc
genotyp
perform
taqman
result
prenat
indoor
exposur
increas
risk
recurr
wheez
year
age
aor
ci
cc
increas
effect
prenat
indoor
exposur
recurr
wheez
aor
ci
p
interact
conclus
indoor
exposur
prenat
period
increas
suscept
recurr
wheez
effect
modifi
polymorph
reduc
exposur
prenat
period
may
prevent
wheez
suscept
children
background
blymphocyt
bl
play
critic
role
system
lupu
erythematosu
sle
bl
deplet
therapi
still
remain
attract
option
despit
disappoint
result
rct
method
twelv
sle
patient
male
mean
age
yr
polyarthralgia
multiorgan
involv
includ
class
iv
iiiv
isnrp
glomerulonephr
case
skin
lesion
case
necrot
ulcer
polyneuropathi
cn
involv
lymphoadenopathi
e
polysieros
treat
withan
ibld
protocol
intoler
convent
immunosuppress
therapi
case
front
line
therapi
case
protocol
rituximab
mgsm
day
dose
one
two
month
associ
iv
administr
mgkg
cyclofosfamid
infus
methylprednisolon
mgkg
follow
oral
prednison
mgdie
rapidli
taper
mgday
week
immunosuppress
mainten
therapi
given
result
ibld
obtain
complet
deplet
bl
month
patient
followedup
month
signific
decreas
p
found
level
esr
baselin
mean
valu
mm
month
end
followup
antidsdna
antibodi
baselin
u
month
end
followup
proteinuria
baselin
hour
month
end
followup
convers
valu
baselin
mgdl
significantli
increas
p
month
mgdl
end
followup
mgdl
three
patient
relaps
month
respect
show
complet
remiss
retreat
month
observ
conclus
data
confirm
opportun
reconsid
regimen
bl
deplet
treatment
sever
form
sle
despit
disappoint
result
rct
promis
role
rituximab
protocol
intensifi
induct
therapi
select
patient
avoid
immunosuppress
mainten
therapi
particularli
appeal
envisag
object
explor
role
cell
neutrophil
airway
inflamm
childhood
neutrophil
asthma
method
twentyeight
children
exacerb
asthmat
without
use
corticosteroid
divid
three
group
eosinophil
asthma
group
ea
group
n
neutrophil
asthma
group
na
group
n
paucigranulocyt
asthma
pga
group
n
accord
induc
sputum
cytologyten
healthi
children
recruit
healthi
control
group
hc
group
n
cell
peripher
blood
express
cell
detect
flow
cytometri
express
peripher
blood
mononuclear
cell
pbmc
detect
realtim
quantit
polymeras
chain
reaction
concentr
induc
sputum
supernat
well
concentr
plasma
cultur
supernat
pmastimul
pbmc
measur
enzym
link
immunosorb
assay
result
percentag
cell
peripher
blood
express
level
pbmc
significantli
higher
na
group
ea
group
pga
group
hc
group
p
level
sputum
level
cultur
supernat
pmastimul
pbmc
significantli
higher
na
group
ea
group
pga
group
hc
group
p
percentag
cell
peripher
blood
level
sputum
supernat
significantli
higher
ea
group
na
group
pga
group
hc
group
p
percentag
cell
peripher
blood
level
sputum
pbmc
cultur
supernat
level
sputum
supernat
correl
posit
percentag
neutrophil
sputum
conclus
cell
cell
involv
pathogenesi
asthma
children
cell
may
mediat
neutrophil
airway
inflamm
asthma
indic
import
role
cell
childhood
neutrophil
asthma
cell
may
maintain
surviv
activ
signal
pathway
background
determin
valu
specif
physiolog
test
well
studi
longterm
asthma
manag
preschool
children
sought
determin
util
impuls
oscillometri
longterm
manag
preschool
children
asthma
exacerb
method
outpati
age
year
old
mildtomoder
asthma
exacerb
shengj
hospit
china
medic
univers
enrol
impuls
oscillometri
perform
immedi
enrol
week
therapi
inhal
corticosteroid
adjust
accord
gina
report
impuls
oscillometri
perform
week
separ
everi
children
differ
resist
resist
reson
frequenc
fre
low
frequenc
integr
reactanc
fre
ax
among
four
visit
measur
repeatedmeasur
analysi
result
children
boy
averag
age
year
old
weight
kg
height
cm
kpal
separ
differ
signific
compar
pair
kpal
separ
differ
signific
except
kpal
separ
differ
signific
except
fre
hz
separ
differ
signific
ax
kpal
separ
differ
signific
conclus
preschool
children
manag
asthma
exacerb
lung
function
assess
impuls
oscillometri
improv
differ
degre
fre
ax
may
reflect
ongo
improv
assess
respiratori
mechan
time
oscillometri
might
offer
use
insight
respons
asthmat
preschool
children
therapi
studi
focu
longer
term
manag
relationship
impuls
oscillometri
airway
inflamm
sulfit
widespread
use
preserv
antioxid
even
cosmet
product
publish
sodium
metabisulfit
could
marker
sulfit
allergi
comet
howev
contact
allergi
sodium
sulfit
less
well
recogn
relationship
sodium
sulfit
cosmet
contact
dermat
rare
known
sought
establish
preval
posit
patch
test
reaction
sodium
sulfit
patient
popul
facial
cosmet
contact
dermat
patient
facial
contact
dermat
includ
perform
korean
standard
patch
test
cosmet
patch
test
sodium
sulfit
patch
test
result
posit
allerg
reaction
occur
sodium
sulfit
test
patient
clinic
patient
sodium
sulfit
posit
reaction
show
aggrav
facial
symptom
use
cosmet
product
includ
sulfit
interestingli
patient
experienc
aggrav
eat
sulfit
contain
food
includ
dri
fruit
fri
potato
can
food
etc
background
children
suscept
air
pollut
known
relat
reduc
lung
function
develop
asthma
object
studi
evalu
longterm
effect
air
pollut
lung
develop
incid
asthma
children
method
total
children
elementari
school
select
rural
area
industri
area
metropolitan
citi
includ
baselin
survey
first
second
year
student
individu
exposur
air
pollut
estim
use
geometr
inform
system
mean
concentr
air
pollut
result
higher
exposur
carbon
monoxid
nitrogen
dioxid
particl
measur
less
associ
newli
diagnos
asthma
period
odd
ratio
ci
confid
interv
ci
ci
respect
children
higher
exposur
ozon
sulfur
dioxid
lung
function
measur
fvc
significantli
decreas
conclus
exposur
air
pollut
significantli
associ
develop
asthma
neg
effect
lungfunct
growth
children
object
tyrphostin
janu
kinas
inhibitor
effect
variou
model
inflammatori
autoimmun
diseas
studi
examin
effect
treatment
mous
model
neutrophil
asthma
na
method
femal
mice
divid
na
group
na
treat
naa
group
normal
control
nc
group
mean
random
number
tabl
na
naa
mice
sensit
lowdos
lipopolysaccharid
lp
ovalbumin
ova
airway
deliveri
day
challeng
stage
na
naa
mice
expos
ova
aerosol
minut
day
day
gener
use
inhal
deliveri
system
aerosol
naa
mice
treat
peritoneum
day
data
collect
day
bronchoalveolar
lavag
fluid
balf
collect
white
blood
cell
count
oper
lung
tissu
stain
concentr
balf
elisa
express
cell
flow
cytometri
determin
result
total
cell
neutrophil
percentag
eosinophil
percentag
count
balf
naa
group
lower
na
group
p
lung
tissu
patholog
chang
improv
naa
group
compar
na
group
balf
cytokin
concentr
naa
group
lower
na
group
still
higher
nc
group
p
cell
percentag
lung
naa
group
lower
na
group
still
higher
nc
group
p
level
naa
group
decreas
compar
na
group
p
express
level
naa
group
higer
compar
na
group
p
conclus
airway
inflamm
mous
model
neutrophil
asthma
improv
treatment
probabl
via
downregul
espress
cell
balf
cytokin
concentr
mous
model
neutrophil
asthma
promot
apoptosi
cell
connect
domin
signal
pathway
background
advers
reaction
radiocontrast
media
rcm
common
caus
advers
drug
reaction
spontan
report
advers
reaction
simplest
use
method
monitor
safeti
issu
rcm
studi
purpos
investig
incid
advers
reaction
rcm
singl
tertiari
hospit
method
individu
case
safeti
report
rcm
submit
spontan
region
pharmacovigil
center
march
februari
analys
case
advers
reaction
intraven
inject
iodin
contrast
media
icm
iohexol
iomeprol
ioversol
iopamidol
iopamid
iobitridol
gadolinum
contrast
ganoten
gadobutrol
gadoben
gadoxet
result
total
advers
reaction
rcm
develop
icm
inject
caus
gadolinum
contrast
overval
incid
icm
advers
reaction
mean
age
case
subject
men
subject
posit
respons
pretest
skin
test
predict
advers
reaction
imag
among
icm
iobitridol
show
highest
rate
advers
reaction
common
advers
reaction
cutan
reaction
gastrointestin
reaction
classifi
sever
mild
reaction
moder
sever
reaction
respect
incid
sever
reaction
iobitridol
iopromid
ioversol
regard
advers
reaction
gadolinium
contrast
reaction
mild
moder
sever
reaction
caus
gadolinium
contrast
conclus
rcm
skin
test
screen
show
efficaci
predict
advers
reaction
incid
advers
reaction
rel
higher
icm
gadolinium
contrast
among
icm
iobitridol
may
develop
advers
reaction
frequent
seriou
one
background
oral
food
challeng
ofc
gold
standard
diagnosi
food
allergi
mani
case
would
reduc
ofc
predict
outcom
ofc
purpos
studi
examin
relationship
clinic
characterist
outcom
cow
milk
cm
ofc
method
medic
record
children
underw
cm
ofc
januari
march
ajou
univers
hospit
review
data
analyz
determin
relationship
ofc
outcom
clinic
paramet
includ
specif
ige
sige
level
milk
casein
measur
ofc
result
twentynin
patient
male
mean
age
year
month
age
month
thirteen
histori
cm
ingest
previou
histori
immedi
reaction
cm
ingest
ofc
perform
detect
clinic
toler
among
report
acut
urticaria
experienc
anaphylaxi
initi
cm
ingest
number
subject
pass
ofc
success
ingest
cumul
dose
ml
cm
without
allerg
reaction
group
p
among
children
fail
ofc
group
f
cutan
symptom
report
upper
respiratori
lower
respiratori
gastrointestin
symptom
note
respect
seven
patient
experienc
anaphylaxi
three
anaphylaxi
histori
initi
cm
ingest
none
cardiovascular
nervou
symptom
ofc
median
cumul
dose
cm
symptom
onset
ofc
ml
median
level
milksig
group
f
higher
group
p
kual
vs
kual
p
median
level
caseinsig
group
f
also
higher
group
p
kual
vs
kual
use
receiv
oper
characterist
curv
optim
cutoff
point
milksig
caseinsig
children
age
month
kual
kual
respect
number
subject
younger
month
two
optim
cutoff
point
group
obtain
initi
level
milksig
caseinsig
age
ofc
anaphylaxi
initi
cm
ingest
significantli
relat
outcom
ofc
past
histori
asthma
signific
factor
associ
increas
risk
ofc
failur
crude
analysi
relat
signific
adjust
confound
factor
conclus
level
sige
milk
casein
significantli
higher
patient
fail
cm
ofc
compar
case
pass
ofc
cutan
symptom
occur
patient
fail
ofc
patient
experienc
anaphylaxi
ofc
comorbid
asthma
signific
factor
associ
increas
risk
ofc
failur
crude
analysi
background
spatial
tempor
variabl
season
pollen
concentr
confound
result
field
studi
new
allergi
medic
allergen
exposur
facil
red
mapl
trial
allergen
challeng
act
provid
stabl
control
pollen
concentr
year
round
offer
altern
field
studi
full
scale
valid
act
ragwe
ambrosia
artemisiifolia
pollen
challeng
perform
method
act
facil
hold
seat
seri
elev
row
pollen
inject
air
suppli
blown
facil
duct
locat
across
top
front
wall
pollen
concentr
act
measur
use
laser
particl
counter
lpc
impact
sampler
technic
valid
lpc
use
assess
longterm
stabil
pollen
level
use
determin
pollen
uniform
locat
room
clinic
valid
thirti
ragwe
allerg
subject
expos
ragwe
hour
two
separ
day
assess
reproduc
rhiniti
symptom
pollen
monitor
min
interv
locat
patient
seat
area
result
threehour
stabil
result
compar
lpc
uniform
test
gave
averag
ragwe
concentr
fronttoback
sd
sidetosid
sd
subject
challeng
mean
pollen
concentr
day
day
plateau
hour
nasal
symptom
score
respect
ocular
symptom
score
respect
conclus
valid
studi
show
ragwe
pollen
level
act
could
maintain
stabl
long
period
subject
respond
allergen
challeng
reproduc
rhiniti
symptom
differ
day
facil
act
provid
suitabl
mean
test
new
allergi
medic
rational
allergen
challeng
chamber
expos
allergensensit
subject
predetermin
concentr
allergen
close
control
environ
provid
mechan
induc
clinic
symptom
measur
effect
medic
method
red
mapl
trial
rmt
allergen
challeng
theatr
act
facil
hold
seat
seri
elev
row
grass
pollen
phleum
pratens
inject
air
suppli
blown
facil
duct
locat
across
top
front
wall
technic
valid
perform
determin
stabil
uniform
pollen
concentr
room
pollen
count
measur
laser
particl
counter
lpc
posit
ft
floor
level
impact
sampler
set
face
level
instal
section
tshape
quadrant
measur
taken
everi
minut
minut
evalu
clinic
respons
grass
pollen
exposur
subject
histori
grass
allergi
posit
skin
prick
test
underw
two
challeng
grass
pollen
nasal
ocular
symptom
score
record
baselin
everi
min
challeng
result
technic
valid
pollen
count
measur
lpc
stabl
hour
lpc
pollen
count
correl
well
count
rang
lpc
mean
pollen
count
section
quadrant
rang
clinic
valid
patient
least
one
total
nasal
symptom
score
tnss
challeng
subject
mean
chang
baselin
tnss
challeng
challeng
total
ocular
symptom
score
toss
respect
conclus
red
mapl
trial
act
demonstr
capac
achiev
maintain
stabl
grass
pollen
concentr
associ
abil
induc
nasal
ocular
symptom
appropri
intens
upon
threehour
allergen
challeng
background
exposur
parent
smoke
associ
wheez
earli
childhood
plenti
paper
show
relationship
parent
smoke
urban
set
rural
set
aim
examin
associ
matern
patern
smoke
preval
asthma
method
follow
isaac
studi
procedur
parent
children
age
year
live
san
francisco
argentina
surround
rural
area
ask
symptom
asthma
matern
smoke
child
first
year
life
current
matern
patern
smoke
result
total
urban
rural
children
studi
matern
patern
smoke
associ
increas
risk
asthma
although
magnitud
or
higher
rural
set
strong
interact
matern
patern
smoke
conclus
studi
confirm
import
parent
smoke
mainli
rural
set
background
object
allerg
rhiniti
ar
common
chronic
allerg
diseas
adult
preval
rang
adult
turkey
ar
lead
substanti
socioeconom
cost
loss
qualiti
life
typic
begin
childhood
adolesc
hereditari
factor
gender
play
import
role
develop
preval
selfreport
physiciandiagnos
ar
exhibit
signific
variabl
across
seven
geograph
region
turkey
purpos
studi
assess
preval
ar
turkish
adult
popul
method
epidemiolog
studi
plan
among
student
celal
bayar
univers
variou
region
turkey
find
preval
allerg
rhiniti
search
geograph
differ
turkey
questionnair
design
collect
data
sociodemograph
featur
symptom
allerg
rhiniti
prior
diagnosi
allerg
rhiniti
made
physician
result
questionnair
relat
allerg
rhiniti
asthma
ask
student
male
femal
current
preval
season
perenni
rhinoconjunct
urticaria
eczema
drug
intoler
pollen
pet
anim
hypersensit
respect
hypersensit
reaction
rate
distinct
common
femal
season
rhiniti
pollen
allergi
preval
west
region
northern
region
signific
geograph
differ
observ
regard
drug
pet
hypersensit
conclus
studi
shown
import
asthma
allerg
diseas
public
health
problem
explan
observ
geograph
differ
need
studi
background
identif
food
allergen
implic
manifest
atop
dermat
central
prevent
seriou
hypersensit
reaction
avoid
unnecessari
costli
elimin
diet
investig
profil
allergen
sensit
zimbabwean
children
present
atop
dermat
method
total
pediatr
patient
atop
dermat
attend
allergi
clinic
zimbabw
evalu
assay
jan
dec
median
age
subject
year
age
rang
year
age
total
allergen
test
patient
result
sensit
least
one
food
allergen
potatospecif
ige
detect
highest
frequenc
twothird
test
children
year
age
food
allergen
sensit
approxim
half
children
older
year
sensit
statist
signific
differ
two
group
rel
risk
ci
term
egg
allergi
statist
signific
differ
year
age
group
rel
risk
ci
p
among
patient
show
posit
result
patient
show
multipl
sensit
allergen
patient
wheat
allergi
also
show
sensit
rice
well
concord
milk
allergi
soy
allergi
peanut
sensit
found
enrol
patient
patient
peanut
allergi
show
crossreact
hazelnut
seriou
advers
effect
peanut
allergi
popul
oral
allergi
syndrom
seriou
anaphylact
reaction
patient
peanut
potato
allergi
conclus
food
allergen
sensit
common
amongst
children
atop
dermat
highest
sensitogen
potato
peanut
associ
sever
allerg
reaction
egg
allergi
predominantli
seen
children
year
age
background
vitamin
import
function
immun
system
recent
year
sever
studi
report
associ
vitamin
level
atopi
asthma
respiratori
tract
infect
object
aim
investig
whether
vitamin
insuffici
asthmat
adult
associ
atopi
poor
asthma
control
frequent
respiratori
tract
infect
whether
patient
benefit
vitamin
supplement
method
studi
includ
adult
patient
diagnos
asthma
first
visit
patient
underw
pulmonari
function
test
skin
prick
test
panel
aeroallergen
level
measur
asthma
control
test
act
questionnair
administ
record
obtain
regard
number
visit
medic
centr
respiratori
tract
infect
previou
year
subsequ
patient
vitamin
defici
receiv
iu
vitamin
daili
month
octob
march
end
period
patient
reassess
result
seventeen
patient
found
vitamin
level
lower
ngml
consid
insuffici
patient
poorer
asthma
control
indic
act
score
significantli
higher
rate
allerg
sensit
compar
vitamin
suffici
asthmat
patient
vitamin
insuffici
averag
number
medic
visit
respiratori
infect
previou
year
vitamin
supplement
averag
act
score
increas
significantli
end
month
period
spirometr
valu
chang
significantli
conclus
found
vitamin
insuffici
patient
asthma
correl
allerg
sensit
vitamin
supplement
patient
result
better
asthma
control
possibl
due
fewer
episod
respiratori
tract
infect
background
object
drug
hypersensit
reaction
dhr
common
public
health
problem
recent
studi
confirm
frequenc
drug
allergi
overestim
patient
physician
aim
studi
determin
preval
characterist
dhr
univers
student
data
epidemiolog
dhr
outpati
popul
rel
scarc
studi
design
determin
preval
self
report
drug
hypersensit
relat
factor
among
young
adult
method
structur
questionnair
administ
univers
student
result
total
student
mean
year
grade
respond
survey
mean
preval
selfreport
drug
hypersensit
frequent
involv
drug
antibiot
follow
analgesisc
common
allerg
reaction
rash
cardiovascular
reaction
respiratori
reaction
aforement
two
system
involv
anaphylaxi
person
histori
allerg
diseas
famili
histori
drug
hypersensit
differ
preval
drug
allergi
femal
patient
compar
male
patient
mean
age
first
drug
allergi
reaction
year
five
hundr
fifti
five
student
antibiot
student
analges
case
need
conclus
mean
preval
selfreport
drug
hypersensit
studi
antibiot
analges
two
drug
famili
frequent
suspect
among
selfreport
drug
hypersensit
reaction
common
manifest
cutan
symptom
drug
provoc
test
need
includ
diagnost
protocol
order
evalu
suspect
dhr
studi
show
selfreport
hypersensit
reaction
drug
highli
preval
educ
patient
physician
manag
drug
hypersensit
seem
necessari
background
one
key
strateg
way
allerg
diseas
treatment
updat
methodolog
creation
new
immunothrop
drug
sublingu
immunotherapi
slit
determin
mucos
toler
develop
process
combin
allerg
rhiniti
palindrom
herpet
infect
hsv
andor
usual
character
rapid
mucos
immun
barrier
function
violat
mucos
barrier
permeabl
chang
inevit
progress
allerg
diseas
take
consider
high
preval
herpet
infect
spread
among
patient
suffer
allerg
diseas
search
optim
slit
treatment
scheme
becom
significantli
import
purpos
current
studi
evalu
slit
effect
among
immunocompromis
patient
suffer
allerg
rhiniti
use
uptod
tablet
allergen
extract
produc
kazakhstan
method
within
open
prospect
research
effect
toler
slit
cours
maintain
use
uptod
tablet
allergen
extract
produc
kazakhstan
analyz
among
patient
age
suffer
allerg
rhiniti
year
herpet
infect
hsv
andor
among
slit
effect
criteria
va
visual
analog
scale
sm
symptom
medic
score
patient
adher
treatment
continu
laboratori
effect
evalu
conduct
use
profil
cytokin
evalu
immunoenzym
method
proinflammatori
tumor
necrosi
factor
inf
antiphlogist
serum
local
fraction
materi
studi
blood
serum
taken
fast
ulnar
vein
nasal
lavag
result
assess
result
excel
good
effect
state
among
patient
among
patient
note
decreas
pharmacomedicin
need
contact
correspond
allergen
overal
health
statu
improv
patient
none
patient
claim
main
diseas
flow
worsen
cytokin
profil
research
treatment
show
inf
content
level
normal
local
serum
fraction
among
patient
rapid
increas
tnf
local
fraction
state
treatment
key
reason
chang
slit
mode
add
immunomodul
therapi
patient
agre
continu
treatment
next
year
conclus
full
slit
cours
success
implement
patient
use
modern
tablet
allergen
extract
produc
kazakhstan
despit
violat
viru
defens
system
mucos
immun
system
state
chang
content
level
among
group
patient
allow
chang
slit
mode
complet
cours
success
slit
use
modern
tablet
medicin
among
immunocompromis
problemat
patient
suffer
allerg
diseas
success
high
effect
method
compli
criteria
ration
pharmacotherapi
background
microrna
mirna
implic
pathogenesi
mani
diseas
includ
atopi
asthma
investig
whether
could
identifi
serum
microrna
earli
childhood
could
use
predict
develop
wheez
children
method
studi
protocol
approv
committe
human
research
chiba
univers
preliminari
microarray
analysi
reveal
dysregul
sever
mirna
includ
sampl
use
studi
birth
cohort
sampl
consist
cord
blood
sampl
sampl
categor
accord
wheez
statu
allergenspecif
ige
level
year
children
episod
wheez
preced
month
consid
wheezer
without
nonwheez
mirna
extract
serum
birth
cohort
sampl
use
commerci
columnbas
kit
level
quantifi
use
realtim
pcr
use
spikeincontrol
differ
express
level
use
cycl
threshold
data
analyz
use
nonparametr
test
graphpad
prism
version
result
level
significantli
elev
age
year
nonwheez
age
year
level
consist
wheezer
suggest
increas
level
may
neg
indic
recurr
wheez
potenti
asthma
later
childhood
see
correl
allergenspecif
ige
level
conclus
may
use
identifi
potenti
wheez
first
year
life
target
gene
regul
mirna
verifi
background
incid
atop
dermat
markedli
increas
recent
recent
year
atop
dermat
develop
due
interact
genet
environment
factor
lack
inform
predictor
atop
dermat
vagin
born
babi
lowincom
popul
object
describ
risk
marker
atop
dermat
occurr
atop
dermat
lowincom
popul
indonesia
method
prospect
surviv
analysi
studi
done
babi
born
vagin
kemayoran
commun
health
centr
central
jakarta
month
period
occurr
atop
dermat
age
month
diagnos
base
hanifinrajka
criteria
prognost
factor
develop
atop
dermat
analyz
spss
statist
use
kaplanmei
test
cox
regress
model
level
signific
result
healthi
term
infant
enrol
studi
maletofemal
ratio
mean
age
onset
atop
dermat
month
rang
month
famili
incom
vari
us
month
mean
incom
us
atop
dermat
occur
smoke
number
peopl
hous
number
sibl
famili
associ
occurr
atop
dermat
bivari
analysi
atop
famili
histori
higher
degre
mother
educ
exclus
breastf
predict
occurr
atop
dermat
multivari
analysi
atop
famili
histori
hr
ci
lower
mother
educ
hr
ci
identifi
prognost
factor
conclus
atop
famili
histori
higher
mother
educ
independ
prognost
factor
occurr
atop
dermat
infant
low
incom
popul
indonesia
background
introduct
monoclon
antibodi
clinic
oncolog
yield
surviv
benefit
cancer
patient
select
target
tumorassoci
antigen
taa
current
research
aim
make
immunotherapi
even
effect
one
promis
approach
use
antibodi
class
igg
ige
studi
thu
investig
potenti
specif
human
epiderm
growth
factor
ige
antibodi
vaccin
approach
compar
wildtyp
wt
transgen
hyper
hypoig
mice
method
three
differ
mice
strain
employ
wt
balbc
mice
mice
display
fold
elev
mean
serum
ige
level
transgen
mice
lack
transmembran
cytoplasm
domain
membranebound
ige
result
reduc
serum
ige
level
wt
mice
strain
divid
group
group
immun
prior
tumor
graft
irrelev
antigen
bsa
passiv
receiv
igg
mous
monoclon
antibodi
remain
mice
graft
tumor
cell
overexpress
monitor
tumor
growth
surviv
result
remain
hyperig
mice
show
significantli
slower
tumor
growth
longer
surviv
compar
wt
balbc
control
hypoig
mice
strain
mice
passiv
immunotherapi
render
signific
surviv
benefit
compar
untreat
group
vaccin
result
overal
longest
surviv
lead
signific
surviv
benefit
compar
well
passiv
antibodi
treat
group
importantli
hyperig
mice
show
signific
surviv
benefit
independ
treatment
conclus
activ
vaccin
surmount
effect
passiv
antibodi
therapi
mous
model
presenc
ige
top
antigenspecif
experi
studi
therefor
suggest
ige
antibodi
may
play
signific
role
innat
cancer
surveil
well
activ
anticanc
immun
respons
refer
migrat
antibodi
secret
cell
toward
depend
isotyp
form
bcr
achatzstraussberg
g
et
al
european
journal
immunolog
effect
transmembran
cytoplasm
domain
ige
ige
respons
achatz
g
et
al
scienc
apr
background
previous
report
consumpt
fructooligosaccharid
fo
pregnant
lactat
women
increas
product
breast
milk
random
placebocontrol
doubleblind
trial
kubota
et
al
underli
mechan
remain
clarifi
method
healthi
pregnant
woman
enrol
written
inform
consent
subject
individu
randomli
assign
fo
meioligop
obtain
meiji
food
materia
compani
limit
fo
n
sucros
placebo
intak
group
trial
compound
g
taken
breakfast
supper
daili
week
gestat
month
deliveri
colostrum
sampl
collect
hospit
childbirth
concentr
measur
elisa
fecal
sampl
week
gestat
collect
home
hospit
subject
gut
microbiota
quantifi
quantit
realtim
pcr
result
exclud
subject
insuffici
test
compound
intak
placebo
fo
group
analyz
differ
characterist
group
concentr
colostrum
sampl
significantli
higher
fo
group
rang
ngml
median
ngml
placebo
group
rang
ngml
median
ngml
p
fecal
number
bifidobacterium
significantli
increas
fo
group
placebo
group
significantli
higher
fo
group
rang
cfug
median
cfug
placebo
group
rang
cfug
median
cfug
intervent
p
concentr
colostrum
show
weak
correl
bifidobacteriumnumb
week
gestat
conclus
data
suggest
mother
intak
prebiot
increas
express
breast
milk
modul
gut
microbiota
object
nintedanib
tyrosin
kinas
inhibitor
recent
nintedanib
show
benefici
effect
patient
ipf
howev
littl
known
regard
effect
nintedanib
asthma
sinc
vegf
pdgf
well
known
mediat
pathogenesi
asthma
aim
evalu
effect
nintedanib
asthma
acut
chronic
mous
model
method
femal
balbc
mice
week
age
use
develop
mous
model
acut
chronic
asthma
ovalbumin
ova
sensit
mice
repeatedli
expos
intranas
ova
administr
mice
treat
nintedanib
ova
challeng
result
compar
control
mice
mice
expos
ova
develop
sustain
eosinophil
airway
inflamm
airway
hyperrespons
ahr
administr
nintedanib
significantli
decreas
total
cell
eosinophil
count
bronchoalveolar
lavag
bal
fluid
also
level
bal
fluid
significantli
lower
nintedanib
group
compar
control
histolog
analysi
fewer
inflammatori
cell
infiltr
nintedanib
group
nintedanib
treatment
significantli
attenu
airway
remodel
includ
fibrosi
smooth
muscl
thicken
protein
gene
express
level
vegf
fgf
pdgf
lower
nintedanib
group
vitro
experi
show
nintedanib
significantli
decreas
fibroblast
prolifer
conclus
result
suggest
nintedanib
administr
attenu
airway
inflamm
ahr
remodel
mous
model
asthma
benefici
effect
nintedanib
via
block
vegf
fgf
pdgf
pathway
background
coronari
angiographi
cag
standard
method
diagnos
coronari
arteri
diseas
iodin
contrast
media
icm
use
cag
induc
immedi
delay
hypersensit
reaction
howev
studi
delay
hypersensit
reaction
icm
rel
report
incid
vari
greatli
therefor
aim
investig
incid
clinic
featur
icminduc
delay
hypersensit
reaction
follow
cag
method
prospect
monitor
icminduc
delay
hypersensit
patient
underw
cag
februari
may
seoul
nation
univers
hospit
icm
agent
use
iodixanol
iopamidol
symptom
monitor
one
hour
three
week
complet
cag
result
total
patient
receiv
cag
studi
period
mean
age
year
male
delay
hypersensit
reaction
occur
patient
common
manifest
skin
rash
follow
chest
discomfort
gastrointestin
symptom
major
skin
reaction
mild
involv
bodi
surfac
mostli
occur
within
day
cag
within
hr
day
day
subgroup
analysi
icm
agent
use
gender
age
show
signific
differ
reaction
incid
clinic
manifest
conclus
incid
proport
delay
hypersensit
reaction
icm
higher
previous
report
knowledg
first
studi
korea
investig
incid
icminduc
delay
hypersensit
follow
cag
background
chronic
idiopath
urticaria
ciu
rel
common
diseas
account
offic
visit
allergist
although
design
idiopath
pathophysiolog
mechan
diseas
report
result
immun
activ
due
varieti
caus
ciu
manifest
immun
activ
approxim
ciu
patient
demonstr
autoimmun
evidenc
presenc
igg
antibodi
receptor
present
mast
cell
basophil
autoantibodi
thyroid
tissu
mani
cellular
cell
surfac
receptor
commonli
coexist
elucid
lack
genet
molecular
level
ideal
better
understand
underli
biolog
could
improv
prognost
indic
also
provid
background
gener
predictor
model
treatment
respond
method
collect
peripher
blood
mononuclear
cell
pbmc
patient
activ
ciu
diseas
nonatop
healthi
control
rna
extract
pbmc
prepar
affymetrix
human
gene
plu
array
hybrid
raw
data
normal
gene
express
ciu
patient
compar
normal
control
result
found
gene
predict
ciu
normal
control
fdr
gene
predictor
differenti
express
p
minimum
differ
ciu
patient
control
predictor
success
distinguish
patient
ciu
control
test
use
leav
one
crossvalid
addit
found
upregul
gene
seen
ciu
strongli
correl
monocyt
identifi
cell
express
cell
surfac
marker
p
r
gene
set
enrich
analysi
ciu
patient
reveal
activ
specif
arm
mapkinas
pathway
util
monocyt
p
r
conclus
gene
express
profil
reliabl
distinguish
patient
ciu
healthi
control
studi
find
suggest
potenti
underli
mechan
ciu
find
may
provid
guidanc
develop
biomark
would
help
determin
subset
patient
would
like
respond
varieti
treatment
option
avail
background
primari
immunodefici
pid
well
known
indonesia
physician
consid
pid
difficult
diagnos
laboratori
equip
indonesia
complet
howev
use
simpl
laboratori
test
cbc
lot
data
retriev
use
clue
diagnos
pid
case
babi
girl
day
old
refer
neonatolog
unit
hospit
due
thrombocytopenia
mark
increas
ast
alt
receiv
ivig
day
previou
hospit
laboratori
test
show
percentag
lymphocyt
rang
retrospect
calcul
reveal
total
lymphocyt
count
rang
normal
valu
neutrophil
count
within
normal
limit
level
igm
igg
antibodi
rubella
increas
accompani
increas
level
igg
antibodi
toxoplasma
cmv
receiv
prc
tc
transfus
diagnos
rubella
infect
discharg
good
condit
day
treatment
hepat
b
bcg
vaccin
outpati
clinic
age
month
experienc
dyspnea
admit
picu
pneumonia
need
ventil
support
laboratori
test
show
lymphopenia
explor
found
increas
level
igm
normal
level
igg
iga
ige
also
decreas
level
hiv
pcr
neg
igm
cmv
posit
treat
gancyclovir
die
day
hospit
discuss
cbc
test
result
automat
includ
valu
total
lymphocyt
includ
percentag
lymphocyt
lymphocyt
percentag
alway
within
normal
limit
treat
physician
concern
low
valu
total
lymphocyt
reflect
low
level
andor
b
lymphocyt
unfortun
patient
underw
sever
infect
test
found
low
lymphocyt
level
increas
level
igm
opportun
explor
pid
especi
case
possibl
sever
combin
immun
defici
scid
first
hospit
newborn
period
awar
pid
patient
could
treat
prevent
possibl
sever
infect
conclus
simpl
test
cbc
need
interpret
detail
presenc
lymphopenia
neutropenia
indic
primari
immunodefici
background
childhood
asthma
control
test
cact
questionnair
measur
level
asthma
control
children
cact
commonli
known
easi
simpl
implement
indonesian
version
cact
wide
use
known
correl
clinic
paramet
sinc
physician
consid
linguist
barrier
use
aim
evalu
concord
indonesian
version
cact
spirometri
children
asthma
method
crosssect
studi
children
age
yearsold
asthma
sever
asthma
children
mental
problem
exclud
subject
consecut
recruit
lung
function
test
peak
flow
meter
twice
day
week
children
fulfil
cact
data
analyz
pearsonspearman
test
see
concord
spirometri
result
includ
subject
age
yearsold
major
subject
boy
good
nutrit
statu
parent
highli
educ
major
subject
show
uncontrol
asthma
cact
mean
sd
mean
variabl
signific
correl
indonesian
version
cact
r
weekli
variabl
conclus
indonesian
version
cact
show
signific
correl
variabl
pfr
replac
need
regular
spirometri
childhood
asthma
rational
asthma
disord
driven
interact
genet
environment
factor
aim
investig
interact
bronchiol
exposur
develop
asthma
longitudin
studi
method
studi
popul
deriv
prospect
followup
survey
children
health
environment
research
cheer
children
elementari
school
seven
citi
enrol
cheer
parent
particip
ask
respond
intern
studi
asthma
allergi
childhood
isaac
questionnair
evalu
presenc
allerg
diseas
risk
factor
genotyp
determin
taqman
assay
exposur
estim
krige
method
result
parent
histori
asthma
adjust
odd
ratio
aor
confid
interv
ci
bronchiol
histori
within
first
year
life
aor
ci
independ
risk
factor
physiciandiagnos
asthma
high
exposur
recent
year
signific
past
episod
bronchiol
high
exposur
combin
preval
asthma
significantli
increas
aor
ci
p
also
increas
risk
asthma
especi
children
gaaa
type
polymorph
aor
ci
p
new
asthma
diagnosi
followup
period
increas
higher
exposur
bronchiol
histori
aor
ci
pfor
interact
conclus
exposur
bronchiol
histori
synergist
increas
asthma
risk
new
develop
asthma
children
particularli
polymorph
find
suggest
bronchiol
earli
life
contribut
develop
asthma
especi
suscept
children
background
highaffin
ige
receptor
compos
play
import
role
igemedi
allerg
respons
report
suppress
stem
cell
factor
receptor
ckit
express
mast
cell
surfac
suppress
mast
cell
activ
induc
crosslink
howev
molecular
mechan
express
activ
suppress
remain
unclear
studi
found
express
et
homolog
factor
ehf
significantli
upregul
mous
bone
marrowderiv
mast
cell
bmmc
role
ehf
mast
cell
report
show
transcript
factor
ehf
contribut
induc
suppress
fceri
ckit
express
fcerimedi
activ
downregul
express
mast
cell
method
bmmc
gener
cultur
bone
marrow
cell
isol
balbc
mice
twoweek
cultur
bone
marrow
cell
cultur
bmmc
medium
presenc
scf
recombin
murin
without
recombin
human
twoweek
cultur
bone
marrow
cell
cultur
day
media
contain
transfect
retrovir
vector
lentivir
vector
encod
flagtag
mous
ehf
siehf
gene
mock
vector
result
suppress
express
transcript
factor
posit
regul
transcript
gene
encod
ckit
mous
bone
marrowderiv
mast
cell
bmmc
addit
express
et
homolog
factor
ehf
member
et
famili
transcript
factor
upregul
signal
bmmc
forc
express
ehf
repress
transcript
gene
encod
ckit
result
reduct
cell
surfac
express
ckit
furthermor
forc
express
ehf
suppress
degranul
product
mrna
level
lower
bmmc
stabli
express
ehf
compar
control
cell
conclus
suppress
ckit
express
suppress
activ
upregul
ehf
mast
cell
long
stand
use
marijuana
may
caus
acut
chronic
bronchiti
premalign
transform
bronchial
line
mucosa
excess
assembl
macrophag
diminish
efficaci
immun
effect
cell
product
inflammatori
cytokin
defens
mechan
princip
consequ
long
term
use
mja
protract
pulmonari
infect
neoplast
malform
pulmonari
infect
result
impair
mucociallari
clearanc
reduc
immunolog
function
macrophag
contamin
mja
product
mix
flora
pathogen
fungal
bacteri
microorgan
individu
aid
may
addit
suscept
pathogen
drastic
chang
regard
infecti
neoplast
malform
amongst
mja
along
tobacco
use
mja
use
alon
mja
contain
immunosuppress
tetrahydrocannabinolamin
thc
impair
immunolog
reactiv
tkiller
cell
macrophag
lymphocyt
product
immunoinhibitori
helper
cell
type
cytokin
presum
thc
work
impair
immunolog
efficaci
therebi
promot
host
invas
bacteri
pathogen
may
consequ
upon
recurr
pulmonari
infect
mja
user
result
short
term
use
mja
may
differ
outcom
long
term
use
conclus
activ
princip
deriv
mja
use
patient
aid
may
benefici
role
regard
appetit
improv
pain
relief
background
immun
respons
allerg
diseas
begin
allergen
sensit
develop
earli
infanc
allergen
sensit
involv
complex
interplay
genet
environment
factor
sensit
pattern
report
chang
age
object
followup
studi
aim
determin
risk
factor
allergen
sensit
year
gusto
grow
singapor
toward
healthi
outcom
birth
cohort
method
analyz
electron
databas
gusto
studi
cohort
follow
sinc
birth
interview
carri
inform
gather
includ
demograph
famili
histori
allergi
social
data
lifestyl
mother
administ
questionnair
obtain
inform
child
health
eight
hundr
fiftyeight
infant
complet
skin
prick
test
spt
allergen
inhal
allergen
hous
dust
mite
dermatophagoid
pteronyssinu
dermatophagoid
farina
blomia
tropicali
well
food
allergen
egg
peanut
cow
milk
month
analys
result
two
hundr
children
posit
spt
dust
mite
andor
food
allergen
month
one
hundr
nineti
four
subject
posit
spt
dust
mite
posit
spt
food
allergen
earli
onset
atop
dermat
month
adjust
odd
ratio
adjor
confid
interv
ci
p
onset
eczema
month
month
adjor
ci
posit
spt
month
adjor
ci
p
significantli
associ
posit
spt
month
conclus
conclus
found
earli
onset
atop
dermat
risk
factor
allergen
sensit
sensit
allergen
may
occur
cutan
rout
impair
skin
barrier
facilit
overlap
rheumatoid
arthriti
ra
system
lupu
erythematosu
sle
rare
clinic
condit
first
describ
rhupu
rhupu
rare
clinic
entiti
preval
main
differenti
diagnos
includ
ra
extraarticular
manifest
sle
rheumatoidlik
articular
lesion
mix
collagen
tissu
diseas
author
consid
rhupu
overlap
condit
polyarthr
sle
sinc
anticcp
antibodi
highli
specif
ra
anti
dna
sm
highli
specif
sle
coexist
rhupu
therefor
diagnosi
rhupu
base
combin
inflammatori
symmetr
eros
polyarthr
clinic
featur
sle
recognit
patient
import
sinc
therapi
outcom
differ
patient
ra
sle
alon
patient
whose
diseas
resist
depend
corticosteroid
methotrex
mtx
azathioprin
aza
use
steroidspar
secondlin
treatment
conflict
result
mtx
seem
effect
control
symptom
data
aza
remain
controversi
tnfblock
agent
infliximab
etanercept
shown
unabl
induc
maintain
diseas
remiss
could
play
import
role
pathogenesi
rhupu
inde
level
elev
activ
diseas
report
three
women
yearold
refractori
rhupu
diseas
durat
year
respect
high
risk
long
last
high
dose
cs
success
treat
humanis
receptor
antibodi
tocilizumab
given
monthli
dose
mgkg
chemotherapeut
drug
therapeut
irradi
demag
lung
anticanc
therapi
childhood
malign
present
investig
base
survey
author
found
pulmonari
function
abnorm
survivor
childhoood
cancer
treat
anticanc
therapi
purpos
present
studi
follow
childhood
cancer
survivor
detect
late
pulmonari
toxic
lung
function
test
perform
spirometri
survivor
particip
studi
felam
male
mean
age
year
time
second
followup
evalu
avarag
time
period
treatment
first
second
followup
evalu
year
respect
author
found
patient
patholog
pulmonari
function
test
result
time
first
followup
evalu
patient
obstruct
patient
mix
patient
restrict
abnorm
howev
patient
abnorm
pulmonari
function
time
second
followup
evalu
patient
obstruct
patient
restrict
pulmonari
function
test
restrict
pulmonari
disord
detect
small
part
treat
patient
obstruct
pulmonari
abnorm
caus
treatment
show
improv
tendenc
time
background
know
individu
natur
exposur
hdm
still
challeng
task
approach
solv
issu
valid
suitabl
person
particl
sampler
origin
design
sampl
pollen
fungal
spore
collect
hdm
materi
natur
appear
quantifi
aeroallergen
materi
method
person
particl
sampler
wearabl
devic
sampl
ambient
air
guid
air
adhes
stripe
particl
deposit
stripe
contain
exchang
cartridg
exposur
stripe
remov
analyz
microscop
biochem
two
properti
person
particl
sampler
examin
correl
sampl
hdm
allergen
concentr
allergen
ambient
air
maximum
particl
size
hdm
materi
could
sampl
analyz
correl
sever
particl
sampler
place
exposur
chamber
abl
gener
defin
constant
hdm
particl
concentr
dedic
period
time
use
grind
hdm
materi
less
sampl
materi
analyz
use
standard
antigen
test
der
der
analyz
maximum
detect
particl
size
differ
grain
size
use
trickl
test
use
full
hdm
bodi
reason
limit
particl
adher
stripe
verifi
microscop
result
environment
chamber
test
proport
relat
ambient
hdm
materi
concentr
allergen
content
sampl
proven
proport
relat
signific
consid
varianc
allergen
concentr
due
dispers
system
well
accuraci
allergen
analysi
maximum
particl
size
test
even
whole
hdm
bodi
could
sampl
thu
stuck
stripe
conclus
person
particl
sampler
suitabl
determin
individu
exposur
hdm
materi
howev
still
proven
concentr
measur
person
particl
sampler
correl
allergen
person
recogn
symptom
real
life
introduct
sever
atop
dermat
ad
seen
case
may
present
rare
uncommon
complic
poor
weight
gain
malnutrit
trace
element
includ
zinc
defici
publish
case
report
larg
studi
particularli
children
object
determin
frequenc
sever
zinc
defici
ad
children
find
associ
zinc
level
ad
sever
bodi
mass
index
method
retrospect
case
control
studi
review
record
children
year
seen
ped
allergyimmunolog
clinic
hamad
gener
hospit
jun
sever
ad
zinc
level
test
addit
demograph
data
lab
test
cbc
differenti
ige
serum
zinc
vitamin
food
allergen
test
spt
specif
ige
scorad
weight
height
collect
result
children
children
found
serum
zinclow
zl
casecontrol
group
agematch
normalzinc
zn
ad
children
group
similar
age
vs
month
sex
coexist
allergi
vs
posit
food
allergen
per
patient
vs
type
food
allergen
zl
higher
posit
famili
histori
allergi
vs
parent
consanguin
vs
zn
besid
zl
higher
wbc
vs
cellsul
peripher
blood
eosinophil
vs
cellsul
ige
vs
kul
lower
serum
zinc
vs
umol
level
lower
bmi
group
similar
scorad
vs
signific
associ
zinc
level
bmi
scorad
compar
control
group
conclus
zinc
defici
quit
common
among
children
sever
ad
seem
posit
famili
histori
parent
consanguin
risk
factor
ad
zinc
defici
children
elev
allerg
inflammatori
maker
irrespect
ad
sever
background
associ
hlab
sever
cutan
advers
drug
reaction
scar
consist
steven
johnson
syndrom
sj
toxic
epiderm
necrolysi
ten
hypersensit
syndrom
hss
drug
rash
eosinophilia
system
symptom
dress
strongli
report
differ
ethnic
popul
strongest
associ
describ
taiwanes
studi
found
patient
allopurinol
induc
scar
ci
vietnam
howev
allel
yet
confirm
reveal
relev
pharmacogenet
risk
factor
situat
allopurinol
induc
scar
preval
high
therefor
studi
sought
determin
associ
hlab
allopurinol
induc
scar
larg
teach
center
allergi
clinic
immunolog
bach
mai
hospit
methodolog
twenti
two
case
scar
caus
allopurinol
confirm
use
establish
criteria
recruit
genom
dna
extract
whole
peripher
blood
edta
use
qiagen
kit
instruct
supplier
polymeras
chain
reaction
use
sequenc
specif
primer
use
detect
hlab
genotyp
amplifi
product
determin
use
agaros
gel
electrophoresi
random
sampl
posit
sampl
valid
use
direct
dna
sequenc
compar
result
methodolog
agreement
found
result
total
patient
compris
sjsten
overlap
hssdress
genotyp
individu
patient
posit
hlab
conclus
result
suggest
strong
associ
hlab
allopurinol
induc
scar
vietnames
find
first
describ
vietnames
popul
consid
hlab
present
gener
vietnames
popul
studi
show
signific
risk
someon
carri
hlab
allel
suffer
drug
induc
scar
treat
allopurinol
individu
suffer
scar
also
burden
health
system
thu
need
address
futur
studi
perform
larger
sampl
individu
follow
casecontrol
studi
glatiram
acet
ga
gener
safe
effect
well
toler
drug
discontinu
treatment
may
requir
case
due
sever
system
postinject
reaction
notabl
spars
data
desensit
protocol
patient
hypersensit
ga
present
case
success
desensit
glatiram
acet
ga
femal
ms
treat
ga
last
four
year
without
advers
reaction
suddenli
ga
inject
develop
gener
urticaria
skin
prick
spt
intraderm
id
test
ga
mannitol
inact
ingredi
copaxon
allergen
potenti
perform
histamin
nacl
use
posit
neg
control
spt
show
borderlin
reaction
ga
wheal
concentr
posit
reaction
shown
intraderm
skin
test
concentr
spt
id
test
mannitol
neg
procedur
desensit
ga
carri
outpati
set
close
medic
supervis
increas
dosag
ga
administ
subcutan
everi
minut
start
dose
follow
gradual
dose
escal
entir
desensit
procedur
last
hour
minut
desensit
procedur
well
toler
advers
event
patient
abl
resum
ga
treatment
recurr
follow
period
month
year
old
femal
treat
ms
ga
month
without
advers
reaction
last
inject
immedi
administr
copaxon
experienc
life
threaten
anaphylaxi
urticaria
angioedema
abdomin
cramp
dyspnea
drop
blood
pressur
loss
conscious
patient
refer
depart
evalu
allergi
test
alreadi
describ
procedur
reveal
posit
id
test
use
exactli
protocol
desensit
inpati
basi
process
experienc
anaphylact
reaction
success
treat
day
patient
abl
toler
ga
patient
receiv
ga
daili
month
without
advers
event
case
illustr
rapid
subcutan
desensit
may
allow
continu
ga
treatment
patient
histori
system
reaction
background
asthma
exacerb
ae
caus
varieti
reason
includ
unrecogn
diseas
undertr
unrespons
convent
therapi
asthma
recent
exposur
trigger
like
virus
usual
rhinoviru
allergen
ae
defin
worsen
asthma
suffici
requir
medic
intervent
usual
administr
oral
steroid
reflect
object
fall
pef
studi
perform
investig
epidem
exacerb
mite
monosensit
asthmat
season
variabl
ae
patient
could
use
tool
conveni
prevent
manag
non
atop
asthmat
patient
use
control
group
way
could
understand
import
trigger
allergen
compar
viru
method
studi
ae
patient
suffer
two
differ
phenotyp
asthma
season
variat
ae
phenotyp
separ
consequ
comparison
evalu
appli
null
hypothesi
null
hypothesi
differ
number
ae
occur
month
year
result
mite
monosensit
patient
montha
number
jan
feb
mar
apr
may
jun
jul
aug
sep
oct
nov
dec
appli
df
obtain
pvalu
therefor
null
hypothesi
accept
statist
signific
differ
number
ae
occur
year
higher
spring
autumn
month
non
atop
patient
montha
jan
feb
mar
apr
may
jun
jul
aug
sep
oct
nov
dec
appli
df
obtain
pvalu
therefor
null
hypothesi
accept
statist
signific
differ
number
ae
occur
year
higher
spring
winter
month
comparison
time
distribut
reveal
signific
differ
pvalu
conclus
result
show
greec
year
ae
season
variabl
non
atop
mite
monosensit
asthmat
differ
result
indic
atop
react
virus
differ
way
compar
non
atop
introduct
larg
number
farmer
work
paddi
field
around
world
suffer
asthma
allergi
system
mycosi
howev
appear
adequ
inform
fungal
aerosol
paddi
field
north
allergin
effect
farmer
larg
lack
aim
studi
assess
concentr
major
airborn
pathogen
fungal
spore
paddi
field
object
identifi
fungal
allergen
caus
respiratori
allergi
among
farmer
immuneclin
techniqu
method
volumetr
assess
airborn
cultur
noncultur
fungal
spore
perform
experiment
site
north
pargana
west
bengal
india
consecut
year
novemb
use
andersen
two
stage
volumetr
sampler
burkard
person
slide
sampler
trap
cultur
noncultur
type
fungal
spore
cultur
fungal
spore
subcultur
medium
isol
identifi
individu
speci
fungal
antigen
prepar
preval
cultur
type
select
fungal
spore
ycell
lysi
reagent
buffer
allergen
potenti
antigen
evalu
atop
farmer
spt
vivo
follow
elisa
igespecif
immunoblot
vitro
antigen
resolv
sd
page
igereact
allergen
identifi
western
immunoblot
result
total
type
fungal
spore
type
viabl
colonyform
fungal
spore
record
major
perenni
cultur
fungal
spore
type
includ
aspergilli
group
fusarium
oxysporum
cladosporium
cladosporioid
nigrospora
oryza
helminthosporium
oryza
alternaria
alternata
drechslera
sp
etc
show
higher
sensit
spt
among
fungal
spore
aspergilli
group
anig
fumigatu
flavu
clavatu
penicillium
claviform
show
highest
reactiv
follow
fusarium
oxysporum
helminthosporium
oryza
alternaria
altern
cladosporium
cladosporioid
nigrospora
sp
spt
carri
adult
agricultur
field
worker
respiratori
disord
total
fungal
protein
anig
fumigatu
flavu
clavatu
penicillium
claviform
fusarium
oxysporum
helminthosporium
oryza
alternaria
altern
cladosporium
cladosporioid
nigrospora
sp
resolv
distinct
band
respect
sd
page
immunoblot
ige
reactiv
allergen
identifi
respect
conclus
airborn
fungal
spore
caus
pathogen
infect
rice
plant
also
caus
respiratori
allergi
among
paddi
field
farmer
western
immunoblot
reveal
major
ige
reactiv
fungal
allergen
find
indic
occup
allergi
fungal
spore
import
health
hazard
among
farmer
west
bengal
titl
studi
efficaci
sublingu
immunotherapi
slit
case
sever
persist
allerg
rhiniti
purpos
ass
efficaci
sublingu
immunotherapi
slit
treatment
sever
persist
allerg
rhiniti
age
group
year
year
either
sex
materi
method
patient
sever
persist
allerg
rhiniti
includ
ass
efficaci
sublingu
immunotherapi
slit
patient
regular
treatment
month
symptom
score
record
regular
interv
beign
slit
complet
mainten
vial
ie
vial
everi
next
mainten
vial
patient
follow
done
time
sublingu
immunotherapi
slit
regular
interv
rescu
medic
exacerb
symptom
pollen
season
also
taken
account
number
aeroallergen
includ
rang
averag
allergensglycerin
aqueou
allergen
extract
variou
allergen
taken
per
sensit
patterndiffer
allergen
extract
suspend
extract
fluid
coca
solut
contain
glycerin
ip
accord
wv
ratio
usual
concentr
initi
build
maintain
result
studi
result
encourag
symptom
score
scale
symptom
mild
moder
sever
patient
sever
symptom
start
sublingu
immunotherapi
complet
month
sublingu
immunotherapi
patient
patient
score
patient
score
patient
score
number
rescu
medic
along
slit
remark
reduc
even
pollen
season
conclus
sublingu
immunotherapi
show
promis
result
case
chronic
allerg
rhiniti
background
mesenchym
stem
cell
msc
came
attract
wide
attent
becom
one
hotspot
diseas
research
decad
present
mechan
msc
work
chronic
asthma
remain
undefin
studi
aim
verifi
whether
msc
play
role
prevent
inflamm
airway
remodel
via
signal
pathway
chronic
asthma
rat
model
method
first
ovalbumin
ova
induc
asthma
model
built
msc
administ
ovalbumininduc
asthma
rat
total
cell
bronchial
alveolar
lavag
fluid
balf
inflammatori
mediat
balf
serum
measur
histolog
examin
lung
tissu
perform
estim
patholog
chang
addit
express
phosphorylatedakt
pakt
group
measur
western
blot
immunohistochemistri
ihc
result
compar
normal
control
group
degre
airway
inflamm
airway
remodel
significantli
increas
asthma
group
contrari
obvious
inhibit
msc
transplant
group
moreov
express
pakt
increas
lung
tissu
asthmat
rat
suppress
msc
transplant
conclus
result
demonstr
msc
transplant
could
suppress
lung
inflamm
airway
remodel
via
signal
pathway
rat
asthma
model
background
allerg
diseas
asthma
atop
dermat
allerg
rhiniti
remark
increas
caus
mainli
allergen
dust
mite
pollen
pet
dander
measur
prevent
control
allerg
diseas
import
measur
allergen
environ
object
establish
highli
sensit
enzymelink
immunosorb
assay
elisa
quantifi
specif
dermatophagoid
mite
allergen
der
p
der
f
der
japanes
cedar
pollen
allergen
cri
j
cri
j
cat
allergen
fel
method
allergen
sampl
incub
well
coat
primari
antibodi
hour
wash
biotinyl
secondari
antibodi
allergen
incub
hour
allergen
detect
use
hrpconjug
streptavidin
substrat
nm
result
work
rang
pgml
der
p
der
f
pgml
der
pgml
cri
j
pgml
cri
j
pgml
fel
system
intra
interassay
coeffici
variat
less
furthermor
assay
show
signific
crossreact
allergen
conclus
establish
elisa
system
allergen
use
qualif
allergen
environ
also
qualiti
control
allergen
product
sublingu
immunotherapi
evalu
allergen
inactiv
effect
industri
product
background
object
yoga
medit
proven
altern
drug
free
treatment
smoke
cessat
allerg
rhiniti
common
seriou
impact
qualiti
life
tobacco
smoker
scientif
studi
done
assess
effect
yoga
airway
resist
tobacco
smoker
main
object
studi
see
yoga
improv
airway
resist
henc
improv
qualiti
life
tobacco
smoker
methodolog
smoker
allerg
rhiniti
chosen
studi
underw
ent
examin
subject
taught
specif
yogasana
ask
practic
period
month
reduc
number
cigarett
object
analysi
subject
analysi
done
yoga
train
month
yoga
practic
object
analysi
upper
airway
resist
measur
use
rhinomanomet
lower
airway
resist
measur
use
spiromet
qualiti
life
analysi
done
use
short
form
health
survey
questionnair
sino
nasal
outcom
test
snot
questionnair
result
data
analyz
pair
test
use
spss
softwar
packag
social
scienc
version
mean
standard
deviat
nasal
airway
resist
found
yoga
pa
pressur
yoga
p
valu
mean
standard
deviat
yoga
yoga
p
valu
qualiti
life
questionnair
show
highli
signific
improv
physic
p
mental
p
composit
score
signific
reduct
snot
score
p
practic
yoga
conclus
result
indic
improv
nasal
airway
resist
practic
yoga
qualiti
life
improv
understood
help
snot
questionnair
healthi
disciplin
yoga
lifestyl
modif
also
help
smoker
decreas
number
cigarett
lead
better
life
titl
studi
incid
sever
persist
allerg
rhiniti
differ
age
group
sex
preval
type
allergen
aeroallergen
food
allergen
respons
sever
persist
allerg
rhiniti
central
india
purpos
know
age
group
sex
maximum
affect
sever
persist
allerg
rhiniti
type
allergen
respons
sever
persist
allerg
rhiniti
materi
method
patient
sever
persist
allerg
rhiniti
differ
age
group
either
sex
rang
year
year
taken
detail
histori
clinic
examin
ent
routin
blood
count
absolut
eosionophil
count
total
serum
ige
estim
patient
antihistamin
minimum
seven
day
allergi
test
modifi
skin
prick
test
method
perform
upper
limb
palmer
aspect
forearm
glycerin
histamin
acid
phosphat
posit
control
glycerin
buffer
salin
neg
control
use
patient
test
allergen
wheal
flare
respons
record
result
studi
patient
either
sex
follow
observ
incid
sever
persist
allerg
rhiniti
differ
age
group
follow
year
patient
year
patient
year
patient
year
patient
year
patient
year
patient
year
patient
previl
sever
persist
allerg
rhiniti
differ
sex
group
follow
male
patient
femal
patient
type
allergen
respons
sever
persist
allerg
rhiniti
follow
differ
aero
allergen
differ
food
allergen
conclus
central
india
incid
sever
persist
allergicrhin
maximum
age
group
year
male
affect
femal
ratio
aeroallergen
mainli
respons
caus
factor
sever
persist
allerg
rhiniti
titl
caus
allergen
case
sever
persist
allerg
rhiniti
central
india
purpos
know
allergen
pattern
central
india
case
sever
persist
allerg
rhiniti
year
materi
method
patient
sever
persist
allerg
rhiniti
age
group
year
age
either
sex
taken
studi
allergen
pattern
modifi
prick
test
detail
histori
clinic
examin
ent
routin
blood
count
absolut
eosionophil
count
serum
ige
estim
patient
antihistamin
minimum
seven
day
allergi
test
modifi
prick
method
perform
upper
limb
palmer
aspect
forearm
glycerin
histamin
acid
phosphat
posit
control
glycerin
buffer
salin
neg
control
use
patient
test
allergen
wheal
flare
respons
record
result
studi
patient
follow
percentag
differ
allergen
posit
group
hous
dust
mite
farina
pollen
prosopi
juliflora
fungu
aspergillu
flavu
insect
cockroach
femal
dust
grain
dust
rice
dander
human
dander
fabric
silk
food
milk
miscellan
parthenium
leav
conclus
studi
gave
us
common
allergen
pattern
central
part
india
case
sever
persist
allerg
rhiniti
pollen
insect
food
dust
mostli
respons
chronic
allerg
rhiniti
background
object
pruritu
itch
defin
cutan
sensat
provok
desir
scratch
pruritu
one
major
symptom
atop
dermat
ad
great
interest
mechan
itch
neuron
pathway
investig
use
differ
approach
still
yet
fulli
understood
aim
studi
achiev
new
data
mechan
chronic
pruritu
mean
innov
neurophysiolog
method
itch
research
method
shortlat
longlat
painrel
somatosensori
electr
evok
potenti
sep
well
longlat
evok
potenti
thermal
stimul
innov
contact
heat
evok
potenti
stimul
chep
studi
adpati
healthi
volunt
quantit
sensori
test
qst
thermal
percept
threshold
perform
adpati
healthi
volunt
result
ad
patient
show
lower
motor
pain
threshold
electr
stimul
sep
record
compar
healthi
individu
brain
hyperact
electr
stimuli
delay
thermal
evok
potenti
elev
cold
warm
coldinduc
pain
threshold
reveal
adgroup
compar
healthi
control
conclus
data
indic
small
nerv
fiber
dysfunct
adpati
may
contribut
pathogenesi
ad
chronic
itch
dysfunct
may
determin
predisposit
atop
dermat
sever
pruritu
tendenc
chronic
cours
although
evalu
requir
overal
neurophysiolog
data
provid
evid
alter
central
respons
affer
input
adpati
suffer
chronic
itch
studi
demonstr
object
approach
assess
function
small
nerv
fiber
patient
chronic
pruritu
object
test
efficaci
safeti
novel
oral
immunotherapi
oit
protocol
peanut
allergi
method
studi
concern
forti
peanutallerg
children
mean
age
year
oral
allergen
prepar
administ
serial
rise
titer
dose
weekli
mg
peanut
protein
mainten
week
result
children
posit
challeng
total
toler
rise
concentr
titer
total
drop
total
toler
rise
concentr
allergen
materi
contain
mg
toler
higher
dose
mainten
mg
proteinday
two
sever
degre
allergen
reaction
mandat
administr
adrenalin
wherea
rest
mild
allerg
reaction
subsid
without
resort
adrenalin
solut
twelv
preimmunotherapi
peanut
ige
kul
requir
dose
adjust
compar
preimmunotherapi
peanut
ige
level
almost
kul
eighteen
mandat
slight
dose
reduct
reaction
possibl
link
factor
exert
infect
fatigu
abil
howev
week
individu
reaction
g
protein
challeng
conclus
studi
serial
dilut
dose
increment
follow
better
outcom
former
trial
higher
fold
amount
peanut
toler
excel
safeti
profil
except
case
seriou
advers
effect
observ
rest
individu
background
proactiv
treatment
atop
dermat
ad
intermitt
applic
antiinflammatori
agent
induct
remiss
recommend
mainten
therapi
longterm
manag
ad
previou
studi
examin
effect
twiceweekli
applic
topic
corticosteroid
tc
hospit
remiss
achiev
dosag
attempt
reduc
frequenc
aim
ceas
usag
tc
object
investig
prognosi
topic
corticosteroid
usag
one
year
proactiv
treatment
children
moderatetosever
ad
method
retrospect
chart
review
conduct
patient
year
age
moderatetosever
ad
scorad
hospit
first
remiss
induct
nation
center
child
health
develop
tokyo
japan
januari
april
frequenc
tc
applic
one
year
admiss
togeth
level
serum
thymu
activationregul
chemokin
tarc
assess
result
seventytwo
patient
met
inclus
criteria
analyz
median
age
month
old
rang
month
admiss
baselin
median
scorad
iqr
patient
went
remiss
within
month
induct
treatment
hospit
proactiv
treatment
remiss
patient
use
hydrocortison
butyr
face
betamethason
valer
bodi
followup
visit
month
admiss
patient
maintain
remiss
face
less
twiceweekli
applic
tc
less
onceweekli
emolli
topic
tacrolimu
twentynin
patient
maintain
good
condit
bodi
less
twiceweekli
tc
applic
less
weekli
emolli
eleven
patient
need
tc
three
four
time
week
due
minor
recurr
proactiv
treatment
median
level
serum
tarc
pgml
admiss
decreas
pgml
month
conclus
proactiv
treatment
moderateto
sever
ad
result
favor
long
termprognosi
oneyear
remiss
twiceweekli
less
applic
tc
allergi
symptom
infant
preliminari
studi
first
two
month
life
abstract
background
object
preval
atop
diseas
rise
sinc
latter
part
genet
environment
factor
determin
dysregul
develop
atop
diseas
first
atop
diseas
manifest
eczema
usual
commenc
earli
infanc
children
atop
dermat
like
develop
respiratori
symptom
year
age
progress
atop
diseas
term
atop
march
perform
databas
show
profil
allergi
symptom
infant
first
two
month
life
method
studi
incid
allergi
symptomp
prospect
birth
cohort
total
infant
follow
two
month
atop
diseas
parent
sibl
record
birth
allergi
symptom
atop
dermat
wheez
gastrointesti
symptomp
record
result
common
initi
symptom
occur
earli
infant
atop
dermat
famili
histori
atop
diseas
atop
dermat
occur
infant
histori
atopi
singl
doubl
parent
atop
histori
respect
infant
atop
dermat
born
section
caesarean
incid
atop
dermat
exclus
breastfeed
infant
wheez
gastrointestin
symptom
detect
studi
conclus
atop
dermat
first
clinic
manifest
allergi
highest
incid
first
two
month
life
keyword
allergi
symptom
atop
dermat
infant
introduct
studi
investig
ar
allerg
rhiniti
affect
factor
korea
sampl
region
ar
one
respiratori
diseas
close
connect
health
korean
peopl
among
diseas
top
rank
outpati
hospit
visit
diseas
relat
respiratori
diseas
korea
method
target
area
seongdong
one
district
seoul
korea
depend
variabl
arv
ar
outpati
hospit
visit
code
independ
variabl
meteorolog
variabl
tm
tavr
tm
prcp
precipit
humid
rh
dtr
diurnal
temp
rang
wv
wind
veloc
pollen
data
poll
count
sum
grass
ragwe
wormwood
japhop
alder
birch
hazelnut
oak
statist
research
includ
factor
analysi
correl
analysi
time
seri
analysi
autocorrel
independ
ttest
perform
result
arv
seongdong
repres
seoul
korea
p
respect
factor
tm
tavr
rh
prove
main
affect
factor
corr
analysi
factor
analysi
rest
variabl
make
main
group
tm
prcp
dtr
poll
wv
bartlett
p
time
seri
analysi
autocorrel
show
variabl
arv
highest
autocorrel
coeffici
everi
p
respect
ar
increas
ar
decreas
year
increas
febapr
decreas
aprjul
increas
julnov
decreas
novfeb
next
year
independ
ttest
top
bottom
arv
period
affect
factor
reveal
follow
increas
dtr
tm
wv
decreas
dtr
tm
prcp
wv
increas
tm
prcp
decreas
tm
wv
rang
main
affect
variabl
year
ar
increas
ar
zvalu
b
follow
tm
b
prcp
b
dtr
b
poll
b
wv
b
show
arv
occur
tm
prcp
summari
seongdong
repres
seoul
korea
p
ar
increas
ar
decreas
year
affect
factor
arv
year
round
tm
prcp
aprnov
wv
novapr
significantli
notic
tmand
prcp
rang
arv
occur
acknowledg
kcdc
ar
db
nhic
meteorolog
db
kma
pollen
db
advanc
research
appli
meteorolog
nation
institut
meteorolog
research
rational
background
allerg
diseas
increas
lao
children
recent
year
lao
pdr
studi
conduct
studi
allerg
risk
develop
allerg
diseas
children
methodolog
use
questionnair
main
symptom
asthma
cow
milk
allergi
allerg
rhiniti
atop
dermat
secondari
symptom
urticaria
drug
allergi
food
allergi
allerg
conjunct
data
collect
parent
famili
member
patient
score
system
main
secondari
symptom
design
score
greater
place
high
risk
categori
develop
allerg
diseas
survey
conduct
januari
may
result
patient
year
age
younger
patient
male
famili
member
patient
main
symptom
allerg
rhiniti
asthma
atop
dermat
cow
milk
allergi
highest
percentag
secondari
symptom
urticaria
drug
allergi
food
allergi
allerg
conjunct
survey
result
indic
patient
score
greater
place
high
risk
categori
remain
score
less
conclus
highest
main
symptom
patient
famili
member
allerg
rhiniti
highest
secondari
symptom
urticaria
allerg
risk
develop
allerg
diseas
lao
children
survey
background
child
asthma
usual
also
anoth
event
food
allergi
aeroinhal
allergi
allerg
rhiniti
atop
dermat
acut
upper
respiratori
tract
infect
urti
unfortun
lack
evid
support
correl
factor
sever
asthma
indonesian
children
aim
studi
find
correl
food
allergi
aeroinhal
allergi
allerg
rhiniti
atop
dermat
acut
upper
respiratori
tract
infect
urti
sever
asthma
pediatr
medicin
depart
saiful
anwar
hospit
indonesia
method
cross
section
studi
done
children
diagnos
asthma
came
pediatr
outpati
clinic
saiful
anwar
hospit
malang
sinc
classif
asthma
sever
children
base
gina
criteria
intermitten
mild
persist
moder
sever
persist
food
allergi
aeroinhal
allergi
base
histori
allergi
posit
result
skin
prick
test
diagnosi
allerg
rhiniti
base
aira
criteria
diagnosi
atop
dermat
base
histori
take
clinic
find
mann
whitney
analysi
use
find
correl
risk
factor
sever
asthma
result
particip
proport
boy
girl
risk
factor
highest
percentag
aeroinhal
allergi
food
allergi
respect
risk
factor
signific
correl
sever
asthma
p
conclus
risk
factor
signific
correl
sever
asthma
pediatr
medicin
depart
saiful
anwar
hospit
indonesia
howev
event
aeroinhal
allergi
food
allergi
high
pediatr
asthma
need
great
concern
anoth
research
need
explor
correl
risk
factor
compon
asthma
sever
asthma
attack
background
airborn
pollen
major
caus
allerg
diseas
pollinosi
recent
sensit
rate
pollen
continu
increas
korea
allergen
pollen
korea
identifi
speci
oak
known
strong
allergen
crossreact
also
report
birth
alder
although
pine
pollen
known
weak
allergen
skin
sensibl
pine
pollen
get
increas
south
korea
recent
region
season
specif
pollen
data
essenti
allerg
patient
provid
fundament
airborn
pollen
data
present
annual
variat
pollen
distribut
concentr
spring
korea
last
four
year
method
collect
airborn
pollen
repres
site
korea
use
daysburkard
sampler
februari
may
seoul
guri
daejeon
daegu
busan
gangneung
jeonju
gwangju
jeju
airborn
pollen
grain
count
identifi
use
light
microscop
x
x
stain
calberla
fuchsin
dye
result
pollen
distribut
pattern
similar
nationwid
howev
calendar
distribut
pollen
differ
inland
jeju
island
pine
oak
ginkgo
tree
frequent
airborn
pollen
korea
highest
rate
pine
pollen
except
jeju
island
japanes
cedar
restrict
jeju
southern
area
korea
kwangju
busan
also
common
pollen
jeju
island
spring
interestingli
pine
pollen
continu
decreas
jeju
could
relat
outbreak
pine
wilt
diseas
background
number
oak
ginkgo
increas
annual
pine
still
common
pollen
south
korea
far
otherwis
noteworthi
concentr
ginkgo
pollen
continu
increas
site
western
area
seoul
jeonju
busan
daejeon
gwangju
jeju
high
rate
ginkgo
pollen
could
relat
urban
actual
street
tree
ginkgo
seoul
ginkgo
pollen
number
western
pollen
station
seoul
show
drastic
increas
year
year
meanwhil
area
show
oak
pollen
increas
second
highest
rate
conclus
result
show
concentr
pollen
could
affect
variou
factor
like
veget
structur
kind
street
tree
endem
tree
diseas
artifici
interfer
studi
may
suggest
tree
physiolog
circadian
chang
trior
biannual
citi
administr
offici
decid
oak
ginkgo
street
tree
leav
oak
gingko
may
intercept
chasmogami
breed
monitor
airborn
pollen
common
grow
speci
tree
like
pine
oak
ginkgo
especi
essenti
demontr
relationship
allerg
sensit
rate
concentr
pollen
korea
background
current
consensu
optim
treatment
eosinophil
esophag
eoe
one
option
elimin
diet
guid
allergi
test
result
shown
effect
vari
degre
greater
efficaci
pediatr
cohort
howev
result
adult
less
promis
higher
rate
neg
allergi
test
hinder
effort
guid
diet
studi
explor
result
allergytest
direct
elimin
diet
group
patient
n
treat
allergi
immunolog
clinic
london
ontario
method
retrospect
chart
review
perform
use
databas
patient
diagnos
eoe
histolog
eohpf
esophag
biopsi
treat
allergi
immunolog
clinic
st
joseph
hospit
london
patient
includ
review
prescrib
elimin
diet
guid
allergi
test
skinprick
test
spt
andor
atopi
patch
test
apt
esophag
biopsi
taken
week
initi
diet
pretreat
eosinophil
count
record
peak
eosinophil
count
recent
biopsi
prior
initi
elimin
diet
result
averag
age
subject
diet
initi
year
averag
subject
elimin
food
diet
postdiet
biopsi
display
significantli
lower
level
peak
eosinophilshpf
compar
prediet
biopsi
averag
vs
p
three
patient
postdiet
biopsi
histolog
threshold
diagnosi
eoe
eohpf
conclus
chart
review
show
patient
undergo
elimin
diet
direct
allergi
test
signific
histolog
improv
diet
must
note
review
control
effect
confound
treatment
ppi
corticosteroid
latter
greater
concern
histolog
result
half
subject
examin
time
postdiet
biopsi
prescrib
swallow
corticosteroid
eoe
howev
steroidprescrib
subject
report
use
steroid
period
immedi
prior
postdiet
biopsi
refer
spergel
jm
brownwhitehorn
tf
cianferoni
shuker
wang
ml
verma
r
liacoura
ca
identif
caus
food
children
eosinophil
esophag
treat
elimin
dietth
journal
allergi
clinic
immunolog
vernon
n
shah
lehman
e
ghaffari
g
comparison
atop
featur
children
adult
eosinophil
esophagitisallergi
asthma
proceed
offici
journal
region
state
allergi
societi
background
numer
food
specif
ige
sige
cutoff
valu
probabl
curv
ofc
outcom
report
use
immunocap
cap
assay
wherea
limit
studi
avail
use
sige
assay
extend
measur
rang
order
establish
interpret
criteria
prospect
analyz
relationship
egg
ofc
outcom
sige
valu
use
cap
two
specif
need
diagnosi
egg
allergi
infant
never
eaten
egg
document
egg
sensit
group
diagnosi
toler
egg
preschool
children
elimin
egg
due
confirm
egg
allergi
group
b
method
multicent
prospect
observ
studi
perform
children
enrol
compris
group
n
year
old
b
n
year
old
ofc
perform
cook
egg
powder
particip
raw
egg
powder
patient
pass
initi
cook
egg
challeng
sige
valu
egg
white
ew
ovomucoid
om
measur
cap
relationship
sige
ofc
outcom
analyz
use
roc
logist
regress
analys
fit
predict
probabl
curv
pc
plot
use
logist
regress
result
children
pass
cook
egg
challeng
subset
pass
challeng
children
given
raw
egg
challeng
children
pass
challeng
two
sige
test
cook
egg
challeng
group
show
similar
perform
area
curv
auc
group
group
b
om
sige
cap
respect
howev
show
higher
cutoff
valu
cap
iual
ual
group
iual
ual
group
b
respect
pc
ew
om
sige
show
wider
distribut
data
across
xaxi
sige
valu
yaxi
probabl
comparison
cap
raw
egg
challeng
group
ew
sige
test
show
similar
perform
auc
group
group
b
cap
respect
howev
pc
raw
egg
challeng
show
significantli
larger
confid
interv
cook
egg
challeng
conclus
overal
result
demonstr
similar
slightli
better
perform
cap
predict
ofc
outcom
background
infect
ascari
lumbricoid
may
induc
high
level
ige
favour
develop
clinic
allergi
report
case
child
atop
dermat
asthma
cure
antihelminth
therapi
mebendazol
method
patient
old
femal
suffer
age
two
month
atop
dermat
age
month
asthma
skin
respiratori
symptom
perenni
worsen
spring
autumn
allergi
test
perform
age
month
gave
posit
result
dermatophagoid
pteronyssinu
prick
test
specif
ige
kul
farina
prick
test
specif
ige
kul
also
tomato
hen
egg
cow
milk
posit
prick
test
total
ige
kul
mild
eosinophilia
detect
peripher
blood
follow
environment
measur
control
hous
dust
mite
elimin
tomato
egg
milk
diet
improv
asthma
atop
dermat
year
age
valu
total
ige
kul
year
age
worsen
dermat
modest
respons
topic
corticosteroid
asthma
longer
present
prick
test
confirm
posit
result
dermatophagoid
tomato
cow
milk
worsen
atop
dermat
occur
year
age
treat
oral
bethametason
topic
picrolimu
septemb
patient
refer
unit
found
peripher
eosinophilia
suspect
parasit
infect
evalu
specif
ige
ascari
valu
kul
total
ige
kul
anthelmint
therapi
prescrib
use
mebendazol
mg
tablet
bid
three
day
repeat
day
result
one
month
first
two
cycl
therapi
patient
show
progress
improv
symptom
eosinophilia
six
month
end
therapi
skin
free
dermat
decreas
observ
eosinophilia
ascarisspecif
ige
kul
conclus
case
show
role
infect
ascari
lumbricoid
patient
longlast
dermat
overlook
fact
adequ
antihelminth
treatment
may
result
complet
recoveri
diseas
background
bronchial
asthma
respiratori
allerg
diseas
preval
saudi
arabia
middleeast
publish
data
indic
diseas
rise
investig
extrins
intrins
factor
caus
diseas
undertaken
differ
place
kingdom
saudi
arabia
howev
studi
presenc
indoor
allergen
clinic
relev
still
lack
clear
understand
region
method
hous
dust
sampl
collect
steril
alk
filter
alk
laboratori
denmark
analyz
variou
indoor
allergen
factor
includ
der
p
der
f
bla
g
per
fel
use
antibodi
elisa
techniqu
indoor
allergen
fungal
flora
also
examin
collect
sampl
cultur
use
dilut
plate
techniqu
sampl
collect
individu
vacuum
cleaner
oper
respect
home
carpet
mattress
sampl
extract
individu
allergen
quantit
use
specif
antibodi
indoor
biotechnolog
usa
alk
laboratori
denmark
elisa
procedur
select
locat
skin
prick
test
conduct
allerg
patient
variou
indoor
allergen
use
commerci
indigen
speci
result
data
two
hous
dust
mite
dermatophagoid
pteronyssinu
der
p
dermatophagoid
farina
der
f
show
higher
concentr
humid
area
countri
particularli
jeddah
concentr
exceed
threshold
level
sensit
exacerb
acut
attack
asthma
central
region
low
humid
show
neglig
presenc
mite
speci
data
jeddah
abha
show
variat
qualit
natur
one
speci
preval
jeddah
preval
abha
variat
also
note
skin
prick
test
taif
data
blattella
germanica
bla
g
bla
g
periplaneta
americana
per
feli
domesticu
fel
show
quantit
region
variat
well
conclus
result
obtain
preval
indoor
aeroallergen
ige
mediat
skin
prick
test
reactiv
indic
region
qualit
quantit
variat
appear
allergen
preval
allergen
region
significantli
relev
ige
sensit
mani
patient
probabl
caus
symptom
data
countri
middleeast
either
limit
none
comparison
therefor
recommend
region
aeroallergen
profil
prepar
conduct
joint
stuid
standard
protocol
better
clinic
diagnosi
treatment
region
background
nonessenti
amino
acid
glycin
gli
shown
act
antiinflammatori
trigger
anim
model
ischem
perfus
postop
inflamm
periodont
diseas
arthriti
obes
inflamm
model
gli
exert
action
bind
glycineg
chlorid
channel
glyr
demonstr
neuron
well
immun
cell
macrophag
polymorphonuclear
neutrophil
lymphocyt
present
studi
aim
evalu
effect
gli
allergi
develop
use
experiment
model
cow
milk
allergi
model
method
femal
mice
supplement
without
gli
oral
gavag
mgmous
hour
sensit
cow
milk
protein
whey
use
cholera
toxin
adjuv
acut
allerg
skin
respons
system
anaphylaxi
assess
intraderm
allergen
challeng
ear
mous
mast
cell
whey
specif
ige
level
assess
one
hour
oral
allergen
challeng
result
intak
gli
significantli
oppos
allergi
develop
concentr
depend
manner
indic
reduct
acut
allerg
skin
respons
wheyinduc
earswel
anaphylaxi
auc
serum
serum
level
whey
specif
ige
au
igeml
result
depict
follow
order
allerg
control
mg
gli
mg
gli
conclus
present
studi
indic
first
time
oral
intak
free
amino
acid
glycin
protect
whey
induc
allergi
develop
addit
studi
warrant
elucid
underli
mechan
involv
demonstr
effect
human
background
asiapacif
burden
respiratori
diseas
apbord
studi
crosssect
observ
studi
conduct
examin
burden
diseas
adult
allerg
rhiniti
ar
asthma
chronic
obstruct
pulmonari
disord
copd
rhinosinus
six
countri
aim
studi
report
result
korea
includ
percentag
patient
receiv
care
respiratori
diseas
frequenc
present
symptom
method
patient
age
year
present
physician
primari
diagnosi
asthma
ar
copd
rhinosinus
enrol
patient
complet
survey
contain
question
relat
demograph
respiratori
symptom
healthcar
resourc
use
qualiti
life
result
total
patient
screen
elig
consent
enrol
highest
percentag
patient
receiv
care
respiratori
disord
primari
diagnosi
ar
ci
follow
asthma
rhinosinus
copd
patient
frequent
diagnos
multipl
respiratori
disord
asthmaar
arrhinosinus
frequent
diagnos
combin
without
condit
among
symptom
report
cough
cough
phlegm
frequent
report
particip
primari
diagnosi
asthma
follow
rhinosinus
copd
ar
addit
cough
cough
phlegm
main
reason
medic
visit
patient
primari
diagnosi
asthma
copd
wherea
nasal
symptom
wateri
runni
nose
block
nose
congest
main
reason
patient
primari
diagnosi
ar
rhinosinus
conclus
asthma
ar
copd
rhinosinus
repres
signific
percentag
patient
respiratori
disord
present
healthcar
profession
korea
mani
patient
present
concomit
diseas
time
identif
symptom
import
implement
effect
diseas
manag
especi
patient
multipl
respiratori
diseas
background
recent
studi
shown
basophil
contribut
initi
inflamm
howev
underli
mechan
proteas
allergen
trigger
basophil
produc
cytokin
remain
unclear
object
object
studi
demonstr
role
mitogen
activ
kinas
mapk
famili
mous
bone
marrowderiv
basophil
bmb
treat
cystein
proteas
allergen
der
f
method
bmb
select
flow
cytometri
mous
bone
marrow
cultur
sort
bmb
stimul
proteolyt
activ
recombin
der
f
express
yeast
pichia
pastori
express
level
cytokin
examin
real
time
pcr
elisa
activ
variou
intracellular
mapk
signal
compon
assess
fac
result
product
mous
basophil
induc
treatment
enzymat
activ
der
f
wherea
inact
der
f
extracellular
signalregul
kinas
erk
cjun
ntermin
kinas
jnk
phosphoryl
upon
treatment
activ
der
f
bmb
addit
treatment
pharmacolog
inhibitor
erk
inhibitor
jnk
inhibitor
abl
inhibit
secret
howev
mapk
inhibit
inhibitor
conclus
data
suggest
involv
erk
jnk
mapk
signal
pathway
product
cytokin
bmb
treat
cystein
proteas
allergen
rder
f
background
mani
kind
vitro
allergi
test
kit
develop
variou
manufactur
wide
util
diagnosi
allergi
vitro
test
kit
allergi
measur
concentr
ige
patient
serum
plasma
bind
allergen
coat
membran
support
nitrocellulos
membran
usual
use
immobil
mani
kind
allergen
sinc
line
blot
assay
rather
dot
blot
assay
good
repeat
reproduc
robust
mani
type
vitro
allergi
test
kit
adopt
technolog
mani
kind
allergen
gener
array
line
per
test
strip
howev
tradit
line
blot
assay
difficult
increas
number
test
item
longnarrow
structur
easi
spillov
solut
incub
sampl
reagent
method
number
test
allergen
increas
achiev
differ
option
one
approach
elong
length
strip
without
chang
gap
line
case
must
devis
solut
overcom
problem
spillov
anoth
option
coat
allergen
compactli
equals
test
strip
band
test
strip
go
thinner
robust
assay
would
diminish
possibl
arrang
strip
two
common
way
adopt
allergi
test
product
use
two
test
strip
per
singl
patient
howev
develop
novel
technolog
parallel
line
array
pla
test
simultan
line
singl
strip
result
produc
kind
narrow
strip
width
assembl
strip
side
side
singl
allergi
test
kit
strip
line
coat
allergen
standard
measur
item
singl
test
sinc
protia
allergyq
use
one
strip
per
singl
patient
rather
two
strip
per
person
tradit
allergi
test
kit
save
test
time
blood
volum
furthermor
diagnost
perform
compar
immunocap
pair
assay
result
good
concord
allergen
p
conclus
protia
allergyq
adopt
pla
technolog
compar
diagnost
perform
tradit
multipl
allergi
test
kit
background
rapid
diagnost
kit
pregnanc
test
wide
use
sampl
urin
serum
plasma
usual
dilut
diluent
buffer
separ
immunochromatograph
method
analyt
test
immobil
nitrocellulos
membran
coat
specif
antibodi
antigen
visual
specif
ag
ab
conjug
gold
nanoparticl
howev
applic
limit
quantit
assay
due
hook
effect
show
fals
neg
result
case
high
concentr
analyt
sampl
method
overcom
hook
effect
devis
innov
rapid
kit
uniqu
competit
method
well
classic
sandwich
method
singl
kit
studi
test
line
prepar
mous
monoclon
antihuman
igg
antihuman
ige
like
classic
rapid
kit
test
line
competit
line
coat
human
igg
human
ige
design
improv
fals
neg
result
due
hook
effect
control
line
prepar
goat
antimous
igg
goat
antihuman
igg
antibodi
mous
igg
conjug
gold
nanoparticl
prepar
laboratori
place
conjug
pad
test
result
immunecheck
human
igg
proteometech
inc
seoul
korea
detect
igg
rang
ugml
know
degre
agreement
quantit
assay
method
compar
assay
result
human
sera
immunoturbidimetr
assay
use
coba
integra
roch
indianapoli
usa
comparison
show
immunecheck
human
igg
degre
agreement
coeffici
determin
immunoturbidimetr
method
detect
limit
immunecheck
human
ige
iuml
total
ige
signal
increas
depend
concentr
ige
conclus
develop
novel
innov
rapid
immunoassay
system
overcom
hurdl
hook
effect
detect
wide
rang
target
molecul
system
benefici
reduc
mislead
test
result
possibl
current
convent
immunoassay
system
background
elev
total
ige
spite
wellknown
limit
frequent
includ
diagnost
criterion
allerg
diseas
mani
kind
vitro
allergi
diagnost
product
measur
concentr
total
ige
multipl
allergi
screen
kit
mediwiss
analyt
gmbh
rbiopharm
eurolin
euroimmun
ag
hitachi
chemic
diagnost
inc
biocheck
gmbh
lowcost
test
use
clinic
rapidli
grow
nowaday
howev
comparison
studi
total
ige
level
multipl
allergi
screen
kit
immunocap
wellknown
quantit
diagnost
kit
allergi
aim
studi
compar
total
ige
concentr
serum
protia
allergyq
multipl
allergi
screen
kit
immunocap
evalu
clinic
usabl
protia
allergyq
method
patient
visit
hospit
korean
medicin
kyung
hee
medic
center
enrol
studi
inform
consent
obtain
patient
five
millilit
whole
blood
collect
vacuum
tube
serum
separ
centrifug
rpm
min
aliquot
sever
roundbottom
tube
frozen
use
immunocap
test
green
cross
laboratori
yonginsi
korea
protia
allergyq
perform
us
correl
two
assay
analyz
passingbablok
regress
analysi
result
averag
total
ige
sera
measur
immunocap
protia
allergyq
kul
respect
passingbablok
regress
analysi
demonstr
immunocap
protia
allergyq
exhibit
almost
perfect
correl
intercept
confid
interv
ci
slope
ci
conclus
protia
allergyq
multipl
allergi
screen
kit
lowcost
screen
test
patient
suspect
allergi
provid
kind
specif
ige
level
also
total
ige
level
even
though
semiquantit
assay
total
ige
concentr
test
allergyq
nearli
equal
immunocap
therefor
may
conveni
tool
measur
specif
ige
total
ige
concentr
background
asthma
consid
common
respiratori
diseas
among
farmer
mani
research
intern
journal
hygien
environment
health
farmer
show
higher
preval
popul
largescal
research
preval
current
state
asthma
among
korean
farmer
b
method
structur
questionnair
use
evalu
demograph
characterist
age
sex
place
resid
smoke
preval
asthma
base
doctor
diagnosi
possibl
risk
factor
like
crop
type
farm
period
pesticid
usag
indoor
cultiv
respiratori
protect
usag
total
farmer
answer
questionnair
c
result
preval
asthma
among
male
farmer
preval
among
femal
farmer
base
korean
nation
health
nutrit
examin
survey
preval
asthma
among
korean
male
preval
among
femal
odd
ratio
asthma
total
pesticid
use
year
year
odd
ratio
indoor
cultiv
conclus
preval
asthma
among
farmer
higher
popul
korea
pesticid
usag
consid
risk
factor
asthma
research
exposur
measur
workrelated
measur
need
background
dietari
intak
posit
neg
impact
actual
perceiv
gener
health
immun
statu
purpos
studi
examin
impact
dietari
intak
varieti
nutrient
perceiv
immun
statu
young
adult
women
method
survey
dietari
intak
perceiv
immun
statu
held
among
young
dutch
women
age
year
old
perceiv
current
immun
statu
score
scale
rang
poor
excel
subsequ
particip
could
indic
whether
perceiv
immun
statu
normal
reduc
food
frequenc
questionnair
complet
record
past
week
food
beverag
intak
data
amount
variou
nutrient
could
estim
includ
fiber
sugar
tryptophan
betacaroten
calcium
niacin
folat
thiamin
carbohydr
riboflavin
vitamin
retinol
vitamin
vitamin
vitamin
c
vitamin
cholesterol
nonparametr
correl
spearman
r
use
examin
associ
perceiv
heath
immun
statu
nutriti
dietari
intak
normal
reduc
perceiv
immun
statu
compar
use
mannwhitney
u
test
result
young
women
mean
sd
age
complet
survey
signific
correl
found
immun
rate
consumpt
tea
r
sugar
r
carbohydr
r
women
report
reduc
perceiv
immun
statu
women
perceiv
reduc
immun
statu
report
consum
significantli
alcohol
significantli
higher
dietari
level
cholesterol
sugar
vitamin
compar
women
report
normal
immun
statu
discuss
find
show
dietari
intak
relat
perceiv
immun
statu
howev
nutrient
bigger
impact
perceiv
immun
statu
other
futur
studi
includ
object
measur
immun
biomark
nutrient
confirm
find
background
antihistamin
cross
bloodbrain
barrier
thu
may
caus
drowsi
result
daili
activ
drive
car
may
impair
purpos
review
compar
effect
differ
antihistamin
drive
perform
method
pubm
cross
refer
search
identifi
doubleblind
placebocontrol
clinic
trial
studi
select
use
standard
onroad
highway
drive
test
normal
traffic
examin
drive
perform
patient
studi
exclud
subject
instruct
maintain
steadi
later
posit
constant
speed
kmh
standard
deviat
later
posit
sdlp
cm
ie
weav
car
primari
outcom
measur
test
magnitud
drive
impair
antihistamin
drug
compar
sdlp
increment
seen
blood
alcohol
concentr
bac
cm
bac
cm
ie
common
legal
limit
drive
result
eighteen
studi
includ
regard
acut
effect
impair
greater
bac
found
singl
dosag
diphenhydramin
emedastin
hydroxyzin
impair
clemastin
triprolidin
mizolastin
acrivastin
dexchlorpheniramin
mequitazin
compar
bac
result
cetirizin
mix
signific
impair
found
terfenadin
loratadin
levocetirizin
desloratadin
ebastin
bilastin
fexofenadin
rupatadin
regard
subchron
effect
day
daili
drug
treatment
signific
drive
impair
found
emedastin
diphenhydramin
clemastin
triprolidin
ebastin
hydroxyzin
mix
result
found
cetirizin
terfenadin
loratadin
signific
drive
impair
found
levocetirizin
acrivastin
fexofenadin
dexchlorpheniramin
bilastin
mequitazin
discuss
antihistamin
drug
may
significantli
impair
drive
perform
impair
often
seen
acut
use
first
secondgener
antihistamin
magnitud
impair
compar
seen
legal
bac
limit
drive
toler
impair
effect
chronic
daili
use
antihistamin
develop
slowli
newer
antihistamin
levocetirizin
fexofenadin
desloratadin
significantli
impair
drive
perform
abstract
anahylact
shock
astmat
statu
seriou
complic
allerg
diseas
might
deadli
outcom
known
literatur
rare
occur
togeth
time
one
patient
athlet
introduc
intens
care
unit
experienc
anaphylact
shock
asthmat
statu
run
grass
field
near
home
upon
arriv
emerg
unit
team
low
blood
preassur
mmhg
low
oxygen
satur
alter
mental
statu
immedi
applic
epinephrin
prednisolon
salbutamol
vital
function
turn
normal
mild
asthma
childhood
last
year
asymptomat
without
medic
recent
yea
hay
fever
grass
pollen
treat
intranas
glucocorticoid
occasionali
urticaria
expos
almond
pork
ten
day
reaction
episod
hive
eat
cake
decor
almond
minut
short
breath
resolv
antihistamin
test
sige
found
strong
sensit
grass
wheat
insect
food
claim
eat
prescrib
selfinject
epinephrin
ask
avoid
run
thrue
grass
field
report
case
male
athlet
suffer
hypotens
asthmat
attack
provok
grass
polen
keyword
anaphylact
shock
asthmat
statu
grass
polen
tel
background
known
respiratori
viral
infect
infanc
caus
asthma
detail
mechan
underli
induct
allerg
inflamm
viru
infect
fulli
understood
mani
paper
shown
pathogenderiv
factor
viru
dna
rna
factor
releas
die
stress
cell
damageassoci
molecular
pattern
damp
recogn
immun
cell
contribut
inflamm
interestingli
host
dna
damp
known
induc
type
immun
respons
exacerb
allerg
inflamm
host
dna
recogn
intracellular
dna
sensor
activ
cyclic
gmaamp
synthas
cga
activ
cga
gener
cyclic
gmpamp
cgamp
second
messeng
hypothes
host
dna
releas
damag
cell
viru
particip
allerg
inflamm
via
action
cgamp
studi
investig
effect
cgamp
onset
asthma
method
hous
dust
mite
antigen
hdm
administ
intranas
mice
without
cgamp
adjuv
mice
challeng
intranas
administr
hous
dust
mite
antigen
hdm
day
twentyfour
hour
last
challeng
collect
blood
balf
lung
serum
antibodi
measur
elisa
cell
balf
analyz
fac
perform
similar
experi
use
geneknockout
mice
evalu
factor
involv
inflamm
model
result
number
eosinophil
balf
significantli
increas
mice
sensit
hdm
cgamp
histolog
analysi
reveal
infiltr
inflammatori
cell
mucuscontain
goblet
cell
lung
also
increas
sensit
hdm
cgamp
moreov
cgampadjuv
hdm
led
airway
hyperrespons
effect
depend
downstream
factor
cgamp
signal
pathway
conclus
cgamp
act
adjuv
induc
allerg
inflamm
lung
result
suggest
cgamp
may
involv
viral
infectioninduc
asthma
releas
damp
introduct
omalizumab
human
recombin
monoclon
antibodi
ige
reduc
serum
free
ige
downregulati
ige
receptor
mast
cell
basophil
approv
treatment
moder
sever
persist
asthma
chronic
idiopath
urticari
bard
et
al
report
success
treatment
sever
recalcitr
eczemat
dermat
set
hie
omalizumab
due
high
serum
ige
level
recalcitr
dermat
prolong
usag
system
corticosteroid
omalizumab
initi
patient
favor
outcom
method
year
old
man
present
diffus
prurit
rash
year
physic
examin
reveal
multipl
discret
confluent
erythemat
macul
plaqu
trunk
back
extrem
laboratori
find
show
extrem
elev
ige
level
iuml
absolut
eosinophil
normal
tryptas
multipl
skin
biopsi
show
nonspecif
dermat
bone
marrow
biopsi
cytogenet
imag
studi
unremark
patient
evalu
dermatolog
hematologyoncolog
specif
diagnosi
given
patient
deni
histori
recurr
infect
skin
abscess
hyperextens
joint
bone
fractur
scoliosi
patient
fail
multipl
system
topic
medic
improv
prednison
result
patient
treat
empir
omalizumab
mg
everi
day
one
month
initi
omalizumab
treatment
dermat
eosinophilia
markedli
improv
conclus
although
omalizumab
effect
patient
chronic
dermat
set
sever
elev
ige
prospect
studi
long
term
followup
requir
confirm
efficaci
omalizumab
recalcitr
dermat
elev
ige
background
natur
histori
prawn
allergi
well
describ
aim
studi
evalu
natur
histori
prawn
allergi
asian
cohort
method
previous
describ
cohort
prawn
allerg
patient
thayalasingam
clin
exp
allergi
patient
agre
recruit
six
monthli
questionnair
administ
skin
prick
test
spt
hous
dust
mite
hdm
dermatophagoid
pteronyssinu
dp
dermatophagoid
farina
df
blomia
tropicali
bt
crude
extract
crab
prawn
custom
made
extract
prawn
speci
penaeu
monodon
tiger
prawn
litopenaeu
vannamei
glass
prawn
panadalu
boreali
angka
prawn
sera
ige
sensit
measur
via
immunocap
dp
df
bt
shrimp
also
collect
compar
previou
data
patient
result
patient
histori
anaphylaxi
posit
oral
food
challeng
ofc
neg
ofc
recruit
mean
age
year
year
recruit
durat
followup
rang
month
mean
month
sixteen
ofc
ofc
continu
eat
prawn
still
ongo
allerg
reaction
two
patient
toler
regular
consumpt
prawn
previou
posit
ofc
comparison
clinic
symptom
show
common
symptom
urticaria
throat
itchi
gener
red
skin
nasal
congest
lip
swell
signific
decreas
number
hospit
visit
allerg
reaction
p
frequenc
posit
spt
prawn
extract
decreas
subject
recruit
compar
subject
follow
statist
signific
chang
specif
ige
level
shrimp
dust
mite
except
signific
decreas
sige
df
p
conclus
prawn
allergi
rel
longstand
ofc
neg
subject
may
continu
allerg
reaction
exposur
suggest
loss
toler
intermitt
presenc
cofactor
lower
threshold
allerg
reaction
introduct
skin
barrier
defect
play
central
role
pathogenesi
atop
dermat
ad
affect
local
immun
skin
hydrat
sever
ad
seen
case
effect
growth
nutrit
known
object
determin
frequenc
sever
hypoalbuminemia
hypoproteinemia
sever
ad
relationship
ad
sever
studi
effect
hypoalbuminemia
hypoproteinemia
growth
children
method
retrospect
studi
record
children
year
seen
ped
allergyimmunolog
clinic
hamad
gener
hospit
jun
sever
ad
serum
albumin
protein
test
also
review
demograph
data
lab
test
cbc
differenti
ige
igg
iga
igm
serum
zinc
food
allergen
test
spt
specif
ige
scorad
anthropometr
data
collect
result
month
old
male
femal
allergi
found
patient
posit
famili
histori
allergi
patient
major
test
posit
one
food
scorad
bodi
mass
index
bmi
wbc
cellsul
eosinophil
cellsul
total
ige
kul
hypoproteinemia
present
patient
hypoalbuminemia
patient
hypoalbuminem
patient
low
bmi
compar
normoalbuminem
patient
bmi
hypoproteinem
patient
bmi
compar
normoproteinem
patient
bmi
scorad
higher
hypoalbuminemiclowbmi
patient
compar
normoalbuminemicnormalbmi
patient
vs
hypoproteinemiclowbmi
patient
compar
normoproteinemicnormalbmi
patient
vs
conclus
patient
sever
atop
dermat
patient
hypoproteinemia
hypoalbuminemia
associ
low
bmi
denot
signific
effect
growth
relat
ad
sever
import
close
monitor
growth
nutrit
biochem
maker
manag
sever
ad
background
asthma
common
chronic
respiratori
diseas
reach
portugues
popul
associ
seriou
health
problem
among
person
year
old
even
though
asthma
often
undertr
misdiagnos
age
group
reason
spirometri
could
import
airway
assess
older
adult
method
within
scope
phase
ii
geria
project
nurs
home
lisbon
randomli
select
everi
nurs
home
resid
met
inclus
criteria
least
year
old
resid
nurs
home
month
present
contraind
lung
function
test
invit
answer
respiratori
health
questionnair
administ
interview
perform
spirometri
descript
analysi
carri
order
assess
frequenc
asthma
wheez
previou
month
chronic
bronchiti
spirometr
chang
kappa
coeffici
use
evalu
agreement
symptom
spirometr
paramet
result
analys
sampl
includ
resid
perform
valid
spirometri
bronchodil
test
major
femal
mean
age
year
sd
year
wheez
previou
month
asthma
report
resid
respect
chronic
bronchiti
symptom
occur
survey
sampl
resid
present
bronchodil
twenti
resid
signific
postbronchodil
improv
ml
agreement
found
symptom
spirometr
paramet
conclus
spirometri
seem
import
tool
complement
questionnair
assess
age
group
underreport
respiratori
diseas
exist
moreov
provid
better
character
obstruct
lung
diseas
background
shrimp
wide
consum
shellfish
common
caus
anaphylaxi
southeast
asia
diagnosi
shrimp
allergi
use
skin
prick
test
spt
specif
ige
sige
may
interf
sensit
hous
dust
mite
hdm
also
preval
area
sensit
allergen
occur
due
cross
reaction
tropomyosin
object
studi
sought
evalu
role
spt
shrimp
sige
shrimp
compon
resolv
diagnost
diagnosi
shrimp
allergi
area
high
preval
hdm
sensit
method
subject
sensit
shrimp
dermatophagoid
pteronyssinu
derp
determin
spt
enrol
allergi
clinic
shrimp
allergi
diagnos
oral
food
challeng
test
convinc
histori
repeat
allerg
symptom
shrimp
ingest
histori
shrimp
induc
anaphylaxi
mean
wheal
size
spt
shrimp
extract
cook
pacif
white
shrimp
sige
der
p
shrimp
rpen
determin
result
fiftyon
subject
enrol
classifi
group
accord
shrimp
reaction
shrimp
allergi
shrimp
toler
age
shrimp
allerg
subject
rang
year
male
femal
onethird
subject
shrimp
allergi
isol
oral
itch
symptom
half
subject
anaphylaxi
median
spt
wheal
size
shrimp
extract
fresh
shrimp
significantli
higher
shrimp
allerg
subject
compar
shrimp
toler
vs
mm
vs
mm
accordingli
spt
shrimp
extract
mm
posit
shrimp
sige
kua
provid
sensit
neg
predict
valu
npv
spt
fresh
shrimp
provid
better
sensit
npv
shrimp
extract
use
cut
valu
sige
rpen
found
low
sensit
high
specif
posit
predict
valu
identifi
patient
shrimp
allergi
size
spt
level
shrimp
sige
sige
significantli
differ
anaphylact
nonanaphylact
subject
conclus
subject
demonstr
sensit
shrimp
hdm
sige
rpen
help
predict
clinic
reaction
spt
sige
shrimp
good
screen
test
spt
fresh
shrimp
higher
sensit
npv
shrimp
extract
sige
rpen
use
predict
sever
shrimp
allerg
popul
background
tree
heaven
spread
prize
ornament
plant
highli
invas
speci
region
worldwid
tree
introduc
arid
semiarid
region
iran
ornament
speci
last
two
decad
despit
increas
report
ailanthu
spp
pollinosi
molecular
studi
topic
aim
studi
identifi
potenti
allergen
protein
altissimapollen
use
anim
model
method
altissima
pollen
collect
urban
green
space
tehran
iran
pollin
period
midapril
midmay
pollen
protein
extract
phosphatebuff
salin
pb
protein
content
altissima
pollen
ap
extract
studi
use
bradford
protein
assay
follow
sdspage
thirti
male
balbc
mice
randomli
divid
two
group
ap
extract
sensit
sham
receiv
pb
ap
extract
inject
intraperiton
regular
interv
one
week
last
inject
intraderm
skin
test
id
perform
abdomen
skin
anim
specif
igebind
protein
ap
extract
identifi
immunoblot
use
pool
sera
sensit
mice
result
total
protein
concentr
ap
extract
per
ap
extract
sdspage
pattern
reveal
protein
band
rang
kd
kd
mean
wheal
diamet
induc
id
significantli
higher
ap
extract
sensit
group
compar
sham
group
immunoblot
use
pool
sera
ap
extract
sensit
mice
reveal
major
igebind
compon
approxim
kd
sever
minor
igebind
protein
rang
kd
conclus
present
studi
sever
ap
extract
igebind
protein
identifi
potenti
caus
immedi
hypersensit
reaction
sensit
subject
find
open
avenu
identif
ap
extract
allergen
protein
allergenbas
diagnosi
patient
suffer
allerg
symptom
pollin
period
speci
background
allergi
immunotherapi
use
treat
allergi
effect
reliev
medic
recommend
age
hand
although
allergi
shot
usual
safe
sometim
side
effect
local
swell
erythema
place
shot
given
anaphylaxi
shock
aim
studi
comparison
reaction
allergi
shot
adult
children
method
studi
side
effect
allergi
shot
compar
patient
year
patient
got
shot
standard
schedul
everi
week
everi
month
stay
offic
minut
everi
time
get
shot
patient
late
onset
reaction
shot
prospectu
telephon
result
patient
gotten
shot
patient
year
patient
year
patient
allerg
rhiniti
allerg
asthma
isol
combin
type
allergi
adult
group
anaphylact
shock
occur
one
patient
eight
attack
gener
urticari
wheez
five
attack
gener
urticari
abdomin
pain
sever
cramp
observ
children
group
system
reaction
two
case
flush
two
case
experienc
headach
shot
sometim
local
swell
erythema
occur
place
shot
two
group
patient
addit
improv
symptom
control
diseas
children
better
adult
conclus
although
seem
tendenc
allergi
shot
children
less
adult
reaction
children
less
adult
children
better
toler
allergi
immunotherapi
introduct
myoton
dystrophi
type
steinert
diseas
genet
determin
disord
belong
group
muscl
dystrophi
mainli
character
myotonia
progress
weak
atrophi
skelet
muscl
patient
heterogen
affect
diseas
vari
slight
clinic
sign
fulli
handicap
pneumonia
import
primari
secondari
caus
death
patient
due
muscl
weak
increas
suscept
mainli
respiratori
infect
howev
anoth
factor
may
hypogammaglobulinaemia
report
patient
remark
date
data
found
natur
impact
hypogammaglobulinemia
infect
rate
patient
method
immun
statu
evalu
retrospect
data
analysi
perform
patient
standard
screen
compris
questionnair
recurr
infect
frequent
use
antibiot
hospit
stay
due
infect
standard
laboratori
test
compris
serum
iga
igm
igg
igg
subclass
nk
b
cell
count
granulocyt
leucocyt
monocyt
count
fac
analysi
also
vaccin
respons
test
perform
result
major
patient
hypogammaglobulinemia
igg
gl
rang
gl
gl
strikingli
select
normal
rang
fifteen
sixteen
patient
none
patient
immun
suppress
medic
overal
rate
pneumonia
nine
seventeen
patient
suffer
pneumonia
least
januari
octob
four
patient
recurr
pneumonia
sinopulmon
infect
infect
also
occur
eg
recurr
urinari
tract
infect
recurr
facial
herp
simplex
erysipela
patient
hypoglobulinemia
rate
pneumonia
compar
patient
whose
total
igg
normal
p
interestingli
three
patient
low
igg
serum
level
also
show
insuffici
vaccin
respons
h
influenza
type
b
andor
pneumonia
two
recurr
infect
includ
pneumonia
patient
met
criteria
common
variabl
immun
defici
cvid
discuss
statist
data
limit
due
small
number
patient
includ
pilot
studi
howev
result
astound
defici
hypogammaglobulinemia
result
impli
screen
immun
defici
part
standard
care
patient
howev
studi
warrant
investig
igg
substitut
therapi
may
lead
decreas
infect
improv
qualiti
life
abstract
object
investig
efficaci
sublingu
immunotherapi
slit
dermatophagoid
farina
persist
allerg
rhiniti
coincid
symptom
improv
chang
serou
sige
sigg
method
sixtyfour
patient
allerg
rhiniti
divid
children
group
adult
group
treat
slit
dermatophagoid
farina
week
total
nasal
symptom
score
nasal
sign
score
va
score
evalu
aft
slit
result
three
score
descend
significantli
p
treatment
two
group
declin
sige
ascent
sigg
clear
conclus
efficaci
slit
dermatophagoid
farina
persist
allerg
rhiniti
promin
accord
three
score
coher
three
score
serou
sige
sigg
wellknown
prolifer
migrat
airway
smooth
muscl
cell
asmc
play
import
role
airway
remodel
asthma
inflamm
affect
cell
prolifer
migrat
antagon
histamin
receptor
shown
antiinflammatori
asthma
studi
perform
identifi
whether
garlic
extract
show
antagonist
effect
histamineinduc
increas
prolifer
migrat
human
asthmat
bronchial
smooth
muscl
cell
habsmc
treatment
habsmc
histamin
significantli
increas
cell
prolifer
migrat
compar
control
p
wound
heal
assay
show
histamin
increas
cell
prolifer
migrat
timedepend
manner
pretreat
garlic
extract
suppress
histamineinduc
prolifer
migrat
respect
addit
histamineinduc
increas
prolifer
migrat
habsmc
inhibit
pretreat
mapk
inhibitor
pretreat
garlic
extract
downregul
histaminestimul
mapk
activ
result
show
garlic
extract
reduc
histamineinduc
cell
migrat
prolifer
downregul
mapk
pathway
suggest
garlic
extract
could
potenti
asthmaprevent
food
nacetylcystein
nac
wide
use
drug
mucolyt
chronic
respiratori
diseas
antidot
acetaminophen
overdos
protect
agent
renal
function
contrastinduc
nephropathi
nac
consid
welltoler
safe
medic
seriou
advers
reaction
report
report
case
contact
dermat
nac
woman
present
symptom
eczemat
skin
lesion
expos
area
hand
arm
face
sever
week
suffer
symptom
rash
itch
sensat
lesion
patient
diagnos
allerg
rhiniti
sensit
hous
dust
mite
symptom
bothersom
previou
histori
drug
allergi
nonsteroid
antiinflammatori
drug
nurs
work
gener
ward
tertiari
hospit
symptom
develop
sinc
start
work
ward
mix
nac
variou
antibiot
normal
salin
serum
total
ige
level
increas
skin
prick
test
reveal
sensit
variou
inhal
allergen
includ
hous
dust
mite
serum
specif
ige
skin
prick
test
antibiot
neg
intraderm
test
nac
show
posit
result
immedi
late
reaction
patch
test
use
nac
also
reveal
posit
result
hour
serum
specif
ige
nachuman
albumin
conjug
detect
enzymelink
immunosorb
assay
report
case
allerg
contact
dermat
due
nac
expos
workplac
introduct
pollen
temperatur
air
pollut
occup
factor
repres
risk
factor
allerg
diseas
among
pollen
import
role
pathogenesi
asthma
depend
global
warm
climat
chang
recent
chang
pollen
appear
studi
purpos
survey
chang
asthma
evalu
relat
pollen
asthma
attack
compar
influenc
seongdong
gu
seoul
repres
urban
area
guri
gyungggido
suburban
area
jeju
rural
area
method
util
nation
health
insur
data
meteorolog
data
air
pollut
data
pollen
data
nation
weather
servic
target
area
seongdong
gu
one
district
seoul
capit
korea
guri
similar
seongdong
gu
aspect
latitud
longitud
suburban
area
jeju
differ
two
area
front
aspect
latitud
island
rural
area
consid
number
asthma
attack
depend
variabl
asthma
attack
defin
case
oral
steroid
use
treat
asthma
attack
confirm
order
distinguish
pediatr
asthma
restrict
age
rang
age
year
independ
variabl
meteorolog
variabl
tmax
tmean
tmin
precipit
humid
dtr
diurnal
temperatur
rang
wind
veloc
pollen
data
count
grass
ragwe
wormwood
japanes
hop
alder
birch
hazelnut
oak
air
pollut
data
atmospher
concentr
co
statist
research
includ
timeseri
analysi
casecrossov
design
perform
result
tree
ragwe
pollen
associ
asthma
attack
largest
magnitud
associ
averag
ci
grass
pollen
minim
associ
outcom
associ
ozon
strongest
day
asthma
attack
ci
ci
respect
decreas
lag
effect
conclus
differ
pollen
type
show
differ
associ
outcom
high
level
tree
pollen
appear
import
risk
factor
asthma
exacerb
geograph
differ
associ
risk
factor
asthma
attack
background
anecdot
observ
higher
incid
emerg
visit
hospit
asthma
exacerb
lunar
month
singapor
postul
due
increas
outdoor
air
pollut
month
secondari
cultur
practic
incens
joss
paper
burn
incens
burn
known
releas
particul
matter
environ
increas
risk
acut
irrit
symptom
well
preval
chronic
respiratori
method
data
emerg
visit
hospit
asthma
exacerb
januari
decemb
collect
singapor
nation
asthma
programm
databas
includ
data
seven
main
govern
restructur
hospit
singapor
linear
regress
perform
use
spss
compar
signific
asthma
exacerb
week
lunar
month
compar
week
nonlunar
month
result
result
show
signific
differ
lunar
week
nonlunar
week
year
lunar
week
significantli
increas
number
emerg
visit
hospit
asthma
exacerb
p
howev
note
incid
significantli
reduc
lunar
week
p
combin
analysi
eight
year
also
show
signific
increas
lunar
week
conclus
signific
increas
incid
emerg
visit
hospit
asthma
exacerb
lunar
month
singapor
refer
incens
smoke
clinic
structur
molecular
effect
airway
diseas
tachang
lin
guha
krishnaswami
david
chi
clinic
molecular
allergi
mechan
asthmat
exacerb
ambient
air
pollut
particl
ghio
aj
expert
rev
respir
med
feb
background
farmer
known
expos
varieti
antigen
caus
allerg
natur
work
environ
howev
industri
structur
korea
chang
significantli
reduc
number
farmer
evolv
result
main
concern
nation
public
health
polici
research
also
rare
studi
perform
determin
statu
allergen
sensit
rate
caus
antigen
korean
domest
farmer
method
total
peopl
rural
area
gyeonggido
enrol
studi
evalu
includ
structur
questionnair
skin
prick
test
inhal
allergen
includ
one
neg
posit
control
statist
analysi
use
multivari
logist
regress
analysi
analyz
associ
posit
preval
risk
factor
result
thirti
peopl
exclud
skin
prick
test
result
invalid
proport
posit
reaction
least
one
allergen
rate
common
sensit
allergen
dpteronyssinu
dfarina
cockroach
grass
pollen
mixtur
order
farmer
answer
mainli
cultiv
flower
adjust
odd
ratio
ci
time
rice
particularli
high
grass
pollen
mixtur
cockroach
mugwort
ragwe
risk
factor
whether
current
engag
agricultur
pesticid
use
indoor
work
find
statist
signific
conclus
studi
signific
evalu
health
risk
occup
exposur
domest
farmer
posit
reaction
skin
prick
test
presenc
allerg
diseas
equal
necessari
interpret
cautious
observ
odd
ratio
appear
high
flower
farmer
show
differ
trend
preval
crop
inhal
allergen
thought
requir
research
futur
introduct
drug
allergi
da
immunolog
mediat
respons
specif
agent
sensit
person
clinic
manifest
da
restrict
certain
syndrom
specif
accept
allerg
natur
may
present
mild
life
threaten
reaction
object
determin
clinic
featur
da
method
patient
clinic
histori
da
refer
dr
kariadi
hospit
semarang
januari
may
age
year
retrospect
identifi
medic
record
drug
allergi
defin
one
drugrel
cutan
reaction
pattern
system
symptom
immunolog
mediat
drug
hypersensit
statist
analys
fisher
exact
test
statist
signific
p
result
total
patient
boy
girl
identifi
mean
age
month
frequenc
sever
malnutrit
wellnourish
respect
patient
month
age
da
neutrophillymphocyt
count
ratio
nlcr
case
common
type
fix
drug
erupt
fde
type
stevenjohnson
syndrom
sj
erythema
multiform
em
drughypersensit
syndrom
dh
antibiot
account
drug
implic
da
case
four
previous
histori
allergi
manifest
patient
famili
histori
allergi
eosinophilia
blood
smear
examin
found
case
da
patient
fde
show
normal
test
liver
function
non
fde
p
correl
da
skin
exfoli
anemia
also
hypoalbuminaemia
clinic
featur
skin
exfoli
correl
nlcr
patient
da
except
fde
receiv
steroid
therapi
mortal
studi
conclus
fix
drug
erupt
common
type
da
found
male
predominantli
affect
antibiot
drug
commonli
involv
background
european
ash
fraxinu
excelsior
common
caus
asthma
allerg
rhiniti
allerg
conjunct
therefor
essenti
studi
period
durat
flower
airborn
regionarea
research
evalu
relat
ash
pollen
count
meteorolog
air
pollut
factor
tehran
six
year
method
first
district
tehran
classifi
northern
southern
eastern
western
central
region
near
tehran
control
zone
pollen
sampl
collect
f
excelsior
tree
plant
area
tehran
also
nonpollut
area
situat
outsid
citi
scan
electron
microscopi
use
examin
compar
shape
structur
nonpollut
pollut
pollen
attempt
made
pollen
count
determin
two
method
spore
trap
gravimetr
durham
method
six
year
airborn
ash
pollen
collect
slide
hour
period
slide
stain
examin
microscop
relationship
ash
pollen
count
meteorolog
paramet
includ
mean
valu
high
low
rate
temperatur
sunshin
hour
high
low
rel
humid
wind
speed
rain
investig
also
air
pollut
data
co
obtain
five
studi
area
tehran
find
relat
grass
pollen
count
result
microscop
examin
show
air
pollut
consider
improv
fragil
pollen
exin
caus
numer
crack
surfac
facilit
pollen
content
liber
pollen
calendar
ash
pollen
type
identifi
six
year
studi
period
area
tehran
pollen
product
higher
south
center
area
lower
area
tehran
major
pollen
season
recogn
jan
april
highest
pollen
count
obtain
march
lowest
jan
ash
pollen
calendar
associ
meteorolog
air
pollut
factor
relat
mainli
daili
temperatur
sunshin
hour
wind
speed
co
conclus
ash
pollen
season
variat
specif
area
countri
help
allerg
patient
decis
life
everi
day
physician
attend
allerg
diseas
manag
hope
data
use
full
patient
physician
tehran
capit
iran
final
result
show
pollut
caus
extend
period
pollin
backgroundaim
allerg
rhiniti
ar
elderli
patient
constantli
increas
extens
life
expect
littl
known
elderli
ar
immunotherapi
elderli
patient
controversi
issu
sinc
proven
evid
safeti
efficaci
treatment
shown
studi
find
characterist
elderli
ar
sensit
hous
dust
mite
hdm
evalu
safeti
efficaci
sublingu
allergenspecif
immunotherapi
method
total
patient
older
year
old
ar
sensit
hdm
ah
ratio
skin
prick
test
andor
immunocap
dfarina
dpteronyssinu
enrol
studi
patient
random
either
medic
group
mite
sublingu
tablet
observ
group
use
doubleblind
method
first
visit
symptom
advers
reaction
monitor
month
result
patient
patient
medic
group
patient
observ
group
regardless
group
mean
age
year
ratio
male
femal
patient
mean
total
ige
specif
ige
dfarina
dpteronyssinu
respect
baselin
mean
valu
total
rhinoconjunct
symptom
score
primari
endpoint
studi
tend
decreas
month
seriou
advers
event
report
patient
well
toler
conclus
sublingu
immunotherapi
tablet
form
elderli
ar
patient
sensit
hdm
worth
tri
safeti
issu
becom
problem
investig
result
need
studi
support
lofarma
spa
milano
itali
background
world
popul
age
usual
defin
elderli
steadili
grow
reflect
gener
trend
age
societi
advanc
age
chronic
diseas
becom
increasingli
preval
contribut
loss
independ
frailti
increas
risk
death
understand
role
environment
factor
specif
respiratori
infect
pathogenesi
chronic
respiratori
diseas
elderli
may
help
decreas
morbid
extend
lifespan
popul
method
healthi
age
research
center
harc
multidisciplinari
research
platform
establish
medic
univers
lodz
involv
research
group
variou
basic
biolog
immunologist
biochemist
molecular
biologist
clinic
geriatrician
psychiatrist
cardiologist
pulmonologist
interest
devot
conduct
research
address
key
issu
relat
pathogenesi
increas
morbid
elderli
popul
present
harc
platform
vehicl
develop
multidisciplinari
research
relat
variou
aspect
respiratori
infect
elderli
result
preliminari
studi
involv
elderli
subject
mean
age
allow
establish
risk
factor
associ
frequent
infect
multivari
analysi
polytherapi
prescript
drug
determin
one
import
risk
factor
frequent
defin
per
year
respiratori
infect
effect
comorbid
risk
factor
respiratori
infect
analyz
crosssect
studi
involv
subject
randomli
select
local
popul
elderli
subject
collabor
psychiatr
preval
spectrum
respiratori
infect
among
patient
variou
psychiatr
disord
studi
although
viral
infect
consid
import
trigger
asthma
exacerb
children
adult
difficult
extrapol
infect
rate
specif
pathogen
studi
older
adult
asthma
studi
current
develop
microbiologist
aim
assess
role
viral
bacteri
trigger
asthma
exacerb
elderli
patient
parallel
vitro
model
assess
peripher
blood
leukocyt
immun
respons
rhinoviru
infect
mirna
express
elderli
patient
without
asthma
introduc
conclus
collabor
within
multidisciplinari
research
team
harc
platform
allow
develop
innov
approach
studi
variou
aspect
respiratori
infect
elderli
popul
project
support
european
commiss
background
capturerecaptur
model
allow
one
estim
number
actual
case
assess
probabl
overlap
case
multipl
sourc
korea
workrel
asthma
surveil
kowa
scheme
design
collect
inform
wra
case
multipl
report
sourc
korea
worker
compens
welfar
servic
occup
physician
allergi
chest
physician
region
workrel
diseas
surveil
system
purpos
studi
estim
number
actual
case
wra
use
capturerecaptur
analysi
method
capturerecaptur
analysi
use
obtain
nearli
unbias
estim
nue
total
number
wra
case
report
kowa
report
sourc
stratifi
categori
follow
worker
compens
scheme
ie
korea
worker
compens
welfar
servic
report
sourc
ie
physician
report
capturerecaptur
analysi
perform
sex
region
specif
industri
number
overlap
report
overlap
report
ie
duplic
case
defin
individu
ident
name
date
birth
resid
registr
number
employ
found
report
categori
result
total
case
wra
report
report
sourc
worker
compens
scheme
occup
physician
allergi
chest
physician
region
surveil
system
number
case
estim
capturerecaptur
method
ci
complet
worker
compens
physician
report
respect
industri
report
case
estim
case
manufactur
sector
ci
region
report
case
estim
case
gyeonggi
incheon
ci
conclus
capturerecaptur
model
allow
estim
true
number
case
assess
complet
surveil
data
method
use
variou
public
health
area
background
asthma
one
import
chronic
diseas
childhood
parent
awar
asthma
symptom
knowledg
asthma
trigger
necessari
everi
step
diagnosi
treatment
method
studi
primari
school
student
parent
leav
lowincom
district
ankara
includ
questionnair
prepar
question
symptom
trigger
asthma
base
isaac
intern
studi
asthma
allergi
childhood
appli
parent
p
valu
result
primari
school
student
mean
age
year
minmax
wheez
attack
recogn
parent
children
children
diagnos
asthma
medic
doctor
previous
children
least
one
smoker
hous
parent
defin
humid
defin
mold
hous
conclus
studi
show
primari
school
student
wheez
indoor
trigger
humid
mold
cigarett
smoke
report
student
parent
especi
low
incom
area
import
educ
parent
indoor
trigger
background
airway
hyperrespons
airway
inflamm
characterist
featur
bronchial
asthma
airway
hyperrespons
usual
measur
direct
stimuli
methacholin
histamin
adenosin
monophosph
act
indirectli
via
secondari
releas
mediat
anoth
stimulu
measur
brochial
hyperrespons
aim
studi
investig
relationship
among
provoc
concentr
methacholin
produc
declin
methacholin
adenosin
inflammatori
marker
newli
diagnos
asthmat
compar
chang
inhal
corticosteroid
treatment
method
perform
prospect
analysi
data
patient
diagnosi
persist
bronchial
asthma
year
predict
patient
assign
two
group
accord
sever
diseas
either
mild
mean
moder
mean
methacholin
adenosin
bronchial
provoc
test
sputum
induct
blood
sampl
perform
treatment
corticosteroid
result
sensit
methacholin
adenosin
bronchial
provoc
test
diagnosi
bronchial
asthma
respect
methacholin
adenosin
improv
corticosteroid
treatment
devid
two
group
accord
sever
mild
group
improv
methacholin
p
corticosteroid
treatment
found
adenosin
moder
group
improv
adenosin
p
corticosteroid
treatment
found
methacholin
pretreat
pre
correl
methacholin
amp
p
p
strong
correl
pre
pre
p
pre
pre
p
observ
found
chang
methacholin
adenosin
treatment
inhal
corticosteroid
correl
eosinophil
percentag
blood
pre
sputum
respect
p
inflammatori
marker
ecp
decreas
treatment
signific
found
conclus
find
show
adenosin
methacholin
use
marker
assess
efficaci
antiinflammatori
therapi
moder
persist
asthma
adenosin
may
valuabl
evalu
efficaci
treatment
methacholin
background
previous
report
elev
calcium
bindingprotein
protein
sputum
neutrophil
sever
uncontrol
asthmat
spite
high
dose
inhal
corticosteroid
treatment
compar
stabl
asthmat
aim
studi
evalu
relat
protein
neutrophil
inflamm
steroid
naiv
mild
sever
asthmat
lung
function
materi
method
sputum
obtain
neversmok
exsmok
asthmat
packyear
protein
measur
inhal
system
corticosteroid
asthmat
snba
inhal
system
steroid
treat
asthmat
stba
normal
control
nc
use
enzymelink
immunosorb
assay
correl
level
inflammatori
cell
annual
rate
exacerb
analyz
result
level
significantli
higher
sputum
snba
stna
normal
control
respect
compar
snba
stna
bronchial
asthma
ba
level
significantli
correl
percentag
neutrophil
eosinophil
r
sputum
correl
persist
observ
snba
ba
divid
group
neutrophil
domin
eosinophil
domin
codomin
paucigranulocyt
group
level
highest
neutrophil
group
pgug
compar
eosinophil
pgug
codomin
pgug
paucigranulocyt
pgug
group
level
significantli
increas
subject
experienc
exacerb
compar
experienc
exacerb
conclus
data
suggest
protein
elev
sputum
asthma
compar
normal
control
level
correl
percentag
neutrophil
sputum
regardless
steroid
treatment
abstract
background
asthma
risk
factor
pneumonia
children
children
asthma
like
pneumonia
need
hospit
especi
children
five
year
old
asthma
pediatr
pneumonia
sever
clinic
symptom
increas
need
mechan
ventil
mortal
object
comprehend
asthma
risk
profil
children
pneumonia
hasan
sadikin
gener
hospit
bandungindonesia
method
retrospect
studi
pediatr
pneumonia
asthma
comorbid
pediatr
ward
depart
hasan
sadikin
gener
hospit
januari
decemb
includ
patient
hospit
pneumonia
asthma
use
icd
j
result
eight
hundr
seventi
three
children
pneumonia
admit
hospit
seven
hundr
thirti
six
patient
comorbid
thirti
six
patient
asthma
twenti
pneumonia
patient
asthma
patient
asthma
congenit
heart
diseas
patient
asthma
comorbid
cerebr
palsi
anemia
malnutrit
diarrhea
pulmonari
tuberculosi
median
age
month
month
old
five
year
old
patient
male
six
patient
histori
allergyasthma
famili
patient
one
asthma
exacerb
last
week
six
patient
previou
hospit
similar
symptom
one
receiv
previou
control
medic
laboratori
find
reveal
white
blood
cell
bacteria
found
blood
cultur
serratia
marcescen
chest
xray
show
bilater
infiltr
eight
patient
sever
asthma
exacerb
length
stay
day
patient
admit
pediatr
intens
care
unit
perish
conclus
asthma
still
risk
factor
children
develop
pneumonia
requir
hospit
background
preval
asthma
children
increas
especi
industri
citi
padang
citi
padang
cement
factori
locat
near
commun
peopl
surround
inhal
dust
pollut
emiss
cement
product
includ
children
want
know
preval
risk
factor
asthma
allerg
diseas
area
method
mayjun
conduct
cross
section
studi
children
around
cement
padang
factori
base
distanc
hous
factori
km
expos
area
km
expos
area
children
age
year
select
use
isaac
questionnair
determin
asthma
allerg
diseas
data
taken
parent
inform
consent
includ
asthma
allerg
rhiniti
atop
dermat
symptom
risk
factor
data
analyz
chisquar
test
result
studi
found
children
expos
area
femal
age
group
half
normal
nutrit
statu
undernourish
asthma
preval
atop
dermat
found
higher
expos
area
expos
area
vs
vs
allerg
rhiniti
higher
expos
area
vs
signific
differ
atop
histori
mother
higher
expos
area
vs
inhal
pollutan
like
pet
cigarret
smoke
kapok
mattress
vapor
gasolin
higher
expos
area
signific
differ
conclus
expos
area
cement
padang
factori
preval
rhiniti
allergi
higher
asthma
atop
dermat
signific
differ
abstract
background
atop
dermat
ad
mostli
frequent
occur
infant
children
intrins
extrins
factor
import
role
ad
epiderm
barrier
injuri
dysregulatori
immun
system
could
induc
vitamin
aim
studi
reveal
relat
serum
level
atop
dermat
occurr
sever
children
method
studi
cross
section
studi
ad
patient
control
serum
level
measur
enzymelink
immunosorb
assay
elisa
evalu
ad
sever
use
sever
score
atop
dermat
scorad
result
acquir
defici
ad
patient
otherwis
control
studi
obtain
median
rate
ad
patient
lower
control
studi
ngml
ngml
median
rate
mild
moder
sever
ad
patient
ngml
ngml
ngml
conclus
serum
level
ad
patient
lower
significantli
control
studi
though
relationship
sever
ad
p
keyword
atop
dermat
sever
atop
dermat
background
dynam
thiol
disulphid
homeostasi
statu
critic
role
antioxid
protect
detoxif
signal
transduct
apoptosi
regul
enzymat
activ
cellular
signal
mechan
transcript
factor
studi
evalu
thiol
disulphid
level
infant
atop
dermat
method
atop
dermat
patient
healthi
children
year
includ
studi
prospect
crosssect
eosinophilia
ige
level
nativ
thiol
sh
total
thiol
disulfid
ss
ss
sh
ss
total
sh
sh
total
sh
valu
measur
method
describ
erel
neseliogl
spss
statist
packag
social
scienc
analyz
use
p
result
atop
dermat
group
nativ
thiol
micro
mol
total
thiol
micro
mol
disulfid
micro
mol
control
group
nativ
thiol
micromol
total
thiol
micro
mol
disulfid
level
found
l
respect
neg
total
thiol
level
eosinophil
r
p
durat
breastfeed
shown
posit
correl
r
p
conclus
studi
show
thioldisulfid
balanc
weaken
children
atop
dermat
seen
part
registr
excess
level
oxid
balanc
studi
first
literatur
result
show
import
ensur
thiol
disulfid
balanc
breastfeed
furthermor
thioldisulfid
balanc
monitor
children
atop
dermat
use
serolog
marker
keyword
atop
dermatitiseczema
atop
dermatitiseczema
pathophysiolog
clinic
research
pediatr
refer
erel
neselioglu
novel
autom
assay
thioldisulphid
homeostasi
clinic
biochemistri
man
admit
recurr
ulcer
mouth
patient
four
month
ago
began
use
brace
front
dental
nickel
sensit
observ
patch
test
emphas
need
question
nickel
allergi
fit
devic
mouth
children
background
antihistamin
wide
use
medic
worldwid
indic
symptomat
treatment
allerg
disord
decreas
gastric
acid
product
consid
excel
safeti
extrem
rare
case
famotidineinduc
anaphylaxi
document
hypersensit
reaction
alkylamin
deriv
pheniramin
also
extrem
rare
method
report
year
old
woman
allerg
background
admit
er
complain
swell
lip
tongu
tighten
throat
dyspnea
gener
itch
urticaria
start
hour
take
medic
compos
naproxen
sodium
famotidin
follow
recoveri
discharg
pheniramin
gener
itch
urticaria
complain
reoccur
hour
take
tablet
rememb
symptom
year
ago
tablet
prescrib
pruritu
famili
doctor
refus
consid
symptom
connect
pheniramin
result
studi
carri
week
last
reaction
first
oral
provoc
test
opt
naproxen
done
neg
neg
skin
prick
test
spt
posit
intraderm
test
idt
famotidin
concentr
mgml
possibl
crossreact
antagonist
assess
spt
ranitidin
idt
ranitidin
mgml
nizatidin
dilut
posit
order
find
safe
altern
skin
test
opt
done
ppi
pantoprazol
omeprazol
esomeprazol
neg
skin
prick
test
idt
pheniramin
dilut
posit
opt
chlorpheniramin
anoth
alkylamin
deriv
neg
conclus
best
knowledg
first
report
case
anaphylact
reaction
famotidin
pheniramin
hypersensit
underli
mechan
relationship
well
understood
could
also
seen
efficaci
receptor
antagonist
treatment
urticaria
also
observ
crossreact
ranitidin
nizatidin
similar
side
chain
ring
structur
type
hypersensit
reaction
may
involv
patient
base
clinic
histori
time
till
reaction
onset
also
skin
test
result
posit
hypersensit
antihistamin
seem
rare
may
undersuspect
underdiagnos
case
suggest
hypersensit
antihistamin
occur
togeth
may
advis
ass
possibl
crossreact
within
antihistamin
receptor
group
also
group
background
util
crude
protein
extract
current
inadequ
identifi
allergen
protein
shellfish
current
three
protein
tropomyosin
arginin
kinas
paramyosin
fulli
identifi
character
potenti
crossreact
allergen
crustacean
mollusk
bioinformat
analysi
could
provid
power
versatil
tool
indepth
molecular
character
biolog
speci
unknown
allergen
bioinformat
approach
recent
use
identifi
put
allergen
rice
chickpea
johnson
grass
pollen
therefor
studi
aim
identifi
put
crossreact
allergen
use
insilico
analysi
transcriptom
mollusk
pacif
oyster
crassostrea
giga
method
sever
allergen
sequenc
relat
shellfish
allergi
includ
black
tiger
prawn
lobster
abalon
document
differ
databas
tblastn
analysi
perform
sequenc
genom
databas
pacif
oyster
retriev
put
crossreact
allergen
sequenc
retriev
sequenc
use
gener
phylogenet
tree
use
neighbor
join
method
softwar
associ
use
muscl
multipl
align
program
follow
structur
model
protein
built
use
chimera
program
addit
whole
protein
extract
analys
mass
spectroscopi
well
ige
bind
protein
shellfish
allerg
patient
result
base
amino
acid
sequenc
similar
crossreact
allergen
sever
put
allergen
gene
identifi
detail
silicoanalysi
genom
data
pacif
oyster
put
oyster
allergen
demonstr
potenti
crossreact
crustacean
allergen
base
conserv
domain
similar
structur
featur
method
also
reveal
presenc
variou
isoform
oyster
allergen
phylogenet
tree
six
differ
allergen
demonstr
pacif
oyster
cluster
correspond
allergen
mollusk
howev
group
distinct
separ
crustacean
allergen
conclus
bioinformat
approach
reveal
sever
put
cross
reactiv
allergen
fulli
elucid
use
less
sensit
immunochem
igebas
method
find
import
develop
specif
allergi
diagnost
shellfish
allergen
insilico
approach
combin
recombin
allergen
gener
emin
method
comprehens
asses
allergen
open
addit
path
effici
allergi
diagnost
immunotherapeut
background
climat
chang
cc
expect
alter
allergen
pollen
season
pollin
tree
weed
grass
potenti
increas
occurr
allerg
airway
diseas
object
sought
examin
spatiotempor
pattern
chang
weed
ragwe
mugwort
tree
birch
oak
grass
multipl
climat
region
relationship
chang
climat
contigu
us
time
year
method
region
assess
south
southeasts
southwestsw
centralc
westw
northeastn
eastnorthcentralenc
westnorthcentralwnc
northwestnw
land
area
coverag
pollen
season
time
hourli
pollen
concentr
due
cc
obtain
use
statist
analys
determinist
simul
base
observ
simul
model
across
conu
result
allergen
pollen
season
repres
tree
weed
grass
across
conu
observ
start
confid
interv
ci
day
earlier
averag
averag
peak
valu
annual
total
daili
count
airborn
pollen
increas
ci
ci
respect
chang
ragwe
pollen
season
time
level
identifi
function
latitud
associ
chang
grow
degre
day
frost
free
day
precipit
conclus
chang
like
due
recent
climat
chang
particularli
enhanc
warm
precipit
higher
latitud
conu
observ
pollen
season
start
date
season
length
airborn
pollen
level
could
correctli
predict
use
bayesian
machin
learn
model
base
local
observ
meteorolog
factor
background
specif
subcutan
immunotherapi
scit
hous
dust
mite
hdm
shown
improv
clinic
symptom
patient
allerg
rhiniti
asthma
china
less
data
regard
efficaci
safeti
immunolog
mechan
specif
sublingu
immunotherapi
slit
allerg
patient
aim
studi
evalu
efficaci
immunolog
mechan
slit
hdm
compar
scit
hdm
rhiniti
patient
hdm
year
treatment
method
recruit
took
place
novemb
septemb
studi
enrol
patient
age
year
old
moderatesever
hdm
induc
allerg
rhiniti
without
asthma
random
three
group
slit
group
scit
group
placebo
follow
schedul
slit
group
allerg
rhiniti
asthma
symptom
medic
score
collect
patient
diari
card
baselin
year
use
assess
efficaci
visual
analogu
score
va
collect
skin
prick
test
totalspecif
ige
perform
baselin
month
treatment
addit
patient
underw
der
p
treg
cell
measur
result
scit
group
signific
improv
chang
baselin
mean
total
rhiniti
symptom
score
compar
placebo
year
therapi
slit
placebo
group
signific
differ
two
group
signific
improv
mean
rhiniti
medic
score
compar
placebo
p
analysi
rhiniti
va
score
chang
baselin
show
result
mean
asthma
symptom
medic
score
show
signific
differ
among
three
group
trend
toward
upregul
rate
treg
cell
baselin
year
scit
slit
subject
compar
placebo
group
p
level
der
p
show
signific
increas
slit
scit
compar
placebo
p
furthermor
mean
level
der
p
scit
group
almost
thirti
time
higher
slit
group
year
therapi
p
conclus
scit
slit
efficaci
patient
moderatesever
hdm
sensit
allerg
rhiniti
year
treatment
scit
also
afford
signific
therapeut
benefit
respect
rhiniti
symptom
score
serum
der
p
treg
cell
may
play
role
modul
immunorespons
specif
immunotherapi
relationship
clinic
efficaci
need
studi
